DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of predissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.
A Toxicological Profile for Toluene was released in 2000. This present edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology and Human Health Sciences  
Environmental Toxicology Branch  
1600 Clifton Road NE  
Mailstop F-57  
Atlanta, Georgia 30329-4027
This page is intentionally blank.
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch

Regular Mailing Address: 1600 Clifton Road, N.E.
Mail Stop F-57
Atlanta, Georgia 30329-4027

Physical Mailing Address:
4770 Buford Highway
Building 106, 3rd floor, MS F-57
Chamblee, Georgia 30341

***DRAFT FOR PUBLIC COMMENT***
The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, PhD, CIH
Director, National Center for Environmental Health
and Agency for Toxic Substances and Disease Registry,
Centers for Disease Control and Prevention
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

**Primary Chapters/Sections of Interest**

**Chapter 1: Public Health Statement**: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

**Chapter 2: Relevance to Public Health**: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

**Chapter 3: Health Effects**: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

*NOTE*: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

**Pediatrics**: Four new sections have been added to each Toxicological Profile to address child health issues:

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 1</td>
<td>How Can (Chemical X) Affect Children?</td>
</tr>
<tr>
<td>Chapter 1</td>
<td>How Can Families Reduce the Risk of Exposure to (Chemical X)?</td>
</tr>
<tr>
<td>Section 3.7</td>
<td>Children’s Susceptibility</td>
</tr>
<tr>
<td>Section 6.6</td>
<td>Exposures of Children</td>
</tr>
</tbody>
</table>

**Other Sections of Interest**:

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 3.8</td>
<td>Biomarkers of Exposure and Effect</td>
</tr>
<tr>
<td>Section 3.11</td>
<td>Methods for Reducing Toxic Effects</td>
</tr>
</tbody>
</table>

**ATSDR Information Center**

**Phone**: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)

**Internet**: http://www.atsdr.cdc.gov

The following additional material is available online at www.atsdr.cdc.gov:

*Case Studies in Environmental Medicine*—Case Studies are self-instructional publications designed to increase primary care provider’s knowledge of a hazardous substance in the environment and to aid in the evaluation of potentially exposed patients.

*Managing Hazardous Materials Incidents* is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials event.
incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, Patriots Plaza Building, Washington, DC 20201 • Phone: (202) 245-0625 or 1-800-CDC-INFO (800-232-4636).

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Clinical Resources

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Robert Williams, Ph.D.
Sharon Wilbur, M.A.
Jessilynn Taylor, M.S., CDR USPHS
Mike Fay, Ph.D.
ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

Peter McClure, Ph.D., DABT
Kimberly Zaccaria, Ph.D.
H. Danielle Johnson, B.S.
Mario Citra, Ph.D.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for toluene. The panel consisted of the following members:

1. Luis Haro Garcia, Ph.D., Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional Autónoma de México, México DF, México;

2. Zemin Wang, M.D., Ph.D., DABT, Department of Environmental Health, Indiana University, Bloomington, Indiana; and

3. Scott E. Bowen, Ph.D., Associate Professor and BCN Area Chair, President, Michigan Chapter of the Society for Neuroscience, WSU Psi Chi Advisor, Department of Psychology, Wayne State University, Detroit, Michigan.

These experts collectively have knowledge of toluene’s physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.
CONTENTS

DISCLAIMER ................................................................................................................................. ii
UPDATE STATEMENT .................................................................................................................. iii
FOREWORD ................................................................................................................................. v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS ........................................................... vii
CONTRIBUTORS .......................................................................................................................... ix
PEER REVIEW ............................................................................................................................... xi
CONTENT ......................................................................................................................................... xiii
LIST OF TABLES ............................................................................................................................ xvii
LIST OF FIGURES .......................................................................................................................... xix

1. PUBLIC HEALTH STATEMENT FOR TOLUENE ........................................................................ 1

2. RELEVANCE TO PUBLIC HEALTH ........................................................................................ 9
   2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TOLUENE IN THE UNITED STATES .......................................................................................................................... 9
   2.2 SUMMARY OF HEALTH EFFECTS ...................................................................................... 9
   2.3 MINIMAL RISK LEVELS (MRLs) ....................................................................................... 21

3. HEALTH EFFECTS .................................................................................................................. 31
   3.1 INTRODUCTION ................................................................................................................... 31
   3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE ....................................... 31
      3.2.1 Inhalation Exposure ........................................................................................................ 32
         3.2.1.1 Death ......................................................................................................................... 33
         3.2.1.2 Systemic Effects ....................................................................................................... 33
         3.2.1.3 Immunological and Lymphoreticular Effects ........................................................... 115
         3.2.1.4 Neurological Effects ............................................................................................... 126
         3.2.1.5 Reproductive Effects ............................................................................................... 154
         3.2.1.6 Developmental Effects ............................................................................................ 158
         3.2.1.7 Cancer ..................................................................................................................... 164
      3.2.2 Oral Exposure ................................................................................................................. 167
         3.2.2.1 Death ......................................................................................................................... 167
         3.2.2.2 Systemic Effects ....................................................................................................... 168
         3.2.2.3 Immunological and Lymphoreticular Effects ........................................................... 193
         3.2.2.4 Neurological Effects ............................................................................................... 194
         3.2.2.5 Reproductive Effects ............................................................................................... 197
         3.2.2.6 Developmental Effects ............................................................................................ 198
         3.2.2.7 Cancer ..................................................................................................................... 200
      3.2.3 Dermal Exposure ........................................................................................................... 200
         3.2.3.1 Death ......................................................................................................................... 200
         3.2.3.2 Systemic Effects ....................................................................................................... 200
         3.2.3.3 Immunological and Lymphoreticular Effects ........................................................... 203
         3.2.3.4 Neurological Effects ............................................................................................... 203
         3.2.3.5 Reproductive Effects ............................................................................................... 203
         3.2.3.6 Developmental Effects ............................................................................................ 203
         3.2.3.7 Cancer ..................................................................................................................... 203
   3.3 GENOTOXICITY .................................................................................................................. 204
   3.4 TOXICOKINETICS ............................................................................................................. 210
      3.4.1 Absorption ..................................................................................................................... 211
         3.4.1.1 Inhalation Exposure ................................................................................................. 211

***DRAFT FOR PUBLIC COMMENT***
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE</td>
<td>268</td>
</tr>
<tr>
<td>3.11 METHODS FOR REDUCING TOXIC EFFECTS</td>
<td>270</td>
</tr>
<tr>
<td>3.11.1 Reducing Peak Absorption Following Exposure</td>
<td>270</td>
</tr>
<tr>
<td>3.11.2 Reducing Body Burden</td>
<td>271</td>
</tr>
<tr>
<td>3.11.3 Interfering with the Mechanism of Action for Toxic Effects</td>
<td>271</td>
</tr>
<tr>
<td>3.12 ADEQUACY OF THE DATABASE</td>
<td>271</td>
</tr>
<tr>
<td>3.12.1 Existing Information on Health Effects of Toluene</td>
<td>272</td>
</tr>
<tr>
<td>3.12.2 Identification of Data Needs</td>
<td>272</td>
</tr>
<tr>
<td>3.12.3 Ongoing Studies</td>
<td>284</td>
</tr>
<tr>
<td>3.4 METABOLISM</td>
<td>224</td>
</tr>
<tr>
<td>3.4.1 Metabolism has to be quantified with methods that are known</td>
<td>224</td>
</tr>
<tr>
<td>3.4.2 Elimination and Excretion</td>
<td>224</td>
</tr>
<tr>
<td>3.4.4 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models</td>
<td>227</td>
</tr>
<tr>
<td>3.5 MECHANISMS OF ACTION</td>
<td>239</td>
</tr>
<tr>
<td>3.5.1 Pharmacokinetic Mechanisms</td>
<td>239</td>
</tr>
<tr>
<td>3.5.2 Mechanisms of Toxicity</td>
<td>240</td>
</tr>
<tr>
<td>3.5.2.1 Mechanisms of Neurotoxicity</td>
<td>240</td>
</tr>
<tr>
<td>3.5.2.2 Mechanisms of Toxicity to Other Systems</td>
<td>248</td>
</tr>
<tr>
<td>3.5.2.3 Potential Mechanisms of Metabolite-mediated Toxicity</td>
<td>249</td>
</tr>
<tr>
<td>3.5.3 Animal-to-Human Extrapolations</td>
<td>250</td>
</tr>
<tr>
<td>3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS</td>
<td>251</td>
</tr>
<tr>
<td>3.7 CHILDREN’S SUSCEPTIBILITY</td>
<td>254</td>
</tr>
<tr>
<td>3.8 BIOMARKERS OF EXPOSURE AND EFFECT</td>
<td>261</td>
</tr>
<tr>
<td>3.8.1 Biomarkers Used to Identify or Quantify Exposure to Toluene</td>
<td>262</td>
</tr>
<tr>
<td>3.8.2 Biomarkers Used to Characterize Effects Caused by Toluene</td>
<td>262</td>
</tr>
<tr>
<td>3.9 INTERACTIONS WITH OTHER CHEMICALS</td>
<td>263</td>
</tr>
<tr>
<td>3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE</td>
<td>268</td>
</tr>
<tr>
<td>3.11 METHODS FOR REDUCING TOXIC EFFECTS</td>
<td>270</td>
</tr>
<tr>
<td>3.11.1 Reducing Peak Absorption Following Exposure</td>
<td>270</td>
</tr>
<tr>
<td>3.11.2 Reducing Body Burden</td>
<td>271</td>
</tr>
<tr>
<td>3.11.3 Interfering with the Mechanism of Action for Toxic Effects</td>
<td>271</td>
</tr>
<tr>
<td>3.12 ADEQUACY OF THE DATABASE</td>
<td>271</td>
</tr>
<tr>
<td>3.12.1 Existing Information on Health Effects of Toluene</td>
<td>272</td>
</tr>
<tr>
<td>3.12.2 Identification of Data Needs</td>
<td>272</td>
</tr>
<tr>
<td>3.12.3 Ongoing Studies</td>
<td>284</td>
</tr>
<tr>
<td>4. CHEMICAL AND PHYSICAL INFORMATION</td>
<td>287</td>
</tr>
<tr>
<td>4.1 CHEMICAL IDENTITY</td>
<td>287</td>
</tr>
<tr>
<td>4.2 PHYSICAL AND CHEMICAL PROPERTIES</td>
<td>287</td>
</tr>
<tr>
<td>5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL</td>
<td>291</td>
</tr>
<tr>
<td>5.1 PRODUCTION</td>
<td>291</td>
</tr>
<tr>
<td>5.2 IMPORT/EXPORT</td>
<td>291</td>
</tr>
<tr>
<td>5.3 USE</td>
<td>291</td>
</tr>
<tr>
<td>5.4 DISPOSAL</td>
<td>294</td>
</tr>
<tr>
<td>6. POTENTIAL FOR HUMAN EXPOSURE</td>
<td>295</td>
</tr>
<tr>
<td>6.1 OVERVIEW</td>
<td>295</td>
</tr>
<tr>
<td>6.2 RELEASES TO THE ENVIRONMENT</td>
<td>297</td>
</tr>
<tr>
<td>6.2.1 Air</td>
<td>300</td>
</tr>
<tr>
<td>6.2.2 Water</td>
<td>303</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
This page is intentionally blank.
LIST OF FIGURES

2-1. Health Effects of Breathing Toluene ................................................................. 22

2-2. Health Effects of Ingesting Toluene ............................................................... 23

3-1. Levels of Significant Exposure to Toluene – Inhalation ............................. 88

3-2. Levels of Significant Exposure to Toluene – Oral .................................... 184

3-3. Scheme for Toluene Metabolism in Humans and Animals ....................... 220

3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .................................................. 229

3-5. Existing Information on Health Effects of Toluene .................................. 273

6-1. Frequency of NPL Sites with Toluene Contamination .............................. 296
### LIST OF TABLES

3-1. Levels of Significant Exposure to Toluene – Inhalation ................................................................. 34

3-2. Mean Spleen Weight (SE) for PND 21 Mice (n=6/Group) Exposed to Toluene 6 Hours/Day on GD 14 Through PND 21 With and Without Exposure to PGN .................................................. 123

3-3. Levels of Significant Exposure to Toluene – Oral ........................................................................ 169

3-4. Levels of Significant Exposure to Toluene – Dermal .................................................................... 202

3-5. Genotoxicity of Toluene *In Vivo* ...................................................................................................... 205

3-6. Genotoxicity of Toluene *In Vitro* .................................................................................................... 207

3-7. Ongoing Research for Toluene ......................................................................................................... 286

4-1. Chemical Identity of Toluene ........................................................................................................ 288

4-2. Physical and Chemical Properties of Toluene .................................................................................. 289

5-1. Facilities that Produce, Process, or Use Toluene ............................................................................ 292

6-1. Releases to the Environment from Facilities that Produce, Process, or Use Toluene ................. 298

6-2. 2011 NEI Total National Emissions of Toluene .............................................................................. 301

6-3. Toluene Levels in Ambient Air ......................................................................................................... 309

6-4. Weekly Mean Toluene Concentrations (µg/m³) in Indoor Air at 16 Newspaper Stands and the Corresponding Outdoor Air Levels ................................................................................... 320

6-5. Geometric Mean and Selected Percentiles of Blood Toluene in Whole Blood Concentrations (in mg/L) for the U.S. Population from NHANES ...................................................................... 324

7-1. Analytical Methods for Determining Toluene in Biological Materials ........................................... 336

7-2. Analytical Methods for Determining Biomarkers of Toluene in Biological Samples ....................... 339

7-3. Analytical Methods for Determining Toluene in Environmental Samples ..................................... 340

8-1. Regulations, Advisories, and Guidelines Applicable to Toluene ...................................................... 350
This page is intentionally blank.
1. PUBLIC HEALTH STATEMENT FOR TOLUENE

This public health statement summarizes the Division of Toxicology and Human Health Science’s findings on toluene, describes the effects of exposure to it, and describes what you can do to limit that exposure.

The U.S. Environmental Protection Agency (U.S. EPA) identifies the most serious hazardous waste sites in the nation. U.S. EPA then includes these sites the National Priorities List (NPL) and targets it for federal clean-up activities. U.S. EPA has found toluene in at least 1,012 of the 1,699 current or former NPL sites. The total number of NPL sites evaluated for toluene is not known. But the possibility remains that as more sites are evaluated, the number of sites at which toluene is found may increase. This information is important; these sites may be sources of exposure, and exposure to toluene may be harmful.

When a contaminant is released from a large area such as an industrial plant or from a container such as a drum or bottle, it enters the environment. But such a release doesn’t always lead to exposure. You can only be exposed to a contaminant when you come in contact with it. That contact—and therefore that exposure—can occur when you breathe, eat, or drink the contaminant, or when it touches your skin.

Exposure to toluene can affect different people in different ways. Whether you are harmed will depend on such factors as the dose (how much), the duration (how long), and how you happen to contact it. Harm might also depend on whether you’ve been exposed to any other chemicals, as well as your age, sex, diet, family traits, lifestyle, and state of health.

WHAT IS TOLUENE?

Toluene is a clear, colorless liquid with a distinctive smell. It is a good solvent (a substance that can dissolve other substances). Toluene occurs naturally in crude oil and in the tolu tree. It is produced in the process of making gasoline and other fuels from crude oil and in making coke from coal.

Toluene is used in making paints, paint thinners, fingernail polish, lacquers, adhesives, and rubber and in some printing and leather tanning processes. It is used in the production of benzene, nylon, plastics, and polyurethane and the synthesis of trinitrotoluene (TNT), benzoic acid, benzoyl chloride, and toluene diisocyanate. It is also added to gasoline along with benzene and xylene to improve octane ratings.

***DRAFT FOR PUBLIC COMMENT***
WHERE IS TOLUENE FOUND?

Toluene can be released into the air, water, and soil at places where it is produced or used. Toluene is commonly found in air, particularly when there is heavy vehicular traffic. Monitoring data of outdoor air in the United States shows that toluene is present at average levels of approximately 1–35 parts per billion by volume (ppbv). Indoor air samples can contain higher levels of toluene in places where products such as paint thinners, solvents, or tobacco products are used.

Toluene can enter surface waters and groundwater (wells) from solvent and petroleum products spills. Toluene can also leak from underground storage tanks at gasoline stations and other facilities. When toluene-containing products are placed in landfills or waste disposal sites, toluene can enter the soil and water near the waste site. It is possible for toluene to be broken down in subsurface (below ground) water primarily by anaerobic microorganisms. Toluene will readily evaporate into the air or be degraded by microorganisms in surface waters. Leaking underground storage tanks can contaminate the soil with toluene and other petroleum-product components. Toluene in surface soils rapidly evaporates into the air. Toluene is readily broken down to other chemicals by microorganisms in the soil.

HOW MIGHT I BE EXPOSED TO TOLUENE?

Toluene enters the environment when you use materials that contain it, such as paints, paint thinners, adhesives, fingernail polish, and gasoline; it evaporates rapidly from these materials and becomes mixed with the air you breathe.

Individuals who work with gasoline, paint, lacquer, or dyes have greater exposures to toluene, as do individuals who smoke or intentionally inhale products containing toluene for its euphoric effects.

HOW CAN TOLUENE ENTER AND LEAVE MY BODY?

Toluene can enter your body from the air, water, or soil. You are exposed to toluene by breathing outdoor or indoor air containing this substance. Gasoline contains toluene and so do some other products used in occupational or home settings (e.g., solvents, paint thinners). Inhalation and dermal exposure is possible when using these products.

***DRAFT FOR PUBLIC COMMENT***
Toluene is not frequently detected in drinking water. If you are using a well that has been contaminated by toluene from an accidental spill, you may ingest some; however, this route of exposure is less likely than breathing in toluene from air. Toluene evaporates quickly from soils. Therefore, it is unlikely you will be exposed to it from soil, unless you come in contact with soil near a hazardous waste site containing it or an accidental spill.

When you breathe toluene, it is taken directly into your blood from your lungs. Similarly, when you touch products containing toluene (e.g., nail polish remover) or bathe in water containing toluene, toluene can pass through your skin into your bloodstream. When you ingest food or drink containing toluene, it is also absorbed from your GI tract into your bloodstream. Factors such as your age, sex, body composition, and health status affect what happens to toluene once it is in your body.

After being taken into your body, the majority of toluene is removed from your body within a day; however, a small amount may accumulate in fat tissue with daily exposure. Toluene may leave your body unchanged in the air you breathe out or in your urine after some of it has been changed to other chemicals. Generally, your body turns toluene into less harmful chemicals such as hippuric acid. More information on how toluene can enter and leave your body can be found in Chapter 3.

**HOW CAN TOLUENE AFFECT YOUR HEALTH?**

A serious health concern is that toluene may have an effect on your nervous system (brain and nerves). Nervous system effects can be temporary, such as headaches, dizziness, or unconsciousness. However, effects such as incoordination, cognitive impairment, and vision and hearing loss may become permanent with repeated exposure, especially at concentrations associated with intentional solvent abuse. High levels of toluene exposure during pregnancy, such as those associated with solvent abuse, may lead to retardation of mental abilities and growth in children. Other health effects of potential concern may include immune, kidney, liver, and reproductive effects.

Single exposures to toluene or repeated exposures over a few weeks can cause headaches and sleepiness, and can impair your ability to think clearly. Whether or not toluene does this to you depends on the amount you take in, how long you are exposed, and your genetic susceptibility and age. One very dangerous activity is to expose yourself to a large amount of toluene in a short time by deliberately inhaling/sniffing paint or glue. At first, you will feel light-headed. If exposure continues, you can become dizzy, sleepy, or unconscious, and you might even die. Toluene causes death by interfering with
the way you breathe and the way your heart beats. When exposure is stopped, the sleepiness and dizziness will go away and you will feel normal again.

Low to moderate, day-after-day exposure to toluene in your workplace can cause tiredness, confusion, weakness, drunken-type actions, memory loss, nausea, and loss of appetite. These symptoms usually disappear when exposure is stopped. You may experience some hearing and color vision loss after long-term daily exposure to toluene in the workplace. Combinations of toluene and some common medicines like aspirin and acetaminophen may increase the effects of toluene on your hearing. Researchers do not know if the low levels of toluene that you breathe at work will cause any permanent effects on your brain or body after many years. If you choose to repeatedly breathe in toluene from glue or paint thinners, you may permanently damage your brain. You may also experience problems with your speech, vision, or hearing, have loss of muscle control, loss of memory, poor balance, and decreased mental ability.

Some studies in people have shown reproductive effects, such as an increased risk of spontaneous abortions, from exposure to toluene in the workplace. However, other factors, such as exposure to other chemicals, smoking, and alcohol use, may have affected the results of the studies, so it is not possible to say whether toluene has reproductive effects in people. Additionally, exposure to high levels of toluene could possibly damage your kidneys and liver.

The effects of toluene on animals are similar to those seen in humans. The main effect of toluene is on the brain and nervous system, but animals exposed to moderate or high levels of toluene also show harmful effects in their liver, kidneys, and lungs and impaired immune function. Animal studies do not indicate that toluene exposure results in reproductive effects.

Studies in workers and animals exposed to toluene generally indicate that toluene is not carcinogenic (cancer-causing). The International Agency for Research on Cancer determined that toluene is not classifiable as to its carcinogenicity in humans (Group 3). The U.S. EPA determined there is inadequate information to assess the carcinogenic potential of toluene. The American Conference of Governmental Industrial Hygienists determined that toluene is not classifiable as a human carcinogen (A4). The U.S. National Toxicology Program has not considered the carcinogenic potential of toluene.

See Chapters 2 and 3 for more information on health effects of toluene.
1. PUBLIC HEALTH STATEMENT

HOW CAN TOLUENE AFFECT CHILDREN?

This section discusses potential health effects of toluene exposure in humans from when they’re first conceived to 18 years of age, and how you might protect against such effects.

Children may breathe air contaminated with toluene by family use of glues, paints, or cleaning solvents, or by accidents involving products containing toluene. Toluene vapors are heavier than air and since young children are closer to the ground or floor because of their height, they may breathe more toluene than adults during accidental exposures. Also, children have faster breathing rates than adults and may therefore breathe in more toluene. Older children and adolescents may be exposed to toluene if they breathe household products containing it to get “high”. Nursing mothers who breathe toluene in workplace air may transfer some toluene in breast milk to their infants. Toluene is not stored in the body. Toluene in the body either rapidly leaves or is turned into less harmful chemicals. Thus, nursing mothers, who do not currently work in jobs with toluene and who do not deliberately breathe large amounts of toluene, are expected to transfer very little toluene in breast milk.

The effects of toluene on children have not been studied very much, but toluene is likely to produce the same types of effects on the brain and nervous system in children as it does in adults. Some older children and adolescents who have repeatedly breathed large amounts of toluene to get high have developed loss of muscle control, loss of memory, poor balance, and decreased mental abilities. Some of these changes may last for a long time after toluene has left the body. Young animals exposed to toluene have shown changes in behavior, hearing loss, and chemical changes in their brains.

Human fetuses and newborn babies may be more sensitive to toluene than adults, because their bodies may not be as able to turn toluene into less harmful chemicals. Some animal studies suggest that young animals might be more susceptible to toluene effects on health; however, shortly after birth, human babies begin to develop the ability to turn toluene into less harmful chemicals. By the time children are 1–3 years of age, they may be equal to adults in this ability.

Some mothers who breathed large amounts of toluene during pregnancy to get high have had children with birth defects, including retardation of mental abilities and growth. Results from animal studies have found similar effects in newborn animals that had mothers that breathed large amounts of toluene during pregnancy; however, when the animal mothers breathed small amounts of toluene during pregnancy, no
birth defects were found in their newborn animals. When pregnant animals breathe small amounts of toluene during pregnancy, studies show that very little toluene reaches the developing fetus.

More information on the effects of toluene on children can be found in Chapter 3.

**HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO TOLUENE?**

If your doctor finds that you have been exposed to significant amounts of toluene, ask whether your children or unborn baby might also be exposed. Your doctor might need to ask your state health department to investigate.

Toluene is a solvent that is used in making paints, paint thinners, fingernail polish, lacquers, adhesives, and rubber. Toluene is added to gasoline and is used in some printing and leather tanning processes. Follow instructions on product labels to minimize exposure to toluene. Families can reduce their risk of exposure to toluene by using consumer products containing the chemical (such as paints, glues, inks, and stain removers) in well-ventilated areas. When not in use, toluene-containing products should be tightly covered to prevent evaporation into the air. Household chemicals should be stored out of the reach of young children to prevent accidental poisonings. Storing items that contain toluene in the shed or an outside location may reduce exposure. Always store household chemicals in their original labeled containers. Never store household chemicals in containers that children would find attractive to eat or drink from, such as old soda bottles. Keep your Poison Control Center’s number next to the phone.

Cook foods if possible. Evaporation due to cooking tends to decrease the amount of toluene found in hot foods or water. Use bottled water if you have concerns about the presence of toluene in your tap water. Prevent children from eating or playing in the dirt if you live near a waste site that has been contaminated with toluene.

Your children may be exposed to toluene by inhaling products that contain it. Sometimes, older children sniff household chemicals in an attempt to get high. Talk with children about the dangers of sniffing chemicals.
1. PUBLIC HEALTH STATEMENT

ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO TOLUENE?

Toluene and its breakdown products (metabolites) can be measured in blood and urine. However, the detection of toluene or its metabolites cannot predict the kind of health effects that might develop from that exposure. Because toluene and its metabolites leave the body fairly rapidly, the tests need to be conducted within days after exposure.

For more information on the different substances formed by toluene breakdown and on tests to detect these substances in the body, see Chapters 3 and 7.

WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?

The federal government develops regulations and recommendations to protect public health. Regulations can be enforced by law. Federal agencies that develop regulations for toxic substances include the Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA), and the Food and Drug Administration (FDA). Recommendations provide valuable guidelines to protect public health but cannot be enforced by law. Federal organizations that develop recommendations for toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety and Health (NIOSH).

Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect animals; levels are then adjusted to help protect humans. Sometimes these not-to-exceed levels differ among federal organizations. Different organizations use different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or emphasize some factors over others, depending on their mission.

Recommendations and regulations are also updated periodically as more information becomes available. For the most current information, check with the federal agency or organization that issued the regulation or recommendation.

The EPA has recommended a drinking water guideline value of 1 mg/L for toluene. OSHA has set a legal limit for workers of 200 ppm for toluene in air averaged over an 8-hour workday. NIOSH has set a

***DRAFT FOR PUBLIC COMMENT***
1. PUBLIC HEALTH STATEMENT

recommended limit of 100 ppm for toluene in air averaged over a 10-hour workday. ACGIH recommends that toluene in workplace air not exceed 20 ppm (average levels over 8 hours).

More information on federal and state government regulations and guidelines for toluene in air and water can be found in Chapter 8.

WHERE CAN I GET MORE INFORMATION?

If you have any questions or concerns, please contact your community or state health or environmental quality department, or contact ATSDR at the address and phone number below. ATSDR can also provide publicly available information regarding medical specialists with expertise and experience recognizing, evaluating, treating, and managing patients exposed to hazardous substances.

- Call the toll-free information and technical assistance number at 1-800-CDCINFO (1-800-232-4636) or

- Write to:
  Agency for Toxic Substances and Disease Registry
  Division of Toxicology and Human Health Sciences
  1600 Clifton Road NE
  Mailstop F-57
  Atlanta, GA 30329-4027

Toxicological profiles and other information are available on ATSDR’s web site: http://www.atsdr.cdc.gov.
2. RELEVANCE TO PUBLIC HEALTH

2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TOLUENE IN THE UNITED STATES

Toluene is a clear colorless liquid possessing high vapor pressure and low to moderate water solubility. It is used as a solvent and as an additive in gasolines to improve octane ratings. It is also frequently used to produce other chemicals such as benzene and toluene diisocyanate.

Given its vapor pressure, toluene tends to partition to the atmosphere. Automobile emissions are the principal source of toluene in ambient air, with levels fluctuating in proportion to automobile traffic. Toluene can also be a common indoor contaminant, and indoor air concentrations are often several times higher than outside air. This is likely due to release of toluene from common household products (paints, paint thinners, adhesives, and nail polish in which it is used as a solvent) and from cigarette smoke.

In the atmosphere, toluene is principally degraded by reaction with photochemically generated hydroxyl radicals, but may also degrade through reaction with nitrate radicals and ozone. When released to water surfaces, toluene is expected to volatilize quickly. It may also be biodegraded under aerobic and anaerobic conditions, but hydrolysis is not an important environmental fate process. Toluene does not bioconcentrate or bioaccumulate significantly in aquatic organisms. If released to soil, toluene is expected to volatilize quickly. In the case of a large spill, some toluene may leach into groundwater because it possesses high mobility in soils. Biodegradation in soils may also occur with half-lives ranging from a few hours to several days depending upon the environmental conditions.

The general population is primarily exposed to toluene through the inhalation of ambient air. Ingestion of toluene from contaminated water and food is possible; however, this is a less likely exposure route since toluene is not frequently detected in drinking water and food. Dermal exposure from gasoline or solvents that contain toluene is also possible. Occupational exposure to toluene is expected to be greater than general population exposure for persons employed in heavy traffic occupations (e.g., toll attendants, automobile workers etc.) and persons who frequently use solvents or other products that contain toluene.

2.2 SUMMARY OF HEALTH EFFECTS

Death. Case studies that reported on deaths in humans due to exposure to toluene have generally not provided information on dose. In one instance, ingestion of approximately 625 mg/kg resulted in death.
within 30 minutes. The cause of death appeared to be profound disruption of central nervous system function.

An acute 7-hour inhalation LC$_{50}$ value of 5,320 ppm has been reported for mice and acute oral LD$_{50}$ values in adult rats ranged from 5,500 to 7,400 mg/kg. In 13-week gavage studies, all rats and mice that received 5,000 mg/kg died within the first week. Mortality was also high for groups receiving 2,500 mg/kg, with 8/10 male rats, 1/10 female rats, and 4/10 male and female mice dying before the end of the study. A dose of 1,250 mg/kg/day was lethal in 1/10 female mice, but no deaths occurred in male mice or in rats of either sex.

**Systemic Effects.**

**Respiratory Effects.** The primary effect of toluene on the respiratory tract following inhalation is irritation. Studies with volunteers and exposed workers have demonstrated that toluene is a mild-to-moderate respiratory irritant. Early animal studies reported respiratory irritation and pulmonary lesions in rats exposed to high concentrations of toluene. The findings of one study are supported by more recent observations of nasal lesions (including metaplasia of olfactory epithelium and degeneration of respiratory epithelium) in rats exposed to concentrations ranging from 600 to 1,200 ppm, 6.5 hours/day, 5 days/week for 2 years. Mice exposed by the same exposure protocol to a similar range of concentrations, however, did not display upper or lower respiratory tract lesions. In shorter duration studies, reversible nasal olfactory degeneration was observed in mice exposed to 1,000 ppm, 5 hours/day, 5 days/week for 4 weeks and inflammatory cell infiltration in peribronchial and alveolar regions, alveolar edema, and interstitial fibrosis and necrosis was observed in rats exposed to 3,000 ppm, 8 hours/day, 6 days/week for 12 weeks.

Only limited data regarding respiratory effects following oral exposure to toluene were located. Following lethal ingestion of approximately 625 mg/kg toluene, lung congestion and hemorrhage were reported in an adult male. Mucosal lesions and pronounced edema were observed during a bronchoscopy following a nonlethal ingestion of paint thinner by a 15-month-old girl. No respiratory effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks or 590 mg/kg/day for 6 months. No changes in lung weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls.

***DRAFT FOR PUBLIC COMMENT***
### Cardiovascular Effects

Inhalation exposure to toluene at concentrations >1,000 ppm has been associated with alterations of the heart rhythm in both humans and animals, but exposure of rats or mice to concentrations as high as 12,000 ppm (3 hours/day) for intermediate durations up to 1,200 ppm (6–6.5 hours/day) for chronic durations produced no histological changes in heart tissue. Additionally, no histological changes in the heart were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (6 hours/day; pre-mating and mating, gestation, and lactation) in a multigenerational study. There may be intraspecies differences in the cardiac response to toluene that make some individuals more susceptible than others to potentially fatal arrhythmias; the degree of hypoxia may also be important.

Cardiac effects have been noted following oral exposure to doses >1,200 mg/kg. Cardiac edema and congestion were observed in rats given single gavage doses of 5,200 mg/kg, compared with controls. Increased relative heart weights were noted in rats exposed to toluene at 1,250 mg/kg/day for 13 weeks and myocardial degeneration was present in mice exposed to 5,000 mg/kg/day. All of the mice receiving 5,000 mg/kg/day died during the first weeks of exposure. No effects on the weight or gross morphology of the heart were noted in rats receiving 590 mg/kg/day for 6 months, and no significant treatment-related findings were observed in electrocardiograms or cardiac histology in rats given single oral doses of up to 1,000–1,200 mg/kg.

### Gastrointestinal Effects

Gastric pain was reported by a man who accidently ingested 30 mL of an organic solvent containing toluene and other chemicals. Gastrointestinal effects were not reported in other case studies of oral exposure.

The only gastrointestinal effect reported after exposure to toluene was ulceration of the forestomach of rats exposed to 600 and 1,200 ppm by inhalation for 2 years. Similar effects were not seen in mice exposed under the same conditions or in rats or mice orally exposed to 2,500 mg/kg/day for 13 weeks. Additionally, no gastrointestinal effects were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (6 hours/day; pre-mating and mating, gestation, and lactation) in a multigenerational reproductive toxicity study.

### Hematological Effects

Before the mid-1950s, chronic occupational exposure to toluene was associated with hematological effects. However, these effects are now attributed to benzene, a common contaminant of toluene at that time. More recent studies of workers exposed to toluene or to mixed solvents containing toluene have not found consistent evidence for abnormal hematological parameters.
Following acute exposures, no effects on leukocyte counts were observed in volunteers exposed to 800 ppm toluene for 3 hours, and two workers accidentally exposed to about 1,862 ppm for 2–3 hours had normal values for hematological variables. Decreased leukocyte and white blood cell counts were observed in dogs and rats repeatedly exposed to airborne toluene, but have not been observed consistently in other studies of rats and mice repeatedly exposed by inhalation or by oral administration. In one study, rats exposed to high concentrations (2,500 or 5,000 ppm) of toluene for 7 hours each day had decreased leukocyte counts following exposure; however, the leukocyte numbers generally returned to normal by the next day. The toxicological significance of a transitory decrease in numbers of leukocytes is not apparent. In chronic-duration studies, rats exposed to 100 or 300 ppm toluene had significantly reduced hematocrit levels, but no consistent effects on hematological variables were reported for mice or rats exposed to toluene at levels up to 1,200 ppm for 15 months or 2 years.

Musculoskeletal Effects. Rhabdomyolysis (an acute disease of the skeletal muscles leading to breakdown of muscle tissue, leading to release of myoglobin into the blood and urine) was reported in two case studies of chronic toluene abuse: a man who had been sniffing glue containing toluene for 18 years, and a 48-year-old man who was a chronic toluene abuser who had been inhaling one tube of toluene-containing glue per day in the month preceding admission.

No musculoskeletal effects were reported in mice or rats after inhalation exposure up to 1,200 ppm for 15 months or 2 years or oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks. Additionally, no musculoskeletal effects were reported in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study. However, bone mineral density and bone mineral content were significantly (p<0.05) decreased in the right femoral neck of mice exposed to 300 ppm toluene 6 hours/day for 8 weeks.

Hepatic Effects. Studies of chronic toluene abusers, occupationally exposed workers, and laboratory animals have provided little support for irreversible liver damage due to inhaled toluene. Some studies of workers who were occupationally exposed to average concentrations between about 30 and 350 ppm toluene reported liver effects such as increased serum levels of alkaline phosphatase (AP), but others recorded no adverse effects on serum liver enzyme levels. Results from studies of animals exposed by inhalation for acute, intermediate, or chronic durations indicate that daily 6–8-hour exposures to concentrations above 300 ppm, but not below, can lead to increased liver weights and induction of hepatic cytochrome P450 levels. There are a few reports of toluene-induced effects that may be associated with
liver damage (e.g., increased serum levels of liver enzymes in rats exposed to 2,000 ppm for 48 hours, rats exposed to 3,000 ppm, 1 hour/day for 30 days, and rats exposed to 300 ppm, 6 hours/day for 4 weeks; increased hepatic fibrosis and apoptosis in rats exposed to 3,000 ppm, 1 hour/day for 30 days or 8 hours/day, 6 hours/week for 12 weeks; and increased endoplasmic reticulum in hepatocytes after exposure of rats, mice, and rabbits to 795 ppm 8 hours/day for 7 days), but no significant histopathological liver changes or liver weight changes were observed in well-conducted chronic-duration studies in which rats and mice were exposed to concentrations as high as 1,200 ppm, 6.5 hours/day, 5 days/week for 2 years. Results from intermediate-duration oral studies in rats and mice support the idea that toluene does not cause degenerative liver effects, but, at sufficiently high doses, produces liver weight increases that are likely associated with enzyme induction.

Studies of liver effects following oral exposure in humans are limited to two case studies. The liver of an adult male who died from toluene ingestion (625 mg/kg) was found to be enlarged on autopsy; however, clinical chemistry did not reveal abnormal liver function in a 15-month-old girl following accidental ingestion of paint thinner. Evidence from intermediate-duration animal studies indicates that exposure to toluene results in increased liver weights; however, reported effective dose levels vary widely between studies, species, and sex. Increased liver weight has been reported in male mice exposed to 105 mg/kg/day in drinking water for 28 days, but not 5, 22, or 84 mg/kg/day. Following exposure to 0, 312, 625, 1,250, 2,500, or 5,000 mg/kg/day via gavage for 12 weeks, significant increases in liver weight were observed in male and female rats exposed to ≥625 and ≥1,250 mg/kg/day, respectively, and male and female mice exposed to ≥1,250 and ≥312 mg/kg/day, respectively. No treatment-related changes in liver weight were observed in female rats exposed to 590 mg/kg/day via gavage for 6 months. No treatment-related gross or histopathological lesions of the liver were reported in any oral study.

An acute oral study in rats reports that single gavage doses of 5,200 mg/kg produced slight degeneration of hepatocytes, mononuclear cell infiltration, increased apoptosis, and increased serum levels of AST and ALT; however, no alterations in liver weight or histology were reported in pregnant rats exposed to 1,250 mg/kg/day toluene via gavage from gestation day (GD) 16 to 19 or female mice exposed to 600 mg/kg/day toluene via gavage for 14 days. Increased hepatic cell apoptosis was also reported in rats exposed to 650 mg/kg/day via gavage for 45 days.

**Renal Effects.** Studies of chronic toluene abusers, occupationally exposed workers, and laboratory animals have provided little support for irreversible kidney damage due to inhaled toluene. Chronic abuse of toluene can produce acidosis, but in most cases, renal dysfunction is transient, and normal function
returns when exposure ceases. Studies of workers occupationally exposed to 100–200 ppm toluene, which assessed changes in tests of kidney function, have not shown consistent effects across studies. Animal studies indicate that inhalation of toluene causes concentration-dependent kidney damage in rats, but only after repeated exposure to concentrations ≥600 ppm for at least 6 hours/day.

The majority of oral exposure studies in animals do not report renal effects. No treatment-related changes in kidney weight were reported in female rats exposed to 590 mg/kg/day via gavage for 6 months, male and female mice exposed up to 2,500 mg/kg/day via gavage for 13 weeks, male mice exposed to 5–105 mg/kg/day in drinking water for 28 days, or female mice exposed to 600 mg/kg/day via gavage for 14 days. However, following exposure to 0, 312, 625, 1,250, 2,500, or 5,000 mg/kg/day via gavage for 12 weeks, significant increases in kidney weight were observed in male and female rats exposed to ≥625 and ≥1,250 mg/kg/day, respectively. No changes in histopathology or renal function were reported in any intermediate-duration study. However, evidence for renal pathology was reported in dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19. Kidneys from toluene-exposed dams demonstrated swollen tubules, tissue adhesion to Bowman's capsule, and areas of solidification within glomeruli that were not observed in control dams. No exposure-related changes were observed in kidney weight.

**Endocrine Effects.** Current data do not provide consistent evidence of endocrine disruption in toluene-exposed humans. Elevated plasma levels of triiodothyronine (T3), but not free thyroxine (T4) or thyroid stimulating hormone (TSH), were observed in male printers exposed to 36 ppm toluene compared to an unexposed referent group. No change was observed in serum prolactin levels. Studies of blood levels of reproductive hormones in repeatedly exposed workers or acutely exposed human subjects have not provided strong and consistent evidence of exposure-related effects.

Similarly, evidence for endocrine effects in animals following acute- or intermediate-duration inhalation exposure to toluene is not consistent across studies and does not clearly identify toluene as an endocrine disrupting chemical. Elevated prolactin levels were reported in rats after exposure to 80 ppm toluene 6 hours/day 5 days/week for 4 weeks or 80–1,000 ppm 6 hours/day for 3 days. However, no changes in prolactin levels were found in rats after exposure to 40–320 ppm 6 hours/day 5 days/week for 4 weeks, 500 ppm toluene 6 hours/day for 3 days, or 1,000 ppm 6 hours/day for 5 days. No statistically significant, dose-related changes in serum levels of, luteinizing hormone (LH), follicle stimulating hormone (FSH), corticosterone levels, growth hormone, or TSH were reported in male Sprague-Dawley rats exposed up to 3,000 ppm toluene 6 hours/day for 3 days or 1,000 ppm 6 hours/day for 5 days. Serum
2. RELEVANCE TO PUBLIC HEALTH

Adrenocorticotropic hormone (ACTH) and corticosterone levels, along with increased adrenal weight and adrenocortical cell size, were observed in in male rats exposed to 1,500 ppm 4 hours/day for 7 days. This exposure scenario was shown to cause, in companion studies, neuronal damage and an increase in glucocorticoid receptor in the hippocampus, suggesting a possible disruption in the neuroendocrine axis. However, no effects on endocrine glands (pancreas, adrenal, or thyroid) were reported in other studies of rats exposed to 200–5,000 ppm toluene for 7 hours/day for 5 weeks, F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation, mice exposed to up to 2,500 ppm for 14 weeks, rats exposed to up to 3,000 ppm for 15 weeks, or mice and rats exposed to up to 1,200 ppm for 2 years.

Limited data are available regarding endocrine effects following oral exposure. Serum corticosterone and ACTH levels were significantly elevated in male mice exposed to 105 mg/kg/day toluene in drinking water for 28 days, compared with controls. Levels were not significantly elevated following exposure to 5 or 22 mg/kg/day. Microscopic examination revealed no effects on the adrenal or thyroid glands in rats and mice administered 312–2,500 mg/kg/day toluene by gavage for 13 weeks.

Dermal Effects. Skin irritation can occur in humans and animals dermally exposed to toluene. In humans, this may be due to the degreasing action of toluene and its removal of protective skin oils. However, exposure to toluene vapors of 100–2,000 ppm for 95 days (pre-mating and mating, gestation, and lactation) in a multigenerational study had no effects on the skin in F0 and F1 parental rats or F1 and F2 weanlings. Repeated or continuous contact with undiluted toluene in guinea pigs and mice leads to swelling, inflammatory cell infiltration, and increased epidermal thickness.

Ocular Effects. Humans have reported eye irritation following exposure to toluene vapors at concentrations ≥100 ppm. This is probably the result of direct contact of toluene vapor with the outer surface of the eye and thus, is not a true systemic effect. Slight to moderately severe irritation of rabbit eyes has been reported following direct application of toluene to the conjunctiva. Reports of color vision deficits in occupationally exposed workers have been postulated to involve toluene interference with dopaminergic mechanisms of retinal cells or toxic demyelination of optic nerve fibers.

Body Weight Effects. Findings regarding body weight effects in animals following inhalation exposure are inconsistent across studies. Weight loss has been reported to occur in rats following acute-duration exposure of 1,500–2,000 ppm; and intermediate-duration exposure (3–23 weeks) to toluene concentrations ranging from 200 to 12,000 ppm. In mice, weight loss has been reported following

***DRAFT FOR PUBLIC COMMENT***
intermediate-duration exposure (8–14 weeks) to toluene concentrations ranging from 100 to 12,000 ppm. In contrast, no exposure-related effects on body weights were observed in rats or mice following intermediate-duration exposure (20–95 days) at concentrations ranging from 1,000 to 6,000 ppm or chronic-duration exposure (2 years) up to 1,200 ppm.

The majority of oral exposure animal studies do not report body weight effects. No dose-related changes in body weight were reported in male rats following single gavage administration of up to 1,000 mg/kg, female mice exposed to 600 mg/kg/day via gavage for 14 days, male mice administered 5–105 mg/kg/day toluene in their drinking water for 28 days, or female rats and female mice given gavage doses of up to 2,500 mg/kg/day for 13 weeks. However, body weights were 16% lower in male mice given 1,250 mg/kg/day and 19% lower in male rats given 2,500 mg/kg/day by gavage for 13 weeks. Maternal weight gain was 24% lower in rats given 520 mg/kg/day toluene by gavage from GD 6 to 19, compared with control rats, but there was no change in maternal body weight gain in rat dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19.

**Immunological and Lymphoreticular Effects.** Only limited data are available on the immunological effects of toluene in humans. These studies do not identify consistent or strong evidence for toluene effects on immune system end points such as counts of blood lymphocytes or levels of blood immunoglobulins.

In animals, there is evidence that toluene may lead to immune depression. A series of studies evaluated immune end points in male CD-1 mice (5/group) administered toluene in their drinking water for 28 days at concentrations of 0, 5, 22, or 105 mg/kg/day or 0, 22, or 84 mg/kg/day. In one study, significantly decreased thymus weight and significantly depressed immune responses were observed in all *in vitro* immune assays (mitogen-stimulated lymphocyte proliferation, mixed lymphocyte reaction, interleukin 2 [IL-2] production assay, and antibody plaque-forming cell [PFC] response) at 105 mg/kg/day, compared with controls. IL-2 production and mitogen-stimulated lymphocyte proliferation were also significantly increased at 22 mg/kg/day, compared with controls. Significantly depressed immune responses were observed in the PFC assay and mixed lymphocyte reaction at 84 mg/kg/day. The mixed lymphocyte reaction was also significantly depressed at 22 mg/kg/day. In another study, the IL-2 production assay was significantly depressed at 105 mg/kg/day. Taken together, these studies consistently reported diminished immune responses in multiple *in vitro* immune assays following *in vivo* exposure to 84–105 mg/kg/day in drinking water for 28 days, compared with controls. A couple of immune assays were altered at 22 mg/kg/day, but findings were not consistent between the studies. Additionally, the antibody
PFC assay was significantly altered at 84 and 105 mg/kg/day, but not at 22 mg/kg/day. The PFC \textit{in vitro} assay is considered the most predictive assay of impaired immune function. Collectively, results from these studies support a no-observed-adverse-effect level (NOAEL) of 22 mg/kg/day for immune effects. Decreased resistance to mortality from respiratory infection by \textit{Streptococcus zooepidemicus} was observed in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm, but not 1 ppm. However, in an acute oral study, exposure to 600 mg/kg/day via gavage for 14 days did not diminish immune response in \textit{in vitro} immune assays or decrease host resistance to \textit{Listeria monocytogenes}, \textit{Streptococcus pneumoniae}, \textit{Plasmodium yoelii}, B16F10 melanoma cells, or PYB6 fibrosarcoma in female mice, compared with controls.

No evidence for exposure-related adverse changes in weight or histology of the spleen or thymus has been reported in animals exposed by inhalation for intermediate or chronic durations. Thymus weight was significantly decreased in male mice exposed to 105 mg/kg/day via gavage for 28 days, but not to 5–84 mg/kg/day. No changes in spleen weight were observed at any dose. No changes in thymus or spleen weight were observed in female mice exposed to 600 mg/kg/day via gavage for 14 days or rats or mice exposed up to 2,500 mg/kg/day via gavage for 13 weeks. No gross or histopathological lesions of the spleen or thymus were reported in any oral study.

\textbf{Neurological Effects.} Dysfunction of the central nervous system is a critical human health concern following acute, intermediate, or chronic inhalation exposure to toluene. Chronic toluene abuse in humans has been associated with neurotoxic symptoms, narcosis, permanent damage to the central nervous system, and death. Self-reported neurological symptoms and reduced ability in tests of cognitive and neuromuscular function have been observed in humans occupationally exposed to average concentrations as low as 40–150 ppm. Performance deficits in tests of neurobehavior have also been observed in volunteers acutely exposed to controlled concentrations >50 ppm and in laboratory animals repeatedly exposed to >1,000 ppm toluene.

Studies of occupationally exposed workers also indicate that chronic exposure to average concentrations as low as 50–130 ppm damages hearing and color vision presumably involving, at least in part, effects on neurological components of these systems.

Numerous studies in animals have also reported neurological alterations following acute, intermediate, or chronic inhalation exposure to toluene. Consistently reported effects following acute exposure include overt signs of neurotoxicity (ataxia, tremors, inability to walk); increased, followed by decreased,
2. RELEVANCE TO PUBLIC HEALTH

Locomotor activity at ≥500 ppm; impaired learning and/or memory at 125–4,000 ppm; and impaired motor coordination and reflexes at ≥100 ppm. However, studies of rodents exposed for intermediate durations to concentrations as high as 1,000 ppm have not found strong and consistent evidence for exposure-related changes for these neurological end points. Hearing loss in animals has been observed following acute- and intermediate-duration exposure to toluene at concentrations of ≥250 ppm in guinea pigs and ≥1,000 ppm in rats. Observed hearing loss may not be solely due to neurological damage, as exposure to 500–2,000 ppm leads to altered energy production and damage in cochlear hair cells. Other effects that have been reported include alterations in visual-evoked brain potentials (VEPs), altered pain perception, decreased olfactory sensitivity, altered sleep patterns, altered brain weight and volume in rats, altered levels of glial fibrillary acidic protein (GFAP) and markers of oxidative stress, and altered levels of neurotransmitters, precursors, and receptors.

Limited data are available regarding neurological effects following oral exposure. Neurological effects were reported in three case reports of toluene ingestion: severe depression of central nervous system function was the probable cause of death for a 51-year-old man who ingested approximately 60 mL (625 mg/kg) of toluene; a man who accidently ingested 30 mL of an organic solvent containing toluene and other chemicals was drowsy and complained of dizziness; and depressed consciousness, lethargy, hypotonia, and nystagmus were observed in a 15-month-old girl following accidental ingestion of paint thinner. Effects reported following acute-duration oral exposure in animals include transient increases in motor activity in rats; decreased in the flash-evoked brain potential (FEP) wave pattern amplitudes in male rats; and outer hair cell (OHC) loss in the cochlea of rats. However, no changes in brain weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls. Effects reported following intermediate-duration oral exposure in animals include regional specific neurotransmitter alterations; increased relative brain weights in male and female rats and male, but not female, mice; cellular necrosis in the hippocampus and cerebellum of male and female rats; and overt signs of neurotoxicity.

Reproductive Effects. Current data do not provide convincing evidence that acute or repeated inhalation exposure to toluene may cause reproductive effects in humans. Limited evidence in humans indicates that occupational exposure to toluene (and other solvents) may lead to an increased incidence of spontaneous abortion or decreased fecundity in female workers. A few studies in animals exposed to toluene via inhalation at concentrations ≥2,000 ppm reported effects on male and female reproductive tissues, including abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries of female rats and reduced sperm count, motility, and quality and altered reproductive organ
weight and histology in male rats. However, changes in sperm count and epididymus weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating. The majority of animal studies provided little evidence for toluene reproductive toxicity. Studies in rats exposed repeatedly by inhalation to toluene, including a 2-generation reproductive toxicity study, have shown no evidence of adverse effects on mating or fertility at tested concentrations as high as 1,200–2,000 ppm. In addition, the majority of numerous gestational exposure studies in rodents reported no exposure-related changes in reproductive indices.

Available data from oral exposure studies in animals do not provide evidence of reproductive effects following toluene exposure. No significant differences in the mean number of implantations per dam, corpora lutea per dam, live fetuses per litter, total number of resorptions per dam, and/or pre- or post-implantation loss were reported when rats and mice were exposed to toluene during gestation. Increased relative testicular weights were reported in male mice exposed to 1,250 and 2,500 mg/kg/day by gavage for 13 weeks. However, no effects on the weight of the prostate, testes, uterus, or ovaries were observed in rats and female mice exposed to 312–2,500 mg/kg/day. Reproductive performance was not evaluated in these 13-week studies.

**Developmental Effects.** There are a number of published reports of birth defects, similar to those associated with fetal alcohol syndrome, that have been described in children born to women who intentionally inhaled large quantities of toluene or other organic solvents during pregnancy. Defects described include microcephaly, central nervous system dysfunction, growth deficiency, cranofacial and limb abnormalities, and reversible renal tubular acidosis. Studies of women exposed during pregnancy to much lower concentrations of toluene in the workplace are restricted to a retrospective study of 14 women in Finland occupationally exposed to mixed solvents that suggested that solvent exposure may increase risk for central nervous system anomalies and neural tube closure defects.

The reports of birth defects in solvent abusers suggest that high-level exposure to toluene during pregnancy can be toxic to the developing fetus. The available human data, however, do not establish causality between low-level or occupational exposure to toluene and birth defects, because of the small sample size and the mixed solvent exposure experienced by the subjects, the lack of other studies of possible birth defects in children of occupationally exposed women, and the likelihood that the high exposure levels experienced by pregnant solvent abusers (4,000–12,000 ppm) overwhelm maternal protection of the developing fetus from absorbed toluene. Experiments with pregnant mice demonstrated that 10-minute exposures to 2,000 ppm resulted in low uptake of toluene into fetal tissue and suggest that,
at lower exposure levels, absorbed toluene is preferentially distributed to maternal adipose tissue before
distribution to the developing fetus.

A number of developmental toxicity studies with rats, mice, and rabbits involving toluene exposure by
inhalation during gestation have been conducted to further describe developmentally toxic effects from
toluene and exposure-response relationships. The results indicate that toluene did not cause maternal or
developmental toxic effects in animals at exposure levels <1,000 ppm administered for 6–7 hours/day
during gestation. Predominant effects reported at concentrations ranging from 1,000 to 3,000 ppm
include retarded fetal growth and skeletal development and altered development of behavior in offspring,
and were almost always accompanied by signs of maternal toxicity. Other animal studies reported that
continuous, 24-hour/day exposure during gestation caused maternal body weight depression and effects
on fetuses including depressed body weight and delayed skeletal ossification at toluene concentrations as
low as 133–399 ppm in rats, mice, and rabbits. Increased malformations and fetal death have been
observed when animals were exposed during gestation to higher concentrations modeling solvent abuse
(8,000–16,000 ppm, 15–30 minutes/day).

In animal studies of oral exposure during gestation, toluene was not a developmental toxicant when
administered orally at 1,800 or 2,350 mg/kg/day to pregnant mice during the period of organogenesis in
two developmental screening studies. In a comprehensive developmental toxicity study in rats, a
statistically significant increase in the incidence of dilated renal pelvis in the left kidney was observed in
fetuses from dams exposed to 1,250 mg/kg on GDs 16–19 via gavage, compared with controls. No
changes were observed in any other developmental end point. In other studies, exposure of pregnant rats
to gavage doses of 650 mg/kg/day toluene in corn oil on GDs 6–19 produced offspring with decreased
body weights, delayed ossification, smaller brain volumes, decreased forebrain myelination per cell, and
decreased cortical cell proliferation and migration, compared with controls.

Performance deficits in a few neurobehavioral tests were observed in one study in offspring of pregnant
mouse dams exposed by inhalation to 2,000 ppm, but not 200 or 400 ppm, for 60 minutes 3 times/day on
GDs 12–17. Performance deficits were not observed in offspring of pregnant rat dams exposed by
inhalation to up to 2,000 ppm for 6 hours/day during gestation. Drinking water exposure during gestation
and lactation at doses of 106 mg/kg/day resulted in changes in postweaning open-field locomotor activity
in rat offspring.
2. RELEVANCE TO PUBLIC HEALTH

Cancer. Human and animal studies generally do not support a concern for the carcinogenicity of toluene. Thirteen human epidemiology studies were located that assessed toluene exposure as a possible risk factor for cancer: five cohort studies of workers exposed predominantly to toluene and eight studies involving subjects exposed to mixtures of solvents including toluene. Cancers of most sites were not significantly associated with toluene exposure in any study, and there was weak consistency in the findings of those studies that did find association of a particular cancer type with toluene exposure. The information from these studies is inadequate to assess the carcinogenic potential of toluene, predominantly because of the lack of consistent findings across the studies and the likelihood that many of the studied groups were exposed to multiple chemicals. The validated animal inhalation bioassays were negative; however, one available oral study showed a nondose-related increase in a variety of tumors. Dermally administered toluene markedly inhibits skin tumorigenesis in the two-stage mouse model utilizing phorbol-12-myristate-13-acetate (PMA) as a promoter. The reduction in tumorigenesis was observed in mice initiated with dermal applications of benzo(a)pyrene or 7,12-dimethylbenz(a)-anthracene. Thus, the data do not support a firm conclusion regarding the carcinogenicity of toluene. As such, the U.S. EPA determined that there is inadequate information to assess the carcinogenic potential of toluene, IARC determined that toluene is not classifiable as to its carcinogenicity in humans (Group 3), and ACGIH determined that toluene is not classifiable as a human carcinogen (A4). The NTP has not considered the carcinogenic potential of toluene.

Major health effects of toluene inhalation in humans and animals and ingestion in animals and the lowest concentrations at which these effects have been observed are shown in Figures 2-1 and 2-2. An estimate of exposure levels posing minimal risk to humans (MRL) are also presented in these figures. An MRL is an estimate of the daily human exposure that is likely to be safe over a certain period of exposure. MRLs are not intended to define clean-up or action levels, but are intended only to serve as a screening tool to help public health professionals decide where to look more closely. Therefore, MRLs are set at levels well below where effects have been observed.

2.3 MINIMAL RISK LEVELS (MRLs)

Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for toluene. An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of exposure. MRLs are based on
### Figure 2-1. Health Effects of Breathing Toluene

<table>
<thead>
<tr>
<th>Effects in Humans</th>
<th>Concentration in Air (ppm)</th>
<th>Effects in Animals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developmental effects(^a) in offspring of women who intentionally inhaled toluene</td>
<td>4,000</td>
<td>Respiratory(^b) and renal effects(^c) after chronic exposure</td>
</tr>
<tr>
<td>Neurological effects(^d) in healthy volunteers after acute exposure</td>
<td>75</td>
<td>Liver effects(^d) after acute, intermediate, or chronic exposure</td>
</tr>
<tr>
<td>Neurological effects(^d) after occupational exposure, respiratory effects(^d) after acute exposure</td>
<td>50</td>
<td>Developmental effects(^d) after gestational exposure</td>
</tr>
<tr>
<td>Neurological effects(^d) in toluene-sensitive subjects after acute exposure</td>
<td>15</td>
<td>Neurological effects(^d) after acute exposure</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>Neurological effects(^d) after intermediate exposure</td>
</tr>
</tbody>
</table>

**Acute MRL:** 2 ppm  
**Chronic MRL:** 1 ppm

---

\(^a\)Birth defects similar to fetal alcohol syndrome  
\(^b\)Nasal lesions  
\(^c\)Nephropathy  
\(^d\)Increased liver weight, induction of hepatic P450 levels, increased serum levels of liver enzymes  
\(^e\)Depressed fetal body weight and delayed skeletal ossification  
\(^f\)Increased locomotor activity  
\(^g\)Impairments in psychomotor testing  
\(^h\)Altered measures of visual and auditory electrophysiology  
\(^i\)Irritation of nose and throat  
\(^j\)Altered sleep behavior  
\(^k\)Impairments in neuropsychological testing
Figure 2-2. Health Effects of Ingesting Toluene

<table>
<thead>
<tr>
<th>Dose (mg/kg/day)</th>
<th>Effects in Animals</th>
</tr>
</thead>
<tbody>
<tr>
<td>650</td>
<td>Developmental effects(a) after gavage exposure during gestation</td>
</tr>
<tr>
<td>625</td>
<td>Renal effects(b) after intermediate gavage exposure</td>
</tr>
<tr>
<td>250</td>
<td>Neurological effects(c) after acute gavage exposure</td>
</tr>
<tr>
<td>106</td>
<td>Neurobehavioral effects(d) after pre- and post-gestational drinking water exposure</td>
</tr>
<tr>
<td>105</td>
<td>Hepatic effects(e) after intermediate drinking water exposure</td>
</tr>
<tr>
<td>84</td>
<td>Immune system effects(f) after intermediate duration exposure in drinking water</td>
</tr>
</tbody>
</table>

* Decreased body weights, delayed ossification, smaller brain volumes, decreased forebrain myelination per cell, and decreased cortical cell proliferation and migration

* Increased kidney weight

* Altered measures of visual electrophysiology

* Increased open-field activity (lack of habituation)

* Increased liver weight

* Diminished immune responses in multiple in vitro immune assays following in vivo exposure
noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure.

Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an example, acute inhalation MRLs may not be protective for health effects that are delayed in development or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis. As these kinds of health effects data become available and methods to assess levels of significant human exposure improve, these MRLs will be revised.

Adverse effects on the nervous system are critical effects of concern from acute, intermediate, or chronic exposure to toluene. Acute exposure is associated with reversible neurological symptoms progressing from fatigue, headaches, and decreased manual dexterity to narcosis with increasing exposure levels. Reversible neurological impairment from acute exposure likely involves the direct interaction of toluene with nervous system membranes. Degenerative changes in white matter regions of the brain have been correlated with the severity of persistent neurological impairment in individuals who abused solvents and have repeatedly inhaled toluene at high exposure levels (4,000–12,000 ppm). Results from studies of groups of occupationally exposed workers suggest that chronic exposure to toluene at lower exposure levels (from about 50 to 200 ppm) can produce subtle changes in neurological functions including cognitive and neuromuscular performance, hearing, and color discrimination. Supporting data come from studies of toluene-exposed animals showing changes in behavior, hearing loss, and subtle changes in brain structure, electrophysiology, and levels of neurotransmitters.

Other effects of concern include immune system effects, liver effects, kidney effects, and developmental effects. Evidence from a few animal studies suggests that repeated exposure to toluene can suppress the immune system, although current data from human studies are limited and inconclusive. Various reports indicate hepatic and renal effects following inhalation and oral exposure to toluene; however, there is little support for irreversible damage to the liver or kidney. Case reports of birth defects in children of mothers who abused toluene during pregnancy suggest that exposure to high levels of toluene may be toxic to the developing fetus. Results from animal studies indicate that toluene is not a teratogenic agent, but can retard fetal growth and skeletal development and adversely influence behavior of offspring at exposure levels that produce maternal toxicity.
Available evidence does not support adverse effects on reproductive performance as a noncancer health effect of concern from toluene exposure.

Issues relevant to children are explicitly discussed in Section 3.7, Children’s Susceptibility and Section 6.6, Exposures of Children.

**Inhalation MRLs**

- An MRL of 2 ppm (7.6 mg/m³) has been derived for acute-duration (14 days or less) inhalation exposure to toluene.

This MRL is based on a study by Little et al. (1999) in which the effects of toluene on human subjects with a history of solvent exposure and adverse reactions to toluene (i.e., clinically sensitive to toluene) were assessed in a battery of neuropsychological tests prior to and after a 20-minute exposure to 15 ppm toluene (see Appendix A). The battery of tests included immediate and delayed prose memory, reaction time, letter cancellations, digit symbol, focal length, and STROOP color and color-word tasks. Statistically significant (p<0.05) impairments were measured in immediate and delayed prose memory (number of items recalled decreased 31%), the digit symbol test (number of correct items decreased 11%), and the letter cancellation test (percent correct decreased 5%) following a 15-minute exposure to 15 ppm toluene, compared with pre-exposure scores. A near-significant 15% increase in reaction time was also observed (p=0.06). No significant difference between pre- and post-exposure values was found for focal length or the STROOP tests. The minimally adverse lowest-observed-adverse-effect level (LOAEL) of 15 ppm was divided by an uncertainty factor of 9 (3 for use of a minimally adverse LOAEL and 3 to account for human variability [a full uncertainty factor of 10 is not necessary as the observed effects were noted in a susceptible/sensitive group of individuals]) to derive the MRL of 2 ppm. More details of the development of this MRL can be found in Appendix A.

- No MRL has been derived for intermediate-duration (15–364 days) inhalation exposure to toluene.

No data were considered suitable for use in deriving an intermediate-duration MRL for inhalation exposures. ATSDR believes that the chronic inhalation MRL would also be protective for intermediate-duration exposures.
• An MRL of 1 ppm (3.8 mg/m³) was derived for chronic-duration (365 days or more) inhalation exposure to toluene.

The chronic inhalation MRL is based on a NOAEL of 45 ppm toluene for neurological effects based on a series of studies by the same group of investigators assessing subjective neurological symptoms, performance on psychomotor tasks, color vision, and hearing in groups of German photogravure printers employed for an average duration of 13.5 years (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002). These studies compared neurological end points in workers with high exposure to toluene (printers, n=106–181) with workers with low exposure to toluene (end-processors, n=86–152). Current toluene air exposure levels for printers and end-processors were 24.6–26 and 3–3.5 ppm, respectively (measured twice yearly from 1996 to 2001). Historical exposure levels for printers prior to 1995 and prior to 1975 were 40 and 140 ppm, respectively. Historical exposure levels for end-processors prior to 1995 and prior to 1975 were 5 and 40 ppm, respectively. Using job history and current exposure and historical exposure levels, individual time-weighted average (TWA) exposure levels were calculated. The average TWA levels for printers and end-processors were calculated to be 45 and 10 ppm for subjects included in analyses by Schäper et al. (2003, 2008), 45 and 9 ppm for subjects included in analyses by Seeber et al. (2004, 2005) and Zupanic et al. (2002), and 43 and 9 ppm for subjects included in analyses by Schäper et al. (2004). Schäper et al. (2003, 2008) did not find any statistically significant differences in audiometric readings from four readings over 5 years in 181 printers, compared with 152 end-processors; Schäper et al. (2004) did not find any differences in color vision assessed 4 times over 5 years in 154 printers, compared with 124 end-processors; and Seeber et al. (2004, 2005) and Zupanic et al. (2002) did not find any increase in subjective neurological complaints or decreased performance in psychomotor tasks in 106–154 printers, compared with 86–124 end-processors. The NOAEL of 45 ppm was adjusted for continuous exposure (45 ppm x 5 days/7 days x 8 hours/24 hours = 10.7 ppm) and was divided by an uncertainty factor of 10 to account for human variability to derive the MRL of 1 ppm.

Most of the data on health effects in humans chronically exposed to toluene come from occupational studies or medical reports of solvent abusers. In both situations, concurrent exposure to other chemicals can limit the usefulness of the data for development of guidelines or standards. In addition, there are other confounding variables, especially in the occupational setting, such as alcohol consumption patterns, employment history, diet, use of medications, noise, and fluctuations in atmospheric toluene levels during different portions of the day, all of which complicate evaluation of dose-response patterns. These complexities were considered in selecting the studies for derivation of the MRL (see Appendix A for more details).
EPA (2005) has recommended a similar chronic RfC of 5 mg/m³ (1.33 ppm) based on the arithmetic mean (34 ppm) of the NOAELs from a subset of the highest quality studies investigating neurological effects in workers occupationally exposed predominantly to toluene (Abbate et al. 1993; Boey et al. 1997; Cavalleri et al. 2000; Eller et al. 1999; Foo et al. 1990; Murata et al. 1993; Nakatsuka et al. 1992; Neubert et al. 2001; Vrca et al. 1995; Zavalic et al. 1998a). ACGIH (2007) has recommended a Threshold Limit Value (TLV) of 20 ppm toluene based on subclinical changes in blue-yellow color vision and the potential for spontaneous abortion in female workers (Campagna et al. 2001; Cavalleri et al. 2000; Ng et al. 1992b). This value is designed to be protective for healthy adult workers exposed 8 hours/day, 5 days/week for up to 45 years. Adjusting the value for a continuous exposure lasting up to 70 years yields a value of 4 ppm (25 ppm x 5 days/7 days x 8 hours/24 hours x 45 years/70 years = 4 ppm). This figure is slightly higher than the current chronic-duration MRL, but does not include an uncertainty factor to protect susceptible populations. Use of an uncertainty factor of 10 (10 for human variability) would arrive at a value to 0.4 ppm, which is slightly lower than the current MRL.

**Oral MRLs**

- An MRL of 0.8 mg/kg has been derived for acute (14 days or less) oral exposure to toluene.

This MRL was based on a LOAEL of 250 mg/kg from a study of FEP wave forms in male Long-Evans rats administered doses of 0, 250, 500, or 1,000 mg/kg toluene by gavage (Dyer et al. 1988). FEP tests were administered 45 minutes later as a test of the ability of the nervous system to process visual information. The amplitude of the N3 peak of the FEP was decreased by toluene exposure at all doses (p<0.0001). This decrease in peak amplitude was not dose-related. Dyer et al. (1988) also carried out a time-course study in which toluene was administered to male Long-Evans rats (16 per group) at doses of 0 and 500 mg/kg by gavage, and FEP tests were performed 4, 8, 16, and 30 hours later. In the time course study, 500 mg/kg also decreased the amplitude of the FEP; at this dose, little change in magnitude of peak N3 depression had occurred 8 hours posttreatment; by 16 hours, recovery was complete. The LOAEL of 250 mg/kg was divided by an uncertainty factor of 300 (3 for use of a minimally adverse LOAEL, 10 for interspecies extrapolation, and 10 for intraspecies variability) to derive the MRL of 0.8 mg/kg. More details of the development of this MRL can be found in Appendix A.
2. RELEVANCE TO PUBLIC HEALTH

- An MRL of 0.2 mg/kg/day has been derived for intermediate-duration (15–364 days) oral exposure to toluene.

This MRL was based on a NOAEL of 22 mg/kg/day from a series of studies evaluating immune endpoints in male CD-1 mice administered toluene in their drinking water for 28 days at concentrations of 0, 5, 22, or 105 mg/kg/day (Hsieh et al. 1989, 1991) or 0, 22, or 84 mg/kg/day (Hsieh et al. 1990a). In Hsieh et al. (1989, 1990a), rats were weighed, sacrificed, and examined for gross pathological lesions at 28 days. Spleen and thymus were weighed and hematology was performed. Spleens were assessed for cellularity, and splenocytes were used in *in vitro* immune assays (mitogen-stimulated lymphocyte proliferation, mixed lymphocyte reaction, IL-2 production assay, and antibody PFC response). Hsieh et al. (1990a) also measured the *in vitro* cell-mediated cytolysis response. In Hsieh et al. (1991), immune function was only assessed using the IL-2 assay in cultured splenocytes. In Hsieh et al. (1989), significantly decreased thymus weight and significantly depressed immune responses were observed in all *in vitro* immune assays at 105 mg/kg/day, compared with controls. IL-2 production and mitogen-stimulated lymphocyte proliferation were also significantly increased at 22 mg/kg/day compared with controls. In Hsieh et al. (1990a), significantly depressed immune responses were observed in the PFC assay and mixed lymphocyte reaction at 84 mg/kg/day. The mixed lymphocyte reaction was also significantly depressed at 22 mg/kg/day. In Hsieh et al. (1991), the IL-2 production assay was significantly depressed at 22 mg/kg/day. Taken together, these studies consistently reported diminished immune responses in multiple *in vitro* immune assays following *in vivo* exposure to 84–105 mg/kg/day in drinking water for 28 days, compared with controls. A couple of immune assays were altered at 22 mg/kg/day, but findings were not consistent between the three Hsieh studies. Additionally, the antibody PFC assay was significantly altered at 84 and 105 mg/kg/day, but not at 22 mg/kg/day (Hsieh et al. 1989, 1990a). The PFC *in vitro* assay is considered the most predictive assay of impaired immune function (Luster et al. 1992). Collectively, results from these studies support a NOAEL of 22 mg/kg/day for immune depression. The NOAEL of 22 mg/kg/day was divided by an uncertainty factor of 100 (10 for interspecies extrapolation and 10 for intraspecies variability) to derive the MRL of 0.2 mg/kg/day. More details of the development of this MRL (including consideration of other effects as bases of the intermediate-duration oral MRL) can be found in Appendix A.

- No MRL was derived for chronic-duration (365 days or more) oral exposures because there were no suitable data for toluene.

EPA (2005) has recommended a chronic oral reference dose (RfD) of 0.08 mg/kg/day based on a benchmark dose limit (BMDL) of 238 mg/kg/day for increased kidney weight in male rats from the
13-week NTP (1990) study. The derivation included an uncertainty factor of 3,000 (10 for interspecies extrapolation, 10 for intraspecies variability, 10 for use of a subchronic study, and 3 for database uncertainties). If the UF for subchronic to chronic is removed, the value is 0.8 mg/kg/day, which is well within an order of magnitude of the derived intermediate MRL of 0.2 mg/kg/day.
This page is intentionally blank.
3. HEALTH EFFECTS

3.1 INTRODUCTION

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of toluene. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.

A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.

3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE

To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).

Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a considerable amount of judgment may be required in establishing whether an end point should be classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be insufficient data to decide whether the effect is indicative of significant dysfunction. However, the Agency has established guidelines and policies that are used to classify these end points. ATSDR believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is considered to be important because it helps the users of the profiles to identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these
effects to human health.

The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and
figures may differ depending on the user's perspective. Public health officials and others concerned with
appropriate actions to take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.

A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.

3.2.1 **Inhalation Exposure**

Adverse effects on the nervous system are critical effects of concern from inhalation exposure to toluene
as evidenced by results from studies of workers acutely or chronically exposed to toluene in workplace
air, studies of volunteers under controlled acute exposure conditions, and studies of chronic solvent
abusers predominantly exposed to toluene. Observed effects include reversible neurological symptoms
from acute exposure progressing from fatigue, headache, and decreased manual dexterity to narcosis with
increasing exposure level, degenerative changes in white matter in chronic solvent abusers, and subtle
changes in neurological functions including cognitive and neuromuscular performance, hearing, and color
discrimination in chronically exposed workers. Studies of toluene-exposed animals provide supporting
data showing changes in behavior, hearing loss, and subtle changes in brain structure, brain
electrophysiology, and brain chemistry. Case reports of birth defects and developmental delays in
children of mothers who abused solvents, including toluene, during pregnancy suggest that exposure to
high levels of toluene may be toxic to the developing fetus. A number of developmental toxicity studies
with rats, mice, and rabbits exposed to airborne toluene indicate that toluene was not a developmental
toxicant at levels below those inducing maternal toxicity. At doses that impaired maternal body weight
gain, developmental effects observed included retarded fetal growth and skeletal development and altered
development of behavior in offspring. At high concentrations modeling solvent abuse, increased
malformations and fetal death were also observed.
3.2.1.1 Death

Limited data are available on toluene-associated deaths due to solvent abuse or occupational exposure and these studies do not indicate exposure concentrations. Paterson and Sarvesvaran (1983) reported on a teenager who died following an episode of glue sniffing. In Virginia, 39 deaths were attributed to inhalant abuse from 1987 to 1996 (Bowen et al. 1999a). The majority of deaths (70%) occurred at ≤22 years of age, and males accounted for 95% of all inhalant abuse deaths; however, only two deaths were attributed to intentional toluene inhalation. In Japan, a man died of cardiac arrest after painting a bathroom using a sealer containing 65% toluene (Shibata et al. 1994) and a woman died of adrenal hemorrhage after sniffing thinner containing 67% toluene (Kamijo et al. 1998). In Great Britain, approximately 80 deaths per year have been associated with solvent abuse (Anderson et al. 1985). Approximately half these cases were attributed to cardiac arrhythmias, central nervous system depression, asphyxia, and hepatic and renal failure (Anderson et al. 1982). Among the 52 cases with a toxicological report, 42 mentioned toluene (Anderson et al. 1982). Toxicokinetic extrapolation from blood toluene concentration in a dead patient was used to estimate that 1 hour of exposure to 1,800–2,000 ppm toluene may be fatal to humans (Hobara et al. 2000a, 2000b).

There are only a few animal inhalation studies that have examined the lethality of toluene, and there is evidence from an intermediate-duration study suggesting that mice may be more sensitive than rats. An inhalation LC50 value (concentrations causing death in of 50% of the animals) of 5,320 ppm has been reported for mice (Svirbely et al. 1943). In 14 to 15 week studies, exposure to 3,000 ppm toluene for 6.5 hours/day, 5 days/week, caused 80% mortality in male rats, 60% mortality in male mice, and 100% mortality in female mice, but no deaths among female rats (NTP 1990). Death also occurred among female mice exposed to 625 (10%), 1,250 (10%), and 2,500 (40%) ppm toluene (NTP 1990).

LOAEL values for deaths in the NTP (1990) study and the LC50 from the Svirbely et al. (1943) report are recorded in Table 3-1 and plotted in Figure 3-1.

3.2.1.2 Systemic Effects

Data are available pertaining to respiratory, cardiovascular, hematological, musculoskeletal, hepatic, renal, endocrine and ocular effects in humans and animals after inhalation exposure to toluene. In addition, there are data on gastrointestinal, dermal, body weight, and other systemic effects in animals after inhalation exposure to toluene. All systemic effects are discussed below. The highest NOAEL
Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACUTE EXPOSURE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Mouse (Swiss-Webster)</td>
<td>7 hr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Human</td>
<td>6 hr</td>
<td>Resp</td>
<td>40 M</td>
<td>100 M (irritation of the nose)</td>
<td>Andersen et al. 1983</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ocular</td>
<td></td>
<td>40 M</td>
<td></td>
<td>100 M (irritation of the eyes)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Human</td>
<td>6.5 hr (Occup)</td>
<td>Resp</td>
<td>100 M (irritation of the nose and throat)</td>
<td>Baelum et al. 1985</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ocular</td>
<td></td>
<td>100 M</td>
<td></td>
<td>(irritation of the eyes)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Human</td>
<td>7-8 hr</td>
<td>Resp</td>
<td>200 M (mild throat irritation)</td>
<td>Carpenter et al. 1944</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ocular</td>
<td></td>
<td>200 M</td>
<td></td>
<td>(eye irritation)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Human</td>
<td>2 hr</td>
<td>Resp</td>
<td>1862 M</td>
<td>1862 M (sinus tachycardia)</td>
<td>Meulenbelt et al. 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardio</td>
<td></td>
<td></td>
<td></td>
<td>1862 M (sinus tachycardia)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemato</td>
<td></td>
<td></td>
<td></td>
<td>1862 M (liver enlargement)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatic</td>
<td></td>
<td></td>
<td></td>
<td>1862 M (ocular irritation)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ocular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL (ppm)</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------------</td>
<td>-------------</td>
<td>-----------</td>
</tr>
<tr>
<td>6</td>
<td>Human</td>
<td>3 hr</td>
<td>Resp</td>
<td>1862 M</td>
<td></td>
<td>1862 M (sinus bradycardia)</td>
<td></td>
<td>Meulenberg et al. 1990</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td></td>
<td>1862 M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td></td>
<td>1862 M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td></td>
<td>1862 M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Human</td>
<td>4.5 hr</td>
<td>Resp</td>
<td></td>
<td>50 M</td>
<td>(irritation of the throat)</td>
<td></td>
<td>Muttray et al. 2005</td>
</tr>
<tr>
<td>8</td>
<td>Human</td>
<td>6.5 hr</td>
<td>Renal</td>
<td></td>
<td>102 M</td>
<td></td>
<td></td>
<td>Nielsen et al. 1985</td>
</tr>
<tr>
<td>9</td>
<td>Human</td>
<td>2 hr</td>
<td>Resp</td>
<td></td>
<td>48 M</td>
<td>(mucous membrane irritation)</td>
<td></td>
<td>Orbaek et al. 1998</td>
</tr>
<tr>
<td>10</td>
<td>Human</td>
<td>2 hr</td>
<td>Resp</td>
<td></td>
<td>48 F</td>
<td>(mucous membrane irritation)</td>
<td></td>
<td>Osterberg et al. 2003</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td>11</td>
<td>Human</td>
<td>6 hr/d</td>
<td>Resp</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td>Rahill et al. 1996</td>
</tr>
<tr>
<td>12</td>
<td>Human</td>
<td>3 hr</td>
<td>Resp</td>
<td>800</td>
<td></td>
<td></td>
<td></td>
<td>von Oettingen et al. 1942</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>800</td>
<td>Cardio</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>800</td>
<td>Hemato</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rat (Sprague-Dawley)</td>
<td>3 d 6 hr/d</td>
<td>Endocr</td>
<td>500 M (increased serum corticosterone)</td>
<td>Andersson et al. 1980</td>
<td></td>
<td>Endpoints assessed: Serum levels of corticosterone, prolactin, growth hormone, FSH, and LH.</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Rat (Sprague-Dawley)</td>
<td>5 d 6 hr/d</td>
<td>Endocr</td>
<td>1000 M</td>
<td>Andersson et al. 1980</td>
<td></td>
<td>Endpoints assessed: Serum levels of corticosterone, prolactin, growth hormone, FSH, and LH.</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------</td>
<td>-----------------------------------</td>
<td>------------</td>
<td>-------------</td>
<td>--------------------------</td>
<td>---------------</td>
<td>----------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>15</td>
<td>Rat (Sprague-Dawley)</td>
<td>3 d 6 hr/d</td>
<td>Endocr</td>
<td></td>
<td>80 M (increased serum prolactin)</td>
<td></td>
<td>Andersson et al. 1983a</td>
<td>Endpoints assessed: Serum corticosterone, prolactin, growth hormone, FSH, and LH.</td>
</tr>
<tr>
<td>16</td>
<td>Rat (Wistar)</td>
<td>7 d 4 hr/d</td>
<td>Endocr</td>
<td></td>
<td>1500 M (18% increase in adrenal weight and increased adrenocortical cell size; increased serum ACTH and corticosterone)</td>
<td></td>
<td>Gotohda et al. 2005</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Rat (Wistar)</td>
<td>7 d 4 hr/d</td>
<td>Hepatic</td>
<td></td>
<td>3000 M (increase biochemical markers of liver fibrosis)</td>
<td></td>
<td>Gotohda et al. 2009</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Rat (Wistar)</td>
<td>Gd 7-20 6 hr/d</td>
<td>Endocr</td>
<td></td>
<td>1500 F (reduced maternal plasma corticosterone levels)</td>
<td></td>
<td>Hougaard et al. 2003</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Rat (Fischer-344) d</td>
<td>6 h/d, for 3 or 7 d</td>
<td>Endocr</td>
<td></td>
<td>1000 M (significantly increased serum corticosterone)</td>
<td></td>
<td>Little et al. 1998</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>------------------</td>
<td>--------------</td>
<td>-----------</td>
<td>-------------</td>
</tr>
<tr>
<td>20</td>
<td>Rat (Sprague-Dawley)</td>
<td>48 hr</td>
<td>Hemato</td>
<td>2000 M</td>
<td>(increased hematocrit and blood glucose)</td>
<td>Tahti et al. 1983</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>2000 M</td>
<td>(increased serum ALT and AST)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>2000 M</td>
<td>(body weight decrease 10%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Rat</td>
<td>7 d 8 hr/d</td>
<td>Hepatic</td>
<td>795 F</td>
<td>(increased liver weight 12%, increased smooth and rough endoplasmic reticulum)</td>
<td>Ungvary et al. 1982</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Rat (Wistar)</td>
<td>6 hr</td>
<td>Hepatic</td>
<td>4000</td>
<td>(increased CYP2E1 and decreased CYP 2 C11 in liver)</td>
<td>Wang et al. 1996</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Mouse</td>
<td>7 d 8 hr/d</td>
<td>Hepatic</td>
<td>795 F</td>
<td>(increased liver weight 11% and cytochrome P-450 30%)</td>
<td>Ungvary et al. 1982</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Dog</td>
<td>1 hr</td>
<td>Hemato</td>
<td>200</td>
<td>(decreased leukocytes)</td>
<td>Hobara et al. 1984a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/ Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td>25</td>
<td>Dog</td>
<td>4 hr</td>
<td>Hemato</td>
<td>700</td>
<td></td>
<td>(decreased leukocytes)</td>
<td></td>
<td>Hobara et al. 1984a</td>
</tr>
<tr>
<td>26</td>
<td>Rabbit</td>
<td>7 d 8 hr/d</td>
<td>Hepatic</td>
<td>795 F</td>
<td></td>
<td>(increased liver weight 14%, cytochrome P-450-35%, and cytochrome b5-25%)</td>
<td></td>
<td>Ungvary et al. 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Rat (Sprague-Dawley) Gd 7-17 6 hr/d</td>
<td></td>
<td>600 F</td>
<td>(significant decrease thymus weights in dams)</td>
<td></td>
<td></td>
<td></td>
<td>Ono et al. 1995</td>
</tr>
<tr>
<td>28</td>
<td>Mouse (CD-1)</td>
<td>3 hr</td>
<td>1 F</td>
<td>2.5 F</td>
<td></td>
<td>(decrease to mortality from infection with S. zooepidemicus)</td>
<td></td>
<td>Aranyi et al. 1985</td>
</tr>
<tr>
<td>Measurment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Human</td>
<td>6 hr</td>
<td></td>
<td>40 M</td>
<td></td>
<td>(headaches, dizziness, intoxication)</td>
<td></td>
<td>Andersen et al. 1983</td>
</tr>
<tr>
<td>30</td>
<td>Human</td>
<td>6.5 hr (Occup)</td>
<td></td>
<td>100 M</td>
<td></td>
<td>(intoxication, dizziness, decreased manual performance and color perception)</td>
<td></td>
<td>Baelum et al. 1985</td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Human</td>
<td>8 hr</td>
<td></td>
<td></td>
<td></td>
<td>100</td>
<td></td>
<td>Dick et al. 1984</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(impaired performance on visual-vigilence task)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Human</td>
<td>7 hr</td>
<td></td>
<td></td>
<td></td>
<td>75</td>
<td></td>
<td>Echeverria et al. 1991</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(dose-related impairment of performance on recognition, pattern memory, and one-hole test results)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Human</td>
<td>20 min</td>
<td></td>
<td>100 M</td>
<td></td>
<td>100 M</td>
<td>300 M</td>
<td>Gamberale and Hultengren 1972</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(increased simple and choice reaction time)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Human</td>
<td>4 hr</td>
<td></td>
<td>80 M</td>
<td></td>
<td></td>
<td></td>
<td>Iregren 1986</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Human</td>
<td>4 hr</td>
<td></td>
<td>40 F</td>
<td></td>
<td></td>
<td></td>
<td>Lammers et al. 2005a</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endpoints evaluated: choice reaction time, simple reaction time, color-word vigilance, or memory reproduction.
Table 3-1  Levels of Significant Exposure to Toluene - Inhalation  (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>a</td>
<td>Human</td>
<td>4 hr 30 min on, 30 min off</td>
<td></td>
<td>110 M</td>
<td></td>
<td></td>
<td>Lammers et al. 2005a</td>
<td>Endpoints evaluated: battery of neurobehavioral tasks, sleep quality questionnaire.</td>
</tr>
<tr>
<td>37</td>
<td>Human</td>
<td>20 min</td>
<td></td>
<td>15 b</td>
<td></td>
<td></td>
<td>Little et al. 1999</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Human</td>
<td>28-41 min (Occup)</td>
<td></td>
<td>332 M</td>
<td></td>
<td></td>
<td>Muttray et al. 1999</td>
<td>Endpoint evaluated: color vision before and after cleaning a print machine with toluene.</td>
</tr>
<tr>
<td>39</td>
<td>Human</td>
<td>4.5 hr</td>
<td></td>
<td>50 M</td>
<td></td>
<td></td>
<td>Muttray et al. 2005</td>
<td>Endpoints evaluated: subjective symptoms, pupillographic sleepiness test.</td>
</tr>
<tr>
<td>40</td>
<td>Human</td>
<td>4 hr</td>
<td></td>
<td>80 M</td>
<td></td>
<td></td>
<td>Olson et al. 1985</td>
<td>Endpoints evaluated: subjective symptoms, simple reaction time, choice reaction time, and memory-reproduction.</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>------------------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>41</td>
<td>Human</td>
<td>2 hr</td>
<td></td>
<td>48 M</td>
<td></td>
<td>(self-reported fatigue in individuals with toxic encephalopathy)</td>
<td>Orbaek et al. 1998</td>
<td>Endpoints assessed: Subjective symptoms in healthy subjects and subjects with toxic encephalopathy.</td>
</tr>
<tr>
<td>42</td>
<td>Human</td>
<td>2 hr</td>
<td></td>
<td>48 M</td>
<td></td>
<td></td>
<td>Osterberg et al. 2000</td>
<td>Endpoints assessed: Attention and motor speed in healthy subjects and subjects with toxic encephalopathy.</td>
</tr>
<tr>
<td>43</td>
<td>Human</td>
<td>2 hr</td>
<td></td>
<td>48 F</td>
<td></td>
<td>(self-reported fatigue in individuals with multiple chemical sensitivity)</td>
<td>Osterberg et al. 2003</td>
<td>Endpoints assessed: Subjective symptoms and attention and motor speed in healthy subjects and subjects with MCS.</td>
</tr>
<tr>
<td>44</td>
<td>Human</td>
<td>6 hr</td>
<td></td>
<td>100</td>
<td></td>
<td>(decreased performance on neuropsychological tests)</td>
<td>Rahill et al. 1996</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Human</td>
<td>3 or 8 hr</td>
<td></td>
<td>100</td>
<td>200</td>
<td>(drowsiness, headache, confusion, weakness)</td>
<td>von Oettingen et al. 1942</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>NOAEL (ppm)</td>
<td>LOAEL Less Serious (ppm)</td>
<td>LOAEL Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>-------------</td>
<td>-------------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>---------------</td>
<td>----------</td>
</tr>
<tr>
<td>46</td>
<td>Monkey (Cynomolgus)</td>
<td>50 min</td>
<td>1000 F</td>
<td>2000 F (cognitive and motor skills impaired)</td>
<td>3000 F (overt signs of neurotoxicity)</td>
<td>Taylor and Evans 1985</td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Rat</td>
<td>8 hr</td>
<td></td>
<td>900 M (altered patterns of sleep and wakefulness)</td>
<td></td>
<td>Arito et al. 1988</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Rat (Long- Evans)</td>
<td>1-4 hr</td>
<td></td>
<td>1000 M (decreased F2 amplitude in VEPs)</td>
<td></td>
<td>Boyes et al. 2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Rat (Fischer-344 (W)</td>
<td>2 hr</td>
<td></td>
<td>110 M (decreased REM sleep)</td>
<td></td>
<td>Ghosh et al. 1989</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Rat (Fischer-344)</td>
<td>2 hr</td>
<td></td>
<td>110 M (changes in sleep pattern)</td>
<td></td>
<td>Ghosh et al. 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Rat (DA/HAN)</td>
<td>4 hr or 5d, 3 hr/d</td>
<td></td>
<td>100 M (nystagmus and altered opticokinetic response)</td>
<td></td>
<td>Hogie et al. 2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Rat (Wistar)</td>
<td>30 min</td>
<td></td>
<td>1000 M (impaired learning and memory, decline in conditioned avoidance response)</td>
<td></td>
<td>Huerta-Rivas et al. 2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>-------------</td>
<td>-------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Rat (Sprague-Dawley)</td>
<td>10 d 16 hr/d</td>
<td>100 M (diminished auditory response)</td>
<td>Johnson 1992</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Rat (Sprague-Dawley)</td>
<td>2 wk 5 d/wk 16 hr/d</td>
<td>100 M (diminished auditory response)</td>
<td>Johnson et al. 1988</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Rat</td>
<td>20 min</td>
<td>1000 (increased locomotor activity)</td>
<td>Kim et al. 1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Rat (Wistar)</td>
<td>4 hr</td>
<td>125 M (a temporary decline in conditioned avoidance response)</td>
<td>Kishi et al. 1988</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Rat (Fischer-344)</td>
<td>6 h/d, for 3 or 7 d</td>
<td>1000 M (decreased GFAP in thalamus and increased corticosterone)</td>
<td>Little et al. 1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Rat (Wistar)</td>
<td>10 d 6 hr/d</td>
<td>1500 M</td>
<td>Lund and Kristiansen 2008</td>
<td>Endpoints examined: brainstem auditory responses, distortion product otoacoustic emissions.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Route</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>59</td>
<td>Rat (CD)</td>
<td>4 hr</td>
<td></td>
<td>810 M</td>
<td>1660 M</td>
<td>3100 M (overt signs of neurotoxicity)</td>
<td>Mullin and Krivanek 1982</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Rat (Fischer-344)</td>
<td>30 min</td>
<td></td>
<td></td>
<td>500 M</td>
<td>(changes in flash-evoked and somatosensory-evoked potentials)</td>
<td>Rebert et al. 1989b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>Rat</td>
<td>4 hr</td>
<td></td>
<td></td>
<td>1000 M</td>
<td>(sleep pattern disturbances- reduced slow wave sleep and increased paradoxical phase)</td>
<td>Takeuchi and Hisanaga 1977</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>Rat</td>
<td>2-4 hr</td>
<td></td>
<td></td>
<td>480</td>
<td>(decreased performance in rewarded task)</td>
<td>Wood et al. 1983</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>Mouse CFW (ChasRiver Swiss) albino</td>
<td>30 min</td>
<td></td>
<td>250</td>
<td>500</td>
<td>(increased locomotor activity)</td>
<td>Bowen and Balster, 1998</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/ Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>--------------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>Mouse (CFW)</td>
<td>30 min</td>
<td></td>
<td>1000</td>
<td>2000 M (decreased anxiety)</td>
<td>Bowen et al. 1996</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>Mouse (Multiple)</td>
<td>30 min</td>
<td></td>
<td></td>
<td>100 M (increased locomotor activity)</td>
<td>Bowen et al. 2010</td>
<td>Balb/CBY.J, C57BL/6J, and DBA/2J showed effects at identified LOAEL; Swiss Webster mice showed similar effects at higher concentrations.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>Mouse (C57BL/6N)</td>
<td>5 d 72 min/d</td>
<td></td>
<td>100</td>
<td>1000 M (increased locomotor activity)</td>
<td>Bushnell et al. 1985</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>Mouse (C57BL/6N)</td>
<td>30 min</td>
<td></td>
<td>1000</td>
<td>2000 M (increased locomotor activity)</td>
<td>Conti et al. 2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>Mouse (Swiss-Webster)</td>
<td>30 min</td>
<td></td>
<td>500</td>
<td>1000 M (increased nociception)</td>
<td>Cruz et al. 2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Mouse (CBA/CA; C57BL/6J)</td>
<td>7 d 12 hr/d</td>
<td></td>
<td>1000 F</td>
<td>(accelerated hearing loss in genetically predisposed mice)</td>
<td>Li et al. 1992</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1  Levels of Significant Exposure to Toluene - Inhalation

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL Less Serious (ppm)</th>
<th>LOAEL Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>70</td>
<td>Mouse (129/Sv-ter)</td>
<td>30 min</td>
<td></td>
<td></td>
<td>1000 M (increased locomotor activity)</td>
<td></td>
<td>Lopez-Rubalcava and Cruz 2000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>Mouse ddy</td>
<td>8 hr</td>
<td></td>
<td>500 M</td>
<td></td>
<td></td>
<td>Matsuoka et al. 1997</td>
<td></td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>Mouse (Swiss-Webster)</td>
<td>30 min</td>
<td></td>
<td>500 M</td>
<td>1000 (increased nociception)</td>
<td></td>
<td>Paez-Martinez et al. 2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>Mouse (Swiss-Webster)</td>
<td>7 d 30 min/d</td>
<td></td>
<td>1000 M</td>
<td>2000 M (increased locomotor activity)</td>
<td></td>
<td>Tomaszycki et al. 2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>Mouse (CD-1)</td>
<td>6x 1 hr/x</td>
<td></td>
<td>300 M</td>
<td>560 M (increased activity)</td>
<td></td>
<td>Wood and Colotla 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>Gn Pig (pigmented)</td>
<td>5 d 8 hr/d</td>
<td></td>
<td>250 (transient mid- and high-frequency hearing loss)</td>
<td></td>
<td>McWilliams et al. 2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>Other</td>
<td>10 d 8 or 12 hr/d</td>
<td></td>
<td>2000</td>
<td></td>
<td></td>
<td>Davis et al. 2002</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 3. HEALTH EFFECTS

**TOLUENE**

---

*Endpoints examined: GFAP, c-jun, and c-fos mRNA levels in cerebrum.*

---

***DRAFT FOR PUBLIC COMMENT***
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>77</td>
<td>Human</td>
<td>3 hr</td>
<td></td>
<td></td>
<td></td>
<td>50</td>
<td>(altered LH secretion)</td>
<td>Luderer et al. 1999</td>
</tr>
<tr>
<td>78</td>
<td>Rat (Crl:CD (SD) BR VAF/Plus)</td>
<td>Gd 6-15 6 hr/d</td>
<td></td>
<td>3000 F</td>
<td></td>
<td></td>
<td></td>
<td>API 1991; Roberts et al. 2007 Pregnancy outcomes examined.</td>
</tr>
<tr>
<td>79</td>
<td>Rat (Crl:CD BR VAF/Plus)</td>
<td>Gd 6-15 6 hr/d</td>
<td></td>
<td>3500 F</td>
<td></td>
<td>5000 F (increased post-implantation loss; total fetal resorption in 6/9 dams)</td>
<td>API 1992</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>Rat (Wistar)</td>
<td>Gd 7 - 20 6 hr/d</td>
<td></td>
<td>1800 F</td>
<td></td>
<td></td>
<td>Dalggaard et al. 2001 Pregnancy outcomes examined.</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>Rat (Wistar)</td>
<td>Gd 7-20 6 hr/d</td>
<td></td>
<td>1500 F</td>
<td></td>
<td></td>
<td>Hougaard et al. 2003; Ladefoged et al. 2004 Pregnancy outcomes examined.</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 7-17 6 hr/d</td>
<td></td>
<td>2000 F</td>
<td></td>
<td></td>
<td>Ono et al. 1995 Pregnancy outcomes examined.</td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-20 6 hr/d</td>
<td></td>
<td>1500 F</td>
<td></td>
<td></td>
<td>Saillenfait et al. 2007 Pregnancy outcomes examined.</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>----------------------------------</td>
<td>-------------</td>
<td>-------</td>
<td>-------------------</td>
<td>-------------</td>
<td>----------</td>
<td>---------------</td>
</tr>
<tr>
<td>85</td>
<td>Rat (Wistar)</td>
<td>7 d 8 hr/d</td>
<td>3000 F</td>
<td></td>
<td>(structural variations in antral follicles in ovary)</td>
<td></td>
<td>Tap et al. 1996</td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>Rat (Wistar)</td>
<td>Gd 9-21 6 hr/d</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td>Thiel and Chahoud 1997</td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>Mouse (CD-1)</td>
<td>Gd 7-16 7 hr/d</td>
<td>400 F</td>
<td></td>
<td></td>
<td></td>
<td>Courtney et al. 1986</td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>Mouse (CD-1)</td>
<td>Gd 12-17 3x/d 60 min</td>
<td>2000 F</td>
<td></td>
<td></td>
<td></td>
<td>Jones and Balster, 1997</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>Rabbit</td>
<td>Gd 6-18 6 hr/d</td>
<td>500 F</td>
<td></td>
<td></td>
<td></td>
<td>Klimisch et al. 1992</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>Rabbit</td>
<td>Gd 7-20 24 hr/d</td>
<td>133 F</td>
<td>266</td>
<td>(4/8 dams aborted)</td>
<td></td>
<td>Ungvary and Tatrai 1985</td>
<td></td>
</tr>
<tr>
<td>Developmental</td>
<td>Rat (CRL:COBS CD (SD) BR)</td>
<td>Gd 6-15 6 hr/d</td>
<td>400</td>
<td></td>
<td></td>
<td></td>
<td>API 1978</td>
<td></td>
</tr>
</tbody>
</table>

Endpoints examined: number of implantation sites, live and dead fetuses, and resorptions; fetuses were weighed and examined for external malformations.
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>92</td>
<td>Rat (Crl:CD (SD) BR VAF/Plus)</td>
<td>Gd 6-15 6 hr/d</td>
<td>1500</td>
<td>3000</td>
<td>Decreased fetal weight and increased incidence of fetuses with unossified sternebrae)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>93</td>
<td>Rat (Crl:CD BR VAF/Plus)</td>
<td>Gd 6-15 6 hr/d</td>
<td>2000</td>
<td>3500</td>
<td>(20% decrease in fetal body weight, total absorption at higher exposure levels)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-20 2x/d 30 min</td>
<td>8000</td>
<td>12000</td>
<td>(increased number of litters with malformed, runted, or dead pups)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-20 2x/day 15 min</td>
<td>8000</td>
<td>12000</td>
<td>(decreased pup body weight, increased number of litters with malformed, runted, or dead pups, impaired negative geotaxis in offspring)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>96</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-20 2x/d 15 min</td>
<td>System</td>
<td>8000</td>
<td>12000</td>
<td>(decreased pup birth weight; decreased sensitivity to amphetamine-induced locomotion in males on PND28)</td>
<td>Bowen et al. 2007</td>
<td>Endpoints examined: pup weight on Ppd 1 and 21, open-field activity on Ppd 22, 42, and 63, amphetamine-induced locomotion on Ppd 28.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-20 2x/day 30 min</td>
<td>System</td>
<td>8000</td>
<td>12000</td>
<td>(decreased fetal weight and length, decreased placental weight)</td>
<td>Bowen et al. 2009a</td>
<td>Endpoints examined: pup weight on Ppd 1 and 21, open-field activity on Ppd 22, 42, and 63, amphetamine-induced locomotion on Ppd 28.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-20 2x/d 15 min</td>
<td>System</td>
<td>8000</td>
<td>12000</td>
<td>(altered reward-seeking behavior and increased impulsivity in offspring)</td>
<td>Bowen et al. 2009b</td>
<td>Endpoints examined: pup weight on Ppd 1 and 21, open-field activity on Ppd 22, 42, and 63, amphetamine-induced locomotion on Ppd 28.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Rat (Wistar)</td>
<td>Gd 7 - 20 6 hr/d</td>
<td>System</td>
<td>1800 M</td>
<td></td>
<td>(decreased neonatal weight, increased apoptosis in cerebral granule layer of cerebellum at Ppd 21)</td>
<td>Dalgaard et al. 2001</td>
<td>Endpoints examined: pup weight, external malformations, paired testes weight and histopathology, brain weight, and brain apoptosis.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1  Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>Rat (Wistar)</td>
<td>Gd 7-20 6 hr/d</td>
<td></td>
<td>1500</td>
<td>(reduced pup birth weight)</td>
<td></td>
<td>Hougaard et al. 2003</td>
<td></td>
<td>No other developmental endpoints were examined.</td>
</tr>
<tr>
<td>101</td>
<td>Rat CFY</td>
<td>Gd 1-8, 24 hr/d</td>
<td></td>
<td>399</td>
<td>(increased incidence of fetuses with skeletal retardation)</td>
<td>399 F (5/14 dams died)</td>
<td>Hudak and Ungvary 1978</td>
<td></td>
<td></td>
</tr>
<tr>
<td>102</td>
<td>Rat CFY</td>
<td>Gd 9-14, 24 hr/d</td>
<td></td>
<td>399</td>
<td>(increased incidence of fetal skeletal anomalies)</td>
<td></td>
<td>Hudak and Ungvary 1978</td>
<td></td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-20 2x/day 15 min</td>
<td></td>
<td>8000</td>
<td>12000 (decreased pup birth weight)</td>
<td></td>
<td>Jarosz et al. 2008</td>
<td></td>
<td>Endpoints examined: pup weight on Ppd 1 adn 30, metabolism in offspring (energy expenditure, respiratory quotient, body fat content).</td>
</tr>
<tr>
<td>104</td>
<td>Rat (Wistar)</td>
<td>Gd 7-20 8 hr/d</td>
<td></td>
<td>1500</td>
<td>(reduced postnatal growth, increased apoptosis in the cerebellum of offspring)</td>
<td></td>
<td>Ladefoged et al. 2004</td>
<td></td>
<td>Endpoints examined: pup weight Ppd 1, 7, 23, external malformations, spatial learning in PNW5 female, brain apoptosis on Ppd 6, 22, 24, 27.</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
</tr>
<tr>
<td>105</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 7-17 6 hr/d</td>
<td></td>
<td>2000</td>
<td></td>
<td></td>
<td></td>
<td>Ono et al. 1995</td>
<td>Dams sacrificed on GD20; standard developmental endpoints assessed.</td>
</tr>
<tr>
<td>106</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 7-17 6 hr/d</td>
<td></td>
<td>600</td>
<td>2000</td>
<td>(decreased pup weight)</td>
<td></td>
<td>Ono et al. 1995</td>
<td>Endpoints examined: pup weight, growth, dev't, survival, reflex dev't Ppd 6-10, Pnw 4 neurobehavior, and Ppd 21 and 56 hemato, biochem, and organ wt.</td>
</tr>
<tr>
<td>107</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-20 6 hr/d</td>
<td></td>
<td>500</td>
<td>1500</td>
<td>(decreased fetal weight)</td>
<td></td>
<td>Saillenfait et al. 2007</td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>Rat (Wistar)</td>
<td>Gd 9-21 6 hr/d</td>
<td></td>
<td>600</td>
<td>1000</td>
<td>(decreased pup weight and delayed vaginal opening)</td>
<td>1200 (significantly increased postnatal/preweaning mortality in offspring)</td>
<td>Thiel and Chahoud 1997</td>
<td>Endpoints examined: pup weight, survival, development, ontogeny of reflexes, neurobehavior, and F1 mating and fertility.</td>
</tr>
<tr>
<td>109</td>
<td>Mouse (CD-1)</td>
<td>Gd 7-16 7 hr/d</td>
<td></td>
<td>200</td>
<td></td>
<td>(increased number of litters with fetuses with dilated renal pelvis)</td>
<td></td>
<td>Courtney et al. 1986</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/ Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>--------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>Mouse CFLP</td>
<td>Gd 6-13, 24 hr/d</td>
<td></td>
<td>133</td>
<td>(decreased fetal body weight)</td>
<td>Hudak and Ungvary 1978</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>Mouse (CD-1)</td>
<td>Gd 12-17 3x/d 60 min</td>
<td></td>
<td>400</td>
<td>2000</td>
<td>Jones and Balster, 1997</td>
<td>Endpoints examined: pup weight, growth, reflex ontogeny, neurobehavior.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>Mouse</td>
<td>Gd 6-15 3-4 hr/d</td>
<td></td>
<td>133</td>
<td>266</td>
<td>Ungvary and Tatrai 1985</td>
<td>Endpoints examined: pup weight, growth, reflex ontogeny, neurobehavior.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>113</td>
<td>Rabbit</td>
<td>Gd 6-18 6 hr/d</td>
<td></td>
<td>500</td>
<td></td>
<td>Klimisch et al. 1992</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>114</td>
<td>Rabbit</td>
<td>Gd 7-20 14 d 24 hr/d</td>
<td></td>
<td>133 F</td>
<td>266 F (4/8 does aborted)</td>
<td>Ungvary and Tatrai 1985</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INTERMEDIATE EXPOSURE**

**Death**

| 115          | Rat (Fischer- 344) | 15 wk 5 d/wk 6.5 hr/d |        | 3000 M (8/10 died) | NTP 1990 |
| 116          | Mouse (B6C3F1)    | 14 wk 5 d/wk 6.5 hr/d |        | 3000 M (6/10 died) | NTP 1990 |
### Table 3-1  Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>117</td>
<td>Human</td>
<td>2-14 mo 8 hr/d (Occup)</td>
<td>Hepatic</td>
<td>167 F</td>
<td></td>
<td></td>
<td>Seiji et al. 1987</td>
<td></td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>Rat (CD)</td>
<td>95 d 7 d/wk 6 hr/d</td>
<td>Resp</td>
<td>2000</td>
<td></td>
<td></td>
<td>API 1985; Roberts et al. 2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Rat (Fischer- 344)</td>
<td>42 d 5 d/wk 6 hr/d</td>
<td>Bd Wt</td>
<td>1000 M</td>
<td></td>
<td></td>
<td>API 1997</td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>Rat (Long- Evans)</td>
<td>13 wk 5 d/wk 6 hr/d</td>
<td>Bd Wt</td>
<td>1000 M</td>
<td></td>
<td></td>
<td>Beasley et al. 2010</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>121</td>
<td>Rat (Long-Evans)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td>Bd Wt</td>
<td>1000 M</td>
<td></td>
<td>Beasley et al. 2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>122</td>
<td>Rat (albino)</td>
<td>8 wk 5 d/wk 70 min/d</td>
<td>Resp</td>
<td>12000 M</td>
<td></td>
<td>Bruckner and Peterson 1981b</td>
<td></td>
<td>Endpoints evaluated: body weight, organ weight and histology; upper respiratory tract histology not assessed.</td>
</tr>
</tbody>
</table>

- Cardio 12000 M
- Hepatic 12000 M (11% decrease in liver weight, elevated liver enzymes in serum)
- Renal 12000 M (27% decrease in kidney weight)
- Bd Wt 12000 M (20% reduction in body weight gain)

<table>
<thead>
<tr>
<th>123</th>
<th>Rat (Sprague-Dawley)</th>
<th>4 wk 5 d/wk 6 hr/d</th>
<th>Endocr</th>
<th>320 M</th>
<th></th>
<th>Hillefors-Berglund et al. 1995</th>
<th></th>
<th>No change in serum prolactin levels.</th>
</tr>
</thead>
<tbody>
<tr>
<td>124</td>
<td>Rat (Wistar)</td>
<td>30 d 24 hr/d</td>
<td>Hepatic</td>
<td>400 M</td>
<td></td>
<td>Ikeda et al. 1986</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Bd Wt 200 M (decreased body weight gain)
Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>125</td>
<td>Rat (Wistar)</td>
<td>20 d 4 hr/d</td>
<td>Bd Wt</td>
<td>1500 M (body weight decrease 18%)</td>
<td>Ishigami et al. 2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>126</td>
<td>Rat (Wistar)</td>
<td>12 wk 6 d/wk 8 hr/d</td>
<td>Resp</td>
<td>3000 M (increased pulmonary inflammation, edema, fibrosis, and necrosis)</td>
<td>Kanter 2011a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>127</td>
<td>Rat (Wistar)</td>
<td>12 wk 6 d/wk 8 hr/d</td>
<td>Hepatic</td>
<td>3000 M (enlarged hepatic sinusoids filled with blood and minimal hepatic fibrosis, increased number of apoptotic liver cells)</td>
<td>Kanter 2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>128</td>
<td>Rat (Sprague-Dawley)</td>
<td>30 d 24 hr/d</td>
<td>Hepatic</td>
<td>320 M</td>
<td>Kyrklund et al. 1987</td>
<td>Endpoint assessed: liver weight.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>320 M (10% decreased body weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>129</td>
<td>Rat (Fischer-344)</td>
<td>13 wk 5 d/wk 15-35 min, 4-9 x/d</td>
<td>Bd Wt</td>
<td>8000 M (23% decreased body weight gain)</td>
<td>Mattsson et al. 1990</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1  Levels of Significant Exposure to Toluene - Inhalation

(continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>130</td>
<td>Rat (Fischer-344)</td>
<td>15 wk 5 d/wk 6.5 hr/d</td>
<td>Resp</td>
<td>1250</td>
<td>2500 (9-15% increased relative lung weight)</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>1250</td>
<td>2500 (6-11% increased relative heart weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>3000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>3000 M</td>
<td>1250 F (decreased leukocytes)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>625 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>625 M</td>
<td>1250 M (9% increase in relative liver weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1250 F</td>
<td>2500 F (16% increase in relative liver weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>625</td>
<td>1250 (increased relative kidney weights)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>3000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1250</td>
<td>2500 (15% decreased in body weight)</td>
<td>3000 M (25% decrease in body weight)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>131</td>
<td>Rat (Sprague-Dawley)</td>
<td>21 d 6 hr/d</td>
<td>Ocular</td>
<td>600</td>
<td>2000 F (lacrimation)</td>
<td></td>
<td>Ono et al. 1996</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>132</td>
<td>Rat (Sprague-Dawley)</td>
<td>90 d 6 hr/d</td>
<td>Hemato</td>
<td>2000 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>600 M</td>
<td>2000 M</td>
<td>(increase in kidney weights, necrosis of kidney tubules)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>2000 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>133</td>
<td>Rat (Sprague-Dawley)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td>Resp</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Poon et al. 1994</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Endpoints evaluated: organ weight and histology, upper respiratory tract histology.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>30</td>
<td>300</td>
<td>(significantly increased serum alkaline phosphatase in males &amp; variation hepatocellular size in females)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>300 M</td>
<td>30 F</td>
<td>(mild reduction in follicle size in thyroid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>134</td>
<td>Rat (Fischer- 344)</td>
<td>23 wk 7 d/wk 8 hr/d 60, 30, 15 min/hr</td>
<td>Bd Wt</td>
<td>2200 M</td>
<td></td>
<td>(decreased body weight gain)</td>
<td></td>
<td></td>
<td>Pryor 1991</td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Duration/ Frequency (Route)</th>
<th>Exposure/ System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>135</td>
<td>Rat (Fischer-344)</td>
<td>11 wk 7 d/wk 8 hr/d</td>
<td>Bd Wt</td>
<td></td>
<td>2000 M (decreased body weight gain)</td>
<td>Pryor 1991</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>136</td>
<td>Rat (Wistar)</td>
<td>30 d 1 hr/d</td>
<td>Hepatic</td>
<td></td>
<td>1000 M (hepatocyte degeneration, pericentral fibrosis, increased markers of apoptosis)</td>
<td>Tas et al. 2011</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>137</td>
<td>Rat (Wistar)</td>
<td>30 d 1 hr/d</td>
<td>Hepatic</td>
<td></td>
<td>1000 M (hepatocyte degeneration, increased number of apoptotic liver cells)</td>
<td>Tas et al. 2013a</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>138</td>
<td>Rat (Sprague-Dawley)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td>Endocr</td>
<td>80</td>
<td></td>
<td></td>
<td></td>
<td>von Euler et al. 1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1  Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>Key to Species</th>
<th>NOAEL (ppm)</th>
<th>System</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>139</td>
<td>Rat (NS)</td>
<td>5 wk 5 d/wk 7 hr/d</td>
<td>Resp</td>
<td>600</td>
<td>Hemato</td>
<td>600</td>
<td>(irritation of the lung)</td>
<td>2500</td>
<td>(pulmonary lesions)</td>
<td>von Oettingen et al. 1942</td>
<td>Endpoints evaluated: hematology, organ histology.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>140</td>
<td>Mouse (BALB/c)</td>
<td>8 wks 6 hr/d</td>
<td>Musc/skel</td>
<td>300 M</td>
<td>(decreased bone mineral density and content in femoral neck)</td>
<td>Atay et al. 2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>141</td>
<td>Mouse (Swiss-Webster)</td>
<td>40 d 30 min/d</td>
<td>Bd Wt</td>
<td>6000 M</td>
<td>Bowen and McDonald 2009</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Route</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>--------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>142 Mouse (ICR)</td>
<td>8 wk 5 d/wk 70 min/d</td>
<td>Resp</td>
<td>12000 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bruckner and Peterson 1981b</td>
<td></td>
<td>Endpoints evaluated: body weight, organ weight and histology; upper respiratory tract histology not assessed.</td>
<td></td>
</tr>
<tr>
<td>143 Mouse (ICR)</td>
<td>8 wk 3 hr/d 5 d/wk</td>
<td>Resp</td>
<td>4000 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bruckner and Peterson 1981b</td>
<td></td>
<td>Endpoints evaluated: body weight, organ weight and histology; upper respiratory tract histology not assessed.</td>
<td></td>
</tr>
</tbody>
</table>

**Cardio 12000 M**

- Hepatic: 12000 M (decreased liver weight)
- Renal: 12000 M (decreased kidney weight)

**Bd Wt 12000 M** (20% reduction in body weight)

**Resp 4000 M**

- Cardio: 4000 M (increased relative liver weight, elevated serum glutamic oxaloacetic transaminase)
- Renal: 4000 M
- Bd Wt: 4000 M (5-10% decrease in body weight gain)
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>144</td>
<td>Mouse (C3H/HeN)</td>
<td>12 wk 5 d/wk 6 hr/d</td>
<td>Resp</td>
<td>50 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fujimaki et al. 2007</td>
</tr>
<tr>
<td>145</td>
<td>Mouse</td>
<td>20 d 6 hr/d</td>
<td>Hemato</td>
<td>10 M (decreased white blood cells and thrombocytes)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Horiguchi and Inoue 1977</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bd Wt</td>
<td></td>
<td>1000 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Jacquot et al. 2006</td>
</tr>
<tr>
<td>146</td>
<td>Mouse (OF-1)</td>
<td>4 wk 5 d/wk 5 hr/d</td>
<td>Resp</td>
<td>1000 F (inflammation and decreased cell number in olfactory epithelium)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kjellstrand et al. 1985</td>
<td></td>
</tr>
<tr>
<td>147</td>
<td>Mouse</td>
<td>30 d 24 hr/d</td>
<td>Hepatic</td>
<td>150 F (increased liver weight-9.6%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
<td>----------</td>
</tr>
<tr>
<td>148</td>
<td>Mouse (B6C3F1)</td>
<td>14 wk 5 d/wk 6.5 hr/d</td>
<td>Resp</td>
<td>1250 M</td>
<td></td>
<td>2500 M (5% increase in relative lung weight)</td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100 F</td>
<td></td>
<td>(12% increase in relative lung weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>2500 M</td>
<td></td>
<td>2500 F (14% increase in relative heart weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1250 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>625 M</td>
<td>1250 M</td>
<td>1250 M (9% increase in relative liver weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100 F</td>
<td></td>
<td>625 F (6% increase in relative liver weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>2500 M</td>
<td>1250 F</td>
<td>1250 F (7% increase in relative kidney weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>625 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1250 M</td>
<td>2500 M</td>
<td>2500 M (12% decreased in body weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100 F</td>
<td></td>
<td>100 F (13% decrease in body weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3-1  Levels of Significant Exposure to Toluene - Inhalation

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>149 Immuno/ Lymphoret</td>
<td>Rat (CD)</td>
<td>95 d 7 d/wk 6 hr/d</td>
<td></td>
<td>2000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>150</td>
<td>Rat (Fischer-344)</td>
<td>42 d 5 d/wk 6 hr/d</td>
<td></td>
<td>1000 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>151</td>
<td>Rat (Fischer-344)</td>
<td>15 wk 5 d/wk 6.5 hr/d</td>
<td></td>
<td>3000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>152</td>
<td>Rat (Sprague-Dawley)</td>
<td>90 d 6 hr/d</td>
<td></td>
<td>600</td>
<td>2000 M (decrease in thymus weights)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>153</td>
<td>Rat (Sprague-Dawley)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>154</td>
<td>Rat (NS)</td>
<td>5 wk 5 d/wk 7 hr/d</td>
<td></td>
<td>5000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to</td>
<td>Species (Strain)</td>
<td>Exposure/ Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------------</td>
<td>--------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>--------</td>
<td>-----------</td>
<td>---------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>155</td>
<td>Mouse (B6C3F1)</td>
<td>14 wk 5 d/wk 6.5 hr/d</td>
<td></td>
<td>2500</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td>Endpoints evaluated: spleen and thymus weight and histology.</td>
<td></td>
</tr>
<tr>
<td>156</td>
<td>Rat (CD)</td>
<td>95 d 7 d/wk 6 hr/d</td>
<td></td>
<td>2000</td>
<td></td>
<td>API 1985; Roberts et al. 2003</td>
<td>Endpoint evaluated in 2-generation study: brain weight, brain and spinal cord histology in F0/F1 parents and F1/F2 weanlings.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>157</td>
<td>Rat (Fischer-344)</td>
<td>42 d 5 d/wk 6 hr/d</td>
<td></td>
<td>100 M (changes in GFAP levels in brain) 3000 M (overt signs of neurotoxicity)</td>
<td></td>
<td>API 1997</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>158</td>
<td>Rat</td>
<td>3 wk 5 d/wk 8 hr/d</td>
<td></td>
<td>900 M (prolonged slow-wave sleep and paraoxical sleep latencies)</td>
<td></td>
<td>Arito et al. 1988</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>159</td>
<td>Rat (Long-Evans)</td>
<td>4 or 13 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>1000 M</td>
<td></td>
<td>Beasely et al. 2010</td>
<td></td>
<td>Endpoints evaluated: neurobehavioral battery.</td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>Rat (Long-Evans)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>1000 M</td>
<td></td>
<td>Beasely et al. 2012</td>
<td></td>
<td>Endpoints evaluated: neurobehavioral battery.</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>--------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>161</td>
<td>Rat (Sprague-Dawley)</td>
<td>16 wk 104 hr/wk</td>
<td></td>
<td></td>
<td>40 (decreased rearing behavior)</td>
<td>Berenguer et al. 2003</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>162</td>
<td>Rat (Sprague-Dawley)</td>
<td>16 wk 104 hr/wk</td>
<td></td>
<td></td>
<td>40 (decreased rearing activity)</td>
<td>Berenguer et al. 2004</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>163</td>
<td>Rat (Long-Evans)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td></td>
<td></td>
<td>1000 M (loss of hair cells in organ of Corti)</td>
<td>Campo et al. 1997</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>164</td>
<td>Rat (Sprague-Dawley)</td>
<td>30 d 24 hr/d</td>
<td></td>
<td></td>
<td>320 M (decreased weight of brain and cerebral cortex)</td>
<td>Kyrklund et al. 1987</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>165</td>
<td>Rat (Wistar)</td>
<td>90 d 5 d/wk 6 hr/d</td>
<td></td>
<td></td>
<td>500 M</td>
<td>Lund and Kristiansen 2008</td>
<td>Brainstem auditory responses, distortion product otoacoustic emissions.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>166</td>
<td>Rat (Fischer-344)</td>
<td>50 d 24 hr/d</td>
<td></td>
<td></td>
<td>600 M</td>
<td>Miyagawa et al. 1995</td>
<td>Endpoint examined: learning and memory (radial arm maze).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>167</td>
<td>Rat (Fischer- 344)</td>
<td>15 wk 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1250</td>
<td>2500</td>
<td>(ataxia, increased relative brain weight)</td>
<td>NTP 1990</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>168</td>
<td>Rat (Fischer- 344)</td>
<td>16 wk + 5 wk 7 d/wk 14 hr/d</td>
<td></td>
<td>700 M</td>
<td>1000 M</td>
<td>(diminished auditory response)</td>
<td>Pryor et al. 1984b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>169</td>
<td>Rat (Sprague- Dawley)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>80</td>
<td></td>
<td></td>
<td>Rogers et al. 1999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>170</td>
<td>Rat (Sprague- Dawley)</td>
<td>13 wk 8 hr/d</td>
<td></td>
<td>1000 M</td>
<td></td>
<td></td>
<td>Tahti et al. 1983</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>171</td>
<td>Rat (Sprague- Dawley)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>80 M</td>
<td></td>
<td>(decreased cortical area in parietal cortex, impaired motor coordination)</td>
<td>von Euler et al. 2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>172</td>
<td>Rat (NS)</td>
<td>5 wk 5 d/wk 7 hr/d</td>
<td></td>
<td>600</td>
<td>2500</td>
<td>(overt signs of neurotoxicity)</td>
<td>von Oettingen et al. 1942</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>--------</td>
<td>-------------------</td>
<td>--------------</td>
<td>-----------</td>
<td>---------------</td>
<td>----------</td>
</tr>
<tr>
<td>173</td>
<td>Rat (Wistar)</td>
<td>4 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>25 M</td>
<td>100 M  (increased escape response in hot-plate test)</td>
<td>Wladerna and Tomas 2002</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>174</td>
<td>Rat (Long- Evans)</td>
<td>3 wk 2x/wk 2 hr/d</td>
<td></td>
<td>178 M</td>
<td>(increased nose poking)</td>
<td>Wood and Cox 1995</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>175</td>
<td>Mouse (B6C3F1)</td>
<td>14 wk 5 d/wk 6.5 hr/d</td>
<td></td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td>176</td>
<td>Mouse (C3H/HeN)</td>
<td>6 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>50 M</td>
<td></td>
<td></td>
<td></td>
<td>Win-Shwe et al. 2010c</td>
<td></td>
<td>Endpoint examined: learning and memory (Morris water maze).</td>
</tr>
<tr>
<td>177</td>
<td>Mouse (BALB/c)</td>
<td>3 d plus 4 wk 30 min/d</td>
<td></td>
<td>90 M</td>
<td></td>
<td></td>
<td></td>
<td>Win-Shwe et al. 2010d</td>
<td></td>
<td>Endpoint examined: learning and memory (Morris water maze).</td>
</tr>
<tr>
<td>178</td>
<td>Gn Pig (pigmented)</td>
<td>4 wk 5 d/wk 8 hr/d</td>
<td></td>
<td>500</td>
<td></td>
<td>(transient mid- and high-frequency hearing loss)</td>
<td></td>
<td>McWilliams et al. 2000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>--------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>179</td>
<td>Rat (CD)</td>
<td>95 d 7 d/wk 6 hr/d</td>
<td></td>
<td>2000</td>
<td></td>
<td></td>
<td>API 1985; Roberts et al. 2003</td>
<td>Endpoints examined: reproductive performance in 2-generation study (F0 and F1 parental animals).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>180</td>
<td>Rat (Wistar)</td>
<td>Gd 7 - Ppd 18 6 hr/d</td>
<td></td>
<td>1200 F</td>
<td></td>
<td></td>
<td>Dalgaard et al. 2001</td>
<td>Pregnancy outcomes examined.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>181</td>
<td>Rat (Wistar)</td>
<td>Gd 7 - Ppd 18 6 hr/d</td>
<td></td>
<td>1200 F</td>
<td></td>
<td></td>
<td>Hass et al. 1999</td>
<td>Pregnancy outcomes examined.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>182</td>
<td>Rat (Wistar)</td>
<td>20 d 4 hr/d</td>
<td></td>
<td>1500 M</td>
<td></td>
<td></td>
<td>Ishigami et al. 2005</td>
<td>Endpoints examined: reproductive organ weights, spermatogenesis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>183</td>
<td>Rat (Wistar)</td>
<td>12 wk 6 d/wk 8 hr/d</td>
<td></td>
<td>3000 M</td>
<td></td>
<td></td>
<td>Kanter 2011b</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3-1  Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>184</td>
<td>Rat (Fischer-344)</td>
<td>15 wk 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1250 M</td>
<td>2500 M (15% increased testis weight)</td>
<td>3000 F</td>
<td>NTP 1990</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>185</td>
<td>Rat (Sprague-Dawley)</td>
<td>90 d 6 hr/d</td>
<td></td>
<td>600 M (slightly decreased (13%) sperm count)</td>
<td>2000 M (significantly decreased (26%) sperm count and decrease (15%) in wts of epididymes, but no effect on indices of fertility)</td>
<td>Ono et al. 1996</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>186</td>
<td>Rat (Sprague-Dawley)</td>
<td>5 wk 7 d/wk 2 hr/d</td>
<td></td>
<td>4000 M</td>
<td>6000 M (significantly decreased sperm count (66%), motility (78%), and ovum penetration (76%))</td>
<td>Ono et al. 1999</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>187</td>
<td>Mouse (CD-1)</td>
<td>8 wk 5 d/wk 6 hr/d</td>
<td></td>
<td>400 M</td>
<td></td>
<td>Ono et al. 1999</td>
<td>API 1981</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>188</td>
<td>Mouse (B6C3F1)</td>
<td>14 wk 5 d/wk 6.5 hr/d</td>
<td></td>
<td>2500</td>
<td>NTP 1990</td>
<td></td>
<td>comments</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endpoints evaluated: organ weight and histology; reproductive function not assessed.

Endpoints examined: dominant lethal mutations, pre- and postimplantation losses after mating with unexposed females.
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developmental</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>189</td>
<td>Rat (CD)</td>
<td>95 d plus Gd 1-20 and Ppd 5-21</td>
<td></td>
<td>500</td>
<td></td>
<td>2000</td>
<td>Less Serious (ppm)</td>
<td>(reduced fetal and pup body weights in F1 and F2 generations)</td>
<td>API 1985; Roberts et al. 2003</td>
<td>2-generation reproduction study.</td>
</tr>
<tr>
<td>190</td>
<td>Rat (Wistar)</td>
<td>Gd 7 - Ppd 18 6 hr/d</td>
<td></td>
<td>1200 M</td>
<td></td>
<td></td>
<td>Serious (ppm)</td>
<td>(decreased neonatal body weight)</td>
<td>Dalgaard et al. 2001</td>
<td>Endpoints examined: pup weight, external malformations, offspring sperm parameters at Ppd 100.</td>
</tr>
<tr>
<td>191</td>
<td>Rat (Wistar)</td>
<td>Gd 7 - Ppd 18 6 hr/d</td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td>(decreased neonatal body weight, delayed development of reflexes and increased locomotor activity in offspring)</td>
<td>Hass et al. 1999</td>
<td>Pregnancy outcomes examined.</td>
<td></td>
</tr>
<tr>
<td>192</td>
<td>CFY</td>
<td>Gd 1-21, 8hr/d</td>
<td></td>
<td>266</td>
<td></td>
<td></td>
<td>(increased incidence of fetal skeletal retardation)</td>
<td>Hudak and Ungvary 1978</td>
<td></td>
<td></td>
</tr>
<tr>
<td>193</td>
<td>Rat (Wistar)</td>
<td>Ppd 1-28 12 hr/d</td>
<td></td>
<td>100</td>
<td></td>
<td></td>
<td>(decreased growth of hippocampus)</td>
<td>Slomianka et al. 1990</td>
<td>Endpoints examined: body weight, brain histology and hippocampal volume on Ppd 29.</td>
<td></td>
</tr>
</tbody>
</table>
Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>194</td>
<td>Rat (Wistar)</td>
<td>Ppd 1-28 12 hr/d</td>
<td></td>
<td></td>
<td></td>
<td>500 M</td>
<td>Slomianka et al. 1992</td>
<td></td>
<td>Toluene</td>
</tr>
<tr>
<td>196</td>
<td>Human &gt;3 yr</td>
<td>Hemato</td>
<td>600</td>
<td></td>
<td></td>
<td></td>
<td>Banfer 1961</td>
<td></td>
<td>Toluene</td>
</tr>
<tr>
<td>197</td>
<td>Human &gt;5 yr (avg = 20 yr) (Occup)</td>
<td>Resp</td>
<td>186 (mucosal irritation)</td>
<td>Deschamps et al. 2001</td>
<td>Toluene</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>198</td>
<td>Human at least 20 yr (Occup)</td>
<td>Cardio</td>
<td>24 M</td>
<td>Gericke et al. 2001</td>
<td>Toluene</td>
<td>Endpoints examined: blood pressure, clinical chemistry, glomerular filtration rate.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatic</td>
<td>24 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Toluene</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal</td>
<td>24 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Toluene</td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>199</td>
<td>Human</td>
<td>40 mo (average) (Occup)</td>
<td>Hemato</td>
<td>83 F</td>
<td></td>
<td></td>
<td></td>
<td>Matsushita et al. 1975</td>
<td></td>
<td>Endpoints evaluated: hematology, clinical chemistry.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>83 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>Human</td>
<td>16 +/- 13 years</td>
<td>Renal</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
<td>Stengel et al. 1998</td>
<td></td>
<td>No changes in biomarkers of renal damage when 17 subjects with hypertension were excluded.</td>
</tr>
<tr>
<td>201</td>
<td>Human</td>
<td>3-39 yr (Occup)</td>
<td>Hepatic</td>
<td>29 M (increased levels of alkaline phosphatase)</td>
<td></td>
<td></td>
<td></td>
<td>Svensson et al. 1992b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>202</td>
<td>Human</td>
<td>&gt;10 yr</td>
<td>Hemato</td>
<td>110 (increased leukocytes)</td>
<td></td>
<td></td>
<td></td>
<td>Tahti et al. 1981</td>
<td></td>
<td></td>
</tr>
<tr>
<td>203</td>
<td>Human</td>
<td>NS (Occup)</td>
<td>Hemato</td>
<td>24.7</td>
<td></td>
<td></td>
<td></td>
<td>Ukai et al. 1993</td>
<td></td>
<td>Endpoints evaluated: hematology, clinical chemistry.</td>
</tr>
</tbody>
</table>

**Table Notes:**
- **System:** Hemato for hematology, Hepatic for hepatic.
- **Chemical Form:** LOAEL indicates Lowest Observable Adverse Effect Level, NOAEL indicates No Observable Adverse Effect Level.
### Table 3-1  Levels of Significant Exposure to Toluene - Inhalation

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>204 Human</td>
<td>73-96 mo (Occup)</td>
<td>Hemato</td>
<td>46 M</td>
<td>(significant decrease in relative number of lymphocyte)</td>
<td>Yin et al. 1987</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>41 F</td>
<td>(significant decrease in relative number of lymphocyte)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>205 Rat</td>
<td>106 wk (Fischer-344) 5 d/wk 6 hr/d</td>
<td>Resp</td>
<td>300</td>
<td></td>
<td>CIIT 1980; Gibson and Hardisty 1983</td>
<td>Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardio</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hemato</td>
<td>100 (decreased hematocrit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatic</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>206</td>
<td>Rat (Fischer-344)</td>
<td>2 yr 5 d/wk 6.5 hr/d</td>
<td>Resp</td>
<td>600</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Less Serious</td>
<td>Serious</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>600</td>
<td>(nasal inflammation, degeneration of olfactory and nasal respiratory epithelium)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardio</td>
<td></td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gastro</td>
<td></td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemato</td>
<td></td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Musc/skel</td>
<td></td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatic</td>
<td></td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal</td>
<td></td>
<td></td>
<td>600</td>
<td>(increased severity of nephropathy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endocr</td>
<td></td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bd Wt</td>
<td></td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>--------------</td>
</tr>
<tr>
<td>207</td>
<td>Rat (Fischer- 344)</td>
<td>15 mo 5 d/wk 6.5 hr/d</td>
<td>Resp</td>
<td>600</td>
<td>(mild-to-moderate degeneration of the olfactory and respiratory epithelium)</td>
<td>1200</td>
<td>NTP 1990</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>-------------------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>208</td>
<td>Mouse (B6C3F1)</td>
<td>2 yr 5 d/wk 6.5 hr/d</td>
<td>Resp</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>209 Mouse</td>
<td>(B6C3F1)</td>
<td>15 mo 5 d/wk 6.5 hr/d</td>
<td>Resp</td>
<td>1200 M</td>
<td>1200 F</td>
<td>NTP 1990</td>
<td>Toluene</td>
<td>Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>600 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immuno/ Lymphoret</td>
<td>Human</td>
<td>13 yr (average)</td>
<td></td>
<td>637 M</td>
<td></td>
<td>Pelcova et al. 1990</td>
<td>Toluene</td>
<td>Endpoint evaluated: serum immunoglobulin levels.</td>
</tr>
<tr>
<td>210</td>
<td>Human</td>
<td>16 +/- 13 yr</td>
<td></td>
<td>44</td>
<td></td>
<td>Stengel et al. 1998</td>
<td>Toluene</td>
<td>Endpoint evaluated: serum IgE levels.</td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (Less Serious ppm)</th>
<th>LOAEL (Serious ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>212</td>
<td>Human</td>
<td>73-96 mo (Occup)</td>
<td></td>
<td></td>
<td>46 M (significantly decreased lymphocytes and increased eosinophils)</td>
<td></td>
<td>Yin et al. 1987</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>41 F (significantly decreased lymphocytes and increased eosinophils)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>213</td>
<td>Rat (Fischer-344)</td>
<td>2 yr 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td>Endpoints evaluated: spleen and thymus weight and histology.</td>
</tr>
<tr>
<td>214</td>
<td>Mouse (B6C3F1)</td>
<td>2 yr 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1200 F</td>
<td>120 M (increased incidence of pigmentation of the spleen)</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td>Endpoints evaluated: spleen and thymus weight and histology.</td>
</tr>
<tr>
<td>Neurological</td>
<td>215</td>
<td>Human 12-14 yr (Occup)</td>
<td></td>
<td></td>
<td>97 M (increased wave latencies for BAEPs)</td>
<td></td>
<td>Abbate et al. 1993</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>216</td>
<td>Human 4.9 yr (average)</td>
<td></td>
<td></td>
<td>90.9 (statistically significant performance deficits on neurobehavioral tests)</td>
<td></td>
<td>Boey et al. 1997</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>217</td>
<td>Human</td>
<td>0-40 yr (average = 14 yr) (Occup)</td>
<td></td>
<td>27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chouaniere et al. 2002</td>
<td>Toluene</td>
</tr>
<tr>
<td>218</td>
<td>Human</td>
<td>&gt;5 yr (average = 20 yr) (Occup)</td>
<td></td>
<td>186</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Deschamps et al. 2001</td>
<td>Toluene</td>
</tr>
<tr>
<td>219</td>
<td>Human</td>
<td>5.7 yr (Occup)</td>
<td></td>
<td>88 F</td>
<td>(statistically significant performance deficits on neurobehavioral tests)</td>
<td></td>
<td></td>
<td>Foo et al. 1990</td>
<td>Toluene</td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>Human</td>
<td>at least 20 years (Occup)</td>
<td></td>
<td>24 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gericke et al. 2001</td>
<td>Toluene</td>
</tr>
<tr>
<td>221</td>
<td>Human</td>
<td>99 mo (mean) (Occup)</td>
<td></td>
<td>20</td>
<td>75</td>
<td>(statistically significant impairments in attention and motor performance)</td>
<td></td>
<td></td>
<td>Kang et al. 2005</td>
<td>Toluene</td>
</tr>
<tr>
<td>222</td>
<td>Human</td>
<td>40 mo (average) (Occup)</td>
<td></td>
<td>83 F</td>
<td></td>
<td>(abnormal tendon reflex, decr. grasping power and agility of fingers, general weakness)</td>
<td></td>
<td></td>
<td>Matsushita et al. 1975</td>
<td>Toluene</td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>223</td>
<td>Human</td>
<td>1-25 yr (Occup)</td>
<td></td>
<td></td>
<td>122 M</td>
<td>(hearing loss)</td>
<td></td>
</tr>
<tr>
<td>224</td>
<td>Human</td>
<td>1-36 yr (Occup)</td>
<td></td>
<td></td>
<td>83 M</td>
<td>(lowered coefficient of variation in electrocardiographic R-R intervals and maximal motor and sensory nerve conduction velocities in median nerve)</td>
<td></td>
</tr>
<tr>
<td>225</td>
<td>Human</td>
<td>NS (Occup)</td>
<td></td>
<td></td>
<td>46 F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>226</td>
<td>Human</td>
<td>unspecified (Occup)</td>
<td></td>
<td>33</td>
<td>75</td>
<td>(impaired visual perception)</td>
<td></td>
</tr>
<tr>
<td>227</td>
<td>Human</td>
<td>4-43 yr (median = 29 yr) (Occup)</td>
<td></td>
<td></td>
<td>140 M</td>
<td>(increased incidence of self-reported neurological symptoms [initial]; statistically significant performance deficits on neurobehavioral tests [follow-up] )</td>
<td></td>
</tr>
<tr>
<td>228</td>
<td>Human</td>
<td>13.4 yr (average) (Occup)</td>
<td></td>
<td></td>
<td>$45$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reference**
- Morata et al. 1997
- Murata et al. 1993
- Nakatsuka et al. 1992
- Neubert et al. 2001
- Orbaek and Nise 1989; Nordling Nilson et al. 2010
- Schaper et al. 2003; 2008

**Comments**
- Endpoint evaluated: color vision.
- Endpoints evaluated: subjective symptoms, battery of neurobehavioral tasks.
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>229</td>
<td>Human</td>
<td>7 or 23 yr (mean) (Occup)</td>
<td></td>
<td>c 43</td>
<td></td>
<td></td>
<td></td>
<td>Schaper et al. 2004</td>
<td>Toluene</td>
<td>Endpoint evaluated: color vision.</td>
</tr>
<tr>
<td>230</td>
<td>Human</td>
<td>13.4 yr (mean) (Occup)</td>
<td></td>
<td>c 45</td>
<td></td>
<td></td>
<td></td>
<td>Seeber et al. 2004; 2005</td>
<td>Toluene</td>
<td>Endpoints examined: symbol digit substitution, switching attention, memory span, self-reported symptoms.</td>
</tr>
<tr>
<td>231</td>
<td>Human</td>
<td>(Occup)</td>
<td></td>
<td>36</td>
<td>76</td>
<td></td>
<td></td>
<td>Ukai et al. 1993</td>
<td>Toluene</td>
<td></td>
</tr>
<tr>
<td>232</td>
<td>Human</td>
<td>21.4 yr (average) range 4-30 yr (Occup)</td>
<td></td>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td>Vrca et al. 1995</td>
<td>Toluene</td>
<td></td>
</tr>
<tr>
<td>233</td>
<td>Human</td>
<td>4-30 years</td>
<td></td>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td>Vrca et al. 1996</td>
<td>Toluene</td>
<td></td>
</tr>
<tr>
<td>234</td>
<td>Human</td>
<td>3-33 years</td>
<td></td>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td>Vrca et al. 1997b</td>
<td>Toluene</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>------------------</td>
<td>--------------</td>
<td>-----------</td>
<td>-------------</td>
<td>----------</td>
</tr>
<tr>
<td>235</td>
<td>Human</td>
<td>73-96 mo (Occup)</td>
<td></td>
<td>46 M (headaches, dizziness)</td>
<td></td>
<td>41 F (headaches, dizziness)</td>
<td></td>
<td>Yin et al. 1987</td>
<td></td>
<td></td>
</tr>
<tr>
<td>236</td>
<td>Human</td>
<td>17 yr (average) (Occup)</td>
<td></td>
<td>35 (increased color confusion index)</td>
<td></td>
<td></td>
<td></td>
<td>Zavalic et al. 1998a, c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>237</td>
<td>Human</td>
<td>16.8 +/- 5.94 yr</td>
<td></td>
<td>120 (increased color confusion index)</td>
<td></td>
<td></td>
<td></td>
<td>Zavalic et al. 1998b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>238</td>
<td>Human</td>
<td>15 yr (mean) (Occup)</td>
<td></td>
<td>45 M</td>
<td></td>
<td></td>
<td></td>
<td>Zupanic et al. 2002</td>
<td>Endpoints examined: subjective symptoms, manual dexterity.</td>
<td></td>
</tr>
<tr>
<td>239</td>
<td>Rat (Fischer-344)</td>
<td>2 yr 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td>Endpoints assessed: brain weight and histology, clinical signs.</td>
<td></td>
</tr>
<tr>
<td>240</td>
<td>Rat (Fischer-344)</td>
<td>15 mo 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td>Endpoints assessed: brain weight and histology, clinical signs.</td>
<td></td>
</tr>
<tr>
<td>241</td>
<td>Mouse (B6C3F1)</td>
<td>2 yr 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td>Endpoints assessed: brain weight and histology, clinical signs.</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>LOAEL</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>242</td>
<td>Mouse (B6C3F1)</td>
<td>15 mo 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1200</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>243</td>
<td>Human</td>
<td>at least 20 years (Occup)</td>
<td>24 M</td>
<td>24 M</td>
<td>24 M</td>
<td>Gericke et al. 2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>244</td>
<td>Human</td>
<td>40 mo (average) (Occup)</td>
<td>83 F</td>
<td>83 F (dysmenorrhea)</td>
<td></td>
<td>Matsushita et al. 1975</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>245</td>
<td>Human</td>
<td>6 yr (Occup)</td>
<td>88 F</td>
<td>88 F</td>
<td></td>
<td>Ng et al. 1992a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>246</td>
<td>Human</td>
<td>10 yr (Occup)</td>
<td>88</td>
<td>88 (increased incidence of spontaneous abortions (12.4/100 compared to 2 control groups (2.9/100 and 4.5/100))</td>
<td></td>
<td>Ng et al. 1992b</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1 Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>247 Human</td>
<td>25 yr (median)</td>
<td>0.5-37 yr (Occup)</td>
<td>248 Human</td>
<td>3-39 yr (Occup)</td>
<td></td>
<td>36 M (decreased levels of LH, FSH, and free testosterone)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Svensson et al. 1992a</td>
<td></td>
</tr>
<tr>
<td>248 Human</td>
<td>3-39 yr (Occup)</td>
<td></td>
<td>249 Rat (Fischer-344)</td>
<td>106 wk</td>
<td>5 d/wk</td>
<td>6 hr/d)</td>
<td>29 M</td>
<td></td>
<td></td>
<td></td>
<td>Svensson et al. 1992b</td>
<td>Increasing workplace air concentrations were not significantly (p &gt; 0.05) associated with plasma concentrations of repro hormones after age adjustment.</td>
</tr>
<tr>
<td>249 Rat (Fischer-344)</td>
<td>106 wk</td>
<td>5 d/wk</td>
<td>6 hr/d)</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CIIT 1980; Gibson and Hardisty 1983</td>
<td>Endpoints evaluated: reproductive organ weight and histology.</td>
<td></td>
</tr>
<tr>
<td>250 Rat (Fischer-344)</td>
<td>2 yr</td>
<td>5 d/wk</td>
<td>6.5 hr/d)</td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td>Endpoints evaluated: organ weight and histology; reproductive function was not assessed.</td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-1  Levels of Significant Exposure to Toluene - Inhalation (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (ppm)</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>251</td>
<td>Mouse (B6C3F1)</td>
<td>2 yr 5 d/wk 6.5 hr/d</td>
<td></td>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endpoints evaluated: organ weight and histology; reproductive function not assessed.

---

**a** The number corresponds to entries in Figure 3-1.

**b** Used to derive an acute inhalation minimal risk level (MRL); concentration (15 ppm) divided by an uncertainty factor of 9 (3 for use of a minimal LOAEL and 3 for human variability observed effects were noted in a susceptible/vulnerable group of individuals, therefore a full uncertainty factor of 10 for human variability is not necessary), resulting in an MRL of 2 ppm (7.6 mg/m³).

**c** Used to derive a chronic inhalation minimal risk level (MRL) along with 5 companion studies supporting a NOAEL of 45 ppm for neurological effects; concentration was adjusted to a continuous exposure basis (45 ppm x 5d/7d x 8hr/24hr = 10.7 ppm) and divided by an uncertainty factor of 10 for human variability, resulting in an MRL of 1 ppm (3.8 mg/m³)

ACTH = adrenocorticotropic hormone; ALT = alanine amino transferase; AST = aspartate aminotransferase; BAEP = brainstem auditory evoked potential; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = Female; FSH = follicle stimulating hormone; Gastro = gastrointestinal; Gd = gestational day; GFAP = glial fibrillary acidic protein; Gn Pig = guinea pig; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LC50 = lethal concentration, 50% kill; LH = luteinizing hormone; LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); MCS = multiple chemical sensitivity; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; Occup = occupational; Pnw = post-natal week; Ppd = post-parturition day; REM = rapid eye movement; Resp = respiratory; VEP = visual evoked potential; wk = week(s); x = time(s); yr = year(s)
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation

Acute (≤14 days)

Cancer Effect Level - Animals
LOAEL, More Serious - Animals
LOAEL, Less Serious - Animals
NOAEL - Animals

Cancer Effect Level - Humans
LOAEL, More Serious - Humans
LOAEL, Less Serious - Humans
NOAEL - Humans

LD50/LC50
Minimal Risk Level for effects other than Cancer
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Acute (≤14 days)
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Acute (≤14 days)
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Acute (≤14 days)
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Intermediate (15-364 days)

Systemic

3. HEALTH EFFECTS

3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)
3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Intermediate (15-364 days)
Figure 3.1 Levels of Significant Exposure to Toluene - Inhalation (Continued)
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Chronic (≥365 days)

Systemic

ppm

Respiratory Cardiovascular Gastrointestinal Hematological Musculoskeletal

Cancer Effect Level - Animals
LOAEL, More Serious - Animals
LOAEL, Less Serious - Animals
NOAEL - Animals

Cancer Effect Level - Humans
LOAEL, More Serious - Humans
LOAEL, Less Serious - Humans
NOAEL - Humans

LD50/LC50

Minimal Risk Level for effects other than Cancer

***DRAFT FOR PUBLIC COMMENT***
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Chronic (≥365 days)

Systemic

ppm

0.1 1 10 100 1000 10000

Hepatic  Renal  Endocrine  Body Weight  Immuno-Lymph

Cancer Effect Level-Animals
LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
Cancer Effect Level-Humans
LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans

LD50/LC50
Minimal Risk Level for effects other than Cancer

Weight no/Lymph or TOLUENE

***DRAFT FOR PUBLIC COMMENT***

3. HEALTH EFFECTS

96
Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Chronic (≥365 days)
values and all LOAEL values from each reliable study for systemic effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

**Respiratory Effects.**

**Overview.** In humans, respiratory tract irritation has been reported from exposure to toluene under controlled and occupational exposure conditions (Andersen et al. 1983; Baelum et al. 1985; Carpenter et al. 1944; Hellquist et al. 1983; Orbaek et al. 1998; Osterberg et al. 2003; Winchester and Madjar 1986). In animal studies, evidence for histological damage to the nose or lung has been reported following intermediate- and chronic-duration inhalation exposure to toluene, most clearly at concentrations ≥600 ppm 6 hours/day (Fujimaki et al. 2007; Jacquot et al. 2006; Kanter 2011a; NTP 1990; Poon et al. 1994; von Oettingen et al. 1942).

**Controlled Exposure Human Studies.** Irritation of the nose and throat was reported in printers exposed to 100 ppm toluene for 6.5 hours (Baelum et al. 1985) and in volunteers exposed to 200 ppm toluene for 7–8 hours (Carpenter et al. 1944). Exposure of volunteers to 40 ppm of toluene for 6 hours did not produce statistically significant differences in the results of tests measuring nasal mucus flow and lung function or in subjective evaluations of air quality, but irritation of the nose was noted at 100 ppm (Andersen et al. 1983). Scores for throat irritation were significantly increased in 20 males during a 4.5-hour exposure to 50 ppm toluene, compared with pre-exposure scores, but no significant increases were observed for nasal irritation or coughing (Muttray et al. 2005). Mucous membrane irritation of progressive severity was reported by volunteers during exposure to progressively higher toluene concentrations of 0, 3, 6, 12, 24, and 48 ppm toluene over a 90-minute period (Orbaek et al. 1998; Osterberg et al. 2003); median maximal scores for mucous membrane irritation (scale of 0–100) at 48 ppm were about 70 for subjects with multiple chemical sensitivity diagnosis and about 30 for healthy subjects (Osterberg et al. 2003). In other controlled-exposure studies, volunteers reported that they did not experience respiratory or mucous membrane irritation during exposure to 800 ppm toluene for 3 hours (von Oettingen et al. 1942) or 1,862 ppm for 2 hours (Meulenbelt et al. 1990). No changes in lung function were reported for volunteers exposed to 100 ppm toluene for 6 hours, 30 minutes of which were spent exercising (Rahill et al. 1996).

**Occupational Exposure Human Studies.** Ten paint-sprayers exposed to 13 detected solvents (primarily 0.8–4.8 ppm toluene and isobutylacetate) and dusts had morphological changes in the nasal mucosa (Hellquist et al. 1983). However, there was no conclusive association between duration of exposure and
mucosal abnormalities. Forty-two workers exposed to mixtures of solvents, of which toluene was generally a major component, reported symptoms of nasal irritation, in addition to eye irritation, nausea, skin conditions, dizziness, and headaches (Winchester and Madjar 1986). The concentrations of toluene to which the workers were exposed ranged from 1 to 80 ppm (mean of 15 ppm). However, concurrent exposure to a mixture of solvents and dusts in these studies precludes establishing an unequivocal causal relationship between exposure to toluene and mucosal irritation. Eight workers from a print factory exposed to <200 ppm toluene for >18 months had normal chest roentgenograms and did not report breathing difficulty (Guzelian et al. 1988). In another study, increased mucosal irritation scores were reported in 72 workers exposed to toluene for an average of 20 years, compared with 61 unexposed referents (Deschamps et al. 2001). The toluene-exposed group consisted of 36 printer and machine factory workers and 36 laboratory workers exposed to toluene (but no other solvent) at toluene concentrations of 9–83 and 184-467 ppm, respectively. Since the exposed groups were analyzed together, the LOAEL for this assessment is determined to be the average of the midpoints of the exposed ranges (midpoint of 46 ppm for factory workers; midpoint of 325.5 ppm for laboratory workers; average of 186 ppm).

Intermediate-Duration Animal Studies. Following intermediate-duration exposure of animals to concentrations ≥600 ppm 6 hours/day, signs of pulmonary or nasal inflammation have been observed in a number of studies. Rats exposed to 600 ppm for 5 weeks, 7 hours/day showed irritation of the lungs and rats exposed to 2,500 and 5,000 ppm had pulmonary lesions (von Oettingen et al. 1942). Rats exposed to 3,000 ppm 8 hours/day 6 days/week for 12 weeks showed signs of pulmonary inflammatory responses including inflammatory cell infiltration in peribronchial and alveolar regions, alveolar edema, and interstitial fibrosis and necrosis (Kanter 2011a). Mice exposed to 1,000 ppm 5 hours/day, 5 days/week for 4 weeks showed time-dependent and reversible changes in the number of cells in, and the thickness of, the nasal olfactory epithelium that were indicative of degenerative processes followed by regenerative processes (Jacquot et al. 2006). Significantly (p>0.05) increased relative lung weights were reported in male and female rats and male and female mice exposed to 2,500 and 3,000 ppm (6.5 hours/day, 5 days/week for 14–15 weeks); these concentrations also induced ataxia in rats and dyspnea and increased early mortality in mice (NTP 1990). Relative lung weights were also increased at lower exposure levels (100, 625, and 1,250 ppm) in female mice, but the degree of change did not increase with increasing concentration (NTP 1990). The increased lung weights observed in the NTP (1990) studies were not accompanied with increased incidences of histological lesions in the lung, trachea, or nose in the 2500- or 3,000-ppm groups, compared with controls. No signs of respiratory distress or histological abnormalities were observed in the lungs of mice exposed to 4,000 ppm 3 hours/day, for 8 weeks, or in rats and mice.
exposed to 12,000 ppm for seven 10-minute periods per day separated by a 20-minute recovery period (Bruckner and Peterson 1981b). Additionally, no histological abnormalities in the lung were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003). However, these studies did not include a histological examination of the upper respiratory tract and may therefore not have observed damage to this region. In addition, the lack of pulmonary abnormalities in Bruckner and Peterson (1981b) at higher concentrations than those in the NTP (1990) studies may be explained by the shorter daily duration of exposure (3 hours/day versus 6 hours/day).

Following intermediate-duration to concentrations <600 ppm, histological lesions in the respiratory tract have not been observed consistently across studies. Sprague-Dawley rats exposed to 30 or 300 ppm toluene 6 hours/day, 5 days/week for 4 weeks showed no clear-cut evidence for exposure-related histological lesions in the nose, trachea, or lung (Poon et al. 1994). Incidences of epithelial degeneration of the nasolacrimal ducts (with average severity scores in parentheses on a scale of 1=minimal, 2=mild, 3=moderate, and 4=marked) were 4/6 (0.5), 6/6 (1.50), and 3/6 (0.42) in control through high-concentration males, respectively, and 1/6 (0.25), 5/6 (0.38), and 3/6 (0.33) in females, respectively. In the trachea, subepithelial lymphoid proliferation was observed in 3/6 (0.15), 3/6 (0.35), and 3/6 (0.25) male rats, respectively, and 5/6 (0.29), 3/6 (1.15), and 3/6 (0.71) female rats, respectively (Poon et al. 1994). In another study, no exposure-related changes were detected by light microscopy in the nose, trachea, or lung of female C3H/HeN mice exposed to 0 or 50 ppm 6 hours/day 5 days/week for 12 weeks, but significant (p<0.05) changes were found in a few bronchoalveolar lavage (BAL) indices of airway inflammation and a few neurotrophic factors in exposed mice, compared with control mice (Fujimaki et al. 2007). Significant changes after 12 weeks of exposure included increased numbers of inflammatory cells and macrophages (~1.95 times control values), but no changes in the number of lymphocytes or levels of 5/6 cytokines (tumor necrosis factor [TNF-α], monocyte chemoattractant protein [MCP-1], macrophage inflammatory protein [MIP-1α], interleukin-1β and interleukin-6); levels of interferon-gamma (IFN-γ) were significantly lower than control levels (~0.7 times control value). BAL fluid from exposed mice showed increased levels of neurotrophin-3 (~1.12 times control value) and decreased levels of substance P (~0.5 times control value), but no significant changes in nerve growth factor (NGF) levels (Fujimaki et al. 2007). The biological adversity of the observed changes in BAL fluid end points at 50 ppm is currently uncertain, but the histological results clearly identify 50 ppm 6 hours/day 5 days/week for 12 weeks as a NOAEL for histological signs of respiratory irritation in mice.
3. HEALTH EFFECTS

**Chronic-Duration Animal Studies.** Inflammation of the nasal mucosa, erosion and metaplasia of the olfactory epithelium, and degeneration of the respiratory epithelium were reported in male and female rats exposed to 600 or 1,200 ppm for 15 months or 2 years (6.5 hours/day, 5 days/week) (NTP 1990). At the end of 2 years, there were significant (p<0.05) increases in the incidence of erosion of the olfactory epithelium (males: 0/50, 3/50, and 8/49; females: 2/49, 11/50, and 10/50 at 0, 600, and 1,200 ppm, respectively) and degeneration of the respiratory epithelium (males: 15/50, 37/50, and 31/49; females: 29/49, 45/50, and 39/50 at 0, 600, and 1,200 ppm, respectively). Exposed female rats also showed significant increases in inflammation of the nasal mucosa (27/49, 41/50, and 41/50 at 0, 600, and 1,200 ppm, respectively) and metaplasia of the olfactory epithelium (0/49, 1/50, and 5/50 at 0, 600, and 1,200 ppm, respectively). Exposed rats showed no increased incidences of lung lesions compared with controls (NTP 1990). Increased incidences of nasal or lung lesions were not observed in mice exposed to the same concentrations for 2 years, but minimal hyperplasia of the bronchial epithelium was observed in 4/10 female mice exposed to 1,200 ppm for 15 months (NTP 1990). No histopathological lesions were observed in the upper respiratory tract or lungs of rats exposed for 2 years to 300 ppm toluene (6 hours/day, 5 days/week) (CIIT 1980; Gibson and Hardisty 1983).

**Cardiovascular Effects.**

**Overview.** Cardiac arrhythmia has been reported as a cause of death in fatal acute inhalation of solvents containing toluene (Anderson et al. 1982; Shibata et al. 1994). Following nonfatal acute exposures to high concentrations of toluene (>1,500 ppm), transient tachycardia and bradycardia have been reported (Einav et al. 1997; Meulenbelt et al. 1990). In addition, several cases of cardiac abnormalities associated with chronic toluene abuse have been reported (see Vural and Ogel 2006 for review). However, repeated inhalation exposure studies in laboratory animals at concentrations as high as 1,200 ppm do not provide convincing support for a direct effect of toluene on the cardiovascular system (Bruckner and Peterson 1981b; CIIT 1980; NTP 1990). One study of acute exposure of dogs to a lethal concentration of toluene (~30,000 ppm) reported the induction of arrhythmia, but the authors suggested that this was due to a predisposing arrhythmia-producing heart abnormality (Ikeda et al. 1990). Other studies of acute exposure have reported a nonsignificant increase in heart rate in rats exposed to 66,276 ppm toluene for 30 minutes (Vidrio et al. 1986) and a reduction of experimentally-induced arrhythmia in rats exposed to 6,867 ppm toluene, 10 minutes before aconitine treatment to induce arrhythmias (Magos et al. 1990).

Cardiac arrhythmias were noted in two adult males who were found semi-conscious after suffering from toluene intoxication (>7,000 mg/m³ toluene, 1,862 ppm) while removing glue from tiles in a swimming pool.
3. HEALTH EFFECTS

pool (Meulenbelt et al. 1990). Response seemed to be variable between these individuals. One man was exposed for 2 hours and exhibited a rapid heartbeat (sinus tachycardia), while the second man, exposed for 3 hours, exhibited a slow heartbeat (bradycardia) (Meulenbelt et al. 1990). Severe sinus bradycardia was also reported in a comatose man with severe toluene intoxication who had sniffed vapors from approximately 250 mL of thinner containing more than 50% toluene (Einav et al. 1997). No effects on systolic or diastolic blood pressure or pulse rate were reported in volunteers exposed to 800 ppm toluene for 3 hours (von Oettingen et al. 1942), but several cases of cardiac abnormalities associated with toluene abuse have been reported (see Vural and Ogel 2006 for review). No significant differences in prevalences of subjects with abnormally high blood pressure were found between a group of German rotogravure printers expected to have been exposed to toluene and a reference group of non-exposed paper industry workers (Gericke et al. 2001).

Cardiovascular response was assessed in 25 dogs killed by rebreathing 1 L of air containing 30,000 ppm toluene via an endotracheal tube (Ikeda et al. 1990). In most cases, death was due to hypoxia, but four of the dogs developed transient arrhythmia and in one case, death was due to ventricular fibrillation. The authors suggested that toluene had a direct effect on the septal and ventricular muscles of the heart, which permitted the development of fatal arrhythmias in sensitive dogs (Ikeda et al. 1990). Inhalation by anesthetized rats of 66,276 ppm toluene for 30 minutes (35 minutes inhalation of this concentration was fatal) produced a nonsignificant increase in heart rate and changes in electrocardiographs indicative of depressed ventricular conduction (Vidrio et al. 1986). However, in rats with arrhythmias induced by aconitine injection or coronary ligation, a 15-minute exposure to 6,867 ppm toluene, 10 minutes before aconitine treatment significantly reduced the number of ventricular ectopic beats (Magos et al. 1990).

No histological abnormalities were observed in the hearts of mice exposed to 4,000 ppm for 3 hours/day, for 8 weeks or to mice and rats exposed to 12,000 ppm for 70 minutes/day for 8 weeks (Bruckner and Peterson 1981b). Additionally, no histological abnormalities in the heart were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003). There were also no histopathological lesions of the heart that could be attributed to toluene in rats exposed to 300 ppm for 24 months (6 hours/day) (CIIT 1980; Gibson and Hardisty 1983) or in rats or mice exposed to up to 1,200 ppm for 24 months (6.5 hours/day) (NTP 1990). However, there were increased heart weights in rats and female mice exposed to 2,500 ppm toluene for 14–15 weeks (6.5 hours/day) (NTP 1990).
3. HEALTH EFFECTS

**Gastrointestinal Effects.** No studies were located regarding gastrointestinal effects in humans after inhalation exposure to toluene.

The incidence of ulcers of the forestomach was marginally, but not significantly, increased in male rats exposed to concentrations of 600–1,200 ppm toluene for 2 years (NTP 1990). These effects were not reported in mice or female rats exposed under the same conditions or in rats and mice exposed for only 15 months. There were no gastrointestinal effects in rats and mice exposed to up to 2,500–3,000 ppm toluene for 14–15 weeks (NTP 1990). Additionally, no histological abnormalities in the gastrointestinal tract were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003).

**Hematological Effects.** Consistent evidence for hematological effects has not been reported after inhalation exposure to toluene in the majority of recent human and animal studies. However, before the mid-1950s, chronic occupational exposure to toluene was associated with hematological effects in some studies (Greenburg et al. 1942; Wilson 1943). These effects are now attributed to concurrent exposure to benzene, a common contaminant of toluene at that time (EPA 1985c). More recent studies of workers exposed to toluene or to mixed solvents containing toluene have not found consistent evidence for abnormal hematological parameters (Banfer 1961; Matsushita et al. 1975; Tahti et al. 1981; Ukai et al. 1993; Yin et al. 1987).

**Human Studies.** Following acute exposures, no effects on leukocyte counts were observed in volunteers exposed to 800 ppm toluene for 3 hours (von Oettingen et al. 1942), and two workers accidentally exposed to about 1,862 ppm for 2–3 hours had normal values for hematological variables (Meulenbelt et al. 1990).

Consistent evidence for hematological effects has not been reported in workers chronically exposed to toluene. Ukai et al. (1993) reported no hematologic effects in 452 toluene-exposed shoemakers and printers (average exposure of 24.7 ppm) compared with unexposed controls from the same factories. Exposure was estimated from personal monitoring data, and at least 90% of total solvent exposure was due to toluene. No significant hematological effects were observed in workers engaged in shoemaking (Matsushita et al. 1975) or printing (Banfer 1961) who were exposed to toluene for several years. The studies were limited by small cohort size and a lack of historical exposure data. Shoemakers were exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–
200 ppm) in summer and printers were exposed to atmospheric concentrations of toluene up to 600 ppm, but individual exposure monitoring was generally not performed. As a result, the studies had only limited power to detect adverse hematological effects in toluene-exposed workers. Workers involved in printing, shoemaking, and audio equipment production, and exposed to toluene at 41 ppm (females) or 46 ppm (males) had significantly decreased relative (but not absolute) lymphocyte counts when compared to controls; leukocyte counts were not different between exposed and nonexposed workers (Yin et al. 1987). In contrast, workers exposed for several years to toluene (benzene concentration <0.01%) in a tarpaulin factory had increased blood leukocyte counts (Tahti et al. 1981). Toluene exposure concentrations, which ranged from 20 to 200 ppm, were similar to those reported by Banfer (1961). However, this study is limited by small cohort size, a lack of historical exposure monitoring, and the probability that workers were exposed to mixtures of chemicals. Lymphocyte and leukocyte counts were not significantly (p>0.05) different in a group of 25 nonsmoking subjects with >5 years exposure to toluene in shoe-repair facilities, compared with 25 nonsmokers without occupational exposure to toluene (Akbas 2004).

**Animal Studies.** Results of animal studies do not provide consistent evidence for hematological effects following inhalation exposure to toluene.

Following acute inhalation exposure, increased hematocrit and blood glucose levels have been observed in male rats exposed to 2,000 ppm toluene for 48 hours (Tahti et al. 1983). Erythrocyte membranes were stronger and less susceptible to lysis in rats exposed to 2,000 ppm of toluene than in controls (Korpela et al. 1983). This was demonstrated to be a reversible phenomenon since membrane strength returned to normal after toluene had dissipated from the system (Korpela and Tahti 1984). Other lipophilic agents such as anesthetics, tranquilizers, narcotics, and steroids have a similar effect on membrane strength (Magos et al. 1990).

In another acute exposure study, decreased leukocyte counts were observed in dogs exposed acutely to ≥500 ppm toluene for 1 hour or 700 ppm for 4 hours (Hobara et al. 1984a), but intermediate-duration exposure studies provide conflicting evidence for this effect. Positive reports include concentration-related decreases in thrombocytes in mice exposed to 10–1,000 ppm for 20 days (Horiguchi and Inoue 1977), reversible decreased leukocyte counts in rats exposed to 2,500 or 5,000 ppm for 5 weeks (von Oettingen et al. 1942), and decreased leukocytes in female rats exposed to concentrations >1,250 ppm for 15 weeks (NTP 1990). In contrast, no hematological effects were reported for male rats exposed to up to 3,000 ppm for 15 weeks or male or female mice exposed to up to 1,200 ppm for 14 weeks (NTP 1990),
male rats exposed to 2,000 ppm 6 hours/day for 90 days (Ono et al. 1996), or rats exposed to 300 ppm 6 hours/day, 5 days/week for 4 weeks (Poon et al. 1994).

In chronic-duration studies, rats exposed to 100 or 300 ppm toluene had significantly reduced hematocrit levels (CIIT 1980; Gibson and Hardisty 1983), but no consistent effects on hematological variables were reported for mice or rats exposed to toluene at levels up to 1,200 ppm for 15 months or 2 years (NTP 1990).

**Musculoskeletal Effects.** A 29-year-old man who had been sniffing glue containing toluene (concentration not specified) for 18 years and complained of severe muscle weakness was diagnosed with rhabdomyolysis (an acute disease of the skeletal muscles evidenced by myoglobin in the blood and urine) (Hong et al. 1996). Rhabdomyolysis was also diagnosed in a 48-year-old man, who was a chronic toluene abuser and had been inhaling one tube of toluene-containing glue per day in the month preceding admission (Karmakar and Roxburgh 2008).

No histological effects on bone were reported in mice or rats exposed to toluene at concentrations up to 1,200 ppm for 15 months or 2 years (NTP 1990). Additionally, no histological abnormalities were observed in bone or skeletal tissue from F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003). However, bone mineral density and bone mineral content were significantly (p<0.05) decreased in the right femoral neck of mice exposed to 300 ppm toluene 6 hours/day for 8 weeks (Atay et al. 2005).

**Hepatic Effects.**

**Overview.** Studies of chronic toluene abusers or occupationally-exposed humans have provided inconsistent evidence for liver damage due to inhaled toluene. Some studies of workers who were occupationally exposed to average concentrations between about 30 and 350 ppm toluene reported liver effects such as increased serum levels of AP (Guzelian et al. 1988; Svensson et al. 1992b), but others recorded no adverse effects on serum liver enzyme levels (Gericke et al. 2001; Lundberg and Hakansson 1985; Matsushita et al. 1975; Seijii et al. 1987; Ukai et al. 1993). A number of animal studies have reported increased liver sizes or histological changes in mice or rats repeatedly exposed to concentrations ranging from 300 ppm 6 hours/day 5 days/week for 4 weeks to 3,000 ppm 6 hours/day for 15 weeks (Bruckner and Peterson 1981b; Gotohda et al. 2009; Kanter 2012; Kjellstrand et al. 1985; NTP 1990;
3. HEALTH EFFECTS

Poon et al. 1994; Tas et al. 2011, 2013a), but other studies have recorded no effects on liver histology in rats or mice exposed to concentrations of up to 1,200 ppm for 2 years (CIIT 1980; Gibson and Hardisty 1983; Kyrklund et al. 1987; NTP 1990).

**Human Studies.** Eight men from a printing factory employing 289 workers exposed to toluene at concentrations of less than 200 ppm (further information on air toluene levels not reported) exceeded the upper end of the normal range for blood levels of bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and AP and had an ALT/AST ratio >1 (Guzelian et al. 1988). Liver biopsies showed centrilobular and periportal fat accumulation and Kupffer cell hyperplasia. None of the men reported drinking alcohol to excess, but they may have had minimal occupational exposure to methyl alcohol, ethyl alcohol, diethyl ether, trichloroethylene, and lacquer thinners which could have confounded the results. Serum AP values were significantly greater than controls in a group of 47 rotogravure workers occupationally exposed to a TWA toluene concentration of 11–47 ppm (midpoint 29 ppm) for 3–39 years than in controls (Svensson et al. 1992b). The difference in AP values remained significant when the data were corrected to eliminate nine workers who reported consumption of alcoholic beverages. No significant elevations in serum liver enzymes were found in another group of 452 shoemakers and printers (exposed to average concentrations of 24.7 ppm toluene) compared with unexposed workers from the same factories (Ukai et al. 1993). Serum ALT and AST levels were not altered printers and non-printers exposed to median toluene levels of 24 and 4.1 ppm toluene for at least 20 years, compared with unexposed referents (Gericke et al. 2001). Women working in a shoe factory for an average of >3 years and exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer (average of winter and summer exposure, 83 ppm) showed no changes in several serum variables indicative of liver damage compared with a control group of unexposed workers from the same factory (Matsushita et al. 1975). A group of 157 female shoemakers exposed for 2–14 months to toluene (7–324 ppm) had decreased serum levels of lactate dehydrogenase (LDH) as compared to controls, but levels of eight other serum enzymes monitored as indices of liver damage were normal (Seiji et al. 1987). These workers were also exposed to n-hexane, cyclohexane, and methyl ethyl ketone at concentrations generally 1/10th of the toluene concentration. A group of 47 Swedish paint industry workers exposed for >10 years to mixed organic solvents (xylene, toluene, isobutanol, n-butanol, ethanol, ethylacetate, n-butylacetate, mineral spirits, methylacetate, methylene chloride, methyl ethyl ketone, and isopropanol) did not have elevated serum concentrations of liver enzymes when compared with nonexposed controls (Lundberg and Hakansson 1985). An early study of 106 painters exposed to toluene in an airplane factory reported enlargement of the liver in 30.2% of the exposed men, versus 7% of the control group (Greenburg et al. 1942). However, before the mid-1950s, chronic occupational exposure to
3. HEALTH EFFECTS

toluene was associated with exposure to benzene, a common contaminant of toluene at that time (EPA 1985c), and this is a confounding factor for this study.

Several case studies have reported effects on the liver from toluene exposure, although the exposure concentration is generally unknown. Acute fatty liver during pregnancy was reported in a 26-year-old woman exposed for at least 2 months to toluene in glue. A liver biopsy done 9 days postpartum showed cytoplasmic change in the hepatocytes; however, there was no clinical or biochemical evidence of liver disease 1 month later (Paraf et al. 1993). A painter who had been exposed to toluene for 5 years exhibited hepatotoxicity, with fatty degeneration of hepatocytes and infiltration by lymphocytes (Shiomi et al. 1993). No effects on blood levels of bilirubin, AP activity, serum AST activity, or serum ALT activity were reported for two workers accidentally exposed to 1,862 ppm toluene for 2–3 hours; however, the liver was enlarged upon palpation in one man (Meulenbelt et al. 1990).

Animal Studies. Acute exposure to toluene has been reported to produce biochemical and ultrastructural changes in the livers of experimental animals. Mice, rats, and rabbits exposed to 795 ppm of toluene for 7 days showed increased liver weights and cytochrome P450 levels compared to unexposed controls (Ungvary et al. 1982). Electron microscopy revealed ultrastructural changes (increased rough or smooth endoplasmic reticulum) in the livers of all three species (Ungvary et al. 1982). Cytochrome b5 levels were also increased in exposed rats and rabbits but were not measured in mice (Ungvary et al. 1982). Male rats exposed to 2,000 ppm toluene for 48 hours had increased serum levels of ALT and AST (Tahti et al. 1983). Exposure of rats to 4,000 ppm toluene for 6 hours resulted in significant increases in hepatic levels of cytochrome P450 (CYP) 2E1, increased hepatic activities of nitrosodimethylamine demethylase and 7-pentoxyresorufin O-depentylase and decreased levels of CYP2C11 (Wang et al. 1996). Increased expression of markers of fibrosis (α-smooth muscle actin, collagen, glucocorticoid receptors, and leptin receptors) was observed in livers of male rats exposed to 1,500 ppm 4 hours/day for 7 days (Gotohda et al. 2009). Rats exposed to 1,500 ppm toluene, 4 hours/day for 7 days demonstrated increased markers of oxidative stress, including 8-Oxo-2’-deoxyguanosine (8-OH-dG) and superoxide dismutase in the liver; however, no significant changes in lipid peroxidase or 4-hydroxy-nonenal levels were seen (Tokunaga et al. 2003).

Intermediate exposure of animals to inhaled toluene has been associated with changes in liver weight, histology, or biochemistry in some, but not all, studies. Increased liver weights were reported for male mice exposed to 4,000 ppm toluene, 3 hours/day, 5 days/week for 8 weeks (Bruckner and Peterson 1981b), female mice exposed to 150 ppm continuously for 30 days (Kjellstrand et al. 1985), rats exposed
3. HEALTH EFFECTS

to $\geq 1,200$ ppm (males) or $\geq 2,500$ ppm (females), or mice exposed to $\geq 625$ ppm for 14 or 15 weeks (NTP 1990). In other studies, male rats and mice exposed to 12,000 ppm toluene for 8 weeks (seven 10-minute exposures separated by 20-minute recovery periods) had decreased liver weights (Bruckner and Peterson 1981b), and no change in liver weight was observed in rats or mice exposed continuously to 150–400 ppm (Ikeda et al. 1986; Kjellstrand et al. 1985; Kyrklund et al. 1987) or rats exposed to 30 or 300 ppm toluene 6 hours/day, 5 days/week for 4 weeks (Poon et al. 1994). No effect on the liver was reported for rats exposed to 200–5,000 ppm toluene for 7 hours/day for 5 weeks (von Oettingen et al. 1942). Several other studies have reported histological or biochemical changes associated with liver damage in animals after intermediate-duration inhalation exposure to toluene. These effects include: increased serum AP activity in male rats exposed to 300 ppm for 6 hours/day, 5 days/week for 4 weeks (Poon et al. 1994); centrilobular hepatocellular hypertrophy in male mice exposed to 2,500–3,000 ppm 6.5 hours/day 5 days/week for 14 weeks (NTP 1990); enlarged hepatic sinusoids filled with blood, minimal hepatic fibrosis (mean severity score of 0.78 on a scale of 0 for no fibrosis through 4 for complete cirrhosis), and increased apoptotic cells in livers in male rats exposed to 3,000 ppm 8 hours/day 6 days/week for 12 weeks (Kanter 2012); and increased serum activities of ALT and AST (but not AP), hepatocyte degeneration, mild pericentral fibrosis, and increased levels of Bax protein (a marker of apoptosis) and apoptotic cells in livers of male rats exposed to 3,000 ppm 1 hour/day for 30 days (Tas et al. 2011, 2013a). No weight changes or histological abnormalities in the liver were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003).

In chronic studies, no exposure-related increased incidences of gross or histopathological liver lesions or changes in liver weight were found in rats exposed to toluene at 300 ppm 6 hours/day 5 days/week for 2 years (CIIT 1980; Gibson and Hardisty 1983) or rats or mice exposed to up to 1,200 ppm 6.5 hours/day, 5 days/week for 15 months or 2 years (NTP 1990).

Renal Effects.

Overview. Studies of chronic toluene abusers, occupationally exposed workers, and laboratory animals have provided little support for irreversible kidney damage due to inhaled toluene. Chronic abuse of toluene can produce acidosis, but in most cases, renal dysfunction was transient, and normal function returns when exposure ceased (Baskerville et al. 2001; Dickson and Luks 2009; Goodwin 1988; Kamijo et al. 1998; Meulenbelt et al. 1990; Patel and Benjamin 1986; Tang et al. 2005). Studies of workers occupationally exposed to 100–200 ppm toluene, which assessed changes in tests of kidney function,
3. HEALTH EFFECTS

have not shown consistent effects across studies (Askergren et al. 1981a, 1981b; Gericke et al. 2001; Gonzalez-Yerba et al. 2006; Nielsen et al. 1985; Stengel et al. 1998). Animal studies indicate that inhalation of toluene caused concentration-dependent kidney damage in rats, but only after repeated exposure to concentrations $\geq 600$ ppm for at least 6 hours/day (Bruckner and Peterson 1981b; CIIT 1980; Gibson and Hardisty 1983; NTP 1990; Ono et al. 1996; von Oettingen et al. 1942).

**Human Studies.** Numerous cases have been reported where toluene abuse was associated with acidosis (Baskerville et al. 2001; Dickson and Luks 2009; Gerkin and LoVecchio 1998; Goodwin 1988; Jone and Wu 1988; Kamijima et al. 1994; Kamijo et al. 1998; Kaneko et al. 1992; Meulenbelt et al. 1990; Patel and Benjamin 1986; Tang et al. 2005; Tsao et al. 2011). Acidosis generally reflects the inability of the kidneys to maintain the pH balance of the blood due either to saturation of kidney transport of hydrogen ions or a defect in tubular function. Associated changes with toluene-induced acidosis and renal tubular dysfunction are low serum levels of potassium (hypokaelemia) and phosphate (hypophostaemia) (Baskerville et al. 2001; Tang et al. 2005; Tsao et al. 2011). Severe renal tubular acidosis was observed in five pregnant women who were chronic abusers of paints containing toluene (Goodwin 1988). When paint-sniffing ended, normal acid-base balance returned within 72 hours, indicating that permanent damage to the tubules had not occurred. Recovery of normal acid-base balance after abuse was stopped also was reported in several other cases (e.g., Baskerville et al. 2001; Dickson and Luks 2009; Tsao et al. 2011). However, one 19-year-old male chronic solvent abuser was found, through a renal biopsy, to have severe tubular interstitial nephritis and focal tubular necrosis indicative of prolonged irritation of the kidney (Taverner et al. 1988). This patient required hemodialysis to correct hematuria and oliguria which was present at the time of his hospital admission. Hemodialysis was also required for a 22-year-old male chronic solvent abuser with acidosis and hypokalemia (Gerkin and LoVecchio 1998). A 22-year-old woman, who had sniffed approximately 6 L of toluene during the previous month, was found to have metabolic acidosis and histological evidence of tubular injury. The acidosis normalized, but both proximal and distal tubular dysfunction persisted (Kamijima et al. 1994). Proteinuria, hematuria, and urinary calculi were reported in three solvent abuse case studies (Kaneko et al. 1992); the abused product was primarily toluene in one case. An autopsy of a 19-year-old woman, who had sniffed thinner containing 67% toluene for 5 years, revealed severe renal tubular degeneration and necrosis (Kamijo et al. 1998).

A group of 43 printing trade workers exposed to inks containing toluene, alcohols, and ethyl acetate for 9–25 years were experimentally exposed to 382 mg/m³ (102 ppm) of toluene for 6.5 hours (Nielsen et al. 1985). No significant differences in excretion of albumin and $\beta$-2-microglobulin were observed either

***DRAFT FOR PUBLIC COMMENT***
before or after exposure when the workers were compared to controls matched by age, educational level, and smoking habits (Nielsen et al. 1985).

In a longitudinal study of 92 printers exposed to 97–232 mg/m³ (26–62 ppm) toluene, markers of early renal damage (microalbumin, N-acetyl-b-D-glucosaminidase, and alanine-aminopeptidase) were not significantly elevated in urine, but creatinine clearance was higher among exposed workers than 74 unexposed control subjects (Stengel et al. 1998). Multiple regression analysis indicated a slight increase in N-acetyl-b-D-glucosaminidase urinary levels with increasing cumulative toluene exposure (+2% per 100 ppm x years), but this relationship was not apparent when 17 subjects with hypertension were excluded from the analysis.

Albumin excretion levels were significantly increased in a group of 134 workers exposed to 5–23 ppm styrene (52 plastic boat manufacturers), 80–106 ppm toluene (42 printers), or unspecified levels of xylene and toluene (40 paint manufacturers), compared with 48 unexposed referents (Askergren et al. 1981a). However, when the solvent-specific subgroups were analyzed separately, only the styrene-exposed workers varied significantly from control. β-2-microglobulin excretion levels where not significantly altered compared with controls when workers were analyzed together or by solvent-specific exposure group (Askergren et al. 1981a). Similarly, no significant changes in glomerular filtration rate between a group of 107 workers exposed to styrene (33 plastic boat manufacturers), toluene (34 printers), and xylene and toluene (40 paint manufacturers), compared with 48 unexposed referents (Askergren et al. 1981b). For the studies by Askergren et al. (1981a), a NOAEL for renal function in this assessment was determined to be the midpoint of the toluene exposure range in printers (93 ppm). Glomerular filtration rate and serum creatinine levels were also not altered in printers and non-printers exposed to median toluene levels of 24 and 4.1 ppm toluene for at least 20 years, compared with unexposed referents (Gericke et al. 2001).

An increased (p<0.05) prevalence of abnormally high urinary activities of N-acetyl-β-D-glucosaminidase (NAG) was observed in a group of 50 toluene-exposed shoe workers (exposure level unspecified), compared with 25 control subjects (26/50 versus 4/25; Gonzalez-Yerba et al. 2006). However, the prevalences of abnormally high urinary albumin excretion, another indicator of renal damage, were not significantly different between the exposed and control groups.

**Animal Studies.** The only renal effects reported in an acute-duration study were increased markers of oxidative stress, including 8-OH-dG and superoxide dismutase, in the kidneys of rats exposed to
3. HEALTH EFFECTS

1,500 ppm toluene, 4 hours/day for 7 days; however, no significant changes lipid peroxidase or 4-hydroxy-nonenal levels were seen (Tokunaga et al. 2003). In intermediate-duration animal studies, histological changes in the kidney have not been observed consistently across studies. Reports of toluene-induced renal histological changes include renal casts in rats exposed to 600–5,000 ppm 7 hours/day for 5 weeks (von Oettingen et al. 1942) and slight to mild necrosis of kidney tubules (5/8 versus 0/8 in controls) with increased kidney weights in male rats exposed to 2,000 ppm toluene (but not 600 ppm), 6 hours/day for 90 days (Ono et al. 1996). No exposure-related renal histological changes were observed in mice exposed to 4,000 ppm 3 hours/day for 8 weeks showing decreased absolute, but not relative, kidney weight (Bruckner and Peterson 1981b); mice and rats showing decreased absolute kidney weights following exposure to 12,000 ppm for 70 minutes/day, 5 days/week for 8 weeks (Bruckner and Peterson 1981b); female mice showing increased relative kidney weight following exposure to 1,250 ppm 6.5 hours/day 5 days/week for 14 weeks (NTP 1990); male or female rats showing increased relative kidney weight after exposure to concentrations between 1,250 to 3,000 ppm 6.5 hours/day 5 days/week for 15 weeks (NTP 1990); male or female rats exposed to 30 or 300 ppm 6 hours/day 5 days/week for 4 weeks (Poon et al. 1994); or F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003).

In chronic-duration animal inhalation studies, evidence for exposure-related renal histological changes is not consistent across studies. No exposure-related renal histological lesions were found in rats exposed to 300 ppm 6 hours/day 5 days/week for 2 years (CIIT 1980; Gibson and Hardisty 1983) or mice exposed to up to 1,200 ppm 6.5 hours/day 5 days/week for up to 2 years (NTP 1990). In male and female rats in the 2-year NTP (1990) study, nearly all control and exposed rats showed nephropathy at sacrifice, but the mean severity score for nephropathy was statistically significantly ($p<0.05$) increased in the high-exposure group (1,200 ppm), compared with the controls (3.2 versus 2.8 in males and 2.7 versus 2.4 in females). In addition, the incidence of renal tubule casts increased with increasing exposure level in male rats: 1/50 in controls; 2/50 at 600 ppm; and 5/50 at 1,200 ppm (NTP 1990).

**Endocrine Effects.** A 29-year-old man who had been sniffing glue containing toluene (concentration not specified) for 18 years was diagnosed with hypothyroidism (Hong et al. 1996). An autopsy of a 19-year-old woman who had been sniffing thinner (67% toluene) for 5 years revealed histological evidence of massive bilateral adrenal hemorrhage with severe degeneration and necrosis of the adrenal cortex (Kamijo et al. 1998). Serum levels of T3 were significantly increased in printers exposed to toluene for an average of 25 years (current median exposure level, 36 ppm), compared with unexposed...
controls (Svensson et al. 1992a). Serum levels of T4, TSH, and prolactin were not altered between exposed and referent groups; however, TSH levels were significantly inversely related with cumulative toluene exposure. Serum levels of prolactin were not changed in workers exposed to median toluene levels of 29 ppm for 3–39 years, compared with control subjects (Svensson et al. 1992b).

Several studies of blood levels of reproductive hormones in repeatedly exposed workers or acutely exposed human subjects have not provided strong and consistent evidence of exposure-related effects. These studies are discussed in Section 3.2.1.5, Reproductive effects.

Workers exposed to a mixture of styrene (0–5.9 ppm), toluene (0–2.02 ppm), and xylene (0–32.65 ppm) demonstrated an increase in fasting insulin and glucose levels compared with unexposed controls (Won et al. 2011). A homeostasis model assessment of insulin resistance levels (HOMA-IR) was significantly higher in the exposed group. After adjustment for age, smoking, alcohol consumption, waist and hip circumference, weight, and regular exercise, fasting glucose levels were still significantly higher in the exposed group, but HOMA-IR was no longer significant. Adjusted analysis was not reported for fasting insulin levels. The results of this study are confounded by mixed exposure and its significance is therefore uncertain.

Evidence for endocrine effects in animals following acute- or intermediate-duration inhalation exposure to toluene is not consistent across studies and does not clearly identify toluene as an endocrine-disrupting chemical.

Serum prolactin levels were significantly (p<0.05) increased (by 62% compared with control values) in male Sprague-Dawley rats, 17 days after exposure to 80 ppm toluene 6 hours/day 5 days/week for 4 weeks (Von Euler et al. 1994). A companion study found no significant changes in serum prolactin levels in rats 29–40 days after exposure to 40, 80, 160, or 320 ppm by the same exposure protocol (Hillefors-Berglund et al. 1995).

Significant (p<0.05) decreases (28 or 47%) in rat brain GFAP induced by exposure to 1,000 ppm toluene, 6 hours/day for 3 or 7 days was associated with significantly increased serum levels of corticosterone (about 393 or 600% increased, compared with control) (Little et al. 1998). Thymus and adrenal weights in exposed rats were not significantly different from nonexposed control values.
Male rats exposed to 1,500 ppm 4 hours/day for 7 days showed significantly (p<0.05) increased adrenal weight (118.2% of control) and adrenocortical cell size (150.7% of control), but not adrenocortical cell number; increased serum levels of ACTH (151.5% of control) and corticosterone (176.1% of control); increased adrenal gland levels of mRNA for a steroid metabolism enzyme, cytochrome P450 side-chain cleavage (P450scc; 131.5% of control); and decreased body weight (92.1% of control) (Gotohda et al. 2005). This exposure scenario was shown to cause, in companion studies, neuronal damage and an increase in glucocorticoid receptor in the hippocampus, suggesting a possible link between the elevated serum levels of ACTH and corticosterone and elevated hippocampal glucocorticoid receptor mRNA (Gotohda et al. 2000a, 2000b, 2002).

No statistically significant (p>0.05) trends for changed levels of FSH, LH, corticosterone, growth hormone, or TSH with increasing exposure level were found in male Sprague-Dawley rats exposed to 80, 500, 1,500, or 3,000 ppm toluene 6 hours/day for 3 days (Andersson et al. 1983b). A significant (p<0.01) trend for increased serum prolactin levels with increasing exposure level was found. Mean prolactin level in 3,000-ppm rats was about 250% of the control value, whereas means in 80-, 500- and 1,500-ppm rats were about 180, 150, and 160% of the control mean, respectively.

In pregnant Wistar rats exposed to 0 or 1,500 ppm 6 hours/day on GDs 7–20, significantly (p<0.05) depressed serum levels of corticosterone were found in exposed dams when measured on GD 14 (88% of control) and GD 18 (60% of control) (Hougaard et al. 2003). Other endocrine end points were not measured in this study.

Female, but not male, rats exposed to 30 or 300 ppm toluene for 6 hours/day, 5 days/week for 4 weeks showed a treatment-related reduction in follicle size of the thyroid (Poon et al. 1994).

No effect on the adrenal glands was reported for rats exposed to 200–5,000 ppm toluene for 7 hours/day for 5 weeks (Von Oettingen et al. 1942). In a multigenerational study, no histological abnormalities on
the pancreas, adrenal, or thyroid glands were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003). Mice exposed to up to 2,500 ppm for 14 weeks (NTP 1990), rats exposed to up to 3,000 ppm for 15 weeks, and mice and rats exposed to up to 1,200 ppm for 2 years (NTP 1990) showed no histological abnormalities in the pancreas, adrenal, or thyroid glands.

**Dermal Effects.** No studies were located regarding dermal effects in humans after inhalation exposure to toluene.

In a multigenerational study, no effects on the skin were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003).

**Ocular Effects.** Humans exposed for 6–8 hours to toluene concentrations of ≥100 ppm developed irritation of the eyes (Andersen et al. 1983; Baelum et al. 1985; Carpenter et al. 1944; Meulenbelt et al. 1990). No irritation was reported with 6 hours of exposure to 40 ppm toluene (Andersen et al. 1983). Reports of color vision deficits in occupationally exposed workers have linked increased color confusion with chronic exposure to toluene (Campagna et al. 2001; Cavalleri et al. 2000; Muttray et al. 1997, 1999; Zavalic et al. 1998a, 1998b, 1998c). These studies are discussed in the Section 3.2.1.4, Neurological Effects.

Pregnant rats exposed to 2,000 ppm 6 hours/day for 21 days showed lacrimation (Ono et al. 1996), but no lacrimation or discharge was reported for male, female, or pregnant female rats exposed to 100–2,000 ppm, 6 hours/day for 95 days (API 1985; Roberts et al. 2003). Results from studies of visual impairment in rats after acute or intermediate inhalation exposure to toluene are discussed in Section 3.2.1.4, Neurological Effects.

**Body Weight Effects.** No studies were located regarding body weight effects in humans after inhalation exposure to toluene.

Findings regarding body weight effects in animals are inconsistent. Body weights in rats decreased compared with controls following inhalation exposure to toluene concentrations of 2,000 ppm for 48 hours (Tahti et al. 1983); 1,500 ppm, 4 hours/day for 7 or 20 days (Gotohda et al. 2005; Ishigami et al. 2005); 2,000 ppm, 8 hours/day, 7 days/week for 11 or 23 weeks (Pryor 1991); 320 ppm, 24 hours/day for
3. HEALTH EFFECTS

30 days (Kyrklund et al. 1987); 8,000 ppm 2–2.5 hours/day, 5 days/week for 13 weeks (Mattsson et al. 1990); 12,000 ppm 70 minutes/day, 5 days/week for 8 weeks (Bruckner and Peterson 1981b); and 2,500 ppm, 6.5 hours/day for 15 weeks (NTP 1990). Significantly decreased body weight gain was observed in male rats continuously exposed to 200 or 400 ppm for 30 days (Ikeda et al. 1986). Decreased body weights were seen in female and male mice exposed 6.5 hours/day for 14 weeks to concentrations ≥100 and 2,500 ppm, respectively (NTP 1990), and in male mice exposed to 4,000 ppm, 3 hours/day or 12,000 ppm 70 minutes/day for 8 weeks (Bruckner and Peterson 1981b). In contrast, no exposure-related effects on body weights were observed in rats or mice exposed to 1,000 ppm toluene for 6 hours/day, 5 days/week, for 20, 28, 42, or 90 days (API 1997; Beasley et al. 2010, 2012; Horiguchi and Inoue 1977), mice exposed to up to 6,000 ppm toluene 30 minutes/day for 40 days (Bowen and McDonald 2009), rats exposed to up to 2,000 ppm toluene 6 hours/day for 90 or 95 days (API 1985; Ono et al. 1996; Roberts et al. 2003), or rats or mice exposed to up to 1,200 ppm toluene 6–6.5 hours/day for 15 months or 2 years (CIIT 1980; Gibson and Hardisty 1983; NTP 1990); mean body weights in exposed animals were within 10% of control means.

Other Systemic Effects. No studies were located regarding other systemic effects in humans or animals after inhalation exposure to toluene.

3.2.1.3 Immunological and Lymphoreticular Effects

Overview. Human studies of immunological end points in toluene-exposed subjects do not identify consistent or strong evidence for toluene effects on immune system end points such as counts of blood lymphocytes or levels of blood immunoglobulins (Little et al. 1999; Pelclova et al. 1990; Stengel et al. 1998; Yin et al. 1987). In animal studies, evidence for toluene effects on the immune system includes the finding of decreased resistance to mortality from respiratory infection by S. zooepidemicus in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm, but not 1 ppm (Aranyi et al. 1985). No evidence for exposure-related adverse changes in weight or histology of the spleen or thymus has been reported in animals exposed by inhalation for intermediate (NTP 1990; Poon et al. 1994; von Oettingen et al. 1942) or chronic durations (NTP 1990). In a series of studies from a single laboratory, intermediate-duration inhalation exposures of normal or allergy-challenged [ovalbumin (OVA)-immunized and challenged] mice to toluene concentrations <100 ppm have been reported to modulate immune system end points, but mechanistic understanding of the observed changes is insufficient to determine their biological adversity (Fujimaki et al. 2009a, 2009b, 2010, 2011; Liu et al. 2010; Takeda et al. 2013; Win-Shwe et al. 2007a, 2010a, 2010b, 2012a, 2012b; Yamamoto et al. 2009).
Occupational Human Exposure Studies. No differences in serum IgG, IgA, or IgM values were noted between a group of 42 rotogravure printers exposed to concentrations of 104–1,170 ppm (midpoint, 637 ppm) for an average of 13 years and a group of 16 office and technical workers exposed to toluene concentrations ranging from 2.1 to 4.3 ppm at the same facility (Pelclova et al. 1990). Blood IgE levels in 92 printers exposed to 97–232 mg/m³ (26–62 ppm) toluene for an average of 16 years were not significantly elevated compared to unexposed controls, but a dose-response relationship was observed between cumulative toluene exposure and IgE levels (Stengel et al. 1998). Relative lymphocyte counts in blood (but not absolute counts) were significantly decreased in a group of workers who were involved in shoemaking, printing, or audio equipment production and were predominately exposed to toluene (Yin et al. 1987). Mean toluene exposures were 41 ppm for females and 46 ppm for males over an average of 82 months.

A number of other studies have examined immune-related end points in toluene exposed workers, but the results of these studies are confounded by mixed exposure to other solvents. A decrease in the T lymphocyte count of workers occupationally exposed to a mixture of benzene (0–116 ppm), toluene (0–160 ppm), and xylene (0–85 ppm) was observed (Moszczynsky and Lisiewicz 1984). However, no signs of diminished immunological function or disturbances in immune skin reactions against such antigens as tuberculin or distreptase were observed in the subjects studied. The reduction of T lymphocytes may have been the result of the depressive effect of benzene on the lymphocyte system. Workers exposed to a mixture of 0.8–40 ppm toluene (0.003–0.16 mg/L), 56–940 ppm benzene (0.18–3.0 mg/L), and 40–609 ppm xylene (0.18–3.0 mg/L) had significantly lower serum IgG and IgA levels than unexposed controls (Lange et al. 1973). Leukocyte agglutinins for autologous leukocytes and increased leukoagglutination titer in human sera after incubation with the solvents were also observed (Lange et al. 1973). No effects on natural killer cell activity or serum levels of IL-2 or γ-IFN were observed in shoe factory workers, compared with a control group of workers not exposed to solvents (Yucesoy et al. 1999). Mean 8-hour TWA breathing zone concentrations of solvents in shoe workplaces were about 58 ppm for n-hexane, 27 ppm for toluene, and 11 ppm for methyl ethyl ketone. Mean concentrations of hippuric acid and 2.5-hexadione in exposed workers were about 2- and 3-fold higher than concentrations in nonexposed controls (Yucesoy et al. 1999). Multiple linear regression analysis showed significantly (p<0.05) decreased production of TNF, but not IL-10 or IL-12, in cultured peripheral blood mononuclear cells from a high accumulated exposure group of paint factory workers, compared with a low-exposure group (Haro-Garcia et al. 2012). Mean 8-hour TWA concentrations of solvents in the factory were about 12 mg/m³ for benzene, 28 mg/m³ (7 ppm) for toluene, and 19.5 mg/m³ for xylene. Mean urinary

***DRAFT FOR PUBLIC COMMENT***
concentrations of S-phenylmercapturic acid were about 3.4 and 2.4 µmol/mol creatinine in the high- and low-exposure groups, respectively (Haro-Garcia 2012). Workers exposed to a mixture of styrene (0–5.9 ppm), toluene (0–2.02 ppm), and xylene (0–32.65 ppm) demonstrated a significant increase in serum TNFα compared with unexposed controls (Won et al. 2011). No change was observed in IL-1β or IL-6. However, alterations in serum TNFα were significantly associated with urinary phenylglyoxylic acid levels, not urinary hippuric acid levels, indicating that alterations are associated with styrene exposure rather than toluene exposure (Won et al. 2011).

**Controlled Exposure Human Studies.** Serum levels of T-cell proteins specific for a benzoic acid-human serum albumin antigen were elevated following a 20-minute exposure to 15 ppm in a group of 20 subjects who were clinically sensitive to toluene, compared with a group of 16 subjects who were not sensitive to toluene (Little et al. 1999). No significant differences in levels of IgG specific to the antigen were found between the groups following exposure to toluene. These findings may indicate sensitization to benzoic acid, a metabolite of toluene.

**Animal Studies.** Single 3-hour exposures of mice to 2.5, 10, 25, 50, 100, 250 or 500 ppm toluene, immediately before inhalation exposure to aerosols of *S. zooepidemicus*, significantly (p<0.05) decreased the resistance to mortality from the respiratory infection (Aranyi et al. 1985). For example, the respective mortality percentages in exposed and control groups were: 500 ppm, 56.8 and 20.7%; 50 ppm, 25.0 and 6.4%; and 2.5 ppm, 26.1 and 12.6%. A 3-hour exposure to 1.0 ppm toluene once or for 5 or 20 consecutive days did not significantly change the resistance to infection-induced mortality, compared with control, nonexposed mice. In another assay, mice were exposed to varying concentrations (0.1, 2.5, 5, 10, 25, 50, 100, 250, or 500 ppm) of toluene for 3 hours, followed immediately by inhalation exposure to aerosols of 35S-labeled *Klebsiella pneumonia* and determination of the percent of bacteria killed in the lungs 3 hours later (Aranyi et al. 1985). Exposure before infection to toluene at all concentrations except 5 and 50 ppm significantly (p<0.05) decreased the pulmonary bactericidal activity, but no clear dose-response relationship was apparent. For example, the percentages of bacteria killed in 3 hours in respective exposed and control groups were: 500 ppm, 85.9 and 71.9%; 100 ppm, 87.3 and 73.4%; 50 ppm, 82.3 and 84.1%; and 2.5 ppm, 84.6 and 79.2%. A 3-hour exposure to 1.0 ppm toluene once or for 5 or 20 consecutive days before infection did not consistently produce significant (p<0.05) changes in pulmonary bactericidal activities against *K. pneumonia*. The results show most clearly that acute exposure to toluene concentrations ≥2.5 ppm decreased the resistance to mortality from respiratory infection with *S. zooepidemicus*. 

***DRAFT FOR PUBLIC COMMENT***
3. HEALTH EFFECTS

No changes in weight or histology of the spleen were recorded for rats exposed to 30–5,000 ppm toluene, 6–7 hours/day for 4–5 weeks (Poon et al. 1994; von Oettingen et al. 1942) or for rats and mice exposed to toluene concentrations up to 3,000 ppm for 14–15 weeks (NTP 1990). In rats and mice exposed to concentrations of toluene up to 1,200 ppm, 6.5 hours/day for 2 years, an increased incidence of pigmentation of the spleen was observed in male mice exposed to concentrations ≥120 ppm (NTP 1990).

Decreased thymus weights were observed in male rats exposed to 2,000 ppm 6 hours/day for 90 days (Ono et al. 1996) and in dams exposed to 600 ppm 6 hours/day during GDs 7–17 (Ono et al. 1995). However, no effects on the thymus were reported in rats and mice exposed 6 hours/day to up to 1,200 ppm for 2 years or up to 3,000 ppm toluene for 14–15 weeks (NTP 1990) or in male rats exposed to 1,000 ppm toluene for 6 hours/day for up to 42 days (API 1997).

In a multigenerational study, no histological abnormalities were observed the thymus or spleen from F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003).

The highest NOAEL values and all LOAEL values for each reliable study for immunological effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

In a series of studies from a single laboratory, intermediate-duration inhalation exposures of normal or allergy-challenged (OVA-immunized and challenged) adult mice to toluene concentrations <100 ppm have been reported to modulate a number of immune system end points (Fujimaki et al. 2009a, 2009b, 2010, 2011; Liu et al. 2010; Takeda et al. 2013; Win-Shwe et al. 2007a, 2010a). Examined end points included BAL fluid cell counts, mRNA or protein levels for inflammatory cytokines, anti-microbial peptides, neurotrophins, neurotrophin receptors or other immune regulatory transcription factors in lung, BAL fluid or hippocampus, and plasma levels of antibodies. Another series of studies from the same laboratory examined immune system end points in postnatal day (PND) 21 male BALB/c mice exposed to 0, 5, or 50 ppm toluene 6 hours/day on GD 14 through 21 (Yamamoto et al. 2009) or on GDs 14–18, PNDs 2–6, or PNDs 8–12 (Win-Shwe et al. 2010b, 2012a, 2012b). Examined end points included brain, thymus, or spleen weights, plasma levels of antibodies, and mRNA levels for cytokines and transcription factors in the spleen or hippocampus. Current mechanistic understanding of the observed findings in these studies, which include evidence for non-monotonic dose-related changes in several end points (described in more detail in the following paragraphs), is insufficient to determine their possible
3. HEALTH EFFECTS

biological adversity, and NOAEL or LOAELs from these studies are not included in Table 3-1 or Figure 3-1.

In allergy-challenged male C3H/HeN mice exposed nose-only to 0, 9, or 90 ppm 30-minutes on days 0, 1, 2, 7, 14, 21, and 28, significantly (p<0.05) changed numbers of macrophages were found in BAL fluid samples from 9-ppm mice (~50% increased over non-exposed control) and 90-ppm mice (~25% decreased over control) (Win-Shwe et al. 2007a). Significantly increased numbers of macrophages also were found in BAL fluid in normal C3H/HeN mice exposed to 9 ppm (~130% increased) and 90 ppm (~260% increased). No significant exposure-related changes were found in other cellular end points in BAL fluid from exposed normal or allergy-challenged mice: numbers of total inflammatory cells, neutrophils, lymphocytes, or eosinophils. Levels of mRNAs for certain cytokines in lungs of allergy-challenged mice were significantly changed in 9-ppm mice (IL-5, ~100% increased) and 90-ppm mice (IFN-γ, ~70% decreased), but no exposure-related changes were noted in mRNAs for IL-4 or IL-12. In allergy-challenged mice, significant (p<0.05) changes were found in plasma levels of total IgE at 90 ppm (~100% increased), anti-OVA IgE at 9 ppm (~500% increased), total IgG1 at 9 and 90 ppm (~75% increased at each concentration), and anti-OVA IgG1 at 9 ppm (~90% increased); no significant changes were found in plasma levels of total IgG2 and anti-OVA IgG2. In allergy-challenged mice, toluene exposure led to several significant biochemical changes in the lungs, including increased plasma NGF in 9-ppm mice (~200% increased) and decreased lung levels of mRNA for brain-derived nerve factor (BDNF, ~40% decreased) and tropomyosin-related kinase A (Trk A, ~50% decreased) in 9- and 90-ppm mice; no significant exposure-related changes were found in lung levels of mRNAs for NGF, neurotrophin-3 (NT-3), or Trk B. The neurotrophins were measured in these studies to investigate a hypothesis that low-level toluene exposure may aggravate airway inflammation responses in allergy-challenged mice by modulating signaling pathways in neurological and immune systems (i.e., modulating neuroimmune cross talk).

In another study with allergy-challenged male C3H/HeN mice exposed nose-only to 0 or 9 ppm for 30 minutes on days 0, 1, 2, 7, 14, 21, and 28, significantly (p<0.05) increased total cell and macrophage counts (both ~200% increased) were found in BAL fluid from 9-ppm mice, compared with controls (Fujimaki et al. 2009a). No significant exposure-related changes were found in numbers of polymorphonuclear leukocytes and lymphocytes. Levels of BDNF in BAL fluid from 9-ppm mice were also significantly increased (~130%). Levels of NGF in BAL fluid were not increased in exposed mice, but plasma levels of NGF were significantly increased by about 120% above levels in non-exposed mice. Exposure-related effects were diminished by treatment with anti-CD4 antibody. The latter result suggests

***DRAFT FOR PUBLIC COMMENT***
that the observed toluene-induced effects may involve CD4+ cells, which have been reported to produce BDNF and NGF.

In allergy-challenged male C3H/HeN mice exposed nose-only to 0, 9, or 90 ppm 30 minutes/day on days 0, 1, 2, 7, 14, 21, 28, 35, 42, 49, and 56, significant (p<0.05) exposure-related changes were found in lung levels of mRNAs for NGF (~70% increased over nonexposed controls), the NGF receptor, Trk A (~100% increased), CCL2 (~140% increased), and CCL3 (~90% increased) at 9 ppm, but not at 90 ppm (Fujimaki et al. 2009b). No significant exposure-related changes were found in lung levels of mRNA for p75 neurotrophin receptor (p75NTR). Light microscopy of lungs from allergy-challenged mice exposed to 9 ppm showed peribronchial inflammation with eosinophil infiltration, but incidences of mice with this condition were not reported by the study authors. In mice that were not allergy challenged (“unchallenged” mice), exposure to 9 ppm led to slight hyperplasia of bronchial epithelia without accumulation of macrophages and neutrophils. Immunohistological examination for NGF-positive cells showed a “few” NGF-positive bronchial epithelial cells in 9-ppm unchallenged mice and “marked increase” in 9-ppm allergy-challenged mice. The study report did not mention histological findings for the 90-ppm unchallenged or allergy-challenged mice.

Similarly, C3H/HeN mice exposed nose-only to 0 or 9 ppm for 30 minutes/day on days 0, 1, 2, 7, and 14 or days 0, 1, 2, 7, 14, 21, 28, 35, 42, and 49 demonstrated qualitative damage to the tracheal epithelial structure in exposed groups with >50% of the epithelial cells in the trachea being “remarkably damaged” in mice exposed up to day 49 (Takeda et al. 2013). Again, incidences of mice with these findings were not reported by the study authors. The allergy-challenged group did not differ from the toluene-only group. No damage was observed with a single 30-minute exposure to 9 ppm, and no lymphocyte infiltration was observed in any group. This study also examined protein expression of biophylaxis factors in the lungs, including toll-like receptor 2 (TLR2), α defensin (NP-3), and β defensins (BD 1-4). BD-2 was significantly decreased with exposure until day 14 or 49 (~10 and 50%, respectively) while BD-4 was significantly increased (~80%) with the shorter exposure group, but significantly decreased (~35%) with longer exposure. No changes were observed in NP-3, BD-1, BD-3, or TLR2 levels. Protein expressions in allergy-challenge mice were not reported.

Thymus cells, but not spleen cells, from normal male C3H/HeN mice exposed to 50 ppm 6 hours/day, 5 days/week for 3 weeks (in inhalation chambers) showed enhanced proliferation in culture (measured by rate of thymidine incorporation into DNA) by concanavalin A (Con A), compared with cells from nonexposed mice (Liu et al. 2010). Thymocytes from toluene-exposed mice also showed increased levels
of the cytokine, IL-2, in response to Con A, and enhanced DNA-binding activities of transcription factors involved in IL-2 production (NF-κB, STAT5, and NF-AT), compared with thymocytes from non-exposed mice (Liu et al. 2010).

Cultured spleen cells from male B10.BR mice exposed to 50 ppm toluene 6 hours/day, 5 days/week for 6 weeks in inhalation chambers showed significantly enhanced LPS-stimulated proliferation in normal mice and decreased LPS-stimulated proliferation in allergy-challenged, compared with spleen cells from B10.BR mice exposed to 0 or 5 ppm toluene (Fujimaki et al. 2010). In contrast, cultured spleen cells from normal or allergy-challenged male C57Bl/10 mice exposed to 0, 5, or 50 ppm by the same protocol for 6 weeks showed no significant (p>0.05) difference in Con A- or LPS-stimulated proliferation. Spleens from allergy-challenged B10.BR mice exposed to 5 ppm showed significantly increased mRNA levels, compared with controls, for transcription factors Foxp3, STAT5, and STAT6, but no changes in these transcription factors were apparent in spleens from normal or allergy-challenged B10.BR mice exposed to 50 ppm or in normal or allergy-challenged C57Bl/10 mice (Fujimaki et al. 2010).

Levels of hippocampal mRNAs for two neurotrophins and their receptors (NGF, Trk A, BDNF, and Trk B) were significantly (p<0.05) increased in normal male C3H/HeN mice exposed to 500 ppm 6 hours/day 5 days/week for 6 weeks inhalation chambers, but not after exposure to 5 or 50 ppm (Win-Shwe et al. 2010a). In allergy-challenged male C3H/HeN mice, hippocampal mRNA levels for NGF were significantly increased in 50-ppm mice, but not in 5- or 500-ppm mice. Exposure of normal male BALB/c and C57BL/10 mice by the same protocol to 5, 50, or 500 ppm did not produce significant (p>0.05) changes in these end points, except for increased mRNA for BDNF in 500-ppm normal BALB/c mice. The results demonstrate differences among mouse strains in responsiveness of these end points to toluene exposure.

Significantly (p<0.05) increased number of total cells in BAL fluid samples (~50% increased over the non-exposed control value) was observed in allergy-challenged male C3H/HeN mice exposed to 50 ppm toluene 6 hours/day, 5 days/week for 6 weeks, but no significant changes were observed in allergy-challenged mice exposed to 5 or 500 ppm, or to allergy-challenged mice after 3 weeks of exposure to any of the three tested concentrations (5, 50, or 500 ppm; Fujimaki et al. 2011). No significant changes were found in numbers of other cell types found in BAL fluid (macrophages, lymphocytes, neutrophils, eosinophils) at any of the three tested concentrations in allergy-challenged mice after 3 or 6 weeks of exposure. No significant (p>0.05) exposure-related changes in BAL fluid cell counts were noted in normal mice exposed to 5, 50, or 500 ppm. Also reported for 50-ppm allergy-challenged mice were
increased hypertrophy and hyperplasia in bronchial epithelium and mucus secretion in lungs without accumulation of alveolar inflammatory cells (but incidence was not reported) and significantly increased lung levels of fibronectin (35% increased compared with 0-ppm allergy-challenged mice), but not fibronectin. The report did not mention histological findings in lungs of 5- or 500-ppm mice. Significantly (p<0.05) increased splenic mRNA levels for immune regulatory transcription factors (STAT3, STAT4, STAT5, STAT6, GATA3, Foxp3, IL-4, and IL-12) were measured in 50-ppm allergy-challenged mice; in 5- or 500-ppm mice mRNA levels for most of these transcription factors in spleens were not significantly different from levels in spleens of 0-ppm allergy-challenged mice. In exposed allergy-challenged mice, the only significant (p<0.05) change in levels of plasma immunoglobulins was for increased total IgG1 at 50 ppm (~90% increased); no significant exposure-related changes were found in levels of total IgE, IgG2a, or antigen-specific antibodies (anti-OVA IgE, anti-OVA IgG1, anti-OVA IgG2a). The authors concluded that although exposure to 50 ppm toluene increased the expression of transcription factors in the spleen and plasma levels of total IgG1, the overall results “did not show a strong correlation between toluene exposure and exacerbation of allergic responses.”

Yamamoto et al. (2009) examined spleen weight, plasma antibody levels, and splenic mRNA levels for cytokines and transcription factors in PND 21 male mice exposed to 0, 5, or 50 ppm 6 hours/day on GD 14 through PND 21 with or without exposure to peptidoglycan (PGN, a putative suppressor of type 2 humoral allergic responses). Findings for PND 21 mice exposed to toluene without peptidoglycan exposure were:

- increased absolute (29% increased) and relative (24% increase) spleen weight at 50 ppm, compared with 0- or 5-ppm mice (see Table 3-2);
- significantly decreased plasma levels of IgE and IgG2a antibodies at 50 ppm and significantly increased levels of IgG1 antibodies at 5 and 50 ppm; and
- significantly decreased splenic mRNA levels for transcription factors T-bet, GATA-3, and Foxp, but no exposure-related changes in splenic mRNA levels of cytokines IFN-γ, IL-12, IL-4, or IL-5.

When the dams and offspring were exposed to PGN several times during gestation and through PND 21, a different pattern of findings emerged in PND 21 male offspring:

- increased absolute (≥32% increase) and relative (≥35% increase) spleen weights in all PGN+toluene groups, compared with 0-ppm toluene alone controls, but no significant differences among the PGN+toluene groups (see Table 3-2);
- no significant differences in IgE levels among PGN+ toluene groups; significantly decreased plasma levels of IgG1 at PGN+50 ppm and IgG2a at PGN+5 ppm and PGN+50 ppm, compared with PGN+0 ppm controls;
### Table 3-2. Mean Spleen Weight (SE) for PND 21 Mice (n=6/Group) Exposed to Toluene 6 Hours/Day on GD 14 Through PND 21 With and Without Exposure to PGN

<table>
<thead>
<tr>
<th>Exposure group</th>
<th>Spleen weight (mg)</th>
<th>Relative spleen weight (% spleen: body weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 ppm</td>
<td>74.73 (3.63)</td>
<td>0.81 (0.043)</td>
</tr>
<tr>
<td>5 ppm</td>
<td>68.75 (3.10)</td>
<td>0.71 (0.028)</td>
</tr>
<tr>
<td>50 ppm</td>
<td>96.40 (5.84)</td>
<td>1.01 (0.054)</td>
</tr>
<tr>
<td>0 ppm + PGN</td>
<td>105.03 (5.39)</td>
<td>1.16 (0.055)</td>
</tr>
<tr>
<td>5 ppm + PGN</td>
<td>105.68 (3.65)</td>
<td>1.15 (0.037)</td>
</tr>
<tr>
<td>50 ppm + PGN</td>
<td>98.62 (5.31)</td>
<td>1.09 (0.058)</td>
</tr>
</tbody>
</table>

*a* p<0.01, compared with 5-ppm toluene group, as reported by study authors.

*b* p<0.01, compared with 0-ppm toluene group, as reported by study authors.

GD = gestation day; PGN = peptidoglycan; PND = postnatal day; SE = standard error

Source: Yamamoto et al. 2009
3. HEALTH EFFECTS

- significantly decreased splenic mRNA levels for Foxp3 at PGN+5 ppm and PGN+50 ppm, compared with PGN+0 ppm, but no exposure-related changes in splenic mRNA levels of cytokines IFN-γ, IL-12, IL-4, IL-5, T-bet or GATA-3 among PGN+toluene groups.

This study found toluene-induced increased spleen weight in offspring at 50 ppm, but no apparent response of spleen weight to toluene with co-exposure to PGN, a suppressor of type 2 humoral allergic responses. Mechanistic understanding is insufficient to determine the adversity of the observed pattern of changes in plasma immunoglobulins and splenic mRNA levels for transcription factors related to type 1 and type 2 immune responses in the spleen.

Win-Shwe et al. (2010b) examined weights of brain, lung, thymus, and spleen, and hippocampal mRNA levels for neurotrophic factors, inflammatory cytokines, astrocyte marker GFAP, microglia marker Iba1, and several other transcription factors in PND 21 male mice exposed to 0, 5, or 50 ppm 6 hours/day on GDs 14–18, PNDs 2–6, or PNDs 8–12. No significant (p>0.05) exposure-related changes were found in body weight or weights of brain, lung, thymus, or spleen. Statistically significant changes (compared with nonexposed controls) were reported in hippocampal mRNA levels for the following neuroimmune factors in PND 21 male mice:

- increased NGF at 50 ppm with PND 2–6 exposure and at 5 ppm (but not 50 ppm) with PND 8–12 exposure;
- increased BDNF at 5 and 50 ppm with PND 8–12 exposure;
- increased CCL3 at 5 ppm with PND 8–12 exposure;
- increased TNF-α at 50 ppm with PND 2–6 exposure and at 5 ppm with PND 8–12 exposure;
- increased GFAP at 5 ppm with PND 8–12 exposure;
- increased Iba1 at 50 ppm with GD 14–18 exposure and at 5 ppm with PND 8–12 exposure;
- increased HO-1 at 50 ppm with PND 2–6 and 5 ppm with PND 8–12;
- increased TLR4 at 5 ppm with PND 8–12 exposure; and
- increased NF-κB at 50 ppm with PND 2–6 and at 5 and 50 ppm with PND 8–12 exposure.

Most of the examined neuroimmune factors were upregulated at 5 ppm (but not 50 ppm) with PND 8–12 exposure. Of the 10 factors examined, only one (CCL2) was not upregulated. It is unclear why exposure to 50 ppm in this period did not upregulate most of the factors upregulated by 5 ppm with PND 8–12.
3. HEALTH EFFECTS

exposure. Exposure during GDs 14–18 upregulated only GFAP at 5 ppm and Iba1 at 50 ppm, whereas exposure during PNDs 2–6 upregulated only NGF, TNF-α, HO-1, and NF-κB at 50 ppm.

Win-Shwe et al. (2012a) examined lung, spleen, and thymus weights, plasma levels of antibodies, percentage distribution of splenic T lymphocytes, and splenic mRNA levels for inflammatory cytokines and transcription factors in PND 21 male mice exposed to 0, 5, or 50 ppm 6 hours/day on GDs 14–18, PNDs 2–6, or PNDs 8–12. The only significant (p<0.05) exposure-related changes found in body weight or weights of thymus, left lung, or spleen were decreased weight of thymus and spleen at 5 ppm (but not 50 ppm) with PND 8–12 exposure. The magnitudes of these decreases were not reported. Statistically significant changes (p<0.05, compared with nonexposed controls) reported in blood and splenic immune system end points in PND 21 male mice included:

- decreased plasma levels of total IgG2a antibodies at 5 ppm (but not 50 ppm) with PND 2–6 exposure and increased levels at 5 ppm (but not 50 ppm) with PND 8–12 exposure;
- decreased plasma levels of total IgG1 antibody at 5 and 50 ppm with GDs 14–18 and PND 8–12 exposure and at 50 ppm with PND 2–6 exposure;
- decreased percentage CD+4 splenic T lymphocytes at 50 ppm with PND 2–6 and 8–12 exposure;
- decreased IL-12 mRNA levels in spleen at 5 and 50 ppm with PNDs 2–6 and 8–12 exposure; and
- decreased T-bet and Foxp3 mRNA levels in spleen at 5 and 50 ppm with PND 2–6 and 8–12 exposure.

No significant exposure-related changes were found in IFN-γ or GATA3 mRNA levels in spleen.

Exposure during PNDs 8–12 produced changes in a greater number of examined end points in PND 21 mice than exposure during GDs 14–18 (decreased plasma total IgG1 at 5 and 50 ppm) or PNDs 2–6 (decreased IgG2a antibodies, IgG1 antibodies, and percentage of CD+4 lymphocytes in spleen at 5 ppm, and decreased splenic IL-12, T-bet, and Foxp3 mRNA at 5 and 50 ppm) (Win-Shwe et al. 2012a). End points modulated with PND 8–12 exposure were:

- decreased thymus and spleen weight at 5 ppm;
- increased IgG2a antibodies at 5 ppm;
- decreased plasma IgG1 antibodies and decreased splenic mRNA levels for IL-12, T-bet, and Foxp3 at 5 and 50 ppm; and
- decreased percentage of CD+4 and CD8+ lymphocytes in the spleen at 50 ppm.

***DRAFT FOR PUBLIC COMMENT***
3. HEALTH EFFECTS

Following the same gestational and postnatal exposure protocol, mRNA levels of neurotrophic factors (NGF, BDNF), pro-inflammatory cytokines (CCL2, CCL3, TNF-α), NGF transcription factor NF-kB, neurogenesis modulator toll-like receptor 4 (TLR4), oxidative stress marker HO-1, astrocyte marker GFAP, and microglia marker Iba-1 were determined in the hippocampus of offspring on PND 21 (Win-Shwe et al. 2012b). Significantly increased mRNA levels (~133-600%) were reported for NGF, BDNF, TNF-α, CCL3, NF-kB, TLR4, GFAP, Iba-1, and HO-1 in the 5 ppm group exposed from PND 8 to 12, NGF, TNF-α, NF-kB, and HO-1 in the 50 ppm group exposed from PND 2 to 6, and NF-kB in the 50 ppm group exposed from PND 8 to 12. No mRNA alterations were observed with exposure from GD 14 to 18, compared with control. No changes were found in neonatal body weight or relative organ weights of the brain, thymus, lung, or spleen in any exposure group.

3.2.1.4 Neurological Effects

Overview. Dysfunction of the central nervous system is a critical human health concern following acute, intermediate, or chronic inhalation exposure to toluene. Chronic toluene abuse in humans has been associated with neurotoxic symptoms, narcosis, permanent damage to the central nervous system, and death (Aydin et al. 2002, 2003; Byrne et al. 1991; Caldemeyer et al. 1996; Capron and Logan 2009; Deleu and Hanssens 2000; Devathasan et al. 1984; Filley et al. 1990; Ryu et al. 1998; Gupta et al. 2011; Hormes et al. 1986; Hunnewell and Miller 1998; Ikeda and Tsukagoshi 1990; Kamran and Bakshi 1998; King et al. 1981; Kiyokawa et al. 1999; Kucuk et al. 2000; Maas et al. 1991; Maruff et al. 1998; Meulenberg et al. 1990; Miyagi et al. 1999; Papageorgiou et al. 2009; Poblano et al. 1996; Rosenberg et al. 1988a, 1988b, 2002; Ryu et al. 1998; Suzuki et al. 1983; Uchino et al. 2002; Yamanouchi et al. 1995). Self-reported neurological symptoms and reduced ability in tests of cognitive and neuromuscular function have been observed in humans occupationally exposed to average concentrations as low as 40–150 ppm (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Murata et al. 1993; Nordling Nilson et al. 2010; Orbach and Nise 1989; Ukai et al. 1993; Yin et al. 1987). Performance deficits in tests of neurobehavior have also been observed in healthy volunteers acutely exposed to controlled concentrations >40 ppm (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1991; Rahill et al. 1996; von Oettingen et al. 1942) and in laboratory animals repeatedly exposed to >1,000 ppm toluene (Baydas et al. 2005; Bikashvili et al. 2012; Bowen et al. 2007; Castilla-Serna et al. 1991; Duncan et al. 2012; Lorenzana-Jimenez and Salas 1990; Mattsson et al. 1990; Miyagawa et al. 1998; Oshiro et al. 2007; Pryor 1991; Pryor and Rebert 1992). Studies of occupationally exposed workers also indicate that chronic exposure to average concentrations as low as 50–130 ppm damages hearing and color vision presumably involving, at least in part, effects on neurological
3. HEALTH EFFECTS


Controlled Human Exposures

**Overview.** Acute exposure of healthy human subjects to toluene concentrations ≤50 ppm did not result in adverse neurological effects in a number of studies (Andersen et al. 1983; Lammers et al. 2005a; Muttray et al. 2005; Osterberg et al. 2000, 2003), and concentrations ≥75 ppm resulted in subtle neurological impairments in most studies (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1991; Gamberale and Hultengren 1972; Rahill et al. 1996; von Oettingen et al. 1942). In contrast, studies examining individuals who were clinically sensitive to toluene (e.g., multiple chemical sensitivities) found minor neurological deficits at concentrations as low as 12–48 ppm (Little et al. 1999; Orbaek et al. 1998; Osterberg et al. 1998; Osterberg et al. 2003).

**Healthy Volunteers.** No significant, dose-related increases in subjective complaints of neurological effects and/or altered performance on neurobehavioral tasks were observed in a number of studies of healthy volunteers following exposure to toluene concentrations of 10–50 ppm for 2–6 hours (Andersen et al. 1983; Muttray et al. 2005; Osterberg et al. 2000, 2003). Similarly, 11 males exposed to 40 ppm toluene for 4 hours did not attain impaired scores on six neurobehavioral measures designed to assess mood and cognitive and motor functions, compared with pre-exposure scores (Lammers et al. 2005a). However, blood toluene levels, measured at 60, 120, 240, and 360 minutes after onset of exposure, were significantly associated with impaired performance on one motor performance test (finger tapping with alternating hands). Similar results were observed when the same 11 males were exposed to 110 ppm for four 30-minute exposures over 4 hours, 1 week later (Lammers et al. 2005a). Since blood toluene levels were only correlated with 1/6 neurobehavioral measures, and there were no significant differences between pre- and post-exposure scores, 40 ppm for 4 hours and 110 ppm for four 30-minute exposures are considered NOAELs for neurological effects. In other studies, volunteers exposed to 80 ppm toluene for 4 hours did not demonstrate impairments in choice reaction time, simple reaction time, color-word vigilance, or memory reproduction (Iregren et al. 1986; Olson et al. 1985).
3. HEALTH EFFECTS

In repeat-measure experiments, increased subjective complaints and deficits in neurological effects were observed between 75 and 200 ppm after exposure for 7–8 hours (Andersen et al. 1983; Echeverria et al. 1991; von Oettingen et al. 1942) and 300 ppm toluene after exposure for 20 minutes (Gamberale and Hultengren 1972). Concentration-related impairments were observed during the digit span, pattern recognition, pattern memory, and one-hole tests in 42 volunteers exposed to 0, 75, and 150 ppm toluene for 7 hours on sequential days, compared with their own pre-exposure measures (Echeverria et al. 1991). There were no exposure-related changes in the results on simple reaction time, mood (profile on mood scale), visual memory, hand-eye coordination, verbal short-term memory, finger tapping, reaction time, continuous performance test, or critical tracking test (Echeverria et al. 1991). Sixteen volunteers exposed to 0, 10, 40, and 100 ppm toluene for 6 hours on sequential days reported a statistically significant increase in the occurrence of headache, dizziness, and feeling of intoxication during the 100 ppm exposure, but not during the other concentrations (Andersen et al. 1983). Statistically significant exposure-related deficits were not observed in any of the eight performance tests designed to assess concentration, vigilance, motor coordination, visual perception, and cognitive function. However, for three of the tests (screw-plate [motor coordination], Landolt’s ring [visual perception], and multiplication), there was a borderline significant deficit associated with toluene exposure (p=0.05–0.1), and the subjects felt that the tests were more difficult and strenuous during the 100 ppm exposure (Andersen et al. 1983). Following acute exposures to toluene at concentrations of 0, 50, 100, 200, 400, and 600 ppm for 8 hours and 800 ppm for 3 hours on subsequent days, three volunteers reported drowsiness and headache at 200 ppm that became more severe with exposure duration and at higher concentrations, characterized by impaired intellectual, psychomotor, and neuromuscular effects (von Oettingen et al. 1942). Concentration-dependent increases in simple and choice reaction times were measured in 12 volunteers exposed to increasing concentrations of toluene at 0, 100, 300, 500, and 700 ppm for 20-minute intervals (Gamberale and Hultengren 1972). Compared with 0 ppm values, these increases were significant at 300 ppm. Perception speed was also impaired, but not significantly different from 0 ppm values until concentrations of 700 ppm (Gamberale and Hultengren 1972).

Single-measure studies consistently report impaired performance on neurobehavioral tasks following exposure to 100 ppm for 6–8 hours (Baelum et al. 1985; Dick et al. 1984; Rahill et al. 1996). Forty-three solvent-exposed printers and 43 referents without history of exposure were exposed to 0 or 100 ppm toluene for 6.5 hours (Baelum et al. 1985). Within each group (printers and referents), about half of subjects were exposed to 100 ppm and the other half were exposed to normal air. Both printers and referents exposed to 100 ppm had increased complaints of fatigue, sleepiness, and feelings of intoxication, compared with mean values for unexposed control subjects. Both exposed groups also

***DRAFT FOR PUBLIC COMMENT***
showed significant decreases in manual dexterity (peg-board task), visual perception (Landolt’s ring test), and color discrimination, compared with control values. No consistent differences were observed in neurobehavioral performance between exposed printers and exposed referents (Baelum et al. 1985). Six volunteers exposed to 100 ppm toluene for 6 hours, followed by exercise, showed significantly lower results on neuropsychological tests than volunteers exposed to clean air only (Rahill et al. 1996). Additionally, exposure to 100 ppm for 8 hours led to impaired performance on the visual-vigilance task, but not choice-reaction time or pattern recognition, compared with unexposed controls (Dick et al. 1984).

Susceptible Populations. Individuals with multiple chemical sensitivity or toxic encephalopathy had significantly higher self-reported scores of fatigue (headache, drowsiness, decreased concentration) during exposure to increasing toluene concentrations over 2 hours (0 ppm [20 minutes], 3 ppm [10 minutes], 6 ppm [10 minutes], 12 ppm [20 minutes], 24 ppm [10 minutes], 48 ppm [20 minutes], and 0 ppm [10 minutes]), compared with healthy referents (Orbaek et al. 1998; Osterberg et al. 2003). During these studies, psychomotor tests were performed before exposure and during the 12- and 48-ppm exposure periods. Both healthy referents and individuals with multiple chemical sensitivity showed increased response time in the reaction-time test (visual stimuli) following exposure, compared with pre-exposure scores (Osterberg et al. 2003). However, the increase was not dose-related in healthy individuals, and exposure-related impairments were not observed in the reaction time-inhibition test (with auditory alarm) or digit symbol test in either group (Osterberg et al. 2003). In a companion study, there were no observed psychomotor impairments in exposed individuals with toxic encephalopathy or healthy referents using the same protocol (Osterberg et al. 2000). A LOAEL of 48 ppm for the studies conducted by Orbaek et al. (1998) and Osterberg et al. (2003) was determined for susceptible individuals based in increased self-reported fatigue. A NOAEL could not be determined, as fatigue scores were not reported at individual exposure concentrations.

Little et al. (1999) reported that 20 subjects who were clinically sensitive to toluene showed statistically significant impairments in immediate and delayed prose memory (number of items recalled decreased 31%), the digit symbol test (number of correct items decreased 11%), and the letter cancellation test (percent correct decreased 5%) following a 15-minute exposure to 15 ppm toluene, compared with their pre-exposure scores. A near-significant 15% increase in reaction time was also observed (p=0.06). No significant differences between pre- and post-exposure values were found for focal length or the STROOP tests. An acute inhalation MRL of 1.5 ppm was calculated as described in the footnote in Table 3-1 and Appendix A, based on the minimally adverse LOAEL (15 ppm) for neurological effects in susceptible populations from the study by Little et al. (1999).
The highest NOAEL values and all LOAEL values for each reliable controlled human exposure study for neurological effects are recorded in Table 3-1 and plotted in Figure 3-1.

**Occupational Exposure Human Studies**

**Overview.** Several studies of workers repeatedly exposed predominantly to toluene in workplace air at concentrations ranging from 35 to 200 ppm have found evidence for increased incidence of self-reported neurological symptoms (Guzelian et al. 1988; Matsushita et al. 1975; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1987); performance deficits in neurobehavioral tests (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Orbaek and Nise 1989); hearing loss (Morata et al. 1997); changes in auditory-evoked potentials and/or VEPs (Abbate et al. 1993; Vrca et al. 1995, 1996, 1997a, 1997b), and color vision loss (Campagna et al. 2001; Cavalleri et al. 2000; Zavalic et al. 1998a, 1998b, 1998c). Several occupational studies identify NOAELs for these effects in the range of 20–187 ppm toluene (Deschamps et al. 2001; Gericke et al. 2001; Kang et al. 2005; Nakatsuka et al. 1992; Neubert et al. 2001; Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002). A series of studies investigating a number of neurological end points in German rotogravure printers support a NOAEL of 45 ppm (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002), and served as the basis for the chronic-duration inhalation MRL of 1 ppm for toluene (see footnote of Table 3-1, Section 2.3 and Appendix A).

**Neurobehavioral Effects and Self-Reported Neurological Symptoms.** The majority of studies show that workers (e.g., rotogravure printers) with long-term occupational exposure to toluene at concentrations <50 ppm did not report increased neurological symptoms or show impaired overall performance on neuropsychological or psychomotor tests (Eller et al. 1999; Gericke et al. 2001; Kang et al. 2005; Neubert et al. 2001; Seeber et al. 2004, 2005; Zupanic et al. 2002). One study of 89 rotogravure and offset printers exposed to toluene for an average of 14 years reported a statistically significant correlation between current exposure levels (0–27 ppm) and impaired performance for the digit span memory test after adjustment for sex, age, synonym score, history of central nervous system diseases, alcohol consumption, psycho-active drug consumption in the last day, concentration in performing tests, and computer experiments (Chouanière et al. 2002). However, no significant association was observed between current exposure levels and scores for three other memory tasks (associate learning, associate recall, pattern memory), simple reaction time tests, symbol digit substitution tests, or self-reported neurotoxic symptoms. Using work history and historical exposure levels (0–179 ppm), a cumulative
3. HEALTH EFFECTS

exposure index for toluene exposure was calculated for each individual (0–2,353 ppm-years [mean 392 ppm-years]). There were no significant correlations between cumulative exposure indices and performance on any psychomotor task or self-reported neurotoxic symptoms (Chouanière et al. 2002). Since current exposure levels were only correlated with 1/6 neurobehavioral measures, and there were no correlations between cumulative exposure indices and performance in any of the tests, 27 ppm is considered an occupational NOAEL for neurological effects.

In contrast, the majority of studies with average exposure estimates in the range of 70–100 ppm reported subtle, but statistically significant, performance deficits in neurobehavioral and psychomotor tests (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005). Twenty workers from oil refinery, gravure printing, and rubber boat manufacturing exposed to 70–80 ppm toluene had significant impairments on the finger tapping and selective attention tests and nonsignificant impairments in the digit span backward test, compared with 21 referent workers with exposure <10 ppm (Kang et al. 2005). However, 30 workers exposed to 10–30 ppm toluene did not differ from the referent group (Kang et al. 2005). Based on these findings, NOAEL and LOAEL levels were estimated at 20 and 75 ppm, respectively. Abnormal tendon reflexes, decreased grasping power and agility of fingers, and generalized weakness were significantly decreased in 38 female shoemakers who were exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer for an average of 40 months, compared with 16 controls (Matsushita et al. 1975). The LOAEL for neurological effects is estimated at 83 ppm (the average between summer and winter exposures). A strong correlation between impaired neurobehavioral performance and toluene exposure was seen in 30 female workers exposed to 88 ppm toluene, compared with 30 workers in the same facility exposed to only 13 ppm (Foo et al. 1990). The higher exposure group received poorer test scores in tests of visual retention, visual reproduction, trail making, grooved peg board, digit span, and digit symbol, but not on tests of simple reaction time and finger tapping. Another group of 29 exposed workers in Singapore (average TWA toluene exposure of 90.9 ppm) showed performance deficits on eight neurobehavioral tests, compared with a control group (average TWA exposure of 12.2 ppm). The exposed group showed significantly impaired verbal and nonverbal memory, compared with controls, as measured by the digit span and visual reproduction tests (Boey et al. 1997). Similarly, statistically significant impairments in tests for visuospatial function, number learning, and word recognition were observed in 49 rotogravure workers exposed to <20 ppm for 12 years plus >100 ppm for 4–27 years, compared with 19 referents (Eller et al. 1999). Thirty workers in the same plant only exposed to <20 ppm for 1–12 years did not differ from the referent group. Reported exposure level information was inadequate to determine NOAEL/LOAEL levels.
Increased self-reporting of neurological symptoms has also been associated with occupational toluene exposure at concentrations ≥40 ppm (Guzelian et al. 1988; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1997). Forty-four men and 57 women exposed to TWA concentrations of 46 and 41 ppm toluene, respectively, during shoemaking, printing, and audio equipment production had increased complaints of headaches, dizziness, and sleep difficulties, compared with 127 control subjects (Yin et al. 1987). Increased subjective complaints of neurological symptoms both during and after work was reported in a group of 452 workers exposed predominantly to toluene (geometric mean 24.7 ppm) compared with 517 unexposed referents (Ukai et al. 1993). Statistically (p<0.01) increased complaints during work included headache and floating sensation, and statistically increased complaints regarding symptoms outside work over the past 3 months included inability to concentrate, hearing loss, speech difficulties, anosmia, and reduced strength. When exposed workers were analyzed by toluene exposure levels (1–20, 21–50, 51–100, and >100 ppm), workers exposed to >100 and >50 ppm demonstrated significantly increased subjective complaints during and after work, respectively, compared with workers exposed to 1–20 ppm (Ukai et al. 1993). No increase in complaints was observed between the groups exposed to 1–20 and 21–50 ppm. The NOAEL and LOAEL values for increased self-reported neurological symptoms were determined to be 36 and 75 ppm for this assessment, based on the midpoints of the 21–50 and 51–100 ppm group (Ukai et al. 1993). Workers in a printing factory (exposed to <200 ppm toluene) returning to work after a 4-day vacation reported a feeling of mild intoxication to which they became tolerant within 1 or 2 days (Guzelian et al. 1988).

Complaints of fatigue, recent short-term memory problems, concentration difficulties, and mood lability were significantly (p<0.05) increased in 30 rotogravure printers exposed to 11.6–453 ppm toluene for 4–43 years in two plants; taking the midpoints in the ranges of concentration estimates, a representative exposure concentration of 140 ppm was determined (Orbaek and Nise 1989). However, no significant impairments were found between printers and controls in a battery of psychometric tests. In a 20-year follow-up of 12 printers and 19 controls from the cohort, there was no longer any significant (p>0.05) differences in incidences of reported subjective neurological symptoms (Nordling Nilson et al. 2010). In follow-up psychometric testing, the general performance deteriorated in 10/11 tests measured in both groups, compared with the initial assessments. In two measures (reasoning and associative learning), the deterioration in the exposed group was significantly greater than the referents. When the results of the 20-year follow-up were compared between the groups, the exposed group performed significantly worse on 2/11 tests (verbal memory and sustained attention). Taken together, these two studies indicate a LOAEL of 140 ppm for increased incidence of self-reported neurological symptoms in the initial
3. HEALTH EFFECTS

assessment and statistically significant performance deficits on neurobehavioral tests during the 20-year follow-up study.

Consistent with the data present above, a meta-analysis of the findings from studies of workers predominantly exposed to toluene concluded that occupational toluene exposure has a negative impact on neurobehavior at exposure concentrations >89 ppm (Meyer-Baron 2005). However, one study included in the meta-analysis reported no alterations in subjective neurological complaints or performance in neurobehavioral tests in 26 printer factory workers, 10 machine factory workers, and 36 laboratory workers who were exposed exclusively to toluene for at least 5 years (average 19.9 years), compared with 61 unexposed workers (Deschamps et al. 2001). Toluene air concentrations, measured by personal air monitoring over an entire work-shift, ranged from 9 to 83 ppm in the factories and from 184 to 467 ppm in the laboratories; however, the two groups were combined for analysis. Since neurological evaluations were conducted after 2 days without exposure (toluene in expired air <0.3 ppm), the lack of observed effects may indicate that impaired neurological effects do not persist after the solvent is eliminated from the body. Since the exposed groups were analyzed together, the NOAEL for this assessment is determined to be the average of the midpoints of the exposed ranges (midpoint factory, 46 ppm; midpoint laboratory, 325.5 ppm; average, 186 ppm).

A number of studies of humans chronically exposed to mixtures of solvents containing toluene provide supporting evidence for toluene-mediated general neurological and neurobehavioral effects, but concurrent exposure to other solvents limits the conclusions that can be drawn from the results. Impaired performance on multiple tasks measuring visual intelligence, cognition, memory, and perception were observed in 100 car painters exposed to mixed solvents including toluene, xylene, and various aliphatic hydrocarbons, alcohols, esters, ketones, and terpenes for 1–40 years, compared with 101 unexposed railway workers (Hanninen et al. 1976). In a group of 325 paint factory workers exposed to benzene, toluene, xylene, n-hexane, methyl iso-butyl ketone, n-butyl acetate, and acetone for an average of 5 years, reduced ability in pattern comparison and memory tasks was correlated with combined solvent exposure (Tsai et al. 1997). A significant reduction in the Santa Ana dexterity test and a nonsignificant reduction in visual retention were observed in 40 female shoemakers exposed to toluene, methyl ethyl ketone, n-hexane, cyclohexane, dichloroethylene, trichloroethylene, benzene, and xylene, compared with 28 unexposed referents (Lee et al. 1998a). Self-reported neurological symptoms were increased in lacquer-ware manufacturers exposed to toluene, butyl-acetate, and ethyl-acetate, compared with nine unexposed referents (Tanaka et al. 2003). Similarly, increased self-reported neurological symptoms were significantly associated with a “solvent summation index” in 637 printers exposed to one or more of the
following solvents: toluene (0–90.9 ppm), n-hexane (0.12–94.5 ppm), benzene (0–8.8 ppm), and isopropyl alcohol (0–374 ppm), compared with 125 unexposed referents (Yu et al. 2004). However, self-reported neurological symptoms in a furniture factory were not increased in painters/varnishers exposed to toluene, benzene, and xylene compared to unexposed referents (Mandiracioglu et al. 2011). Another neurological effect reported with occupational mixed solvent exposure is increased postural sway in U.S. Air Force workers exposed to jet fuel (mean cumulative exposure 23.8 ppm toluene) (Smith et al. 1997).

**Auditory System Effects**

**Overview.** The limited number of occupational studies assessing hearing loss suggest that effects may occur at concentrations >50 ppm, consistent with findings for other neurological end points. One occupational study indicated that exposure to an average of 122 ppm toluene may lead to hearing deficits (Morata et al. 1997), and altered brainstem auditory-evoked potential (BAEP) have also been reported following occupational exposure to 50–100 ppm (Abbate et al. 1993; Vrca et al. 1996, 1997a). However, no evidence for hearing loss was found in workers exposed to 45 ppm (Schäper et al. 2003, 2008). Hearing loss produced by toluene exposure may not be due solely to neurological damage, as animal studies indicate that solvent exposure damaged the OHCs in the cochlear that are responsible for amplifying incoming sound waves prior to signal transduction (Campo et al. 1997, 1998; Johnson and Canlon 1994; Lataye and Campo 1997; Lataye et al. 1999; Waniusiow et al. 2008). However, a battery of audiological tests performed for a case-series report indicated that hearing loss observed in seven workers exposed to toluene and/or xylene was due to retrocochlear or central abnormalities, rather than cochlear damage (Gopal 2008).

**Hearing Loss.** In a cross-sectional examination of 124 Brazilian workers exposed to various levels of noise and a variety of organic solvents, including toluene at TWA concentrations ranging from 0.037 to 244 ppm, (midpoint=122 ppm), 49% of workers experienced hearing loss (Morata et al. 1997). Toluene exposure (and exposure to a number of other solvents including ethanol and ethyl acetate) was estimated by personal monitoring and measurement of hippuric acid in urine samples. Confidence in the study is limited because of exposure to multiple solvents and possible confounding from noise exposure. However, logistic regression analysis showed hippuric acid concentration to be significantly associated with hearing loss and the odds ratio (OR) estimates for hearing loss were 1.76 times greater for each gram of hippuric acid per gram creatinine (95% confidence interval [CI] 1.00–2.98).
3. HEALTH EFFECTS

Schäper et al. (2003, 2008) found no evidence of hearing loss in a longitudinal 5-year study in rotogravure printers exposed to TWA levels of 45 ppm (n=181), compared with a low-exposure group of end-process workers exposed to TWA levels of 10 ppm (n=152). Both groups had average noise exposure levels of 82 dB(A). Additionally, a stepwise regression analysis of a subgroup of 80 workers with toluene exposure ranging from 1 to 69 ppm for 3–38 years did not find a correlation between hearing loss and toluene exposure levels, urinary hippuric acid concentration, or length of employment (Schäper et al. 2003, 2008).

Multiple studies of humans chronically exposed to mixtures of solvents containing toluene provide supporting evidence for toluene-mediated hearing loss, but concurrent exposure to other solvents limits the conclusions that can be drawn about toluene toxicity. Reduced upper limit of hearing was observed in workers currently exposed to styrene, toluene, and methanol for at least 5 years during the production of plastic buttons or bathtubs (Morioka et al. 1999). In a large study of 1,319 aluminum workers, multivariate analysis identified exposure to solvents (toluene, xylene, and methyl ethyl ketone) as a risk factor for high-frequency hearing loss (Rabinowitz et al. 2008). High-frequency hearing loss was also associated with cumulative total solvent exposure in paint and varnish workers exposed to ethylbenzene, xylene, trimethylbenzene, and toluene (Sulkowski et al. 2002). Similarly, paint and lacquer workers exposed to solvent mixtures including toluene had increased incidences of hearing loss, compared to unexposed controls (Juárez-Pérez et al. 2014; Zamyslowska-Szmythke et al. 2011). Workers from various industries exposed to a mixture of n-hexane and toluene and noise demonstrated increased mean hearing thresholds, compared with workers exposed to noise-only and unexposed referents (Sliwinska-Kowalska et al. 2005). A group of workers exposed to mixed solvents (white spirits, thinner, toluene, and xylene) who were admitted to the hospital due to suspicion of solvent-induced chronic toxic encephalopathy had reduced scores in tests of distorted speech and cortical response audiometry compared to unexposed controls (Niklasson et al. 1998).

**BAEPs.** Studies reporting altered BAEP following occupational exposure provide supporting evidence that toluene exposure may lead to hearing loss. Occupational exposure to an average of 97 ppm toluene for 12–14 years had an apparent effect on hearing in 40 rotogravure workers when BAEP results were compared to a group of 40 workers who were of comparable age but were not exposed to toluene (Abbate et al. 1993). Workers were carefully screened to eliminate slight hearing abnormalities or exposure to other chemicals. Two series of stimuli were used, one with 11 repetitions/second and one with 90 repetitions/second. In both cases the intensity was 80 dB/nHL. Mean latencies were significantly higher for the exposed group than the control group for each BAEP wave evaluated (I, III, and V).
Discernment mean values for the exposed and control groups were distributed homogeneously with very little overlap of exposed and control responses for both the 11-repetition and 90-repetition cycles. Wave I showed the most pronounced increase in latency. According to the authors, the effects on Wave I could be due to either a change in the membrane of the peripheral receptor, a modification of the structure of the junction, or a change in the stimulus transduction mechanism.

In another study, BAEPs in 49 printers exposed to toluene for an average 20 years were found to be affected, with a significant decrease in all wave amplitudes and a significant increase all wave latencies, compared with 59 unexposed referents (Vrca et al. 1996). Average toluene blood levels in printers and controls were 0.036 and 0.00096 mg/L, respectively. Based on blood levels, companion studies estimated averaged toluene exposure levels to be between 40 and 60 ppm (Vrca et al. 1995, 1997a). In the 49 exposed printers, increased wave latencies were significantly correlated with increased duration of exposure, except for the P2 wave (Vrca et al. 1997a).

Additionally, BAEPs in 77 paint factory workers exposed to a mixture of 14 solvents (including toluene) for an average of 10 years were found to be affected, with differences observed between right and left ear mean latencies in waves I, III, and V and intervals I-V, I-III, and III-V, compared with 84 unexposed referents (Juárez-Pérez et al. 2014). Multiple linear regression models for waves and interpeak interval latencies for both ears showed a significant increase in latencies in the exposed group. The TWA median toluene exposure was 3.5 ppm and industrial noise was <85 dBA; however, concurrent exposure to other solvents limits the conclusions that can be drawn about toluene toxicity from this study.

**Visual System Effects**

*Overview.* Occupational studies indicate that long-term exposure to toluene may result in color vision loss (Campagna et al. 2001; Cavalleri et al. 2000; Muttray et al. 1997; Zavalic et al. 1998a, 1998b, 1998c) and altered VEPs (Vrca et al. 1995, 1997a, 1997b). However, it is not clear whether the impairment of color vision produced by toluene exposure is due solely to neurological damage or also involves damage to other parts of the eye. Toluene exposure causes eye irritation in humans (Andersen et al. 1983; Baelum 1990; Carpenter et al. 1944; Meulenbelt et al. 1990) and animals (Ono et al. 1996, 1999), but no studies examining the eyes for structural damage following chronic toluene exposure were located.

*Color Vision.* Multiple studies indicate that long-term occupational exposure to toluene can cause color vision loss. The color confusion index (CCI) was statistically significantly increased by 14% in
32 printers exposed to geometric mean toluene concentrations of 156 ppm, compared with 83 unexposed controls on Monday morning prior to their work shift (Zavalic et al. 1998a). The CCI in 41 shoemakers exposed to geometric mean toluene concentrations of 35 ppm was not significantly elevated when compared with controls. When alcohol consumers were excluded, the CCI in 27 shoemakers and 10 printers was significantly increased by 4 and 11%, respectively, compared with 36 controls. When adjusted for age and alcohol consumption, CCIs were significantly higher in both shoemakers and printers (adjusted mean CCI values were not reported). Individual adjusted CCIs were significantly correlated with individual exposure estimates (air, blood, or urine) in printers, but not shoemakers. Further analysis of color vision loss in these groups of workers demonstrated that both blue-yellow and red-green color confusion (dyschromatopsia type II and II) were significantly increased in printers, compared with unexposed workers, but there was no significant difference in the prevalence of either type of color confusion in shoemakers compared with unexposed workers (Zavalic et al. 1998c). Taken together, these studies indicate a clear LOAEL of 156 ppm for color vision loss in printers, based on increased CCIs significantly associated with individual estimates of toluene exposure and increased prevalence of dyschromatopsia. A NOAEL of 35 ppm was identified, as it is unclear if the statistically significant findings for increased CCI in the small sample of non-alcohol consuming workers or adjusted CCIs in all workers represents an adverse effect, especially since the magnitude of change was small and individual CCIs in this group were not associated with toluene exposure estimates in the air, blood, or urine.

Statistically significant increases in color confusion and total confusion indices were also reported in 33 toluene-exposed rubber workers, compared with 16 unexposed controls of similar age (Cavalleri et al. 2000). The indices were positively correlated with cumulative toluene exposure indices calculated from urinary toluene levels and duration of employment; however, air concentration levels were not reported.

Additional studies indicate that observed color vision impairments result from chronic, rather than acute, exposure. Color vision was assessed on Monday and Wednesday mornings in 45 male printers exposed to mean concentrations of ~120 ppm toluene (Zavalic et al. 1998b). Compared with unexposed controls, printers demonstrated a statistically significantly increase in CCI, but results did not differ between examinations on Monday and Wednesday. Similarly, in 59 male rotogravure workers occupationally exposed to unspecified levels of toluene for periods of 1 month to 36 years (mean of 10 years), results of color vision testing did not differ between the beginning and the end of the workweek (Muttray et al. 1995). A second study compared color vision in eight printers (occupationally exposed to toluene) and eight workers previously unexposed to toluene, before and after cleaning a print machine with toluene (Muttray et al. 1999). The task took 28–41 minutes and involved exposure to 300–362 ppm toluene.
(1,115–1,358 mg/m³). No impairment in color vision was recorded for either group. However, a comparison of the precleaning performance of the printers with that of a group of matched controls showed a nonsignificant decrease in color vision for the printers, which may indicate a chronic effect of toluene exposure on color vision (Muttray et al. 1999).

In contrast, no alterations were observed in red/green or blue/yellow color vision in 74 workers who were exposed to solvents (primarily [>90%] toluene: 46 ppm geometric mean), compared with 120 age-matched controls from clerical sections of the same factories (Nakatsuoka et al. 1992). Likewise, a 5-year longitudinal study in 333 rotogravure workers exposed to “high” or “low” TWA toluene levels of 43 or 9 ppm, respectively, did not find an increase in CCI associated with toluene exposure levels or duration using multiple regression analysis (Schäper et al. 2004). The analysis was adjusted for exposure level and duration, age, eye (right/left), occupational qualification, and examination year.

Color vision impairment has also been reported in humans chronically exposed to mixtures of solvents containing toluene, but concurrent exposure to other solvents limits the conclusions that can be drawn concerning toluene toxicity in these particular studies. Campagna et al. (2001) reported statistically significantly increased incidence of dyschromatopsia and increased CCI in 72 printers (high-exposure) and 34 non-printers (ambient exposure) in a French photogravure plant for an average of 18–19 years, compared with 19 unexposed bookbinding workers of similar age from the same town. Geometric means of current toluene exposure levels, past cumulative toluene exposure, and past cumulative hydrocarbon exposure (e.g., toluene, xylene) were 136 mg/m³ (36 ppm), 1,299 mg/m³ x years, and 1,793 mg/m³ x years in printers and 32 mg/m³ (8.5 ppm), 299 mg/m³ x years, and 534 mg/m³ x years in non-printers, respectively. After adjusting for age and alcohol consumption, CCIs were significantly correlated (p<0.05) with current toluene exposure, past cumulative toluene exposure, and past cumulative hydrocarbon exposure (Campagna et al. 2001). Therefore, the significant effects observed may not be attributable specifically to toluene exposure, especially in the ambient-exposure group in which toluene exposure only accounted for 56% of past cumulative hydrocarbon exposure. Similarly, workers exposed to mixed solvents (including toluene, xylene, ethyl benzene, propyl benzene, ethyl toluene, methyl ethyl ketone, methyl isobutyl ketone, and perchloroethylene) during a spraying process showed a significant impairment of color vision with errors of the blue-yellow type, compared with unexposed referents similar in age, consumption of alcohol, and smoking habits (Muttray et al. 1997).

**VEPs.** Occupational exposure to toluene may also affect VEPs. A series of studies evaluated VEPs (P300, N75, N145, and P100 waves) in printers occupationally exposed to average concentrations of

***DRAFT FOR PUBLIC COMMENT***
50 ppm toluene for an average of 20 years and unexposed controls (Vrca et al. 1995, 1997b). There was a significant increase in the number of exposed individuals displaying reduced amplitude of P300R waves and prolonged latency of the accompanying spontaneous wave P300F (Vrca et al. 1997b). The amplitudes of the N75, P100, and N145 waves (Vrca et al. 1995) and the latency of the P100 wave were significantly increased in exposed subjects compared with controls (Vrca et al. 1995). In the exposed printers, wave amplitudes decreased significantly with the duration of exposure (Vrca et al. 1997a).

**Visual Perception.** Toluene exposure may also alter visual perception; however, the available evidence is limited to one study. The frequency at which individual flickers of light appeared to be a steady light source (flicker fusion frequency) was assessed in a large cohort of 1,290 printers occupationally exposed to toluene for an undefined number of years (Neubert et al. 2001). In a subgroup of 47 workers exposed to toluene concentrations of 70–80 ppm, 4 and 5% decreases in flicker fusion frequency before and after their 6-hour work shift, respectively, were found, compared with 200 unexposed referents. This small decrease was only statistically significant after the acute work-shift exposure. There was no change in flicker fusion frequency in the remaining workers exposed to 4–70 ppm, compared with unexposed referents. Based on these findings, NOAEL and LOAEL values for impaired visual perception were estimated at 33 and 75 ppm, respectively, based on the midpoint of the exposure ranges for the high- and low-exposure groups.

**Nerve Conduction Impairment.** There is limited evidence that occupational exposure to toluene may alter nerve conduction in the peripheral and autonomic nervous systems. Murata et al. (1993) compared cardiac autonomic function in printers exposed to 83 ppm airborne toluene for 1–36 years with matched controls. Autonomic function was evaluated from measurements of heart rate, the coefficient of variation in electrocardiographic R-R intervals, the distribution of nerve conduction velocities, and the maximal motor and sensory nerve conduction velocities in the median nerve. Some printers reported subjective symptoms such as fatigue, headache, and irritation. Heart rate was not significantly different in exposed individuals and controls. However, there were statistically significant reductions in electrocardiographic R-R intervals, indicating possible dysfunction of the autonomic nervous system. There was a significant decrease in the motor and sensory conduction velocity in the palm segment of the median nerve in toluene-exposed workers, but there was no significant difference in the distribution of the nerve conductance velocities between exposed and control subjects (Murata et al. 1993).

In support, altered nerve conduction has been observed in workers exposed to solvent mixtures. Compared with unexposed referents, bone glue factory workers exposed to an undefined solvent mixture
had an increased incidence of paresthesia and abnormal electromyography readings (Al-Batanony et al. 2012), and paint and lacquer workers exposed to white spirit, toluene, butyl acetate, ethyl acetate, and xylene had altered peripheral nerve conduction (Jovanovic et al. 2004).

The highest NOAEL values and all LOAEL values for each reliable human occupational exposure for neurological effects following exposure predominantly to toluene are recorded in Table 3-1 and plotted in Figure 3-1. Supporting studies reporting neurological effects following exposures to solvent mixtures are not included in Table 3-1.

**Accidental and Intentional High-Dose Human Exposure**

Humans exposed to high levels of toluene as a result of solvent abuse or industrial accidents have displayed serious central nervous system dysfunction. Accurate exposure data are not available for these individuals, but the concentrations inhaled by chronic abusers have been estimated to range from 4,000 to 12,000 ppm (Gospe et al. 1994). In some cases, the degree of central nervous system depression was sufficient to result in death. Prolonged abuse has been reported to cause permanent damage resulting in abnormal electroencephalogram (EEG) activity, ataxia, tremors, muscle weakness, temporal lobe epilepsy, paranoid psychosis, personality changes, hallucinations, nystagmus (involuntary eye movement), altered brain chemistry and impaired speech, intelligence, hearing, and vision (Aydin et al. 2003; Byrne et al. 1991; Capron and Logan 2009; Devathasan et al. 1984; Gupta et al. 2011; Hunnewell and Miller 1998; King et al. 1981; Kiyokawa et al. 1999; Maas et al. 1991; Maruff et al. 1998; Meulenburg et al. 1990; Miyagi et al. 1999; Papageorgiou et al. 2009; Peralta and Chang 2012; Poblano et al. 1996; Ryu et al. 1998; Suzuki et al. 1983; Uchino et al. 2002).

Results from case studies of toluene abusers suggest that some of the neurological symptoms associated with chronic toluene abuse may be the result of permanent structural changes in the brain. Evaluation of chronic toluene abusers by magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT) has shown an increase in the white matter signal, a loss of gray and white matter differentiation, and decreased perfusion in the cerebral cortex, basal ganglia, and thalami (Aydin et al. 2002, 2003; Caldemeyer et al. 1996; Filley et al. 1990; Ikeda and Tsukagoshi 1990; Kamran and Bakshi 1998; Kucuk et al. 2000; Rosenberg et al. 1988a, 2002; Ryu et al. 1998; Uchino et al. 2002; Yamanouchi et al. 1995). Cerebral, cerebellar, and brainstem atrophy were also present (Deleu and Hanssens 2000; Ryu et al. 1998; Gupta et al. 2011; Kamran and Bakshi 1998; Papageorgiou et al. 2009; Rosenberg et al. 1988b). Correlations between clinical signs of neurological impairment and damage visible in MRI
images have also been reported (Caldemeyer et al. 1996; Hormes et al. 1986; Kiyokawa et al. 1999; Rosenberg et al. 1988b, 2002; Uchino et al. 2002). Abnormalities in MRI and brainstem auditory-evoked response (BAER) results were still present in chronic abusers who had refrained from toluene exposure for two to nine months (Rosenberg et al. 1988b).

**Animal Studies**

*Neurobehavior*

**Overview.** Numerous studies have evaluated neurobehavior in animals following toluene exposure using tests to evaluate locomotor activity, exploratory behavior, learning and memory, and anxiety-like behaviors. Acute-duration studies consistently demonstrated increased, followed by decreased, locomotor activity at exposure levels ≥500 ppm, cognitive deficits have been reported at concentrations as low as 125 ppm, and anti-anxiety-like effects at higher concentrations (≥2,000 ppm). In contrast, studies of rodents exposed for intermediate durations to concentrations as high as 1,000 ppm have not found strong and consistent evidence for exposure-related changes in neurobehavioral end points.

**Acute-Duration Studies.** Most acute exposure studies have reported a biphasic response with low-concentration stimulation and high-concentration depression of locomotor activity. Single or repeated exposure to toluene exposure for 30–72 minutes at concentrations of 500–3,000 ppm produced increased locomotor activity in mice; however, initial increases in locomotion were followed by a decrease in activity at concentrations of 3,000–10,000 ppm or repeated exposure to lower concentrations (Bowen and Balster 1998; Bowen et al. 2010; Bushnell et al. 1985; Conti et al. 2012; Kim et al. 1998; Lopez-Rubalcava and Cruz 2000; Tomaszycki et al. 2013; Wood and Colotla 1990). In adolescent and young adult rats exposed to 0, 1,000, 2,000, 4,000, or 6,000 ppm for 30 minutes, increased locomotor activity compared with controls was found only at concentrations ≥4,000 ppm, although exploratory behavior was significantly reduced in the 6,000 ppm group (Huerta-Rivas et al. 2012). Exploratory behavior during the conditioned defensive burying task was increased in mice exposed to 4,000 or 6,000 ppm, but not 500–2,000 ppm (Paez-Martinez et al. 2003).

In several animal studies, acute exposure to toluene also diminished cognitive ability, but the lowest exposure levels required to impair learning and/or memory ranged from 125 to 4,000 ppm, depending upon the species, task, and duration of exposure. Monkeys exposed to concentrations of 0, 100, 200, 500, 1,000, 2,000, 3,000, or 4,500 ppm toluene (head only) for 50 minutes on 2 days separated by 3 days without exposure showed significantly increased response time and decreased accuracy on a test of
conditioned response to a reward stimulus for concentrations $\geq$2,000 ppm, compared with controls (Taylor and Evans 1985). Exposure of rats to 125, 250, or 500 ppm toluene for 4 hours caused a decline in lever-press shock avoidance performance 20 minutes after exposure, compared with pre-exposure performance, but recovery was complete 2 hours later (Kishi et al. 1988). Exposure to $\geq$480 ppm toluene for 4 hours decreased the ability of trained rats to perform a sequence of lever press actions associated with a reward (milk) (Wood et al. 1983). Statistically significantly impaired learning and memory in the object recognition task and a decline in the conditioned step-through inhibition avoidance response were found in adolescent and young adult rats exposed to 1,000, 2,000, 4,000, or 6,000 ppm for 30 minutes, compared with unexposed controls (Huerta-Rivas et al. 2012). These effects were also present in adolescent and young adult rats exposed to 6,000 ppm for 30 minutes 2 times/day for 10 days (lower exposure levels were not evaluated). Similarly, impaired learning coupled with decreased anxiety-like behavior during the conditioned defensive burying task were reported in mice exposed to 4,000 or 6,000 ppm for 30 minutes, compared with unexposed controls, but not in mice exposed to 500, 1,000, or 2,000 ppm (Paez-Martinez et al. 2003). Decreased anxiety was also observed during the elevated-plus maze in male mice exposed to $\geq$2,000 ppm for 30 minutes, compared with unexposed controls, but not in mice exposed to 1,000 ppm (Bowen et al. 1996).

**Intermediate-Duration studies.** Studies of rodents exposed for intermediate durations to concentrations as high as 1,000 ppm have not found strong and consistent evidence for exposure-related changes in neurobehavioral end points. In rats exposed to 0, 10, 100, or 1,000 ppm 6 hours/day 5 days/week for 4 weeks, statistically significant decreased accuracy was observed in a signal detection task in 1,000-ppm rats, but no exposure-related changes were found in motor activity, anxiety-like behavior, or acquisition of a visual discrimination task or lever-press response at any exposure level (Beasley et al. 2012). In contrast, rats similarly exposed for 13 weeks were delayed in their acquisition of the lever-press response at 1,000 ppm, compared with unexposed controls, but no impairments were observed in a signal detection task, motor activity, anxiety-like behavior, acquisition of a visual discrimination task, or fear conditioning (Beasley et al. 2010). When rats exposed to 100–1,000 ppm toluene for 13 weeks were challenged with acute exposures of 1,200–2,400 ppm toluene 33–42 weeks later, previous exposure did not alter performance in the signal detection task (Beasely et al. 2010). In another study, prior exposure to 80 ppm for 4 weeks (5 days/week, 6 hours/day) did not influence the performance of rats 2 weeks later in a lever-press task following acute challenges to 20 daily “trigger” exposures of 10 ppm toluene for 1 hour (Rogers et al. 1999). Trigger-exposed animals, with or without prior exposure, showed statistically significant ($p<0.05$) increased lever presses and increased incorrect lever presses during training, compared with unexposed rats, indicating that these effects are mediated by the acute 10-ppm triggers.
rather than prior 80-ppm exposures. Similarly, no adverse effects were observed in spatial learning, open-field activity, and/or passive or active avoidance tasks in mice exposed to 0 or 50 ppm for 6 weeks (Win-Shwe et al. 2010c), mice exposed to 0, 9, or 90 ppm toluene for 4 weeks (Win-Shwe et al. 2010d), rats exposed to 0, 25, 100, or 250 for 4 weeks (Wiaderna and Tomas 2002), rats exposed to 0 or 80 ppm for 4 weeks (von Euler et al. 2000), or young rats exposed to 0 or 600 ppm toluene for 50 days (Miyagawa et al. 1995). No statistically significant changes in general locomotor activity were observed in rats exposed to 40 ppm toluene for 16 weeks, compared with controls; however, rearing behavior was statistically significantly decreased (Berenguer et al. 2003, 2004). Nose-poking exploratory behavior was increased in rats exposed to 178, 300, or 560 ppm toluene for 3 weeks (2 times/week, 2 hours/day), compared with their pre-exposure behavior (Wood and Cox 1995).

**Impaired Motor Coordination and Reflexes**

**Overview.** Impaired motor coordination and decreased reflexes have been observed in animals following acute- and intermediate-duration exposures to toluene; however, acute-duration studies are limited and findings from intermediate-duration studies are inconsistent.

**Acute-Duration Studies.** Acute exposure in monkeys and rats concentrations ≥3,000 ppm caused overt signs of neurological motor impairments such as ataxia, tremors, and inability to walk (Mullin and Krivanek 1982; Taylor and Evans 1985). Concentration-related impairments in motor coordination and reflexes were observed in rats following a single 4-hour exposure to concentrations of 0, 810, 1,660, 3,100, or 6,250 ppm, resulting in decreased lift and pinna reflexes and impaired performance during vertical bar placing and horizontal rod grasping (Mullin and Krivanek 1982). The impairment observed at 810 ppm was borderline, but the majority of rats in the 1,600 group failed reflex testing. Overt signs of neurotoxicity, including ataxia, tremors, and inability to walk, were observed at ≥3,100 ppm (Mullin and Krivanek 1982). A few rats failed reflex testing and demonstrated tremors in the 810 ppm group. Impaired motor coordination on the rotarod was found in mice exposed to 6,000 ppm toluene for 30 minutes, compared with unexposed controls, but lower exposures (500–4,000 ppm) did not change motor coordination (Paez-Martinez et al. 2003). In another study, no exposure-related impairment of rotarod test performance was reported for mice exposed to toluene at concentrations up to 8,000 ppm for 30 minutes (Cruz et al. 2001).

Rats exposed to 100 ppm for 4 hours or 3 hours/day for 5 days exhibited an altered opticokinetic response, displaying slower and more irregular eye movements while tracking a moving object, compared
with pre-exposure values (Hogie et al. 2009). Following exposure, rats also demonstrated unsteady eye positions at rest (nystagmus). These findings indicate potential disturbances in the vestibular and opto-oculomotor systems, suggesting that the cerebellum may be a target site for toluene.

**Intermediate-Duration Studies.** Overt signs of neurological motor impairments, such as ataxia, tremors, and inability to walk, were observed in rats, but not in mice, exposed to ≥2,500 ppm for 5–15 weeks, compared with unexposed controls (API 1997; NTP 1990; von Oettingen et al. 1942). In rats exposed to 80 ppm for 4 weeks, impaired motor skills in beam walking were found, requiring a significantly wider beam to maintain balance (von Euler et al. 2000). The study authors reported that the impairment was predominantly due to improper placement of hindlimbs. In contrast, motor impairments in the tilting plane or rotarod test were not found in rats exposed to 1,000 ppm toluene for 8 hours/day, 7 days/week for 13 weeks (Tahti et al. 1983).

**Nociception.** Toluene exposure can alter pain perception in animals; however, alterations in nociception may be species-, concentration-, and duration-dependent. Mice exposed to toluene at 500–8,000 ppm for 30 minutes exhibited a dose-related increase in nociception in the hotplate test (Cruz et al. 2001; Paez-Martinez et al. 2008). In both studies, mice exhibited decreased latencies for paw-licking that were significantly shorter at 1,000 ppm, compared with unexposed controls. Cruz et al. (2001) also reported statistically significant decreases in latencies for the antialgesic flexor reflex and escape responses at 2,000 and 6,000 ppm, respectively. In rats exposed to 0, 25, 100, or 250 ppm 6 hours/day, 5 days/week for 4 weeks increased escape behavior in the hot-plate test in the 100- and 250-ppm groups was observed, which likely accounts for the observed increased paw-lick latencies (rather than decreased nociception) (Wiaderna and Tomas 2002). A clearer demonstration of decreased nociception was found in rats exposed to 6,000 ppm toluene for 30 minutes that required significantly increased shock intensity to elicit flinch, jump, or vocalization responses, compared with unexposed controls (Huerta-Rivas et al. 2012). No change in nociception was observed at 1,000, 2,000, or 4,000 ppm, and this effect was not observed in rats exposed to 6,000 ppm for 30 minutes 2 times/day for 10 days (Huerta-Rivas et al. 2012).

**Auditory System**

**Overview.** Hearing loss in animals has been observed following acute- and intermediate-duration exposure to toluene at concentrations in ≥250 ppm in guinea pigs (McWilliams et al. 2000) and ≥1,000 ppm in rats (Johnson 1992; Johnson et al. 1988; Pryor et al. 1984b). Observed hearing loss may
not be solely due to neurological damage, as exposure to 500–2,000 ppm leads to altered energy production and damage in cochlear hair cells (Campo et al. 1997; McWilliams et al. 2000).

Hearing loss was examined in rats exposed to 0, 400, 700, or 1,000 ppm 14 hours/day for 16 weeks using both behavioral and electrophysiological methods (Pryor et al. 1984b). Diminished auditory responses in a conditioned pole-climb avoidance response (CAR) task using a 20-kHz tone and increased BAER thresholds were measured in rats exposed to 1,000 ppm, compared with unexposed controls (Pryor et al. 1984b). Similarly, diminished auditory brainstem responses were measured in rats exposed to 1,000 ppm toluene for 16 hours/day for 10 days or 2 weeks, compared with controls (Johnson 1992; Johnson et al. 1988). The effects persisted at least 4–6 months post-exposure and were compounded by post-exposure high noise levels. However, following shorter daily durations (6 hours/day), diminished brainstem auditory responses or distortion product otoacoustic emissions (DPOAE) were only observed in rats exposed to up to 1,500 ppm for 10 days when exposure was combined with wide-band or impulse noise (92 dB SPL; peak level for impulse 130 dB), compared with unexposed and noise-only exposed groups (Lund and Kristiansen 2008). Toluene exposure for 6 hours/day, 5 days/week for 90 days did not impair hearing at levels up to 500 ppm, with or without noise exposure at 90 dB SPL (Lund and Kristiansen 2008).

Sensitivity to toluene-induced hearing loss may be species-specific. Guinea pigs may be more sensitive than rats to toluene-induced hearing loss. Transient, dose-related impairments in mid- to high-frequency hearing were observed in guinea pigs exposed to 250, 500, or 1,000 ppm toluene 8 hours/day for 5 days, compared with controls, as measured by brainstem auditory responses or DPOAE (McWilliams et al. 2000). When guinea pigs in the 500 ppm group were exposed for an additional 3 weeks, hearing loss was more pronounced (McWilliams et al. 2000). However, chinchillas may be less sensitive than rats. While toluene led to decreased auditory evoked potentials in rats exposed to 2,000 ppm toluene for 10 days (8 or 12 hours/day), compared with unexposed controls, auditory evoked potentials were not altered in similarly exposed chinchillas (Davis et al. 2002).

Toluene had a more pronounced effect on hearing loss in mice that had a genetic predisposition for early onset spontaneous auditory degeneration than on mice that were predisposed to late onset moderate hearing loss following exposure to 1,000 ppm toluene for 12 hours/day for 7 days (Li et al. 1992). Thus, the severity of toluene-induced hearing loss appears to be influenced by genetic susceptibility.
3. HEALTH EFFECTS

**Visual System.** FEP responses were abnormal in rats exposed to single 30-minute exposures to 500–16,000 ppm toluene (Rebert et al. 1989a, 1989b). This technique measures the electrical response of the visual components of the nervous system to a high intensity flashing strobe light. Distortion of the FEP waveform is indicative of impaired visual response to light. Similarly, F2 wave amplitudes of VEPs were decreased 40–65% in rats exposed to 1,000–4,000 ppm toluene for 1–4 hours in a dose-related manner (Boyes et al. 2007). Two hours after exposure ended, partial recovery was found in the 4,000-ppm group but not in the 3,000 ppm group.

**Olfactory System.** Decreased avoidance of a toluene-containing arm in a T-maze during was observed in female mice exposed following exposure to 1,000 ppm toluene 5 hours/day, 5 days/week for 4 weeks, compared with pre-exposure measures (Jacquot et al. 2006). Decreased olfactory sensitivity continued for 2 weeks following cessation of exposure. This behavior was accompanied by reversible olfactory inflammation and decreased numbers of olfactory epithelial cells, perhaps indicating that olfactory sensitivity was decreased by exposure to toluene (Jacquot et al. 2006). However, this could instead indicate tolerance to toluene odor with repeat exposures and/or toluene-seeking behavior (see the section on Animal Studies Modeling High-Concentration Solvent Abuse).

**Sleep Patterns.** Toluene exposure also changes sleep patterns in animals. Both single 4- or 8-hour episodes of toluene exposure (900–4,000 ppm) and repeated exposures, 8 hour/day for 3 weeks (900 and 2,700 ppm), changed patterns of sleep and wakefulness in rats (Arito et al. 1988; Takeuchi and Hisanaga 1977). After the single exposures, there was a decrease in wakefulness and an increase in slow-wave sleep; a prolonged sleep latency was apparent for the 2 days following exposure. Latency was defined as the time interval between the end of the exposure period and the beginning of a particular phase of the sleep cycle. Following the 3-week exposures, there was an increase in wakefulness during the dark period on the 2 days after exposure and a decrease in slow wave sleep on the first day. Exposure to concentrations of 100–700 ppm for 2 hours increased the duration of the wake cycle and decreased both rapid-eye movement and nonrapid eye movement sleep in a concentration-related fashion in young and adult male rats (Ghosh et al. 1989, 1990).

**Brain Weight, Volume, and Histology.** Altered brain weight and volume have been reported in rats, but not in mice, following intermediate-duration exposure to toluene. In rats exposed to 80 ppm 6 hours/day, 5 days/week for 4 weeks, the area of the cerebral cortex measured by MRI and D3 receptor autoradiography was decreased significantly by 4 and 10%, respectively, compared with controls (von Euler et al. 2000). MRI analysis indicated that the main effect was in the parietal cortex, which was
significantly decreased in area by 6%. However, no change was observed in total brain weight or volume (von Euler et al. 2000). Similarly, no change in total brain weight was reported in rats up to 320 ppm using the same protocol (Hillefors-Berglund et al. 1995). In contrast, rats exposed continuously to 320 ppm for 30 days, both cerebrocortical and total brain weight were significantly decreased compared with control by 4 and 8%, respectively (Kyrklund et al. 1987). There was also a decrease in the total phospholipid content of the cerebral cortex accompanied by a small increase in phosphatidic acid levels. These data suggest a breakdown of phospholipids resulting in a loss of gray matter (Kyrklund et al. 1987). The mechanism of action for this effect is uncertain. Following exposure to toluene at 0, 100, 625, 1,250, 2,500, or 3,000 ppm 6.5 hours/day, 5 days/week, for 15 weeks, relative brain weights were increased significantly in rats exposed to 2,500 or 3,000 ppm, compared with controls (NTP 1990). However, no changes in brain weights were observed in mice similarly exposed to concentrations up to 2,500 ppm for 14 weeks or in rats or mice exposed by the same protocol to toluene at concentrations up to 1,200 ppm for 2 years (NTP 1990). The mechanism(s) underlying the apparent species difference in the intermediate-duration NTP study is unknown. In a multigenerational study, no changes in brain weight were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003). No gross or microscopic brain tissue changes were observed in any of the mouse or rat studies described above.

**GFAP Levels.** Changes in brain levels of GFAP, a structural marker for astrocytes, have been found in toluene-exposed rats. Rats exposed to 1,000 ppm toluene for 3 or 7 days exhibited a significant decrease in GFAP levels in the thalamus (Little et al. 1998). Rats exposed to 100–3,000 ppm toluene 6 hours/day, 5 days/week for up to 42 days exhibited changes in the concentration of GFAP in the cerebellum, hippocampus, and thalamus (API 1997). For the first week of exposure, GFAP concentration of exposed animals was significantly increased in the cerebellum and hippocampus, and decreased in the thalamus compared with unexposed controls (API 1997). After 21 days, the concentration of GFAP in the hippocampus was significantly decreased in rats exposed to 1,000 ppm compared with controls, while at 42 days, rats exposed to 300 ppm had significantly higher concentrations of GFAP in the cerebellum compared with controls, but rats exposed to 1,000 ppm did not (API 1997). In mice exposed to 500–2,000 ppm for 8 hours, no significant alterations in c-Fos, c-Jun, or GFAP mRNA levels in the cerebrum were found (Matsuoka et al. 1997).

**Oxidative Stress Markers in Brain Tissue.** Increased oxidative stress has been observed in the rat brain following acute- or intermediate-duration inhalation exposure. Increased glutathione peroxidase activity and H$_2$O$_2$-induced chemiluminescence in cortical brain tissue were reported for rats exposed to 500 ppm
3. HEALTH EFFECTS

toluene for 4 hours/day, 5 days/week for 1 month, compared with controls, indicating toluene-induced free radical processes (Burmistrov et al. 2001). These effects were not seen at 50 ppm. However, no changes in free or total malondialdehyde levels, another marker of oxidative stress, were observed in rats exposed to 1,000 ppm, 6 hours/day for 10 days, compared with controls (Chalansonnet et al. 2013). Similarly, no significant changes in brain levels in markers of oxidative stress, including lipid peroxidase, superoxide dismutase, or 4-hydroxy-nonenal, or total brain DNA levels of 8-OH-dG were observed in rats exposed to 1,500 ppm, 4 hours/day for 7 days (Tokunaga et al. 2003). The adversity of these findings are unclear, therefore NOAELs and LOAELs for changes in brain oxidative stress markers are not included in Table 3-1.

Brain Tissue Changes in Levels of Neurotransmitters, Synthesis, and Binding Sites

Overview. Changes in the levels of brain neurotransmitters and their precursors and metabolites have been observed in rodents exposed by inhalation to toluene for acute and intermediate durations. Alterations in neurotransmitter synthesis and binding have also been reported. Current mechanistic understanding is inadequate to determine the biological adversity of the observed changes and findings from these studies are not included in Table 3-1.

Following exposure to 1,000–4,000 ppm toluene for 20 minutes, dopamine (DA) levels were increased in the cerebellum and striatum of rats, while norepinephrine (NE) and serotonin (5-HT) were significantly increased in the cerebellum and cortex (Kim et al. 1998). Increased concentrations of DA in the straitum, NE in the medulla and midbrain, and 5-HT in the cerebellum, medulla, and striatum were observed in rats exposed to 1,000 ppm, but not 100 or 300 ppm, for 8 hours, compared with controls (Rea et al. 1984). In other studies, increased levels of DA and noradrenaline were observed in several brain regions in rats exposed to 80–3,000 ppm, 6 hours/day for 3–5 days (Andersson et al. 1980, 1983b); however, decreased DA levels and rates of turnover were observed in several areas of the nucleus caudate in the brain of rats exposed to 80 ppm toluene, 6 hours/day for 3 days (Fuxe et al. 1982). Altered DA turnover was also reported in rats exposed to 40 ppm toluene for 16 weeks, compared with controls, as demonstrated by significant localized increases in DA levels, as well as decreases in the levels of its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) and its precursor dihydroxyphenylalanine (DOPA) (Berenguer et al. 2003, 2004). No statistically significant exposure-related changes were observed in the 5-HT neurotransmitter system. Altered levels of noradrenaline and DA were observed in select brain areas of male rats continuously exposed to 400 ppm toluene for 30 days, compared with controls (Ikeda et al. 1986). The directionality and magnitude of change varied across brain regions, and no effects were
3. HEALTH EFFECTS

observed at 200 ppm. The biological adversity of region-specific neurotransmitter changes in the absence of behavioral effects is unknown.

Several statistically significant changes in the activities of enzymes responsible for neurotransmitter synthesis (glutamic acid decarboxylase, choline acetyltransferase, and aromatic amino acid decarboxylase) in different areas of the brain were seen in male rats exposed to toluene at concentrations of 50–1,000 ppm for 4 weeks or 500 ppm for 12 weeks (Bjornaes and Naalsund 1988). Concentration-response trends were not apparent in the data and there were variant responses by different areas of the brain. Exposure to 400 ppm toluene 7 hours/day for 10 days produced a statistically significant increase in the total dehydrogenase activity in the brains of female mice (Courtney et al. 1986). Minimal, but statistically significant, alterations in monoamine neurotransmitter synthesis (tyrosine and tryptophan hydroxylase enzyme activities) were reported in the brainstem and hypothalamus of rats exposed to 40 ppm toluene 104 hours/week for 16 weeks, but not in other brain regions (Soulage et al. 2004). The direction and magnitude of changes (17–44%) differed between brain regions and sexes. Due to the lack of concentration-related effects and/or variability of the responses between brain regions and sexes, NOAEL/LOAEL values for these studies could not be determined for this assessment.

Toluene exposure at 80 ppm for 4 weeks was found to affect DA D2 agonist binding in the rat caudate-putamen (Hillefors-Berglund et al. 1995; von Euler et al. 1993). Von Euler et al. (1994) also reported that rats exposed to 80 ppm had increased serum prolactin levels, which could be related to a possible interaction between toluene and the pituitary DA D2 receptor since this receptor normally inhibits the release of prolactin into serum. However, in another study, no significant exposure-related changes in serum prolactin levels were reported with 4-week exposures to concentrations up to 320 ppm (Hillefors-Berglund et al. 1995). There were also no changes in DA D2 receptor binding 4 weeks after cessation of a 4-week exposure to 80 ppm toluene (von Euler et al. 2000). There is some evidence of changes in glutamate and gamma amino butyric acid (GABA) binding in male rats exposed to toluene at concentrations of 50–1,000 ppm for 4 weeks or 500 ppm for 12 weeks (Bjornaes and Naalsund 1988). Binding increased in most of the brain areas studied, but decreased in some areas. Because of the variability in response, the biological adversity of the observed changes cannot be determined.

**Gene Expression Changes in Brain Tissue**

*Overview.* Numerous gene expression changes have been observed in brain tissue of rats and mice following acute or intermediate inhalation exposure. Results of these studies vary greatly, and indicate
that gene expression changes are species-, strain-, dose-, duration-, and lifestage-dependent, and that immune status may affect gene expression changes in the brain. Current mechanistic understanding is inadequate to determine the biological adversity of the observed changes in gene expression, and findings from these studies are not included in Table 3-1.

In rats, microarray analysis 6 and 18 hours following an acute 6-hour exposure to 1,000 ppm identified 226 and 3,352 differentially expressed genes in the striatum (p<0.05), respectively, compared with controls (Hester et al. 2011). Pathway analysis identified synaptic transmission and plasticity as the predominate pathways affected by acute toluene exposure (Hester et al. 2011). However, gene expression changes from the acute study by Hester et al. (2011) were not predictive of gene expression changes in rats exposed to 0, 10, 100, or 1,000 ppm toluene for 6 hours/day, 5 days/week for 64 days (Hester et al. 2012). In the intermediate-duration study, microarray analysis 18 hours after the final exposure identified 22, 57, and 94 differentially expressed genes in the striatum (p<0.05) in the 10-, 100-, and 1,000-ppm groups, respectively, compared with control. However, only 57 differentially expressed genes were found in both the acute study (Hester et al. 2011) and the intermediate-duration study (Hester et al. 2012), and the direction of change (up- or down-regulation) was inconsistent. Additionally, altered gene expression in the intermediate-duration study did not demonstrate consistent dose-related changes in gene expression (Hester et al. 2012).

Win-Shwe et al. (2007a) reported upregulation of memory-related genes in the hippocampus in BALB/c mice following 30-minute exposures to 9 ppm toluene for 3 consecutive days followed by 1 day/week for 4 weeks. These changes may be mediated by T-cell activation, as nude mice similarly exposed did not demonstrate memory-gene upregulation (Win-Shwe et al. 2007a). However, when the study was repeated in C3H/HeN mice, changes in expression of memory-related genes in the hippocampus were not statistically significant in mice exposed to 9 or 90 ppm, compared with unexposed C3H/HeN mice (Win-Shwe et al. 2010c). Gestational and prenatal exposure studies found that exposure to toluene during development significantly altered hippocampal memory-related gene expression with exposure to 5 or 50 ppm from PND 8 to 12 and 50 ppm from PND 2 to 6, but not with exposure to 5 or 50 ppm from GD 14 to 16 (Win-Shwe et al. 2010b).

When C3H/HeN, BALB/c, and C57BL/10 mice were exposed to 0, 5, 50, or 500 ppm toluene for 6 hours/day, 5 days/week for 6 weeks, changes in mRNA levels of neurotrophins (NGF, BDNF) and their receptors (TrkA, TrkB) in the hippocampus differed between strains (Win-Shwe et al. 2010a). In C3H/HeN mice, mRNA levels for NGF, BDNF, TrkA, and TrkB were all significantly upregulated.
(p<0.01) in the 500-ppm group, compared with controls. However, only BDNF was significantly upregulated in BALB/C mice exposed to 500 ppm, and no significant changes were observed in C57BL/10 mice (Win-Shwe et al. 2010a). There were no significant, dose-related gene expression changes in marker genes for NGF signal-transduction or dopamine signaling pathways; however, HO-1 mRNA levels (a marker for oxidative stress) were significantly upregulated in the 500-ppm C3H/HeN group. The immune system may have a role, as neurotrophin mRNA levels were increased in allergy-challenged C3H/HeN mice exposed to 50 ppm, compared with controls, but not in allergy-challenged mice exposed to 500 ppm (Win-Shwe et al. 2010a). Similarly, in a separate study, the same exposure protocol led to upregulation of mRNA levels of neuroinflammatory genes TLR4 and NF-κB in the hippocampus following exposure to 50 ppm, but not 5 or 500 ppm, in C3H/HeN mice (Win-Shwe et al. 2011).

Following exposure to 0 or 50 ppm, 6 hours/day, 5/days week for 6 or 12 weeks, mRNA levels for synaptic plasticity genes were measured in the hippocampus of C3H/HeN mice (Ahmed et al. 2007). Significant upregulation (p<0.05) was found in mRNA levels of N-methyl-D-aspartate (NMDA) receptor subunit 2B, CaMKIV, CREB-1, and FosB/ΔFosB in mice exposed to 50 ppm for 12 weeks, compared with controls. No changes were found in NMDA receptor NR2 or CREB-2 after 12 weeks, and no significant changes in any mRNA levels for these genes were observed after exposure for 6 weeks (Ahmed et al. 2007).

**Neurodevelopment.** Studies examining neurotoxic effects of gestational and/or neonatal exposure during critical periods of neurodevelopment are discussed in Section 3.2.1.6, Developmental Effects.

The highest NOAEL values and all LOAEL values for each reliable study for neurological effects in each species and duration category in are recorded in Table 3-1 and plotted in Figure 3-1.

**Animal Studies Modeling High-Concentration Solvent Abuse**

**Overview.** Numerous animal studies model human solvent abuse using single or repeat exposure to high concentrations of toluene (most concentrations >1,000 ppm). Examined end points in these studies were the same as those examined in animal studies at lower exposure levels or included abuse-related behaviors (e.g., reward-seeking, tolerance) or brain systems (e.g., mesolimbic system). Due to adequate dose-response information from lower-dose studies, LOAELs from these studies are not included in Table 3-1.
3. HEALTH EFFECTS


**Abuse-Specific Behaviors.** Since toluene is often intentionally inhaled to become intoxicated, multiple animal studies have been conducted assessing dependence, reward-seeking behavior, and tolerance following toluene exposure. Removal of mice following exposure to 250 ppm toluene continuously for 4 days resulted in chemical withdrawal, as evidenced by increased handling-induced convulsions (Wiley et al. 2003). Multiple studies report that mice and rats show conditioned place preference after acute exposure to toluene concentrations of ≥700 and ≥1,895 ppm, respectively, preferring the toluene-filled chamber over an air-filled chamber (Funada et al. 2002; Gerasimov et al. 2003; Lee et al. 2006; Schiffer et al. 2006). When rats were evaluated in a wait-for-reward task 22–23 hours after daily 30-minute exposures to 0, 1,000, 3,600, or 6,000 ppm for 40 days, a higher response-to-reinforcer ratio and decreased number of rewards received was observed in the 3,600- and 6,000-ppm groups, compared with controls (Bowen and McDonald 2009). Altered performance persisted during the 40-day recovery period.

***DRAFT FOR PUBLIC COMMENT***
TOLUENE

3. HEALTH EFFECTS

Tolerance to toluene and toluene-induced effects with repeated exposure to >1,000 ppm has been noted in various neurobehavioral tests, including the righting-reflex (Lorenzana-Jimenez and Salas 1990), pain perception (Huerta-Rivas et al. 2012), visual signal detection (Oshiro et al. 2007, 2011), and locomotor activity (Bowen et al. 2007).

**Mesolimbic System.** Consistent with observed patterns of abuse in humans, acute exposure to high toluene levels of 4,000–7,000 ppm in animals can affect the mesolimbic system, which plays an important role in drug dependence. This system contains both dopaminergic and serotonergic pathways, and includes multiple brain structures such as the frontal cortex, hippocampus, basal ganglia, nucleus accumbens, specific areas of the brainstem, and the white matter tracts connecting them. Effects observed include increased c-Fos activity (neural activity) in catecholaminergic cells of the nucleus accumbens shell (Tomaszycki et al. 2013), increased c-Fos activity in the forebrain and midbrain structures implicated in reward, emotion, and olfactory stimulation (Perit et al. 2012), persistent alterations in excitatory synaptic strength of mesolimbic dopamine (DA) neurons (Beckley et al. 2013), increased activation of DA neurons in the ventral tegmental area of the midbrain (Riegel and French 2002), increased DA and noradrenaline levels in the medial prefrontal cortex and nucleus accumbens (Koga et al. 2007). Effects on the dopaminergic system may be changed with continued abuse, and may indicate potential compensatory mechanisms following repeat exposure. Mice exposed once to 2,000–4,000 ppm showed significant increases in DA release in the caudate-putamen and nucleus accumbens; however, repeated exposures to the same concentrations over 7 days resulted in a significant decrease in DA release in the nucleus accumbens (Apawu et al. 2014). Toluene abuse may also lead to cross-sensitization to other drugs, as acute exposure to toluene increased diazepam-induced locomotion (Wiley et al. 2003), apomorphine-induced locomotion (Wiaderna and Tomas 2002), cocaine-induced locomotion (Beyer et al. 2001), and cocaine-induced increases in DA levels in the nucleus accumbens (Gerasimov et al. 2002c).

Effects observed in the mesolimbic system may result from permanent brain injury. Numerous animal studies report injury to multiple regions of the brain following acute or repeated exposure to concentrations of toluene ranging from 1,500 to 6,000 ppm, including degenerative changes and ultrastructural damage in the hippocampus, frontal cortex, and brain stem (Kanter 2008a, 2008b, 2011c, 2013), decreased or shrunken cells in the hippocampus (Gotohda et al. 2002; Korbo et al. 1996; Zhvania et al. 2012), impaired dendritic outgrowth in the frontal cortex (Pascual and Bustamante 2010), and white matter damage in anterior commissure (Duncan et al. 2012).

***DRAFT FOR PUBLIC COMMENT***
3. HEALTH EFFECTS

3.2.1.5 Reproductive Effects

Overview. Current data do not provide convincing evidence that acute or repeated inhalation exposure to toluene may cause reproductive effects in humans. Limited evidence in humans indicates that occupational exposure to toluene may lead to an increased incidence of spontaneous abortion (Lindbohm et al. 1992; Ng et al. 1992b; Taskinen et al. 1989) or decreased fecundity in female workers (Plenge-Böenig and Karmaus 1999). A few studies in animals exposed to toluene via inhalation at concentrations ≥2,000 ppm reported effects on male and female reproductive tissues, including abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries of female rats (Tap et al. 1996) and reduced sperm count, motility, and quality and altered reproductive organ weight and histology in male rats (Kanter 2011b; Ono et al. 1996, 1999). However, changes in sperm count and epididymus weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating (Ono et al. 1996). The majority of animal studies provided little evidence for toluene reproductive toxicity. Studies in rats exposed repeatedly by inhalation to toluene, including a 2-generation reproductive toxicity study, have shown no evidence of adverse effects on mating or fertility at tested concentrations as high as 1,200–2,000 ppm (API 1981, 1985; Ono et al. 1996; Roberts et al. 2003; Thiel and Chaboud 1997). In addition, the majority of gestational exposure studies reported no exposure-related changes in reproductive indices (see citations below).

Human Studies. Ng et al. (1992b) reported a significant increase in spontaneous abortion for women employed in an audio speaker factory and exposed to 50–150 ppm (mean of 88 ppm) for 10 years (12.4%), compared with controls exposed to 0–25 ppm toluene from the same factory (2.9%) and unexposed controls from the general population (4.5%). The majority of women examined did not smoke or drink and were of similar socioeconomic status (Ng et al. 1992b). Exposed workers did not report increased incidence for menstrual cycle irregularities, altered extent of uterine bleeding, or occurrence of dysmenorrhea (Ng et al. 1992a). Other possible confounding factors such as exposure to chemicals other than toluene were minimized by inclusion of controls who carried out similar types of work, but did not use toluene-based adhesives (Ng et al. 1992b). Increased incidence of dysmenorrhea was reported in 38 female shoemakers who were exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer for an average of 40 months, compared with 16 controls (Matsushita et al. 1975). No other reproductive end points were assessed by Matsushita et al. (1975). The concentration for reproductive effects is estimated at 83 ppm (the average between summer and winter exposures). The incidence of spontaneous abortions exceeded population norms among
3. HEALTH EFFECTS

Fecundity (probability of conception) was decreased in female workers, but not in male workers, in German printing facilities for periods when they were employed in printing facilities and exposed to toluene, compared with periods when they were employed in other jobs without toluene exposure (Plenge-Böenig and Karmaus 1999). Toluene exposure was divided into three groups based on work history and exposure measurements from previous years (conducted by industrial hygienists of the Employer’s Liability Insurer): low exposure (e.g., stacking and book binding; <10 ppm), medium exposure (cylinder preparation, galvanisers; 10–30 ppm), and high exposure (printers; <200 ppm before 1984, <100 ppm in 1984–1994, and <50 ppm after 1994). Actual air concentrations of toluene were not reported. Reproductive and work history data collected from workers were analyzed to determine fecundability ratios based on time to pregnancy and periods of unprotected intercourse during exposed and unexposed employment. The analysis included adjustments for age, ethnicity, smoking, parity, pelvic inflammatory diseases, and frequency of sexual intercourse. In women, the fecundability ratio was significantly reduced for periods of toluene exposure (0.47; 95% CI 0.29–0.77), whereas fecundity was not significantly affected in toluene-exposed periods in male workers and their partners. Female workers in this study were exclusively employed in areas of printing facilities (stacking and book binding), with air concentrations expected to be lower than areas of high (operating printing machines) and medium (preparing cylinders) toluene exposure. Men were employed in all three areas.

Several studies of blood levels of reproductive hormones in repeatedly exposed workers or acutely exposed human subjects have not provided strong and consistent evidence of exposure-related effects. No statistically significant changes were observed in serum FSH, LH, or testosterone levels in 1,225 male rotogravure workers exposed to median toluene concentrations of 24 ppm (printers) or 4.5 ppm (non-printers) for at least 20 years, compared with 109 unexposed referents (Gericke et al. 2001). Significantly decreased serum levels of LH, FSH, and testosterone were found in 20 male toluene-exposed rotogravure printers, compared with 44 unexposed referents (Svensson et al. 1992a). TWA air concentration estimates for the exposed workers during the period when blood was sampled ranged from 8 to 111 ppm, with a median of 36 ppm. Increasing workplace air concentrations were not significantly (p>0.05) associated with plasma concentrations of LH, FSH, testosterone, or prolactin, after adjustments for age, in a study of 47 male toluene-exposed printers from two factories (Svensson et al. 1992b). Median serum levels of these hormones in exposed workers were not significantly different from median levels in
46 unexposed referents (Svensson et al. 1992b). TWA air concentrations for the exposed workers during the period when blood was sampled ranged from 1 to 108 ppm (median 11 ppm) in one factory and from 1 to 142 ppm (median 47 ppm) in the second factory (Svensson et al. 1992b). In female U.S. Air Force personnel with mixed exposure to fuel (primarily JP-8 jet fuel) and several solvents, pre-ovulatory LH levels were significantly reduced compared with unexposed female U.S. Air Force personnel (Reutman et al. 2002). No air exposure levels were reported; instead, mean breath concentrations of aromatic and aliphatic hydrocarbons were measured. While mean toluene breath concentrations in the unexposed and exposed group were reported (1.3 and 9 ppb, respectively), analysis was only conducted for the combined concentrations of benzene-toluene-ethylbenzene-xylene (BTEX) (3.8 and 73.5 ppb, respectively). Since no toluene-specific analysis was conducted, and toluene only accounted for 12% of the BTEX breath concentration in the exposed group, it cannot be determined if toluene exposure influenced preovulatory LH levels in this study. In another study, LH, FSH, and testosterone levels were determined in blood samples collected at 20-minute intervals from five men, five women in the luteal phase of the menstrual cycle, and five women in the follicular phase, before, during, and after a 3-hour exposure to 0 or 50 ppm (Luderer et al. 1999). Analysis of variance in data for men and women indicated no statistically significant direct effects of exposure on any hormone end point, with the exception of a significant interaction between exposure and sampling period for LH levels in men, indicating a greater LH decline during toluene exposure than sham exposure. Interpretation of these reproductive hormone data from a biological adversity perspective is constrained by the lack of data on reproductive function and the variance across studies in applying adjustments for confounding factors such as age, smoking and alcohol consumption.

A single case report of testicular atrophy and aspermia involving chronic solvent abuse was located (Suzuki et al. 1983).

**Acute-Duration and Gestational Exposure Animal Studies.** Exposure of female rats to 3,000 ppm toluene for 7 days produced abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries (Tap et al. 1996). However, the majority of gestational exposure studies in rodents did not report exposure-related changes in reproductive end points (e.g., number of litters, gestational age, implantations, pre- or post-implantation loss, number of live and dead pups, sex ratio) at concentrations ranging from 50 to 12,000 ppm (API 1978, 1991, 1992; Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b; Courtney et al. 1986; Dalgaard et al. 2001; Hougaard et al. 2003; Jones and Balster 1997; Klimisch et al. 1992; Ladefoged et al. 2004; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997), despite evidence for maternal toxicity (decreased maternal weight gain).
3. HEALTH EFFECTS

at concentrations as low as 1,200 ppm (API 1991; Dalgaard et al. 2001; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). However, continuous exposure of pregnant rabbits to 267 ppm during days 7–20 of pregnancy produced maternal toxicity (decreased weight gain) and abortions in 4/8 does (Ungvary and Tatrai 1985). Additionally, rats exposed to 5,000 ppm 6 hours/day during days 6–15 of pregnancy resulted in increased post-implantation loss and complete fetal resorption in 6/9 litters (API 1992). These effects were not observed at 133 ppm in rabbits or ≤3,500 ppm toluene in rats (API 1992; Ungvary and Tatrai 1985). Another rat study found no exposure-related effects on mating, fertility, or pregnancy indices for F1 rats that had been exposed in utero to 0, 300, 600, 1,000, or 1,200 ppm toluene for 6 hours/day during GDs 9–21 (Thiel and Chahoud 1997).

Other studies examining reproductive effects in offspring following exposure to toluene during gestation are discussed in Section 3.2.1.6, Developmental Effects.

**Intermediate-Duration Animal Studies.** Significantly decreased sperm counts (26%) and decreased weights of the epididymides (15%) were reported in male rats exposed to 2,000 ppm 6 hours/day for a total of 90 days, including 60 days before mating to females that were exposed for 14 days before and 7 days after mating (Ono et al. 1996). A slight decrease in sperm count (13%) was also observed at 600 ppm, but histological examination of the testes and epididymes found no abnormalities at either concentration. No significant exposure-related effects on mating behavior or fertility indices were found in this study (Ono et al. 1996). Exposure to 3,000 ppm toluene 8 hours/day, 6 days/week for 12 weeks resulted in a statistically significant 23% decrease in mean seminiferous tubule diameter, decreased immunohistological staining for proliferating cell nuclear antigen (PCNA) in spermatogonia and early-stage spermatocytes, decreased spermatogenesis, increased apoptosis in testes, and various histological and ultrastructural abnormalities in testes (Kanter 2011b). In contrast, no statistically significant changes in numbers of spermatogenic cells at various stages in seminiferous tubules, testes weight, testicular histology, or serum hormone levels were found in rats exposed to 4,000 or 6,000 ppm 2 hours/day for 5 weeks, compared with controls, but significant changes in sperm parameters were found in 6,000-ppm rats (Ono et al. 1999). Changes included a 66% decrease in sperm head counts, a 78% decrease in motility, and a 76% decrease in ovum penetration (Ono et al. 1999). In rats exposed to 0 or 1,500 ppm 4 hours/day for 20 days, no exposure-related effects were revealed by histological examination of testis and epididymis sections, by immunohistochemical analysis of testis and epididymis for heat shock protein 70 (HSP70), c-Fos protein, and PCNA, or on testis or epididymis weights, although body weights of exposed rats were significantly lower than controls (Ishigami et al. 2005). In rats exposed to paint thinner (66% toluene) at toluene concentrations of 1,500 ppm for 2 hours for up to 30 days, significantly reduced
3. HEALTH EFFECTS

Seminiferous tubule diameter, testicular weight, and serum and testicular testosterone levels were found (Yilmaz et al. 2006). Other components in paint thinner (acetone, isobutyl acetate, butyl glycol, and isobutanol) may have contributed to these effects.

Exposure of male mice to concentrations of 100 or 400 ppm for 8 weeks did not induce dominant lethal mutations or cause pre- and post-implantation losses after they were mated with nonexposed females (API 1981). There were no treatment-related histopathological lesions in the testes of rats or mice exposed to up to 3,000 ppm toluene for 14–15 weeks although rats showed a 15% increase in testis weight (NTP 1990). In 2-generation reproduction studies in rats, exposure of males and females to concentrations of 100, 500, or 2,000 ppm 6 hours/day for up to 95 days did not adversely affect reproductive parameters (e.g., fertility) or offspring survival compared with unexposed controls (API 1985; Roberts et al. 2003). No effects on reproductive performance or offspring survival were found when males only or females only were exposed to 2,000 ppm by a similar protocol and mated to unexposed partners (Roberts et al. 2003). Additionally, no effects on pregnancy outcomes or offspring survival were observed following exposure to 1,200 ppm 6 hours/day from GD 7 to PND 18 (Dalgaard et al. 2001; Hass et al. 1999).

**Chronic-Duration Animal Studies.** Toluene did not cause altered weight or histopathological lesions of the ovaries or testes in rats exposed to toluene concentrations up to 300 ppm toluene for 24 months (CIIT 1980) or in rats or mice at concentrations up to 1,200 ppm for 2 years (NTP 1990).

The highest NOAEL values and all LOAEL values for each reliable study for reproductive effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

### 3.2.1.6 Developmental Effects

#### Overview.

A number of published reports have described birth defects, similar to those associated with fetal alcohol syndrome, in children born to women who intentionally inhaled large quantities of toluene or other organic solvents during pregnancy (Arnold and Wilkins-Haug 1990; Arnold et al. 1994; Erramouspe et al. 1996; Goodwin 1988; Hersh 1988; Hersh et al. 1985; Lindemann 1991; Pearson et al. 1994; Wilkins-Haug and Gabow 1991a). These reports suggest that exposure to high concentrations of toluene during pregnancy can be toxic to the developing fetus. Studies of women exposed during pregnancy to much lower concentrations of toluene in the workplace are restricted to a retrospective study of 14 women in Finland occupationally exposed to mixed solvents, which suggested that solvent exposure may increase risk for central nervous system anomalies and neural tube closure defects (Holmberg 1979). A number of
developmental toxicity studies with rats, mice, and rabbits involving toluene exposure by inhalation during gestation have been conducted to further describe developmentally toxic effects from toluene and exposure-response relationships. The results indicate that toluene did not cause maternal or developmental toxic effects in animals at exposure levels <1,000 ppm administered for 6–7 hours/day during gestation (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997; Tsukahara et al. 2009; Win-Shwe et al. 2012a, 2012b; Yamamoto et al. 2009). Predominant effects reported at concentrations ranging from 1,000 to 3,000 ppm include retarded fetal growth and skeletal development and altered development of behavior in offspring, and were almost always accompanied by signs of maternal toxicity (API 1991, 1992; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Jones and Balster 1997; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). Other animal studies reported that continuous, 24-hour/day exposure during gestation caused maternal body weight depression and effects on fetuses including depressed body weight and delayed skeletal ossification at toluene concentrations as low as 133–399 ppm in rats, mice, and rabbits (Hudak and Ungvary 1978; Ungvary and Tatrai 1985). Performance deficits in a few neurobehavioral tests were observed in one study of offspring of pregnant mouse dams exposed by inhalation to 2,000 ppm, but not 200 or 400 ppm, for 60 minutes 3 times/day on GDs 12–17 (Jones and Balster 1997). Performance deficits were not observed in offspring of pregnant rat dams exposed by inhalation to up to 2,000 ppm for 6 hours/day during gestation (Hougaard et al. 2003; Ono et al. 1995; Thiel and Chahoud 1997). Increased malformations and fetal death have been observed when animals are exposed during gestation to higher concentrations modeling solvent abuse (8,000–16,000 ppm, 15–30 minutes/day) (Bowen and Hannigan 2013; Bowen et al. 2005, 2009a).

**Human Studies.** Microcephaly, central nervous system dysfunction, attentional deficits, minor craniofacial and limb anomalies, developmental delay, and variable growth have been described in case reports of children who were exposed to toluene *in utero* as a result of maternal solvent abuse during pregnancy (Arnold and Wilkins-Haug 1990; Arnold et al. 1994; Hersh 1988; Hersh et al. 1985; Lindemann 1991; Pearson et al. 1994; Wilkins-Haug and Gabow 1991a). Growth retardation and dysmorphism were reported in five infants born to women who were chronic paint sniffers (Goodwin 1988).

Children born to toluene abusers have exhibited renal tubular acidosis immediately after birth that is thought to be due to alterations in ion gradient maintenance in the renal tubules. The kidney effects are often associated with hyperchloremia (Erramouspe et al. 1996; Goodwin 1988; Lindemann 1991). In one
3. HEALTH EFFECTS

report (Goodwin 1988), the acidosis was resolved within 3 days of birth, while in the other two reports, it took about 2 weeks for the resolution of the metabolic acidosis. There were no abnormalities in the urinary tract of two children born to chronic toluene abusers based on results of a renal ultrasound evaluation (Hersh 1988).

Studies of women exposed during pregnancy to much lower concentrations of toluene in the workplace are restricted to a single study. A retrospective study of 14 women in Finland occupationally exposed to mixed solvents (some of which included toluene), as well as various drugs including aspirin, vasodilators, and diuretics, suggested that solvent exposure may increase the risk of central nervous system anomalies and defects of neural tube closure in children exposed in utero (Holmberg 1979). While these findings suggest that occupational exposure to solvents may be toxic to the developing fetus, the small sample size coupled with multiple chemical exposures cannot support definitive conclusions regarding developmental toxicity of low toluene levels in humans.

*Standard Developmental Toxicity Studies in Animals.* Numerous studies in rats, mice, and rabbits with inhalation exposure to concentrations <1,000 ppm toluene for 1–8 hours/day during various gestational periods have found no exposure-related effects on maternal and developmental end points (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). Exposure to 1,000–3,500 ppm during gestation resulted in decreased fetal/pup weight and/or decreased neonatal growth in a number of studies (API 1991, 1992; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Ladefoged et al. 2004; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). Significantly decreased maternal body weight gain was observed at exposure levels causing decreased weight or growth in offspring, except in studies by Hass et al. (1999), which reported no significant change in maternal body weight gain at 1,200 ppm and Thiel and Chahoud (1997), which reported fetal body weight effects at 1,000 ppm and maternal body weight effects at 1,200 ppm. Additional developmental effects observed in these studies include delayed ossification in rat fetuses following exposure to 3,000 ppm for 6 hours/day from GD 6 to 15 (API 1991; Roberts et al. 2007), increased postnatal/preweaning mortality in rat pups following exposure to 1,200 ppm for 6 hours/day from GD 9 to 21 (Thiel and Chahoud 1997), and total resorption of rat litters with exposure to 5,000 ppm for 6 hours/day from GD 6 to 15 (API 1992). In another study, exposure of pregnant mice to 200 or 400 ppm, 7 hours/day on GDs 7–16 produced significantly increased litters with fetuses with enlarged renal pelvises in the 200-ppm group (but not in the 400-ppm group) and a difference in the distribution of fetuses with varying numbers of ribs in the 400-ppm group, compared with the control group (Courtney et al. 1986). Similarly, exposure of pregnant mice to 133 or 266 ppm,
3–4 hours/day on GDs 6–15, did not significantly affect maternal or fetal survival, or incidences of fetuses with visceral or skeletal anomalies or malformations. However, incidences of fetuses with decreased body weight and skeletal retardations were significantly increased in the group exposed to 266 ppm (Ungvary and Tatrai 1985).

A series of studies indicate that continuous, 24-hour/day exposure during gestation can cause maternal and developmental toxicity at toluene concentrations as low as 133–399 ppm in rats, mice, and rabbits (Hudak and Ungvary 1978; Ungvary and Tatrai 1985). In pregnant rats exposed to 399 ppm, 24 hours/day on GDs 1–8 or 9–14, no statistically significantly increased incidences of fetuses with visceral or skeletal malformations were found (Hudak and Ungvary 1978). However, 5/14 dams died, fetal body weight was decreased, and retardation of fetal skeletal development occurred with exposure on GDs 1–8, and 2/21 dams died and increased incidences of skeletal anomalies (extra ribs, fused sternebrae) were found with exposure on GDs 9–14 (Hudak and Ungvary 1978). No maternal mortality, fetal weight loss, or fetal malformations were found in another group of rats exposed to 266 ppm, 8 hours/day on GDs 1–21, but significantly increased incidence of fetuses with skeletal retardation occurred (Hudak and Ungvary 1978). In mice exposed to 133 ppm, 24 hours/day on GDs 6–13, no effects on maternal survival or incidences of fetuses with malformations were found, but fetal body weight was significantly decreased (Hudak and Ungvary 1978). All 15 pregnant mice died that were exposed to 399 ppm, 24 hours/day on GDs 6–13 (Hudak and Ungvary 1978). In rabbits exposed to 133 ppm, 24 hours/day on GDs 7–20, no significant effects were found on maternal or fetal survival, fetal body weight, or incidences of fetuses with skeletal retardation, minor anomalies, or skeletal or visceral malformations (Ungvary and Tatrai 1985). Following exposure to 266 ppm by the same protocol, 2/8 rabbit dams died, 4/8 dams aborted, and no live fetuses were found at sacrifice (Ungvary and Tatrai 1985).

Studies of Reproductive System Development in Animals. Studies of inhalation exposure of rats to concentrations as high as 1,800 ppm for 6 hours/day during gestation and/or early postnatal periods have provided little evidence of adverse effects on reproductive performance in adulthood. Female offspring of dams exposed to 1,200 ppm toluene, 6 hours/day on GDs 9–21 showed a significant delay in reproductive development (vaginal opening) compared with unexposed controls, but no significant exposure-related effects on mating, fertility, or pregnancy indices were observed in groups of male and female F1 offspring exposed during gestation to 300, 600, 1,000, or 1,200 ppm (Thiel and Chahoud 1997). In another study, no exposure-related changes were observed in the appearance of sexual maturation landmarks in male or female rat offspring of dams exposed to 1,200 ppm toluene, 6 hours/day on GD 7 to PND 18 (Hass et al. 1999). No significant changes in the percent of motile sperm or any
parameters of sperm motility on PND 100 were observed in male offspring of dams exposed to 1,200 ppm toluene, 6 hours/day from GD 7 to PND 18 (Dalgaard et al. 2001). In male offspring of dams exposed to 1,800 ppm toluene, 6 hours/day from GD 7 to 20, no significant changes in testicular weight or histology at PND 11, 21, or 90 were found, compared with controls (Dalgaard et al. 2001). Additionally, no significant changes in serum prolactin or LH were observed in 8-week-old male rats following neonatal exposure to 80 ppm for 6 hours/day from PND 1 to 7, compared with controls (von Euler et al. 1989b). However, Tsukahara et al. (2009) reported that nose-only exposures of 0.09–9 ppm for 90 minutes/day in dams from GD 14.5 to 18.5 statistically significantly decreased fetal serum testosterone and 3β-HSD steroidogenic enzyme immunoreactivity in fetal testes in the 0.9 and 9 ppm groups, and significantly decreased 3β-HSD mRNA levels in the 0.9 ppm group only. These effects were more pronounced at 0.9 ppm than 9 ppm and were not accompanied by any histological changes in the fetal testes; mechanistic understanding is inadequate to determine biologically adversity of the observed effects.

**Studies of Neurological Development in Animals.** Gestational exposure by inhalation to toluene concentrations as high as 1000–1,500 ppm did not affect the performance of offspring in neurobehavioral tests in several animal studies (Jones and Balster 1997; Ladefoged et al. 2004; Ono et al. 1995; Thiel and Chahoud 1997); at 2,000 ppm, one study reported some statistically significant performance deficits in mouse offspring (Jones and Balster 1997), whereas another found no statistically significant deficits in rat offspring (Ono et al. 1995).

Mouse pups from dams exposed to 2,000 ppm for 60 minutes, 3 times/day on GDs 12–17 gained less weight between PND 2 and 8 compared with unexposed controls, and showed statistically significant increased latency of righting reflex on PNDs 1, 5, and 6, decreased forelimb grip strength on PNDs 5–7 and 9–11, and increased latency to climb in the inverted screen test on PNDs 14–17 (Jones and Balster 1997). No statistically significant effects on these end points were observed after exposure to 200 or 400 ppm by the same protocol, and no effects on times to reach developmental landmarks such as incisor eruption and eye opening were noted in any of the exposure groups (Jones and Balster 1997).

In another study, offspring of rat dams exposed to 600 or 2,000 ppm, 6 hours/day on GDs 7–17 showed no statistically significant differences from control rats in postnatal viability or physical development through PND 21, tests of reflexes on PNDs 6–10, locomotor activity during postnatal week 4, balance on a rotating rod during postnatal week 7, or learning ability in the Biel water maze test during postnatal week 6 (Ono et al. 1995).
3. HEALTH EFFECTS

No consistent, concentration-dependent performance deficits were found in tests of reflexes on PND 3, balance on a rotating rod on PND 18, locomotor activity on PNDs 31–34, or discrimination learning on PNDs 70–81 in rat offspring of dams exposed to 300, 600, 1,000, or 1,200 ppm, 6 hours/day on GDs 9–21, compared with controls (Thiel and Chahoud 1997).

No changes were observed in Morris water maze spatial learning and memory in female offspring following exposure to 1,500 ppm for 6 hours/day from GD 7 to 20, compared with controls (Ladefoged et al. 2004).

Exposure of pregnant rats to 1,200 ppm toluene, 6 hours/day from GD 7 to PND 18 produced statistically significant decreased postnatal growth (PNDs 0–10), delayed ontogeny of reflexes between PND 2 and 13, and increased open-field locomotor activity on PND 28 in male and female offspring, compared with unexposed controls (Hass et al. 1999). Significantly increased latency to find the hidden platform in the Morris water maze test after platform relocation was found in 13-week-old exposed female offspring, compared with nonexposed female offspring, when data were analyzed on an individual basis, but not on a litter basis. No consistent significant effects were observed in rotarod performance on PNDs 22–26, auditory brainstem responses at 4 months, or in physical development (e.g., eye opening) on PND 14 (Hass et al. 1999).

Decreased neonatal growth, impaired auriculonasoccephalic reflex (reflexive movement to thermal and olfactory stimuli, e.g., “dummy dam”), impaired ability to locate a visible platform in the Morris water maze, and impaired learning in the passive avoidance task were reported for neonatal rats exposed by inhalation to 500 ppm on PNDs 7–30 (Museridze et al. 2010). However, the available report did not indicate the daily exposure duration used in this study, provided no indication that air concentrations were measured during the exposure periods, and used mongrel rats.

Significant localized changes in dopamine and noradrenaline neurotransmitter levels and utilization were observed in 8-week-old adult male rats that were exposed to 80 ppm for 6 hours/day from PND 1 to 7, compared with controls (von Euler et al. 1989b). Neurotransmitter levels were increased in some areas of the brain, were decreased in some areas, and remained the same in other areas. Localized changes in dopamine and noradrenaline neurotransmitter levels and utilization were also observed in 8-week-old rats exposed both neonatally on PNDs 1–7 and again for 3 days during postnatal week 8 to 80 ppm (6 hours/day), compared with previously unexposed 8-week-old rats (von Euler et al. 1989b).
biological adversity of region-specific neurotransmitter alterations in the absence of neurobehavioral changes is unknown.

Biochemical and cellular changes in brain tissues have been reported in several studies of animals exposed to toluene by inhalation during gestation or during early postnatal periods. In rats, offspring of dams exposed to 1,500–1,800 ppm during gestation had elevated levels of cerebellar apoptosis during postnatal development (Dalgaard et al. 2001; Ladefoged et al. 2004) and increased in vitro generation of reactive oxygen species in cultured synaptosomes (Edelfors et al. 2002), and neonatal rats exposed to 100–500 ppm had reversible decreases in the volume of the granular cell layer in the dentate of the hippocampus (Slomianka et al. 1990). In mice, offspring of dams exposed to 400 ppm had elevated LDH activity on PND 21 (Courtney et al. 1986). Mechanistic understanding is inadequate to determine the biological adversity of these effects.

**Animal Studies Modeling High Concentration Solvent Abuse.** A series of studies in rats were designed to model human solvent abuse during pregnancy to determine if repeated brief exposures to very high concentrations during gestation could cause adverse developmental effects. These studies found that exposure to 8,000–16,000 ppm for 15–30 minutes twice daily from GD 8 to 20 caused decreased maternal body weight gain; decreased pup/fetal weight, length, and postnatal growth; decreased placental weight; increased number of litters with malformed, runted, or dead pups; impaired motor coordination in offspring; and altered reward-seeking behavior with increased impulsivity in offspring (Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b; Jarosz et al. 2008). No changes were found in the achievement of physical landmarks (Bowen and Hannigan 2013; Bowen et al. 2005).

The highest NOAEL values and all LOAEL values for each reliable study for developmental effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

### 3.2.1.7 Cancer

**Human Studies.** Thirteen human epidemiology studies were located that assessed toluene exposure as a possible risk factor for cancer. Cancers of most sites were not significantly associated with toluene exposure in any study, and there was weak consistency in the findings of those studies that did find association of a particular cancer type with toluene exposure. Five cohort studies involved occupationally exposed workers exposed predominantly to toluene (Antilla et al. 1998; Lehman and Hein 2006; Svensson et al. 1990; Walker et al. 1993; Wiebelt and Becker 1999), whereas the remainder of the human
studies primarily involved subjects exposed to mixtures of solvents including toluene (Austin and Schnatter 1983; Blair et al. 1998; Carpenter et al. 1988; Gérin et al. 1998; Lundberg and Milatou-Smith 1998; Olsson and Brand 1980; Wen et al. 1985; Wilcosky et al. 1984). The information from these studies is inadequate to assess the carcinogenic potential of toluene, predominantly because of the lack of consistent findings across the studies and the likelihood that many of the studied groups were exposed to multiple chemicals.

Svensson et al. (1990) compared cancer incidence and mortality in a cohort of Swedish printers, exposed primarily to toluene and employed for at least 3 months between 1925 and 1985, to mortality and cancer incidence for the region. Current and historical monitoring data were used to estimate yearly average concentrations of toluene in the air. Concentrations had declined from about 450 ppm in the 1940s to 30 ppm by the mid-1980s. There were indications of excess risk of morbidity (standardized incidence ratio, SIR) and mortality (standardized mortality ratio, SMR) for respiratory tract cancer (SMR, 1.4; 95% CI, 0.7–2.5; n=11; SIR, 1.8; 95% CI, 1.0–2.9; n=16), stomach cancer (SMR 1.4, 95% CI 0.7–2.5, n=11; SIR 1.8, 95% CI 1.0–2.9, n=16), stomach cancer (SMR 2.7, 95% CI 1.1–5.6, n=7; SIR 2.3, 95% CI 0.9–4.8, n=7), and colo-rectal cancer (SMR 2.2, 95% CI 0.9–4.5, n=7; SIR 1.5, 95% CI 0.7–2.8, n=9), but there was no significant association between increased risk and cumulative exposure.

Walker et al. (1993) conducted a cohort mortality study among 7,814 shoe-manufacturing workers (2,529 men and 5,285 women) from two plants in Ohio in operation since the 1930s. Workers were exposed to solvents and solvent-based adhesives. Based on results of a hygiene survey (1977–1979), exposure was thought to be primarily to toluene (10–72 ppm), but other chemicals (e.g., 2-butanone, acetone, and hexane) were also recorded at similar concentrations. IARC (1999) noted that benzene may have been present as an impurity of toluene. Mortality follow up was from 1940 to 1982 and relative risk estimates (SMRs) were derived using the general population of the United States as controls. There were excess risks of lung cancer for both men (SMR 1.6, 95% CI 1.2–2.0, n=68) and women (SMR 1.3, 95% CI 0.9–1.9, n=31), but smoking may have been a confounding factor and relative risk of lung cancer did not increase with increasing duration of employment. There was a slight excess risk for colon cancer among men (SMR 1.3, 95% CI 0.8–2.1, n=18) and women (SMR 1.2, 95% CI 0.8–1.8, n=28). Other cancers showed no excess risk. In a follow-up study of this cohort, an excess of lung cancer deaths persisted with additional follow-up through 1999 (SMR 1.36, 95% CI 1.19–1.54, n=248), but the relative risk of lung cancer still did not increase with increasing duration of employment (Lehman and Hein 2006). No other cancers showed excess risk in this follow-up.
Antilla et al. (1998) carried out a retrospective cohort analysis of 5,301 workers (3,922 male and 1,379 female) monitored for biological markers of occupational exposure to styrene, toluene or xylene over the period 1973–1992. No increase in overall cancer risk or risk for cancers at specific tissue sites was associated with exposure to toluene, except for a nonsignificant increase in the incidence of lung cancer in individuals exposed to toluene for more than 10 years (SIR 1.62, 95% CI 0.33–4.73, three cases). Antilla et al. (1998) noted, however, that these workers may also have been exposed to benzene.

Wiebelt and Becker (1999) examined cancer incidence and mortality in a cohort of 6,830 German males employed in rotogravure printing plants for at least one year between 1960 and 1992, and compared them to mortality and cancer incidence for West Germany. Workers were divided into three work areas: printing/proof printing (<100 ppm after 1985, <200 ppm 1960–1985), printing cylinder preparation (<30 ppm) and finishing (<30 ppm). When the three groups were examined together, no statistically significant increases in overall cancer risk or risk for cancers at specific tissue sites were associated with exposure to toluene. When analyzed by work area, a strong increase in mortality from bone and connective tissue cancers was found in the workers from the highest exposure group (printers) based on a small number of observed cases. SMRs for bone and connective tissue cancers were 8.1 (95% CI 1.4–32.4; three cases) and 6.3 (95% CI 1.2–25.9; three cases), respectively. Wiebelt and Becker (1999) noted that the significance of these findings is unclear as they have not been previously associated with toluene exposure. Nonsignificant increases in mortality from lung cancer were observed in printers (SMR 1.3, 95% CI 0.7–2.5) and finishers (SMR 1.8, 95% CI 0.8–4.4); however, the risk was greater in the group with the lower toluene exposure levels.

Many of the other human epidemiological cancer studies showed positive associations between exposure to toluene and cancer at one or more tissue site, but individuals were exposed to multiple chemicals in all of these studies (Austin and Schnatter 1983; Blair et al. 1998; Carpenter et al. 1988; Gérin et al. 1998; Lundberg and Milatou-Smith 1998; Olsson and Brandt 1980; Wen et al. 1985; Wilcosky et al. 1984). Nested case-control studies included studies of prostate and brain cancer within cohorts of Texas petrochemical plant workers (Austin and Schnatter 1983; Wen et al. 1985), of lung cancer, stomach cancer, and leukemia among U.S. rubber workers (Wilcosky et al. 1984), cancer of the central nervous system among a group of Tennessee nuclear facility workers (Carpenter et al. 1988), prostate cancer and multiple myeloma among Swedish paint industry workers (Lundberg and Milatou-Smith 1998), and multiple myeloma, nonHodgkin’s lymphoma, and breast cancer among aircraft maintenance facility workers (Blair et al. 1998). Community-based case-control studies examined possible associations...
3. HEALTH EFFECTS

between Hodgkin’s disease in Swedish patients and controls (Olsson and Brandt 1980) and several cancer types in Canadian patients and controls (Gérin et al. 1998).

**Animal Studies.** Inhalation cancer bioassays carried out in experimental animals have produced no evidence to support toluene as a potential carcinogen. No increased incidences of treatment-related neoplastic lesions were observed in Fischer 344 rats or B6C3F1 mice exposed to toluene concentrations up to 1,200 ppm for 6.5 hours/day, 5 days/week for 2 years (Huff 2003; NTP 1990). Similar results were reported for another study in which Fischer 344 rats were exposed to toluene concentrations up to 300 ppm 6 hours/day, 5 days/week for 2 years, but the maximum exposure concentration in this study was likely below that necessary to approach a maximum tolerated dose (CIIT 1980; Gibson and Hardisty 1983). The NTP (1990) study was well conducted, achieved the maximum tolerated dose, and provides evidence suggesting a lack of carcinogenicity of toluene in experimental animals.

### 3.2.2 Oral Exposure

Studies of the effects of oral exposure to toluene are limited. Only four case studies were located regarding health effects in humans after oral exposure to toluene and there are only a minimal number of animal studies.

#### 3.2.2.1 Death

**Human Case Study.** Ingestion of approximately 60 mL (625 mg/kg) of toluene proved fatal for a 51-year old male (Ameno et al. 1989). Death occurred within 30 minutes of ingestion. The autopsy results revealed constriction and necrosis of the myocardial fibers, a markedly swollen liver, congestion and hemorrhage of the lungs, and acute tubular kidney necrosis. The probable cause of death was determined to be severe depression of central nervous system function.

**Acute-Duration Animal Studies.** The limited number of studies on the acute oral toxicity of toluene in animals have focused on lethal effects. The acute oral LD$_{50}$ of toluene in adult rats ranged from 5.5 to 7.4 g/kg (Kimura et al. 1971; Smyth et al. 1969; Withey and Hall 1975; Wolf et al. 1956). Age may play a role in determining the lethal dose for toluene. The LD$_{50}$ value for 14-day-old rats was 3.0 g/kg, which is markedly lower than the adult values (Kimura et al. 1971).

**Intermediate-Duration Animal Studies.** Mice were more sensitive than rats to the lethal effects of toluene in 13-week gavage studies. All rats and mice that received 5,000 mg/kg died within the first
week. Mortality was also high for groups receiving 2,500 mg/kg with eight out of ten male rats, one out of ten female rats, and with four out of ten male and female mice dying before the end of the study. A dose of 1,250 mg/kg/day was lethal in 10% of female mice but no deaths occurred in male mice or in rats of either sex (NTP 1990). LOAEL values from each reliable study for death in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.2 Systemic Effects

Overview. Human data pertaining to the systemic effects of oral exposure to toluene are limited to four case studies (Ameno et al. 1989; Caravati and Bjerk 1997; Einav et al. 1997; Malingre et al. 2002). Animal data are also limited, but include cardiovascular, hematological, hepatic, renal, and body weight effects in rats and mice exposed orally to toluene at dosage levels ranging from 312 to 2,500 mg/kg/day for 13 weeks (NTP 1990), hepatic effects in mice exposed to 105 mg/kg/day for 28 days (Hsieh et al. 1989), and hepatic effects in rats exposed to 5,200 mg/kg/day for up to 45 days (Kamel and Shehata 2008). However, no cardiovascular, hematological, hepatic, or renal effects were reported in rats exposed to 590 mg/kg/day for 6 months (Wolf et al. 1956). Acute exposure to single doses ≥1,000 mg/kg have resulted in cardiovascular and hepatic effects (Ayan et al. 2013; Gordon et al. 2010; Tas et al. 2013b). All systemic effects are discussed below. The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

Respiratory Effects.

Human Case Studies. Lung congestion and hemorrhage were reported in one case report involving lethal ingestion of approximately 625 mg/kg toluene by an adult male (Ameno et al. 1989). A 15-month-old girl who accidently ingested paint thinner was intubated after presenting with severe central nervous system depression (Malingre et al. 2002). Extubation the following day resulted in serious respiratory stridor and bronchoscopy showed mucosal lesions and pronounced edema. The patient was re-intubated for an additional 8 days. No residual damage was observed following extubation (Malingre et al. 2002). No additional studies were located regarding respiratory effects in humans after oral exposure to toluene.

Animal Studies. No respiratory effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks (NTP 1990) or 590 mg/kg/day for 6 months (Wolf et
**Table 3-3 Levels of Significant Exposure to Toluene - Oral**

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Human</td>
<td>once</td>
<td></td>
<td></td>
<td></td>
<td>625 (death in 30 minutes)</td>
<td></td>
<td>Ameno et al. 1989</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Rat (Sprague-Dawley)</td>
<td>NS (G)</td>
<td></td>
<td></td>
<td></td>
<td>5568 (LD50 young adult rat)</td>
<td></td>
<td>Kimura et al. 1971</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Rat (Sprague-Dawley)</td>
<td>NS (G)</td>
<td></td>
<td></td>
<td></td>
<td>6438 (LD50 adult rat)</td>
<td></td>
<td>Kimura et al. 1971</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Rat (Sprague-Dawley)</td>
<td>NS (G)</td>
<td></td>
<td></td>
<td></td>
<td>2610 (LD50 14 day-old rat)</td>
<td></td>
<td>Kimura et al. 1971</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Rat</td>
<td>NS (G)</td>
<td></td>
<td></td>
<td></td>
<td>7300 (LD50)</td>
<td></td>
<td>Smyth et al. 1969</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Rat</td>
<td>once (G)</td>
<td></td>
<td></td>
<td></td>
<td>5580 M (LD50 adult rats)</td>
<td></td>
<td>Withey and Hall 1975</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Rat (Wistar)</td>
<td>once (G)</td>
<td></td>
<td></td>
<td></td>
<td>7000 (LD50 young adult rats)</td>
<td></td>
<td>Wolf et al. 1956</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Human</td>
<td>once</td>
<td>Resp</td>
<td>625 M</td>
<td>625 M (lung congestion and hemorrhage)</td>
<td>Ameno et al. 1989</td>
<td>Case report</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>625 M</td>
<td>625 M (necrosis of myocardial fibers)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>625 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>625 M</td>
<td>625 M (enlarged liver)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>625 M</td>
<td>625 M (acute tubular necrosis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Rat (Wistar)</td>
<td>once</td>
<td>Hepatic</td>
<td>5200 M</td>
<td>(Slight degeneration of hepatocytes and mononuclear cell infiltration; increased serum AST, ALT; increased apoptosis)</td>
<td>Ayan et al. 2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Rat (Long-Evans)</td>
<td>once</td>
<td>Cardio</td>
<td>1200 M</td>
<td></td>
<td></td>
<td>Gordon et al. 2007</td>
<td>Observed tachycardia and hypertension attributed to increased locomotion; no change in ECG.</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Rat (Brown Norway)</td>
<td>once (GO)</td>
<td>Cardio</td>
<td>600 M</td>
<td>1000 M (6, 8, and 13% decrease in relative heart weight in young, middle aged, and aged rats)</td>
<td>Gordon et al. 2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1000 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-19 1x/d (GO)</td>
<td>Bd Wt</td>
<td>520 F (24% decrease in maternal body wt gain)</td>
<td></td>
<td></td>
<td>Gospe et al. 1994</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rat (Wistar)</td>
<td>once (G)</td>
<td>Cardio</td>
<td>5200 M (congestion, edema and apoptosis in cardiac tissue)</td>
<td></td>
<td></td>
<td>Tas et al. 2013b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 16-19 (GO)</td>
<td>Hepatic</td>
<td>1250 F</td>
<td></td>
<td></td>
<td>Warner et al. 2008</td>
<td>Hepatic NOAEL is for maternal liver weight and histology.</td>
<td></td>
</tr>
</tbody>
</table>
# Table 3-3 Levels of Significant Exposure to Toluene - Oral

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Mouse (B6C3F1)</td>
<td>14 d (GO)</td>
<td>Resp</td>
<td>600 F</td>
<td>Burns et al. 1994</td>
<td>Endpoints examined: organ weight and histology, clinical chemistry, hematology.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hemato 600 F (increased reticulocytes)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatic 600 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Renal 600 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bd Wt 600 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immuno/ Lymphoret</td>
<td>Mouse (B6C3F1)</td>
<td>14 d (GO)</td>
<td></td>
<td>600 F</td>
<td>Burns et al. 1994</td>
<td>Endpoints examined: spleen and thymus weight and histology, bone marrow cell count, immune function assays, host-resistance assays.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological</td>
<td>Human</td>
<td>once</td>
<td></td>
<td></td>
<td>Ameno et al. 1989</td>
<td>Case report</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td>625 M (severe central nervous system depression)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Rat (Long- Evans) (GO)</td>
<td>once</td>
<td>250 M (decrease in amplitude in FEP N3 peak)</td>
<td>Dyer et al. 1988</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Rat (Long- Evans) (GO)</td>
<td>once</td>
<td>400 M 800 M (increased locomotor activity)</td>
<td>Gordon et al. 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species/Strain</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>----------------------</td>
<td>-----------</td>
<td>---------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Rat (Brown Norway)</td>
<td>once (GO)</td>
<td></td>
<td>300 M</td>
<td>650 M (increased locomotor activity)</td>
<td></td>
<td></td>
<td>Gordon et al. 2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Rat (Sprague-Dawley)</td>
<td>once (G)</td>
<td></td>
<td>2610 M</td>
<td>(increase in motor activity, lacrimation and salivation)</td>
<td></td>
<td></td>
<td>Mehta et al. 1998</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Mouse (B6C3F1)</td>
<td>14 d (GO)</td>
<td></td>
<td>600 F</td>
<td></td>
<td></td>
<td>Burns et al. 1994</td>
<td>Endpoints examined: brain weight and histology.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reproductive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-21 (GO)</td>
<td></td>
<td>650 F</td>
<td></td>
<td></td>
<td>Gospe and Zhou 2000</td>
<td>Endpoints evaluated: litter size.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 16-19 (GO)</td>
<td></td>
<td>1250 F</td>
<td></td>
<td></td>
<td>Warner et al. 2008</td>
<td>Endpoints evaluated: number of corpora lutea, implantations, pre- and post-implantation loss, resorptions, and live fetuses/litter.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Mouse (CD-1)</td>
<td>Gd 7-14 1x/d (GO)</td>
<td></td>
<td>2350 F</td>
<td></td>
<td></td>
<td>NIOSH 1983</td>
<td>Endpoints evaluated: number viable and totally resorbed litters.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Mouse (ICR)</td>
<td>Gd 8-12 5 d (G)</td>
<td></td>
<td>1800 F</td>
<td></td>
<td></td>
<td>Seidenberg et al. 1986</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Rat</td>
<td>Gd 6-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gospe and Zhou 1998</td>
<td></td>
<td>(delayed brain development of fetus)</td>
</tr>
<tr>
<td>28</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-21 (GO)</td>
<td></td>
<td>650</td>
<td>11.9% decrease in fetal brain weights, 21% decrease in fetal weights, delayed skeletal ossification)</td>
<td>Gospe et al. 1996</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-19 1x/d (GO)</td>
<td></td>
<td>520 (9.4% reduction in fetal weight)</td>
<td></td>
<td></td>
<td>Gospe et al. 1994</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-19 1x/d (GO)</td>
<td></td>
<td></td>
<td></td>
<td>650</td>
<td>Gospe et al. 1996</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-3  Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 16-19 (GO)</td>
<td></td>
<td>1250</td>
<td></td>
<td>(increased incidence of grade 3 or 4 left renal pelvis dilation)</td>
<td></td>
<td>Warner et al. 2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Mouse (CD-1)</td>
<td>Gd 7-14 1x/d (GO)</td>
<td></td>
<td>2350</td>
<td></td>
<td></td>
<td></td>
<td>NIOSH 1983</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Mouse (ICR)</td>
<td>Gd 8-12 5 d (G)</td>
<td></td>
<td>1800</td>
<td></td>
<td></td>
<td></td>
<td>Seidenberg et al. 1986</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INTERMEDIATE EXPOSURE**

**Death**

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Rat (Fischer-344)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td></td>
<td>2500</td>
<td></td>
<td>(8/10 males and 1/10 females died)</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Mouse (B6C3F1)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td></td>
<td>2500 M (4/10 died)</td>
<td></td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1250 F (1/10 died)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Rat (albino)</td>
<td>45 d (G)</td>
<td>Hepatic</td>
<td></td>
<td>650 M (increased levels of markers for hepatic apoptosis and oxidative stress)</td>
<td></td>
<td>Kamel and Shehata 2008</td>
<td></td>
<td>Organ weight and histology were not assessed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td></td>
<td>650 M (increased levels of markers for renal oxidative stress)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Reference</td>
<td>Chemical Form</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Rat (Fischer-344)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td>Resp</td>
<td>2500 M</td>
<td></td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1250 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>625 M (38% increase in relative heart weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1250 F (11% increase in relative heart weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardio</td>
<td></td>
<td></td>
<td></td>
<td>1250 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>625 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastro</td>
<td></td>
<td></td>
<td></td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemato</td>
<td></td>
<td></td>
<td></td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musc/skel</td>
<td></td>
<td></td>
<td></td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic</td>
<td>312 M</td>
<td></td>
<td></td>
<td>625 M (8% increase in liver weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>625 F</td>
<td></td>
<td></td>
<td>1250 F (22% increase in liver weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>312 M</td>
<td></td>
<td></td>
<td>625 M (6% increase in kidney weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>625 F</td>
<td></td>
<td></td>
<td>1250 F (8% increase in kidney weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocr</td>
<td></td>
<td></td>
<td></td>
<td>2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bd Wt</td>
<td>1250 M</td>
<td></td>
<td></td>
<td>2500 M (body weight 19% lower than controls)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2500 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>NOAEL System</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day) System</th>
<th>Serious (mg/kg/day) System</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>Rat (Wistar)</td>
<td>6 mo 5 d/wk 1x/d (G)</td>
<td>Resp 590 F</td>
<td></td>
<td></td>
<td></td>
<td>Wolf et al. 1956</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio 590 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato 590 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic 590 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal 590 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Mouse (CD-1)</td>
<td>28 d (W)</td>
<td>Hemato 105 M</td>
<td></td>
<td></td>
<td></td>
<td>Hsieh et al. 1989</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic 22 M</td>
<td></td>
<td>105 M (significant increase in liver weight-19%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal 105 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt 105 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Mouse (CD-1)</td>
<td>28 d (W)</td>
<td>Hemato 84 M</td>
<td></td>
<td></td>
<td></td>
<td>Hsieh et al. 1990a</td>
<td></td>
<td>Hepatic and renal NOAELs are for organ weight and gross pathology.</td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td>Mouse (CD-1)</td>
<td>28 d (W)</td>
<td>Bd Wt</td>
<td>105 M</td>
<td></td>
<td></td>
<td></td>
<td>Hsieh et al. 1990b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Mouse (CD-1)</td>
<td>28 d (W)</td>
<td>Endocr</td>
<td>22 M</td>
<td>105 M</td>
<td>(increased serum corticosterone and ACTH)</td>
<td></td>
<td>Hsieh et al. 1991</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bd Wt 105 M
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>43</strong> Mouse (B6C3F1)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td>Resp</td>
<td>2500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardio</td>
<td>2500</td>
<td>5000 (myocardial degeneration)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gastro</td>
<td>2500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hemato</td>
<td>2500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>2500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatic</td>
<td>625 M 1250 M 10% increase in relative liver weight)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>312 F (7% increase in relative liver weight)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal</td>
<td>2500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endocr</td>
<td>2500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>625 M 1250 M (body weight 16% lower than controls)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2500 F</td>
<td></td>
</tr>
</tbody>
</table>

**Immuno/ Lymphoret**

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>44</strong> Rat (Fischer- 344)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td>2500</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reference Chemical Form Comments**

- NTP 1990: Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>Mouse (CD-1)</td>
<td>28 d (W)</td>
<td></td>
<td>22 M</td>
<td></td>
<td>105 M (decreased thymus weight; diminished response in immune assays)</td>
<td></td>
<td>Hsieh et al. 1989</td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Mouse (CD-1)</td>
<td>28 d (W)</td>
<td></td>
<td>22 M</td>
<td></td>
<td>84 M (diminished response in immune assays)</td>
<td></td>
<td>Hsieh et al. 1990a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Mouse (CD-1)</td>
<td>28 d (W)</td>
<td></td>
<td>22 M</td>
<td></td>
<td>105 M (decreased interleukin-2 immune response)</td>
<td></td>
<td>Hsieh et al. 1991</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Mouse (B6C3F1)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td></td>
<td>2500</td>
<td></td>
<td>(increased levels of markers for cortical and cerebellar apoptosis and oxidative stress)</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td>ENDPOINTS EVALUATED: spleen and thymus weight and histology.</td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kamel and Shehata 2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Rat (albino)</td>
<td>15, 30, or 45 d (G)</td>
<td></td>
<td></td>
<td></td>
<td>650 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Rat (Fischer-344)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td></td>
<td>625</td>
<td>1250</td>
<td>(brain necrosis)</td>
<td></td>
<td>NTP 1990</td>
<td></td>
<td>ENDPOINTS ASSESSED: brain weight and histology, clinical signs.</td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>Mouse (B6C3F1)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td></td>
<td>625 M</td>
<td>1250 M (12% increase in relative brain weight)</td>
<td>2500 (ataxia, hypoactivity, prostration)</td>
<td>NTP 1990</td>
<td></td>
<td></td>
<td>Endpoints assessed: brain weight and histology, clinical signs.</td>
</tr>
<tr>
<td>52</td>
<td>Rat (albino)</td>
<td>15, 30, or 45 d (G)</td>
<td></td>
<td>650 M</td>
<td>625 M (increased levels of markers for testicular oxidative stress)</td>
<td>NTP 1990</td>
<td></td>
<td>Kamel and Shehata 2008</td>
<td>Reproductive organ weight and histology were not assessed. Reproductive function was not assessed.</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Rat (Fischer-344)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td></td>
<td>2500</td>
<td>NTP 1990</td>
<td>Endpoints evaluated: organ weight and histology; reproductive function not assessed.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Mouse (B6C3F1)</td>
<td>13 wk 5 d/wk 1x/d (GO)</td>
<td></td>
<td>625 M</td>
<td>1250 M (7% increase in relative testicular weight)</td>
<td>NTP 1990</td>
<td>Endpoints evaluated: organ weight and histology; reproductive function not assessed.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Toluene - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developmental</td>
<td>Mouse (Hybrid)</td>
<td>Gd 0-21 + Ppd 0-55 (W)</td>
<td></td>
<td>21</td>
<td>106</td>
<td>(increased open-field activity; lack of habituation)</td>
<td></td>
<td>Kostas and Hotchin 1981</td>
</tr>
</tbody>
</table>

a The number corresponds to entries in Figure 3-2.
b Used to derive an acute oral minimal risk level (MRL); dose (250 mg/kg/day) divided by an uncertainty factor of 300 (3 for use of a minimally adverse LOAEL, 10 for interspecies differences in response, and 10 for human variability), resulting in an MRL of 0.8 mg/kg/day
c Used to derive an intermediate oral minimal risk level (MRL) along with 2 companion studies supporting a NOAEL of 22 mg/kg/day for immunological effects; dose divided by an uncertainty factor of 100 (10 for interspecies differences in response and 10 for human variability), resulting in an MRL of 0.2 mg/kg/day

ACTH = adrenocorticotropic hormone; ALT = alanine amino transferase; AST = aspartate aminotransferase; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); ECG = electrocardiogram; Endocr = endocrine; F = Female; FEP = flash evoked potential; (G) = gavage; Gastro = gastrointestinal; Gd = gestational day; (GO) = gavage in oil; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; Ppd = post-parturition day; Resp = respiratory; x = time(s); (W) = drinking water; wk = week(s)
Figure 3-2 Levels of Significant Exposure to Toluene - Oral

Acute (≤14 days)

Systemic

mg/kg/day

Death

Respiratory

Cardiovascular

Gastrointestinal

Hematological

Hepatic

Renal

Body Weight

Immunolymphoid

Neurological

0.1

1

10

100

1000

10000

2r

3r

5r

6r

7r

4r

8

10r

11r

13r

9r

14r

15m

15m

15m

15m

15m

12r

16m

17

18r

19r

20r

21r

22m

Cancer Effect Level-Animals

LOAEL, More Serious-Animals

NOAEL - Animals

Cancer Effect Level-Humans

LOAEL, More Serious-Humans

NOAEL - Humans

LD50/LC50

Minimal Risk Level

for effects other than Cancer

c-Cat

d-Dog

r-Rat

p-Pig

g-Cow

k-Monkey

m-Mouse

h-Rabbit

a-Sheep

f-Ferret

j-Pigeon

e-Gerbil

s-Hamster

g-Guinea Pig

n-Mink

o-Other

& Cancer Effect Level-Animals

& LOAEL, More Serious-Animals

& LOAEL, Less Serious-Animals

& NOAEL-Animals

& LOAEL, More Serious-Humans

& LOAEL, Less Serious-Humans

& NOAEL-Humans

& LD50/LC50
Figure 3-2 Levels of Significant Exposure to Toluene - Oral (Continued)

Acute (≤14 days)

mg/kg/day

Reproductive  Developmental

26m  33m  25m  32m  24r  31r  23r  27r  28r  30r

Cl-Cat  d-Dog  r-Rat  p-Pig  q-Cow  k-Monkey  m-Mouse  h-Rabbit  o-Other  f-Ferret  j-Pigeon  e-Gerbil  s-Hamster  g-Guinea Pig

Cancer Effect Level-Animals
LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals

Cancer Effect Level-Humans
LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans

LD50/LC50  Minimal Risk Level  for effects
other than Cancer
No changes in lung weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994).

**Cardiovascular Effects.**

**Human Case Studies.** One case study involving lethality in humans reported necrosis of myocardial fibers after oral exposure to 625 mg/kg toluene (Ameno et al. 1989). Severe sinus bradycardia was reported in a man who accidentally ingested 30 mL of an organic solvent containing toluene and other chemicals (Einav et al. 1997). No cardiovascular effects were reported in a 15-month-old girl following ingestion of paint thinner (Malingre et al. 2002).

**Acute-Duration Animal Studies.** Cardiac edema and congestion were observed in rats given single gavage doses of 5,200 mg/kg, compared with controls (Tas et al. 2013b). The number of TUNEL-labeled cardiac cells were significantly increased by ~7-fold in treated rats and semi-quantitative caspase-3 labeling was increased, compared with controls, indicating increased apoptosis in heart tissue. Blood levels of troponin T, a marker for ischemic heart damage, were also significantly increased 14-fold in toluene-exposed rats, compared with controls. No significant changes in heart rate or blood pressure were observed (Tas et al. 2013b).

In a multi-dose study, rats were given single oral doses of 0, 400, 800, and 1,200 mg/kg in random order, with 72 hours between each dose (Gordon et al. 2007). Heart rate and blood pressure were significantly elevated following the 800 and 1,200 mg/kg doses for ~1 hour, compared with the vehicle control dose; however, these findings coincided with significant, dose-related increases in motor activity. Therefore, they likely do not represent adverse cardiac effects of toluene exposure. No significant treatment-related findings were observed in electrocardiograms (Gordon et al. 2007), indicating a 1,200 mg/kg NOAEL for cardiac effects.

Transient increases in heart rate and motor activity were also observed in young, middle aged, and aged rats following single gavage doses of 0, 300, 650, or 1,000 mg/kg, and no treatment-related histopathological changes were observed in cardiac tissue in any age group (Gordon et al. 2010). However, relative heart weights of young, middle aged, and aged rats given 1,000 mg/kg were statistically significantly reduced by 6, 8, and 13%, respectively, compared with controls, indicating adverse cardiac effects. Several changes in iron content, enzyme activities and mRNA levels for genes involved in thrombosis, vasoconstriction, and inflammation were also noted in cardiac tissue by Gordon.
et al. (2010). Activity of aconitase was significantly decreased in the young and middle aged rats at 1,000 mg/kg, activity of ferritin was significantly increased in the middle aged rats at 1,000 mg/kg, and activity of mitochondrial ubiquinone reductase was significantly increased in the middle-aged rats at 650 and 1,000 mg/kg. No exposure-related changes in other cardiac biochemical end points (superoxide dismutase, glutathione transferase, glutathione, mitochondrial aconitase, mitochondrial isocitrate dehydrogenase, or mitochondrial ferritin) were found. Additionally, cardiac mRNA levels for genes involved in thromobis, oxidative stress, vasoconstriction, and inflammation were assessed in cardiac tissue from rats in the control and 1,000-mg/kg groups. Statistically significant alterations in mRNA levels, compared with controls, included: decreased tissue factor (TF, a thrombosis marker) in exposed young rats; increased macrophage inflammatory protein-2 (MIP-2, an inflammatory marker) and decreased endothelin-1 and endothelin receptor-B (ET-1, ET-B, vasoconstriction markers) in exposed middle-aged rats; and decreased MIP-2 and ET-1 in exposed aged rats. Overall, exposure-induced changes in relative heart weight and in biochemical end points and gene expression in cardiac tissue did not reveal clear age-related effects.

**Intermediate-Duration Animal Studies.** Increased relative heart weights were noted in rats exposed to toluene at 1,250 mg/kg/day for 13 weeks and myocardial degeneration was present in mice exposed to 5,000 mg/kg/day (NTP 1990). All of the mice receiving 5,000 mg/kg/day died during the first weeks of exposure. No effects on the weight or gross morphology of the heart were noted in rats receiving 590 mg/kg/day for 6 months (Wolf et al. 1956).

**Gastrointestinal Effects.** Gastric pain was reported by a man who accidently ingested 30 mL of an organic solvent containing toluene and other chemicals (Einav et al. 1997). Gastrointestinal effects were not reported in other case studies of oral exposure (Ameno et al. 1989; Malingre et al. 2002).

No gastrointestinal effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks (NTP 1990).

**Hematological Effects.** No studies were located regarding hematological effects in humans after oral exposure to toluene.

There were no changes in erythrocytes, hemoglobin, hematocrit, leukocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), or mean corpuscular hemoglobin concentration (MCHC) in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. **DRAFT FOR PUBLIC COMMENT**
However, reticulocytes were significantly increased by 87%, compared with controls (Burns et al. 1994). There were no changes in total erythrocytes in male mice administered 5–105 mg/kg/day toluene in their drinking water for 28 days, although there was a nonsignificant decrease in the concentrations of leukocytes, lymphocytes, and neutrophils (Hsieh et al. 1989). No significant changes were found in the concentrations of erythrocytes, leukocytes, lymphocytes, or neutrophils in male mice administered 22 or 84 mg/kg/day toluene in their drinking water for 28 days, compared with controls (Hsieh et al. 1990a). No effect on erythrocyte counts, leukocyte counts, or hemoglobin concentrations resulted in rats exposed to 590 mg/kg/day for 6 months (Wolf et al. 1956). Neither rats nor mice given doses of 312–2,500 mg/kg/day for 13 weeks displayed any compound-related differences in hematological parameters (NTP 1990).

**Musculoskeletal Effects.** No studies were located regarding musculoskeletal effects in humans after oral exposure to toluene.

No musculoskeletal effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks (NTP 1990).

**Hepatic Effects.**

**Human Case Studies.** The liver of an adult male who died from toluene ingestion (625 mg/kg) was found to be enlarged on autopsy (Ameno et al. 1989). Clinical chemistry did not reveal abnormal liver function in a 15-month-old girl following accidental ingestion of paint thinner (Malingre et al. 2002).

**Acute-Duration Animal Studies.** Slight degeneration of hepatocytes and mononuclear cell infiltration were observed in rats given single gavage doses of 5,200 mg/kg, compared with controls (Ayan et al. 2013). The number of TUNEL-labeled hepatic cells were significantly increase by ~6-fold in exposed rats and semi-quantitative Bax and caspase-3 labeling was increased, compared with controls, indicating increased apoptosis in hepatic tissue. Serum levels of AST and ALT were significantly increased in toluene-treated rats by 119 and 60%, respectively, compared with controls (Ayan et al. 2013). However, no alterations in liver weight or histology were reported in pregnant rats exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19 (Warner et al. 2008) or female mice exposed to 600 mg/kg/day toluene via gavage for 14 days (Burns et al. 1994), compared with controls.
3. HEALTH EFFECTS

**Intermediate-Duration Animal Studies.** In male mice, there was a significant increase in liver weight after 28 days of ingestion of 105 mg/kg/day toluene in drinking water, but not at doses of 22 mg/kg/day or lower (Hsieh et al. 1989). In a separate study, 22 or 84 mg/kg/day in drinking water for 28 days did not alter liver weight in exposed male mice, compared with controls (Hsieh et al. 1990a). Relative liver weights increased significantly over control levels in mice administered toluene by gavage for 13 weeks with doses ≥312 mg/kg/day in females and ≥1,250 mg/kg/day in males (NTP 1990). In female rats, the liver weights were increased by exposure to doses ≥1,250 mg/kg/day and in male rats by exposure to doses ≥625 mg/kg/day. No treatment-related gross or histopathological lesions of the liver were reported by NTP (1990) in these 13-week studies. When rats were exposed for a longer duration, liver weights were not affected and there were no treatment-related lesions in rats that received 590 mg/kg/day toluene by gavage for 6 months (Wolf et al. 1956).

Increased hepatic cell apoptosis, indicated by increased caspase-3 activity, and changed markers of oxidative stress were observed in the liver of rats exposed to 650 mg/kg/day via gavage for 45 days, compared with controls (Kamel and Shehata 2008). Exposed rats showed significant increases in hepatic levels of thiobarbituric acid reactive substances (end products of lipid peroxidation), glutathione disulphide, and glutathione-S-transferase activities, as well as significantly decreased reduced glutathione levels and glutathione reductase activities. Effects were more pronounced at 45 days than after 15 or 30 days of exposure. No exposure-related changes were seen in hepatic activities of superoxide dismutase, glutathione peroxidase, or the inflammation marker COX-2 (Kamel and Shehata 2008).

**Renal Effects.**

**Human Case Studies.** Acute tubular necrosis was reported after a lethal exposure to 625 mg/kg (Ameno et al. 1989), and acidosis was noted in a nonlethal case report of thinner consumption (Caravati and Bjerk 1997). Clinical chemistry did not reveal abnormal kidney function in a 15-month-old girl following accidental ingestion of paint thinner (Malingre et al. 2002).

**Acute-Duration Animal Studies.** Evidence for renal pathology was reported in dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19 (Warner et al. 2008). Kidneys from toluene-exposed dams demonstrated swollen tubules, tissue adhesion to Bowman’s capsule, and areas of solidification within glomeruli that were not observed in control dams. No exposure-related changes were observed in kidney weight. No changes in kidney weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994).
Intermediate-Duration Animal Studies. There were no changes in kidney weight for male mice administered doses of 5–105 mg/kg/day in drinking water for 28 days (Hsieh et al. 1989, 1990a) or in female mice given doses of 312–2,500 mg/kg/day by gavage for 13 weeks (NTP 1990). There was a significant decrease in the absolute kidney weight for male mice administered 2,500 mg/kg/day for 13 weeks but no change in the relative kidney weight (NTP 1990). There were significant increases in the relative kidney weights in male rats administered toluene doses ≥625 mg/kg/day by gavage for 13 weeks and in females administered doses of 1,250 mg/kg/day (NTP 1990). In addition, lethal exposures of the rats to 5,000 mg/kg/day resulted in hemorrhages of the urinary bladder. No effects on the weight or gross morphology of the kidney were recorded for rats receiving 590 mg/kg/day toluene for months (Wolf et al. 1956).

Minor changes in several markers of oxidative stress were observed in kidneys of rats following exposure to 650 mg/kg/day for 15, 30, or 45 days via gavage (Kamel and Shehata 2008). Exposure resulted in significant increases in renal levels of thiobarbituric acid reactive substances and glutathione disulphide and significantly decreased glutathione reductase activity, compared with controls. Effects were most pronounced after 45 days of exposure. No exposure-related changes were seen in renal levels of reduced glutathione or activities of superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, COX-2 or caspase-3 (Kamel and Shehata 2008).

Endocrine Effects. No studies were located regarding endocrine effects in humans after oral exposure to toluene.

Serum corticosterone and ACTH levels were significantly elevated in male mice exposed to 105 mg/kg/day toluene in drinking water for 28 days, compared with controls (Hsieh et al. 1991). Levels were not significantly elevated following exposure to 5 or 22 mg/kg/day. Microscopic examination revealed no effects on the adrenal or thyroid glands in rats and mice administered 312–2,500 mg/kg/day toluene by gavage for 13 weeks (NTP 1990).

Dermal Effects. No studies were located regarding dermal effects in humans or animals after oral exposure to toluene.

Ocular Effects. No studies were located regarding ocular effects in humans or animals after oral exposure to toluene.
3. HEALTH EFFECTS

**Body Weight Effects.** No studies were located regarding body weight effects in humans after oral exposure to toluene.

**Acute-Duration Animal Studies.** There were no dose-related changes in body weight for male rats following single gavage administration of 0, 300, 650, or 1,000 mg/kg (Gordon et al. 2010). No body weight effects were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994). There was also no change in maternal body weight gain in rat dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19, compared with controls (Warner et al. 2008). However, maternal weight gain was 24% lower in rats given 520 mg/kg/day toluene by gavage from GD 6 to 19, compared with control rats (Gospe et al. 1994).

**Intermediate-Duration Animal Studies.** There were no changes in body weight for male mice administered 5–105 mg/kg/day toluene in their drinking water for 28 days (Hsieh et al. 1989, 1990a, 1990b, 1991). There was also no significant difference in body weights for female rats and female mice given gavage doses of up to 2,500 mg/kg/day for 13 weeks (NTP 1990). However, body weights were 16% lower in male mice given 1,250 mg/kg/day and 19% lower in male rats given 2,500 mg/kg/day by gavage for 13 weeks (NTP 1990).

### 3.2.2.3 Immunological and Lymphoreticular Effects

No studies were located regarding immunological effects in humans after oral exposure to toluene.

A series of studies investigated the effects of exposure to toluene in drinking water for 28 days on the immune system end points in male mice (Hsieh et al. 1989, 1990a, 1991). Thymus weights, mixed lymphocyte culture responses, and antibody PFC responses were decreased at doses of 105 mg/kg/day, and mitogen-stimulated lymphocyte proliferation and IL-2 immunity were depressed by doses of 22 and 105 mg/kg/day, compared with controls (Hsieh et al. 1989). A dose of 5 mg/kg/day had no effect upon any of these indicators of immune system function. In another study, IL-2 immune response was significantly decreased only at 105 mg/kg/day (no other immune end points were evaluated) (Hsieh et al. 1991). In another study, antibody PFC responses were depressed at doses of 84 mg/kg/day, and mixed lymphocyte culture responses were depressed at 22 or 84 mg/kg/day (Hsieh et al. 1990a). No significant changes were observed in thymus weight, mitogen-stimulated lymphocyte proliferation, IL-2 immunity, or cell-mediated cytotoxicity at doses up to 84 mg/kg/day (Hsieh et al. 1990a). Collectively, these studies
support a NOAEL of 22 mg/kg/day for immune effects, as consistent immune effects were not observed until dose levels of 84–105 mg/kg/day. No effects on the histology or weight of the spleen or thymus were reported in rats and mice given gavage doses of up to 2,500 mg/kg/day toluene for 13 weeks (NTP 1990). The NOAEL of 22 mg/kg/day for immune effects based on the studies by Hsieh (1989, 1990a, 1991) was used as the basis for the intermediate-duration oral MRL (0.2 mg/kg/day) (see Section 2.3 and Appendix A).

In an acute-duration 14-day study, neither diminished in vitro immune responses nor impaired host-resistance was observed in female mice exposed to 600 mg/kg/day toluene via gavage, compared with vehicle controls (Burns et al. 1994). Spleen and thymus weights and histology were also not altered in exposed animals.

The highest NOAEL values and all LOAEL values for each reliable study for immunological effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

### 3.2.2.4 Neurological Effects

**Human Case Studies.** Severe depression of central nervous system function was the probable cause of death for a 51-year-old man who ingested approximately 60 mL (625 mg/kg) of toluene (Ameno et al. 1989). A man who accidently ingested 30 mL of an organic solvent containing toluene and other chemicals was drowsy and complained of dizziness (Einav et al. 1997). In a nonlethal case study, depressed consciousness, lethargy, hypotonia, and nystagmus were observed in a 15-month-old girl following accidental ingestion of paint thinner (Malingre et al. 2002).

**Acute-Duration Animal Studies.** Male and female rats exposed to single gavage doses of 2,610, 3,915, or 5,220 mg/kg exhibited changes on a variety of neurological tests (Mehta et al. 1998). Significantly greater increases in motor activities were seen at all doses in both male and female rats on day 1; by day 14 after exposure, there were no significant differences, except for vertical motor activity in female rats was significantly reduced at the 2,620 and 3,915 mg/kg/day doses. A dose-dependent increase in abnormal gait was seen on day 1 for male rats at all doses, while female rats exhibited abnormal gait at 3,915 and 5,220 mg/kg. A dose-dependent increase in lacrimation and salivation was seen on day 1 for both males and females at all doses (Mehta et al. 1998).

***DRAFT FOR PUBLIC COMMENT***
Dose-related increases in motor activity were observed in rats given single oral doses of 0, 400, 800, and 1,200 mg/kg in random order, with 72 hours between each dose (Gordon et al. 2007). Changes were transient in nature, lasting ~60 minutes, and were statistically significant at 800 and 1,200 mg/kg, compared with the vehicle control. Similarly, transient dose-related increases in motor activity were observed in young (4 months), middle-aged (12 months), and aged (24 months) male rats given single gavage doses of 0, 300, 650, or 1,000 mg/kg (Gordon et al. 2010). Changes were only statistically significantly increased in young rats given 650 or 1,000 mg/kg and old rats given 1,000 mg/kg.

In another study, 24-month-old rats showed more pronounced increased horizontal activity in response to single gavage doses of 650 or 1,000 mg/kg toluene than younger rats (1, 4, or 12 months of age) (MacPhail et al. 2012).

Two studies have examined changes in oxidative stress markers (Kodavanti et al. 2011) and gene expression (Royland et al. 2012) in rats following single gavage doses of 0, 650, or 1,000 mg/kg toluene, but mechanistic understanding is inadequate to determine the biological adversity of the observed changes. Kodavanti et al. (2011) measured levels of reactive oxygen species (NQO1, UBIQ-RD), total antioxidant substances, enzymes involved in antioxidant homeostasis (superoxide dismutase, gamma-glutamylcysteine synthetase, glutathione transferase, glutathione peroxidase, and glutathione reductase) and markers of oxidative damage (total aconitase and protein carbonyls) in the frontal cortex, cerebellum, striatum, and hippocampus of young, middle-aged, and aged rats 4 hours after single gavage doses of 0, 650, or 1,000 mg/kg toluene. Multiple indicators of oxidative stress were found to increase with toluene exposure, but findings varied greatly between brain regions and age groups. Multivariate analysis indicated that 12-month-old “middle-aged” rats were more susceptible to oxidative damage in the frontal cortex and cerebellum than younger or older age groups (Kodavanti et al. 2011). Microarray analysis of the hippocampi of young, middle-aged, and aged rats following single gavage doses of 0, 650, or 1,000 mg/kg indicated that only two genes reached a significant threshold (>1.25-fold, dose-related change) with toluene exposure, but 56 genes demonstrated a significant age-toluene interaction (Royland et al. 2012). Toluene-related genes were Lrpap1 and Ralgps2, which are both associated with dementia and Alzheimer’s. Age-toluene interaction genes include those involved in immune response, cytoskeleton, protein and energy metabolism, and oxidative stress.

No changes in brain weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994).
Outer hair cell loss was observed in the area of cochlea responsive to medium frequencies (10–25 kHz) of rats exposed to 780 mg/kg toluene via gavage 5 days/week for 2 weeks (Gagnaire and Langlais 2005). Apical and basal portions of the cochlea were spared. Cell counts were determined with cochleograms and using electron microscopy, but the available report did not specify whether or not unexposed controls were assessed in this study.

Single doses of 250–1,000 mg/kg administered by gavage to male rats caused a decrease in the FEP wave pattern amplitudes (Dyer et al. 1988). This suggests that toluene may have an effect on the visual system at high doses. The minimally adverse LOAEL of 250 mg/kg for the effects of FEP waveform was used as the basis for the acute-duration oral MRL (0.8 mg/kg) (see Section 2.3 and Appendix A).

**Intermediate-Duration Animal Studies.** Brain levels of norepinephrine (NE), dopamine (DA), serotonin (5-HT), and their respective metabolites, vanillylmandelic acid (VMA), homovanillic acid (HVA), and 5-hydroxyindolacetic acid (5-HIAA) were altered in six areas of the brain in male CD-1 mice administered toluene (5–105 mg/kg/day) in their drinking water for a 28-day period (Hsieh et al. 1990b). Significant increases of NE, DA, and 5-HT were present in the hypothalamus at all dose levels. The maximum increase occurred with the 22 mg/kg/day dose and there were lesser increases for both the 5 and 105 mg/kg/day doses. Roughly similar fluctuations were seen in the concentrations of VMA and HVA, which are metabolites of DA and NE, and 5-HIAA, a serotonin metabolite. In the corpus striatum, the levels of DA and 5-HT were significantly increased at the two highest doses. The level of VMA was also increased significantly at the same doses. In the medulla oblongata, the concentrations of NE, VMA, and 5-HIAA were significantly increased at the 22 mg/kg/day dose, but not at the other doses, while the levels of 5-HT were significantly increased at the 22 and 105 mg/kg/day doses. NE concentrations were elevated in the midbrain. An additional study confirmed increased NE, but not VMA, in the hypothalamus using the same protocol (Hsieh et al. 1991). Again, the maximum increase occurred with the 22 mg/kg/day dose and there were lesser increases for both the 5 and 105 mg/kg/day doses (no other neurotransmitters were examined). Due to the lack of dose response, lack of information on persistence of changes, and unclear association with neurobehavior, it cannot be determined if these changes are adverse. Therefore, a NOAEL/LOAEL was not established for the brain biochemical changes reported in this study.

Exposure to 1,250 and 2,500 mg/kg/day for 13 weeks resulted in increased relative brain weights in male mice (NTP 1990). Cellular necrosis was present in the hippocampus and cerebellum of rats exposed to 1,250 and 2,500 mg/kg/day, but increases in brain weight were only apparent with the 2,500 mg/kg/day
3. HEALTH EFFECTS

dose (NTP 1990). Clinical signs in rats and mice exposed to 2,500 and 5,000 mg/kg/day included ataxia, hypoactivity, prostration, and tremors. No neurological effects were seen in mice or rats at dose levels of 625 mg/kg/day (NTP 1990).

In a study of rats exposed to 0 or 650 mg/kg/day for 15, 30, or 45 days, exposed rats showed increased caspase-3 activity and changed markers of oxidative stress in the cerebellum and cerebral cortex, compared with unexposed controls (Kamel and Shehata 2008). Altered markers of oxidative stress included increased levels of thiobarbituric acid reactive substances and glutathione disulphide, increased activity of superoxide dismutase, and decreased levels of reduced glutathione and activities of glutathione reductase and glutathione peroxidase. No changes were seen in the activities of glutathione-S-transferase or the inflammation marker COX-2 (Kamel and Shehata 2008).

Studies examining neurotoxic effects of gestational exposure during critical periods of neurodevelopment are discussed in Section 3.2.2.6, Developmental Effects.

The highest NOAEL values and all LOAEL values for each reliable study for neurological effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.5 Reproductive Effects

No studies were located regarding reproductive effects in humans after oral exposure to toluene.

There was no significant difference in the mean number of implantations per dam, corpora lutea per dam, live fetuses per litter, the total number of resorptions per dam, or pre- or post-implantation loss in pregnant rats exposed to 1,250 mg/kg on GDs 16–19, compared with controls (Warner et al. 2008). Similarly, there was no effect on the number of mice producing viable litters following oral administration of 2,350 mg/kg on GDs 7–14 (NIOSH 1983). Litter size was not changed in mice administered 1,800 mg/kg on GDs 8–12 (Seidenberg et al. 1986) or rats administered 650 mg/kg on GDs 6–21 (Gospe and Zhou 2000).

Increased relative testicular weights were reported in male mice exposed to 1,250 and 2,500 mg/kg/day by gavage for 13 weeks (NTP 1990). However, no effects on the weight of the prostate, testes, uterus, or ovaries were observed in rats or female mice exposed to 312–2,500 mg/kg/day (NTP 1990). Reproductive performance was not evaluated in these 13-week studies.
Changes in several biochemical markers of oxidative stress were observed in testes of rats following exposure to 650 mg/kg/day for 15, 30 or 45 days via gavage (Kamel and Shehata 2008). Testicular levels of glutathione disulphide were increased and levels of reduced glutathione and glutathione reductase activity were significantly decreased, compared with control values. No exposure-related changes were seen in activities of superoxide dismutase, glutathione peroxidase, or glutathione-S-transferase, levels of thiobarbituric acid reactive substances or activities of COX-2 or caspase-3 (Kamel and Shehata 2008).

The highest NOAEL values and all LOAEL values for each reliable study for reproductive effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.6 Developmental Effects

No studies were located regarding developmental effects in humans after oral exposure to toluene.

Toluene was not a developmental toxicant when administered orally to pregnant mice during the period of organogenesis in two developmental screening studies (NIOSH 1983; Seidenberg et al. 1986). No changes were observed in litter size, litter weight, or external malformations of dead neonates following exposure to 1,800 mg/kg/day via gavage on GDs 8–12, compared with vehicle controls (Seidenberg et al. 1986). Similarly, no changes were observed in total litter weights, numbers of animals producing litters and with totally resorbed litters, or number of live and dead pups per litter following exposure to 2,350 mg/kg/day via gavage on GDs 7–14, compared with vehicle controls (NIOSH 1983).

In a comprehensive developmental toxicity study in rats, a statistically significant increase in the incidence of dilated renal pelvis in the left kidney was observed in fetuses from dams exposed to 1,250 mg/kg/day on GDs 16–19 via gavage, compared with controls (Warner et al. 2008). Renal pelvis dilation was graded from 1 to 4, with grade 1 representing a normal kidney and grade 4 showing >50% dilation. The incidence of fetuses with grade 3 or 4 dilated left and right renal pelvis in treated fetuses was 14.6 and 12.4%, respectively, compared with respective control incidences of 5.5 and 8.9%. Incidences of litters with fetuses with grade 3 or 4 renal pelvis dilation were 7/8 for left kidney for exposed versus 2/8 in controls and 6/8 for right kidney in exposed versus 5/8 in controls. No changes were observed in any other soft-tissue anomalies, malformations, skeletal variations, ossification, or fetal body weight. Warner et al. (2008) also reported accelerated development of the cochlea in treated fetuses accompanied by increased numbers of apoptotic cells in the cochlea, compared with controls. The
biological significance of this finding is unknown. Based on the result of apoptosis analysis in the cochlea, the investigators suggested that toluene may induce excessive cell death resulting in premature maturation of the cochlea.

Following exposure of pregnant rats to gavage doses of 520 or 650 mg/kg/day toluene in corn oil on GDs 6–19, fetuses showed significantly reduced body weight, delayed skeletal ossification, smaller brain volumes, and decreases in forebrain myelination per cell compared with controls (Gospe and Zhou 1998; Gospe et al. 1994, 1996). The difference in forebrain myelination was the only difference that remained between exposed and control offspring by PND 21 (Gospe and Zhou 1998). Cortical cell proliferation and migration were also altered in offspring following exposure of pregnant rats to gavage doses of 650 mg/kg/day toluene in corn oil on GDs 6–19 (Gospe and Zhou 2000). Cortical cell density was significantly decreased by 12.5% in all layers of the cerebral cortex in toluene-exposed pups on PND 21, compared with controls. The greatest decrease (26.8%) was observed in layer IV. Decreased density was attributed to altered neurogenesis, as neurons labeled with bromodeoxyuridine (BrdU) from injections on GDs 13–21 were decreased in numbers and exhibited altered migration patterns (Gospe and Zhou 2000).

Neurological development was assessed in mice exposed to 0, 4, 21, or 106 mg/kg/day toluene from GD 0 through PND 55 (via their dams during gestation and lactation and drinking water thereafter) (Kostas and Hotchin 1981). No exposure-related changes were observed in neonatal survival or growth, attainment of physical landmarks (eye opening, pinnae detachment), surface righting, or startle-response. Significantly decreased habituation (i.e., less activity with time in chamber) during a 20-minute open-field activity assessment was observed in mice receiving 106 mg/kg/day toluene, compared with controls. In controls, activity counts during the last 5 minutes of the trial were reduced by ~45% compared with counts during the first 5 minutes; however, activity counts were only decreased by ~17% in mice exposed to 106 mg/kg/day. Habituation was not altered in other exposure groups. Additionally, rotorod performance was impaired during the first two of four consecutive trials in all exposed mice when measured on PNDs 45–55, compared with controls. However, the effect on rotorod performance diminished with increasing dose. Time spent on the rod in the 4, 21, and 106 mg/kg/day groups was decreased by approximately 20, 16, and 8%, respectively, in trial 1 and by 27, 16, and 9%, respectively, in trial 2, compared with controls. Although time spent on the rod was statistically significantly decreased compared with controls at 4 and 21 mg/kg/day for trial 1, and at all exposures for trial 2, the changes are interpreted to be of questionable exposure-related adversity because the magnitude of effect diminished with increasing dose. The lack of impairments in the later trial may be due to compensation by the mice, as suggested by the study authors. The NOAEL and LOAEL values for neurodevelopmental effects in
this study are 21 and 106 mg/kg/day, respectively, based on increased open-field activity and lack of habituation in high-dose mice.

The highest NOAEL values and all LOAEL values for each reliable study for developmental effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

### 3.2.2.7 Cancer

No studies were located regarding carcinogenic effects in humans after oral exposure to toluene.

There is one oral study on the carcinogenic effects of toluene in animals. Toluene was administered at doses of 500 and 800 mg/kg/day to male and female rats for 104 weeks (Maltoni et al. 1997). A nondose-related increase in total malignant tumors in both males and females at all dose levels, in mammary gland tumors in females at the lower dose, in head cancers in males at the higher dose and females at the lower dose, in lymphomas and leukemias in males at the higher dose and females at both doses, were observed (Maltoni et al. 1997). However, the increased incidences were not dose-related and confidence in the study is low.

### 3.2.3 Dermal Exposure

There are limited data on the effects of dermal exposure to toluene. There are studies describing occupational exposure of humans to toluene (see Section 3.2.1). Toxicokinetic data (Section 3.4) indicate that humans and animals can absorb toluene across the skin. Studies of dermal exposure to toluene in humans and animals are discussed below.

#### 3.2.3.1 Death

No studies were located regarding lethal effects in humans or animals after dermal exposure to toluene.

#### 3.2.3.2 Systemic Effects

Data are available regarding dermal effects in humans and animals after dermal exposure to toluene. No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, or musculo-skeletal effects in humans or animals after dermal exposure to toluene. In addition, there are data on hepatic, renal, and ocular effects in animals after dermal exposure to toluene. The highest NOAEL values
and all LOAEL values for each reliable study for systemic effects in each species and duration category are recorded in Table 3-4.

**Hepatic Effects.** No studies were located regarding hepatic effects in humans after dermal exposure to toluene.

Application of 1 mL toluene to the skin of guinea pigs for 16 hours did not alter liver morphology (Kronevi et al. 1979). Because only one dose of toluene was applied and more sensitive indicators of liver toxicity were not monitored, conclusions cannot be derived regarding the hepatic effects of toluene following dermal exposure.

**Renal Effects.** No studies were located regarding renal effects in humans after dermal exposure to toluene.

Application of toluene to the skin of guinea pigs for 16 hours did not alter renal morphology (Kronevi et al. 1979). The limitations of this study were discussed in the previous section.

**Dermal Effects.** In humans, dermal contact with toluene may cause skin damage because it removes skin lipids (EPA 1983a). Workers exposed to mixtures of solvents, of which toluene was generally the major component, reported problems with the skin of their hands (Winchester and Madjar 1986). The specific symptoms associated with the reported skin abnormalities were not reported. Increased complaints of itching and dermatitis of the hands was reported in in 38 female shoemakers who were exposed to toluene vapor concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer for an average of 40 months, compared with 16 controls (Matsushita et al. 1975). Eye irritation in humans occupationally exposed to toluene vapors has also been reported (Meulenbelt et al. 1990).

Repeated application of undiluted toluene (amount unstated) to the rabbit ear or shaved skin produced slight to moderate irritation (Wolf et al. 1956). In guinea pigs, continuous contact with toluene resulted in shrinkage and dissolution of the cell nuclei, cellular edema, and cellular infiltration of the dermis (Kronevi et al. 1979). Application of toluene to the skin of guinea pigs, 3 times/day for 3 days, resulted in redness and an increase in epidermal thickness (Anderson et al. 1986). In mice, application of 25 µL undiluted toluene once weekly for 5 weeks to the dorsal surface of the ear lobe resulted in significant ear swelling that peaks at 1 hour post application starting on week 2 (Saito et al. 2011). After the 5-week
### Levels of Significant Exposure to Toluene - Dermal

<table>
<thead>
<tr>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL</th>
<th>Less Serious</th>
<th>Serious</th>
<th>Reference</th>
<th>Chemical Form</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACUTE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gn Pig (albino)</td>
<td>3 d 3x/d</td>
<td>Dermal</td>
<td>10 uL M</td>
<td>(skin irritation)</td>
<td></td>
<td>Anderson et al. 1986</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gn Pig (albino)</td>
<td>0.25-16 hr</td>
<td>Hepatic</td>
<td>1 mL</td>
<td></td>
<td></td>
<td>Kronevi et al. 1979</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td></td>
<td></td>
<td>1 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermal</td>
<td></td>
<td></td>
<td>1 mL</td>
<td>(karyopyknosis, karyolysis, perinuclear edema, spongiosis, junctional separation, cellular infiltration)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>once</td>
<td>Ocular</td>
<td>0.1 mL</td>
<td>(eye irritation)</td>
<td></td>
<td>Exxon Chemical Co. 1962</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INTERMEDIATE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse (BALB/c)</td>
<td>5 wk 1x/wk</td>
<td>Dermal</td>
<td>25 uL F</td>
<td>(swelling at application site (ear lobe), inflammatory cell invasion)</td>
<td></td>
<td>Saito et al. 2011</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Note: d = day(s); F = Female; Gn pig = guinea pig; hr = hour(s); LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; x = time(s); wk = weeks(s)*
exposure, microscopic examination of the ears revealed marginal inflammatory cell invasion. No significant dermal changes were observed following five applications of diluted toluene (25 or 50% in acetone) (Saito et al. 2011). Collectively, these data suggest that undiluted toluene is slightly-to-moderately irritating to the skin.

**Ocular Effects.** No studies were located regarding ocular effects in humans after dermal exposure to toluene.

Slight irritation of the conjunctival membranes, but no corneal injury, was observed in rabbit eyes following direct application of toluene (Exxon Chemical Co. 1962; Mobil Oil Corp. 1975; Wolf et al. 1956). Moderately severe injury to the eyes of rabbits following direct application of a 40% solution of toluene has also been reported (Carpenter and Smyth 1946). These data suggest that toluene is slightly-to-moderately irritating to the eyes.

No studies were located regarding the following effects in humans or animals after dermal exposure to toluene:

3.2.3.3 Immunological and Lymphoreticular Effects

3.2.3.4 Neurological Effects

3.2.3.5 Reproductive Effects

3.2.3.6 Developmental Effects

3.2.3.7 Cancer

No studies were located for cancer effects in humans after dermal exposure to toluene.

Dermally administered toluene markedly inhibits skin tumorigenesis in the two-stage mouse model utilizing phorbol-12-myristate-13-acetate (PMA) as a promoter (Weiss et al. 1986). The reduction in tumorigenesis was observed in mice initiated with dermal applications of benzo(a)pyrene or 7,12-dimethylbenz(a)anthracene. The pattern of inhibition indicated that the observed effect was not likely to be due to a direct chemical effect on the promoter. The authors speculated that toluene competed for a PMA receptor site, interfered with a biochemical process within the cell membrane, or affected the intracellular cascade between the membrane and the nucleus.
3. HEALTH EFFECTS

3.3 GENOTOXICITY

Overview. There is no conclusive evidence to support that toluene is a genotoxic agent. Results from human occupational exposure studies are inconsistent, and are limited by small cohort size (15–45/group), lack of historical exposure monitoring, and (in some cases) concurrent exposure to other chemicals. Most short-term in vivo tests in laboratory animals have not found genotoxic effects. Similarly, genotoxic effects were not induced in the majority of in vitro assays. Results of in vivo studies and in vitro genotoxicity studies are summarized in Table 3-5 and Table 3-6, respectively.

Human Occupational Studies. Multiple studies have assessed genotoxic end points in printers with occupational exposure predominately to toluene; however, cohort sizes are small and the results are inconsistent between studies. Chromosomal abnormalities (e.g., aberrations, breaks, gaps) have been reported in peripheral lymphocytes of printers exposed to a median time-weighted air level of 150 mg/m³ (40 ppm) toluene per week (Nise et al. 1991), printers exposed to 104–1,170 ppm toluene and office and technical workers exposed to 2.1–4.3 ppm plus 0–2 hours/day in the rotogravure workshop (Pelclová et al. 1990), printers exposed to 30–1,550 mg/m³ (8–410 ppm) (Pelclová et al. 2000), and printers exposed to 200–300 ppm toluene (Bauchinger et al. 1982), compared with unexposed referents. Examination of former printers 4 months to 2 years after cessation of exposure to toluene found that more than 2 years without exposure was necessary to remove a significantly higher incidence of chromatid aberrations in workers than in never-exposed controls (Schmid et al. 1985). In other studies, exposure-related changes in chromosomal abnormalities were not induced in printers exposed to 7–112 ppm toluene (Maki-Paakkanen et al. 1980) or printers exposed to 56–824 ppm toluene (Forni et al. 1971). Increased sister chromatid exchanges have been reported in peripheral lymphocytes of printers exposed to 200–300 ppm toluene (Bauchinger et al. 1982) and printers exposed to a median air toluene concentration of 252 mg/m³ (67 ppm) (Hammer 2002; Hammer et al. 1998), compared with unexposed referents. In printers, the number of sister chromatid exchanges was significantly correlated with urinary para-cresol levels and the urinary cresol/hippuric acid ratio (Hammer 2002); weak correlations with urinary hippuric acid and ortho-cresol were not significant (0.05<p<0.1). When smokers were excluded, only the urinary cresol/hippuric acid ratio was significantly associated with the number of sister chromatid exchanges (Hammer 2002). In other studies, exposure-related changes in sister chromatid exchanges were not induced peripheral lymphocytes from printers exposed to 7–112 ppm toluene (Maki-Paakkanen et al. 1980), or printers exposed to 104–1,170 ppm toluene and office and technical workers exposed to 2.1–4.3 ppm plus 0–2 hours/day in the rotogravure workshop (Pelclová et al. 1990). Additionally, increased
### Table 3-5. Genotoxicity of Toluene In Vivo

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>End point</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-mammalian cells:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grasshopper (vapor)</td>
<td>Mitotic arrest in embryos (intact chorion)</td>
<td>+</td>
<td>Liang et al. 1983</td>
</tr>
<tr>
<td>Mammalian cells:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats (inhalation)</td>
<td>Chromosomal aberrations in bone marrow cells</td>
<td>+</td>
<td>Dobrokhotov and Enikeev 1977</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Chromatid breaks and gaps in peripheral lymphocytes</td>
<td>+</td>
<td>Bauchinger et al. 1982</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Chromosome changes in peripheral lymphocytes</td>
<td>–</td>
<td>Forni et al. 1971</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Chromosomal aberrations in peripheral lymphocytes</td>
<td>–</td>
<td>Haglund et al. 1980</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Chromosome changes in peripheral lymphocytes</td>
<td>–</td>
<td>Maki-Paakkenen et al. 1980</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Chromosome gaps in peripheral lymphocytes</td>
<td>+</td>
<td>Nise et al. 1991</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Aberrant cells and chromosome breaks in peripheral lymphocytes</td>
<td>+</td>
<td>Pelclova et al. 1990</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Aberrant cells in peripheral lymphocytes</td>
<td>+</td>
<td>Pelclova et al. 2000</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Chromosome aberrations in peripheral lymphocytes</td>
<td>+</td>
<td>Schmid et al. 1985</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Chromatid exchanges in peripheral lymphocytes</td>
<td>+</td>
<td>Bauchinger et al. 1982</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Sister chromatid exchange in peripheral lymphocytes</td>
<td>–</td>
<td>Haglund et al. 1980</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Sister chromatid exchange in peripheral lymphocytes</td>
<td>+</td>
<td>Hammer 2002; Hammer et al. 1998</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Sister chromatic exchange in peripheral lymphocytes</td>
<td>–</td>
<td>Maki-Paakanen et al. 1980</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Sister chromatid exchange in peripheral lymphocytes</td>
<td>–</td>
<td>Pitarque et al. 2002</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Sister chromatid exchange in peripheral lymphocytes</td>
<td>–</td>
<td>Pitarque et al. 1990</td>
</tr>
<tr>
<td>Human&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Sister chromatid exchange in peripheral lymphocytes</td>
<td>–</td>
<td>Richer et al. 1993</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Sister chromatid exchange in peripheral lymphocytes</td>
<td>–</td>
<td>Schmid et al. 1985</td>
</tr>
<tr>
<td>Rats (inhalation)</td>
<td>DNA damage and repair in lymphocytes</td>
<td>–</td>
<td>Martinez-Alfaro et al. 2010</td>
</tr>
<tr>
<td>Mice (inhalation)</td>
<td>DNA damage in blood, bone marrow and liver</td>
<td>–</td>
<td>Plappert et al. 1994</td>
</tr>
<tr>
<td>Human&lt;sup&gt;d&lt;/sup&gt;</td>
<td>DNA damage in peripheral lymphocytes</td>
<td>+</td>
<td>Cok et al. 2004</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>DNA damage in whole blood</td>
<td>+</td>
<td>Heuser et al. 2005</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>DNA damage in leukocytes</td>
<td>+</td>
<td>Heuser et al. 2007</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>DNA damage in whole blood</td>
<td>+</td>
<td>Moro et al. 2012</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>DNA damage in leukocytes</td>
<td>–</td>
<td>Pitarque et al. 1999</td>
</tr>
<tr>
<td>Mice (inhalation)</td>
<td>Micronuclei in erythrocytes</td>
<td>–</td>
<td>Bird et al. 2010</td>
</tr>
<tr>
<td>Mice (inhalation)</td>
<td>Micronuclei in bone marrow cells</td>
<td>–</td>
<td>Wetmore et al. 2008</td>
</tr>
</tbody>
</table>
### Table 3-5. Genotoxicity of Toluene In Vivo

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>End point</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Micronuclei in buccal cells</td>
<td>+</td>
<td>Gonzalez-Yebra et al. 2009</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Micronuclei in peripheral lymphocytes and buccal cells</td>
<td>–</td>
<td>Heuser et al. 2005</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Micronuclei in peripheral lymphocytes and buccal cells</td>
<td>–</td>
<td>Heuser et al. 2007</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Micronuclei in buccal cells</td>
<td>–</td>
<td>Moro et al. 2012</td>
</tr>
<tr>
<td>Human&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Micronuclei in peripheral lymphocytes</td>
<td>+</td>
<td>Nise et al. 1991</td>
</tr>
<tr>
<td>Human&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Micronuclei in peripheral lymphocytes</td>
<td>+</td>
<td>Pitarque et al. 2002</td>
</tr>
<tr>
<td>Mice (inhalation)</td>
<td>Dominant lethal mutations in sperm cells</td>
<td>–</td>
<td>API 1981</td>
</tr>
<tr>
<td>Human&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Cell cycle delay, cell mortality in peripheral lymphocytes</td>
<td>–</td>
<td>Richer et al. 1993&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Occupational exposure to predominantly toluene (printers).

<sup>b</sup>Occupational exposure to mixed solvents (e.g., shoe makers, paint manufacturers).

<sup>c</sup>Controlled exposure in healthy volunteers.

<sup>d</sup>Intentional exposure in chronic glue sniffers.

+ = positive result; – = negative result.
## Table 3-6. Genotoxicity of Toluene *In Vitro*

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>End point</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prokaryotic organisms:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Salmonella typhimurium</em> (TA98, TA100, TA1535, TA1537, TA1538)</td>
<td>Gene mutation</td>
<td>–</td>
<td>Bos et al. 1981</td>
</tr>
<tr>
<td><em>S. typhimurium</em> (TA98, TA100, UTH8413, 8414)</td>
<td>Gene mutation</td>
<td>–</td>
<td>Connor et al. 1985</td>
</tr>
<tr>
<td><em>S. typhimurium</em> (TA1535, PSK1002)</td>
<td>Gene mutation</td>
<td>No data</td>
<td>Nakamura et al. 1987</td>
</tr>
<tr>
<td><em>S. typhimurium</em> (TA98, TA100, TA1535, TA1537)</td>
<td>Gene mutation</td>
<td>No data</td>
<td>Nestmann et al. 1980</td>
</tr>
<tr>
<td><em>Escherichia coli</em> (P3478)</td>
<td>Gene mutation</td>
<td>No data</td>
<td>Fluck et al. 1976</td>
</tr>
<tr>
<td><strong>Mammalian cells:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human lymphocytes</td>
<td>Sister chromatid exchange and chromosomal aberrations</td>
<td>No data</td>
<td>Gerner-Smidt and Friedrich 1978</td>
</tr>
<tr>
<td>Human lymphocytes</td>
<td>Sister chromatid exchange and chromosomal aberrations</td>
<td>No data</td>
<td>NTP 1990</td>
</tr>
<tr>
<td>Human HL-60 cells</td>
<td>DNA damage</td>
<td>No data</td>
<td>+</td>
</tr>
<tr>
<td>Human lymphocytes</td>
<td>Micronuclei</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

* + = positive result; – = negative result
sister chromatid exchange frequencies were not observed in peripheral lymphocytes from former printers, 4 months to 2 years after cessation of exposure to toluene, compared with never-exposed controls (Schmid et al. 1985). Lymphocytes from printers exposed to a median time-weighted air level of 150 mg/m³ (40 ppm) toluene per week were found to be significantly more sensitive to the production of micronuclei after stimulation with pokeweed mitogen than lymphocytes from unexposed controls (Nise et al. 1991).

Some studies indicate that exposure to rotogravure ink mist may contribute to genotoxic findings in some rotogravure printers, as they are potential sources of polycyclic aromatic hydrocarbons from carbon black (Hammer et al. 1998; Pelclova et al. 1990, 2000). However, printing inks were not mutagenic in Salmonella typhimurium bacterial assays (Pelclova et al. 2000).

Evidence for genotoxicity in occupational studies of industries with exposure to toluene plus other solvents is also inconsistent. Solvent exposure-related changes in chromosome aberrations or sister chromatid exchanges in peripheral lymphocytes were not induced in Swedish paint industry workers exposed to toluene air concentrations ranging from 1 to 1,257 mg/m³ (1–334 mg/m³), compared with matched controls (Haglund et al. 1980). Sister chromatid exchanges were also not increased in Bulgarian shoe workers exposed to mean current TWA toluene concentrations of 76 or 236 mg/m³ toluene (20 or 63 ppm), compared with unexposed referents (Pitarque et al. 2002). DNA damage, assessed by the Comet assay, was increased in whole blood or leukocytes in Brazilian shoe workers exposed to solvent-based adhesive (mainly toluene, air concentration not reported) (Heuser et al. 2005, 2007) and Mexican painters exposed to unreported concentrations of toluene (Moro et al. 2012), compared with unexposed controls. However, no exposure-related differences in DNA damage in leukocytes were found between Bulgarian shoe workers exposed to 96.0–412.3 mg/m³ toluene (28–121 ppm) and unexposed controls, as assessed by the Comet Assay (Pitarque et al. 1999). Increased micronuclei induction was observed in peripheral lymphocytes or buccal cells in Bulgarian shoe workers exposed to mean current TWA toluene concentrations of 76 or 236 mg/m³ toluene (20 or 63 ppm) (Pitarque et al. 2002) and Mexican shoe workers exposed to median toluene air concentrations of 31.6 mg/m³ (8 ppm) (Gonzalez-Yebra et al. 2009), compared with control. Using multivariate analysis of age, body mass index (BMI), smoking, alcohol consumption, exposure duration, and exposure levels of acetone, ethyl acetate, methyl ethyl ketone, and toluene in Mexican shoe workers, the only variable statistically significantly associated with micronuclei induction was toluene concentration (Gonzalez-Yebra et al. 2009). However, micronuclei induction was not associated with solvent exposure in Brazilian shoe makers exposed to solvent-based...
3. HEALTH EFFECTS

adhesive (Heuser et al. 2005, 2007) or Mexican painters exposed to unreported concentrations of toluene (Moro et al. 2012).

**Human Solvent Abuse Study.** DNA damage, determined by the Comet assay, was significantly increased in peripheral lymphocytes of chronic glue sniffers, compared with age-matched controls (Cok et al. 2004). However, when only nonsmokers were assessed, there was no difference in the mean total comet score between glue sniffers and controls. Exposure levels are unknown; however, the mean value of the hippuric acid and ortho-cresol excretion rates for glue sniffers were 73- and 1,582-fold higher, respectively, than in controls.

**Controlled Exposure Study.** Toluene did not induce sister chromatid exchanges in lymphocytes of volunteers exposed to 50 ppm airborne toluene for 7 hours/day for 3 days on three occasions at 2-week intervals (Richer et al. 1993).

**Animal Studies.** Most in vivo tests in laboratory animals have not reported toluene-induced genotoxicity. Toluene did not induce DNA damage in the blood, bone marrow, or liver of mice exposed to 500 ppm toluene for 6 hours/day, 5 days/week for 8 weeks, as assessed by Comet assay (Plappert et al. 1994). Similarly, DNA damage and repair was not induced in lymphocytes of rats exposed to paint thinner composed of toluene, acetone, ethano, isobutyl acetate, isobuthanol, butyl glycol, ethyl-benzene, and trimethylbenzene at toluene levels of 3,000 ppm twice daily for 15 minutes for 6 weeks, as assessed by Comet assay and H2O2 damage and repair (Martinez-Alfaro et al. 2010). Toluene did not induce micronuclei formation in bone marrow cells or erythrocytes of mice following exposure to 100 ppm 6 hours/day for 8 days (Bird et al. 2010; Wetmore et al. 2008). Toluene did not induce dominant lethal mutations in sperm cells of mice exposed to 400 ppm for 6 hours/day, 5 days/week for 8 weeks, but female mice were not assessed for genotoxic effects (API 1981). In a Russian study, toluene was reported to induce chromosomal aberrations in the bone marrow cells of rats following chronic inhalation exposure (duration and concentrations not available (Dobrokhotov and Enikeev 1977). Additionally, when grasshopper (*Melanoplus sanguinipes*) embryos (chorion intact) were suspended in sealed containers and exposed to toluene vapors of 0, 40,000, 200,000, 400,000, or 800,000 ppm for 16 hours, mitotic arrest was induced at 200,000 ppm (higher concentrations were lethal) (Liang et al. 1983).

**In vitro Studies.** Toluene did not induce gene mutations in bacterial cells in several studies with or without metabolic activation (Bos et al. 1981; Connor et al. 1985; NTP 1990) or without activation (Nakamura et al. 1987; Nestmann et al. 1980; Fluck et al. 1976), sister chromatid exchange or
chromosomal aberrations in human lymphocytes without metabolic activation (Gerrner-Smidt and Friedrich 1978; NTP 1990), or micronuclei in human lymphocytes with or without metabolic activation (Zarani et al. 1999). DNA damage was increased in human promyelocytic leukemia HL-60 cells treated with 1.14 and 2.74 nM toluene without metabolic activation, compared with untreated controls, as evidenced by significant, dose-related increases in tail moment in the Comet assay (Sarma et al. 2011).

3.4 TOXICOKINETICS

*Overview.* Studies with volunteers and laboratory animals indicate that toluene is rapidly absorbed from the respiratory tract with less rapid absorption occurring in the gastrointestinal tract and skin (Bushnell et al. 2007; Nadeau et al. 2006; Pyykko et al. 1977; Sullivan and Conolly 1988; Thrall and Woodstock 2002; Thrall et al. 2002a). Studies with animals exposed by inhalation or oral routes showed that absorbed toluene is distributed widely to tissues throughout the body with preferential distribution to adipose tissue, brain, bone marrow, liver, and kidney. Absorbed toluene is distributed in pregnant animals, as well as to the developing fetus. The primary initial steps in toluene metabolism in humans and laboratory animals are side-chain hydroxylation (to form benzyl alcohol) catalyzed predominantly by the cytochrome P450 (CYP) isozyme, CYP2E1 (Nakajima and Wang 1994; Nakajima et al. 1991, 1992a, 1992b, 1993, 1997; Tassaneeyakul et al. 1996) followed by oxidation to benzoic acid. Most of the benzoic acid is then conjugated with glycine to form hippuric acid, but a small portion can be conjugated with UDP-glucuronate to form the acyl-glucuronide. Studies with volunteers and human liver microsomes indicate that a very small portion (<1–5%) of absorbed toluene can be converted by CYP1A2, CYP2B2, or CYP2E1 to ortho- or para-cresol, which are excreted in the urine as sulfate or glucuronate conjugates (Baelum et al. 1993; Nakajima et al. 1997; Tassaneeyakul et al. 1996). In both humans and rats, up to about 75–80% of inhaled toluene that is absorbed can be accounted for as hippuric acid in the urine (Lof et al. 1993; Wang and Nakajima 1992). Remaining absorbed toluene is excreted unchanged in exhaled air and urine and as conjugates of minor metabolites in urine (Ducos et al. 2008; Janasik et al. 2008, 2010; Lof et al. 1993; Ogata 1984; Pierce et al. 2002; Tardif et al. 1998). Analyses of kinetic data for toluene concentrations in blood, exhaled breath, adipose tissue, or urine following inhalation exposure of humans indicate that most absorbed toluene is rapidly eliminated from the body and that a smaller portion (that which gets into adipose tissues) is slowly eliminated (Janisik et al. 2008; Leung and Paustenbach 1988; Lof et al. 1993; Nise et al. 1989; Pellizzari et al. 1992; Pierce et al. 1996, 1999, 2002). For example, elimination kinetics for toluene-exposed workers have been described by a three-phase elimination model with half-times of 9 minutes, 2 hours, and 90 hours for toluene in blood and a single median elimination half-time of 79 hours for toluene in fat (Nise et al. 1989). In a study of
volunteers exposed by inhalation to about 50 ppm for 4 hours, a two-phase decline of urinary toluene concentration was observed with half-lives of 0.88 and 12.9 hours (Janisik et al. 2008).

3.4.1 Absorption

3.4.1.1 Inhalation Exposure

In humans exposed to 80 ppm toluene, uptake was rapid as shown by the appearance of toluene (2–5 μmol/L) in the blood within 10–15 minutes of exposure (Hjelm et al. 1988) and by a high correlation between the alveolar and arterial concentrations of toluene both during and after exposure (Carlsson 1982). About 50% of deuterium labeled toluene was absorbed from the lungs in volunteers exposed to 53 ppm for 2 hours during a period of light exercise (Lof et al. 1993). Seven humans exposed to 50 ppm toluene in a closed chamber showed an average retention of 83% of the inspired concentration (Benoit et al. 1985). In volunteers exposed to 50 ppm toluene for 7 hours while exercising or at rest, concentrations of toluene in expired air and ortho-cresol (a toluene metabolite), in urine collected at the end of exposure were higher during exercise than during periods at rest (~140–200% increase for blood concentrations and ~120% increase for urinary ortho-cresol) (Nadeau et al. 2006). The results are indicative of higher rates of uptake (and excretion) of inhaled toluene during exercise than at rest.

Toluene was rapidly absorbed via the lungs of rats; the log concentrations of toluene in the blood and brain were linear functions of the log concentration of toluene in the air (Benignus et al. 1984). In dogs, toluene was found in the arterial and venous blood 2 minutes after the start of exposure (Hobara et al. 1984b). Toluene concentrations in blood and brain increased rapidly during 60-minute inhalation exposures of physically active and sedentary rats to 2,000 ppm (Bushnell et al. 2007). Physical activity during inhalation increased the uptake of toluene into the blood and brain. After 60 minutes of exposure, physically active rats showed toluene concentrations in blood and brain that were ~26 and ~40% higher, respectively, than concentrations in sedentary rats (Bushnell et al. 2007).

No information was located regarding possible differences in absorption of inhaled toluene by humans or animals with differences in age.

3.4.1.2 Oral Exposure

Complete gastrointestinal absorption of toluene in human subjects was indicated by monitoring exhaled air for toluene and urine for toluene metabolites (hippuric acid and ortho-cresol) following oral admin-
administration of toluene as a 2 mg/min infusion for 3 hours through a feeding tube into the stomach (Baelum et al. 1993). Absorption of orally administered toluene has also been observed in rats, but oral absorption rates appear to be slower than pulmonary absorption (Pyykko et al. 1977; Sullivan and Conolly 1988). In these rat studies, maximum blood concentrations were observed 1.5–3 hours after gavage administration, whereas maximum blood levels following inhalation were reached in 15–30 minutes.

No significant (p>0.05) differences between physically active and sedentary rats were found in the time course of the increase of concentrations of toluene in blood and brain following administration of single gavage doses of ~800 mg/kg (Bushnell et al. 2007). Comparison with results from inhalation exposure suggests that physical activity may not influence the uptake of orally administered toluene to the same degree that it influences uptake of inhaled toluene.

Ingestion of soil contaminated with toluene can be a concern at hazardous waste sites. Binding to soil does not prevent absorption. The time course for absorption of toluene mixed with sandy soil or clay soil was increased when compared to the time course for pure toluene, but the total amount absorbed was the same based on the area under the blood toluene concentration curve (Turkall et al. 1991).

Studies with brush border membrane vesicles isolated from rat intestines and exposed to toluene indicate that toluene absorption occurs through the lipophilic matrix of the membrane (Alcorn et al. 1991). The removal of proteins from the membrane surface had no effect upon the toluene partition coefficient, but factors affecting the nonesterified membrane fatty acids reduced absorption. In this same in vitro study of membrane partitioning, vesicles harvested from the proximal, middle, and distal intestinal segments showed no differences, indicating that concentration and surface area, rather than membrane structure, are the factors determining the amount of toluene absorbed from each portion of the small intestines. Since toluene absorption occurs through the lipid matrix of the membrane, absorption can occur through the mouth and stomach, as well as the small intestines. The amount of toluene absorbed from each organ of the gastrointestinal tract will depend on residence time, absorptive surface area, and partitioning between membrane lipids and lipids in the gastrointestinal tract.

No information was located regarding possible differences in absorption of ingested toluene by humans or animals with differences in age.


3. HEALTH EFFECTS

3.4.1.3 Dermal Exposure

Results from early studies indicated that toluene is absorbed slowly through human skin (Dutkiewicz and Tyras 1968). The rate of absorption of toluene in human forearm skin was found to range from 14 to 23 mg/cm²/hour. EPA (1992f) estimated a human dermal permeability coefficient, Kp, of 1 cm/hour, based on these data. Based on these estimates, Brown et al. (1984) calculated that bathing in water containing 0.005–0.5 mg toluene/L (15 minutes/day) would result in absorbed dermal dose ranges of 0.0002–0.02 mg/kg/day for a 70-kg adult and 0.0004–0.04 mg/kg/day for a 10.5-kg infant.

Soaking the skin of two volunteers with toluene for 5 minutes resulted in a maximum concentration of toluene in blood of 5.4 μmol/L (Aitio et al. 1984). Individual differences were marked, and dramatic changes in blood concentrations were observed over short periods of time. Similar individual differences and highly variable results were reported by Sato and Nakajima (1978) in a study using five volunteers.

Monster et al. (1993) investigated dermal absorption of toluene in 6 rotogravure printing workers. The workers washed their hands with toluene for 5 minutes, and alveolar air samples were collected up to 24 hours after exposure. The concentrations measured the next morning in exhaled air ranged between 0.5 and 10 mg/m³, clearly demonstrating dermal absorption of toluene.

Dermal permeability coefficients were estimated for human subjects wearing swimsuits who were submerged to neck level for up to 25–30 minutes in warm tap water initially containing 500 µg/L toluene (Thrall et al. 2002a). Subjects were provided purified breathing air, and exhaled breath was continuously analyzed for toluene before, during, and after exposure to track the absorption and exhalation of toluene. A human PBPK model, modified from a rat model for dermal absorption (Thrall and Woodstock 2002), was fit to each exhalation time course dataset to estimate a dermal permeability coefficient, Kp. Estimated Kp values (n = 6) ranged from 0.03 to 0.020 cm/hour, with an average value of 0.012 (standard deviation [SD]=0.007) cm/hour. In a second phase involving dermal and inhalation exposure, subjects breathed room air while they were submerged, and exhaled breathe was collected and analyzed. Transient peak concentrations of toluene in exhaled breath occurred earlier and were about 50% greater than levels during dermal-only exposure; these observations are consistent with a more rapid absorption through the respiratory tract than through skin. Thrall et al. (2002a) concluded, based on room air monitoring data and comparison of exhaled breath profiles for dermal-only and dermal+inhalation exposures, that inhalation exposure to volatilized toluene under these conditions was transient and contributed little to the overall total body from bathing in toluene-contaminated water.

***DRAFT FOR PUBLIC COMMENT***
Toluene in aqueous solution and neat toluene were absorbed through the skin of rats (Morgan et al. 1991). Three solution strengths (0.162, 0.333, and 0.448 mg/L) were tested. Although the blood toluene levels for each strength were near the analytical detection limits, the results of this study indicate that toluene absorption was significant, since only 1% of the body surface was exposed.

A dermal permeability coefficient, Kp, of 0.74 cm/hour (SD=0.005) was measured for male F344 rats exposed under occluded conditions to aqueous toluene solutions of 0.5 or 0.2 mg/mL applied to a 2.5-cm diameter patch of clipper-shaved skin on the back (Thrall and Woodstock 2002). Immediately following application, individual rats were placed in an off-gassing chamber, and exhaled breath of toluene was monitored continuously as chamber concentrations. Rapid absorption was indicated with peak chamber concentrations noted within 1–1.5 hours after exposure started; chamber concentrations showed steady declines thereafter through 4–5 hours. Based on amounts of toluene remaining on the skin at the end of exposure, average percentage absorption of the applied doses were 45 and 42%, respectively, for the low- and high-dose levels (1.75 and 4.14 mg/kg). Using a method similar to Thrall et al. (2002a), a PBPK model was used to estimate a Kp for each exhaled breath dataset; the average Kp value across datasets was 0.074 cm/hour (SD=0.005).

Dermal absorption also occurs when animals are exposed to toluene vapors. In nude mice exposure to 300, 1,000, or 3,000 ppm toluene under conditions where there was no respiratory intake of toluene, led to a dose-related and duration-related increase in whole body toluene levels (Tsuruta 1989). The calculated skin absorption coefficient was 1.24 cm/hour. The skin absorption rate for the 300 ppm concentration was 0.0009 mg/cm²/hour; for the 1,000 ppm concentration, it was 0.0046 mg/cm²/hour; and for the 3,000 ppm concentration, it was 0.0144 mg/cm²/hour. Exposure of guinea pigs to an unspecified concentration of toluene for 1 minute, with the skin wiped dry and 1 minute exposures continuing every 30 minutes, for 4 hours, resulted in lower levels of toluene absorption than with continuous exposure for 4 hours (Boman et al. 1995).

No information was located regarding possible differences in absorption of dermally applied toluene by humans or animals with differences in age.
3. HEALTH EFFECTS

3.4.2 Distribution

3.4.2.1 Inhalation Exposure

There is a positive correlation between the levels of toluene in alveolar air and the levels in blood in both humans and animals (Hjelm et al. 1988; Lof et al. 1990; Ovrum et al. 1978). With an exposure in humans of 80 ppm toluene for 4 hours, toluene levels in the blood reached a plateau of 6–7 μmol/L at approximately 2 hours (Hjelm et al. 1988; Lof et al. 1990). In humans, the toluene is distributed between the plasma and red blood cells at approximately a 1:1 ratio according to in vitro data; in rats, the ratio is 1:2 based on in vivo data (Lam et al. 1990). In the red blood cells, toluene appears to be associated with hemoglobin rather than the cell membrane. It is hypothesized that toluene interacts with the hydrophobic core of the heme protein. The interaction of the toluene with the red blood cell increases the amount of toluene that can be accommodated by the aqueous blood medium and facilitates transport of toluene to all areas of the body (including the brain) at a rate that is greater than if toluene was transported only in the plasma.

Autopsies of toluene-exposed humans indicate that absorbed toluene is distributed to lipid-rich and highly vascular tissues such as the brain. For example, toluene levels in the brain and liver of a 16-year-old male who died following an episode of glue sniffing were 297 and 89 μg/mg, respectively (Paterson and Sarvesvaran 1983). Concentrations in the blood were 20.6 μg/mL of toluene and 3.0 μg/mL of acetone. In a man who died following a fall while exposed to toluene during painting, tissue levels of toluene in blood, lung, liver, and brain were 48, 35, 65, and 80 μg/g, respectively (Takeichi et al. 1986).

Within the human brain, toluene has a greater affinity for areas of the brain that contain lipid-rich white matter, such as the brain stem, rather than the areas with larger amounts of gray matter (Ameno et al. 1992). The hippocampus and cerebellum had lower brain: blood toluene ratios than the spinal cord, midbrain, medulla oblongata, and pons. The brain stem controls many involuntary aspects of cardiac, respiratory, and vasomotor function.

Concentrations of toluene in subcutaneous adipose tissue of male subjects exposed during rest or physical exercise to 300 mg/m³ of toluene were determined (Carlsson and Ljungquist 1982). After exposure at rest for 2 hours, the mean concentration of toluene in adipose tissue was 0.7 mg/kg. The corresponding value after 2 hours of work was 9.9 mg/kg. Linear regression analysis indicated that toluene concentrations in adipose tissue were lower in subjects with large amounts of body fat.
The human data for distribution to the brain are supported by autoradiography studies using mice. Immediately after inhalation, a high level of radioactivity was found in the body fat, bone marrow, spinal nerves, spinal cord and white matter of the brain of exposed mice (Bergman 1983). Radioactivity was also observed in the blood, kidney, and liver at lower levels. Autoradiography of mice sacrificed immediately after the cessation of exposure revealed a very high concentration of nonvolatile radioactivity in the kidney, particularly the medullary region. Nonvolatile radiation found in the liver and kidney suggests rapid formation and excretion of toluene metabolites.

A one-compartment model was developed for blood and whole-brain toluene levels based on data from rats exposed to 575 ppm toluene for up to 240 minutes (Benignus et al. 1981). Estimated saturation asymptotes were 10.5 ppm for venous blood and 18.0 ppm for brain, respectively. Blood and brain levels achieved 95% of their estimated asymptotes in 53 and 58 minutes, respectively. The distribution half-life for a 30-minute exposure of rats to 2,000 ppm toluene was 0.34 hours, while that for exposure to 10,000 ppm was 0.6 hours (Ameno et al. 1992).

Toluene was rapidly distributed to the tissues in rats after 1, 2, or 3 days of exposure to 100 ppm for 12 hours per day (Zahlsen et al. 1992). Homeostasis was attained in 1 day for the kidney, brain, and liver, whereas toluene concentrations continued to increase in perirenal fat deposits. Once exposures ceased, toluene concentrations declined within 12 hours to near baseline levels for all tissues except in fat. The toluene in rat brains was distributed to the brain stem and midbrain (Ameno et al. 1992), a distribution that parallels that observed in humans and mice (Ameno et al. 1992; Bergman 1983). These regions have a high concentration of white matter.

Toluene was detected in blood, brain, auditory nerves, and the organ of Corti, but not in cerebrospinal fluid or inner ear fluids sampled from rats immediately following inhalation exposure to 1750 ppm toluene for 10 hours (Campo et al. 1999).

In mice exposed nose-only to 0, 0.9, 9, 50, or 90 ppm toluene for 30 minutes, toluene concentrations in the hippocampus showed statistically significant (p<0.05) concentration-dependent increases after exposure to air concentrations ≥9 ppm, compared with control values (Nakajima et al. 2006). This study used a solid-phase microextraction fiber inserted into the hippocampus and gas chromatography and mass spectrometry to determine brain concentrations in mice. Examination of mice exposed to 50 ppm toluene showed that toluene concentrations in the brain returned to control levels 60 minutes after exposure ceased.
Toluene distribution to several tissues was followed in dogs exposed through inhalation of 30,000 ppm toluene from a plastic bag for 10 minutes. The toluene level in the arterial blood was 129±54.8 μg/mL while that in the venous blood was 112±48.5 μg/mL. The liver and brain contained roughly equivalent concentrations of toluene (184 and 191 μg/g), while the toluene in the kidneys was 99 μg/g (Ikeda et al. 1990).

Distribution of toluene (assayed by autoradiography and tissue concentrations of radioactivity) in pregnant mice was also characterized by preferential uptake in maternal lipid-rich tissues (brain and fat) immediately after 10-minute inhalation exposures to 14C-labeled toluene at approximately 2,000 ppm (Ghantous and Danielsson 1986). It was thought that toluene, due to its high lipid solubility and low molecular weight, might easily transfer across the placenta, but concentrations of radioactivity in fetal tissues were only about 4% of concentrations in maternal brain and adipose tissue immediately after exposure, and rapidly decreased within 4 hours of cessation of exposure. These results suggest that absorbed toluene is preferentially distributed to maternal adipose tissues in pregnant mice and that distribution to the developing fetus is limited with short-term exposure to the relatively high (compared with occupational exposures) concentration of 2,000 ppm. This concentration, however, is low compared with concentrations experienced by toluene abusers (4,000–12,000 ppm as cited by Gospe et al. 1994). Ghantous and Danielsson (1986) suggested that the lower lipid content in fetal tissue compared with maternal tissue could explain the low uptake of toluene into fetal tissue.

Following repeated inhalation exposure of pregnant rats to 8,000 or 12,000 ppm for 15, 30, or 45 minutes twice daily from GD 8 through GD 20, measurable concentrations of toluene were found in the placenta, amniotic fluid, and fetal brain collected from exposed dams on GD 20 (Bowen et al. 2007). Regardless of daily exposure regimen or exposure level, amniotic fluid concentrations were ~<10% of concentrations in GD 20 maternal saphenous blood samples. Concentrations in fetal brain were similar to maternal blood concentrations at GD 20, whereas concentrations in placenta were higher. Concentrations of toluene in maternal cerebellum, liver, kidney, and heart tissue on GD 20 (but not lung) were higher than concentrations in GD 20 maternal saphenous blood. The results, consistent with those of Ghantous and Danielsson (1986), indicate that toluene was transported to the fetal brain, and that fetal brain concentrations were similar to maternal blood levels, but were lower than maternal brain concentrations.
3. HEALTH EFFECTS

No studies were located that examined *in vivo* distribution of toluene into breast milk in humans or animals. Although breast milk is high in lipid content, it is unknown if there may be preferential uptake of toluene into other maternal lipid-rich tissues. A published estimate of the human milk/blood partition coefficient for toluene, 2.68, was lower than estimates of coefficients for partitioning of toluene between other tissues and human blood, including liver or highly perfused tissues/blood (4.91) and fat/blood (60.01) (Fisher et al. 1997). Transfer from blood to a tissue, however, is also dependent on the rate of perfusion of the tissue with blood. Fisher et al. (1997) used these partition coefficient values in a physiologically-based pharmacokinetic (PBPK) model designed to predict transfer of volatile chemicals into breast milk, but human or animal pharmacokinetic data for lactational transfer of toluene were not available to validate or modify the model.

Coexposure of rats to xylene increased the concentrations of toluene in the blood and brain in the 19 hours after exposure as compared to exposure to toluene alone (Tardif et al. 1992). This was, apparently, the result of suppressed toluene metabolism because of competition between toluene and xylene for active sites on enzymes responsible for metabolizing both compounds. Pulmonary excretion of toluene was also decreased when exposure to both compounds occurred. As a result, the half-lives for both toluene and xylene were increased.

Blood and brain toluene levels in rats exposed to 2000 or 4000 ppm for 4 hours during daylight were significantly higher at the end of exposure and 40 minutes after the cessation of exposure than in animals exposed in the dark (Harabuchi et al. 1993). This suggests that circadian rhythms may have an influence on toluene absorption, distribution, and excretion.

### 3.4.2.2 Oral Exposure

In one human who died 30 minutes after ingestion of 625 mg/kg toluene, the liver was found to have the highest concentration of toluene (433.5 μg/g) followed by the pancreas (88.2 μg/g), brain (85.3 μg/g), heart (62.6 μg/g), blood (27.6 μg/g), body fat (12.2 μg/g), and cerebrospinal fluid (11.1 μg/g) (Ameno et al. 1989). The short interval between toluene exposure and death limited the distribution of the toluene to the peripheral body tissues.

When rats were orally exposed to 400 mg/kg toluene, the peak concentration in the blood occurred 1.5 hours after exposure (Ameno et al. 1992). In the brain, the highest brain: blood toluene ratios were
found in the pons and caudate-putamen, as opposed to the hippocampus (Ameno et al. 1992). Toluene
distribution in the brain was similar with inhalation and oral exposure (Ameno et al. 1992).

3.4.2.3 Dermal Exposure

No studies were located regarding the distribution of toluene in humans or animals after dermal exposure.

3.4.2.4 Other Routes of Exposure

In baboons intravenously injected with $^{11}$C-labeled toluene, maximal concentrations of radioactivity in
different brain regions were attained within 1–4 minutes of injection (Gerasimov et al. 2002a, 2002b).
Concentrations of radioactivity steadily declined thereafter through about 45 minutes of monitoring. The
results are indicative of rapid distribution from the blood to the brain and rapid clearance. Half-times for
clearance from the brain ranged from about 10 to 20 minutes in three experiments. Similar experiments
with mice showed similarly rapid distribution to the brain and rapid clearance from the brain following
intravenous injection (Gerasimov et al. 2002a, 2002b).

3.4.3 Metabolism

Studies of urinary metabolites in toluene-exposed humans (Andersen et al. 1983; Angerer 1979; Angerer
et al. 1998a; Baelum et al. 1987, 1993; Dossing et al. 1983b; Inoue et al. 1986; Jonai and Sato 1988;
Kawai et al. 1992a, 1992b, 1993, 1996; Lof et al. 1990, 1993; Maestri et al. 1997; Ng et al. 1990) and rats
(Blay et al. 1949; van Doorn et al. 1980; Wang and Nakajima 1992) have identified hippuric acid (the
glycine conjugate of benzoic acid) as the major urinary metabolite of toluene. Minor urinary metabolites
(in approximate order of decreasing abundance) include: the glucuronyl conjugate of benzoic acid; sulfate
and glucuronide conjugates of ortho- and para-cresol; S-benzylmercapturic acid; and S-p-toluyl-
mercapturic acid. Based on these results and the results from in vitro studies, including recent studies
with human and rat liver microsomes (Nakajima and Wang 1994; Nakajima et al. 1991, 1992a, 1992b,
1993, 1997; Tassaneeyakul et al. 1996), a scheme for toluene metabolism in humans and animals is
presented in Figure 3-3.

The initial steps are methyl and ring hydroxylations that are catalyzed by cytochrome P450 (CYP)
isozymes. Methyl hydroxylation to form benzyl alcohol was the predominant first step in human
Figure 3-3. Scheme for Toluene Metabolism in Humans and Animals

Proposed enzymes are noted in parentheses.

Sources: Angerer et al. 1998a; IARC 1999; Nakajima and Wang 1994; Nakajima et al. 1997; Tassaneeyakul et al. 1996
liver microsomes. Ring hydroxylation to form ortho- or para-cresols in these studies usually represented less than 5% of total metabolite formation.

Results from in vitro studies indicate that CYP2E1 is the most active CYP isozyme in forming benzyl alcohol and CYP1A2 is the most active in forming ortho- and para-cresols. Using monoclonal antibodies to CYP isozymes as in vitro metabolic inhibitors in rat microsome preparations, Nakajima et al. (1991) demonstrated that CYP2E1 (at low toluene concentrations) contributes to the formation of benzyl alcohol and para-cresol, CYP1A1/2 contributes to ortho- and para-cresol formation, and CYP2B1/2 and CYP2C11/6 (at higher toluene concentrations) contribute to the formation of benzyl alcohol and ortho- and para-cresol. Biphasic enzyme kinetics for the formation of benzyl alcohol from toluene were observed in human liver microsomes, supporting the concept that at least two isozymes with differing affinity for toluene can catalyze benzyl alcohol formation (Tassaneeyakul et al. 1996). The high-affinity component in human liver microsomes was markedly inhibited (about 90% inhibition) by 50 μM diethyldithiocarbamate, an inhibitor of CYP2E1, whereas inhibitors of other CYP isozymes produced generally less than 10% inhibition of the high affinity component (Tassaneeyakul et al. 1996). Other inhibitors tested (and the CYP forms that they are expected to inhibit) were: furafylline (CYP1A2), coumarin (CYP2A6), mephenytoin (CYP2C19), quinidine (CYP2D6), sulfaphenazole (CYP2D6), and troleandomycin (CYP3A) (Tassaneeyakul et al. 1996). Using microsomes from cells in which cDNAs for eleven different human CYP isozymes were expressed, Nakajima et al. (1997) demonstrated that CYP2E1 was the most active in forming benzyl alcohol, followed in order by CYP2B6, CYP2C8, CYP1A2, and CYP1A1. The activities of CYP2A6, CYP2C9, CYP2D6, CYP3A3, CYP3A4, and CYP3A5 in metabolizing toluene were negligible. CYP1A2 also was active in forming ortho- and para-cresol (22 and 35% of total metabolites) and CYP2E1 and CYP2B6 catalyzed the formation of para-cresol (11–12% of total metabolites) (Nakajima et al. 1997). Comparison of the in vitro catalytic activities of human recombinant CYP2E1, CYP2A6, and CYP2A13 (a form that is highly expressed in human respiratory tract tissues) to form benzyl alcohol from toluene indicated the following order of catalytic activities: CYP2A13 > CYP2A6 > CYP2E1 (Fukami et al. 2008). The latter observations suggest that there may be tissue specificities in the principal forms of CYPs catalyzing the initial step in toluene metabolism. Kinetic constants (e.g., Km and Vmax) were comparable for recombinant wild-type CYP2E1 (CYP2E1.1) and allelic variants of CYP2E1 (CYP2E1.2, CYP2E1.3, and CYP2E1.4) to convert toluene to benzyl alcohol (Hanioka et al. 2010). The variants were made by site-directed mutagenesis involving amino acid substitutions to reflect CYP2E1 polymorphisms identified in human populations at frequencies ranging from 1.3 to 2.6%. **DRAFT FOR PUBLIC COMMENT**
Benzyl alcohol is thought to be converted to benzoic acid in two steps by alcohol dehydrogenase and aldehyde dehydrogenase (see Figure 3-3). Conjugation with glycine to form hippuric acid can represent 83–94% of urinary metabolites of toluene in rats (Nakajima and Wang 1994). Hippuric acid formation from benzoic acid (a common component of the diet) is catalyzed by acyl-CoA synthetase and acyl-CoA: amino acid N-acyltransferase. Conjugation of benzoic acid with glucuronic acid to form benzoyl glucuronide is catalyzed by UDP-glucuronyl transferase and can account for 3–9% of urinary metabolites in rats (Nakajima and Wang 1994). In plasma samples collected in baboons 30 minutes following intravenous injection of $^{11}$C-toluene, relative amounts of radioactivity were 34% in unchanged toluene, 40% in benzoyl glucuronide, 18% in hippuric acid, 1% in benzyl alcohol and benzaldehyde, and 3% in benzoic acid (Gerasimov et al. 2002a).

The 2,3- and 3,4-epoxide intermediates, precursors of ortho- and para-cresol, are thought to be oxidation products of the catalytic actions of CYP1A2, CYP2E1, and CYP2B6 (Nakajima et al. 1997). Ortho- and para-cresol and their conjugates have been reported to account for 0.5–1.1 and 2.5–14.2%, respectively, of urinary metabolites in rats (Nakajima and Wang 1994). S-benzyl mercapturic acid, a minor urinary metabolite identified in humans, is thought to be formed via conjugation of benzyl alcohol with glutathione (catalyzed by glutathione-S-transferases), followed by the concerted catalytic actions of $\gamma$-glutamyltranspeptidase, amino peptidase M, and N-acetyltransferase to release glutamic acid and glycine and add an acetyl group (Angerer et al. 1998a) (see Figure 3-3). The formation of another minor human urinary metabolite, S-p-toluylmercapturic acid, is thought to proceed by a similar series of reactions from the proposed intermediate, 3,4-toluene epoxide (Angerer et al. 1998a).

The liver is expected to be the prime site of toluene metabolism, based on the high concentration of CYP isozymes in the liver relative to other tissues. For example, levels of CYP2E1 in human lung microsomes were 10.5% of liver activities (Wheeler et al. 1992). Studies with rats indicate that toluene exposure causes changes in CYP-associated enzyme activities and CYP isozymes themselves in the liver (see Nakajima and Wang 1994 for review). For example, single 6-hour exposures to toluene induced hepatic CYP2E1 levels and associated nitrosodimethylamine demethylase activities (at concentrations $\geq$1,000 ppm), induced CYP2B1/2 and CYP3A1/2 levels (at concentrations $>2,000$ ppm), decreased CYP2C11/6 levels (at 4,000 ppm), and did not change CYP1A2 levels (Wang et al. 1993). Other rat experiments involving longer durations of exposure and potentially higher dose levels have consistently observed induction of hepatic activities of aryl hydrocarbon hydroxylase (AHH) and ethoxyresorufin O-deethylase (EROD), activities associated with CYP1A1/2 (see Nakajima and Wang 1994). Rats given single intraperitoneal injections of 5 mmol toluene/kg showed induction of ethoxycoumarin O-deethylase.
3. HEALTH EFFECTS

(ECOD) and EROD activities in liver, but no induction was apparent in lung or kidney tissues (Pyykko et al. 1987). Exposure of rats to 375 ppm toluene, 6 hours/day for up to 5 days or 125 ppm for 6 hours did not significantly change activities of AHH, EROD, or benzylxyresorufin (BROD) in liver microsomes compared with activities in nonexposed controls, but significantly decreased activities of AHH (by up to about 50%), BROD (by 30–70%), and 2-aminofluorene N-hydroxylase (by up to about 50%) in lung microsomes without altering EROD activities (Furman et al. 1998). The results from these rat studies suggest that toluene exposure at concentrations ≥1,000 ppm, but not at lower concentrations, induces hepatic CYP enzymes involved in its own metabolism and metabolism of other xenobiotics, and that exposure to 125 or 375 ppm may cause a decrease in pulmonary activities of certain CYP mixed function oxidases. Consistent with the idea of no CYP induction with low-level exposure is the report that workers exposed to 100 ppm toluene did not display increased ability to clear antipyrine (Dossing et al. 1983c).

Levels of CYP isozymes in rat fetal livers are very low, but increase rapidly after birth (Nakajima and Wang 1994). By 10 days after birth, rats of both sexes are capable of responding to toluene exposure by inducing hepatic CYP-associated enzyme activities (Pyykko 1983b). Comparison of rates of metabolism in liver microsomes from male and female rats at 3 weeks (immature) and 18 weeks of age (mature) and in pregnant female rats on gestations days 10 and 21 indicate that age, gender, and pregnancy can influence rates of hepatic toluene metabolism and induction of CYP isozymes (Nakajima et al. 1992b). Rates (on a mg protein basis) of high-affinity toluene metabolism were not statistically significantly different between immature and mature male rats, but rates of low-affinity toluene metabolism were four-fold higher in mature rats compared with immature rats (Nakajima et al. 1992b). In contrast, rates of high-affinity toluene metabolism were lower in mature than in immature female rats, but rates of low-affinity toluene metabolism were not statistically different between immature and mature female rats. Rates of high- and low-affinity toluene metabolism were significantly lower in pregnant rats compared with nonpregnant rats.

Given the lack or low levels of several CYP isozymes in the developing human fetus (Leeder and Kearns 1997), it is expected that the capacity for metabolic detoxification of toluene is low in the developing fetus. Rat studies indicate that levels of CYP isozymes involved in toluene metabolism, however, are rapidly increased following birth, and suggest that capabilities to carry out Phase I toluene metabolism at low exposure levels during neonatal periods may exceed those at sexual maturity and pregnancy (Nakajima et al. 1992b). CYP2E1, one of the principal CYP isozymes involved in the major toluene pathway (Nakajima et al. 1997; Tassaneeyakul et al. 1996), is reported to be expressed several hours after
birth in humans and continues to increase during the first year of life (Vieira et al. 1996). Phase II enzymes involved in toluene metabolism (e.g., N-acetyl transferases, UDP-glucuronyl transferases, and sulfotransferases) also show changes during human neonatal development with adult activities reported to be present by 1–3 years of age (Leeder and Kearns 1997). Although no studies were located directly comparing toluene metabolic capacity in children and adults, the limited available information suggest that children past early neonatal periods may be equally able as adults in metabolically disposing of toluene at low exposure levels expected to be found in the general environment or at sites adjacent to waste sites.

### 3.4.4 Elimination and Excretion

#### 3.4.4.1 Inhalation Exposure

Studies with humans and laboratory animals indicate that following acute periods of inhalation exposure to toluene, absorbed toluene is excreted predominately in the urine as metabolites (hippuric acid, benzoyle glucuronide, ortho- and para-cresol and their sulfate and glucuronide conjugates, S-benzyl mercapturic acid, and S-p-tolyl mercapturic acid, as discussed in Section 3.4.3) and, to a lesser extent, as non-metabolized toluene in exhaled air and urine (Ducos et al. 2008; Janasik et al. 2008, 2010; Lof et al. 1993; Ogata 1984; Tardif et al. 1998). For example, following a 2-hour exposure with light physical exercise to deuterium-labeled toluene at a concentration of 200 mg/m³ (53 ppm), an average 78% of retained label was excreted as urinary hippuric acid within 20 hours by a group of nine volunteers (Lof et al. 1993). A significant portion of absorbed toluene in this and other studies has been estimated to be exhaled as non-metabolized toluene (7–20% of absorbed toluene) (Carlsson 1982; Leung and Paustenbach 1988; Lof et al. 1993). Although unchanged toluene in urine is expected to be a minor elimination route based on mass balance, elimination kinetics data for toluene in urine following acute exposure of volunteers are consistent with the recommended use of this end point as a biomarker of exposure for toluene-exposed workers (ACGIH 2010; Ducos et al. 2008; Janisik et al. 2008, 2010). For example, following 4-hour exposure to 200 mg/m³ (53 ppm), a two-phase decline of urinary toluene concentration was observed with half-lives of 0.88 and 12.9 hours. The correlation coefficient between toluene air concentrations (20, 60, or 100 mg/m³; ~5, 16, or 27 ppm) and urinary toluene concentrations in the last 2 hours of exposure was 0.998 (Janisik et al. 2008).

Analyses of kinetic data for toluene concentrations in blood, exhaled breath, or adipose tissue or urine following inhalation exposure of humans (Leung and Paustenbach 1988; Lof et al. 1993; Pellizzari et al. 1992; Pierce et al. 1996, 1999) and rats (Rees et al. 1985) indicate that most absorbed toluene is rapidly
eliminated from the body and that a smaller portion (that which gets into adipose tissues) is slowly eliminated (Leung and Paustenbach 1988; Lof et al. 1993; Nise et al. 1989; Pellizzari et al. 1992; Pierce et al. 1996, 1999, 2002). Using three-phase exponential mathematical models to describe curves of human blood concentration as a function of time up to 3–5 hours after 2-hour exposures to 100 or 53 ppm toluene, calculated half-lives (the time to decrease the amount in the phase by one-half) were 1.5 and 3 minutes for the initial phase, 26 and 40 minutes for the second phase, and 3.7 and 12.3 hours for the final phase (Lof et al. 1993; Sato et al. 1974). Elimination half-lives ranged from about 12 to 65 hours (0.5 to 2.7 days) in subcutaneous adipose tissue samples taken from 12 subjects at several times within 8 days of cessation of exposure to about 80 ppm toluene for four consecutive 30-minute periods (Carlsson and Ljungquist 1982). Increasing elimination half-lives were significantly correlated with increasing amounts of body fat (Carlsson and Ljungquist 1982). The time courses of toluene concentrations in blood and subcutaneous fat of rotogravure printers exposed to 35–246 mg/m³ (9–65 ppm) toluene during and after a 5-day workweek were described by a three-phase elimination model with half-times of 9 minutes, 2 hours, and 90 hours for toluene in blood and a single median elimination half-time of 79 hours for toluene in fat (Nise et al. 1989). Using PBPK models, mean terminal half-lives of about 30–38 hours were calculated for changes in blood toluene concentrations between 50 and 100 hours after cessation of 2-hour inhalation exposures of male subjects to 50 ppm ¹H₈-toluene and 50 ppm ²H₈-toluene (Pierce et al. 1996, 1999). During this terminal phase of disposition, >95% of toluene is expected to be in adipose tissue and the release of toluene from adipose tissues has been proposed to be the rate-limiting step (Pierce et al. 1999). Analysis of rates of exhalation of nonmetabolized toluene and urinary excretion of metabolites from 2-hour exposures of male subjects to 50 ppm ²H₆-toluene indicated the following distribution of the total dose: 13% ²H₆-toluene in exhaled breath, and 75% ³H₆-hippuric acid, 0.31% ²H₇-ortho-cresol, 0.53% ²H₇-meta-cresol, and 11% ²H₇-para-cresol in urine (Pierce et al. 2002). In studies with rats exposed for 2 hours to 1,000, 1,780, or 3,000 ppm toluene, two-phase exponential models were used to calculate average elimination half-lives of approximately 6 and 90 minutes, but blood toluene concentrations were monitored in this study for no more than 2 hours following exposure (Rees et al. 1985).

Correlations between work place air concentrations of toluene and urinary excretion of unchanged toluene, hippuric acid, or ortho-cresol have been noted in a number of field studies (see ACGIH 2001 and 2010 for reviews and citations of these studies). Currently, ACGIH (2010, 2013) recommends using a combination of three biological exposure indices (BEIs®) to assess exposure of workers to toluene in the workplace: ortho-cresol and unchanged toluene levels in blood immediately prior to the last shift of a workweek. The recommendation was made based on analyses of numerous field studies examining
toluene blood concentrations and urinary concentrations of ortho-cresol and toluene in workers exposed to varying workplace air concentrations of toluene (see ACGIH 2010 for review). The specific values for these BEIs® correspond to concentrations likely to be observed in individuals exposed by inhalation to 20 ppm, the current ACGIH 8-hour TWA Threshold Limit Value (TWA-TLV®) for occupational exposure to toluene (ACGIH 2010). Previously, the level of hippuric acid in urine at the end of a workshift was recommended as a biomarker of exposure, but this recommendation was withdrawn because background urinary hippuric acid (from consumption of benzoate in foods and beverages) is expected to mask contributions from workplace exposure to toluene, especially at concentrations <50 ppm (ACGIH 2001, 2010). Other urinary biomarkers of exposure that have been proposed include benzylmercapturic acid (Inoue et al. 2002, 2004; Maestri et al. 1997) and S-p-toluylmercapturic acid (Angerer et al. 1998a).

3.4.4.2 Oral Exposure

Following oral administration of toluene to eight male subjects by a 2 mg/minute infusion for 3 hours through a feeding tube into the stomach, nonmetabolized toluene was detected in alveolar air samples for up to 4 hours after cessation of exposure and rates of urinary excretion of hippuric acid and ortho-cresol were elevated compared with values under nonexposed conditions (Baelum et al. 1993). A 6 mg/minute infusion for 30 minutes did not change the rates of urinary excretion of hippuric acid and ortho-cresol, but increased, by four-fold, the area-under-the-curve (AUC) for alveolar toluene concentration compared with the values for the 2-mg/minute exposure protocol. Accompanying the 2-mg/minute exposure protocol with oral doses of ethanol (0.32 g/kg, corresponding to two alcoholic drinks) decreased hippuric acid urinary excretion and dramatically increased the AUC for alveolar toluene concentration (by about 850-fold in one experiment and 56-fold in another). These data indicate that orally administered toluene is eliminated similarly to inhaled toluene, (i.e., by urinary excretion of metabolites and exhalation of nonmetabolized toluene), and that ingestion of ethanol can have a dramatic effect on metabolism and subsequent elimination of toluene. The results are consistent with other studies showing that ethanol inhibits the major toluene metabolic pathway, side-chain oxidation (Dossing et al. 1984; Wallen et al. 1984).

No other studies were located regarding the excretion of toluene in humans or animals after oral exposure.
3.4.4.3 Dermal Exposure

Following a 5-minute episode of hand-washing in toluene while wearing an airstream helmet to limit inhalation exposure, toluene concentrations in exhaled air from human subjects peaked at about 1 ppm at 22 minutes and declined to about 0.03 ppm at 24 hours (Monster et al. 1993). The results from this study indicate that dermally absorbed toluene can be eliminated as the parent compound in exhaled breath, but provide no information concerning the possible urinary excretion of metabolites.

No other studies were located regarding elimination of toluene following dermal exposure. As discussed in Section 3.4.1., studies in humans and rats have monitored concentrations of unchanged toluene in exhaled breath during and following dermal exposure to aqueous solutions of toluene to estimate dermal permeability coefficients (Thrall et al. 2002a; Thrall and Woodstock 2002). Like the study by Monster et al. (1993), they demonstrate that dermally absorbed toluene can be exhaled unchanged, but they do not provide information about the relative importance of urinary excretion of unchanged toluene or metabolites following dermal exposure.

3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models

Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and disposition of chemical substances to quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that will be delivered to any given target tissue following various combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the relationship between target tissue dose and toxic end points.

PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate and characterize the relationships between: (1) the external/exposure concentration and target tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from route to route, between species, and between subpopulations within a species. The biological basis of PBPK models results in more meaningful extrapolations than those generated with the more conventional use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance-specific physicochemical parameters, and species-specific physiological and biological parameters. The numerical estimates of these model parameters are incorporated within a set of differential and algebraic equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations provides the predictions of tissue dose. Computers then provide process simulations based on these solutions.

The structure and mathematical expressions used in PBPK models significantly simplify the true complexities of biological systems. If the uptake and disposition of the chemical substance(s) are adequately described, however, this simplification is desirable because data are often unavailable for many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The adequacy of the model is, therefore, of great importance, and model validation is essential to the use of PBPK models in risk assessment.

PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste sites) based on the results of studies where doses were higher or were administered in different species. Figure 3-4 shows a conceptualized representation of a PBPK model.

If PBPK models for toluene exist, the overall results and individual models are discussed in this section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.


***DRAFT FOR PUBLIC COMMENT***
Figure 3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance

Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation.

Source: adapted from Krishnan and Andersen 1994
describe the kinetics of dermally applied aqueous solutions of toluene are also available for humans (Thrall et al. 2002a) and rats (Thrall and Woodstock 2002), but models to describe kinetics following oral exposure to toluene have not been developed.

Available models are all modifications of the standard four-compartment PBPK model developed for styrene (Ramsey and Andersen 1984) in which:

(1) absorption into the lung blood is assumed to be dependent on the inhaled concentration of toxicant, the concentration of toxicant in alveolar air, blood flow to the lung, the blood/air partition coefficient, and alveolar ventilation rates,

(2) exchange of toxicant between arterial blood and tissue compartments is flow-limited,

(3) changes in the amount of toxicant in three nonmetabolizing tissue compartments (adipose tissue, slowly perfused tissues, and rapidly perfused tissues) are described by mass transfer differential equations with tissue volume, blood flow through the tissue (i.e., tissue perfusion rate), arterial blood toxicant concentration, and tissue/blood partition coefficients as explanatory variables, and

(4) changes in toxicant amount in the liver (the fourth compartment) are described by similar differential equations that additionally include a Michaelis-Menten term for overall rates of toxicant metabolism.

**Human Models.** The five-compartment human model for toluene developed by Pierce et al. (1996) includes an additional equation describing mass balance across the lung that has a Michaelis-Menten metabolic term (Pierce et al. 1996). The model assumes that toluene metabolism in the liver and lung are adequately described by subject-specific maximal rate constants for liver and lung (“Vmax-h and Vmax-p” of 52.1xBW^{0.7} μmol/hour and 0–0.7x52.1xBW^{0.7} μmol/hour, respectively) and a common Km (5.97 μmol/L). The Km and Vmax-h values were based on those derived by fitting a Ramsey and Andersen-type four-compartment PBPK model (in which all parameters were constant except Vmax and Km) to toluene uptake data for rats placed in closed chambers at several initial toluene concentrations (Tardif et al. 1993). The human Vmax-h was estimated for each subject by multiplying the rat Vmax-h by the subject’s body weight to the 0.7 power; the rat Km was taken as the human value (Pierce et al. 1996). The lung Vmax (Vmax-p) was estimated by model-fitting for each subject, allowing the value to range between 0 and 70% of the liver Vmax, Vmax-h. This procedure was based on observations that levels of CYP2E1 in human lung microsomes were 10.5% of liver activities (Wheeler et al. 1992), and 12 human liver samples showed a seven-fold range of CYP2E1 contents (Thummel et al. 1993).

Another singular feature of the Pierce human model is that subject-specific parameters such as age, height, weight, alveolar ventilation rate, adipose tissue fraction, and blood/air partition coefficient are put
into the model (Pierce et al. 1996). Volumes of the tissue compartments in the model were scaled to each subject’s body weight. Blood flows to the slowly and rapidly perfused tissues and the liver were taken as fractions of a standard human cardiac output scaled to body weight to the 0.74 power (in units of liter-hour), whereas subject-specific blood flows to the adipose tissue were estimated by model fitting (holding other parameters constant) allowing the fraction of cardiac output that perfuses adipose tissue to range between 0.06 and 0.18. The decision to “model-fit” this parameter within these bounds was based on published observations that adipose blood flows among individuals range widely from about 0.06 to 0.18 of total cardiac output. Tissue/blood partition coefficients used in the model for the slowly and rapidly perfused tissue, the liver, and adipose tissue were 1.54, 4.64, 4.64, and 55.9, respectively.

The initial development and validation of the human model involved comparing model fits with measured data (blood concentrations) for a group of 26 male volunteers who were exposed to 100 ppm toluene (50 ppm $^1$H$_8$-toluene and 50 ppm $^2$H$_8$-toluene) for a 2-hour period (Pierce et al. 1996). Venous blood concentrations of $^1$H$_8$- and $^2$H$_8$-toluene were measured at intervals for 120 hours post exposure. Prior to exposure, information on age, body weight, and adipose tissue fraction were obtained. During exposure, individual ventilation rates and blood/air partition coefficients for toluene were measured. Measures of the goodness-of-fit of the model predictions to the data were compared using subject-specific values, average values from the 26 subjects, and average literature values for: body weight, adipose tissue fraction, ventilation rate, blood/air partition coefficient, maximum velocity of pulmonary metabolism, and fraction of cardiac output to adipose tissue. The measured concentrations of toluene in blood showed a ten-fold interindividual range of variation. Subject-specific modeling explained 91% of the data variability, compared with 53% using literature values for model parameters (Pierce et al. 1996).

Pierce et al. (1998) used the human model to estimate toluene concentrations in alveolar breath reflective of exposure to 50 ppm toluene for 8 hours/day (the ACGIH 8-hour TWA TLV for toluene in 1998). Calculated values were ≤10 μmol/m$^3$ for samples taken just before the final shift of a workweek and ≤150 μmol/m$^3$ postexposure. It was proposed that toluene breath sampling would be a rapid, noninvasive biomarker of toluene exposure in workers that is not contaminated by endogenous sources. Pierce et al. (1999) also used the human model as a research tool to ascribe differences in toxicokinetic behavior of $^1$H$_8$- and $^2$H$_8$-toluene to underlying physiological mechanisms.

Jonsson and Johansen (2001) modified the Pierce et al. (1996) model to incorporate, and estimate inter- and intra-individual variability in, exercise-induced changes in perfusion of fat tissue. The modified model split the muscle compartment into working and resting muscle compartments, and the fat

***DRAFT FOR PUBLIC COMMENT***
compartment into perirenal and subcutaneous fat. Model parameters were expressed as prior
distributions, rather than point estimates, based on literature values. The model was fit by Markov chain
Monte Carlo simulation to time-course data for toluene concentrations in arterial blood, exhaled breath,
and subcutaneous fat for six individuals exposed by inhalation to 80 ppm for 2 hours during rest and
moderate to heavy exercise (50–150 W). The fitting exercise indicated that the kinetic data was best
described when no increase in perfusion of subcutaneous fat with exercise was allowed and increased
perfusion of perirenal fat induced by physical work was set to a constant level, rather than scaled
proportionally to the increase in oxygen uptake with increasing workload.

Another human PBPK model has been developed for volatile organic compounds that models transfer of
toxicant via lactation from a mother to a nursing infant, but in vivo pharmacokinetic data for toluene in
breast milk were not available to validate this model (Fisher et al. 1997). This model is an adaptation of
the Ramsey and Andersen design with the addition of a fifth compartment, a nonmetabolizing milk
compartment with a varying volume. The model includes equations describing the rate of change in the
amount of toxicant ingested by a nursing infant from the milk compartment, the rate of change in the
amount of milk in the mammary tissue lumen, and the rate of change in the amount of toxicant in breast
milk. The model used Michaelis-Menten kinetic constants for toluene metabolism in the liver estimated
for rats (Vmax 7.5 mg/kg/hour; Km 0.3 mg/L); the rat Vmax was scaled for use in the model by
multiplying it by a reference body weight (60 kg) to the 0.74 power. Human milk/blood partition
coefficients for 19 volatile organic chemicals were experimentally determined using samples from
volunteers; the coefficient for toluene was 2.68. Other tissue/blood partition coefficients for toluene used
in the model included 4.91 for rapidly perfused tissue and for liver, 1.61 for slowly perfused tissue, and
60.01 for adipose tissue.

Fisher et al. (1997) used the model to estimate the amount of toluene an infant would ingest via milk if
the mother was occupationally exposed to toluene at the ACGIH (1999) TLV (50 ppm) throughout a
workday. The model predicted that such an infant would have a daily intake of 0.46 mg toluene, which is
below the U.S. EPA Health Advisory, 2.0 mg/day, for chronic ingestion of 1 L/day of toluene-
contaminated water by a 10-kg child.

Tardif et al. (1995) developed a four-compartment PBPK model for toluene in humans by modification of
a four-compartment rat model developed by Tardif et al. (1993), in which all metabolism occurred in the
liver. Physiological parameters for the human model were taken from the literature (e.g., alveolar
ventilation rate and cardiac outputs had values of 18.0 L/hour/kg body weight for subjects at rest).
Coefficients for human tissue:blood partitioning were calculated by dividing rat tissue:air values by a human blood:air coefficient (15.6) taken from the literature. The metabolic constant, $K_m$ (0.55 mg/L), was assumed to be the same in rats and humans, and the human $V_{max}$ (4.8 mg/hour/kg) was converted from the rat value by using body weight$^{0.75}$ allometric scaling. The model was linked to a similar model for xylene; linking occurred by competitive metabolic inhibition in the liver. The linked models were evaluated by comparing predicted and observed values for toluene (and xylene) concentrations in alveolar air and blood. The predicted values were judged to be “in accord” with observed values from a study of volunteers exposed to 50 ppm toluene, 40 ppm xylene, or 50 ppm toluene+40 ppm xylene for 7 hours (Tardif et al. 1991). Simulations with the model indicated that blood concentrations and extent of metabolism for the two solvents during combined exposure at 50 ppm toluene and 100 ppm xylene would not be more than 10% changed, compared with exposure to the individual solvents alone (Tardif et al. 1995).

Tardif et al. (2002) modified the unlinked human PBPK model developed by Tardif et al. (1995) to include the description of urinary excretion of ortho-cresol. The fraction of total metabolites excreted as ortho-cresol (0.00078) was estimated by fitting the model to data for urinary ortho-cresol levels in toluene-exposed workers (Truchon et al. 1999). Values for urinary excretion rate of creatinine (12.06 µmol/hour/kg) and urine output (1.848 mL/hour/kg) were taken from the literature. The model was used with Monte Carlo simulation to explore how published estimates of human population variance for parameters for excretion, physiology, and metabolism would influence concentrations of toluene in blood and ortho-cresol in urine. The resultant distribution for ortho-cresol excretion at the end of the first 8-hour workday in the week with 50 ppm toluene had a geometric mean of 0.635 mmol/mol creatinine with lower and upper 95% confidence limits of 0.23 and 1.75 mmol/mol creatinine. For blood toluene concentration prior to the last workday in the week, a somewhat smaller distribution of values was indicated with a geometric mean of 120.6 µg/L and 95% confidence limits of 64.5 and 225.7.

Nong et al. (2006) modified the adult PBPK model developed by Tardif et al. (1995) to incorporate data on age, body weight, liver volume, and hepatic CYP2E1 content from a study by Johnsrud et al. (2003) of 116 children (41 males, 75 females) ranging from newborn to 17 years of age. The model calculated hepatic clearance normalized on hepatic CYP2E1 content. The modified model, using child-specific data, was used to simulate time courses of toluene concentrations in blood of individual children of varying ages exposed by inhalation to 1 ppm toluene for 24 hours. The results indicated that the AUCs for simulated toluene blood concentrations in these children varied by a factor of about 6, compared with a factor of about 20 for the range of hepatic CYP2E1 contents. In neonates (<1 month old) with low and
3. HEALTH EFFECTS

high hepatic CYP2E1 content (<3.69 and >3.69 pmol/mg protein), 95\textsuperscript{th} percentile simulated AUC values were 3.9-fold and 2.5 higher than the 50\textsuperscript{th} percentile AUC value for adults. The 95\textsuperscript{th} percentile AUC values in children in older age groups (1 month–1 year; 1–11 years; 12–17 years) were less elevated; ratios of 95\textsuperscript{th} percentile AUCs for children: the 50\textsuperscript{th} percentile adult AUC value for these age groups were 1.57, 1.49, and 1.35, respectively.

Sari-Minodier et al. (2009) made further refinements of the Tardif et al. (2002) model to include a kidney compartment, and different physiological parameters (alveolar air ventilation, cardiac output, and fractions of total cardiac output to each compartment) for different levels of physical activity (measured in watts of work, W). Also included were modified values for the fraction of toluene metabolized to ortho-cresol (0.0012) and the ortho-cresol urinary excretion rate based on the best fit of simulations to observed time course data for volunteers exposed to 50 ppm for 7 hours (Tardif et al. 1998). The revised model was evaluated by comparing simulated values to observed data for concentrations of unchanged toluene in blood and urine in six volunteers exposed to 5.3, 16.0, or 26.6 ppm toluene for 8 hours at rest (Janasik et al. 2008), and for alveolar toluene concentrations and urinary ortho-cresol concentrations in four volunteers exposed to 50 ppm for 7 hours with different scenarios of physical activity (Nadeau et al. 2006). Sari-Minodier et al. (2009) considered the comparisons between simulated and empirical values to be “satisfactory.” The modified model was used to simulate values for blood toluene concentration at the end of an 8-hour work shift and urinary concentrations of toluene and ortho-cresol at the end of a workweek under different levels of activity. The model predicted that these biological exposure indices for toluene were increased by ~2–3-fold by 50 W activities versus 12.5 W resting activities at an air concentration of 20 ppm toluene.

Thrall et al. (2002a) developed a human PBPK model for toluene with six compartments (lung, richly perfused tissues, slowly perfused tissues, skin, fat, and liver) to simulate dermal exposure scenarios. The model was modified from a model for rats of similar structure as described by Thrall and Woodstock (2002). In these models, absorption to blood occurs though the lung and the skin, metabolism only occurs in the liver, and the skin compartment represents exposed skin; unexposed skin is lumped in the slowly perfused tissue compartment. Metabolic constants were the same as those used by Tardif et al. (1995). Physiological parameters included 348 L/hour for cardiac output and alveolar ventilation. Blood flow to compartments was distributed as percentages of cardiac output: liver 25%; fat 6%, rapidly perfused 49%; slowly perfused 15%; and total skin 5%. Tissue volume as percentages of body weight were: 4% liver; 20% fat; 5% rapidly perfused; 52% slowly perfused; and 4% total skin. Partition coefficients were: 1.75 saline:air; 13.9 blood:air; 83.5 liver:air; 1021 fat:air; 27.7 muscle:air; and 43.0 skin:air. Dermal
exposures were simulated by an equation relating the rate of change in toluene concentration in the skin to dermal flux and dermal perfusion. Body weight was an input so that the model could be used to estimate dermal permeability coefficients (Kp, a parameter for the dermal flux equation) for individual subjects of varying body weights, by optimization of fit to exhaled breath data collected before, during, and after subjects were dermally exposed to aqueous solutions of toluene. Estimated Kp values for six subjects ranged from 0.004 to 0.020 cm/hour, with an average of 0.012 cm/hour (SD=0.007).

Benignus et al. (2006) combined a commercially available general whole-body human physiological model (named QCP2004) with a human PBPK model modified from the Tardif et al. (1995) model. The combined model (named GPAT for general physiology and toxicokinetic model) was developed to reduce the calculational complexity associated with time-dependent changes in exposure concentrations and human physical activity. The QCP2004 model provided estimates of physiological parameters required by the PBPK model under varying levels of human physical activity. The Tardif et al. (1995) human PBPK model was modified to include a brain compartment and new partition coefficients estimated by Thrall et al. (2002b). QCP2004 model simulations for minute ventilation, cardiac output, and hepatic blood flow were compared with observed data for these end points in humans with varying levels of physical activity (0—200 W). The simulated values for these physiological parameters were mostly within 95% confidence limits for regression lines relating observed values and levels of activity from a number of published studies for each physiological end point. Values for blood toluene concentrations were simulated with the GPAT model and compared with published sets of observed values measured in human subjects exposed to toluene for short periods (30–120 minutes) under varying levels of physical activity. Simulated values and observed values for blood toluene concentrations in the published studies, regardless of exposure concentration or activity level, were plotted and fitted to a linear regression model. Comparison of an “identity line” (on which all points would lie if the model predicted perfectly) and the regression line indicated that the identity line was within the 95% confidence limits of the regression line.

Animal Models. The four-compartment rat PBPK model for toluene developed by Tardif et al. (1993) restricted metabolism to the liver compartment. The Km (0.55 mg/L) and Vmax (4.8 mg/hour/kg) values were derived by fitting the model (in which all parameters were held constant except Vmax and Km) to toluene uptake data for rats housed in closed chambers for 5 hours at several initial toluene concentrations (75, 150, or 225 ppm) (Tardif et al. 1993). The model used 18.0 as the blood/air toluene partitioning coefficient, and the following for partitioning between blood and tissue groups: 4.64 for liver and rapidly perfused tissue, 1.54 for slowly perfused tissue, and 56.7 for adipose tissue. Reference rates for alveolar ventilation (15 L/hour/kg) and cardiac output (15 L/hour/kg) were scaled by a factor of body weight to the
0.74 power. Model predictions of venous blood concentrations in rats during and after 5-hour exposures to toluene concentrations of 75, 150, or 225 ppm compared favorably (by visual inspection) with empirical data.

Tardif et al. (1993) linked the rat PBPK model for toluene to a similar PBPK model for xylene via the metabolism term in the liver compartment to test if there was no metabolic interaction between these compounds or if a metabolic interaction existed that could be described by competitive, noncompetitive, or uncompetitive inhibitory interaction. A model with a competitive inhibition metabolic term provided the best visual fit to empirical data for air concentrations of toluene and xylene during 5-hour exposures of rats in a closed chamber to mixtures of toluene and xylene at several initial concentrations.

A five-compartment rat PBPK model developed by DeJongh and Blaauboer (1996) is similar in design to the Tardif rat PBPK model except that it contains an additional compartment, (i.e., the brain, which was assumed to be nonmetabolizing). The model used the same toluene partition coefficients used in the Tardif et al. (1993) rat model; the brain/blood partition coefficient, 2.0, was estimated from a published value for the human brain/air coefficient and the rat blood/air coefficient. Reference rates for alveolar ventilation (14 L/hour/kg) and cardiac output (14 L/hour/kg) were scaled by a factor of body weight to the 0.74 power. With other parameters in the model held constant, models with different published values of \( V_{\text{max}} \) and \( K_{\text{m}} \) for toluene metabolism in rat liver from two \( \textit{in vivo} \) and six \( \textit{in vitro} \) rat studies were compared for their ability to fit empirical data from several studies for toluene blood concentrations or toluene brain concentrations in rats exposed to inhaled toluene. DeJongh and Blaauboer (1996) judged that a \( V_{\text{max}} \) of 4.31 mg/kg/hour and \( K_{\text{m}} \) of 0.26 mg/L gave the overall best fit to the empirical data, but noted that differences were generally small among predictions from models with the various values of \( V_{\text{max}} \) and \( K_{\text{m}} \).

Dejongh et al. (1998) used their rat PBPK model for toluene and similar models for 14 other volatile organic chemicals to examine a hypothesis that the acute lethality of volatile organic chemicals is related to their ability to distribute into the brain. Using these models to calculate the dose in the brain associated with the \( LC_{50} \) for the compounds, it was noted that the products of the \( LC_{50} \) and their respective exposure durations ranged by about 60-fold, whereas the PBPK-derived brain doses associated with the \( LC_{50} \) ranged by about 6-fold. Dejongh et al. (1998) concluded that this observation supports the hypothesis that the acute lethality of volatile organic chemicals, including toluene, is directly related to the extent of their distribution into the brain.

***DRAFT FOR PUBLIC COMMENT***
van Asperen et al. (2003) modified the five-compartment DeJongh and Blaauboer (1996) rat model with slightly different metabolic constants (Vmax of 4 mg/kg/hour and Km of 0.2851 mg/L) and a modified blood:air coefficient (13 versus 18 in the previous model). Other physiological parameters and partition coefficients were identical to those in the Dejongh and Blaauboer (1996) model. The model with the revised blood:air coefficient provided better fit of time-course data for blood and brain toluene concentration in Wistar-derived rats exposed for 7.5 hours to a constant concentration of about 2,667 ppm or five fluctuating peak concentrations of about 8,000 ppm for 0.5 hours separated by 1-hour intervals without toluene. Blood and brain concentrations were determined several times during and after exposure up to 24 hours after the start of exposure. The modified model was used to examine predicted brain dose-effect relationships in a visual discrimination task in rats exposed to toluene via constant and fluctuating exposure scenarios. Effects on end points measuring “dissinhibition of responding” were most pronounced in groups with the highest estimated brain concentrations at the time of testing, but a monotonic relationship for increasing magnitude of effect and increasing brain concentration was not evident.

Thrall and Woodstock (2002) developed a rat PBPK model for toluene with six compartments (lung, richly perfused tissues, slowly perfused tissues, skin, fat, and liver) to simulate dermal exposure scenarios. The rat model was adapted from the rat model developed by Tardif et al. (1993). In the modified model, absorption to blood occurs though the lung and the skin, metabolism only occurs in the liver, and the skin compartment represents exposed skin; unexposed skin is lumped in the slowly perfused tissue compartment. Dermal exposures were simulated by an equation relating the rate of change in toluene concentration in the skin to dermal flux and dermal perfusion. Body weight was an input so that the model could be used to estimate dermal permeability coefficients (Kp, a parameter for the dermal flux equation) for individual rats of varying body weights. This was done by optimization of fit of the model to exhaled breath data collected when rats were dermally exposed to aqueous solutions of toluene. Metabolic constants were the same as those used by Tardif et al. (1993). Physiological parameters included 5.4 L/hour for cardiac output and alveolar ventilation. Blood flow to compartments was distributed as percentages of cardiac output: liver 25%; fat 5%, rapidly perfused 51%; slowly perfused 15%; and total skin 5%. Tissue volume as percentages of body weight were: 4% liver; 8% fat; 5% rapidly perfused; 64% slowly perfused; and 10% total skin. Partition coefficients were: 1.2 saline:air; 18.0 blood:air; 83.5 liver:air; 1021 fat:air; 27.7 muscle:air; and 43.0 skin:air. The rat PBPK model was used to estimate a Kp for each exhaled breath dataset; the average Kp value across datasets was 0.074 cm/hour (SD=0.005).
Kenyon et al. (2008) developed a seven-compartment PBPK model for inhalation exposure of rats to toluene that included compartments for the lung, brain, richly perfused tissues, slowly perfused tissues, fat, gastrointestinal tract, and liver. Metabolism was restricted to the liver, and metabolic constants were those determined by Tardif et al. (1993). Partition coefficients were those determined by Thrall et al. (2002b). Values for cardiac output and alveolar ventilation were calibrated/optimized by fitting of the model to time-course data for toluene blood concentrations in Long-Evans rats under three different experimental conditions: “normal” rats with a diurnal cycle of being active and fed at night; “sedentary, day-acclimated” rats acclimated to be fed and active during the light diurnal cycle, but not performing a task; and “active, day-acclimated” rats acclimated to be fed and active during light hours and performing a lever pressing task. Blood flow fractions to tissues and volumes of tissue compartments were based on literature values for Long-Evans rats. The calibrated/optimized model was evaluated for its ability to predict time-course data for blood and brain concentrations of toluene collected from rats in several other pharmacokinetic studies under various physical activity and exposure conditions. Statistical analyses of plots of predicted versus observed blood concentration data from five other studies indicated no significant (p<0.05) difference from a fitted regression line and a “unity” line. For predicted versus observed brain concentration data from four studies, the fitted regression had a slope of 0.850 that was significantly (p<0.05) less than the unity line slope of 1.0. Most of this discrepancy was attributed to brain concentration data from a single study of Wistar rats for which the model consistently overpredicted brain concentration; when these data were excluded, the slope of the regression line was 1.01.

Oshira et al. (2011) modified the Kenyon et al. (2008) rat model for inhalation exposure to include hepatic enzyme induction as an empirical step function. When the Kenyon et al. (2008) model was used to simulate toluene brain concentrations during exposures of Long-Evans rats to 775 or 1,125 ppm for 24 hours, the model adequately described brain concentrations at 1 and 6 hours of exposure, but overpredicted brain concentrations at 24 hours and at 6 hours after exposure ceased. The modified model (which included graded fold increases of the maximum rate of toluene metabolism in the liver [VmaxC] used in the original model) provided better predictions of brain concentrations at 24 and 30 hours after exposure started. The modified model was used to predict brain concentrations of toluene during 1- and 24-hour exposures to several air concentrations and examine relationships between estimated brain concentrations and effects on a trained behavior task (visual signal detection). The dose-effect relationship for response latency in this task after 1 hour of exposure was shifted to the left on the dose axis, compared with the 24-hour dose-effect relationship. The results are consistent with the hypotheses that the rats developed a behavioral tolerance to toluene within 24 hours of exposure and that behavioral effects from 24-hour exposures cannot be accurately extrapolated from 1-hour exposure data.
3. HEALTH EFFECTS

3.5 MECHANISMS OF ACTION

3.5.1 Pharmacokinetic Mechanisms

Absorption. In humans and animals, toluene is rapidly absorbed by inhalation exposure (Benignus et al. 1984; Hjelm et al. 1988; Hobara et al. 1984b; Lof et al. 1993). Animal studies have shown that toluene is absorbed less rapidly by the oral route (Ameno et al. 1992; Pyykko 1983b; Sullivan and Conolly 1988), and dermal route (Dutkiewicz and Tyras 1968; Thrall and Woodstock 2002; Thrall et al. 2002a). Studies with brush border membrane vesicles isolated from rat intestines and exposed to toluene indicate that toluene absorption occurs through the lipid matrix of the membrane (Alcorn et al. 1991).

Distribution. Toluene has been identified in brain, liver, lung, and blood in humans following toluene exposure (Paterson and Sarvesvaran 1983; Takeichi et al. 1986). Within the human brain, toluene has a greater affinity for areas of the brain that contain lipid-rich white matter, such as the brain stem, rather than the areas with larger amounts of grey matter (Ameno et al. 1992). The human data are supported by animal studies where distribution of toluene was found to be characterized by uptake in lipid tissues (brain and fat) immediately following inhalation exposure (Bergman 1983; Bowen et al. 2007; Campo 1999; Ghantous and Danielsson 1986; Ikeda 1990; Nakajima et al. 2006; Kenyon et al. 2008; van Asperen et al. 2003).

Metabolism. Studies of urinary metabolites in toluene-exposed humans have identified hippuric acid (the glycine conjugate of benzoic acid) as the major urinary metabolite of toluene. Minor urinary metabolites (in approximate order of decreasing abundance) include: the glucuronyl conjugate of benzoic acid; sulfate and glucuronide conjugates of ortho- and para-cresol; S-benzylmercapturic acid; and S-p-toluylmercapturic acid. CYP2E1 is thought to be the principal enzyme responsible for catalyzing the formation of benzyl alcohol from toluene, but other CYP forms capable of catalyzing this reaction include CYP1A1, CYP1A1, CYP2A6, CYP2A13, CYP2B6, and CYP2C8 (Fukami et al. 2008; Nakajima et al. 1997). Benzyl alcohol is thought to be converted to benzoic acid by alcohol dehydrogenase and aldehyde dehydrogenase. Hippuric acid formation from benzoic acid is catalyzed by acyl-CoA synthetase and acyl-CoA:aminio acid N-acyltransferase, whereas benzoyl glucuronide formation from benzoic acid is catalyzed by UDP-glucuronyl transferase (Nakajima and Wang 1994). The formation of ortho- and para-cresol is thought to be catalyzed from benzoic acid by CYP1A2, CYP2E1, and CYP2B6 through epoxide intermediates (Nakajima et al. 1997). The liver appears to be the principal site of metabolism of
toluene, but evidence of metabolism in other tissues like the lung is available (Fukami et al. 2008; Wheeler et al. 1992).

**Excretion.** In both humans and rats, up to about 75–80% of inhaled toluene that is absorbed can be accounted for by urinary excretion of the principal metabolite, hippuric acid (Lof et al. 1993; Ogata 1984; Tardif et al. 1998). Excretion of unchanged toluene and minor metabolites including S-benzyl mercapturic acid, S-p-toluoyl mercapturic acid, and conjugates of ortho- and para-cresol account for less than 5% of absorbed toluene, but assays for urinary levels of unchanged toluene and ortho-cresol can provide reliable biomarkers of toluene exposure (ACGIH 2010; Ducos et al. 2008; Janisik et al. 2008, 2010). Excretion of nonmetabolized toluene in exhaled air can represent from 7 to 20% of absorbed toluene, depending on exposure conditions (Carlsson 1982; Leung and Paustenbach 1988; Lof et al. 1993). Although the liver is expected to be the main site of metabolism of toluene, CYP2E1, one of the principal isozymes catalyzing the initial reaction in the principal toluene metabolic pathway, has been detected in human lung microsomes at concentrations about 10-fold less than in liver microsomes (Wheeler et al. 1992). Under conditions in which the main pathway of toluene metabolism is inhibited by co-exposure with ethanol, exhalation of nonmetabolized toluene can become a principal route of excretion (Baelum et al. 1993).

### 3.5.2 Mechanisms of Toxicity

#### 3.5.2.1 Mechanisms of Neurotoxicity

Dysfunction of the central nervous system is a critical human health concern following acute, intermediate, or chronic inhalation exposure to toluene. Therefore, the mechanisms of toluene toxicity have been investigated predominantly in the nervous system. Proposed mechanisms of toxicity include altered membrane and membrane channel properties; direct damage to brain structures via lipid damage, oxidative stress, and/or apoptosis; altered neurotransmitter synthesis, release, degradation, and receptor binding; disruption of the hypothalamic-pituitary-adrenal axis; and neuroinflammation.

**Mechanisms of Central Nervous System Depression and Narcosis.** The mechanism by which acute exposure to toluene brings about neurological effects such as central nervous system depression and narcosis is generally thought to involve, at least in part, reversible interactions between toluene (the parent compound and not its metabolites) and components (lipids or proteins) of nervous system membranes. Support of parent-material involvement comes from the observation that pretreatment of rats with phenobarbital increased the rate of *in vivo* toluene metabolism and shortened the time of recovery.
3. HEALTH EFFECTS

from narcosis from single intraperitoneal doses of toluene (Ikeda and Ohtsuji 1971). Other support for this hypothesis includes the transient nature of anesthesia from acute, high-level exposure to toluene and the rapidity with which toluene-induced changes in brain biochemical variables can be measured. For example, within 0.25–1 hour of intraperitoneal injection of 1-g/kg doses of toluene into rats, brain synaptosomes showed decreased phosphatidylethanolamine content, altered phospholipid methylation activities, altered outer membrane fluidity, and increased Na+-K+-ATPase activities (LeBel and Schatz 1988, 1989, 1990). Similarly, increased Na+-K+-ATPase activities were observed in brain homogenates of rats sacrificed 15 minutes after an intraperitoneal injection of 35 mg/kg toluene or ortho-cresol (Calderon-Guzman et al. 2005). In culture systems, decreased Mg++-ATPase activities were measured in brain synaptosomes isolated from rat brains immediately following a 2-hour exposure to 2,000 ppm toluene (Korpela and Tahti 1988), near-significant increases in calcium leakage were observed in synaptosomes of PND 25–43 offspring exposed to 1,800 ppm for 6 hours/day from GD 7 to 20, compared with unexposed offspring (Edelfors et al. 2002), and increased LDH and calcium leakage were observed in a neuroblastoma cell line (SH-SY5Y) following in vitro toluene exposure (McDermott et al. 2007). On a molecular scale, the acute anaesthetic actions of toluene and other agents have been postulated to involve intercalation of toluene into the lipid bilayer of nerve membranes and/or reversible interactions with proteins in the membrane (Franks and Lieb 1985, 1987).

More recently, acute effects of toluene and other volatile organic chemicals on neuronal functions have been proposed to involve interactions with voltage- and ligand-gated ion channels in nerve tissue. In various cell preparations, toluene has been shown to disrupt currents mediated by GABA receptors (Beckstead et al. 2000), N-methyl-D-aspartate (Cruz et al. 1998, 2000, 2003), nicotinic acetylcholine receptors (Bale et al. 2002, 2005), muscarinic acetyl choline receptors (Tsuga et al. 1999; Wu et al. 2002), voltage-sensitive Ca\(^{2+}\) channels (Shafer et al. 2005; Tillar et al. 2002), calcium-activated and G-coupled potassium channels (Del Re et al. 2006), and gap junctions (Del Re and Woodward 2005).

**Mechanisms of Structural Brain Damage.** Clinically obvious neurological impairment (e.g., gait and speech abnormalities) and brain atrophy have been observed in several cases of chronic toluene-inhalation abuse. MRI of the brain of solvent abusers (Filley et al. 1990; Rosenberg et al. 1988a, 1988b) suggests preferential atrophy in lipid-rich regions of the brain. Rosenberg et al. (1988a, 1988b) found MRI evidence of diffuse central nervous system demyelination in 6 toluene abusers with clinically obvious neurological impairment, whereas Filley et al. (1990) noted that the degree of MRI-detected white matter abnormality in 14 solvent abusers was correlated with neurological impairment. The observed changes in MRI signals may be related to lipid compositional changes in the white matter, since these regions are
more lipid-rich than gray matter (Ameno et al. 1992). These observations are consistent with a hypothesis that chronic exposure to high concentrations of toluene brings about structural changes in the brain related to lipid compositional changes. Supporting evidence for this hypothesis includes observations of changed phospholipid composition of rat brain synaptosomes following acute exposure to toluene (Lebel and Schatz 1988, 1989, 1990), decreased phospholipid concentrations in the cerebral cortex of rats following 30 days of continuous exposure to 320 ppm (Kyrklund et al. 1987), degenerative changes and ultrastructural damage in the hippocampus, frontal cortex, and brain stem (Kanter 2008a, 2008b, 2001, 2013), decreased or shrunken cells in the hippocampus (Gelazonia et al. 2006a; Gotohda et al. 2002; Korbo et al. 1996; Zhvania et al. 2012), impaired dendritic outgrowth in the frontal cortex (Pascual and Bustamante 2010), and white matter damage in anterior commissure (Duncan et al. 2012). It is uncertain if toluene-induced changes in membrane phospholipid content may be caused by increased breakdown of phospholipids or inhibition of synthesis.

Brain damage may be mediated through apoptotic pathways. Increased apoptosis has been observed in the rat brain following acute or intermediate-duration oral exposure to 650 mg/kg/day (Kamel and Shehata 2008). Following exposure to 1,500–1,800 ppm, 6 hours/day from GD 7 to 20, increased apoptosis was observed in the cerebellum of rat pups at PNDs 21 and 27 (but not PNDs 11, 22, 24, or 90) (Dalgaard et al. 2001; Ladefoged et al. 2004). No changes in hippocampal apoptosis were observed. Additionally, a significant increase in caspase-3 activity was observed in the cerebellum on PND 6, but not PNDs 22, 24, or 27, indicating increased caspase-3 mediated apoptosis (Ladefoged et al. 2004). A study in rat astrocyte cultures also reported that observed apoptosis following in vitro toluene exposure was caspase-dependent, and that stimulation of p42/44 mitogen activated protein kinase (MAPK) by toluene functions to promote cell survival (Lin et al. 2002).

Damage to brain structures may also result from oxidative stress, as increased markers of oxidative stress have been observed in the rat brain following acute- or intermediate-duration inhalation exposure to concentrations as low as 500 ppm (Baydas et al. 2003, 2005; Burmistrov et al. 2001; Coskun et al. 2005; Kodavanti et al. 2011; Royland et al. 2012). Increased markers of oxidative stress have also been observed in rats following acute or intermediate-duration oral exposure to 650 mg/kg/day (Kamel and Shehata 2008). Following gestational exposure to 1,800 ppm for 6 hours/day from GD 7 to 20, increased reactive oxygen species were produced in response to in vitro exposure to toluene in cultured synaptosomes from PND 25 to 43 offspring (Edelfors et al. 2002). Lipid peroxidation in rat brain was also increased following intraperitoneal injections of toluene or its metabolites (ortho-, para-, and meta-cresol) (Calderon-Guzman et al. 2005). This mechanism is plausible in humans, as increased
markers of oxidative stress have been observed in workers exposed to solvent mixtures (Halifeoglu et al. 2000; Kim et al. 2011; Won et al. 2011).

**Mechanisms of Mild Neurological Impairment.** Mechanistic understanding is poor of effects that have been associated with intermediate and chronic exposure to toluene in workplace air such as increased incidence of self-reported neurological symptoms (Guzelian et al. 1988; Matsushita et al. 1975; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1987), performance deficits in neurobehavioral tests (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Orbaek and Nise 1989); hearing loss (Morata et al. 1997), changes in auditory and/or visual-evoked potentials (Abbate et al. 1993; Vrca et al. 1995, 1996, 1997a, 1997b), and color vision loss (Campagna et al. 2001; Cavalleri et al. 2000; Zavalic et al. 1998a, 1998b, 1998c), but several mechanistic actions have been postulated.

One mechanistic hypothesis postulates that repeated interaction of toluene with membrane proteins and/or phospholipids in brain cells can change activities of enzymes involved in the synthesis and/or degradation of neurotransmitters and that levels of neurotransmitters at particular sites in the brain may be involved in producing subtle neurological effects. Some evidence for this hypothesis comes from observations of increased concentrations of dopamine, norepinephrine, and 5-hydroxytryptamine in rats exposed to 1,000–4,000 ppm for 30 minutes (Kim et al. 1998), 1,000 ppm for 8 hours (Rea et al. 1984), or up to 105 mg/kg/day in drinking water for 28 days (Hsieh et al. 1990b, 1991); decreased dopamine levels and rates of turnover in several areas of the nucleus caudate in the brain of rats exposed to 80 ppm toluene, 6 hours/day for 3 days (Fuxe et al. 1982); increased levels of dopamine and noradrenaline in several brain regions in rats exposed to 80–3,000 ppm, 6 hours/day for 3 days (Andersson et al. 1983b); decreased activities of aromatic acid decarboxylase, an enzyme involved in synthesis of neurotransmitters, in the brain stem of rats exposed to 250 or 1,000 ppm, 8 hours/day, 5 days/week for 4 weeks (Bjornaes and Naalsund 1988); significantly increased in dopamine levels, decreased levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylalanine (DOPA), and altered monoamine neurotransmitter synthesis (tyrosine and tryptophan hydroxylase enzyme activities) in rats exposed to 40 ppm toluene 104 hours/week for 16 weeks (Berenguer et al. 2003, 2004; Soulage et al. 2004); and significant localized changes in dopamine and noradrenaline neurotransmitter levels and utilization in 8-week-old adult male rats exposed to 80 ppm for 6 hours/day from PND 1 to 7, compared with control (von Euler et al. 1989b). Altered neurotransmitter levels have also been reported in several animal studies at concentrations modeling solvent abuse (>1,000 ppm) (Apawu et al. 2014; Alfaro-Rodriguez et al. 2011; Gerasimov et al. 2002c; Koga et al. 2007; O’Leary-Moore et al. 2007, 2009; Ono et al. 1999; Paez-Martinez et al. 2008; Tsuga and Honma 2000; Williams et al. 2005) and following toluene injection (Calderon-Guzman et al.
3. HEALTH EFFECTS

Based on *in vitro* and *in vivo* microdialysis studies, Riegel et al. (2007) suggested that observed increases in dopamine levels may result from direct stimulation of dopamine neurons in the ventral tegmental area, resulting in increased dopamine release into the nucleus accumbens of the mesolimbic system. Another *in vivo* microdialysis study reported dose-related decreases in extracellular acetylcholine levels in the striatum and hippocampus following intraperitoneal injections of 200–2,000 mg/kg, which peaked 2–3 hours post-injection (Honma and Suda 2004). However, acetylcholine levels in striatal and hippocampal homogenates were significantly increased, suggesting that decreased extracellular levels were due to decreased acetylcholine release from nerve terminals.

Another mechanistic hypothesis postulates that repeated exposure to toluene may cause neurological effects by changing the binding of neurotransmitters to membrane receptors. In support of this hypothesis, persistent changes in brain-tissue dopamine D2 receptor binding and increased serum prolactin levels were found in rats 17 days after exposure to 80 ppm toluene 6 hours/day, 5 days/week for 4 weeks (von Euler et al. 1993, 1994). It was speculated that the increase in serum prolactin level could be related to a possible interaction between toluene and the pituitary dopamine D2 receptor; this receptor normally inhibits the release of prolactin into serum. Correlated with these biochemical changes were a significantly increased locomotor activity (approximately 2-fold) in response to injections of apomorphine (a dopamine) and a significantly increased escape latency (indicating impaired spatial learning and memory) in a water maze task, both observed 14–17 days after the 4-week toluene exposure (von Euler et al. 1994). Whether or not this hypothesis is related to effects observed in occupationally exposed humans is uncertain; Svensson et al. (1992b) did not find changes in serum prolactin levels in toluene-exposed printing workers compared with controls. Additionally, in another animal study, no significant exposure-related changes in serum prolactin levels in rats were reported with 4-week exposures to concentrations up to 320 ppm (Hillefors-Berglund et al. 1995). There were also no changes in dopamine D3 receptor binding 4 weeks after cessation of a 4-week exposure to 80 ppm toluene (von Euler et al. 2000).

However, there is some evidence of changes in glutamate and GABA binding in male rats exposed by inhalation to toluene at concentrations of 50–1,000 ppm for 4 weeks or 500 ppm for 12 weeks (Bjornaes and Naalsund 1988) and binding to muscarinic acetylcholine receptors in male rats following exposure to ≥500 ppm for 6 hours (Tsuga and Honma 2000). Various alterations in receptor subunit levels were observed in the mesolimbic system of the rat brain following exposure to 8,000 ppm 30 minutes/day for 10 days, including increases GABA$_{A}$$\alpha$1, NR1, NR2, and GluR2/3 subunits in medial prefrontal cortex and decreased GABA$_{A}$$\alpha$1 and NR1 subunits in the substantia nigra (Williams et al. 2005).
Further evidence of alterations in neurotransmitter systems comes from injection studies. Following intraperitoneal injections of 250–750 mg/kg, rats showed dose-related increases in locomotor activity, motor incoordination, and memory impairment during neurobehavioral testing (Lo et al. 2009). Pretreatment with dopamine D1, D2, and D3 receptor antagonists (SCH23390, raclopride, nafadotride, respectively) prevented locomotor effects, and all behavioral alterations were prevented with pretreatment with d-serine, a co-agonist at the glycine binding site of NMDA receptors (Lo et al. 2009). Similarly, the NMDA co-agonist, sarcosine, was able to attenuate neurobehavioral alterations in rats following intraperitoneal injections of 250–750 mg/kg toluene (Chan et al. 2012) and the D2 antagonist remoxipride was able to attenuate locomotor effects in rats following intraperitoneal injections of 600–1,200 mg/kg toluene (Riegel and French 1999). Additionally, locomotor effects following an intraperitoneal injection of 600 mg/kg were significantly attenuated when neurotransmission in the mesolimbic nucleus accumbens was altered via 6-hydroxydopamine lesions (6-OHDA) or the mGlu2/3 receptor agonist LY379268 (Riegel et al. 2003). Observed increases in depressive-like behavior in the forced swim and tail suspension tests, 1 and 4 days following intraperitoneal injection of 500 mg/kg toluene, were prevented with administration of serotonin-reuptake inhibitors (fluoxetine and imipramine) (Yang et al. 2010). Decreased NMDA-mediated calcium signaling and NR2B subunits have been reported in cerebellar granule cells cultured from rat pups following daily intraperitoneal injections from PND 4 to 10 (Chen et al. 2004, 2005). Following daily intraperitoneal injections of toluene on PNDs 4–9 or 21–26, NMDA receptor-mediated excitatory postsynaptic currents (EPSCs) were enhanced following electrical stimulation, but decreased in response to exogenous NMDA in PND 30–38 hippocampal slices (Chen et al. 2011). However, paired-pulse facilitation of NMDA currents was only observed in rats exposed to toluene from PND 4 to 9 (Chen et al. 2011).

Significant decreases (28 or 47%) in rat brain GFAP induced by exposure to 1,000 ppm toluene, 6 hours/day for 3 or 7 days have been associated with increased serum levels of corticosterone (Little et al. 1998). The decreases in GFAP were observed in the thalamus and hippocampus, regions of the brain that are reported to be involved in controlling serum glucocorticoid levels and have high concentrations of glucocorticoid receptors, respectively (Little et al. 1998). Little et al. (1998) postulated that decreases in brain GFAP may be a consequence of toluene disruption of the hypothalamic-pituitary-adrenal axis and/or hormonal homeostasis, but noted that the available evidence is inadequate to firmly establish cause and effect. Decreased GFAP was also observed in neonatal rat brains following daily intraperitoneal injections of 750 mg/kg from PND 4 to 10 (Burry et al. 2003) and in cultured astrocyte precursor cells following in vitro exposure to toluene, suggesting that toluene exposure could disrupt early brain development (Yamaguchi et al. 2002). Additionally, in vitro toluene exposure inhibited proliferation of
3. HEALTH EFFECTS

primary rat cortical astrocyte cultures (Burry et al. 2003). The possible mechanistic connections of these observations to toluene-induced changes in neurobehavior are uncertain. In contrast, GFAP levels were significantly increased in the hippocampus, cerebellum, and spinal cord of male rats exposed to 1,500 ppm, 4 hours/day for 4–10 days (Gotohda et al. 2000a, 2000b) and in the hippocampus, cortex, and cerebellum of male rats exposed to 3,000 ppm paint thinner (66% toluene) 1 hour/day for 45 days (Baydas et al. 2003).

Numerous gene expression changes have been observed in brain tissues of rats and mice following acute or intermediate inhalation exposure or injection; however, current understanding is inadequate to determine the mechanistic significance of these findings. Genes demonstrating significantly altered expression levels are involved in synaptic transmission and plasticity (Ahmed et al. 2007; Hester et al. 2011, 2012), memory (Win-Shwe and Fujimaki 2012; Win-Shwe et al. 2007a, 2010b, 2010c), neurotrophic factors (Win-Shwe et al. 2010a; Gotohda et al. 2000b), and oxidative stress (Win-Shwe et al. 2010a). Results of these studies vary greatly, and indicate that gene expression changes are species-, strain-, dose-, duration-, and lifestage-dependent. A series of studies suggest that neurobehavior may be altered through neuroimmune effects, such as neuroinflammation, and that immune status may affect gene expression changes in brain neuroinflammation (Win-Shwe et al. 2010a, 2011, 2012a, 2012b). Epigenetic alterations (histone acetylation) in the dentate gyrus of rats exposed to 1,000–6,000 ppm for 30 minutes or 10 days (30 minutes, 2 times/day) (Huerta-Rivas et al. 2012) and in the nucleus accumbens and ventral tegmental area of rats exposed to 6,000 ppm for 10 30-minute session over 8 days (Sanchez-Serrano et al. 2011).

**Mechanisms of Hearing Loss.** There is evidence that hearing loss induced by inhalation exposure to toluene is produced by toluene itself and not by its metabolites. Phenobarbital pretreatment, which increases the rate of *in vivo* metabolism of toluene, prevented hearing loss in rats exposed to 1,500–2,000 ppm toluene, 8 hours/day for 7 days (Pryor et al. 1991), rats exposed to 1,700–2,000 ppm toluene, 6 hours/day, 5 days/week for 6 weeks (Campo et al. 2008), and rats exposed to a single gavage dose of 1,500 mg/kg (Campo et al. 2008). Inhibition of P450 metabolism by SKF525-A in guinea pigs resulted in altered auditory thresholds following exposure to 1,750 ppm toluene 6 hours/day, 5 days/week for 4 weeks; toluene administration alone did not change auditory thresholds (Waniusiow et al. 2009). Acivicin pretreatment, which inhibits γ-glutamyl transferase and the production of cysteine S-conjugates during toluene metabolism, did not alter hearing loss in rats exposed to 1,750 ppm toluene, 6 hours/day 5 days/week for 4 weeks, suggesting that toluene-induced hearing loss is not mediated by the cysteine S-conjugate metabolic pathway (Waniusiow et al. 2008).
Multiple studies in animals indicate that hearing loss observed with occupational toluene exposure may be due, in part, to direct damage to the OHCs of the cochlea that are responsible for amplifying incoming sound waves prior to signal transduction (Campo et al. 1997, 1998; Johnson and Canlon 1994; Lataye and Campo 1997; Lataye et al. 1999; Waniusiow et al. 2008). Phenobarbital pretreatment also reduced OHC loss in rats exposed to 1,700–2,000 ppm toluene, 6 hours/day, 5 days/week for 6 weeks, compared with toluene-treatment alone (Campo et al. 2008). Additionally, rats that were given large gavage doses of ethanol (4 g/kg/day) and daily inhalation exposure to toluene concentrations of 1,750 ppm, 6 hours/day, 5 days/week for 4 weeks showed significantly greater hearing loss (as measured by BAEP) and OHC loss in the ear than those exposed to toluene alone (Campo et al. 1998). Co-exposure to ethanol caused a significant decrease in hippuric acid urinary excretion rates compared with exposure to toluene alone, indicating that these large doses of ethanol inhibited the metabolism of toluene (Campo et al. 1998). Since exposure to ethanol alone in this study did not affect hearing or OHC loss in the ear, ethanol inhibition of toluene metabolism and subsequent potentiation of toluene-induced loss of hearing are consistent with the idea that toluene itself is responsible for these effects.

Mechanistic understanding at the molecular and cellular level is limited regarding how toluene exposure leads to a loss of OHC in the ear and the degree to which toluene effects on neural cell membranes may be involved. However, a series of recent papers propose that toluene modifies the response of protective acoustic reflexes to loud noises via anticholinergic effects, which could potentially result in increased noise-induced hearing loss (Campo et al. 2007; Lataye et al. 2007; Maguin et al. 2009; Venet et al. 2011). Following an injection of 116.2 nM toluene directly into the carotid artery supplying the tested cochlea, electrophysiological responses of OHCs (cochlear microphonic potentials; CMPs) to noise (65–95-dB SPL) were significantly increased in an intensity-dependent manner in anesthetized rats (Campo et al. 2007; Lataye et al. 2007). This suggests that toluene affects: (1) endocochlear potential or OHC membrane conductance; (2) how OHC stereocilia move; and/or (3) the inner- or middle-ear muscle reflex via alterations in the efferent pathway (preventing protective reflexive actions). The intensity-dependent increase suggests that the increased CMP amplitudes were due to altered inner-ear and/or middle ear acoustic reflexes (Lataye et al. 2007). Since acoustic reflexes can be stimulated in both ears following loud noises in one ear, further support for toluene-mediated alterations in acoustic reflexes comes from increased CMP amplitudes following both ipsilateral (same side) and contralateral (opposite side) noise stimulation (Campo et al. 2007). Additionally, toluene exposure did not alter CMPs in rats with severed middle ear muscles (Campo et al. 2007); however, CMPs were not altered from baseline following noise exposure prior to toluene injections, limiting the interpretation of these results. Since the auditory
3. HEALTH EFFECTS

Efferent system is a cholinergic descending pathway, and toluene has been shown to alter currents in nicotinic acetylcholine receptors (Bale et al. 2002, 2005) and muscarinic acetylcholine receptors (Tsuga et al. 1999; Wu et al. 2002), Campo et al. (2007) hypothesized that observed alterations in acoustic reflexes in middle ear muscles result from anticholinergic actions of toluene. In support, CMP responses following injections of antagonists of cholinergic receptors and antagonists of calcium-gated acetylcholine channels were of similar magnitude to responses to toluene (Lataye et al. 2007; Maguin et al. 2009). Another study examined noise-induced distortion product otoacoustic emissions (DPOAE) to evaluate the effect of toluene exposure on noise-induced suppression of cochlear responses (Venet et al. 2011). Similar to CMP responses, DPOAE amplitude suppression to ipsilateral and contralateral stimuli was decreased in rats injected with 116 nM toluene; however, no cochlear damage was observed (Venet et al. 2011). Additionally, a clear dose-response effect was not observed, as contralateral noise-induced suppression is increased in rats injected with 58 nM toluene, and no clear effects were observed at 58 nM toluene with ipsilateral stimuli or 87 nM toluene with either ipsilateral and contralateral stimuli (Venet et al. 2011).

Mechanisms of Vision Impairment. The molecular mechanism and pathogenesis of color vision impairment (dyschromatopsia) associated with occupational and intentional abusive exposure to toluene and other organic solvents are not clearly understood, but it has been postulated that toluene interference with dopaminergic mechanisms of retinal cells or toxic demyelination of optic nerve fibers may be involved (Muttray et al. 1997, 1999; Zavalic et al. 1998a, 1998b, 1998c). Alterations observed in VEPs may be mediated through alterations in glutamatergic receptors, as treatment with MK801 (a non-competitive antagonist of the NMDA receptor) prevents the reduction of VEP amplitude observed following acute exposure to 2,000 ppm toluene (Bale et al. 2007).

3.5.2.2 Mechanisms of Toxicity to Other Systems

Mechanistic studies in other systems are limited, but suggested mechanisms are similar to those observed for neurotoxicity, including altered membrane properties, apoptosis, oxidative stress, and gene expression alterations.

Altered Membrane Properties. As observed in nervous system cultures, altered membrane properties were reported following toluene exposure in Jurkat T cells, as evidenced by increased LDH and calcium leakage (McDermott et al. 2007).
3. HEALTH EFFECTS

**Apoptosis and Oxidative Stress.** As observed in nervous tissue, increased markers of oxidative stress have been observed in liver, kidney, and testes in rats following acute or intermediate-duration oral exposure to 650 mg/kg/day (Kamel and Shehata 2008). Additionally, increased apoptosis has been observed in the liver, but not kidney or testes, in rats following intermediate-duration oral exposure to 650 mg/kg/day (Kamel and Shehata 2008). Additional evidence for oxidative stress in reproductive organs include increased activities for glutathione peroxidase in ovaries of rats exposed to 500 ppm toluene for 4 hours/day, 5 days/week for 1 month (Burmistrov et al. 2001), attenuation of sperm parameter changes and testicular damage in rats exposed to 6,000 ppm toluene for 2 hours/day for 5 weeks following pre-treatment with antioxidant thymoquinone (Kanter 2011b), and increased 8-oxodG formation in testes along with decreased sperm counts and serum testosterone in male rats given daily intraperitoneal injections of 50 or 500 mg/kg for 10 days (Nakai et al. 2003). In another study, no significant changes in testicular or epididymal levels of several markers of oxidative stress were observed in rats exposed to 1,500 ppm, 4 hours/day for 7 days (Tokunaga et al. 2003).

An *in vitro* study in human leukemia cells reports significant increases in apoptosis and dose-related (but nonsignificant) increases in reactive oxygen species production (Sarma et al. 2011). In porcine proximal tubular cells (LLC-PK1), both apoptosis and lipid peroxidation were significantly increased following *in vitro* exposure to toluene (Al-Ghamdi et al. 2003, 2004).

**Gene Expression Changes in Tissues Other than the Brain.** Changes in mRNA levels for genes involved in oxidative stress thrombosis, vasoconstriction and inflammation were noted in rat cardiac tissue following single gavage doses of 1,000 mg/kg (Gordon et al. 2010). In a series of studies from a single laboratory, intermediate-duration inhalation exposures of normal or allergy-challenged (ovalbumin [OVA]-immunized and challenged) mice to toluene concentrations ranging from 5 to 90 ppm have been reported to produce non-monotonic dose-related changes in the mRNA levels for inflammatory cytokines, neurotrophins, neurotrophin receptors or other immune regulatory transcription factors in lung, BAL fluid, thymus, or spleen (Fujimaki et al. 2009b, 2010, 2011; Liu et al. 2010; Yamamoto et al. 2009; Win-Shwe et al. 2007a). As with the neurological gene expression studies, current understanding is inadequate to determine the mechanistic significance of these findings.

**3.5.2.3 Potential Mechanisms of Metabolite-mediated Toxicity**

The postulated arene oxide intermediates formed in the metabolic pathway from toluene to *ortho-* or *para*-cresol are highly reactive and expected to bind to cell proteins and RNA, thereby potentially leading
3. HEALTH EFFECTS

to cellular dysfunction and degeneration. Studies with human and rat liver microsomes and tissue slices showed that incubation with labeled toluene leads to incorporation of the label into microsomal proteins and RNA in an NADP-requiring reaction (Chapman et al. 1990). It does not appear likely, however, that this mechanism of action is the primary mode of toluene’s toxicity, especially at air concentrations below 100 ppm that are of occupational and public health concern, because:

1. the liver is expected to be the main site of toluene metabolism,
2. the pathway to the cresol isomers accounts for less than 1–5% of metabolized toluene (see Section 3.4.3),
3. results from animals studies and studies of toluene-exposed workers do not identify the liver as the most sensitive target organ (see Section 3.2.1), and
4. degenerative lesions in nervous tissues have not been detected by light microscopy in rats and mice exposed to concentrations as high as 1,200 ppm 6.5 hours/day, 5 days/week for up to 2 years (CIIT 1980; NTP 1990).

The available evidence, however, is not sufficient to discard the hypothesis that this mode of action (i.e., cellular degeneration caused by reactive metabolic intermediates) may play some role in toluene toxicity, especially with repeated high-level exposures such as those experienced by toluene abusers.

3.5.3 Animal-to-Human Extrapolations

Many laboratory animal species have been used to describe toluene toxicity, but the most commonly used species is the rat. As described in Section 3.4, the toxicokinetic data gathered from rat studies compare favorably with the information available from human studies. In addition, neurological effects observed in rats including changes in locomotor activity, changes in visual- and auditory-evoked brainstem potentials, hearing loss, and changes in brain chemistry appear to be related to critical neurological effects observed in humans after acute or repeated exposure to toluene including self-reported neurological symptoms, impaired performance in neurobehavioral tests, hearing loss, and color vision impairment. Given the availability of data for humans exposed by inhalation, MRLs for inhaled toluene are derived without extrapolating from the available animal toxic-effects data. In contrast, acute- and intermediate-duration MRLs for oral exposure to toluene are based on extrapolating effects in rats to humans (see Section 2.3 and Appendix A).
As discussed in Section 3.4.5, a number of PBPK models are available that describe the kinetics of toluene after inhalation exposure for humans (Benignus et al. 2006; Fisher et al. 1997; Jonsson and Johanson 2001; Sari-Minodier et al. 2009; Nong et al. 2006; Pierce et al. 1996, 1999; Tardif et al. 1995, 2002) and rats (DeJongh and Blaauboer 1996, 1997; Kenyon et al. 2008; Oshiro et al. 2011; Tardif et al. 1993; van Asperen et al. 2003). PBPK models to describe the kinetics of dermally applied aqueous solutions of toluene are also available for humans (Thrall et al. 2002a) and rats (Thrall and Woodstock 2002), but models to describe kinetics following oral exposure to toluene have not been developed.

Benignus et al. (2007) used available PBPK models for inhaled toluene in humans (Benignus et al. 2006) and rats (Kenyon et al. 2008) to examine the relative sensitivity of neurobehavioral end points in humans and rats acutely exposed to inhaled toluene. End-point-specific dose-response relationships were constructed relating brain concentrations (estimated with pertinent PBPK models) with the magnitude of effect (expressed as a logistic function where a value of 1 means that the end point has been maximally affected) from studies of toluene effects on neurobehavioral end points in humans and rats. A single human dose-response relationship was constructed from six studies of choice reaction times in toluene-exposed human subjects. This relationship was compared with relationships constructed from studies of four neurobehavioral end points in toluene-exposed rats: VEPs, signal detection accuracy, signal detection reaction time, and escape-avoidance correct response rate. The comparison showed that the relationships for human choice reaction time and rat VEP were close to overlapping, consistent with human and rat equivalence in sensitivity to these two types of neurobehavioral end points. The dose-response relationships for the other rat neurobehavioral end points were shifted to the right on the brain concentration x-axis and showed lower slopes in the following progression: rat signal detection reaction time, rat signal detection accuracy, and rat escape-avoidance correct response rate. Benignus et al. (2007) noted that the progression for lower toluene sensitivity in end points was correlated with a progression for more control on the behavior being measured.

Further development of a human PBPK model that includes partitioning of inhaled and ingested toluene to the brain and a similarly designed rat PBPK model may be useful in improving extrapolation from the oral exposure rat data in deriving oral MRLs for toluene.

3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS

Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals
3. HEALTH EFFECTS

with this type of activity are most commonly referred to as *endocrine disruptors*. However, appropriate terminology to describe such effects remains controversial. The terminology *endocrine disruptors*, initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to develop a screening program for “...certain substances [which] may have an effect produced by a naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning *endocrine disruptors*. In 1999, the National Academy of Sciences released a report that referred to these same types of chemicals as *hormonally active agents*. The terminology *endocrine modulators* has also been used to convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist in the natural environment. Examples of natural hormone mimics are the isoflavonoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are similar in structure and action to endogenous estrogen. Although the public health significance and descriptive terminology of substances capable of affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992).

Current data do not provide consistent evidence of endocrine disruption in toluene-exposed humans. Most case studies of chronic abusers of toluene and other solvents have not reported effects on endocrine organs, but there are reports of effects that may be associated with endocrine disruption in groups of toluene-exposed workers including delayed time to pregnancy among wives of men exposed to mixed organic solvents including toluene (Sallmen et al. 1998), increased incidence of spontaneous abortions in female toluene-exposed electronics workers (Ng et al. 1992b), and incidences of spontaneous abortion above population norms in other small groups of toluene-exposed female workers or wives of male workers (Lindbohm et al. 1992; Taskinen et al. 1989). However, small numbers and lack of adjustment for possible confounding factors in some of these studies precludes drawing definite conclusions.

***DRAFT FOR PUBLIC COMMENT***
Additionally, studies of blood levels of reproductive hormones in repeatedly exposed workers or acutely exposed human subjects have not provided strong and consistent evidence of exposure-related effects (Luderer et al. 1999; Svensson et al. 1992a, 1992b).

Similarly, evidence for endocrine effects in animals following acute- or intermediate-duration inhalation exposure to toluene is not consistent across studies and does not clearly identify toluene as an endocrine-disrupting chemical. Female rats exposed to 30 or 300 ppm, 6 hours/day, 5 days/week for 4 weeks showed a mild reduction in follicle size of the thyroid in one study (Poon et al. 1994). Additionally, increased adrenal weight and adrenocortical cell size, along with serum ACTH and corticosterone levels, were observed in in male rats exposed to 1,500 ppm 4 hours/day for 7 days (Gotohda et al. 2005). This exposure scenario was shown to cause, in companion studies, neuronal damage and an increase in glucocorticoid receptor in the hippocampus, suggesting a possible disruption in the neuroendocrine axis (Gotohda et al. 2000a, 2000b, 2002). However, results from several other studies in rats and mice found no histological evidence of toluene-induced changes in endocrine organs including the thyroid, adrenal glands, or pancreas following intermediate or chronic, oral, or inhalation exposure (API 1985; Roberts et al. 2003; NTP 1990; Von Oettingen et al. 1942) or dose-related changes in endocrine hormones (Andersson et al. 1980, 1983b).

There is limited evidence that exposure to toluene may damage the reproductive organs in animals, but available data do not support that toluene effects reproductive performance. Effects on male reproductive tissues have been observed in a few studies of animals exposed by inhalation to concentrations ≥2,000 ppm (e.g., reduced sperm count, motility, and quality; and altered reproductive organ weight and histology) (Kanter 2011b; Ono et al. 1996, 1999), but changes in sperm count and epididymus weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating (Ono et al. 1996). Increased relative testicular weights were reported in male mice exposed to 1,250 and 2,500 mg/kg/day by gavage for 13 weeks (NTP 1990). However, no effects on the weight of the prostate, testes, uterus, or ovaries were observed in rats and female mice exposed to 312–2,500 mg/kg/day (NTP 1990). Exposure of female rats to 3,000 ppm, 8 hours/day for 7 days produced abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries (Tap et al. 1996). However, no histopathological effects on the prostate, testes, uterus, or ovaries were observed in rats and female mice gavaged with 312–2,500 mg/kg/day or exposed to concentrations up to 2,500 ppm toluene for 6.5 hours/day for 14–15 weeks or up to 1,200 ppm for 6–6.5 hours/day for 2 years (CIIT 1980; NTP 1990). Studies in rats exposed repeatedly by inhalation to toluene, including a 2-generation reproductive toxicity study, have shown no evidence of adverse
3. HEALTH EFFECTS


There is evidence that toluene exposure can perturb the hypothalamic-pituitary axis in rats leading to persistent increases in serum levels of prolactin. Elevated prolactin levels were reported in rats after exposure to 80 ppm toluene 6 hours/day 5 days/week for 4 weeks (Von Euler et al. 1994) or 80–1,000 ppm 6 hours/day for 3 days (Andersson et al. 1983b). Von Euler et al. (1993, 1994) speculated that the increase in serum prolactin level could be related to a possible interaction between toluene and the pituitary dopamine D2 receptor which inhibits the release of prolactin into serum. However in other studies, no changes in prolactin levels were found in rats after exposure to 40–320 ppm 6 hours/day 5 days/week for 4 weeks (Hillefors-Berglund et al. 1995), 500 ppm toluene 6 hours/day for 3 days, or 1,000 ppm 6 hours/day for 5 days (Andersson et al. 1980). In addition, a study of toluene-exposed workers found no evidence for changed prolactin levels, compared with control subjects (Svensson et al. 1992a, 1992b).

No in vitro studies were located regarding endocrine disruption of toluene.

3.7 CHILDREN’S SUSCEPTIBILITY

This section discusses potential health effects from exposures during the period from conception to maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. Relevant animal and in vitro models are also discussed.

Children are not small adults. They differ from adults in their exposures and may differ in their susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less susceptible than adults to health effects, and the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are critical periods of structural and functional development during both prenatal and postnatal life, and a particular structure or function will be most sensitive to disruption during its critical period(s). Damage may not be evident until a later stage of development. There are often differences in pharmacokinetics and metabolism between children and adults. For example, absorption may be different in neonates because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, infants have a larger proportion of their bodies as extracellular water, and their brains and livers are proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964). The fetus/infant has an immature (developing) blood-brain barrier that past literature has often described as being leaky and poorly intact (Costa et al. 2004). However, current evidence suggests that the blood-brain barrier is anatomically and physically intact at this stage of development, and the restrictive intracellular junctions that exist at the blood-CNS interface are fully formed, intact, and functionally effective (Saunders et al. 2008, 2012).

However, during development of the blood-brain barrier, there are differences between fetuses/infants and adults which are toxicologically important. These differences mainly involve variations in physiological transport systems that form during development (Ek et al. 2012). These transport mechanisms (influx and efflux) play an important role in the movement of amino acids and other vital substances across the blood-brain barrier in the developing brain; these transport mechanisms are far more active in the developing brain than in the adult. Because many drugs or potential toxins may be transported into the brain using these same transport mechanisms—the developing brain may be rendered more vulnerable than the adult. Thus, concern regarding possible involvement of the blood-brain barrier with enhanced susceptibility of the developing brain to toxins is valid. It is important to note however, that this potential selective vulnerability of the developing brain is associated with essential normal physiological mechanisms; and not because of an absence or deficiency of anatomical/physical barrier mechanisms.

The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing; as it raises a very important toxicological question as to whether these mechanisms provide protection for the developing brain or do they render it more vulnerable to toxic injury. Each case of chemical exposure
should be assessed on a case-by-case basis. Research continues into the function and structure of the blood-brain barrier in early life (Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).

Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth and development, levels of particular enzymes may be higher or lower than those of adults, and sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the child more or less susceptible also depends on whether the relevant enzymes are involved in activation of the parent compound to its toxic form or in detoxification. There may also be differences in excretion, particularly in newborns who all have a low glomerular filtration rate and have not developed efficient tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). Children and adults may differ in their capacity to repair damage from chemical insults. Children also have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly relevant to cancer.

Certain characteristics of the developing human may increase exposure or susceptibility, whereas others may decrease susceptibility to the same chemical. For example, although infants breathe more air per kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their alveoli being less developed, which results in a disproportionately smaller surface area for alveolar absorption (NRC 1993).

Data from controlled-exposure studies of volunteers, studies of occupationally exposed humans, case reports of toluene abuse, and studies of animals after inhalation or oral exposure indicate that the nervous system is a critical target of toluene toxicity (see Chapter 2 and Sections 3.2 for more details). The effects of toluene have not been thoroughly studied in children, but the limited available data suggest that the nervous system is also a likely target of toluene toxicity in children. There are numerous reports of adolescents who repeatedly inhaled high levels (4,000–12,000 ppm) of toluene and developed persistent central nervous system dysfunction (e.g., Byrne et al. 1991; Devasthasan et al. 1984; King et al. 1981). Neurological effects reported following toluene inhalation exposure in young animals (neonatal-young adult) are similar to those reported in adults, including changed levels of brain neurotransmitters (O’Leary-Moore et al. 2009; von Euler et al. 1989b); high frequency hearing loss (Pryor and Rebert 1992; Pryor et al. 1984a); increased locomotor activity (Bowen et al. 2007; Samuel-Herter et al. 2013); impaired motor coordination (Samuel-Herter et al. 2013); and altered pain perception (Castilla-Serna et al. 1991).
Available information regarding age-related differences in toluene metabolism suggests that developing fetuses and children at very early stages of development may be more susceptible to toluene toxicity than adults, and that children past early neonatal periods may have the same capability as adults to dispose of toluene at low exposure levels. The capacity for metabolic detoxification of toluene is expected to be low in the developing human fetus because several CYP isozymes are either absent or expressed at very low levels (Leeder and Kearns 1997). However, rat studies indicate that levels of CYP isozymes involved in toluene metabolism are rapidly increased following birth and suggest that capabilities to carry out Phase I toluene metabolism at low exposure levels during neonatal periods may exceed those at sexual maturity and pregnancy (Nakajima et al. 1992b). CYP2E1, one of the principal CYP isozymes involved in the major toluene metabolic pathway (Nakajima et al. 1997; Tassaneeyakul et al. 1996), is expressed several hours after birth in humans and continues to increase during the first year of life (Vieira et al. 1996). Phase II enzymes involved in toluene metabolism (e.g., N-acetyl transferases, UDP-glucuronyl transferases, and sulfotransferases) also show changes during human neonatal development with adult activities present by 1–3 years of age (Leeder and Kearns 1997). There are other physiological differences between adults and children (e.g., children have higher brain mass per unit of body weight, higher cerebral blood flow per unit of brain weight, and higher breathing rates per unit of body weight: see Snodgrass [1992]), but their contributions to possible age-related differences in susceptibility to toluene toxicity are currently uncertain.

Results from animal studies indicating that younger animals may be more susceptible to toluene toxicity than adults are restricted to markedly lower LD_{50} values for 14-day-old rats compared with adult rat values (Kimura et al. 1971) and more severe high frequency hearing loss in young rats exposed to toluene compared with adult rats (Pryor et al. 1984a). The human brain grows rapidly for the first 2 years of life and continues more slowly until full brain cell numbers, complete myelination of subcortical white matter, and complete elaboration of dendrites and axons are attained at adulthood (Snodgrass 1992). It is unknown if the relatively long period of development of the human brain may make juvenile humans more susceptible to toluene toxicity than juvenile nonprimate animals.

Recent studies investigating age-related susceptibility to “binge” toluene exposure in rats do not clearly support increased susceptibility in young versus adult rats. Following 15- or 30-minute exposures to ~5,000 ppm toluene, increased locomotor activity, altered exploration, and impaired motor coordination and gait were observed in adolescent (1 month), young adult (2–3 months), adult (5–6 months) and older adult (10–12 months) rats, with no apparent age-related effects (Samuel-Herter et al. 2013). However, the duration to recover from toluene-induced motor impairments was significantly longer in adolescent and
young adults (Samuel-Herter et al. 2013). Following exposure to 0, 2,000, 4,000, or 8,000 ppm toluene for 20 minutes/day for 10 days, age- and sex-dependent increases in locomotion were observed in adolescent (PND 28), young adult (PND 44), and adult (PND 70) rats; however, adolescent rats were not identified as a susceptible group (Bowen et al. 2007). In the adolescent rats, increases were significant in females from all exposure groups and males from the 4,000 and 8,000 ppm groups during week 2 of exposure. In the young adult and adult rats, increases were significant in females from the 4,000 and 8,000 ppm groups and in males from the 8,000 ppm group during week 2 of exposure; these increases were significantly greater in magnitude than observed changes in adolescents from the same dose groups. Additionally, adult females and males from the 8,000 ppm group showed significantly increased locomotor behavior during week 1, from day 1 and 3, respectively. These results suggest that while effects may be observed at lower doses in adolescents, the effects may take longer to manifest and may be smaller in magnitude, compared with adults (Bowen et al. 2007). Another study evaluated potential differences in toluene-induced locomotor effects in adolescent (PND 28) and adult (PND 90) male rats exposed to 0, 8,000, or 16,000 ppm for 12 days using three different exposure patterns: standard (two 15-minute exposures separated by a 105-minute break), rapid (two 15-minute exposures separated by a 15-minute break), and paced (six 5-minute exposures separated by 25-minute breaks) (Batis et al. 2010). Locomotor activity was assessed during each exposure period and during a 30-minute “recovery” period immediately following the final toluene exposure each day. While locomotor activity was significantly altered in both exposure groups at both ages, subtle differences were noted. Adolescents displayed greater toluene-induced locomotor activity on the first day and generally greater increases in activity over all days than adults during toluene exposure; however, adults displayed greater toluene-induced locomotor activity than adolescent in the “recovery” period following exposure on the first and subsequent days. Age group differences were most pronounced in the paced “binge-like” exposure protocol. The subtle age-related effects described in these studies may be mediated by age-dependent neurochemical changes observed (O’Leary-Moore et al. 2009). Following acute, high-dose exposure to 8,000–12,000 ppm toluene, no significant changes were found in neurotransmitter, n-acetyl-aspartate (NAA), choline-containing compounds, creatine, glutamate, glutamine, GABA, or lactate levels in adolescent brains; however, decreased levels of choline and GABA in the frontal cortex and stratum, decreased glutamine and NAA levels in the frontal cortex, and a wide-ranging increase in lactate were observed in young adult brains (O’Leary-Moore et al. 2009).

Case reports of birth defects in solvent abusers suggest that high-level exposure to toluene during pregnancy can be toxic to the developing fetus (Arnold et al. 1994; Erramouspe et al. 1996; Goodwin 1988; Hersch 1988; Hersch et al. 1985; Lindemann 1991; Pearson et al. 1994). It is likely that the high
3. HEALTH EFFECTS

Exposure levels experienced by pregnant solvent abusers (4,000 to 12,000 ppm) overwhelm maternal mechanisms that protect the developing fetus from absorbed toluene at lower exposure levels. Experiments with pregnant mice demonstrated that 10-minute exposures to 2,000 ppm resulted in low uptake of toluene into fetal tissue and suggest that, at lower exposure levels, absorbed toluene is preferentially distributed to maternal adipose tissue before distribution to the developing fetus (Ghantous and Danielsson 1986). Following repeated inhalation exposure of pregnant rats to higher concentrations (8,000 or 12,000 ppm) for 15, 30, or 45 minutes twice daily from GD 8 to 20, amniotic fluid concentrations were ~<10% of concentrations in maternal blood samples, concentrations in fetal brain were similar to maternal blood concentrations, and concentrations in placenta were higher (Bowen et al. 2007). Concentrations of toluene in fetal brain were less than concentrations in maternal brain.

The results from animal studies indicate that toluene did not cause maternal or developmental toxic effects in animals at inhalation exposure levels <1,000 ppm administered for 6–7 hours/day during gestation (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997; Tsukahara et al. 2009; Win-Shwe et al. 2012a, 2012b; Yamamoto et al. 2009) or at oral exposure levels of 1,800–2,350 mg/kg/day during the period of organogenesis in two developmental screening studies (NIOSH 1983; Seidenberg et al. 1986). With higher inhalation exposure levels (≥1,000 ppm), predominant effects include retarded fetal growth and skeletal development and altered development of behavior in offspring, and were almost always accompanied by signs of maternal toxicity (API 1991, 1992; Bowen and Hannigan 2013; Bowen et al. 2005, 2009a; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Roberts et al. 2007; Jones and Balster 1997; Ono et al. 1995; Saillenfait et al. 2007; Thiel and Chahoud 1997). Other animal studies reported that continuous, 24-hour/day exposure during gestation caused maternal body weight depression and effects on fetuses including depressed body weight and delayed skeletal ossification at toluene concentrations as low as 133–399 ppm in rats, mice, and rabbits (Hudak and Ungvary 1978; Ungvary and Tatrai 1985). In a comprehensive developmental toxicity study in rats, a statistically significant increase in the incidence of dilated renal pelvis in the left kidney was observed in fetuses from dams exposed to 1,250 mg/kg/day on GDs 16–19 via gavage, compared with controls (Warner et al. 2008). No changes were observed in any other developmental end point. However, exposure of pregnant rats to gavage doses of 650 mg/kg/day toluene in corn oil on GDs 6–19 produced offspring with decreased body weights, delayed ossification, smaller brain volumes, decreased forebrain myelination per cell, and decreased cortical cell proliferation and migration (Gospe and Zhou 1998, 2000; Gospe et al. 1996).
Performance deficits in a few neurobehavioral tests were observed in one study in offspring of pregnant mouse dams exposed by inhalation to 2,000 ppm, but not 200 or 400 ppm, for 60 minutes 3 times/day on GDs 12–17 (Jones and Balster 1997). Performance deficits were not observed in offspring of pregnant rat dams exposed by inhalation to up to 2,000 ppm for 6 hours/day during gestation (Hougaard et al. 2003; Ono et al. 1995; Thiel and Chahoud 1997). Drinking water exposure during gestation and lactation at doses of 106 mg/kg/day resulted in changes in postweaning open-field locomotor activity in rat offspring (Kostas and Hotchin 1981).

In general, available information suggests that toluene is not a potent teratogenic agent with *in utero* exposure, but can retard fetal growth and skeletal development and adversely influence development of behavior of offspring at exposure levels above those that form the basis of the inhalation and oral MRLs for toluene.

Transfer of toluene to nursing infants from breast milk of currently exposed mothers is expected to be a possibility because of the lipophilicity of toluene and the relatively high lipid content of breast milk. Elimination kinetics data for nonpregnant or nonlactating humans and rats following toluene exposure, however, indicate that most absorbed toluene is rapidly eliminated from the body and that a much smaller portion (that which gets into adipose tissues) is slowly eliminated (Janisik et al. 2008; Leung and Paustenbach 1988; Lof et al. 1993; Nise et al. 1989; Pellizzari et al. 1992; Pierce et al. 1996, 1999, 2002; see Section 3.4.4). Thus, mobilization during pregnancy or lactation of stored toluene from preconception exposure does not appear to be a major concern.

Fisher et al. (1997) developed a human PBPK model that predicts transfer of toxicant via lactation from a mother to a nursing infant and used the model to estimate the amount of toluene an infant would ingest via milk if the mother was occupationally exposed to toluene at the ACGIH (1999) TLV (50 ppm) throughout a workday. The model predicted that such an infant would have a daily oral intake of 0.46 mg toluene/day. This value is below the U.S. EPA Health Advisory, 2.0 mg/day, for chronic ingestion of 1 L/day of toluene-contaminated water by a 10-kg child, a daily oral intake for a 10-kg child (8 mg/day) associated with the acute oral MRL for toluene (0.8 mg/kg/day), and a daily oral intake for a 10-kg child (2.0 mg/day) associated with the intermediate oral MRL for toluene (0.2 mg/kg/day). No human (or animal) studies were located regarding *in vivo* distribution of toluene into breast milk or elimination kinetics from breast milk, and the Fisher et al. (1997) PBPK model has not been validated with *in vivo* data.
3. HEALTH EFFECTS

3.8 BIOMARKERS OF EXPOSURE AND EFFECT

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).

A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several factors can confound the use and interpretation of biomarkers of exposure. The body burden of a substance may be the result of exposures from more than one source. The substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the body by the time samples can be taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to toluene are discussed in Section 3.8.1.

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an organism that, depending on magnitude, can be recognized as an established or potential health impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these markers are not often substance specific. They also may not be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by toluene are discussed in Section 3.8.2.

A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Toluene

In a number of field studies, correlations have been noted between workplace air toluene concentrations and toluene concentrations in blood or urine, or hippuric acid or ortho-cresol concentrations in urine of workers (see ACGIH 2001 and 2010 for reviews and citations of these studies). Other urinary biomarkers of exposure that have been examined include benzyl alcohol (Ikeda et al. 2008; Kawai et al. 2007), benzylmercapturic acid (Ikeda et al. 2008; Inoue et al. 2002, 2004, 2008; Maestri et al. 1997), and S-p-toluylmercapturic acid (Ikeda et al. 2008; Inoue et al. 2008; Angerer et al. 1998a). A preliminary study also examined toluene concentration in saliva as a possible biomarker of exposure, which showed a correlation coefficient with air concentrations of 0.77, compared with 0.93 for urinary toluene concentration (Ferrari et al. 2008).

Currently, ACGIH (2010, 2013) recommends using a combination of three biomarkers to assess exposure of workers to toluene: ortho-cresol and unchanged toluene levels in urine at the end of a workshift and toluene levels in blood immediately prior to the last shift of a workweek. The recommendation was made based on analyses of numerous field studies examining toluene blood concentrations and urinary concentrations of ortho-cresol and toluene in workers exposed to varying workplace air concentrations of toluene. Previously, the level of hippuric acid in urine at the end of a workshift was recommended as a biomarker of exposure, but this recommendation was withdrawn because background urinary hippuric acid from consumption of benzoate in foods and beverages is expected to mask contributions from workplace exposure to toluene, especially at concentrations below 50 ppm (ACGIH 2001, 2010). Results from studies comparing the effectiveness of various biomarkers at high (>50 ppm) and low (<10 ppm) air concentrations indicate that toluene concentrations in blood or urine are more accurate at low air concentration than urinary concentrations of examined metabolites (Ikeda et al. 2008; Inoue et al. 2008; Kawai et al. 2008; Lovreglio et al. 2010; Takeuchi et al. 2002; Ukai et al. 2007).

3.8.2 Biomarkers Used to Characterize Effects Caused by Toluene

There are no specific biomarkers used to characterize the effects from toluene exposure. Changes in the brain, which are detected through MRI or BAER techniques in combination with an exposure history, can be used to evaluate the degree of central nervous system damage experienced by a known toluene abuser. This approach does not appear to offer potential as a method of measuring the effects of short- or long-term, low-level exposures as are likely to occur with environmental releases. Micronuclei induction in buccal cells and/or peripheral lymphocytes have been suggested as biomarkers of effect for solvent...
exposure (Gonzalez-Yebra et al. 2009; Heuser et al. 2007; Pitarque et al. 2002); however, evidence for micronuclei induction following exposure to toluene or mixed solvents is inconsistent (Gonzalez-Yebra et al. 2009; Heuser et al. 2005, 2007; Moro et al. 2012; Nise et al. 1991; Pitarque et al. 2002) and induction of micronuclei in these cells is not expected to be only produced by solvents. Similarly, altered gene expression profiles in blood cells could potentially serve as biomarkers of effect, but human (Kim et al. 2011) and animal studies (Ahmed et al. 2007; Fujimaki et al. 2009a, 2009b, 2011; Hester et al. 2011, 2012; Kodavanti et al. 2011; Liu et al. 2010; Royland et al. 2012; Takeda et al. 2013; Win-Shwe et al. 2007a, 2010a, 2010b, 2010c, 2011; Yamamoto et al. 2009) have not identified concentration-related gene expression changes in blood, nervous, or immune tissue following toluene exposure. A detailed discussion of the effects of toluene exposure is included in Section 3.2.

3.9 INTERACTIONS WITH OTHER CHEMICALS

Alteration of toluene metabolism may influence toluene’s toxic effects because toluene metabolism predominately represents a detoxification process (see Section 3.5.2). Hypothetically, compounds that stimulate or inhibit metabolism of toluene may respectively decrease or increase toluene toxicity, although the possible exhalation of unmetabolized toluene represents an alternate dispositional pathway that may be utilized under conditions inhibiting mainstream toluene metabolism. Several metabolic interactions between toluene and other chemicals have been studied. The results present evidence that alteration of toluene metabolism may influence toluene toxicity and that toluene can influence the toxicity of other chemicals.

Phenobarbital pretreatment, which increases the rate of in vivo metabolism of toluene by inducing CYP isozymes, prevented hearing loss in rats exposed to 1,500–2,000 ppm toluene, 8 hours/day for 7 days (Pryor et al. 1991), rats exposed to 1,700–2,000 ppm toluene, 6 hours/day, 5 days/week for 6 weeks (Campo et al. 2008), and rats exposed to a single gavage dose of 1,500 mg/kg (Campo et al. 2008). Conversely, rats that were given large gavage doses of ethanol (4 g/kg/day) and daily inhalation exposure to toluene concentrations of 1,750 ppm, 6 hours/day, 5 days/week for 4 weeks showed significantly greater changes in auditory-evoked brainstem potentials and OHC loss in the ear than those exposed to toluene alone (Campo et al. 1998). Co-exposure to ethanol caused a significant decrease in hippuric acid urinary excretion rates compared with exposure to toluene alone, indicating that these large doses of ethanol inhibited the metabolism of toluene (Campo et al. 1998). Consistent with the idea that co-exposure to ethanol inhibits toluene metabolism are observations that ingestion of ethanol prolongs the presence of toluene in blood in humans (Imbriani and Ghittori 1997; Wallen et al. 1984) and rats (Romer***DRAFT FOR PUBLIC COMMENT***
3. HEALTH EFFECTS

et al. 1986). These results indicate that toluene-induced hearing loss is caused by toluene itself and not its metabolites, and that workers exposed to toluene who regularly drink alcohol may be at greater risk of developing toluene-related neurological problems than nondrinkers.

Concurrent chronic ethanol ingestion and acute toluene inhalation in rats was associated with a modest elevation in plasma AST and increases in relative liver weight and liver triglycerides (Howell et al. 1986). Toluene also antagonized the hypertriglyceridemia associated with chronic ethanol ingestion. This study suggests that combined ethanol and chronic occupational toluene exposure may have the potential to augment alcohol-induced fatty liver.

Benzene, xylene, and toluene are metabolized through cytochrome P-450 oxidation. Benzene is converted to phenol, hydroquinone, catechol, and phenyl mercapturic acid; xylene is converted to methyl hippuric acids, and toluene forms hippuric acid, \textit{ortho}-cresol, and \textit{para}-cresol. The excretion of metabolites was investigated in four groups of workers who were exposed in the workplace to benzene and toluene, to a mixture of both solvents, or to no solvents (Inoue et al. 1988). Analysis of the data on excretion of urinary metabolites indicated that simultaneous exposure to both benzene and toluene inhibited the microsomal metabolism of both compounds through the cytochrome P-450 system. Toluene had more of an inhibitory effect on benzene metabolism than benzene had on toluene metabolism. This observation was confirmed in rodent studies using 6-hour inhalation exposures to benzene, toluene, or a mixture of both compounds, with pharmacokinetic modeling of the exposure data (Purcell et al. 1990). Combinations of either 200 ppm toluene with 1,000 ppm benzene or 1,000 ppm toluene with 200 ppm benzene were tested. The fit of the actual closed chamber concentrations for the individual chemicals with the model results, suggests that the interaction of benzene and toluene are noncompetitive. The data from studies of the benzene-toluene interaction may indicate that workers exposed to mixtures of both solvents have a lower risk of benzene-induced leukopenia than workers exposed to benzene alone (Purcell et al. 1990). Exposure to 50 ppm benzene and 50 or 100 ppm toluene, 6 hours/day for 8 days (over 15 days) caused a significant induction of hepatic CYP 2E1, which did not occur with individual exposure to benzene or toluene (Wetmore et al. 2008). Additionally, rats exposed to 50 ppm benzene plus 100 ppm toluene (but not 50 ppm toluene) showed a significant increase in the number of micronucleated bone marrow cells and erythrocytes (~50–70%), compared with exposure to 50 ppm benzene alone (Bird et al. 2010; Wetmore et al. 2008). Micronuclei induction in erythrocytes following exposure to 50 ppm benzene plus 100 ppm toluene, 6 hours/day for 8 consecutive days was also significantly greater than exposure to 50 ppm benzene alone (~200%); however, it was ~70% less than micronuclei induction by 150 ppm benzene alone (Bird et al. 2010). Exposure to toluene alone at 50 or 100 ppm did not induce
micronuclei (Bird et al. 2010; Wetmore et al. 2008). Therefore, while these findings are suggestive that toluene enhances benzene toxicity, there is not clear evidence for the mechanism of joint toxic action.

Toluene and xylene are also often found together in mixtures such as paint thinners. Human exposure to low levels of both solvents (50 ppm xylene, 40 ppm toluene) did not modify the conversion of either substance to its urinary metabolites (Kawai et al. 1992b; Tardif et al. 1991). However, at higher concentrations (80 or 150 ppm xylene, 95 or 150 ppm toluene), the blood and exhaled air concentrations of both solvents were increased compared to the controls exposed to either solvent alone, indicating that metabolism of both solvents was decreased by the coexposure paradigm (Tardif et al. 1991, 1992).

Similarly, coexposure of toluene, methyl ethyl ketone and isopropyl alcohol at low concentrations in rats had no effect on the urinary excretion of hippuric acid, while high concentrations resulted in decreased levels of hippuric acid (Uaki et al. 1995). Tardif et al. (1993) reported that a linked PBPK model for toluene and xylene with a competitive inhibition metabolic term provided the best visual fit (compared with non- or competitive inhibition metabolic terms) to empirical data for air concentrations of toluene and xylene during 5-hour exposures of rats in a closed chamber to mixtures of toluene and xylene at several initial concentrations. Using an interactions-based biological hazard index, PBPK-based model predictions indicated that interactions between toluene, m-xylene, and ethylbenzene are not strictly additive (especially at higher concentrations levels); however, competitive inhibition is expected to be negligible at low individual solvent concentrations (e.g., 20 ppm) (Haddad et al. 1999).

Toluene and n-hexane, which are used together in some glues and paints, are neurotoxic chemicals that act by different modes at different sites. Toluene effects on the central nervous system are thought to be facilitated by toluene itself, whereas n-hexane affects the peripheral nervous system through the production of a toxic metabolite, 2,5-hexanedione (Ali and Tardif 1999). The initial metabolism of both compounds has been demonstrated to principally involve CYP isozymes including CYP2E1 and CYP2B6 (Ali and Tardif 1999). Under in vitro conditions with rat liver microsomes, a noncompetitive inhibition of each other’s metabolism was demonstrated (Perbellini et al. 1982). In studies comparing urinary excretion of metabolites in rats exposed to mixtures of toluene and n-hexane or to each solvent alone, co-exposure inhibited the urinary excretion of 2,5-hexanedione to a larger extent than the urinary excretion of toluene metabolites, hippuric acid, and ortho-cresol (Ali and Tardif 1999; Iwata et al. 1983; Perbellini et al. 1982). The results from these studies suggest that toluene is a more effective inhibitor of n-hexane metabolism than is n-hexane of toluene metabolism. However, in eight healthy male volunteers who were exposed to combinations of toluene and n-hexane via feeding tubes at rates of 1.5 or 4 mg/minutes and 0.3 or 1.0 mg/minutes, respectively, for 60 minutes, the high-dose of n-hexane significantly decreased

***DRAFT FOR PUBLIC COMMENT***
3. HEALTH EFFECTS

urinary hippuric acid excretion, but toluene exposure did not alter the urinary excretion of 2,5-hexanedione (Baelum et al. 1998). Co-exposure of rats to 1,000 ppm toluene and 1,000 ppm n-hexane (12 hours/day for 16 weeks) decreased toxic effects of n-hexane on the peripheral nervous system compared with exposure to 1,000 ppm n-hexane alone (Takeuchi et al. 1981). Another rat study found confirming results in that co-exposure to 1,200 ppm toluene and 4,000 ppm n-hexane (14 hours/day for 9 weeks) decreased n-hexane-induced effects on the peripheral nervous system compared with n-hexane alone, and had only slight effects on toluene-induced hearing loss and motor dysfunction compared with toluene alone (Pryor and Rebert 1992). Human and rat PBPK models have been developed to model the combined exposure and disposition of inhaled toluene and n-hexane (Ali and Tardif 1999; Yu et al. 1998). Model simulations predicted that co-exposure to n-hexane and toluene at constant concentrations corresponding to their occupational exposure limits (50 ppm) would lead to only a slight effect on the kinetics of their respective metabolism and disposition, but that the interaction could change with fluctuations in worker activity loads and workplace air concentrations (Ali and Tardif 1999; Yu et al. 1998). In support, n-hexane metabolism (as measured by end-of-shift free-2,5-hexanedione levels in urine) was not modified by co-exposure to toluene in workers exposed to various solvent mixtures in an adhesive tape factory at concentrations below occupational exposure limits, as determined by multiple regression analysis (Kawai et al. 2000).

McDermott et al. (2008) examined potential interactions of in vitro solvent exposure on LDH leakage, calcium levels, and glutathione redox status of human Jurkat T-cells. Nine binary mixtures of toluene, n-hexane, and methyl ethyl ketone (MEK) were evaluated, using three exposure levels per solvent based on concentration-response data for the individual solvents. The resulting data were analyzed using both isobolographic and Berenbaum’s combination index analysis to test for interaction. The findings indicated greater-than-additive interactions between toluene+n-hexane and toluene+MEK for both LDH leakage and glutathione redox status (GSH and GSSG levels, GSH/GSSG ratio). Greater-than-additive interactions were also observed between toluene+n-hexane for perturbations in calcium levels; however, less-than-additive interactions were observed between toluene+MEK at higher MEK concentrations (McDermott et al. 2008).

An individual's drug therapy can have an influence on toluene toxicity. Haloperidol (an antipsychotic) functions by blocking dopamine receptors in the brain. The combination of haloperidol with toluene exacerbates dopamine depletion in several areas of the brain, thus changing the pharmacodynamics of the haloperidol. Individuals who take haloperidol should be counseled by their physician if environmental or occupational exposure to toluene is possible (von Euler et al. 1988b).
Studies in humans and rats indicate that the common analgesics, acetaminophen and aspirin, may inhibit toluene metabolism and influence toluene toxicity. CYP2E1 is involved in the initial step of the principal metabolic pathway for toluene and acetaminophen, and represents a potential site for a competitive metabolic interaction. Aspirin and one of the principal downstream metabolites of toluene, benzoyl coenzyme A, are conjugated with glycine. When glycine pools are depleted by competition for glycine by aspirin metabolism, toluene metabolism may be inhibited. In volunteers exposed for 4 hours to 300 mg/m³ toluene (80 ppm) with or without doses (1,000 mg/70 kg=14.3 mg/kg) of acetaminophen (paracetamol) or acetyl salicylic acid (aspirin), co-exposures with these analgesics increased the concentration of toluene in the blood compared with exposure to toluene alone (Lof et al. 1990). Acetaminophen co-exposure also significantly increased the area under the blood concentration versus time curve and the apparent blood clearance of toluene, consistent with an inhibition of toluene metabolism. Co-exposure of rats for 10 days to higher oral doses of aspirin (acetyl salicylic acid: 100 mg/kg, twice daily) and inhalation exposure to toluene (1,000 ppm, 14 hours/day) caused a more severe loss of hearing (assessed 2–5 days or 4 months after cessation of exposure) compared with exposure to toluene alone (Johnson 1992). Treatment with aspirin alone at these doses did not cause hearing loss in the rats. These results are consistent with the hypothesis that high doses of aspirin may potentiate toluene effects on hearing by inhibiting toluene metabolism.

The benzoic acid metabolite of toluene is conjugated with glycine to produce hippuric acid. Toluene potentiation of developmentally toxic effects in rats from high doses of aspirin has been attributed to metabolic competition for glycine pools (Ungvary et al. 1983). Pregnant rats that were given 250 mg/kg acetyl salicylic acid on GD 12 and exposed to toluene at concentrations of 1,000, 2,000, or 3,600 mg/m³ (265, 531, or 956 ppm) on GDs 10–13 showed maternal effects (decreased food consumption and body weight gain and increased relative liver weight) and fetal effects (retardation of skeletal development and increased incidence of fetal malformations) that were more severe than those observed in rats exposed to 250 mg/kg acetyl salicylic acid alone. The effects were comparable in severity to those observed in rats exposed to 500 mg/kg salicylic acid alone. In this study, no maternal or fetal effects were observed in a group of rats exposed to 956 ppm toluene on GDs 10–13 without coexposure to acetyl salicylic acid. The maternal and fetal effects of co-exposure to acetyl salicylic acid and toluene were diminished to the severity of the 250-mg/kg acetyl salicylic acid alone level when the administration of the acetyl salicylic acid dose was preceded by two hours with a gavage dose of 5,000 mg/kg glycine.
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE

A susceptible population will exhibit a different or enhanced response to toluene than will most persons exposed to the same level of toluene in the environment. Reasons may include genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters result in reduced detoxification or excretion of toluene, or compromised function of organs affected by toluene. Populations who are at greater risk due to their unusually high exposure to toluene are discussed in Section 6.7, Populations with Potentially High Exposures.

One of the primary target organs of toluene is the central nervous system, and it is generally thought to be due at least in part, to reversible interactions between toluene (the parent compound, not its metabolite) and the lipid or protein components of nervous system membranes (mechanisms of toxicity are discussed in detail in Section 3.5.2). The main pathway of toluene metabolism leads to the production of hippuric acid, which is excreted in the urine. The predominant first step in human and rat metabolism of toluene is catalyzed primarily by the CYP 2E1 isozyme. Later steps in this pathway involve the enzymes alcohol dehydrogenase, aldehyde dehydrogenase, acyl-coenzyme A synthase, and acyl-coenzyme A:amino acid N-acyl transferase (metabolism is discussed in detail in Section 3.4.3).

Environmental or genetic factors that decrease the capacity for metabolic detoxification of toluene are likely to increase susceptibility. This is supported by experiments in which inhibiting or enhancing toluene metabolism via CYP 2E1 respectively enhanced or inhibited toluene-induced hearing loss in rats (Campo et al. 1998, 2008; Pryor et al. 1991). Chronic consumers of alcohol, and users of any medication that interfered with toluene metabolism, would be likely to have an increased risk for this reason. Differences in the relative efficiency of enzymes found in ethnic populations may also lead to differences in toluene susceptibility. For instance, ethnic variations in the occurrence of CYP isozymes, alcohol dehydrogenase, and aldehyde dehydrogenase are known to exist (Kawamoto et al. 1995, 1996; Kim et al. 1997). For example, DNA damage in leukocytes from Brazilian shoe workers exposed to solvent-based adhesive (mainly toluene, air concentration not reported) was significantly increased in workers with polymorphisms in the glutathione S-transferase P1 gene (GSTP1; Ile/Val or Val/Val) compared with GSTP1 Ile/Ile workers (Heuser et al. 2007). Similarly, increased micronuclei in Bulgarian shoe workers were only observed in workers with a null glutathione S-transferase M1 (GSTM1) genotype, although sister chromatid exchanges were not associated with GSTM1 genotype (or solvent-exposure) (Pitarque et al. 2002). Additionally, in healthy South Korean males living in Ulsan City, which houses several industrial complexes, urinary 8-OHdG and hippuric acid levels were only significantly correlated in
3. HEALTH EFFECTS

individuals with $GSTM1$-null, glutathione S-transferase T1($GSTT1$)-null, and aldehyde dehydrogenase 2 ($ALDH2$) *2/*2 genotypes (Kim et al. 2011).

Studies in various inbred and outbred mouse strains indicate that genetic differences can lead to differential susceptibility to various chemicals, particularly drugs of abuse (Crabbe et al. 1994, 2005). Bowen et al. (2010) investigated the effects of acute toluene exposure on locomotor behavior in four genetically divergent strains of mice, Balb/CBYJ, C57BL/6J, DBA/2J, and Swiss Webster. During a 30-minute exposure to 100, 2,000, 8,000, or 10,000 ppm toluene, all strains showed a qualitatively biphasic increase in locomotor activity, compared with pre-exposure activity levels, which is consistent with reports of initial increases in locomotion at lower concentrations followed by a decrease in activity at concentrations of 3,000–10,000 ppm (Bowen and Balster 1998; Conti et al. 2012; Kim et al. 1998; Lopez-Rubalcava and Cruz 2000). However, while increased activity was observed in all exposure groups for the inbred Balb/CBYJ, C57BL/6J, and DBA/2J mice, activity was not significantly increased in outbred Swiss Webster mice until ≥2,000 ppm. Furthermore, when the mice were exposed to a 2,000-ppm toluene challenge, following exposure to 8,000 ppm for 30 minutes/day for 14 days, DBA/2J mice showed the greatest sensitization to toluene-induced locomotor effects among the four strains. Bowen et al. (2010) concluded that genetic differences must account for the differential sensitivity to the effects of toluene exposure, and suggested that inter-strain variations in the dopaminergic system may underlie the observed differences.

Nutritional status may also affect susceptibility to toluene. Liver metabolism of toluene in rats fasted for 1 day was significantly increased compared with rats that had been fed (Nakajima and Sato 1979). However, long-term malnutrition may increase susceptibility to the developmental effects of toluene. Skeletal development in the fetuses of rats that were malnourished throughout pregnancy and injected with 1.2 g/kg/day toluene was retarded to a significantly greater extent than in the fetuses of well-nourished dams injected with toluene (da Silva et al. 1990).

Individuals with pre-existing medical conditions may also be more susceptible to the effects of toluene. Individuals with pre-existing defects in heart rhythm may have a greater risk than healthy individuals for experiencing tachycardia or cardiac fibrillation following exposure to high levels of toluene. The presence of toluene in the air reduces the concentration of oxygen and can lead to hypoxia when exposure concentrations are high. Thus, individuals with asthma or other respiratory difficulties may be at increased risk with exposure to high atmospheric concentrations of toluene. Genetic predisposition for hearing loss may increase the risk for toluene-induced ototoxicity (Johnson 1992; Li et al. 1992).
Both children and aging adults could potentially have increased susceptibility to toluene exposure. Children’s susceptibility is discussed in Section 3.7. No studies investigating toluene exposure in aging humans were located. A limited number of oral exposure studies in rats did not identify a clear pattern for age-related susceptibility for toluene-induced changes in locomotor activity, oxidative stress markers, cardiac biomarkers, or gene expression changes (Gordon et al. 2010; Kodavanti et al. 2011; MacPhail et al. 2012; Royland et al. 2012).

3. METHODS FOR REDUCING TOXIC EFFECTS

This section will describe clinical practice and research concerning methods for reducing toxic effects of exposure to toluene. However, because some of the treatments discussed may be experimental and unproven, this section should not be used as a guide for treatment of exposures to toluene. When specific exposures have occurred, poison control centers and medical toxicologists should be consulted for medical advice. The following texts provide specific information about treatment following exposures to toluene:


3.11.1 Reducing Peak Absorption Following Exposure

The absorption of toluene is rapid and virtually complete following acute inhalation and oral exposures. Toluene appeared in the blood of 10 human subjects within 10–15 minutes of exposure to 78 ppm toluene in the air, signifying rapid absorption through the lungs. When exposure occurs by the oral route, uptake into the blood is expected to be slightly slower due to the time needed for transit to the small intestines. Since toluene is absorbed across the lipid matrix of the cell membrane (Alcorn et al. 1991) some absorption can occur from the mouth and stomach. However, most of the toluene will be absorbed through the intestines due to large exposed surface area of the villi and microvilli. Other factors that will influence uptake from the gastrointestinal tract are lipid content of the gastrointestinal contents and the magnitude of the toluene exposure. Absorption of inhaled toluene is increased by exercise and so a
reduction of physical activity during exposure is likely to reduce absorption (Bushnell et al. 2007; Nadeau et al. 2006; Rahill et al. 1996). However, there is no effective way to reduce peak absorption following inhalation exposure. Emesis is contraindicated in cases of toluene ingestion due to the risk of aspiration. The use of activated charcoal and lavage may help to reduce oral exposure and rapid rinsing of the skin with water or washing with soap and water will reduce the opportunity for dermal absorption. If the eyes are affected, proper rinsing procedures should be followed.

### 3.11.2 Reducing Body Burden

The total body burden of toluene is reduced by measures that increase the rate of metabolism and excretion. Oxygen therapy and positive-pressure ventilation have been used as emergency treatments following episodes of toluene abuse (Graham 1990). This procedure promotes the loss of unmetabolized toluene from the lungs.

Increased fluid consumption, which increases the rate of urine production and excretion, will help to decrease the toluene body burden since toluene metabolites are water soluble and excreted in the urine. In cases where kidney function has been impaired, renal dialysis has been used to remove toluene metabolites from the body (Graham 1990).

### 3.11.3 Interfering with the Mechanism of Action for Toxic Effects

In cases where toluene has caused cardiac arrhythmias, antiarrhythmic medications have been used to control the heart beat (Graham 1990). No other medical practices for ameliorating the toxic effects of toluene were identified in the available literature. When toluene exposures are unavoidable, as in the workplace, avoidance of alcohol or medications that may inhibit metabolic disposition of toluene is another measure that can be taken to reduce health risks from exposure.

### 3.12 ADEQUACY OF THE DATABASE

Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of toluene is available. Where adequate information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of toluene.
The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that, if met, would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

### 3.12.1 Existing Information on Health Effects of Toluene

The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to toluene are summarized in Figure 3-5. The purpose of this figure is to illustrate the existing information concerning the health effects of toluene. Each dot in the figure indicates that one or more studies provide information associated with that particular effect. The dot does not necessarily imply anything about the quality of the study or studies, nor should missing information in this figure be interpreted as a “data need”. A data need, as defined in ATSDR’s *Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles* (Agency for Toxic Substances and Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from the scientific literature.

As shown in Figure 3-5, there is a considerable body of data on the health effects of toluene in humans following acute, intermediate, and chronic inhalation exposures. It appears that clinical effects of high concentrations on the major target organ, the central nervous system, have been well characterized. However, many of the available reports lack quantitative information on exposure levels and there is still much that must be learned about the ultra-structural molecular level of toxicity. There are some oral, but essentially no dermal, data available; however, these are not primary routes by which humans are exposed to toluene. Figure 3-5 also shows that considerable animal toxicity data for inhalation exposure are available. However, there are limited oral and dermal data from animal studies.

### 3.12.2 Identification of Data Needs

**Acute-Duration Exposure.** The acute effects of toluene exposure in humans have been well-studied, and identify the nervous system as a critical acute toxicity target of toluene, with subtle neurological effects at exposures >40 ppm in healthy individuals and as low as 15 ppm in clinically sensitive
3. HEALTH EFFECTS

Figure 3-5. Existing Information on Health Effects of Toluene

- **Inhalation**
  - Death Acute Intermediate Chronic Immunologic/Lymphoretic Neurologic Reproductive Developmental Genotoxic Cancer
  - Human
  - Animal

- **Oral**
  - Death Acute Intermediate Chronic Immunologic/Lymphoretic Neurologic Reproductive Developmental Genotoxic Cancer
  - Human
  - Animal

- **Dermal**
  - Death Acute Intermediate Chronic Immunologic/Lymphoretic Neurologic Reproductive Developmental Genotoxic Cancer
  - Human
  - Animal

● Existing Studies

***DRAFT FOR PUBLIC COMMENT***
individuals (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1991; Gamberale and Hultengren 1972; Little et al. 1999; Orbaek et al. 1998; Osterberg et al. 2000, 2003; Rahill et al. 1996; von Oettingen et al. 1942). Supporting data for neurological effects as a critical acute effect are provided by studies of animals after inhalation exposure that consistently report altered locomotor activity at exposure levels ≥500 ppm and cognitive deficits at concentrations as low as 125 ppm (Arito et al. 1988; Boyes et al. 2007; Bowen and Balster 1998; Bowen et al. 2010; Bruckner and Peterson 1981a, 1981b; Bushnell et al. 1985; Conti et al. 2012; Cruz et al. 2001; Ghosh et al. 1989, 1990; Hinman 1987; Hogie et al. 2009; Huerta-Rivas et al. 2012; Johnson 1992; Johnson et al. 1988; Kishi et al. 1988; Li et al. 1992; Little et al. 1998; Lopez-Rubalcava and Cruz 2000; McWilliams et al. 2000; Mullin and Krivanek 1982; Paez-Martinez et al. 2003; Rebert et al. 1989b; Takeuchi and Hisanaga 1977; Taylor and Evans 1985; Tomaszycki et al. 2013; Wood and Colotla 1990; Wood et al. 1983), as well as numerous additional studies in animals following exposure to “binge-like” levels (1,000–12,000 ppm) modeling human solvent abuse (Apawu et al. 2014; Bale et al. 2007; Batis et al. 2010; Beckley et al. 2013; Beyer et al. 2001; Bowen et al. 2007; Bushnell et al. 2007; Gerasimov et al. 2002c; Gmaz et al. 2012; Gotohda et al. 2000a, 2000b, 2002, 2007; Lammers et al. 2005b; O’Leary-Moore et al. 2007; Oshiro et al. 2007; Paez-Marinez et al. 2008; Pascual and Bustamante 2010; Perit et al. 2012; Riegel and French 2002; Samuel-Herter et al. 2013; Schiffer et al. 2006; Williams et al. 2005). Further support is provided by acute oral exposure studies examining neurological effects in animals (Burns et al. 1994; Dyer et al. 1988; Gordon et al. 2007, 2010; Mehta et al. 1998). It is unlikely that additional standard acute-duration exposure studies in animals would provide new key information on the toxicity of toluene, but special studies that involve a range of exposure levels (including low levels) and employ sensitive, behavioral, ultrastructural, and biochemical measurements may be useful—especially if findings are correlated with observed neurobehavioral alterations. Data for the dermal exposure route are limited; however, this is not a primary route of human exposure. Sufficient data for the oral and inhalation routes were available to derive an acute inhalation MRL based on minimally adverse neurological effects in volunteers with multiple chemical sensitivity exposed to 15 ppm for 20 minutes (Little et al. 1999) and an acute oral MRL based on changes in FEPs observed in mice exposed to 250 mg/kg toluene (Dyer et al. 1988).

**Intermediate-Duration Exposure.** The database is lacking studies on intermediate-duration exposure in humans. Several studies are available on repeated-dose exposure of animals to toluene after inhalation exposure. Similar to acute exposure studies, animal studies report neurological effects following intermediate-duration inhalation exposure at concentrations ranging from 100 to 2,500 ppm (API 1997; Arito et al. 1988; Campo et al. 1997; Kyrklund et al. 1987; McWilliams et al. 2000; NTP 1990; Pryor et al. 1984b; von Oettingen et al. 1942; Wiaderna and Tomas 2002; Wood and Cox 1995).
However, no observed adverse effect levels for intermediate, low-level inhalation exposure in air have not been thoroughly investigated. Determination of these values would be valuable in evaluating the human health risk, and could potentially be used to derive an intermediate-duration MRL for inhalation exposures. Adequate oral intermediate-duration exposure studies have been conducted in rats and mice (Hsieh et al. 1989, 1990a, 1991; NTP 1990), and sufficient data were available to derive an intermediate-duration oral MRL based on toluene-induced immune depression observed at 84–105 mg/kg/day (Hsieh et al. 1989, 1990a, 1991). Neurobehavioral alterations following intermediate-duration oral toluene exposure were limited to increased open-field activity in young mice following pre- and postnatal exposure to 106 mg/kg/day toluene (Kostas and Otchin 1981). Intermediate-duration studies designed to assess neurobehavioral alterations and/or mechanisms of neurotoxicity following oral exposure to toluene may be useful in evaluating human health risk, and could potentially serve as a basis for the deriving the intermediate-duration oral MRL. Studies following dermal exposure are lacking; however, this is not a primary route by which humans are exposed to toluene.


Neurological alterations are also critical effects reported following occupational exposure. Self-reported neurological symptoms and reduced ability in tests of cognitive and neuromuscular function have been reported in humans occupationally exposed to average concentrations as low as 40–150 ppm (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Murata et al. 1993; Nordling Nilson et al. 2010; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1987). Studies of occupationally exposed workers also indicate that chronic exposure to average concentrations as low as 50–130 ppm can damage hearing and color vision presumably involving, at least in part, effects on neurological components of these systems (Abbate et al. 1993; Morata et al. 1997; Vrca et al. 1995, 1996, 1997a, 1997b; Zavalic et al. 1998a, 1988b, 1988c). Sufficient data for the inhalation route were available to derive a chronic MRL based on a lack of adverse effects in subjective neurological symptoms,
performance on psychomotor tasks, color vision, and hearing in groups of German photogravure printers occupationally exposed to toluene (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002).

The chronic effects of toluene have not been investigated in humans or animals following oral or dermal exposures, and the carcinogenic potential has not been studied following dermal exposure; however, these are not considered major routes of toluene exposure.

**Genotoxicity.** Available studies do not clearly identify toluene as a genotoxic agent. Findings from human occupational exposure studies to predominantly toluene are inconsistent, and studies are limited by lack of reporting of historical exposure levels and small cohort sizes (Bauchinger et al. 1982; Forni et al. 1971; Hammer 2002; Hammer et al. 1998; Maki-Paakkenen et al. 1980; Nise et al. 1991; Pelclova et al. 1990; Schmid et al. 1985). *In vivo* animal studies are limited, and findings are also inconsistent (API 1981; Dobrokhotov and Enikeev 1997; Liang et al. 1983; Martinez-Alfaro et al. 2010; Plappert et al. 1994; Wetmore et al. 2008). *In vitro* studies in bacteria and animal cells were almost exclusively negative (Bos et al. 1981; Connor et al. 1985; Fluck et al. 1976; Gerner-Smidt and Friedrich 1978; Nakamura et al. 1987; Nestmann et al. 1980; NTP 1990; Zarani et al. 1999) with the exception of toluene-induced DNA damage in human HL-60 cells (Sarma et al. 2011). To evaluate the potential of toluene to cause chromosomal damage, additional well-designed *in vivo* studies using test material of known purity may be valuable. These tests would aid in determining whether toluene itself has clastogenic potential or whether the positive results that have been reported are due to impurities in the test material (animal studies) or concurrent/previous exposure to other chemicals (human studies) (Bauchinger et al. 1982; Dobrokhotov and Enikeev 1997; Hammer 2002; Hammer et al. 1998; Liang et al. 1983; Nise et al. 1991; Pelclova et al. 1990; Schmid et al. 1985). Because it is believed that toluene toxicity may be mediated, at least in part, through a highly reactive and short-lived arene oxide intermediate, which interacts with cellular proteins and RNA (Chapman et al. 1990), further studies of this interaction may provide useful information.

**Reproductive Toxicity.** In general, available results from studies of toluene-exposed workers and animals suggest that toluene is not a potent reproductive toxicant. There are a few reports that women occupationally exposed to toluene, or wives of men similarly exposed, have an increased risk of spontaneous abortions (Lindbohm et al. 1992; Ng et al. 1992b; Taskinen et al. 1989) or decreased fecundity (Plenge-Böenig and Karmaus 1999), but a causal relationship is not established by these studies due to small sample sizes evaluated, inability to define accurate exposure levels, failure to account for
potentially important confounding variables, and difficulty in validating self-reported data. In addition, one study reported that toluene-exposed male workers showed decreasing plasma levels of the LH, FSH, and testosterone levels with increasing concentrations of toluene (8–<111 ppm) (Svensson et al. 1992a, 1992b). Effects on male reproductive tissues have been observed in a few studies of animals exposed by inhalation to concentrations ≥2,000 ppm (e.g., reduced sperm count, motility, and quality, and altered reproductive organ weight and histology) (Kanter 2011b; Ono et al. 1996, 1999), but changes in sperm count and epididymus weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating (Ono et al. 1996). A single study reported abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles in the ovaries of female rats following a 7-day exposure to 3,000 ppm (Tap et al. 1996), but no histological evidence of structural damage to the reproductive organs was noted in rats and mice exposed orally for intermediate durations or by inhalation for intermediate or chronic durations (NTP 1990). No evidence for impaired reproductive performance or alterations in pregnancy outcomes was found in the majority of animal assays at exposure levels as high as 12,000 ppm (inhalation) or 2,350 mg/kg/day (oral) (API 1978, 1991; Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b; Courtney et al. 1986; Dalgaard et al. 2001; Gospe and Zhou 2000; Hass et al. 1999; Hougaard et al. 2003; Jones and Balster 1997; Klimisch et al. 1992; Ladefoged et al. 2004; NIOSH 1983; Ono et al. 1995, 1996; Roberts et al. 2007; Saillenfait et al. 2007; Seidenberg et al. 1986; Thiel and Chahoud 1997) (including a 2-generation study of rats exposed to up to 2,000 ppm, 6 hours/day [API 1985; Roberts et al. 2003]). However, continuous exposure of pregnant rabbits to 267 ppm during days 7–20 of pregnancy produced maternal toxicity (decreased weight gain) and abortions in 4/8 does (Ungvary and Tatrai 1985) and exposure to 5,000 ppm 6 hour/day during days 6–15 of pregnancy resulted in increased post-implantation loss and complete fetal resorption in 6/9 rats (API 1992). Additional studies of reproductive end points in groups of occupationally exposed workers may be useful in discerning the possible reproductive hazards of toluene in the workplace if large enough groups of workers are examined, exposure levels can be accurately monitored, and confounding variables are accounted for or minimalized. Another 2-generation reproductive study in another animal species (e.g., rabbits) may also help to decrease uncertainty in defining no-effect levels for reproductive effects from toluene.

**Developmental Toxicity.** Published reports of birth defects described in children born to women who abused toluene or other organic solvents during pregnancy suggest that high-level exposure to toluene during pregnancy can be toxic to the developing fetus (Arnold and Wilkins-Haug 1990; Arnold et al. 1994; Erramouspe et al. 1996; Goodwin 1988; Hersh 1988; Hersh et al. 1985; Lindemann 1991; Pearson et al. 1994; Wilkins-Haug and Gabow 1991a). Studies of developmentally toxic effects in
3. HEALTH EFFECTS

children of women exposed during pregnancy to much lower concentrations are restricted to a small study of 14 Finnish women exposed to mixed solvents, suggesting that solvent exposure may increase risk for central nervous system anomalies and neural tube closure defects (Holmberg 1979). The available human data do not establish causality between low-level or occupational exposure to toluene and birth defects, because of the small sample size and the mixed solvent exposure experienced by the subjects in the Holmberg (1979) study and the lack of other studies of possible birth defects in children of women exposed to toluene in the workplace. Additional studies of developmental end points in offspring of mothers exposed to toluene in the workplace may help to clarify the potential for human health risk.

Results from several inhalation exposure studies of animals indicate that exposure to levels of toluene that begin to produce maternal toxicity can cause fetal effects, including reduced fetal survival and retardation of growth and skeletal development (API 1991, 1992; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Hudak and Ungvary 1978; Jones and Balster 1997; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997; Ungvary and Tatrai 1985). No-effect levels in animals for toluene effects on standard developmental end points range from about 133 ppm for a 24 hour/day exposure protocol (Ungvary and Tatrai 1985) to 133–2,000 ppm with 3–6-hour/day protocols (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). In animal studies of oral exposure during gestation, no developmental effects were observed in pregnant mice exposed to oral doses of 1,800 or 2,350 mg/kg/day in two developmental screening studies (NIOSH 1983; Seidenberg et al. 1986), but a statistically significant increase in the incidence of dilated renal pelvis in the left kidney was observed in fetuses from dams exposed to 1,250 mg/kg on GDs 16–19 via gavage in a comprehensive developmental toxicity study in rats (Warner et al. 2008). Exposure of pregnant rats to gavage doses of 650 mg/kg/day produced offspring with decreased body weights, delayed ossification, smaller brain volumes, and decreased forebrain myelination per cell compared with controls (Gospe and Zhou 1998, 2000; Gospe et al. 1996).

Results from studies of neurobehavioral end points in rats following in utero exposure to toluene suggest that maternal exposure to airborne concentrations modeling solvent abuse (8,000–16,000 ppm, 15–30 minutes/day) can impair behavioral development of rat offspring (Bowen and Hannigan 2013; Bowen et al. 2005, 2009a). At lower exposure levels (≤2,000 ppm), maternal exposure for 6 hours/day did not result in altered offspring behavior in rats (Hougaard et al. 2003; Ono et al. 1995; Thiel and Chahoud 1997); however, maternal exposure to 2,000 ppm for 60 minutes 3 times/day can lead to impaired behavioral development of mouse offspring (Jones and Balster 1997). Drinking water exposure during
gestation and lactation at doses of 106 mg/kg/day changes postweaning open-field locomotor activity in rat offspring (Kostas and Hotchin 1981).

Additional studies of sensitive neurological end points, including neurobehavioral end points, in offspring of toluene-exposed pregnant animals may better determine no-effect levels for toluene effects on neurodevelopment. Inhalation exposure studies are likely to be of more relevance to human exposures of concern than oral exposure studies. Developmental effects have not been investigated following dermal exposure; however, this is not a primary route of human exposure.

**Immunotoxicity.** Human studies of immunological end points in toluene-exposed subjects do not identify consistent or strong evidence for toluene effects on immune system end points such as counts of blood lymphocytes or levels of blood immunoglobulins (Little et al. 1999; Pelclova et al. 1990; Stengel et al. 1998; Yin et al. 1987). In animal studies, evidence for toluene effects on the immune system following inhalation exposure are limited to the finding of decreased resistance to mortality from respiratory infection by *S. zooepidemicus* in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm (Aranyi et al. 1985). However, animal data using the oral route of exposure provide some evidence of impaired immune function following intermediate-duration toluene exposure (Hsieh et al. 1989, 1990a, 1991), and these effects were used to derive an MRL of 0.2 mg/kg/day for intermediate-duration oral exposure toluene. Accordingly, oral and inhalation studies in animals designed to clarify the effect of toluene on the immune system, particularly on lymphocyte production and function, antibodies, and interferons, may help determine if toluene was involved in the effects on immunity observed in occupationally exposed workers. Additional studies of the impact of toluene on disease resistance, building on the work of Aranyi et al. (1985), may also be valuable.

3. HEALTH EFFECTS

1987; Hogie et al. 2009; Huerta-Rivas et al. 2012; Johnson 1992; Johnson et al. 1988; Kishi et al. 1988; Li et al. 1992; Little et al. 1998; Lopez-Rubalcava and Cruz 2000; McWilliams et al. 2000; Mullin and Krivanek 1982; Paez-Martinez et al. 2003; Rebert et al. 1989b; Takeuchi and Hisanaga 1977; Taylor and Evans 1985; Tomaszycki et al. 2013; Wood and Colotla 1990; Wood et al. 1983). Available data clearly indicate that the central nervous system is a target, but the molecular mechanisms of toxicity have yet to be elucidated with certainty. Dose-response relationships for central nervous system effects in humans and animals (rats and mice) have been established, but more information concerning the reversibility of effects (especially when exposure is chronic) may be useful. The effects of toluene on neurobehavioral function were used to derive an MRL of 2 ppm for acute inhalation exposure (based on a study by Little et al. 1999) and a chronic-duration MRL of 1 ppm (based on a series of studies by Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002).

The neurological effects of toluene via the oral route have not been extensively investigated, but the available data support the inhalation data in identifying the nervous system as a critical target of toluene toxicity following acute exposure. An acute MRL of 0.8 mg/kg/day was developed based on a change in FEP waveforms in rats exposed to a single dose of toluene (Dyer et al. 1988). Neurobehavioral changes following intermediate-duration oral toluene exposure were limited to increased open-field activity in young mice following pre- and postnatal exposure to 106 mg/kg/day toluene (Kostas and Otchin 1981). Intermediate-duration studies designed to assess neurobehavioral alterations and/or mechanisms of neurotoxicity following oral exposure to toluene may be useful in evaluating human health risk, and could potentially serve as a basis for the deriving the intermediate-duration oral MRL (which is currently based on immune depression). No data on dermal exposure are available, but this is not the primary route of human exposure.

**Epidemiological and Human Dosimetry Studies.** Additional studies of neurological and reproductive end points in groups of toluene-exposed workers may decrease uncertainty in the chronic MRL and may help determine if toluene represents a reproductive health hazard in humans at low exposure levels. These studies will be most useful if groups of workers can be identified whose exposure to other chemicals in the workplace is minimal, if adjustments for lifestyle confounding factors can be made, and if personal air monitoring data are available. Earlier reports of increased risk of spontaneous abortions (Lindbohm et al. 1992; Ng et al. 1992b; Taskinen et al. 1989) and altered plasma levels of male sexual hormones (Svensson et al. 1992a, 1992b) in groups of toluene-exposed workers await confirmation from further research.
Biomarkers of Exposure and Effect.

**Exposure.** Toluene and its metabolites are easily detected in the blood and urine (DeRosa et al. 1985; Hjelm et al. 1988; Kono et al. 1985; Lof et al. 1990; Ogata et al. 1970). However, many toluene metabolites are also produced by other naturally occurring or xenobiotic materials and, thus, are not specific for toluene. Results from studies comparing the effectiveness of various biomarkers at high (>50 ppm) and low (<10 ppm) air concentrations indicate that toluene concentrations in blood or urine are more accurate at low air concentration than urinary concentrations of examined metabolites (Ikeda et al. 2008; Inoue et al. 2008; Kawai et al. 2008; Lovreglio et al. 2010; Takeuchi et al. 2002; Ukai et al. 2007). Currently, ACGIH (2013, 2010) recommends using a combination of three biomarkers to assess exposure of workers to toluene: ortho-cresol and unchanged toluene levels in urine at the end of a workshift and toluene levels in blood immediately prior to the last shift of a workweek.

Other urinary biomarkers of exposure that have been examined include benzyl alcohol (Ikeda et al. 2008; Kawai et al. 2007), benzylmercapturic acid (Ikeda et al. 2008; Inoue et al. 2002, 2004, 2008; Maestri et al. 1997), and S-p-toluylmercapturic acid (Angerer et al. 1998a; Ikeda et al. 2008; Inoue et al. 2008). A preliminary study also examined toluene concentration in saliva as a possible biomarker of exposure, which showed a correlation coefficient with air concentrations of 0.77, compared with 0.93 for urinary toluene concentration (Ferrari et al. 2008). Additional studies may help determine whether these are reliable biomarkers of exposure that can improve the accuracy of monitoring workers’ exposure to toluene.

**Effect.** There are no suitable biomarkers of effect except for changes in the brain found in chronic solvent abusers with obvious neurological dysfunction (Filley et al. 1990; Rosenberg et al. 1988a). Additional information on the mechanism of neurotoxicity may suggest a useful biomarker of either exposure or effect. However, at this time, there is little to suggest that such biomarkers are present for anything other than the abuse paradigm.

**Absorption, Distribution, Metabolism, and Excretion.** The absorption, distribution, metabolism, and excretion of toluene in humans and animals following inhalation exposure are well characterized (Ameno et al. 1992; Andersen et al. 1983; Angerer 1979; Angerer et al. 1998a; Baelum et al. 1987, 1993; Benignus et al. 1981; Benoit et al. 1985; Bergman 1983; Bray et al. 1949; Bushnell et al. 2007; Campo et al. 1999; Carlsson 1982; Carlsson and Ljungquist 1982; Chand and Clausen 1982;
3. HEALTH EFFECTS


Limited data are available on the quantitative absorption and excretion of toluene by the oral and dermal routes. Absorption of orally administered toluene has also been observed in rats, but oral absorption rates appear to be slower than pulmonary absorption (Pyykko et al. 1977; Sullivan and Conolly 1988). Studies of humans and animals indicate that dermal absorption of toluene is slow (Aitio et al. 1984; Dutkiewicz and Ty ras 1968; Thrall and Wood stock 2002; Thrall et al. 2002), but can be significant (Aitio et al. 1984; Monster et al. 1993; Morgan et al. 1991; Sato and Nakajima 1978). Additional studies of dermal uptake of toluene from solution may help to further quantify exposure by this pathway.

PBPK models are available that describe the kinetics of toluene after inhalation exposure for humans (Benignus et al. 2006; Fisher et al. 1997; Jonsson and Johanson 2001; Sari-Minodier et al. 2009; Nong et al. 2006; Pierce et al. 1996, 1999; Tardif et al. 1995, 2002) and rats (DeJongh and Blaurocker 1996, 1997; Kenyon et al. 2008; Oshiro et al. 2011; Tardif et al. 1993; van Asperen et al. 2003). PBPK models to describe the kinetics of dermally applied aqueous solutions of toluene are also available for humans (Thrall et al. 2002) and rats (Thrall and Woodstock 2002), but models to describe kinetics following oral exposure to toluene have not been developed. Further development of a human PBPK model that includes partitioning of inhaled and ingested toluene to the brain and a similarly designed rat PBPK model may be useful in improving extrapolation from the oral exposure rat data and in comparing model-based predictions of human effect levels based on neurological effects in inhalationally-exposed rats with observed effect levels in humans exposed to airborne toluene. Additional studies of the appearance and elimination kinetics of toluene in breast milk may help to validate the human PBPK model developed by Fisher et al. (1997) to estimate transfer of toluene to a nursing infant. It is unlikely that such studies would be done with volunteers, but studies of nursing animals may provide pertinent information if a similar rat PBPK model was developed.

**Comparative Toxicokinetics.** Available data suggest that there are species, age, gender, and strain differences in the metabolism of toluene (Chapman et al. 1990; Inoue et al. 1984, 1986; Nakajima et al.
1992b). Further evaluation of these differences, and comparison of metabolic patterns in humans with those of animals, may help determine the most appropriate species and strain of animal to use in evaluating the risk of human exposure to toluene. Additional evaluation of human variability in disposition of toluene is also warranted.

**Methods for Reducing Toxic Effects.** Oxygen therapy and positive pressure ventilation have been used to reduce the toluene body burden (Graham 1990). Washing of toluene from exposed body surfaces is beneficial. Other than these general guidelines, there is very little information available on methods of mitigating the toxic effects of toluene. Additional data on the outcome of emergency response procedures would be beneficial. Studies of the benefit of diet, ethanol absence, and controlled exposure to prescription or nonprescription drugs on blood levels of toluene and its metabolites could provide information that would be helpful in understanding the impact of these factors on the risks from occupational exposure.

**Children’s Susceptibility.** Data needs relating to both prenatal and childhood exposures, and developmental effects expressed either prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above.

The effects of toluene have not been thoroughly studied in children or immature animals, but the effects observed in juvenile toluene abusers (Byrne et al. 1991; Devasthasan et al. 1984; King et al. 1981) and immature animals exposed to toluene (Bowen et al. 2007; Castilla-Serna et al. 1991; O’Leary-Moore et al. 2009; Pryor and Rebert 1992; Pryor et al. 1984a; Samuel-Herter et al. 2013; von Euler et al. 1989b) are consistent with effects observed in adults. Information regarding age-related differences in toluene metabolism suggests that developing fetuses and children at very early stages of development may be more susceptible to toluene toxicity than adults due to lower capabilities to metabolically detoxify toluene, but, by 1–3 years of age, adult capabilities may be attained (Leeder and Kearns 1997; Nakajima et al. 1992b, 1997; Tassaneeyakul et al. 1996; Vieira et al. 1996). An oral lethality study in rats (Kimura et al. 1971) and a study of toluene-induced hearing loss in young rats (Pryor et al. 1984a) provide the only health effect data suggesting that immature animals may be more susceptible than adult animals. Age-series inhalation studies do not provide consistent evidence of increased neurobehavioral or neurochemical alterations in juvenile or young adult rats, compared with adult rats (Batis et al. 2010; Bowen et al. 2007; O’Leary-Moore et al. 2009; Samuel-Herter et al. 2013). Additional research on the development of metabolic capabilities in newborn and very young children may lead to better understanding of the susceptibility of children to toluene toxicity.
Studies with pregnant mice suggest that distribution of inhaled toluene to fetal tissue is limited due to maternal metabolic detoxification and preferential distribution of nonmetabolized toluene to maternal adipose tissue (Ghantous and Danielsson 1986). Data needs relating to both prenatal and childhood exposures, and developmental effects expressed either prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above.

Transfer of toluene to infants from breast milk of nursing mothers who are concurrently exposed to toluene in the workplace is expected to be a possibility and a concern (see Section 3.7). As discussed in the Absorption, Distribution, Metabolism, and Excretion subsection above, additional studies of the kinetics of elimination of toluene from nursing animals may provide pertinent information to better predict the degree to which toluene may be transferred in breast milk from a toluene-exposed working mother to her nursing infant. Monitoring studies of toluene in breast milk in groups of toluene-exposed lactating women may also provide some pertinent information.

Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: Exposures of Children.

### 3.12.3 Ongoing Studies

Nine ongoing research efforts have been identified that may provide data related to the toxic actions of toluene (RePORTER 2014). These projects are summarized in Table 3-7.

**Human studies:** Dr. Anneclaire De Roos of Drexel University is conducting metanalysis of 13 case-control studies to determine if exposure to solvents, including trichloroethylene, perchloroethyylene, benzene, toluene, and xylene, is a risk factor for multiple myeloma. In a collaborative study between the American University of Beirut and the Oregon Health and Science University, Dr. Iman Nuwayhid is evaluating the neurotoxic effects of solvents (mainly methyl ethyl ketone and toluene) in working male children (ages 10–17 years) from North Lebanon using neurobehavioral testing and functional MRI over a 3-year period. Dr. Wynne Schiffer of the University of Minnesota is conducting a study on functional and structural changes in the adolescent brain following solvent abuse.

**Animal studies:** Dr. Jacob Thomas Beckley of the Medical University of South Carolina is evaluating short- and long-term effects of acute toluene exposure on neuroplasticity, and Dr. Matthew Tracy of
Virginia Commonwealth University is evaluating neurobehavioral changes associated with toluene exposure in mice.

Toxicokinetic studies: Dr. Wayne L. Backes of Louisiana State University Medical Center is continuing his efforts to better characterize the P450 monoxygenase system.

Mechanistic studies: Dr. Keith Shelton of Virginia Commonwealth University is investigating the neuropharmacological mechanisms of action of toluene (and other intentionally solvents) in mice, focusing on the GABAA receptor positive modulatory effects of toluene. Dr. John Woodward of the Medical University of South Carolina is also investigating the neuropharmacological mechanisms of action of toluene, specifically in the glutamatergic system.

Dr. Toni Shippenberg at the National Institute on Drug Abuse is evaluating neurobiological changes (e.g., neurotransmitter changes) in rat brains following alcohol and inhalant abuse; however, current efforts appear to be focused on ethanol abuse.
## Table 3-7. Ongoing Research for Toluene

<table>
<thead>
<tr>
<th>Investigator</th>
<th>Affiliation</th>
<th>Research description</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Backes, W</td>
<td>Louisiana State University Medical Center, New Orleans, Louisiana</td>
<td>Toxicological significance of alkylbenzene metabolism</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>Beckley, JT</td>
<td>Medical University of South Carolina, Charleston, South Carolina</td>
<td>Neuroplasticity associated with acute toluene inhalation</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>De Roos, AJ</td>
<td>Drexel University, Philadelphia, Pennsylvania</td>
<td>Multiple myeloma consortium study of occupational exposures and family history</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>Nuwayhid, IA</td>
<td>American University of Beirut, Lebanon</td>
<td>Neurotoxic effects of solvents on working children</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>Schiffer, WK</td>
<td>University of Minnesota, Minneapolis, Minnesota</td>
<td>Imaging the causes and consequences of adolescent inhalant abuse</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>Shelton, KL</td>
<td>Virginia Commonwealth University, Richmond, Virginia</td>
<td>Discriminative stimulus effects of abused inhalants</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>Shippenberg, T</td>
<td>National Institute on Drug Abuse</td>
<td>Neurobiology of alcohol and inhalant abuse</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>Tracy, M</td>
<td>Virginia Commonwealth University, Richmond, Virginia</td>
<td>Acute and chronic effects of inhalants in intracranial-self-stimulation (ICSS)</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>Woodward, JJ</td>
<td>Medical University of South Carolina, Charleston, South Carolina</td>
<td>Neural actions of toluene</td>
<td>National Institute on Drug Abuse</td>
</tr>
</tbody>
</table>

Source: RePORTER 2014
4. CHEMICAL AND PHYSICAL INFORMATION

4.1 CHEMICAL IDENTITY

Information regarding the chemical identity of toluene is located in Table 4-1.

4.2 PHYSICAL AND CHEMICAL PROPERTIES

Information regarding the physical and chemical properties of toluene is located in Table 4-2.
**Table 4-1. Chemical Identity of Toluene**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical name</td>
<td>Toluene</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>Synonym(s)</td>
<td>Methylbenzene; phenylmethane; benzene, methyl-; toluol; methylbenzol</td>
<td>Haynes et al. 2013; HSDB 2010</td>
</tr>
<tr>
<td>Registered trade name(s)</td>
<td>Methacide; Antisal 1A</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C₇H₈</td>
<td>Haynes et al. 2013; HSDB 2010</td>
</tr>
<tr>
<td>Chemical structure</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>Haynes et al. 2013; HSDB 2010</td>
</tr>
<tr>
<td>Identification numbers:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAS registry</td>
<td>108-88-3</td>
<td>Haynes et al. 2013</td>
</tr>
<tr>
<td>NIOSH RTECS</td>
<td>XS52500000</td>
<td>RTECS 2014</td>
</tr>
<tr>
<td>EPA hazardous waste</td>
<td>U220</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>OHM/TADS</td>
<td>7216928</td>
<td>NFPA 1994</td>
</tr>
<tr>
<td>DOT/UN/NA/IMCO shipping</td>
<td>UN 1294</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>IMCO</td>
<td>3.2</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>HSDB</td>
<td>131</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>NCI</td>
<td>CO7272</td>
<td>HSDB 2010</td>
</tr>
</tbody>
</table>

CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; NFPA = National Fire Protection Association; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; RTECS = Registry of Toxic Effects of Chemical Substances
### Table 4-2. Physical and Chemical Properties of Toluene

<table>
<thead>
<tr>
<th>Property</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>92.13</td>
<td>Fabri et al. 2012</td>
</tr>
<tr>
<td>Color</td>
<td>Colorless</td>
<td>Haynes et al. 2013</td>
</tr>
<tr>
<td>Physical state</td>
<td>Liquid</td>
<td>Haynes et al. 2013</td>
</tr>
<tr>
<td>Melting point</td>
<td>-94.991°C</td>
<td>Fabri et al. 2012</td>
</tr>
<tr>
<td>Boiling point</td>
<td>110.625°C</td>
<td>Fabri et al. 2012</td>
</tr>
<tr>
<td>Density:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>at 20°C</td>
<td>0.8631 g/cm³</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>Vapor density</td>
<td>3.1 (air=1)</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>Odor</td>
<td>Sweet, pungent, benzene-like odor</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>Odor threshold:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>0.024–0.17 mg/L</td>
<td>WHO 2004</td>
</tr>
<tr>
<td>Air</td>
<td>2.14 ppm (8 mg/m³)</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>Solubility:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water at 25°C</td>
<td>526 mg/L</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td>Organic solvent(s)</td>
<td>Miscible with alcohol, chloroform,</td>
<td>HSDB 2010</td>
</tr>
<tr>
<td></td>
<td>ether, acetone, glacial acetic acid,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and carbon disulfide</td>
<td></td>
</tr>
</tbody>
</table>

**Partition coefficients:**

- Log $K_{ow}$: 2.73              
  HSDB 2010
- Log $K_{oc}$: 1.57–2.25         
  HSDB 2010

**Vapor pressure at 25°C:** 28.4 mm Hg  
HSDB 2010

**Henry's law constant:** 6.64x10⁻³ atm·m³/mol  
HSDB 2010

**Autoignition temperature:** 480°C (896°F)  
HSDB 2010

**Flashpoint:** 4°C (40°F, closed cup); 16°C (open cup)  
HSDB 2010

**Flammability limits:** 1.1–7.1%  
HSDB 2010

**Conversion factors ppm (v/v) to mg/m³ in air (20°C):** 1 ppm=3.76 mg/m³  
HSDB 2010

**Explosive limits:** 1.27% lower limit  
Fabri et al. 2012; HSDB 2010

$v/v =$ volume for volume
This page is intentionally blank.
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

5.1 PRODUCTION

Table 5-1 lists the facilities in each state that manufacture or process toluene, the intended use, and the range of maximum amounts of toluene that are stored on site. There are currently 2,234 facilities that produce, process, or use toluene in the United States. The data listed in Table 5-1 are derived from the Toxics Release Inventory (TRI12 2014). Only certain types of facilities were required to report. Therefore, this is not an exhaustive list.

Toluene is produced from the catalytic reforming of refinery streams, with part of the catalytic reformate converted to benzene-toluene-ethylbenzene-xylene (BTEX). Approximately 15% of the toluene produced is separated out of pyrolysis gasoline during the manufacture of ethylene and propylene, ~4% is from separation of coal tar, and ~1% is recovered as a byproduct of styrene manufacture. However, while the largest concentrations of toluene are recovered from catalytic reformate or pyrolysis gasoline, most of the toluene produced is unrecovered (Ozokwelu 2006).

Toluene is widely used and is produced by a large number of domestic chemical and petroleum companies. The 18 companies that currently produce or supply toluene in the United States are: Alon USA Energy, Inc.; BASF FINA Petrochemicals LP, BP America, Inc.; CITGO Petroleum Corporation; ConocoPhilips; The Dow Chemical Company; Equistar Chemical, LP; ExxonMobil Chemical Company; Flint Hills Resources LP; Frontier El Dorado Refining Company; Houston Refining LP; HOVENSA, LLC; Husky Energy Inc.; Marathon Petroleum Company LLC; Shell Chemical LP; Sunoco, Inc.; Total Petrochemicals USA, Inc.; and Valero Energy Corporation (SRI 2010).

5.2 IMPORT/EXPORT

U.S. general imports of toluene in 2012 were estimated at 430 million pounds (195,000 metric tons) (USITC 2013b). Exports during the same year were estimated at 670 million pounds (300,000 metric tons) (USITC 2013a).

5.3 USE

All nonisolated toluene is used in a BTEX mixture added to gasoline to improve octane ratings. Nearly half of the isolated toluene is used to produce benzene from hydrodealkylation processes. Twenty percent
## Table 5-1. Facilities that Produce, Process, or Use Toluene

<table>
<thead>
<tr>
<th>State</th>
<th>Number of facilities</th>
<th>Minimum amount on site in pounds</th>
<th>Maximum amount on site in pounds</th>
<th>Activities and uses&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>AK</td>
<td>8</td>
<td>10,000</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13</td>
</tr>
<tr>
<td>AL</td>
<td>43</td>
<td>1,000</td>
<td>99,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>AR</td>
<td>17</td>
<td>0</td>
<td>49,999,999</td>
<td>1, 2, 3, 5, 6, 7, 9, 10, 11, 12, 14</td>
</tr>
<tr>
<td>AZ</td>
<td>19</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 5, 7, 8, 9, 10, 11, 12</td>
</tr>
<tr>
<td>CA</td>
<td>110</td>
<td>0</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>CO</td>
<td>24</td>
<td>0</td>
<td>499,999,999</td>
<td>1, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13</td>
</tr>
<tr>
<td>CT</td>
<td>26</td>
<td>100</td>
<td>9,999,999</td>
<td>2, 3, 5, 7, 9, 10, 11, 12</td>
</tr>
<tr>
<td>DE</td>
<td>7</td>
<td>1,000</td>
<td>499,999,999</td>
<td>1, 2, 3, 7, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>FL</td>
<td>49</td>
<td>1,000</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 14</td>
</tr>
<tr>
<td>GA</td>
<td>56</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12</td>
</tr>
<tr>
<td>GU</td>
<td>2</td>
<td>1,000</td>
<td>9,999,999</td>
<td>7, 9</td>
</tr>
<tr>
<td>HI</td>
<td>9</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 14</td>
</tr>
<tr>
<td>IA</td>
<td>46</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>ID</td>
<td>3</td>
<td>10,000</td>
<td>9,999,999</td>
<td>2, 4, 7, 9</td>
</tr>
<tr>
<td>IL</td>
<td>123</td>
<td>100</td>
<td>99,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>IN</td>
<td>106</td>
<td>0</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>KS</td>
<td>39</td>
<td>0</td>
<td>10,000,000,000</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14</td>
</tr>
<tr>
<td>KY</td>
<td>48</td>
<td>1,000</td>
<td>99,999,999</td>
<td>1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>LA</td>
<td>93</td>
<td>0</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>MA</td>
<td>52</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 2, 4, 5, 7, 8, 9, 10, 11, 12</td>
</tr>
<tr>
<td>MD</td>
<td>16</td>
<td>1,000</td>
<td>9,999,999</td>
<td>2, 4, 7, 9, 10, 11, 12</td>
</tr>
<tr>
<td>ME</td>
<td>6</td>
<td>0</td>
<td>49,999,999</td>
<td>2, 3, 4, 7, 9, 12</td>
</tr>
<tr>
<td>MI</td>
<td>99</td>
<td>0</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>MN</td>
<td>34</td>
<td>1,000</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>MO</td>
<td>52</td>
<td>1,000</td>
<td>499,999,999</td>
<td>1, 5, 7, 8, 9, 10, 11, 12, 14</td>
</tr>
<tr>
<td>MP</td>
<td>2</td>
<td>100</td>
<td>9,999,999</td>
<td>2, 7, 9</td>
</tr>
<tr>
<td>MS</td>
<td>32</td>
<td>100</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>MT</td>
<td>6</td>
<td>10,000</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14</td>
</tr>
<tr>
<td>NC</td>
<td>64</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>ND</td>
<td>7</td>
<td>100</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 14</td>
</tr>
<tr>
<td>NE</td>
<td>18</td>
<td>100</td>
<td>999,999</td>
<td>1, 5, 7, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>NH</td>
<td>10</td>
<td>0</td>
<td>999,999</td>
<td>2, 3, 7, 8, 9, 10, 11, 12</td>
</tr>
<tr>
<td>NJ</td>
<td>55</td>
<td>100</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>NM</td>
<td>8</td>
<td>100</td>
<td>9,999,999</td>
<td>1, 2, 3, 4, 6, 7, 9, 11, 12</td>
</tr>
<tr>
<td>NV</td>
<td>10</td>
<td>1,000</td>
<td>9,999,999</td>
<td>1, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>NY</td>
<td>74</td>
<td>0</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>OH</td>
<td>148</td>
<td>0</td>
<td>99,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>OK</td>
<td>36</td>
<td>0</td>
<td>999,999,999</td>
<td>1, 2, 3, 4, 6, 7, 9, 10, 11, 12, 13, 14</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
Table 5-1. Facilities that Produce, Process, or Use Toluene

<table>
<thead>
<tr>
<th>State</th>
<th>Number of facilities</th>
<th>Minimum amount on site in pounds</th>
<th>Maximum amount on site in pounds</th>
<th>Activities and uses&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR</td>
<td>23</td>
<td>0</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 14</td>
</tr>
<tr>
<td>PA</td>
<td>86</td>
<td>0</td>
<td>499,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>PR</td>
<td>12</td>
<td>10,000</td>
<td>99,999,999</td>
<td>2, 3, 4, 5, 6, 7, 8, 9, 10, 13</td>
</tr>
<tr>
<td>RI</td>
<td>10</td>
<td>1,000</td>
<td>49,999,999</td>
<td>7, 8, 9, 10, 11, 12</td>
</tr>
<tr>
<td>SC</td>
<td>41</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>SD</td>
<td>10</td>
<td>1,000</td>
<td>999,999</td>
<td>6, 7, 9, 10, 11, 12</td>
</tr>
<tr>
<td>TN</td>
<td>56</td>
<td>0</td>
<td>9,999,999</td>
<td>1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>TX</td>
<td>255</td>
<td>0</td>
<td>999,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>UT</td>
<td>14</td>
<td>100</td>
<td>99,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 12</td>
</tr>
<tr>
<td>VA</td>
<td>48</td>
<td>0</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 5, 7, 9, 10, 11, 12</td>
</tr>
<tr>
<td>VI</td>
<td>2</td>
<td>1,000,000</td>
<td>99,999,999</td>
<td>1, 2, 3, 4, 6, 7, 9, 12</td>
</tr>
<tr>
<td>VT</td>
<td>2</td>
<td>10,000</td>
<td>99,999</td>
<td>7, 10, 12</td>
</tr>
<tr>
<td>WA</td>
<td>26</td>
<td>100</td>
<td>99,999,999</td>
<td>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>WI</td>
<td>66</td>
<td>0</td>
<td>49,999,999</td>
<td>1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14</td>
</tr>
<tr>
<td>WV</td>
<td>17</td>
<td>1,000</td>
<td>49,999,999</td>
<td>1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13</td>
</tr>
<tr>
<td>WY</td>
<td>9</td>
<td>10,000</td>
<td>49,999,999</td>
<td>1, 2, 3, 4, 6, 7, 8, 9, 10, 12, 13, 14</td>
</tr>
</tbody>
</table>

<sup>a</sup>Post office state abbreviations used.
<sup>b</sup>Amounts on site reported by facilities in each state.
<sup>c</sup>Activities/Uses:

1. Produce
2. Import
3. Onsite use/processing
4. Sale/Distribution
5. Byproduct
6. Reactant
7. Formulation Component
8. Article Component
9. Repackaging
10. Chemical Processing Aid
11. Manufacturing Aid
12. Ancillary/Other Uses
13. Manufacturing Impurity
14. Process Impurity

Source: TRI12 2014 (Data are from 2012)
of toluene is used in the production of xylene, 12% is used as a solvent in paints, coatings, gums, resins, rubber, and vinyl organosol, and 10% is used for miscellaneous use, such as for the synthesis of organic chemicals, for use as a denaturant, and for the production of drugs that may be abused. The other 8% is used in the production of toluene diisocyanate (TDI) (Ozokwelu et al. 2006; HSDB 2010).

5.4 DISPOSAL

Toluene is regulated by the Resource Conservation and Recovery Act (RCRA) as a hazardous waste (U220 and F005-spent solvents including toluene) and is therefore subject to RCRA regulations as stated in 40 CFR 261.33 (see Chapter 8). These regulations include standards for storage, transport, and disposal of toluene.

Toluene, or a combination of solvent containing toluene at 10% by volume before use, is regulated by federal laws (State of California 2005). The spent toluene, or toluene that is no longer available except after reprocessing, contains additional constituents that prevents its reuse as a solvent (U.S. DOE 1991). Toluene can be disposed of by controlled incineration. Toluene is a good candidate for liquid injection incineration, rotary kiln incineration, and fluidized bed incineration. Toluene may also be disposed of by atomizing it in a suitable combustion chamber. After treatment at a spill site or waste management facility, toluene sludge can be disposed of at a secure landfill (HSDB 2010).

According to data from the TRI, 1,305,251 pounds of toluene were transferred off-site in 2012, including releases to publically owned treatment works (POTW) (TRI12 2014).

Toluene is listed as a toxic substance under Section 313 of the Emergency Planning and Community Right to Know Act (EPCRA) under Title III of the Superfund Amendments and Reauthorization Act (SARA) (EPA 2006). Disposal of wastes containing toluene is controlled by a number of federal and state regulations (see Chapter 8).
6. POTENTIAL FOR HUMAN EXPOSURE

6.1 OVERVIEW

Toluene has been identified in at least 1,012 of the 1,699 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, the number of sites evaluated for toluene is not known. The frequency of these sites can be seen in Figure 6-1. Of these sites containing toluene, 1,005 are located within the United States, 5 are located in the Commonwealth of Puerto Rico, and 2 are located in the Virgin Islands.

The majority of toluene released to the environment partitions to air. Large amounts of toluene enter the environment each year from production, use, and disposal of industrial and consumer products that contain toluene. The largest source of toluene emissions occurs during the production, transport, and use of gasoline. Small amounts are released in industrial waste water discharges and land disposal of sludges and petroleum wastes.

Toluene in the atmosphere is degraded by reaction with hydroxyl radicals, with a typical half-life of approximately 13 hours (Howard et al. 1991). Toluene in soil or water rapidly volatilizes to air, and that which remains is subject to microbial degradation. As a result of volatilization and degradation occurring in air, soil, and water, toluene levels are not expected to build up in the environment over time.

The concentrations of toluene in air have been found to be quite low in remote areas, but are higher in suburban and urban areas. The automobile emissions are the principal source of toluene in ambient air, with levels fluctuating in proportion to automobile traffic. Levels of toluene in the air are usually higher in areas that are heavily congested with traffic (21.4–98.1 ppbv or 80.5–368.9 µg/m³). Levels in the same study were much lower in the outdoor air in urban areas (1.95 ppbv or 7.3 µg/m³) (Baltrenas et al. 2011). Toluene is also a common indoor contaminant, and indoor air concentrations are often several times higher than outside air. This is likely due to release of toluene from common household products (paints, paint thinners, adhesives, and nail polish in which it is used as a solvent) and from cigarette smoke.

Toluene is occasionally detected in drinking water supplies due to industrial water discharges or from contaminated surface water, but occurrence is not widespread and levels are generally much lower than levels found in the air. In contrast, toluene is a very common contaminant of water and soil in the vicinity of hazardous waste sites.
Figure 6-1. Frequency of NPL Sites with Toluene Contamination

**Derived from HazDat 2007**

Frequency of NPL Sites

- Red: 1-4
- Green: 5-9
- Blue: 10-13
- Yellow: 14-19
- Orange: 24-46
- Dark Green: 65-100

***DRAFT FOR PUBLIC COMMENT***
6. POTENTIAL FOR HUMAN EXPOSURE

The most likely pathway by which people may be exposed to toluene is by breathing contaminated air. Since most people spend a large fraction of the day indoors, indoor air levels are likely to be the dominant source. Higher exposure levels might occur for individuals living near a hazardous waste site or an industrial source of toluene emissions, but these exposures can be estimated only on a site-by-site basis.

Toluene exposure may also occur in the workplace, especially in occupations such as printing or painting, where toluene is used as a solvent. Gas service station workers can be exposed to toluene from the gasoline. Petroleum and coke plant workers may also be exposed to higher levels of toluene than the general population.

6.2 RELEASES TO THE ENVIRONMENT

The Toxics Release Inventory (TRI) data should be used with caution because only certain types of facilities are required to report (EPA 2005b). This is not an exhaustive list. Manufacturing and processing facilities are required to report information to the TRI only if they employ 10 or more full-time employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI chemical in a calendar year (EPA 2005b).

According to the Toxics Release Inventory (TRI), in 2012 approximately 27 million pounds (12 million kg) of toluene was released to the environment from 2,209 manufacturing or processing facilities (TRI12 2014). The most recent TRI data continues to reflect a decline in the total amount of toluene released from facilities required to report to the TRI. Total on- and off-site releases of toluene were approximately 57, 48, 42, 36, 30, 32, 29, and 27 million pounds in 2005, 2006, 2007, 2008, 2009, 2010, 2011, and 2012, respectively (TRI12 2014). Table 6-1 lists the amounts released from these facilities to air, water, land, and publicly owned treatment works (POTWs). Table 6-1 also shows that less than 3% of the total released was injected deep underground and that about 1.3 million pounds of toluene were transferred off-
6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use Toluene\textsuperscript{a}

<table>
<thead>
<tr>
<th>State</th>
<th>RF\textsuperscript{d}</th>
<th>Air\textsuperscript{a}</th>
<th>Water\textsuperscript{e}</th>
<th>Ul\textsuperscript{g}</th>
<th>Land\textsuperscript{h}</th>
<th>Other\textsuperscript{d}</th>
<th>On-site\textsuperscript{i}</th>
<th>Off-site\textsuperscript{j}</th>
<th>On- and off-site</th>
</tr>
</thead>
<tbody>
<tr>
<td>AK</td>
<td>8</td>
<td>20,230</td>
<td>62</td>
<td>0</td>
<td>124</td>
<td>326</td>
<td>20,415</td>
<td>327</td>
<td>20,742</td>
</tr>
<tr>
<td>AL</td>
<td>43</td>
<td>295,971</td>
<td>1</td>
<td>0</td>
<td>1,668</td>
<td>39,374</td>
<td>297,105</td>
<td>39,908</td>
<td>337,013</td>
</tr>
<tr>
<td>AR</td>
<td>16</td>
<td>120,881</td>
<td>19</td>
<td>27</td>
<td>0</td>
<td>4,109</td>
<td>120,926</td>
<td>4,109</td>
<td>125,035</td>
</tr>
<tr>
<td>AZ</td>
<td>19</td>
<td>70,372</td>
<td>0</td>
<td>0</td>
<td>750</td>
<td>292</td>
<td>70,372</td>
<td>1,042</td>
<td>71,414</td>
</tr>
<tr>
<td>CA</td>
<td>106</td>
<td>223,463</td>
<td>37</td>
<td>22</td>
<td>770,210</td>
<td>2,811</td>
<td>969,551</td>
<td>26,991</td>
<td>996,543</td>
</tr>
<tr>
<td>CO</td>
<td>24</td>
<td>100,745</td>
<td>2</td>
<td>0</td>
<td>253</td>
<td>0</td>
<td>100,747</td>
<td>253</td>
<td>100,999</td>
</tr>
<tr>
<td>CT</td>
<td>26</td>
<td>51,670</td>
<td>1</td>
<td>0</td>
<td>62</td>
<td>1</td>
<td>51,671</td>
<td>63</td>
<td>51,734</td>
</tr>
<tr>
<td>DE</td>
<td>7</td>
<td>15,611</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>134</td>
<td>15,616</td>
<td>134</td>
<td>15,750</td>
</tr>
<tr>
<td>FL</td>
<td>49</td>
<td>216,113</td>
<td>34</td>
<td>0</td>
<td>107</td>
<td>14,259</td>
<td>216,147</td>
<td>14,366</td>
<td>230,513</td>
</tr>
<tr>
<td>GA</td>
<td>56</td>
<td>726,385</td>
<td>43</td>
<td>0</td>
<td>1,211</td>
<td>6,934</td>
<td>726,432</td>
<td>8,141</td>
<td>734,573</td>
</tr>
<tr>
<td>GU</td>
<td>2</td>
<td>5,599</td>
<td>0</td>
<td>0</td>
<td>94</td>
<td>0</td>
<td>5,599</td>
<td>94</td>
<td>5,693</td>
</tr>
<tr>
<td>HI</td>
<td>9</td>
<td>22,018</td>
<td>16</td>
<td>0</td>
<td>17</td>
<td>8</td>
<td>22,034</td>
<td>25</td>
<td>22,059</td>
</tr>
<tr>
<td>IA</td>
<td>46</td>
<td>506,570</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>1,313</td>
<td>506,573</td>
<td>1,313</td>
<td>507,886</td>
</tr>
<tr>
<td>ID</td>
<td>3</td>
<td>1,488</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,488</td>
<td>0</td>
<td>1,488</td>
</tr>
<tr>
<td>IL</td>
<td>123</td>
<td>1,046,847</td>
<td>1,112</td>
<td>872</td>
<td>6,798</td>
<td>6,365</td>
<td>1,048,520</td>
<td>13,474</td>
<td>1,061,995</td>
</tr>
<tr>
<td>IN</td>
<td>104</td>
<td>1,859,900</td>
<td>370</td>
<td>0</td>
<td>67,016</td>
<td>20,956</td>
<td>1,860,605</td>
<td>87,637</td>
<td>1,948,242</td>
</tr>
<tr>
<td>KS</td>
<td>38</td>
<td>698,915</td>
<td>53</td>
<td>106</td>
<td>1,934</td>
<td>396</td>
<td>699,287</td>
<td>2,117</td>
<td>701,404</td>
</tr>
<tr>
<td>KY</td>
<td>48</td>
<td>1,715,860</td>
<td>2,244</td>
<td>0</td>
<td>177,643</td>
<td>10,190</td>
<td>1,719,936</td>
<td>186,001</td>
<td>1,905,938</td>
</tr>
<tr>
<td>LA</td>
<td>91</td>
<td>1,215,937</td>
<td>414</td>
<td>3,342</td>
<td>4,318</td>
<td>85,234</td>
<td>1,219,710</td>
<td>89,535</td>
<td>1,309,245</td>
</tr>
<tr>
<td>MA</td>
<td>52</td>
<td>214,671</td>
<td>17</td>
<td>0</td>
<td>52</td>
<td>5,773</td>
<td>214,688</td>
<td>5,825</td>
<td>220,513</td>
</tr>
<tr>
<td>MD</td>
<td>16</td>
<td>30,539</td>
<td>32</td>
<td>0</td>
<td>11</td>
<td>238</td>
<td>30,571</td>
<td>249</td>
<td>30,820</td>
</tr>
<tr>
<td>ME</td>
<td>6</td>
<td>5,972</td>
<td>55</td>
<td>0</td>
<td>0</td>
<td>63</td>
<td>6,027</td>
<td>63</td>
<td>6,090</td>
</tr>
<tr>
<td>MI</td>
<td>97</td>
<td>1,032,607</td>
<td>0</td>
<td>30</td>
<td>46,332</td>
<td>18,216</td>
<td>1,032,804</td>
<td>64,381</td>
<td>1,097,185</td>
</tr>
<tr>
<td>MN</td>
<td>34</td>
<td>368,792</td>
<td>11</td>
<td>0</td>
<td>60</td>
<td>0</td>
<td>368,803</td>
<td>60</td>
<td>368,863</td>
</tr>
<tr>
<td>MO</td>
<td>52</td>
<td>180,221</td>
<td>55</td>
<td>0</td>
<td>62</td>
<td>2,048</td>
<td>180,287</td>
<td>2,100</td>
<td>182,387</td>
</tr>
<tr>
<td>MP</td>
<td>2</td>
<td>1,234</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,234</td>
<td>0</td>
<td>1,234</td>
</tr>
<tr>
<td>MS</td>
<td>32</td>
<td>364,407</td>
<td>33</td>
<td>0</td>
<td>746</td>
<td>108</td>
<td>364,441</td>
<td>853</td>
<td>365,294</td>
</tr>
<tr>
<td>MT</td>
<td>6</td>
<td>56,720</td>
<td>46</td>
<td>0</td>
<td>555</td>
<td>0</td>
<td>56,816</td>
<td>504</td>
<td>57,320</td>
</tr>
<tr>
<td>NC</td>
<td>62</td>
<td>919,143</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>44,105</td>
<td>919,149</td>
<td>44,106</td>
<td>963,255</td>
</tr>
<tr>
<td>ND</td>
<td>6</td>
<td>28,962</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>28,966</td>
<td>0</td>
<td>28,966</td>
</tr>
<tr>
<td>NE</td>
<td>18</td>
<td>49,097</td>
<td>0</td>
<td>0</td>
<td>232</td>
<td>0</td>
<td>49,097</td>
<td>232</td>
<td>49,329</td>
</tr>
<tr>
<td>NH</td>
<td>10</td>
<td>31,815</td>
<td>0</td>
<td>0</td>
<td>27</td>
<td>2</td>
<td>31,816</td>
<td>29</td>
<td>31,845</td>
</tr>
<tr>
<td>NJ</td>
<td>55</td>
<td>124,007</td>
<td>729</td>
<td>55</td>
<td>2,386</td>
<td>4,904</td>
<td>124,750</td>
<td>7,331</td>
<td>132,080</td>
</tr>
<tr>
<td>NM</td>
<td>8</td>
<td>47,511</td>
<td>0</td>
<td>0</td>
<td>1,084</td>
<td>871</td>
<td>47,839</td>
<td>1,627</td>
<td>49,466</td>
</tr>
<tr>
<td>NV</td>
<td>10</td>
<td>344,504</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>344,504</td>
<td>0</td>
<td>344,504</td>
</tr>
<tr>
<td>NY</td>
<td>74</td>
<td>435,152</td>
<td>99</td>
<td>0</td>
<td>851</td>
<td>2,991</td>
<td>435,256</td>
<td>3,837</td>
<td>439,093</td>
</tr>
<tr>
<td>OH</td>
<td>148</td>
<td>670,013</td>
<td>209</td>
<td>14,089</td>
<td>25,416</td>
<td>153,172</td>
<td>670,268</td>
<td>192,632</td>
<td>862,899</td>
</tr>
<tr>
<td>OK</td>
<td>34</td>
<td>744,408</td>
<td>269</td>
<td>6,251</td>
<td>127</td>
<td>2,999</td>
<td>750,577</td>
<td>3,477</td>
<td>754,054</td>
</tr>
</tbody>
</table>

\*\*DRAFT FOR PUBLIC COMMENT\*\*
### Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use Toluene<sup>a</sup>

<table>
<thead>
<tr>
<th>State&lt;sup&gt;c&lt;/sup&gt;</th>
<th>RF&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Air&lt;sup&gt;e&lt;/sup&gt;</th>
<th>Water&lt;sup&gt;f&lt;/sup&gt;</th>
<th>UI&lt;sup&gt;g&lt;/sup&gt;</th>
<th>Land&lt;sup&gt;h&lt;/sup&gt;</th>
<th>Other&lt;sup&gt;i&lt;/sup&gt;</th>
<th>On-site&lt;sup&gt;j&lt;/sup&gt;</th>
<th>Off-site&lt;sup&gt;k&lt;/sup&gt;</th>
<th>Total release</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR</td>
<td>23</td>
<td>59,605</td>
<td>3</td>
<td>0</td>
<td>389</td>
<td>810</td>
<td>59,608</td>
<td>1,199</td>
<td>60,807</td>
</tr>
<tr>
<td>PA</td>
<td>86</td>
<td>1,258,433</td>
<td>236</td>
<td>250</td>
<td>12,534</td>
<td>27,218</td>
<td>1,258,669</td>
<td>40,002</td>
<td>1,298,671</td>
</tr>
<tr>
<td>PR</td>
<td>12</td>
<td>21,765</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>21,767</td>
<td>8</td>
<td>21,775</td>
<td></td>
</tr>
<tr>
<td>RI</td>
<td>10</td>
<td>16,491</td>
<td>16</td>
<td>0</td>
<td>1</td>
<td>5,670</td>
<td>16,507</td>
<td>5,671</td>
<td>22,177</td>
</tr>
<tr>
<td>SC</td>
<td>41</td>
<td>2,885,893</td>
<td>356</td>
<td>0</td>
<td>12,389</td>
<td>29,031</td>
<td>2,886,322</td>
<td>41,347</td>
<td>2,927,669</td>
</tr>
<tr>
<td>SD</td>
<td>10</td>
<td>50,058</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>50,058</td>
<td>0</td>
<td>50,058</td>
<td></td>
</tr>
<tr>
<td>TN</td>
<td>56</td>
<td>1,096,033</td>
<td>70</td>
<td>0</td>
<td>622</td>
<td>23,900</td>
<td>1,096,391</td>
<td>24,234</td>
<td>1,120,625</td>
</tr>
<tr>
<td>TX</td>
<td>249</td>
<td>1,698,337</td>
<td>982</td>
<td>623,761</td>
<td>15,251</td>
<td>177,153</td>
<td>2,323,160</td>
<td>192,324</td>
<td>2,515,484</td>
</tr>
<tr>
<td>UT</td>
<td>13</td>
<td>51,410</td>
<td>5</td>
<td>0</td>
<td>357</td>
<td>11</td>
<td>51,417</td>
<td>366</td>
<td>51,783</td>
</tr>
<tr>
<td>VA</td>
<td>47</td>
<td>890,571</td>
<td>103</td>
<td>0</td>
<td>1,069</td>
<td>133,845</td>
<td>890,714</td>
<td>134,874</td>
<td>1,025,589</td>
</tr>
<tr>
<td>VI</td>
<td>2</td>
<td>18,402</td>
<td>0</td>
<td>0</td>
<td>147</td>
<td>4</td>
<td>18,402</td>
<td>151</td>
<td>18,553</td>
</tr>
<tr>
<td>VT</td>
<td>2</td>
<td>749</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>749</td>
<td>0</td>
<td>749</td>
<td></td>
</tr>
<tr>
<td>WA</td>
<td>26</td>
<td>233,771</td>
<td>121</td>
<td>0</td>
<td>74,379</td>
<td>30</td>
<td>305,313</td>
<td>2,988</td>
<td>308,301</td>
</tr>
<tr>
<td>WI</td>
<td>66</td>
<td>729,534</td>
<td>0</td>
<td>0</td>
<td>258</td>
<td>24,448</td>
<td>729,534</td>
<td>24,706</td>
<td>754,240</td>
</tr>
<tr>
<td>WV</td>
<td>17</td>
<td>347,375</td>
<td>528</td>
<td>0</td>
<td>30,336</td>
<td>2,731</td>
<td>347,919</td>
<td>33,050</td>
<td>380,969</td>
</tr>
<tr>
<td>WY</td>
<td>9</td>
<td>34,547</td>
<td>5</td>
<td>0</td>
<td>1,498</td>
<td>0</td>
<td>34,556</td>
<td>1,494</td>
<td>36,050</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,209</strong></td>
<td><strong>23,957,322</strong></td>
<td><strong>8,401</strong></td>
<td><strong>648,805</strong></td>
<td><strong>1,259,381</strong></td>
<td><strong>853,052</strong></td>
<td><strong>25,421,711</strong></td>
<td><strong>1,305,251</strong></td>
<td><strong>26,726,962</strong></td>
</tr>
</tbody>
</table>

<sup>a</sup>The TRI data should be used with caution since only certain types of facilities are required to report. This is not an exhaustive list. Data are rounded to nearest whole number.

<sup>b</sup>Data in TRI are maximum amounts released by each facility.

<sup>c</sup>Post office state abbreviations are used.

<sup>d</sup>Number of reporting facilities.

<sup>e</sup>The sum of fugitive and point source releases are included in releases to air by a given facility.

<sup>f</sup>Surface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal and metal compounds).

<sup>g</sup>Class I wells, Class II-V wells, and underground injection.

<sup>h</sup>Resource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface impoundments, other land disposal, other landfills.

<sup>i</sup>Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal, unknown

<sup>j</sup>The sum of all releases of the chemical to air, land, water, and underground injection wells.

<sup>k</sup>Total amount of chemical transferred off-site, including to POTWs.

RF = reporting facilities; UI = underground injection

Source: TRI12 2014 (Data are from 2012)

***DRAFT FOR PUBLIC COMMENT***
site (TRI12 2014). The relative proportions of the material transferred off-site that were recycled or entered environmental media are not stated. Releases of toluene to the environment have decreased when compared to data from 1997.

### 6.2.1 Air

Estimated releases of 24 million pounds (~11,000 metric tons) of toluene to the atmosphere from 2,209 domestic manufacturing and processing facilities in 2012, accounted for nearly 90% of the estimated total environmental releases from facilities required to report to the TRI (TRI12 2014). These releases are summarized in Table 6-1.

EPA’s National Emission Inventory (NEI) database contains data regarding sources that emit criteria air pollutants and their precursors, and hazardous air pollutants (HAPs) for the 50 United States, Washington DC, Puerto Rico, and the U.S. Virgin Islands. The NEI database derives emission data from multiple sources, including state and local environmental agencies, the TRI database, computer models for on-road and off-road emissions, and databases related to EPA’s Maximum Achievable Control Technology (MACT) programs to reduce emissions of HAPs. Data downloaded from the 2011 NEI (see Table 6-2) indicated that the total emission of toluene was approximately 1,730,000,000 pounds (785,000 tons), with the biggest contribution arising from consumer and commercial solvent use (EPA 2013a). Nearly all toluene entering the environment is released directly to air or partitions to the atmosphere due to its relatively high vapor pressure (EC 2003). A major source of toluene emissions arises from gasoline use, which typically includes emissions from motor vehicle exhaust, gasoline storage tanks, filling stations, petroleum spills, etc. (EC 2003; Verschueren 1977). The emission rate of toluene from motor vehicle traffic in a Los Angeles roadway tunnel was found to be 748 mg/L of gasoline consumed (Fraser et al. 1998). In addition, the global release from automobile exhaust is estimated to be around 3–8 metric tons per year, and the emission factors from gasoline was 2.22x10⁻⁵–8.46x10⁻⁴ lb/vehicle mile traveled for evaporation from automobile fuel tanks and automobile exhaust emissions (EPA 1994e).

BTEX emissions are primarily due to incomplete combustion of petroleum fuels from gasoline and volatilization of BTEX-based solvents and thinners. BTEX is often studied together because these chemicals comprise 60% of the water-soluble fraction of gasoline (CCME 2004). Toluene, along with the other aromatic hydrocarbons, is added to gasoline to raise the octane rating (Ozokwelu 2006).
<table>
<thead>
<tr>
<th>Emission source</th>
<th>Emissions in tons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agriculture, livestock waste</td>
<td>2.566</td>
</tr>
<tr>
<td>Bulk gasoline terminals</td>
<td>1,989.817</td>
</tr>
<tr>
<td>Commercial cooking</td>
<td>646.584</td>
</tr>
<tr>
<td>Dust, construction dust</td>
<td>0.149</td>
</tr>
<tr>
<td>Fires, agricultural field burning</td>
<td>5,788.053</td>
</tr>
<tr>
<td>Fires, prescribed fires</td>
<td>24,784.188</td>
</tr>
<tr>
<td>Fires, wildfires</td>
<td>30,548.719</td>
</tr>
<tr>
<td>Fuel combustion, commercial/institutional, biomass</td>
<td>4.724</td>
</tr>
<tr>
<td>Fuel combustion, commercial/institutional, coal</td>
<td>0.230</td>
</tr>
<tr>
<td>Fuel combustion, commercial/institutional, natural gas</td>
<td>75.153</td>
</tr>
<tr>
<td>Fuel combustion, commercial/institutional, oil</td>
<td>4.905</td>
</tr>
<tr>
<td>Fuel combustion, commercial/institutional, other</td>
<td>3.239</td>
</tr>
<tr>
<td>Fuel combustion, electric generation, biomass</td>
<td>509.470</td>
</tr>
<tr>
<td>Fuel combustion, electric generation, coal</td>
<td>92.209</td>
</tr>
<tr>
<td>Fuel combustion, electric generation, natural gas</td>
<td>325.570</td>
</tr>
<tr>
<td>Fuel combustion, electric generation, oil</td>
<td>10.029</td>
</tr>
<tr>
<td>Fuel combustion, electric generation, other</td>
<td>17.986</td>
</tr>
<tr>
<td>Fuel combustion, Industrial boilers, ices, biomass</td>
<td>157.859</td>
</tr>
<tr>
<td>Fuel combustion, Industrial boilers, ices, coal</td>
<td>3.036</td>
</tr>
<tr>
<td>Fuel combustion, Industrial boilers, ices, natural gas</td>
<td>407.576</td>
</tr>
<tr>
<td>Fuel combustion, Industrial boilers, ices, oil</td>
<td>19.987</td>
</tr>
<tr>
<td>Fuel combustion, Industrial boilers, ices, other</td>
<td>31.980</td>
</tr>
<tr>
<td>Fuel combustion, residential, natural gas</td>
<td>52.243</td>
</tr>
<tr>
<td>Fuel combustion, residential, oil</td>
<td>1.146</td>
</tr>
<tr>
<td>Fuel combustion, residential, other</td>
<td>0.038</td>
</tr>
<tr>
<td>Fuel combustion, residential, wood</td>
<td>4,118.312</td>
</tr>
<tr>
<td>Gas stations</td>
<td>31,251.987</td>
</tr>
<tr>
<td>Industrial processes, cement manuf</td>
<td>26.102</td>
</tr>
<tr>
<td>Industrial processes, chemical manuf</td>
<td>2,094.087</td>
</tr>
<tr>
<td>Industrial processes, ferrous metals</td>
<td>58.466</td>
</tr>
<tr>
<td>Industrial processes, mining</td>
<td>6.779</td>
</tr>
<tr>
<td>Industrial processes, NEC</td>
<td>2,533.374</td>
</tr>
<tr>
<td>Industrial processes, non-ferrous metals</td>
<td>39.259</td>
</tr>
<tr>
<td>Industrial processes, oil and gas production</td>
<td>9,281.628</td>
</tr>
<tr>
<td>Industrial processes, petroleum refineries</td>
<td>710.439</td>
</tr>
<tr>
<td>Industrial processes, pulp and paper</td>
<td>111.692</td>
</tr>
<tr>
<td>Industrial processes, storage and transfer</td>
<td>2,487.106</td>
</tr>
</tbody>
</table>
### Table 6-2. 2011 NEI Total National Emissions of Toluene

<table>
<thead>
<tr>
<th>Emission source</th>
<th>Emissions in tons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscellaneous non-industrial NEC</td>
<td>7,290.227</td>
</tr>
<tr>
<td>Mobile, aircraft</td>
<td>463.492</td>
</tr>
<tr>
<td>Mobile, commercial marine vessels</td>
<td>39.694</td>
</tr>
<tr>
<td>Mobile, locomotives</td>
<td>187.259</td>
</tr>
<tr>
<td>Mobile, non-road equipment, diesel</td>
<td>1,857.913</td>
</tr>
<tr>
<td>Mobile, non-road equipment, gasoline</td>
<td>144,745.874</td>
</tr>
<tr>
<td>Mobile, non-road equipment, other</td>
<td>4.067</td>
</tr>
<tr>
<td>Mobile, on-road diesel heavy duty vehicles</td>
<td>1,567.312</td>
</tr>
<tr>
<td>Mobile, on-road diesel light duty vehicles</td>
<td>44.951</td>
</tr>
<tr>
<td>Mobile, on-road gasoline heavy duty vehicles</td>
<td>10,911.517</td>
</tr>
<tr>
<td>Mobile, on-road gasoline light duty vehicles</td>
<td>194,777.346</td>
</tr>
<tr>
<td>Solvent, consumer and commercial solvent use</td>
<td>282,997.039</td>
</tr>
<tr>
<td>Solvent, degreasing</td>
<td>365.751</td>
</tr>
<tr>
<td>Solvent, dry cleaning</td>
<td>0.330</td>
</tr>
<tr>
<td>Solvent, graphic arts</td>
<td>4,271.392</td>
</tr>
<tr>
<td>Solvent, industrial surface coating and solvent use</td>
<td>58,964.001</td>
</tr>
<tr>
<td>Solvent, non-industrial surface coating</td>
<td>37,149.628</td>
</tr>
<tr>
<td>Waste disposal</td>
<td>3,232.753</td>
</tr>
<tr>
<td><strong>Sum</strong></td>
<td><strong>867,067.23</strong></td>
</tr>
</tbody>
</table>

NEC = not elsewhere classified; NEI = National Emission Inventory

Source: EPA 2013a
Toluene is used in paints, solvents, adhesives, inks, and similar products and is also released to air upon use. Toluene is also emitted from building and finishing materials in newly constructed apartments. Indoor air exposure to a chemical that is generated at the source (from paints, varnishes, and adhesives) can be of a greater risk than ambient air exposure. Toluene was found at mean concentrations of 63.03 µg/m³ (lower floor), 66.06 µg/m³ (middle floor), and 27.16 µg/m³ (highest floor) in newly constructed apartment buildings in Korea that had been finished with vinyl wallpaper and plywood. The outdoor concentration of toluene in the same study was 11.05 µg/m³. Calculated mean emission rates for toluene were 4,168 µg/hour (lower floor), 4,171 µg/hour (middle floor), and 7,356 µg/hour (highest floor). The authors suggest that an increase in the ventilation on the highest floor may lead to an increase in emissions from the inner surfaces (Sim et al. 2010).

Toluene may also be released during disposal processes. Based on information from 40 medical waste incinerators in the United States and Canada, emission factors for toluene were reported to range from 37.3 to 178 (mean=113) µg/kg waste for uncontrolled emissions and 177–3,000 (mean=1,920) µg/kg waste for controlled emissions (Walker and Cooper 1992). Toluene emissions from coal-fired power stations (119 µg/m³) were reported to be far less than toluene emissions from diesel engines (167–287 µg/m³) and automobiles (15,700–370,000 µg/m³); all measurements were obtained at standard temperature and pressure (20°C and 1 atmosphere pressure) (Garcia et al. 1992).

6.2.2 Water

Estimated releases of 8,400 pounds (~ 3.8 metric tons) of toluene to surface water from 2,209 domestic manufacturing and processing facilities in 2012, accounted for about 0.03% of the estimated total environmental releases from facilities required to report to the TRI (TRI 12 2014). These releases are summarized in Table 6-1.

Toluene may be released to water from industrial discharges and urban wastes, or by spills and leakage of gasoline. However, these releases are believed to comprise only a small fraction of the amount of toluene released to air (EPA 1983e). Emissions into the water and soil sometimes lead to re-emission of toluene into the air (EC 2003).

Waste water containing toluene can potentially emit the chemical into the atmosphere upon contact with ambient air. Toluene can also be discharged as a contaminant into waste water (EPA 1994e). Toluene
levels were reported at 0.22–1.1 mg/L in groundwater contaminated by point emissions. The highest level of toluene contamination in the United States was reported in 1983 at 1.4 μg/L (WHO 2004).

6.2.3 Soil

Estimated releases of 1.3 million pounds (~590 metric tons) of toluene to soils from 2,209 domestic manufacturing and processing facilities in 2012, accounted for about 5% of the estimated total environmental releases from facilities required to report to the TRI (TRI12 2014). An additional 650,000 pounds (~295 metric tons), constituting about 2.4% of the total environmental emissions, were released via underground injection (TRI12 2014). These releases are summarized in Table 6-1.

Release of toluene to land may occur in association with gasoline spills, leaking underground gasoline storage tanks, or land disposal of municipal sludges or refinery wastes. Releases of BTEX to the soil also occur from accidents and spills during transportation and pesticide applications (CCME 2004). In some cases, releases might be significant on a local scale; however, the total amount of toluene released to the environment in soil is considered to be negligible (EPA 1983e).

6.3 Environmental Fate

6.3.1 Transport and Partitioning

Toluene is a volatile liquid at room temperature. Due to its high vapor pressure (28.4 mmHg at 25°C), the majority of toluene released to the environment partitions to air. As discussed in Section 6.2, most toluene is released directly into air, and that which is released to surface water or soil tends to volatilize quickly (EC 2003). Toluene rapidly volatilizes from surface water to air, with a half-life on the order of a few hours at 25°C; however, the volatilization rate is dependent upon conditions of the water body (e.g., depth, current) and the atmosphere (e.g., wind speeds). Laboratory studies also indicate that surfactants can affect volatilization of toluene from water (Anderson 1992).

The rate of volatilization from soils depends on temperature, humidity, and soil type; however, under typical conditions, toluene rapidly volatilizes from soils based on its Henry’s Law constant and vapor pressure (CCME 2004; HSDB 2010).

Toluene is expected to have high to moderate mobility in soil; the soil adsorption coefficient (Koc) values of 37–178 indicate that toluene is not expected to be strongly bound to the soil (HSDB 2010). Humidity
interferes with the adsorption of toluene vapors into soils, with sorption primarily occurring with water vapor rather than toluene in low humidity (Chen and Wu 1998).

Adsorption of toluene to soil is possible under certain conditions. Distilled water removed 9–40% of the toluene adsorbed to samples of five different soils of low organic content within 24 hours, but after 7 days, some of the toluene still remained adsorbed to the soil samples (Pavlostathis and Mathavan 1992). Sorption of toluene can also be dependent on the size of the particles in soils. BTEX was adsorbed more in montmorillonite or illite clays, and less in kaolinite (Site 2001). A gravimetric method indicated that adsorption of gas phase toluene on loam or clay occurs in two stages: fast diffusion and adsorption in macropores, followed by slower diffusion and adsorption in intragrain micropores (Arocha et al. 1996). Temperature is also inversely related to adsorption (Site 2001).

Although the organic carbon content of aquifer materials is an important determinant of toluene migration in groundwater, other factors may be important as well (Larsen et al. 1992). For example, information from waste sites and U.S. coastal plain aquifers indicates that many site-specific hydrogeologic factors can have unpredictable effects on toluene migration (Adams and Golden 1992). In addition, the presence of other gasoline components (benzene, xylene) can impact toluene migration. Competitive sorption between these gasoline components decreases the interaction between toluene and soil, thereby allowing it to move more quickly through the aquifer (Stuart et al. 1991).

Toluene is expected to have a low tendency to bioconcentrate in the fatty tissues of aquatic organisms based on its measured BCF values (Franke et al. 1994). The bioconcentration factor (BCF) values were reported to be 8, 13, and 90 in herring, eels, and golden ide fish, respectively (EC 2003).

6.3.2 Transformation and Degradation

6.3.2.1 Air

Toluene in the atmosphere is rapidly degraded by reaction with hydroxyl radicals to yield cresol and benzaldehyde, which in turn undergo ring cleavage to yield simple hydrocarbons (Davis et al. 1979; Hoshino et al. 1978; Kenley et al. 1973). The estimated rate constant for this process is about 0.6–2.4x10⁻⁵ sec⁻¹, which corresponds to an atmospheric half-life of around 13 hours. The actual half-life may range from 10 to 104 hours depending on atmospheric conditions (Howard et al. 1991). Toluene is also oxidized by reaction with nitrogen dioxide, oxygen, and ozone, but the rates of these reactions are two or more orders of magnitude less than for the hydroxyl radical (Altshuller et al. 1971; Dilling et al. 1976;

Processes for removing toluene from the air include adsorption, thermal and catalytic combustion, phytocatalytic combustion, and biological methods. Biological methods include biotrickling filters, which are filters that move the polluted air and a recycled liquid through a packed bed for the creation of a biofilm. These biofilms facilitate the degradation of toluene in the air for pollution control (Cox et al. 2000). Experiments have been conducted in which Acinetobacter genospecies, a toluene-degrading bacteria, was isolated from a trickle bed air biofilter (TBAB). This newer bacteria showed excellent degradation capabilities. Biofilters are a relatively inexpensive way to eliminate toluene in the air (Hori et al. 2001).

Recently, non-thermal plasma techniques have become prevalent innovative techniques in removing volatile organic compounds from the air. Toluene was removed in a non-thermal reactor at room temperature with a 93% removal efficiency. The experiment yielded decomposition products that included ozone, carbon dioxide, nitric oxide, and nitrogen dioxide (Mista and Kacprzyk 2008).

**6.3.2.2 Water**

There is potential for rapid degradation of toluene in water, especially if there is an electron acceptor available for oxidation (Evans et al. 1991). In surface waters, the biodegradation half-life of toluene was estimated to range from 4 to 22 days and the biodegradation half-life of toluene in groundwater was estimated to range from 7 to 28 days (Howard et al. 1991).

However, groundwater sometimes contains low amounts of dissolved oxygen. Anaerobic degradation of toluene, in this case, is an important fate process in the water (Evans et al. 1991). The biodegradation of toluene in groundwater can be enhanced by the presence of alternative electron acceptors, such as sulfate, nitrate, potassium, bicarbonate, and phosphate (Acton and Barker 1992; Armstrong et al. 1991; Hutchins 1991, Evans et al. 1991). Complete mineralization is possible under the right conditions. Edwards et al. (1992) found that toluene was completely mineralized to carbon dioxide and biomass by an aquifer-derived microorganism that used sulfate as a terminal electron acceptor. The authors found that toluene degradation stopped when the sulfate was removed, and started back up again once the sulfate was added again.
Microbial degradation in contaminated groundwater is also dependent on the depth and placement of the contamination. For instance, toluene degraders, related to *Geobacter* spp., *Desulfocapsa* spp., and *Sedimentibacter* spp. exist primarily in the biogeochemical gradient zone underneath contaminated plume cores. BTEX was found to exist with sulfate and those anaerobic toluene degraders in that gradient zone in a contaminated tar oil plume (Winderl et al. 2007).

Toluene can also be removed in aerobic conditions. In a laboratory study, toluene was removed from waste water by being stripped in an air stripping tank and subsequently degraded by *Pseudomonas putida* in a bioreactor (Dahlan et al. 1999). In a modified closed bottle study (OECD method 301D) referred to as a BOD$_{28}$ study (the biochemical oxygen demand after a 28-day incubation period), toluene degradation was observed at 93% after 14 days at a concentration of 50 mg/L and was reported to be readily biodegradable (Lapertot and Pulgarin 2006).

### 6.3.2.3 Sediment and Soil

Biodegradation of BTEX in soils can be affected by pH, temperature, and salinity. The bacteria responsible for degrading BTEX have a reduced growth rate at highly acidic and alkaline conditions, low and high temperatures, and salty conditions (You et al. 2013). Soils contaminated specifically with toluene can be effectively remediated with a combination of soil vapor extraction and bioremediation. Soils are required to have an organic matter content <14% in order for soil vapor extraction to be effective (Soares et al. 2013).

It was discovered that the concentration of toluene in bioremediation practices has an effect on microbial compositions (Hubert et al. 1999). Addition of large numbers of bacterial cells to toluene-contaminated soils may have no benefit if the concentration of toluene is too low for the bacteria to maintain metabolic activity (Roch and Alexander 1997). Likewise, toluene degradation by bacterial cells is dependent on the types of bacteria. Growth of one strain exposed to a small concentration of toluene (0.01%) was negligible when compared to another strain (Hubert et al. 1999).

In aerobic soils, oxygen acts as the terminal electron acceptor in degradation of the ring cleavage products. Under anaerobic conditions, nitrogen or sulfate can act as the terminal electron acceptor (Beller et al. 1992a, 1992b; Dolfing et al. 1990; Evans et al. 1991). Under favorable conditions (presence of electron acceptors, nutrients, and oxidizable compounds), laboratory studies show that BTEX compounds
are also degraded by bacteria in anaerobic (Langenhoff et al. 1996) or oxygen-limited environments (Lovley 1997; Olsen et al. 1995). Under sulfate-reducing conditions, less than 10% of the toluene carbon was metabolized to benzylsuccinic acid and benzylfumaric acid, whereas >80% was mineralized to carbon dioxide (Beller et al. 1992a). The half-life for biodegradation in soil under laboratory conditions may be as short as 1 hour (Claus and Walker 1964). Based on data from the aerobic degradation of toluene in water, the biodegradation half-life of toluene in soils is expected to range from 4 to 22 days (Howard et al. 1991). Soil biodegradation is not impeded by adsorption (Robinson et al. 1990). The wood-degrading, white-rot fungus, *Phanerochaete chrysoporium*, mineralizes 50% of 2 ppm aqueous solutions of toluene or BTEX compounds to carbon dioxide within 5 days. Non-ligninolytic conditions are favored (Yadav and Reddy 1993).

6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT

Reliable evaluation of the potential for human exposure to toluene depends in part on the reliability of supporting analytical data from environmental samples and biological specimens. Concentrations of toluene in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of current analytical methods. In reviewing data on toluene levels monitored or estimated in the environment, it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods available for monitoring toluene in a variety of environmental media are detailed in Chapter 7.

6.4.1 Air

 Ambient air levels of toluene are typically reported as micrograms per cubic meter of air (µg/m³) or part per billion by volume (ppbv); 3.76 µg/m³ of toluene is equivalent to 1.00 ppbv (see Chapter 4). Occasionally, monitoring data will be reported as parts per billion of carbon (ppbC). The unit ppbC is equivalent to ppbv multiplied by the number of carbons of the analyte.

The EPA Air Quality System (AQS) contains monitoring data of criteria air pollutants and HAPs. Detailed air monitoring data for toluene in various cities/counties in the United States for 2013 are shown in Table 6-3. These data are reported as ppbC. Daily arithmetic mean concentrations of toluene ranged from 0.136 to 35.3 ppbC (0.0194–5.04 ppbv), which were lower than the concentrations dating back to
### Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anchorage, Alaska</td>
<td>45</td>
<td>9.111</td>
<td>8.819</td>
<td>5.64</td>
</tr>
<tr>
<td>Phoenix, Arizona</td>
<td>23</td>
<td>5.922</td>
<td>3.505</td>
<td>5.25</td>
</tr>
<tr>
<td>Phoenix, Arizona</td>
<td>45</td>
<td>5.997</td>
<td>5.606</td>
<td>3.82</td>
</tr>
<tr>
<td>Phoenix, Arizona</td>
<td>6</td>
<td>7.385</td>
<td>6.328</td>
<td>5.55</td>
</tr>
<tr>
<td>Phoenix, Arizona</td>
<td>15</td>
<td>4.957</td>
<td>2.072</td>
<td>4.58</td>
</tr>
<tr>
<td>Phoenix, Arizona</td>
<td>1</td>
<td>4.120</td>
<td>0.000</td>
<td>4.12</td>
</tr>
<tr>
<td>Queen Valley, Arizona</td>
<td>15</td>
<td>0.602</td>
<td>0.442</td>
<td>0.42</td>
</tr>
<tr>
<td>Queen Valley, Arizona</td>
<td>42</td>
<td>0.623</td>
<td>1.059</td>
<td>0.38</td>
</tr>
<tr>
<td>Livermore, California</td>
<td>23</td>
<td>2.753</td>
<td>2.517</td>
<td>1.898</td>
</tr>
<tr>
<td>Livermore, California</td>
<td>5,244</td>
<td>3.238</td>
<td>4.237</td>
<td>1.6682</td>
</tr>
<tr>
<td>Oakland, California</td>
<td>23</td>
<td>4.135</td>
<td>2.825</td>
<td>3.2</td>
</tr>
<tr>
<td>Oakland, California</td>
<td>23</td>
<td>3.728</td>
<td>5.581</td>
<td>1.83</td>
</tr>
<tr>
<td>California</td>
<td>5,377</td>
<td>0.817</td>
<td>0.438</td>
<td>0.6805</td>
</tr>
<tr>
<td>Chico, California</td>
<td>31</td>
<td>3.299</td>
<td>2.620</td>
<td>2.31</td>
</tr>
<tr>
<td>Concord, California</td>
<td>23</td>
<td>1.260</td>
<td>0.895</td>
<td>0.894</td>
</tr>
<tr>
<td>Richmond, California</td>
<td>22</td>
<td>2.106</td>
<td>1.147</td>
<td>1.77</td>
</tr>
<tr>
<td>Crockett, California</td>
<td>21</td>
<td>1.166</td>
<td>0.582</td>
<td>1.15</td>
</tr>
<tr>
<td>Bethel Island, California</td>
<td>15</td>
<td>1.640</td>
<td>2.105</td>
<td>1.058</td>
</tr>
<tr>
<td>San Pablo, California</td>
<td>23</td>
<td>2.552</td>
<td>1.491</td>
<td>2.1</td>
</tr>
<tr>
<td>Martinez, California</td>
<td>23</td>
<td>1.471</td>
<td>1.167</td>
<td>1.09</td>
</tr>
<tr>
<td>San Ramon, California</td>
<td>5,423</td>
<td>1.570</td>
<td>1.360</td>
<td>1.1306</td>
</tr>
<tr>
<td>Fresno, California</td>
<td>31</td>
<td>4.503</td>
<td>3.625</td>
<td>4.2</td>
</tr>
<tr>
<td>Parlier, California</td>
<td>152</td>
<td>1.443</td>
<td>1.965</td>
<td>1</td>
</tr>
<tr>
<td>Clovis, California</td>
<td>142</td>
<td>1.670</td>
<td>1.524</td>
<td>1.2</td>
</tr>
<tr>
<td>Calexico, California</td>
<td>31</td>
<td>9.847</td>
<td>7.093</td>
<td>7</td>
</tr>
<tr>
<td>Bakersfield, California</td>
<td>20</td>
<td>5.404</td>
<td>6.914</td>
<td>3.92</td>
</tr>
<tr>
<td>Bakersfield, California</td>
<td>23</td>
<td>5.168</td>
<td>6.317</td>
<td>3.57</td>
</tr>
<tr>
<td>Bakersfield, California</td>
<td>146</td>
<td>3.839</td>
<td>3.124</td>
<td>2.6</td>
</tr>
<tr>
<td>Shafter, California</td>
<td>47</td>
<td>3.309</td>
<td>3.418</td>
<td>2.2</td>
</tr>
<tr>
<td>Azusa, California</td>
<td>31</td>
<td>6.390</td>
<td>5.036</td>
<td>4.69</td>
</tr>
<tr>
<td>Burbank, California</td>
<td>29</td>
<td>8.446</td>
<td>7.019</td>
<td>5.25</td>
</tr>
<tr>
<td>Los Angeles, California</td>
<td>31</td>
<td>7.294</td>
<td>4.967</td>
<td>5.39</td>
</tr>
<tr>
<td>Pico Rivera, California</td>
<td>679</td>
<td>5.512</td>
<td>3.293</td>
<td>4.59</td>
</tr>
<tr>
<td>Long Beach, California</td>
<td>22</td>
<td>3.971</td>
<td>2.970</td>
<td>2.87</td>
</tr>
<tr>
<td>Madera, California</td>
<td>46</td>
<td>0.813</td>
<td>0.580</td>
<td>0.7</td>
</tr>
<tr>
<td>San Rafael, California</td>
<td>22</td>
<td>2.279</td>
<td>1.749</td>
<td>1.684</td>
</tr>
<tr>
<td>San Francisco-Oakland-Fremont, California</td>
<td>22</td>
<td>0.518</td>
<td>0.392</td>
<td>0.518</td>
</tr>
<tr>
<td>Napa, California</td>
<td>22</td>
<td>3.166</td>
<td>2.179</td>
<td>2.93</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
# Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roseville, California</td>
<td>31</td>
<td>2.461</td>
<td>1.749</td>
<td>1.96</td>
</tr>
<tr>
<td>Rubidoux, California</td>
<td>31</td>
<td>6.117</td>
<td>4.095</td>
<td>4.9</td>
</tr>
<tr>
<td>Chula Vista, California</td>
<td>30</td>
<td>2.714</td>
<td>1.986</td>
<td>2.31</td>
</tr>
<tr>
<td>El Cajon, California</td>
<td>30</td>
<td>4.510</td>
<td>2.766</td>
<td>3.64</td>
</tr>
<tr>
<td>San Francisco, California</td>
<td>22</td>
<td>2.092</td>
<td>1.384</td>
<td>1.61</td>
</tr>
<tr>
<td>San Francisco, California</td>
<td>2</td>
<td>1.390</td>
<td>0.085</td>
<td>1.45</td>
</tr>
<tr>
<td>San Francisco, California</td>
<td>31</td>
<td>3.132</td>
<td>2.003</td>
<td>2.8</td>
</tr>
<tr>
<td>Stockton, California</td>
<td>30</td>
<td>4.356</td>
<td>3.829</td>
<td>2.31</td>
</tr>
<tr>
<td>Redwood City, California</td>
<td>23</td>
<td>3.911</td>
<td>2.918</td>
<td>2.46</td>
</tr>
<tr>
<td>San Jose, California</td>
<td>44</td>
<td>4.374</td>
<td>4.097</td>
<td>2.771</td>
</tr>
<tr>
<td>San Jose, California</td>
<td>31</td>
<td>6.063</td>
<td>5.259</td>
<td>4.76</td>
</tr>
<tr>
<td>Cupertino, California</td>
<td>44</td>
<td>1.248</td>
<td>0.644</td>
<td>1.129</td>
</tr>
<tr>
<td>Vallejo, California</td>
<td>20</td>
<td>2.400</td>
<td>2.353</td>
<td>1.32</td>
</tr>
<tr>
<td>Santa Rosa, California</td>
<td>23</td>
<td>2.275</td>
<td>1.252</td>
<td>2.24</td>
</tr>
<tr>
<td>Simi Valley, California</td>
<td>26</td>
<td>3.236</td>
<td>1.756</td>
<td>2.8</td>
</tr>
<tr>
<td>Denver, Colorado</td>
<td>41</td>
<td>8.523</td>
<td>4.078</td>
<td>7.83</td>
</tr>
<tr>
<td>Parachute, Colorado</td>
<td>37</td>
<td>7.888</td>
<td>4.330</td>
<td>7.58</td>
</tr>
<tr>
<td>Rifle, Colorado</td>
<td>43</td>
<td>5.161</td>
<td>2.245</td>
<td>4.54</td>
</tr>
<tr>
<td>Silt, Colorado</td>
<td>41</td>
<td>6.525</td>
<td>4.690</td>
<td>4.99</td>
</tr>
<tr>
<td>Carbondale, Colorado</td>
<td>22</td>
<td>10.049</td>
<td>11.033</td>
<td>5.8</td>
</tr>
<tr>
<td>Grand Junction, Colorado</td>
<td>45</td>
<td>4.696</td>
<td>3.164</td>
<td>3.79</td>
</tr>
<tr>
<td>Platteville, Colorado</td>
<td>37</td>
<td>8.209</td>
<td>4.705</td>
<td>7.39</td>
</tr>
<tr>
<td>Westport, Connecticut</td>
<td>2,005</td>
<td>0.936</td>
<td>0.847</td>
<td>0.67</td>
</tr>
<tr>
<td>East Hartford, Connecticut</td>
<td>2,008</td>
<td>2.375</td>
<td>2.613</td>
<td>1.6</td>
</tr>
<tr>
<td>New Haven, Connecticut</td>
<td>1,337</td>
<td>4.627</td>
<td>7.395</td>
<td>2.29</td>
</tr>
<tr>
<td>New Castle, Delaware</td>
<td>12</td>
<td>1.917</td>
<td>3.881</td>
<td>0.8</td>
</tr>
<tr>
<td>Wilmington, Delaware</td>
<td>10</td>
<td>1.570</td>
<td>0.540</td>
<td>1.5</td>
</tr>
<tr>
<td>Washington, District of Columbia</td>
<td>60</td>
<td>2.218</td>
<td>1.368</td>
<td>1.77</td>
</tr>
<tr>
<td>Washington, District of Columbia</td>
<td>29</td>
<td>3.209</td>
<td>1.661</td>
<td>2.85</td>
</tr>
<tr>
<td>Washington, District of Columbia</td>
<td>45</td>
<td>1.513</td>
<td>0.920</td>
<td>1.3</td>
</tr>
<tr>
<td>Fort Lauderdale, Florida</td>
<td>29</td>
<td>3.806</td>
<td>2.851</td>
<td>3.36</td>
</tr>
<tr>
<td>Davie, Florida</td>
<td>30</td>
<td>6.040</td>
<td>2.981</td>
<td>5.51</td>
</tr>
<tr>
<td>Dania, Florida</td>
<td>29</td>
<td>35.326</td>
<td>16.243</td>
<td>32.59</td>
</tr>
<tr>
<td>Valrico, Florida</td>
<td>28</td>
<td>1.213</td>
<td>0.868</td>
<td>1.09</td>
</tr>
<tr>
<td>Winter Park, Florida</td>
<td>29</td>
<td>1.654</td>
<td>0.765</td>
<td>1.6</td>
</tr>
<tr>
<td>Saint Petersburg, Florida</td>
<td>25</td>
<td>2.104</td>
<td>1.672</td>
<td>1.53</td>
</tr>
<tr>
<td>Pinellas Park, Florida</td>
<td>27</td>
<td>2.592</td>
<td>1.576</td>
<td>2.3</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
### Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macon, Georgia</td>
<td>13</td>
<td>0.692</td>
<td>0.417</td>
<td>0.6</td>
</tr>
<tr>
<td>Savannah Georgia</td>
<td>12</td>
<td>0.467</td>
<td>0.331</td>
<td>0.6</td>
</tr>
<tr>
<td>Douglas, Georgia</td>
<td>14</td>
<td>0.136</td>
<td>0.174</td>
<td>0</td>
</tr>
<tr>
<td>Atlanta-Sandy Springs-Marietta, Georgia</td>
<td>14</td>
<td>0.364</td>
<td>0.128</td>
<td>0.4</td>
</tr>
<tr>
<td>Atlanta-Sandy Springs-Marietta, Georgia</td>
<td>29</td>
<td>2.328</td>
<td>1.620</td>
<td>1.7</td>
</tr>
<tr>
<td>Atlanta-Sandy Springs-Marietta, Georgia</td>
<td>29</td>
<td>0.931</td>
<td>0.626</td>
<td>0.6</td>
</tr>
<tr>
<td>Atlanta-Sandy Springs-Marietta, Georgia</td>
<td>22</td>
<td>1.073</td>
<td>0.846</td>
<td>0.9</td>
</tr>
<tr>
<td>Atlanta-Sandy Springs-Marietta, Georgia</td>
<td>363</td>
<td>0.906</td>
<td>1.400</td>
<td>0.61</td>
</tr>
<tr>
<td>Atlanta-Sandy Springs-Marietta, Georgia</td>
<td>27</td>
<td>0.826</td>
<td>0.540</td>
<td>0.6</td>
</tr>
<tr>
<td>Atlanta-Sandy Springs-Marietta, Georgia</td>
<td>14</td>
<td>0.300</td>
<td>0.192</td>
<td>0.3</td>
</tr>
<tr>
<td>Conyers, Georgia</td>
<td>30</td>
<td>1.227</td>
<td>0.594</td>
<td>1.1</td>
</tr>
<tr>
<td>Schiller Park, Illinois</td>
<td>45</td>
<td>3.211</td>
<td>2.360</td>
<td>2.81</td>
</tr>
<tr>
<td>Northbrook, Illinois</td>
<td>45</td>
<td>2.690</td>
<td>1.217</td>
<td>2.49</td>
</tr>
<tr>
<td>Northbrook, Illinois</td>
<td>45</td>
<td>3.384</td>
<td>1.484</td>
<td>3.08</td>
</tr>
<tr>
<td>Roxana, Illinois</td>
<td>44</td>
<td>3.115</td>
<td>1.915</td>
<td>2.92</td>
</tr>
<tr>
<td>Clarksville, Indiana</td>
<td>59</td>
<td>4.095</td>
<td>3.534</td>
<td>3.2</td>
</tr>
<tr>
<td>Gary, Indiana</td>
<td>5,953</td>
<td>1.259</td>
<td>1.879</td>
<td>0.81</td>
</tr>
<tr>
<td>Gary, Indiana</td>
<td>54</td>
<td>1.496</td>
<td>0.974</td>
<td>1.2</td>
</tr>
<tr>
<td>Indianapolis, Indiana</td>
<td>4,769</td>
<td>2.820</td>
<td>4.084</td>
<td>1.47</td>
</tr>
<tr>
<td>Cedar Rapids, Iowa</td>
<td>31</td>
<td>2.455</td>
<td>1.891</td>
<td>1.89</td>
</tr>
<tr>
<td>Cedar Rapids, Iowa</td>
<td>31</td>
<td>1.645</td>
<td>1.203</td>
<td>1.21</td>
</tr>
<tr>
<td>Des Moines, Iowa</td>
<td>25</td>
<td>2.234</td>
<td>1.467</td>
<td>1.61</td>
</tr>
<tr>
<td>Des Moines, Iowa</td>
<td>25</td>
<td>1.461</td>
<td>0.692</td>
<td>1.35</td>
</tr>
<tr>
<td>Davenport, Iowa</td>
<td>31</td>
<td>1.806</td>
<td>0.958</td>
<td>1.54</td>
</tr>
<tr>
<td>Davenport, Iowa</td>
<td>31</td>
<td>1.220</td>
<td>0.667</td>
<td>1.01</td>
</tr>
<tr>
<td>Ashland, Kentucky</td>
<td>45</td>
<td>2.094</td>
<td>1.162</td>
<td>1.79</td>
</tr>
<tr>
<td>Carter County, Kentucky</td>
<td>45</td>
<td>0.785</td>
<td>0.442</td>
<td>0.69</td>
</tr>
<tr>
<td>Lexington-Fayette, Kentucky</td>
<td>44</td>
<td>2.446</td>
<td>1.534</td>
<td>2.17</td>
</tr>
<tr>
<td>Smithland, Kentucky</td>
<td>45</td>
<td>0.738</td>
<td>0.340</td>
<td>0.68</td>
</tr>
<tr>
<td>Calvert City, Kentucky</td>
<td>45</td>
<td>0.825</td>
<td>0.484</td>
<td>0.67</td>
</tr>
<tr>
<td>Calvert City, Kentucky</td>
<td>23</td>
<td>1.602</td>
<td>0.545</td>
<td>1.63</td>
</tr>
<tr>
<td>Calvert City, Kentucky</td>
<td>45</td>
<td>1.040</td>
<td>0.450</td>
<td>0.95</td>
</tr>
<tr>
<td>Calvert City, Kentucky</td>
<td>45</td>
<td>1.405</td>
<td>1.239</td>
<td>1.02</td>
</tr>
<tr>
<td>Marshall, Kentucky</td>
<td>45</td>
<td>1.318</td>
<td>0.769</td>
<td>1.05</td>
</tr>
</tbody>
</table>
### Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascension County, Louisiana</td>
<td>354</td>
<td>1.665</td>
<td>1.381</td>
<td>1.1</td>
</tr>
<tr>
<td>Ascension County, Louisiana</td>
<td>44</td>
<td>1.623</td>
<td>0.717</td>
<td>1.5</td>
</tr>
<tr>
<td>Baton Rouge, Louisiana</td>
<td>1,366</td>
<td>2.674</td>
<td>3.579</td>
<td>1.8</td>
</tr>
<tr>
<td>Baton Rouge, Louisiana</td>
<td>40</td>
<td>2.573</td>
<td>1.317</td>
<td>2.3</td>
</tr>
<tr>
<td>East Baton Rouge, Louisiana</td>
<td>332</td>
<td>0.789</td>
<td>0.419</td>
<td>0.7</td>
</tr>
<tr>
<td>East Baton Rouge, Louisiana</td>
<td>41</td>
<td>0.859</td>
<td>0.332</td>
<td>0.8</td>
</tr>
<tr>
<td>Iberville County, Louisiana</td>
<td>752</td>
<td>1.634</td>
<td>3.333</td>
<td>1.2</td>
</tr>
<tr>
<td>Iberville County, Louisiana</td>
<td>45</td>
<td>1.440</td>
<td>0.906</td>
<td>1.2</td>
</tr>
<tr>
<td>Lewiston, Maine</td>
<td>39</td>
<td>1.892</td>
<td>1.064</td>
<td>1.69</td>
</tr>
<tr>
<td>Presque Isle, Maine</td>
<td>28</td>
<td>1.664</td>
<td>1.281</td>
<td>1.3</td>
</tr>
<tr>
<td>Portland, Maine</td>
<td>40</td>
<td>1.749</td>
<td>0.845</td>
<td>1.61</td>
</tr>
<tr>
<td>Portland, Maine</td>
<td>42</td>
<td>1.916</td>
<td>1.002</td>
<td>1.85</td>
</tr>
<tr>
<td>Cumberland, Maine</td>
<td>3,282</td>
<td>0.747</td>
<td>0.476</td>
<td>0.63</td>
</tr>
<tr>
<td>Hancock, Maine</td>
<td>1,271</td>
<td>0.159</td>
<td>0.229</td>
<td>0</td>
</tr>
<tr>
<td>Rumford, Maine</td>
<td>43</td>
<td>1.749</td>
<td>0.810</td>
<td>1.7</td>
</tr>
<tr>
<td>Bangor, Maine</td>
<td>43</td>
<td>2.419</td>
<td>2.952</td>
<td>1.67</td>
</tr>
<tr>
<td>Essex, Maryland</td>
<td>2,136</td>
<td>3.153</td>
<td>3.411</td>
<td>2.16</td>
</tr>
<tr>
<td>Essex, Maryland</td>
<td>42</td>
<td>2.190</td>
<td>1.252</td>
<td>2</td>
</tr>
<tr>
<td>Essex, Maryland</td>
<td>44</td>
<td>3.314</td>
<td>1.664</td>
<td>3.3</td>
</tr>
<tr>
<td>Beltsville, Maryland</td>
<td>236</td>
<td>2.083</td>
<td>1.503</td>
<td>1.68</td>
</tr>
<tr>
<td>Beltsville, Maryland</td>
<td>45</td>
<td>1.723</td>
<td>0.844</td>
<td>1.44</td>
</tr>
<tr>
<td>Beltsville, Maryland</td>
<td>45</td>
<td>1.262</td>
<td>0.635</td>
<td>1.2</td>
</tr>
<tr>
<td>Baltimore, Maryland</td>
<td>40</td>
<td>1.743</td>
<td>0.848</td>
<td>1.7</td>
</tr>
<tr>
<td>Lynn, Massachusetts</td>
<td>57</td>
<td>1.419</td>
<td>1.404</td>
<td>1</td>
</tr>
<tr>
<td>Lynn, Massachusetts</td>
<td>14</td>
<td>1.564</td>
<td>2.122</td>
<td>0.9</td>
</tr>
<tr>
<td>Boston, Massachusetts</td>
<td>59</td>
<td>3.119</td>
<td>2.464</td>
<td>2.4</td>
</tr>
<tr>
<td>Boston, Massachusetts</td>
<td>29</td>
<td>3.459</td>
<td>2.726</td>
<td>2.6</td>
</tr>
<tr>
<td>Midland, Michigan</td>
<td>55</td>
<td>11.382</td>
<td>15.259</td>
<td>6.7</td>
</tr>
<tr>
<td>Midland, Michigan</td>
<td>55</td>
<td>4.700</td>
<td>6.382</td>
<td>3</td>
</tr>
<tr>
<td>Midland, Michigan</td>
<td>54</td>
<td>4.237</td>
<td>2.654</td>
<td>3.7</td>
</tr>
<tr>
<td>Midland, Michigan</td>
<td>56</td>
<td>3.064</td>
<td>2.737</td>
<td>2.6</td>
</tr>
<tr>
<td>Detroit, Michigan</td>
<td>31</td>
<td>3.358</td>
<td>8.100</td>
<td>1.7</td>
</tr>
<tr>
<td>Dearborn, Michigan</td>
<td>44</td>
<td>2.203</td>
<td>1.263</td>
<td>1.93</td>
</tr>
<tr>
<td>Detroit, Michigan</td>
<td>56</td>
<td>11.509</td>
<td>6.751</td>
<td>10.5</td>
</tr>
<tr>
<td>Detroit, Michigan</td>
<td>1</td>
<td>7.630</td>
<td>0.000</td>
<td>7.63</td>
</tr>
<tr>
<td>Detroit, Michigan</td>
<td>54</td>
<td>6.855</td>
<td>4.941</td>
<td>5.88</td>
</tr>
<tr>
<td>Detroit, Michigan</td>
<td>56</td>
<td>14.893</td>
<td>11.019</td>
<td>12.46</td>
</tr>
<tr>
<td>Detroit, Michigan</td>
<td>51</td>
<td>9.318</td>
<td>5.907</td>
<td>7.77</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
### Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blaine, Minnesota</td>
<td>52</td>
<td>1.725</td>
<td>1.159</td>
<td>1.49</td>
</tr>
<tr>
<td>Rosemount, Minnesota</td>
<td>51</td>
<td>1.343</td>
<td>0.862</td>
<td>1.13</td>
</tr>
<tr>
<td>Inver Grove Heights, Minnesota</td>
<td>50</td>
<td>0.700</td>
<td>0.375</td>
<td>0.6</td>
</tr>
<tr>
<td>Rosemount, Minnesota</td>
<td>53</td>
<td>0.761</td>
<td>0.446</td>
<td>0.63</td>
</tr>
<tr>
<td>Rosemount, Minnesota</td>
<td>53</td>
<td>0.710</td>
<td>0.306</td>
<td>0.6</td>
</tr>
<tr>
<td>Apple Valley, Minnesota</td>
<td>53</td>
<td>1.189</td>
<td>0.975</td>
<td>0.95</td>
</tr>
<tr>
<td>Richfield, Minnesota</td>
<td>47</td>
<td>1.335</td>
<td>1.208</td>
<td>1.09</td>
</tr>
<tr>
<td>Minneapolis, Minnesota</td>
<td>16</td>
<td>2.425</td>
<td>1.492</td>
<td>1.93</td>
</tr>
<tr>
<td>Minneapolis, Minnesota</td>
<td>53</td>
<td>2.359</td>
<td>2.073</td>
<td>1.75</td>
</tr>
<tr>
<td>Minneapolis, Minnesota</td>
<td>51</td>
<td>2.063</td>
<td>1.379</td>
<td>1.71</td>
</tr>
<tr>
<td>Minneapolis, Minnesota</td>
<td>51</td>
<td>2.067</td>
<td>1.426</td>
<td>1.57</td>
</tr>
<tr>
<td>Minneapolis, Minnesota</td>
<td>53</td>
<td>2.032</td>
<td>1.674</td>
<td>1.63</td>
</tr>
<tr>
<td>Minneapolis, Minnesota</td>
<td>14</td>
<td>1.781</td>
<td>1.131</td>
<td>1.83</td>
</tr>
<tr>
<td>St. Louis Park, Minnesota</td>
<td>53</td>
<td>1.788</td>
<td>1.511</td>
<td>1.44</td>
</tr>
<tr>
<td>St. Paul, Minnesota</td>
<td>52</td>
<td>2.618</td>
<td>2.048</td>
<td>2.21</td>
</tr>
<tr>
<td>St. Paul, Minnesota</td>
<td>51</td>
<td>1.849</td>
<td>1.222</td>
<td>1.44</td>
</tr>
<tr>
<td>Duluth, Minnesota</td>
<td>49</td>
<td>1.983</td>
<td>1.583</td>
<td>1.6</td>
</tr>
<tr>
<td>St. Paul Park, Minnesota</td>
<td>51</td>
<td>2.044</td>
<td>1.266</td>
<td>1.7</td>
</tr>
<tr>
<td>St. Paul Park, Minnesota</td>
<td>51</td>
<td>2.002</td>
<td>1.266</td>
<td>1.67</td>
</tr>
<tr>
<td>Newport, Minnesota</td>
<td>51</td>
<td>2.675</td>
<td>1.681</td>
<td>2.18</td>
</tr>
<tr>
<td>Bayport, Minnesota</td>
<td>47</td>
<td>0.854</td>
<td>0.556</td>
<td>0.75</td>
</tr>
<tr>
<td>Columbus, Mississippi</td>
<td>45</td>
<td>1.832</td>
<td>1.045</td>
<td>1.46</td>
</tr>
<tr>
<td>Columbus, Mississippi</td>
<td>45</td>
<td>2.315</td>
<td>1.626</td>
<td>1.86</td>
</tr>
<tr>
<td>St. Louis, Missouri</td>
<td>45</td>
<td>2.360</td>
<td>0.995</td>
<td>2.11</td>
</tr>
<tr>
<td>Nashua, New Hampshire</td>
<td>2,726</td>
<td>0.467</td>
<td>0.337</td>
<td>0.39</td>
</tr>
<tr>
<td>Nashua, New Hampshire</td>
<td>10</td>
<td>1.330</td>
<td>0.577</td>
<td>1.3</td>
</tr>
<tr>
<td>Peterborough, New Hampshire</td>
<td>2,662</td>
<td>0.631</td>
<td>0.360</td>
<td>0.54</td>
</tr>
<tr>
<td>Peterborough, New Hampshire</td>
<td>10</td>
<td>0.980</td>
<td>0.839</td>
<td>0.7</td>
</tr>
<tr>
<td>Camden, New Jersey</td>
<td>42</td>
<td>8.830</td>
<td>4.478</td>
<td>7.91</td>
</tr>
<tr>
<td>North Brunswick Township, New Jersey</td>
<td>44</td>
<td>3.780</td>
<td>1.699</td>
<td>3.54</td>
</tr>
<tr>
<td>East Brunswick, New Jersey</td>
<td>594</td>
<td>1.051</td>
<td>0.918</td>
<td>0.8</td>
</tr>
<tr>
<td>Chester, New Jersey</td>
<td>45</td>
<td>3.319</td>
<td>3.016</td>
<td>2.81</td>
</tr>
<tr>
<td>Elizabeth, New Jersey</td>
<td>45</td>
<td>4.876</td>
<td>2.827</td>
<td>5.05</td>
</tr>
<tr>
<td>New York, New York</td>
<td>35</td>
<td>3.014</td>
<td>1.720</td>
<td>2.3</td>
</tr>
<tr>
<td>New York, New York</td>
<td>12</td>
<td>3.825</td>
<td>1.821</td>
<td>3.4</td>
</tr>
<tr>
<td>New York, New York</td>
<td>21</td>
<td>2.900</td>
<td>1.733</td>
<td>2.2</td>
</tr>
<tr>
<td>Rochester, New York</td>
<td>33</td>
<td>1.621</td>
<td>1.918</td>
<td>1.1</td>
</tr>
</tbody>
</table>
### Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asheville, North Carolina</td>
<td>45</td>
<td>2.964</td>
<td>1.850</td>
<td>2.4</td>
</tr>
<tr>
<td>Winston-Salem, North Carolina</td>
<td>44</td>
<td>2.948</td>
<td>2.521</td>
<td>2.1</td>
</tr>
<tr>
<td>Winston-Salem, North Carolina</td>
<td>4</td>
<td>3.400</td>
<td>1.558</td>
<td>3.4</td>
</tr>
<tr>
<td>Charlotte, North Carolina</td>
<td>43</td>
<td>2.730</td>
<td>1.578</td>
<td>2.4</td>
</tr>
<tr>
<td>Candor, North Carolina</td>
<td>45</td>
<td>0.800</td>
<td>0.390</td>
<td>0.7</td>
</tr>
<tr>
<td>Candor, North Carolina</td>
<td>14</td>
<td>0.850</td>
<td>0.429</td>
<td>0.7</td>
</tr>
<tr>
<td>Wilmington, North Carolina</td>
<td>45</td>
<td>1.136</td>
<td>0.870</td>
<td>1</td>
</tr>
<tr>
<td>Wilmington, North Carolina</td>
<td>8</td>
<td>2.000</td>
<td>1.311</td>
<td>1.6</td>
</tr>
<tr>
<td>Raleigh, North Carolina</td>
<td>45</td>
<td>2.604</td>
<td>2.313</td>
<td>1.9</td>
</tr>
<tr>
<td>Raleigh, North Carolina</td>
<td>14</td>
<td>2.086</td>
<td>1.612</td>
<td>1.9</td>
</tr>
<tr>
<td>Middletown, Ohio</td>
<td>11</td>
<td>1.991</td>
<td>1.668</td>
<td>1.4</td>
</tr>
<tr>
<td>Middletown, Ohio</td>
<td>29</td>
<td>2.117</td>
<td>1.303</td>
<td>1.7</td>
</tr>
<tr>
<td>Middletown, Ohio</td>
<td>31</td>
<td>1.971</td>
<td>1.053</td>
<td>1.8</td>
</tr>
<tr>
<td>Cleveland, Ohio</td>
<td>11</td>
<td>15.718</td>
<td>21.266</td>
<td>5</td>
</tr>
<tr>
<td>Brook Park, Ohio</td>
<td>11</td>
<td>9.273</td>
<td>16.867</td>
<td>1.5</td>
</tr>
<tr>
<td>Columbus, Ohio</td>
<td>13</td>
<td>1.738</td>
<td>0.556</td>
<td>1.4</td>
</tr>
<tr>
<td>Cincinnati, Ohio</td>
<td>31</td>
<td>4.932</td>
<td>3.228</td>
<td>4.6</td>
</tr>
<tr>
<td>Cincinnati, Ohio</td>
<td>58</td>
<td>3.871</td>
<td>7.507</td>
<td>2.6</td>
</tr>
<tr>
<td>Steubenville, Ohio</td>
<td>27</td>
<td>5.252</td>
<td>5.660</td>
<td>2.8</td>
</tr>
<tr>
<td>Portsmouth, Ohio</td>
<td>31</td>
<td>0.825</td>
<td>0.784</td>
<td>0.64</td>
</tr>
<tr>
<td>Franklin Furnace, Ohio</td>
<td>31</td>
<td>3.003</td>
<td>11.070</td>
<td>0.84</td>
</tr>
<tr>
<td>Franklin Furnace, Ohio</td>
<td>31</td>
<td>1.033</td>
<td>0.928</td>
<td>0.84</td>
</tr>
<tr>
<td>Yukon, Oklahoma</td>
<td>14</td>
<td>1.971</td>
<td>0.573</td>
<td>2.02</td>
</tr>
<tr>
<td>Oklahoma City, Oklahoma</td>
<td>30</td>
<td>1.585</td>
<td>1.493</td>
<td>1.11</td>
</tr>
<tr>
<td>Oklahoma City, Oklahoma</td>
<td>45</td>
<td>2.688</td>
<td>1.599</td>
<td>2.36</td>
</tr>
<tr>
<td>Tulsa, Oklahoma</td>
<td>45</td>
<td>4.886</td>
<td>3.550</td>
<td>4.1</td>
</tr>
<tr>
<td>Tulsa, Oklahoma</td>
<td>45</td>
<td>6.314</td>
<td>4.338</td>
<td>5.06</td>
</tr>
<tr>
<td>Tulsa, Oklahoma</td>
<td>45</td>
<td>4.526</td>
<td>3.606</td>
<td>3.71</td>
</tr>
<tr>
<td>Portland, Oregon</td>
<td>41</td>
<td>3.551</td>
<td>2.503</td>
<td>2.96</td>
</tr>
<tr>
<td>Portland, Oregon</td>
<td>19</td>
<td>3.531</td>
<td>2.285</td>
<td>3.54</td>
</tr>
<tr>
<td>La Grande, Oregon</td>
<td>28</td>
<td>5.144</td>
<td>0.996</td>
<td>5.04</td>
</tr>
<tr>
<td>Hillsboro, Oregon</td>
<td>36</td>
<td>2.314</td>
<td>1.831</td>
<td>2.04</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>681</td>
<td>3.223</td>
<td>1.998</td>
<td>2.65</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>13</td>
<td>3.713</td>
<td>1.657</td>
<td>3.59</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>44</td>
<td>3.127</td>
<td>1.988</td>
<td>2.5</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>13</td>
<td>3.609</td>
<td>1.879</td>
<td>4.03</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>42</td>
<td>1.117</td>
<td>0.647</td>
<td>1</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>45</td>
<td>2.522</td>
<td>1.398</td>
<td>2.2</td>
</tr>
</tbody>
</table>
## Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>44</td>
<td>3.505</td>
<td>2.433</td>
<td>2.8</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>43</td>
<td>1.756</td>
<td>1.673</td>
<td>1.4</td>
</tr>
<tr>
<td>Providence-New Bedford-Fall River Rhode Island</td>
<td>57</td>
<td>0.491</td>
<td>0.245</td>
<td>0.4</td>
</tr>
<tr>
<td>Providence, Rhode Island</td>
<td>53</td>
<td>2.228</td>
<td>1.823</td>
<td>1.7</td>
</tr>
<tr>
<td>Pawtucket, Rhode Island</td>
<td>53</td>
<td>3.647</td>
<td>2.797</td>
<td>3.1</td>
</tr>
<tr>
<td>East Providence, Rhode Island</td>
<td>468</td>
<td>1.948</td>
<td>1.571</td>
<td>1.5</td>
</tr>
<tr>
<td>East Providence, Rhode Island</td>
<td>51</td>
<td>1.496</td>
<td>1.022</td>
<td>1.2</td>
</tr>
<tr>
<td>East Providence, Rhode Island</td>
<td>51</td>
<td>1.422</td>
<td>0.859</td>
<td>1.3</td>
</tr>
<tr>
<td>San Antonio, Texas</td>
<td>50</td>
<td>2.633</td>
<td>2.129</td>
<td>2.03</td>
</tr>
<tr>
<td>Clute, Texas</td>
<td>55</td>
<td>1.672</td>
<td>1.419</td>
<td>1.47</td>
</tr>
<tr>
<td>Brownsville, Texas</td>
<td>52</td>
<td>1.835</td>
<td>1.027</td>
<td>1.68</td>
</tr>
<tr>
<td>Dallas, Texas</td>
<td>4,540</td>
<td>2.604</td>
<td>12.247</td>
<td>1.31</td>
</tr>
<tr>
<td>Dallas, Texas</td>
<td>55</td>
<td>2.449</td>
<td>2.525</td>
<td>1.75</td>
</tr>
<tr>
<td>Denton, Texas</td>
<td>54</td>
<td>2.353</td>
<td>2.374</td>
<td>1.47</td>
</tr>
<tr>
<td>Odessa, Texas</td>
<td>6,939</td>
<td>3.485</td>
<td>5.354</td>
<td>1.81</td>
</tr>
<tr>
<td>Midlothian, Texas</td>
<td>53</td>
<td>1.028</td>
<td>0.951</td>
<td>0.91</td>
</tr>
<tr>
<td>Ellis, Texas</td>
<td>53</td>
<td>1.012</td>
<td>0.569</td>
<td>0.98</td>
</tr>
<tr>
<td>El Paso, Texas</td>
<td>4,826</td>
<td>5.172</td>
<td>9.110</td>
<td>2.37</td>
</tr>
<tr>
<td>El Paso, Texas</td>
<td>49</td>
<td>4.934</td>
<td>3.214</td>
<td>3.85</td>
</tr>
<tr>
<td>El Paso, Texas</td>
<td>23</td>
<td>6.136</td>
<td>5.072</td>
<td>4.2</td>
</tr>
<tr>
<td>Socorro, Texas</td>
<td>53</td>
<td>5.420</td>
<td>3.247</td>
<td>5.11</td>
</tr>
<tr>
<td>El Paso, Texas</td>
<td>4,453</td>
<td>3.820</td>
<td>6.579</td>
<td>1.6</td>
</tr>
<tr>
<td>Texas City, Texas</td>
<td>51</td>
<td>2.152</td>
<td>1.015</td>
<td>1.96</td>
</tr>
<tr>
<td>Galveston, Texas</td>
<td>24</td>
<td>0.878</td>
<td>0.591</td>
<td>0.91</td>
</tr>
<tr>
<td>Gregg, Texas</td>
<td>55</td>
<td>1.901</td>
<td>1.007</td>
<td>1.68</td>
</tr>
<tr>
<td>Harris, Texas</td>
<td>25</td>
<td>2.954</td>
<td>1.971</td>
<td>2.45</td>
</tr>
<tr>
<td>Channelview, Texas</td>
<td>7,080</td>
<td>4.500</td>
<td>4.429</td>
<td>3.26</td>
</tr>
<tr>
<td>Harris, Texas</td>
<td>25</td>
<td>2.209</td>
<td>1.994</td>
<td>1.75</td>
</tr>
<tr>
<td>Channelview, Texas</td>
<td>53</td>
<td>5.073</td>
<td>3.183</td>
<td>4.69</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>54</td>
<td>3.442</td>
<td>3.284</td>
<td>2.59</td>
</tr>
<tr>
<td>Galena Park, Texas</td>
<td>47</td>
<td>5.671</td>
<td>3.854</td>
<td>5.04</td>
</tr>
<tr>
<td>Baytown, Texas</td>
<td>46</td>
<td>2.697</td>
<td>1.727</td>
<td>2.1</td>
</tr>
<tr>
<td>La Porte, Texas</td>
<td>55</td>
<td>2.349</td>
<td>2.558</td>
<td>1.47</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>4,724</td>
<td>3.113</td>
<td>4.518</td>
<td>1.64</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>49</td>
<td>5.280</td>
<td>5.118</td>
<td>4.48</td>
</tr>
<tr>
<td>Texas, Texas</td>
<td>54</td>
<td>5.989</td>
<td>7.437</td>
<td>4.69</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>55</td>
<td>5.137</td>
<td>14.841</td>
<td>2.17</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>4,901</td>
<td>4.262</td>
<td>5.162</td>
<td>2.68</td>
</tr>
</tbody>
</table>
Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deer Park, Texas</td>
<td>4,235</td>
<td>2.905</td>
<td>12.465</td>
<td>1.38</td>
</tr>
<tr>
<td>Deer Park, Texas</td>
<td>50</td>
<td>2.936</td>
<td>1.973</td>
<td>2.66</td>
</tr>
<tr>
<td>Deer Park, Texas</td>
<td>32</td>
<td>3.310</td>
<td>2.019</td>
<td>2.94</td>
</tr>
<tr>
<td>Pasadena, Texas</td>
<td>7</td>
<td>12.050</td>
<td>9.418</td>
<td>8.26</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>6,526</td>
<td>5.992</td>
<td>13.121</td>
<td>2.85</td>
</tr>
<tr>
<td>Harris, Texas</td>
<td>54</td>
<td>1.126</td>
<td>0.711</td>
<td>0.91</td>
</tr>
<tr>
<td>Mission, Texas</td>
<td>49</td>
<td>1.479</td>
<td>1.245</td>
<td>1.12</td>
</tr>
<tr>
<td>Greenville, Texas</td>
<td>53</td>
<td>1.239</td>
<td>0.701</td>
<td>1.19</td>
</tr>
<tr>
<td>Beaumont, Texas</td>
<td>51</td>
<td>2.394</td>
<td>1.554</td>
<td>2.03</td>
</tr>
<tr>
<td>Port Arthur, Texas</td>
<td>51</td>
<td>3.850</td>
<td>2.569</td>
<td>3.5</td>
</tr>
<tr>
<td>Port Arthur, Texas</td>
<td>47</td>
<td>10.656</td>
<td>7.928</td>
<td>8.89</td>
</tr>
<tr>
<td>Port Neches, Texas</td>
<td>56</td>
<td>1.265</td>
<td>0.728</td>
<td>1.12</td>
</tr>
<tr>
<td>Port Arthur, Texas</td>
<td>56</td>
<td>1.515</td>
<td>1.201</td>
<td>1.19</td>
</tr>
<tr>
<td>Port Arthur, Texas</td>
<td>53</td>
<td>1.754</td>
<td>0.954</td>
<td>1.61</td>
</tr>
<tr>
<td>Nederland, Texas</td>
<td>3,834</td>
<td>1.778</td>
<td>3.395</td>
<td>0.98</td>
</tr>
<tr>
<td>Beaumont, Texas</td>
<td>51</td>
<td>2.777</td>
<td>2.000</td>
<td>2.1</td>
</tr>
<tr>
<td>Johnson, Texas</td>
<td>55</td>
<td>1.221</td>
<td>0.782</td>
<td>1.05</td>
</tr>
<tr>
<td>Conroe, Texas</td>
<td>22</td>
<td>2.059</td>
<td>1.082</td>
<td>2.03</td>
</tr>
<tr>
<td>Corpus Christi, Texas</td>
<td>50</td>
<td>1.830</td>
<td>1.607</td>
<td>1.26</td>
</tr>
<tr>
<td>Corpus Christi, Texas</td>
<td>54</td>
<td>3.206</td>
<td>2.520</td>
<td>2.17</td>
</tr>
<tr>
<td>Corpus Christi, Texas</td>
<td>56</td>
<td>1.444</td>
<td>0.870</td>
<td>1.19</td>
</tr>
<tr>
<td>Corpus Christi, Texas</td>
<td>5,635</td>
<td>1.922</td>
<td>5.686</td>
<td>0.87</td>
</tr>
<tr>
<td>Fort Worth, Texas</td>
<td>4,461</td>
<td>2.223</td>
<td>2.930</td>
<td>1.42</td>
</tr>
<tr>
<td>Fort Worth, Texas</td>
<td>53</td>
<td>2.153</td>
<td>1.317</td>
<td>1.68</td>
</tr>
<tr>
<td>Grapevine, Texas</td>
<td>54</td>
<td>1.349</td>
<td>0.782</td>
<td>1.12</td>
</tr>
<tr>
<td>Austin, Texas</td>
<td>55</td>
<td>2.174</td>
<td>1.425</td>
<td>1.68</td>
</tr>
<tr>
<td>Laredo, Texas</td>
<td>50</td>
<td>7.192</td>
<td>5.914</td>
<td>5.95</td>
</tr>
<tr>
<td>Bountiful, Utah</td>
<td>41</td>
<td>7.332</td>
<td>8.964</td>
<td>5.23</td>
</tr>
<tr>
<td>Bountiful, Utah</td>
<td>41</td>
<td>7.976</td>
<td>7.386</td>
<td>6.12</td>
</tr>
<tr>
<td>Virginia Beach, Virginia</td>
<td>24</td>
<td>0.954</td>
<td>0.519</td>
<td>0.84</td>
</tr>
<tr>
<td>Groveton, Virginia</td>
<td>43</td>
<td>0.874</td>
<td>0.468</td>
<td>0.8</td>
</tr>
<tr>
<td>East Highland Park, Virginia</td>
<td>28</td>
<td>2.543</td>
<td>1.462</td>
<td>2.43</td>
</tr>
<tr>
<td>East Highland Park, Virginia</td>
<td>44</td>
<td>2.041</td>
<td>1.835</td>
<td>1.7</td>
</tr>
<tr>
<td>East Highland Park, Virginia</td>
<td>23</td>
<td>1.752</td>
<td>0.987</td>
<td>1.5</td>
</tr>
<tr>
<td>Hopewell, Virginia</td>
<td>43</td>
<td>2.441</td>
<td>2.029</td>
<td>1.92</td>
</tr>
<tr>
<td>Hopewell, Virginia</td>
<td>44</td>
<td>1.750</td>
<td>1.839</td>
<td>1.3</td>
</tr>
<tr>
<td>Virginia Beach, Virginia</td>
<td>45</td>
<td>1.780</td>
<td>1.129</td>
<td>1.3</td>
</tr>
<tr>
<td>Seattle, Washington</td>
<td>44</td>
<td>2.342</td>
<td>1.215</td>
<td>2.05</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
### Table 6-3. Toluene Levels in Ambient Air

<table>
<thead>
<tr>
<th>Sampling location</th>
<th>Number of samples</th>
<th>Daily arithmetic mean concentration (ppbC)</th>
<th>Standard deviation (ppbC)</th>
<th>Median (ppbC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horicon, Wisconsin</td>
<td>47</td>
<td>1.845</td>
<td>1.395</td>
<td>1.5</td>
</tr>
<tr>
<td>Horicon, Wisconsin</td>
<td>4</td>
<td>1.525</td>
<td>1.269</td>
<td>1.6</td>
</tr>
<tr>
<td>Milwaukee, Wisconsin</td>
<td>22</td>
<td>3.500</td>
<td>1.390</td>
<td>3.4</td>
</tr>
</tbody>
</table>

ppbC = parts per billion (carbon) = ppbv multiplied by the number of carbons in the analyte

Source: EPA 2013b
6. POTENTIAL FOR HUMAN EXPOSURE

sampling period from 13 semi-rural to urban locations in the United States. The states included Maine, Massachusetts, New Jersey, Pennsylvania, Ohio, Illinois, and California (Pankow et al. 2003). The arithmetic mean and median concentrations at these 13 locations were 0.22–2.7 and 0.10–2.4 ppbv (0.83–10.2 and 0.38–9.0 µg/m³), respectively. The measured concentrations exhibited seasonal trends, with the highest levels typically observed during the winter months, particularly in the more urban sampling locations. Older studies have reported toluene levels ranging from 0.9–70.1, 0.06–195, and 2.2–751.5 ppbv (3.4–263.6, 0.23–733.2, and 8.3–2,825.6 µg/m³) in rural (Khalil and Rasmussen 1992), urban (Armstrong et al. 1991; Chan et al. 1991b; Evans et al. 1992; Kelly et al. 1993), and source dominated air samples, respectively (Guldberg 1992; Kelly et al. 1993).

In a study conducted by Iovino et al. (2009), the authors found that the average toluene concentration in the Naples, Italy metropolitan area was 35.0 µg/m³ (9.31 ppbv). The average concentration near suburban areas was 16.2 µg/m³ (4.31 ppbv) and the average concentration far from suburban areas was 15.3 µg/m³ (4.07 ppbv). Higher toluene levels in the outdoor air can be due to location and proximity to urban areas.

Toluene was detected at 1.95 ppbv (7.33 µg/m³) in the outdoor air of the urban zone near a crude oil refinery located in Lithuania. This level was similar to the levels of toluene found in urban areas of European cities; however, there were much higher levels of toluene (21.4–98.1 ppbv or 80.5–369 µg/m³) in the traffic congested areas in those same cities (Baltrenas et al. 2011).

BTEX vehicle emissions from motor exhaust and emissions from the handling, distribution and storage of petrol are a major contributor of atmospheric toluene. Toluene concentrations in India were found to range from 3.26 to 13.68 µg/m³ (0.867–3.64 ppbv) in air samples collected from busy traffic sites (Deole et al. 2004). Toluene levels near an airport were found to be comparable to the atmospheric toluene levels of the neighborhoods near the airport; however, levels were about 70% lower for areas further from the airport. Toluene is generated from kerosene evaporation and combustion from the jet fuel in airplanes (Jung et al. 2011).

In Rome, Italy, the annual average concentrations of toluene in the air decreased from 100 µg/m³ (26.6 ppbv) in 1997 to 10.2 µg/m³ (2.71 ppbv) in 2008. This reduction of toluene in the air was attributed to the decrease of total aromatic hydrocarbons in gasoline, the prevalence of low emission cars, and the increase in refilling stations with closed-loop gasoline vapor systems (Ciarrocca et al. 2012). Concentrations of toluene in air from the inside of vehicles have been reported to range from 0.56 to 42.0 ppbv (2.1–157.9 µg/m³) (Chan et al. 1991a; Lawryk and Weisel 1996; Weisel et al. 1992).
Levels of toluene can be much greater in indoor air as compared to outdoor air depending upon the presence of potential exposure sources. For example, Curry et al. (1994) measured the indoor air concentrations of toluene during normal in home use of nail lacquer products at five different residences in California. The mean toluene levels measured in air during the nail lacquer application ranged from 3,200 to 9,200 µg/m³ (850–2,400 ppbv), while the post-application concentrations ranged from 200 to 1,700 µg/m³ (50–450 ppbv). Toluene was not detected in any of the air samples above the detection limits of 200 µg/m³ (50 ppbv) in air prior to the nail lacquer application.

Hamidin et al. (2013) reported that toluene concentrations in the internal garages and residential indoor air of 32 homes in Brisbane, Australia were much higher than toluene concentrations in the outdoor ambient air. The average toluene concentration in residential indoor air was 10.7 µg/m³ (2.84 ppbv), 25.5 µg/m³ (6.78 ppbv) in internal garages, and 2.3 µg/m³ (0.61 ppbv) in outdoor ambient air.

Toluene levels in indoor air from 16 newspaper stands located in Bari, Italy were shown to be substantially higher than the corresponding outdoor air levels (Caselli et al. 2009). The weekly mean concentrations of toluene in indoor air and outdoor air at these 16 stands are provided in Table 6-4, along with the indoor/outdoor (I/O) ratio of these levels at each site. The authors concluded that toluene levels were much higher inside the newspaper stands than outside because of the ink used to print the newspapers (Caselli et al. 2009).

Massolo et al. (2010) analyzed toluene levels in indoor versus outdoor air at different locations in La Plata, Argentina. The ratio of I/O toluene levels were 1.10, 1.79, 3.11, and 3.45 for industrial, urban, semi-rural, and residential locations, respectively. Both indoor and outdoor levels were highest for the industrialized locations characterized by petrochemical plants and urban locations with heavy vehicular traffic.

Indoor and in-vehicle toluene levels appear to be affected by seasonal changes (Montgomery and Kalman 1989; Weisel et al. 1992). Shields et al. (1996) compared indoor and outdoor levels of volatile organic compounds (VOCs) measured in three types of commercial buildings (telecommunication offices, data centers, and administrative offices) across the United States. The averaged I/O ratios for toluene were 1.6, 4.9, and 2.2 for telecommunication offices, data centers, and administrative offices, respectively. Ventilation differences between the types of buildings were shown to be a major factor in differences between I/O ratios for toluene and other VOCs at these facilities. Mukerjee et al. (1997) reported the
Table 6-4. Weekly Mean Toluene Concentrations (µg/m³) in Indoor Air at 16 Newspaper Stands and the Corresponding Outdoor Air Levels

<table>
<thead>
<tr>
<th>Newspaper stand</th>
<th>Mean indoor air level (µg/m³)</th>
<th>Mean outdoor air level (µg/m³)</th>
<th>I/O ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1,485.6</td>
<td>11.6</td>
<td>128</td>
</tr>
<tr>
<td>2</td>
<td>366.6</td>
<td>7.6</td>
<td>48</td>
</tr>
<tr>
<td>3</td>
<td>766.9</td>
<td>17.8</td>
<td>43.1</td>
</tr>
<tr>
<td>4</td>
<td>644.3</td>
<td>8.5</td>
<td>76</td>
</tr>
<tr>
<td>5</td>
<td>455.8</td>
<td>11.1</td>
<td>41.1</td>
</tr>
<tr>
<td>6</td>
<td>1,170.7</td>
<td>11.9</td>
<td>88.0</td>
</tr>
<tr>
<td>7</td>
<td>614.7</td>
<td>13.3</td>
<td>46.2</td>
</tr>
<tr>
<td>8</td>
<td>444.6</td>
<td>16.7</td>
<td>26.6</td>
</tr>
<tr>
<td>9</td>
<td>703.6</td>
<td>7.8</td>
<td>90</td>
</tr>
<tr>
<td>10</td>
<td>913.9</td>
<td>20.5</td>
<td>44.6</td>
</tr>
<tr>
<td>11</td>
<td>935.2</td>
<td>16.4</td>
<td>57.0</td>
</tr>
<tr>
<td>12</td>
<td>729.8</td>
<td>14.4</td>
<td>50.7</td>
</tr>
<tr>
<td>13</td>
<td>585.8</td>
<td>10.4</td>
<td>56.3</td>
</tr>
<tr>
<td>14</td>
<td>1,055.5</td>
<td>14.2</td>
<td>74.3</td>
</tr>
<tr>
<td>15</td>
<td>693.3</td>
<td>12.9</td>
<td>53.7</td>
</tr>
<tr>
<td>16</td>
<td>858.4</td>
<td>8.6</td>
<td>100</td>
</tr>
</tbody>
</table>

aThe first eight sites are enclosed environments, with sites 2, 5, and 8 possessing air conditioning systems. The final eight sites closely resemble partially enclosed kiosks.

I/O = indoor/outdoor

Source: Caselli et al. 2009
variation of toluene levels in indoor and outdoor air by season of the year in the Lower Rio Grande Valley. Median indoor air levels were 4.80 µg/m³ (1.28 ppbv) and median outdoor levels were 3.10 µg/m³ (0.824 ppbv) during the spring months. The median levels were reported as 7.70 µg/m³ (2.05 ppbv) for indoor air and 1.15 µg/m³ (0.306 ppbv) for outdoor air during the summer months.

In several studies, indoor (home or office) toluene concentrations ranged from 0.7 to 24.2 ppbv (3–91.0 µg/m³) due mostly to infiltration from auto emissions (Chan et al. 1991b; Hodgson et al. 1991; Kelly et al. 1993; Michael et al. 1990; Shields and Weschler 1992). Toluene was among the volatile organic compounds detected in the emissions from sponge rubber carpet cushions (Schaeffer et al. 1996). Indoor toluene can also originate from household products (paints, thinners, glues, etc.) and smoking. The indoor toluene concentrations in a household with smoking residents were found to be greater than those in a nonsmoking household (Montgomery and Kalman 1989).

Volatilization from contaminated tap water is another source of indoor toluene. Efficiencies of toluene volatilization have been estimated for sources such as the kitchen sink (13–26%), residential washing machines (24–99%), residential dishwashers (96–98%), and household showers (61–77%) (Howard and Corsi 1996, 1998; Howard-Reed et al. 1999; Moya et al. 1999). Toluene was found to be emitted at a rate of 40,000 ppb during the charbroiling of hamburger meat over a natural gas fired grill (Schauer et al. 1999a).

Very high concentrations of toluene (53.2–38,038 ppbv or 2.00x10²–143x10⁵ µg/m³) were detected in gas from municipal landfills in Finland (Assmuth and Kalevi 1992). Toluene can enter nearby homes by diffusion and pressure-driven transport from soil (Hodgson et al. 1988).

### 6.4.2 Water

Toluene was one of the most frequently detected volatile organic compounds in a comprehensive survey conducted by the United States Geological Survey (USGS) from 1985 to 2001 of private and public groundwater wells used for drinking water (USGS 2006). Toluene was detected in about 10% of 1,676 aquifer samples analyzed at an assessment level of 0.02 ppb. It was detected in about 2% of 3,457 samples analyzed at an assessment level of 0.2 ppb (Carter et al. 2008; USGS 2006). The median concentration of toluene was 0.032 ppb for all of the samples having positive detections. Toluene was detected in less than 20% of the samples of groundwater taken from alluvial aquifers beneath Denver, Colorado, a major urban center, at a maximum concentration of 1 ppb (Bruce and McMahon 1996).
Toluene was detected in 10 out of 931 samples collected from May 1999 to October 2000 in the USGS National Survey of volatile organic compound contaminants of groundwater and surface water sources used for drinking water supplies (USGS 2003). It was more often detected in surface water sources (1.9% detection frequency) as compared to groundwater sources (0.53% detection frequency) and reservoirs (1.0% detection frequency) at the minimum reporting level of 0.2 ppb.

In addition to the groundwater in the United States, toluene was also found in the groundwater near the Tehran Automobile Industry waste water treatment plant. Toluene was detected with trichloroethylene, tetrachloroethylene, and other volatile organic compounds. The concentration of toluene in the groundwater was not provided (Dobaradaran et al. 2010). Toluene was detected at concentrations of 6,400 and 6,900 ppb in two groundwater sampling wells at a hazardous waste site (Armstrong et al. 1991).

The USGS sampled storm water runoff from 16 cities and metropolitan areas from 11 different states during the period of 1991–1995 (USGS 2000). Toluene and total xylenes were the most frequently detected compounds in the collected samples. Toluene was identified in 137 out of 592 samples at levels ranging from 0.2 to 6.6 ppb.

### 6.4.3 Sediment and Soil

No studies were located regarding levels of toluene in typical urban, suburban, or rural soils. Toluene has been occasionally detected in sediments of surface waters at concentrations averaging 5 ppb (Staples et al. 1985). Toluene was detected in the sediment of lower Passaic River, New Jersey, in the vicinity of combined sewer overflow outfalls (Iannuzzi et al. 1997). The concentrations ranged from 4.0 to 250 ppb. In the absence of continuous releases from a waste site, it is expected that toluene would not persist for long periods in soil, due to its volatility, susceptibility to biodegradation, and water solubility.

### 6.4.4 Other Environmental Media

The concentration of toluene in commercial foodstuffs has not been thoroughly studied. Although the data are limited, toluene is not likely to be found in food (CEPA 1999). Toluene was detected in eggs stored in polystyrene containers that contained toluene (Matiella and Hsieh 1991). Cigarette smoke releases toluene. Grob (1965) estimated that about 80 μg of toluene is released per cigarette. Toluene was detected in a variety of household items including automotive products, household cleaners/polishes,
paint-related products, fabric and leather treatments, lubricants and adhesives (Sack et al. 1992). The levels of toluene in these products varied from 1.8 to 23.3% by weight.

### 6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE

Available data indicate that for the general population, inhalation of toluene is likely to be the main route of exposure. Likewise, the main source of toluene is from vehicle exhaust, although the use of paints, varnishes, lacquers, shoe polishes, and cigarette smoke can contribute to levels indoors and personal exposures (Alexopoulos et al. 2006). The geometric mean and selected percentiles of toluene in whole-blood concentrations (in ng/mL) for the U.S. population from the National Health and Nutrition Examination Survey (NHANES) for 2001–2002, 2003–2004, and 2005–2006 are provided in Table 6-5 (CDC 2013). In addition, toluene was found in 91% of adipose tissue samples from the National Human Adipose Tissue survey. The maximum concentration of toluene in the samples was 250 ppb (HSDB 2010).

The total daily exposure of office workers to volatile organic compounds, including toluene, was analyzed in a study conducted in Milan, Italy. Personal pollutant exposure levels of workers to toluene were 30.9 µg/m³ (8.22 ppbv) from the home, 32.5 µg/m³ (8.64 ppbv) from the office, and 43.6 µg/m³ (11.6 ppbv) from commuting. It was found that the levels of toluene in the workers in the summer (21.5–34.3 µg/m³; 5.72–9.12 ppbv) were lower than levels of toluene in the winter (37.6–53.7 µg/m³; 10.0–14.3 ppbv). Toluene levels in nonsmokers, as compared to smokers, were about the same. In addition, personal exposure levels to toluene were much higher from cars (145.7 µg/m³; 38.8 ppbv) than subways (39.3 µg/m³; 10.4) and buses (44.1 µg/m³; 11.7 ppbv) (Carrer et al. 2000). In a similar study, the personal exposures of traffic police officers in Milan, Italy to toluene were found to be 42.5 µg/m³ (11.3 ppbv). Mean toluene and BTEX levels were higher in the afternoon shifts (Cattaneo et al. 2010).

Personal exposure was the highest when a vehicle was used as the main source of transportation, when a vehicle was used in work, when the participants had a roommate who smoked, in cities, near gas stations, and near busy roads. Levels were 71.6 µg/m³ (19.0 ppbv), 72.5 µg/m³ (19.3 ppbv), 64.0 µg/m³ (17.0 ppbv), 64.0 µg/m³ (17.0 ppbv), 91.9 µg/m³ (24.4 ppbv), and 65.5 µg/m³ (17.4 ppbv), respectively (Alexopoulos et al. 2006). Other transportation-related toluene exposure pathways include inhalation of volatile organic compounds from contaminated air in aircraft cabins (2–135 ppbv for toluene) (Dechow et al. 1997) and breathing air in long road tunnels (97–167.6 ppbv) (Barrefors 1996).
Table 6-5. Geometric Mean and Selected Percentiles of Blood Toluene in Whole Blood Concentrations (in mg/L) for the U.S. Population from NHANES

<table>
<thead>
<tr>
<th>Survey</th>
<th>Geometric mean (95% CI)</th>
<th>50th percentile</th>
<th>75th percentile</th>
<th>90th percentile</th>
<th>95th percentile</th>
<th>Sample size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>0.156 (0.122–0.198)</td>
<td>0.160 (0.120–0.340)</td>
<td>0.260 (0.200–0.430)</td>
<td>0.670 (0.480–0.700)</td>
<td>10.06 (0.700–10.43)</td>
<td>954</td>
</tr>
<tr>
<td>2003–2004</td>
<td>0.114 (0.100–0.129)</td>
<td>0.096 (0.087–0.220)</td>
<td>0.180 (0.110–0.260)</td>
<td>0.430 (0.380–0.680)</td>
<td>0.550 (0.560–0.880)</td>
<td>1,336</td>
</tr>
<tr>
<td>2005–2006</td>
<td>0.137 (0.123–0.152)</td>
<td>0.120 (0.110–0.230)</td>
<td>0.200 (0.130–0.262)</td>
<td>0.550 (0.481–0.814)</td>
<td>0.702 (0.640–0.937)</td>
<td>3,050</td>
</tr>
<tr>
<td>12–19 Years age</td>
<td>2005–2006</td>
<td>0.110 (0.098–0.122)</td>
<td>0.100 (0.094–0.170)</td>
<td>0.150 (0.120–0.180)</td>
<td>0.280 (0.240–0.400)</td>
<td>907</td>
</tr>
<tr>
<td>20–59 Years age</td>
<td>2001–2002</td>
<td>0.156 (0.122–0.198)</td>
<td>0.160 (0.120–0.340)</td>
<td>0.260 (0.200–0.430)</td>
<td>0.670 (0.480–0.700)</td>
<td>954</td>
</tr>
<tr>
<td>20–59 Years age</td>
<td>2003–2004</td>
<td>0.114 (0.100–0.129)</td>
<td>0.096 (0.087–0.220)</td>
<td>0.180 (0.110–0.260)</td>
<td>0.430 (0.380–0.680)</td>
<td>1,336</td>
</tr>
<tr>
<td>20–59 Years age</td>
<td>2005–2006</td>
<td>0.147 (0.133–0.163)</td>
<td>0.120 (0.110–0.260)</td>
<td>0.210 (0.137–0.340)</td>
<td>0.594 (0.505–0.900)</td>
<td>1,505</td>
</tr>
<tr>
<td>≥60 Years age</td>
<td>2005–2006</td>
<td>0.124 (0.100–0.154)</td>
<td>0.114 (0.097–0.190)</td>
<td>0.167 (0.138–0.230)</td>
<td>0.520 (0.370–0.720)</td>
<td>638</td>
</tr>
<tr>
<td>Males</td>
<td>2001–2002</td>
<td>0.165 (0.130–0.209)</td>
<td>0.170 (0.120–0.360)</td>
<td>0.260 (0.230–0.520)</td>
<td>0.780 (0.580–10.06)</td>
<td>450</td>
</tr>
<tr>
<td>Males</td>
<td>2003–2004</td>
<td>0.128 (0.112–0.148)</td>
<td>0.110 (0.096–0.250)</td>
<td>0.190 (0.130–0.310)</td>
<td>0.500 (0.380–0.660)</td>
<td>647</td>
</tr>
<tr>
<td>Males</td>
<td>2005–2006</td>
<td>0.152 (0.139–0.166)</td>
<td>0.130 (0.120–0.280)</td>
<td>0.240 (0.140–0.330)</td>
<td>0.640 (0.550–0.720)</td>
<td>1,441</td>
</tr>
<tr>
<td>Females</td>
<td>2001–2002</td>
<td>0.147 (0.114–0.190)</td>
<td>0.150 (0.110–0.320)</td>
<td>0.240 (0.220–0.390)</td>
<td>0.550 (0.400–0.740)</td>
<td>504</td>
</tr>
<tr>
<td>Females</td>
<td>2003–2004</td>
<td>0.101 (0.086–0.118)</td>
<td>0.085 (0.070–0.190)</td>
<td>0.150 (0.100–0.230)</td>
<td>0.410 (0.340–0.500)</td>
<td>689</td>
</tr>
<tr>
<td>Females</td>
<td>2005–2006</td>
<td>0.124 (0.107–0.144)</td>
<td>0.110 (0.097–0.190)</td>
<td>0.170 (0.130–0.230)</td>
<td>0.470 (0.380–0.550)</td>
<td>1,609</td>
</tr>
<tr>
<td>Mexican/American</td>
<td>2001–2002</td>
<td>0.136 (0.106–0.176)</td>
<td>0.140 (0.080–0.270)</td>
<td>0.210 (0.210–0.340)</td>
<td>0.550 (0.400–0.980)</td>
<td>219</td>
</tr>
<tr>
<td>Mexican/American</td>
<td>2003–2004</td>
<td>0.084 (0.074–0.096)</td>
<td>0.076 (0.064–0.120)</td>
<td>0.100 (0.091–0.170)</td>
<td>0.280 (0.170–0.410)</td>
<td>253</td>
</tr>
<tr>
<td>Mexican/American</td>
<td>2005–2006</td>
<td>0.110 (0.097–0.125)</td>
<td>0.110 (0.096–0.160)</td>
<td>0.140 (0.120–0.170)</td>
<td>0.240 (0.220–0.290)</td>
<td>737</td>
</tr>
<tr>
<td>Non-Hispanic blacks</td>
<td>2001–2002</td>
<td>0.137 (0.089–0.210)</td>
<td>0.150 (0.070–0.310)</td>
<td>0.200 (0.200–0.460)</td>
<td>0.690 (0.390–10.19)</td>
<td>194</td>
</tr>
<tr>
<td>Non-Hispanic blacks</td>
<td>2003–2004</td>
<td>0.105 (0.077–0.144)</td>
<td>0.095 (0.070–0.200)</td>
<td>0.130 (0.130–0.330)</td>
<td>0.440 (0.290–0.620)</td>
<td>297</td>
</tr>
<tr>
<td>Non-Hispanic blacks</td>
<td>2005–2006</td>
<td>0.139 (0.120–0.161)</td>
<td>0.120 (0.099–0.230)</td>
<td>0.190 (0.140–0.290)</td>
<td>0.450 (0.370–0.550)</td>
<td>796</td>
</tr>
<tr>
<td>Non-Hispanic whites</td>
<td>2001–2002</td>
<td>0.165 (0.125–0.217)</td>
<td>0.170 (0.120–0.350)</td>
<td>0.270 (0.240–0.450)</td>
<td>0.710 (0.450–10.12)</td>
<td>467</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-5. Geometric Mean and Selected Percentiles of Blood Toluene in Whole Blood Concentrations (in mg/L) for the U.S. Population from NHANES

<table>
<thead>
<tr>
<th>Survey</th>
<th>Geometric mean (95% CI)</th>
<th>50&lt;sup&gt;th&lt;/sup&gt; percentile</th>
<th>75&lt;sup&gt;th&lt;/sup&gt; percentile</th>
<th>90&lt;sup&gt;th&lt;/sup&gt; percentile</th>
<th>95&lt;sup&gt;th&lt;/sup&gt; percentile</th>
<th>Sample size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Hispanic whites 2003–2004</td>
<td>0.123 (0.110– 0.139)</td>
<td>0.100 (0.092– 0.120)</td>
<td>0.240 (0.210– 0.280)</td>
<td>0.500 (0.400– 0.590)</td>
<td>0.750 (0.590– 0.940)</td>
<td>685</td>
</tr>
<tr>
<td>Non-Hispanic whites 2005–2006</td>
<td>0.144 (0.125– 0.166)</td>
<td>0.130 (0.110– 0.140)</td>
<td>0.260 (0.210– 0.330)</td>
<td>0.600 (0.510– 0.710)</td>
<td>0.880 (0.760– 0.990)</td>
<td>1,291</td>
</tr>
</tbody>
</table>

CI = confidence interval; NHANES = National Health and Nutrition Examination Survey

Source: CDC 2009
6. POTENTIAL FOR HUMAN EXPOSURE

In an industry-sponsored study, personal inhalation exposures to toluene during the application of nail lacquers in residences ranged from approximately 1,030 to 2,820 µg/person/day (Curry et al. 1994). The mean toluene levels measured in the breathing zone during the nail lacquer application ranged from 3,200 to 9,200 µg/m³ (850–2,400 ppbv), while the post-application concentrations ranged from below the detection limits of 200 µg/m³ to 1,700 µg/m³ (50–450 ppbv) Toluene concentrations were monitored 1 hour before application; no toluene was detected in air prior to the nail lacquer application. During-application, sampling started with the first application and ended when the nails were dry. Post-application sampling started 1 hour after the nails were dry for the post-application sample group 1, and 2 hours after the nails were dry for the post-application sample group II.

In an occupational study, workers from gasoline service stations had a geometric mean personal exposure level of 153.1 ppbv (576 µg/m³), and the geometric mean concentration in the workplace air was reported as 99.3 ppbv (373 µg/m³). Toluene exposure may also occur in printing industry where toluene is used as a solvent for inks and dyes. Occupational exposure may also occur during paint stripping operations (Vincent et al. 1994), coke plant operations (Bieniek et al. 2004), and commercial painting (Burstyn and Kromout 2002). Assuming that a worker inhales 10 m³ of air while on the job, and that 50% of the inhaled toluene is absorbed, a workplace concentration of 53.2 ppmv would correspond to an exposure level of 1,000 mg/day. The toluene burden of rotogravure (printing process) workers measured with personal monitoring tubes was found to be higher, ranging from 56 to 451 mg/m³ (15–120 ppmv) than air concentrations monitored during the workday (Hammer et al. 1998).

Exposure could be higher near heavily traveled roadways or point sources of toluene, and could also be increased by frequent use of home products containing toluene. Runners who exercise near highways may be exposed to higher levels of BTEX. Concentrations of toluene in the blood were significantly increased post-exercise in a running study near a roadway. The runners ran for 20 minutes. The mean blood concentrations were 1.4 ng/mL (1.4 ppb) pre-exercise and 2.8 ng/mL (2.8 ppb) post-exercise with a mean increase of 1.4 ng/mL (1.4 ppb). The concentration of toluene in the air was measured as 52 µg/m³ (13.8 ppbv) at the start of the route, 60 µg/m³ (16 ppbv) at the middle of the route, and 52 µg/m³ (13.8 ppbv) at the distant end of the route (Blair et al. 2010). An Alaskan study compared the concentration of toluene in blood before and after pumping of regular and oxygenated gasoline in February (Backer et al. 1997). The median concentration of toluene in blood before pumping gasoline was found to be 0.38 ppb (ng/mL). A greater increase was detected in the blood concentration of toluene after pumping oxygenated gasoline (0.85 ppb) than after pumping regular gasoline (0.74 ppb). In another study, the blood of rotogravure workers was tested before and after the use of toluene to clean containers.
for the primary printing colors. The concentration of toluene in their blood was found to increase from 0.87 to 4.9 mg/L (Muttray et al. 1999). The average levels of toluene measured in personal air samples of these workers ranged from 1,115 to 1,358 mg/m³ (296–361 ppmv).

Toluene concentrations in the blood after rotogravure industry workers shifts were measured in a study conducted by Neubert et al. (2001). Concentrations were the highest from printing and assistance (266.3 µg/L or 266.3 ppb), followed by preparation of printing forms (67.7 µg/L or 67.7 ppb), processing of printed materials (67.7 µg/L for men, 53.2 µg/L for women or 67.7 ppb, 53.2 ppb), and other areas (78.1 µg/L or 78.1 ppb for men, 28.0 µg/L or 28.0 ppb for women).

Cigarette smoking may also significantly increase exposure. In a NHANES 2003–2004 study, levels of toluene among daily smokers were higher than levels of toluene among smokers who smoked less than daily. The levels were 0.327 ng/mL (0.3227 ppb) for daily smokers and 0.082 ng/mL (0.082 ppb) for nondaily smokers (Chambers et al. 2011). Assuming inhalation of about 80–100 µg of toluene per cigarette and 50% absorption (EPA 1983e; Grob 1965), smoking one pack per day would contribute an absorbed dose of about 1,000 µg/day.

Toluene is a volatile component of wood smoke. Emission rates of toluene during wood combustion in home heating units have been reported in the range of 0.15–1 g/kg of wood (Larson and Koenig 1994). Exposure to toluene can also occur from the combustion of solid biomass fuels. The fuels are used as a source of domestic energy in developing countries for cooking, etc. Toluene concentrations were much higher from dung (1.4 µg/m³ or 0.37 ppbv) than from mixed fuel (0.5 µg/m³ or 0.1 ppbv) (Sinha et al. 2006).

Based on average values of toluene in water, exposure by ingestion of contaminated drinking water is likely to be relatively small compared to inhalation. In a survey of bottled drinking water sold in Canada, only 20 (or 11%) of 182 samples analyzed contained measurable amounts of toluene, with an average concentration of 6.92 ppb and a range of 0.5–63 ppb (Page et al. 1993). Toluene is also known to volatilize from various household sources of water such as the kitchen sink, dishwashers, washing machines, and showers; thus, its presence in tap water may ultimately result in inhalation exposure (Howard and Corsi 1996, 1998; Howard-Reed et al. 1999; Moya et al. 1999).

Exposure to gasoline (which contains toluene) has been estimated for a household using gasoline-contaminated water (Beavers et al. 1996). In this house, 694 µg/L of toluene was found in the water,
6. POTENTIAL FOR HUMAN EXPOSURE

which resulted in a level of 664 ppbv in shower air, and 14.9 ppbv in non-shower air. The total daily dose for the exposed subject in this household was estimated as 2,273 µg. Approximately 61% of the dose was due to ingestion and 39% resulted from inhalation from showering and non-showering activities. Personnel working with various types of fuel may be at a risk of toluene exposure. A Finnish study determined the mean exposure of gasoline tanker drivers to toluene during loading and delivery to be 0.63–1.9 mg/m³ (2.4–7.1 ppmv) (Saarinen et al. 1998). The exposure level of aircraft maintenance personnel to toluene in raw JP-8 jet fuel vapor was found to be 6.1±1.5 ppmv (6,100±1,560 ppbv) (Smith et al. 1997).

A number of studies have indicated significant accumulations of toluene in products for human consumption. For example, escaping gasoline vapors from internal combustion engines used or stored near olives during the growing, harvesting, storage, and processing steps in the production of virgin olive oil can cause significant contamination of the product with toluene and other hydrocarbons (Biedermann et al. 1996). Significant concentrations of toluene have also been measured in 8 of 10 species of fruit tested in a European study, which showed higher concentrations of toluene in the peel than in the pulp of the fruit (Górna-Binkul et al. 1996). Dermal absorption of toluene is not a significant route of exposure. Uptake of toluene via skin has been estimated to contribute 1–2% of the body burden received following whole body (including inhalation) exposure (Brooke et al. 1998). Combinations of solvents, however, can enhance the dermal penetration of toluene. Methanol enhances the skin absorption of toluene. Special precautions need to be taken against the skin absorption of toluene when handling paint thinners that contain methanol (Tsuruta 1996).

Although toluene has been found to be a common contaminant at hazardous waste sites, it is not possible to estimate human exposure levels that might occur near waste sites without detailed site-specific information on concentration values in air, water, and soil, and on human intake of these media. Pathways that might be of significance include inhalation of toluene vapors, ingestion of toluene-contaminated water (surface water and/or groundwater), volatilization and inhalation from contaminated water, and dermal contact with toluene-contaminated soil.

6.6 EXPOSURES OF CHILDREN

This section focuses on exposures from conception to maturity at 18 years in humans. Differences from adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults. The developing human’s source of nutrition changes with age: from placental nourishment to breast milk or formula to the diet of older children who eat more of certain types of foods than adults. A child’s behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).

Exposures of the embryo or fetus to volatile organic compounds such as toluene may occur if the expectant mother is exposed to high levels that overwhelm maternal protective mechanisms including metabolic detoxification and disposition of toluene and possible preferential distribution of toluene to maternal adipose tissues (see Chapter 2 and Section 3.3). A newborn infant may be exposed by breathing contaminated air and through ingestion of mother’s milk that can contain small amounts of toluene. Children may be exposed through accidental ingestion of products containing toluene. Older children and adolescents may be exposed to toluene in their jobs or hobbies, or through deliberate solvent abuse by “sniffing.” Contact adhesives often contain toluene, heptane, and methyl ethyl ketone. Although toluene is more toxic than the other ingredients, it evaporates more slowly. Thus, the vapors inhaled when “sniffing” such adhesives will contain less toluene and should be less toxic than would be expected from its liquid composition (Midford et al. 1993).

Human epidemiological studies and case reports discussing reproductive and/or developmental toxicity of toluene in humans have been reviewed. Occupational exposures can occur when workers inhale materials containing toluene such as paints, paint reducers, and paint thinners (Donald et al. 1991b). Inhalant abuse during pregnancy poses significant risks to the pregnancy and endangers both the mother and the fetus. Solvent abuse of toluene for euphoric effects results in exposure levels that equal or exceed those producing adverse effects in animals.

Toluene was detected in breast milk samples obtained from three mothers residing in the Baltimore, Maryland area at a median concentration of 0.46 ng/L (Kim et al. 2007). Transfer of toluene to nursing infants from breast milk is a possible source of toluene exposure; however, since most toluene is rapidly eliminated from the body (see Sections 3.4.4 and 3.7), this exposure route is expected to be low. Kim et al. (2007) used indoor air concentrations of toluene and other volatile organic compounds (VOCs) to estimate the relative exposure dose of these VOCs from inhalation of indoor air as compared to milk.
6. POTENTIAL FOR HUMAN EXPOSURE

ingestion. Infant exposure from inhalation of air was estimated as 4,550 ng/kg body weight/day, which was 55 times greater than the estimated dose from milk ingestion (89 ng/kg body weight/day). A PBPK model has been developed to estimate the amount of chemical that an infant ingests for a given nursing schedule and daily maternal occupational exposure to 50 ppm toluene for 8 hours (Fisher et al. 1997). This PBPK model predicted an ingestion rate of 0.460 mg/day for such an infant.

Young children often play close to the ground and frequently play in dirt, which increases their dermal exposure to toxicants in dust and soil. They also tend to ingest soil, either intentionally through pica or unintentionally through hand-to-mouth activity. Children may be orally and dermally exposed to toluene present as a contaminant in soil and dust, but toluene is not expected to persist for long periods in soil (in the absence of continuous release) due to its volatility, susceptibility to bacterial degradation, and water solubility. It has been demonstrated that the toluene adsorbed on soil is absorbed by the body (Turkall et al. 1991). Toluene in both aqueous solution and vapor phase has also been shown to be absorbed through the human skin, albeit slowly (Brooke et al. 1998; Dukiewicz and Tyras 1968; Tsuruta 1989). Toluene has a Koc range of 37–178, indicating high mobility in soil (HSDB 2010; Wilson et al. 1981). Most of the toluene present in the upper layers of the soil is volatilized to air within 24 hours (vapor pressure of 28.4 mmHg at 25°C) (Balfour et al. 1984; HSDB 2010; Thibodeaux and Hwang 1982). Loss of toluene from the soil decreases the potential of dermal and oral exposure to children, but its rapid volatilization results in inhalation being the most likely route of exposure.

Children breathe in more air per kilogram of body weight than an adult. Therefore, a child in the same micro-environment as an adult may be exposed to more toluene from ambient air. Young children are closer to the ground or floor because of their height. The toluene vapors being heavier than air (vapor density=3.1 g/mL) tend to concentrate near the ground. The children, therefore, may be at greater risk of exposure than adults during accidental spills of toluene.

Children may also be exposed to fumes of toluene and other hydrocarbons by working with or playing near sources of gasoline. Children’s exposure also occurs through accidental ingestion and inspiration of the chemicals into the lungs. Most accident victims are 1- and 2-year-old children and are about evenly divided between males and females. Most incidents occur in the children’s homes and the products are in their normal storage areas. Child-resistant packaging is recommended (Journal of Environmental Health 1997). Children are also exposed to higher concentrations of toluene in central urban areas with high traffic density, where children's blood toluene concentrations are, on average, 56% higher than those of children living in rural areas (Jermann et al. 1989; Raaschou-Nielsen et al. 1997).
Children are also exposed through hobbies and art activities involving glues, adhesives, and paints (McCann 1992). Abuse of toluene-containing products among young people by inhalation (“sniffing”) is a social and clinical concern (Young 1987).

### 6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

In addition to individuals who are occupationally exposed to toluene (see Section 6.5), there are several groups within the general population that have potentially high exposures (higher than background levels) to toluene. These populations include individuals living in proximity to sites where toluene was produced or sites where toluene was disposed, and individuals living near one of the 1,012 NPL hazardous waste sites where toluene has been detected in some environmental media (HazDat 2007).

The population most likely to experience high levels of exposure to toluene includes workers in the printing industry or other industries employing toluene as a solvent. In addition, workers exposed to gasoline vapors are also likely to have higher than average exposure to toluene. Individuals may also be exposed to high levels at home in association with the use of toluene-containing consumer products. Smokers have a considerably higher exposure to toluene than nonsmokers.

Toluene has been frequently identified as a water contaminant in the proximity of hazardous waste sites. Drinking water sources for populations living near a hazardous waste site containing toluene should be evaluated for toluene. If groundwater wells are contaminated, exposure to toluene can occur when the well-water is used for showering, cleaning, cooking, and drinking. Exposure can also occur through contact with contaminated soil.

A troublesome route of exposure to toluene is through deliberate inhalation of fumes from paint thinners, gasoline, glues contact adhesives, and aromatic solvents containing toluene. Inhalant abuse can affect pregnancy outcome (Jones and Balster 1998). Inhalant abuse is an urgent health care problem among youth, including American Indians (Young 1987). Toluene abuse can affect driving (Capron and Logan 2009) and inhibit gap junction currents in human embryonic kidney cells (Del Re and Woodward 2005).

### 6.8 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of toluene is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of toluene.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

6.8.1 Identification of Data Needs

**Physical and Chemical Properties.** The physical and chemical properties of toluene that are needed to evaluate its behavior in the environment are available (Table 4-2). It does not appear that further research in this area is necessary.

**Production, Import/Export, Use, Release, and Disposal.** According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit substance release and off-site transfer information to the EPA. The TRI, which contains this information for 2012, became available in 2014. This database is updated yearly and should provide a list of industrial production facilities and emissions.

The available production data of toluene are up to date; however, it is essential that these data be updated regularly to allow a more accurate determination of the potential for human exposure.

**Environmental Fate.** Existing information indicates that volatilization, followed by reaction with hydroxyl radicals in air, is the principal fate process for toluene in the environment (Davis et al. 1979; EC 2003; Hoshino et al. 1978; Howard et al. 1991; Kenley et al. 1973). Although toluene is not a common contaminant in water, it has been found to occur in both groundwater and surface water near waste sites (HazDat 2007). Additional studies on the rate of volatilization, degradation, and transport of toluene in groundwater, surface water, and soils would be useful for assessing potential human exposure near hazardous waste sites.
Bioavailability from Environmental Media. On the basis of the available data, toluene appears to be bioavailable when it is released to the environment. Inhalation, oral, and dermal absorption occur due to toluene solubility in the lipid matrix of the cell membrane (Alcorn et al. 1991). Absorption is rapid and virtually complete at low exposure concentrations when exposures are oral or respiratory (Alcorn et al. 1991; Carlsson and Ljungqvist 1982; Hjelm et al. 1988). Absorption also occurs through contact with the skin (Dutkiewicz and Tyras 1968). Additional research on bioavailability of toluene from the environment does not appear to be needed.

Food Chain Bioaccumulation. The bioconcentration factor for toluene is relatively low due to its rapid metabolism to more polar molecules with a lower affinity for lipids, and it has little tendency to bind to biomolecules (EC 2003; Franke et al. 1994). Bioaccumulation in the food chain is expected to be low. No data needs are identified.

Exposure Levels in Environmental Media. Reliable monitoring data for the levels of toluene in contaminated media at hazardous waste sites are needed so that the information obtained on levels of toluene in the environment can be used in combination with the known body burden of toluene to assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.

Further studies on toluene levels in food and soil would be useful, since quantitative data for these media are limited. The potential exists for toluene to be present in human and bovine milk. In view of the observation that the highest levels of toluene likely to be encountered by an average citizen occur in the home, studies that identify the sources of toluene in indoor air would be valuable in reducing or eliminating this pathway of exposure.

Exposure Levels in Humans. Exposure of the general population to toluene in air has been monitored for a variety of scenarios (Baltrenas et al. 2011; Bratveit et al. 2004; Ciaroccoa et al. 2012; Deole et al. 2004; EPA 2013b; Hamidin et al. 2013; Iovino et al. 2009; Massolo et al. 2010). Amounts of toluene volatilizing from the household sources such as the kitchen sink, dishwashers, washing machines, and showers have also been estimated (Howard and Corsi 1996, 1998; Howard-Reed et al. 1999; Moya 1999). Combining these data with appropriate toxicokinetic models of toluene absorption, distribution, and excretion in humans would allow for improved estimates of exposure levels in humans. Likewise, more recent data on the ingestion of contaminated drinking water may be useful.

This information is necessary for assessing the need to conduct health studies on these populations.

Exposures of Children. Children may be at a greater risk of inhalation exposure to toluene as they breathe in more air per kilogram of body weight than an adult. They also spend more time closer to ground because of their height. Toluene vapors, being heavier than air, tend to concentrate closer to the ground, thereby increasing the risk of exposure for children.

Means of protecting young children from ingestion of home products containing toluene need study and action. Child-proof containers and clearer warnings to parents should be considered to avoid unwanted exposure.

Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data Needs: Children’s Susceptibility.

Exposure Registries. No exposure registries for toluene were located. This substance is not currently one of the compounds for which a sub-registry has been established in the National Exposure Registry. The substance will be considered in the future when chemical selection is made for sub-registries to be established. The information that is amassed in the National Exposure Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be related to exposure to this substance.

6.8.2 Ongoing Studies

As part of the Third National Health and Nutrition Evaluation Survey (NHANES III), the Environmental Health Laboratory Sciences Division of the National Center for Environmental Health, Centers for Disease Control and Prevention, will be analyzing human blood samples for toluene and other volatile organic compounds. These data will give an indication of the frequency of occurrence and background levels of these compounds in the general population.
7. ANALYTICAL METHODS

The purpose of this chapter is to describe the analytical methods that are available for detecting, measuring, and/or monitoring toluene, its metabolites, and other biomarkers of exposure and effect to toluene. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is to identify well-established methods that are used as the standard methods of analysis. Many of the analytical methods used for environmental samples are the methods approved by federal agencies and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those that are approved by groups such as the Association of Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). Additionally, analytical methods are included that modify previously used methods to obtain lower detection limits and/or to improve accuracy and precision.

7.1 BIOLOGICAL MATERIALS

Toluene can be determined in biological fluids and tissues and breath using a variety of analytical methods. Representative methods are summarized in Table 7-1. Most analytical methods for biological fluids use headspace gas chromatographic (GC) techniques. Breath samples are usually collected on adsorbent traps or in sampling bags or canisters, and then analyzed by GC.

Because of its volatility, toluene is lost from biological samples, such as plant and animal tissue and body fluids, relatively easily. Therefore, samples must be collected and stored with care (e.g., at low temperatures in sealed containers) to prevent analyte loss. While blood sample collection is more invasive than breath or urine samples, maintaining the integrity of blood in the collection, transportation, and storage of the samples is easier. Blood is relatively nonpolar, which results in less diffusion loss (Chambers et al. 2006).

Headspace techniques are usually used to separate toluene from biological fluids such as blood and urine. The headspace method involves equilibrium of volatile analytes such as toluene between a liquid and solid sample phase and the gaseous phase. The gaseous phase is then analyzed by GC. There are two main types of headspace methodology: static (equilibrium) headspace and dynamic headspace which is usually called the "purge and trap" method (Seto 1994). The static headspace technique is relatively simple, but may be less sensitive than the purge-and-trap method. The purge-and-trap method, while providing increased sensitivity, requires more complex instrumentation and may result in artifact formation (Seto 1994). Packed columns and capillary columns are used for chromatographic separation,
Table 7-1. Analytical Methods for Determining Toluene in Biological Materials

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>Lyse; extraction with carbon disulfide</td>
<td>GC/FID</td>
<td>No data</td>
<td>No data</td>
<td>Benignus et al. 1981</td>
</tr>
<tr>
<td>Blood</td>
<td>Purge and trap</td>
<td>No data</td>
<td>7.5 μg/L</td>
<td>No data</td>
<td>Cocheo et al. 1982</td>
</tr>
<tr>
<td>Whole blood</td>
<td>Purge and trap</td>
<td>GC/MS</td>
<td>0.088 μg/L</td>
<td>91–147</td>
<td>Ashley et al. 1992</td>
</tr>
<tr>
<td>Blood</td>
<td>Purge and trap</td>
<td>capillary GC/FID</td>
<td>50 ng/L</td>
<td>50</td>
<td>Fustinoni 1996</td>
</tr>
<tr>
<td>Blood</td>
<td>Headspace extraction</td>
<td>capillary GC/ITD</td>
<td>0.04 μmol/L</td>
<td>No data</td>
<td>Schuberth 1994</td>
</tr>
<tr>
<td>Blood</td>
<td>Headspace SPME</td>
<td>GC/FID</td>
<td>24 pg/mL</td>
<td>No data</td>
<td>Chambers et al. 2006</td>
</tr>
<tr>
<td>Mother’s milk</td>
<td>Purge and trap</td>
<td>capillary GC/FID</td>
<td>No data</td>
<td>63 (chloro-benzene)</td>
<td>Michael et al. 1991</td>
</tr>
<tr>
<td>Urine</td>
<td>Purge and trap</td>
<td>capillary GC/FID</td>
<td>50 ng/L</td>
<td>59</td>
<td>Fustinoni 1996</td>
</tr>
<tr>
<td>Urine</td>
<td>Heated headspace extraction</td>
<td>capillary GC/FID</td>
<td>1 ng/mL</td>
<td>42.3</td>
<td>Lee et al. 1998b</td>
</tr>
<tr>
<td>Urine</td>
<td>Headspace (Purge and Trap)</td>
<td>GC/PID</td>
<td>15 ng/L</td>
<td>No data</td>
<td>Skender et al. 2004</td>
</tr>
<tr>
<td>Biofluids</td>
<td>Headspace extraction</td>
<td>GC/FID</td>
<td>No data</td>
<td>No data</td>
<td>Suitheimer et al. 1982</td>
</tr>
<tr>
<td>Adipose tissue</td>
<td>Evaporation at 150°C into nitrogen, direct gas injection</td>
<td>GC/FID</td>
<td>No data</td>
<td>88–112</td>
<td>Carlsson and Ljungquist 1982</td>
</tr>
<tr>
<td>Brain tissue</td>
<td>Extraction with carbon disulfide; homogenization; centrifugation</td>
<td>GC/FID</td>
<td>No data</td>
<td>No data</td>
<td>Benignus et al. 1981</td>
</tr>
<tr>
<td>Breath</td>
<td>Collection in modified Haldane-Priestly tube; transfer to adsorption tube; thermal desorption</td>
<td>capillary GC/MS</td>
<td>1 nmole</td>
<td>No data</td>
<td>Dyne et al. 1997</td>
</tr>
<tr>
<td>Breath</td>
<td>Collection via spirometer into passivated canisters</td>
<td>capillary GC/MS</td>
<td>low μg/m³</td>
<td>80–136</td>
<td>Thomas et al. 1991</td>
</tr>
<tr>
<td>Breath</td>
<td>Collection via spirometer into 1.8&quot;L passivated canisters</td>
<td>capillary GC/MS</td>
<td>~2 μg/m³</td>
<td>91–104</td>
<td>Thomas et al. 1992</td>
</tr>
<tr>
<td>Breath</td>
<td>Collection via spirometer onto charcoal traps; microwave desorption</td>
<td>capillary GC/MS-SIM</td>
<td>3 μg/m³</td>
<td>No data</td>
<td>Riedel et al. 1996</td>
</tr>
</tbody>
</table>

FID = flame ionization detector; GC = gas chromatography; ITD = ion trap detection; MS = mass spectrometry; SIM = selected ion monitoring
followed by identification and quantitation using various detectors; flame ionization detection (FID),
photoionization detection (PID), and mass spectrometry (MS) are used most often. Other sample
preparation methods have been used, but less frequently. Solvent extraction permits concentration,
thereby increasing sensitivity, but the extraction solvent can interfere with analysis. Direct aqueous
injection is a very rapid method, but sensitivity is low and matrix effects can be a serious problem.

In addition, the dynamic headspace purge-and-trap GC method with PID was utilized for the
determination of toluene in urine samples obtained from participants of Zagreb, Croatia. The detection
limit was 15 ng/L (Skender et al. 2004).

Headspace solid phase microextraction (SPME) is a relatively new alternative method to detect nonpolar
species in the blood. Chambers et al. (2006) utilized this method, along with GC/MS to detect BTEX in
the blood. The authors also improved the technique by minimizing contamination from the vacutainers,
disposable syringes and vial septa. The limit of detection for toluene was 25 pg/mL (Chambers et al.
2006).

A sensitive and reliable method for identification and quantitation of toluene in samples of whole blood
taken from humans following exposure to volatile organic compounds has been developed by researchers
at the Centers for Disease Control and Prevention (Ashley et al. 1992, 1996). The method involves
purge-and-trap of a 10 mL blood sample with analysis by capillary GC/MS. Anti-foam procedures were
used, as well as special efforts to remove background levels of volatile organic compounds from reagents
and equipment (Ashley et al. 1992). The method is sensitive enough (ppt levels) to determine background
levels of volatile organic compounds in the population and provides adequate accuracy (91–147%
recovery) and precision (12% relative standard deviation [RSD]) for monitoring toluene in the population.
Most modern purge and trap methods provide detection limits in the ppt range for toluene in both blood
and urine (Ashley et al. 1992; Fustinoni et al. 1996).

Few methods are available for the determination of toluene in other body fluids and tissues. Toluene may
be extracted from biological materials using solvents such as carbon disulfide (Benignus et al. 1981);
homogenization of tissue with the extractant and lysing of cells improves extraction efficiency. Care
must be taken to avoid loss of low-boiling compounds. Highly purified solvents may be used to minimize
problems with solvent impurities. A modified dynamic headspace method for urine, mother’s milk, and
adipose tissue has been reported (Michael et al. 1980). Volatiles swept from the sample are analyzed by
capillary GC/FID. Acceptable recovery was reported for model compounds, but detection limits were not
reported (Michael et al. 1980). Supercritical fluid extraction using pure carbon dioxide or carbon dioxide with additives has good potential for the extraction of organic analytes such as toluene from biological samples.

Sensitive, reliable methods are available for measuring toluene in breath. Exhaled breath is collected in modified Haldane-Priestly tubes (Dyne et al. 1997), into passivated canisters (Thomas et al. 1992), or directly onto adsorbent traps (Riedel et al. 1996). The detection limits are in the low μg/m³ range (Riedel et al. 1996; Thomas et al. 1991, 1992); accuracy, where reported, is good (≥80%) (Riedel et al. 1996; Thomas et al. 1991, 1992).

Representative methods for determination of biomarkers of exposure to toluene are shown in Table 7-2. Measurement of toluene in blood (Kawai et al. 1993), urine (Kawai et al. 1996) and exhaled air (Lapare et al. 1993) provide reliable markers of exposure to toluene. Measurement of toluene metabolites is also utilized for monitoring toluene exposure in humans. Hippuric acid is formed in the body by the metabolism of toluene, and it is the glycine conjugate of benzoic acid.

High performance liquid chromatography (HPLC) with ultraviolet (UV) detection is usually used for determination of hippuric acid in urine (Kawai et al. 1993; NIOSH 1984a). Other metabolites such as ortho-cresol (Kawai et al. 1996), benzylmercapturic acid (BMA) (Maestri et al. 1997), or S-p-toluyl-mercapturic acid (Angerer 1998a, 1998b) may also be measured. ortho-Cresol is a sensitive marker, but may arise from compounds other than toluene; the usefulness of BMA may be limited by variability among individuals.

Detection of hippuric acid was done by ¹H NMR Spectroscopy after the samples were prepared by adding deuterium oxide (D₂O) and sodium trimethylsilyl [2,2,3,3-²H₄] propionate (TSP) to urine samples of glue abusers (glue sniffers). Toluene is reported as the main component in glue. Hippuric acid levels were the highest after glue sniffing (Kwon et al. 2011).

### 7.2 ENVIRONMENTAL SAMPLES

Methods are available for determining toluene in a variety of environmental matrices. A summary of representative methods is shown in Table 7-3. Validated methods, approved by agencies and organizations such as EPA, ASTM, APHA, and NIOSH, are available for air, water, and solid waste matrices. GC is the most widely used analytical technique for quantifying concentrations of toluene in
### Table 7-2. Analytical Methods for Determining Biomarkers of Toluene in Biological Samples

<table>
<thead>
<tr>
<th>Sample Matrix</th>
<th>Preparation Method</th>
<th>Analytical Method</th>
<th>Sample Detection Limit</th>
<th>Percent Recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood (toluene)</td>
<td>Headspace</td>
<td>GC</td>
<td>No data</td>
<td>No data</td>
<td>Kawai et al. 1993</td>
</tr>
<tr>
<td>Urine (toluene)</td>
<td>Headspace</td>
<td>GC/FID</td>
<td>2 μg/L</td>
<td>No data</td>
<td>Kawai et al. 1996</td>
</tr>
<tr>
<td>Urine (HA)</td>
<td>Extraction with ethyl acetate; evaporation; redissolve in water</td>
<td>HPLC/UV</td>
<td>30 mg/L</td>
<td>No data</td>
<td>NIOSH 1984b</td>
</tr>
<tr>
<td>Urine</td>
<td>Extraction with MTBE, elution with phosphate buffer/methanol/formaldehyde</td>
<td>HPLC</td>
<td>0.1 mmol</td>
<td>101</td>
<td>Tardif et al. 1989</td>
</tr>
<tr>
<td>Urine (o-cresol)</td>
<td>Hydrolysis; solvent extraction</td>
<td>HPLC/UV</td>
<td>0.5 mg/L</td>
<td>95&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Kawai et al. 1996</td>
</tr>
<tr>
<td>Urine (BMA)</td>
<td>Addition of deuterium oxide and TSP to samples</td>
<td>HPLC/Fl</td>
<td>0.5 μg/L</td>
<td>No data</td>
<td>Maestri et al. 1997</td>
</tr>
<tr>
<td>Breath</td>
<td>Collection in Tedlar bags</td>
<td>GC/FID</td>
<td>No data</td>
<td>No data</td>
<td>Lapare et al. 1993</td>
</tr>
</tbody>
</table>

<sup>a</sup>Extraction efficiency.

BMA = benzylmercapturic acid; FID = flame ionization detector; Fl = fluorescence detector; GC = gas chromatography; HA = hippuric acid; HPLC = high performance liquid chromatography; MTBE = methyl tertiary butyl ether; UV = ultraviolet detection
### Table 7-3. Analytical Methods for Determining Toluene in Environmental Samples

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Workplace air</td>
<td>Sorption on activated carbon; extraction with carbon disulfide</td>
<td>GC/FID 0.01 mg</td>
<td>±11.4(^a)</td>
<td>NIOSH 1994 Method 1501</td>
</tr>
<tr>
<td>Workplace air</td>
<td>Sorption on activated charcoal or Radiello diffusive samplers</td>
<td>HPLC 0.5 mg/L or 5 µg/sample</td>
<td>No data</td>
<td>Campos-Candel et al. 2009</td>
</tr>
<tr>
<td>Workplace air</td>
<td>Sorption on activated charcoal or Radiello diffusive samplers</td>
<td>GC/MS 0.6 pg/s or 0.08 µg/sample</td>
<td>No data</td>
<td>Campos-Candel et al. 2009</td>
</tr>
<tr>
<td>Indoor air</td>
<td>Solid phase microextraction (SPME)</td>
<td>GC/MS 0.004 mg/m(^3)</td>
<td>No data</td>
<td>Gorlo et al. 1999</td>
</tr>
<tr>
<td>Air</td>
<td>Sorption onto Tenax(^\circledast); solvent extraction; thermal desorption</td>
<td>GC/MS &lt;0.88 ppbv</td>
<td>111–163</td>
<td>Crist and Mitchell 1986</td>
</tr>
<tr>
<td>Air</td>
<td>Sorption onto Tenax(^\circledast); thermal desorption</td>
<td>GC/MS No data</td>
<td>93–94</td>
<td>EPA 1988a Method TO-1 Krost et al. 1982</td>
</tr>
<tr>
<td>Air</td>
<td>Collection in passivated canisters</td>
<td>GC/MS low ppb</td>
<td>No data</td>
<td>EPA 1988b Method TO-14</td>
</tr>
<tr>
<td>Air</td>
<td>Collection on multisorbent tubes; thermal desorption</td>
<td>GC/MS No data</td>
<td>No data</td>
<td>EPA 1997a Method TO-17</td>
</tr>
<tr>
<td>Air</td>
<td>Collection in sorbent sampler tubes</td>
<td>GC/FID 0.01 mg/sample</td>
<td>94</td>
<td>USEPA, EMMI 1997 NIOSH 1500</td>
</tr>
<tr>
<td>Air</td>
<td>Sorption on activated charcoal; extraction with carbon disulfide</td>
<td>GC/FID 0.01 mg/sample</td>
<td>No data</td>
<td>USEPA, EMMI 1997 NIOSH 4000</td>
</tr>
<tr>
<td>Air</td>
<td>Solid phase membrane samplers (SPMS)</td>
<td>GC/MS 0.0001 µg/sampler</td>
<td>No data</td>
<td>Esteve-Turrillas et al.2009</td>
</tr>
<tr>
<td>Air</td>
<td>Preconcentration in SKS glass tube with charcoal, desorption</td>
<td>GC/MS 1 µg/m(^3)</td>
<td>No data</td>
<td>Nicoara et al. 2009</td>
</tr>
<tr>
<td>Stack gas effluents</td>
<td>Sorption onto Tenax(^\circledast); thermal desorption</td>
<td>GC/MS No data</td>
<td>50–150</td>
<td>USEPA, EMMI 1997 OSW 5041A</td>
</tr>
<tr>
<td>Vehicle exhaust</td>
<td>Direct</td>
<td>GC/FID 0.5 ppb</td>
<td>No data</td>
<td>Dearth et al. 1992</td>
</tr>
<tr>
<td>Drinking water</td>
<td>Purge and trap</td>
<td>capillary 0.01–0.02 ppb</td>
<td>98–99</td>
<td>DeMarini et al. 1991 Method 502.2</td>
</tr>
<tr>
<td>Drinking water</td>
<td>Purge and trap</td>
<td>GC/PID 0.02 ppb</td>
<td>94</td>
<td>EPA 1991a Method 503.1</td>
</tr>
<tr>
<td>Drinking water</td>
<td>Purge and trap</td>
<td>capillary 0.08–0.11 ppb</td>
<td>100–126</td>
<td>EPA 1992a Method 524.2</td>
</tr>
<tr>
<td>Water/waste water</td>
<td>Purge and trap</td>
<td>GC/PID 0.2 ppb</td>
<td>77</td>
<td>EPA 1982b Method 602</td>
</tr>
</tbody>
</table>

\(^{a}\) Estimated based on analysis of spiked samples.

***DRAFT FOR PUBLIC COMMENT***
### Table 7-3. Analytical Methods for Determining Toluene in Environmental Samples

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water/waste water</td>
<td>Purge and trap</td>
<td>GC/MS</td>
<td>6.0 ppb</td>
<td>98–101</td>
<td>EPA 1982c Method 624</td>
</tr>
<tr>
<td>Water/waste water</td>
<td>Addition of isotopically labeled analog; purge and trap</td>
<td>GC/MS</td>
<td>10 ppb</td>
<td>No data</td>
<td>EPA 1984 Method 1624</td>
</tr>
<tr>
<td>Industrial effluents</td>
<td>Purged with inert gas onto Tenax®; thermally desorbed</td>
<td>GC/IDMS</td>
<td>20 ppb</td>
<td>No data</td>
<td>Colby et al. 1980</td>
</tr>
<tr>
<td>Drinking water, waste water</td>
<td>Purged with inert gas onto Tenax®; thermally desorbed, cryofocused</td>
<td>GC/MS</td>
<td>1 ppb</td>
<td>74–107</td>
<td>Michael et al. 1988</td>
</tr>
<tr>
<td>Groundwater</td>
<td>Solid-phase microextraction</td>
<td>GC/FID</td>
<td>2 ppb</td>
<td>No data</td>
<td>Arthur et al. 1992</td>
</tr>
<tr>
<td>Water</td>
<td>Purge and trap</td>
<td>GC/MS</td>
<td>0.047 ppb</td>
<td>106</td>
<td>USEPA, EMMI 1997 APHA 6210-B</td>
</tr>
<tr>
<td>Water</td>
<td>Direct aqueous injection</td>
<td>GC</td>
<td>1.0 ppm</td>
<td>No data</td>
<td>USEPA, EMMI 1997 ASTM D3695</td>
</tr>
<tr>
<td>Water</td>
<td>Purge and trap</td>
<td>GC</td>
<td>0.5 ppb</td>
<td>80–120</td>
<td>USEPA, EMMI 1997 APHA 6220-B</td>
</tr>
<tr>
<td>Water</td>
<td>Dilution in appropriate solvent</td>
<td>FS</td>
<td>2.1 ppm</td>
<td>No data</td>
<td>USEPA, EMMI 1997 ASTM D4763</td>
</tr>
<tr>
<td>Water</td>
<td>Static mode sampling</td>
<td>IMS</td>
<td>No data</td>
<td>No data</td>
<td>Wan et al. 1998</td>
</tr>
<tr>
<td>Groundwater, aqueous sludges, waste solvents, acid and caustic liquors, soils, sediments</td>
<td>Purge and trap</td>
<td>GC/MS</td>
<td>5 ppb</td>
<td>47–150</td>
<td>USEPA, EMMI 1997 OSW8240B-W</td>
</tr>
<tr>
<td>Groundwater, aqueous sludges, waste solvents, acid and caustic liquors, soils, sediments</td>
<td>Purge and trap or direct injection</td>
<td>GC/EC or GC/PID</td>
<td>0.01 ppb</td>
<td>99</td>
<td>USEPA, EMMI 1997 OSW 8021B-PID</td>
</tr>
<tr>
<td>Solid waste</td>
<td>Purge-and-trap</td>
<td>capillary GC/PID</td>
<td>0.01 ppb</td>
<td>99</td>
<td>EPA 1996a Method 8021B</td>
</tr>
<tr>
<td>Solid waste</td>
<td>Purge-and-trap</td>
<td>GC/PID</td>
<td>0.08–0.11 ppb</td>
<td>100–102</td>
<td>EPA 1996b Method 8260B</td>
</tr>
<tr>
<td>Solid waste</td>
<td>Static Headspace sampling (HS)</td>
<td>GC/MS</td>
<td>0.72 ng/L</td>
<td>101</td>
<td>Bernado et al. 2009</td>
</tr>
</tbody>
</table>
Table 7-3. Analytical Methods for Determining Toluene in Environmental Samples

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soil</td>
<td>Methanol extraction; SPE</td>
<td>capillary GC</td>
<td>sub-ppm</td>
<td>&gt;90</td>
<td>Meney et al. 1998</td>
</tr>
<tr>
<td>Soil (screening)</td>
<td>Filter</td>
<td>immunoassay</td>
<td>7 ppm</td>
<td>No data</td>
<td>EPA 1996c Method 4030</td>
</tr>
<tr>
<td>Soils and sediments</td>
<td>Headspace extraction</td>
<td>GC/PID</td>
<td>0.2 ppb</td>
<td>46–148</td>
<td>USEPA, EMMI 1997 OSW 8020A</td>
</tr>
<tr>
<td>Soils and other solid matrices</td>
<td>Headspace extraction</td>
<td>GC/FID/ELCD</td>
<td>No data</td>
<td>No data</td>
<td>USEPA, EMMI 1997 OSW 5021</td>
</tr>
<tr>
<td>Solid waste matrices</td>
<td>Purge and trap or direct aqueous injection or concentration by azeotropic distillation or automated static headspace</td>
<td>GC/MS</td>
<td>0.11 ppb</td>
<td>102</td>
<td>USEPA, EMMI 1997 OSW 8260B</td>
</tr>
<tr>
<td>Plant cuticle</td>
<td>Headspace extraction</td>
<td>GC/FID</td>
<td>No data</td>
<td>No data</td>
<td>Keymeulen et al. 1997</td>
</tr>
<tr>
<td>Food</td>
<td>Headspace extraction, 1 hour at 90°C</td>
<td>GC</td>
<td>No data</td>
<td>No data</td>
<td>Walters 1986</td>
</tr>
<tr>
<td>Foods</td>
<td>Purge and trap</td>
<td>capillary GC/MS</td>
<td>8 ppb</td>
<td>54–76b</td>
<td>Heikes et al. 1995</td>
</tr>
<tr>
<td>Bottled water</td>
<td>Headspace extraction</td>
<td>GC/MS</td>
<td>0.5–1 ppb</td>
<td>No data</td>
<td>Page et al. 1993</td>
</tr>
<tr>
<td>Olive oil</td>
<td>Homogenization; headspace</td>
<td>capillary GC/MS</td>
<td>No data</td>
<td>No data</td>
<td>Biedermann et al. 1995</td>
</tr>
</tbody>
</table>

*aReported accuracy, bIntralaboratory accuracy. Single lab accuracy is reported as 100–106% recovery.

FID = flame ionization detector; FS = fluorescence spectroscopy, ELCD; GC = gas chromatography; IDMS = isotope dilution mass spectrometry; MS = mass spectrometry; PID = photoionization detector; SPE = solid-phase extraction.

***DRAFT FOR PUBLIC COMMENT***
environmental matrices. Various detection devices used for GC include FID, MS, and PID. Because of the complexity of the sample matrix and the usually low concentrations of volatile organic compounds in environmental media, sample preconcentration is generally required prior to GC analysis. Air samples may be collected and concentrated on adsorbent or in canisters for subsequent analysis. Methods suitable for determining trace amounts of toluene in aqueous and other environmental media include three basic approaches to the pretreatment of the sample: gas purge-and-trap technique, headspace gas analysis, and extraction with organic solvent. Purge-and-trap is the most widely used method for the isolation and concentration of volatile organic compounds in environmental samples (Lesage et al. 1993). The purge and trap technique offers advantages over other techniques in that it allows facile isolation and concentration of target compounds, thereby improving overall limits of detection and recovery of sample.

Sampling techniques for air include collection in sample loops, on adsorbent, in canisters, and by cryogenic trapping. The analysis is normally performed by GC/FID, GC/PID, or GC/MS. Detection limits depend on the amount of air sampled, but values in the ppt range have been reported (Dewulf and Van Langenhoven 1997).

BTEX was monitored in the urban air of nine sites by use of GC/MS. Toluene concentrations were the highest among the compounds. The limit of detection was also highest for toluene at 1 µg/m³ (Nicoara et al. 2009).

Toluene may be determined in occupational air using collection on adsorbent tubes, solvent desorption and GC/FID analysis (NIOSH 1994). Detection limits depend upon the amount of air sampled; accuracy is very good (11.4% bias) (NIOSH 1994).

Campos-Candel et al. (2009) compared HPLC-fluorescence (HPLC-FL) to GC/MS measurements of toluene in air samples. The limit of detection for the samples in HPLC-FL method was 0.5 mg/L or 5 µg/sample and the limit of detection for GC/MS was 0.6 pg/s or 0.08 μg/sample. The GC/MS was deemed to be more sensitive.

Esteve-Turrillas et al. (2009) developed a versatile, easy, and rapid atmosphere monitor (V-E-R-A-M) for the detection of BTEX in the air. Solid-phase membrane samplers (SPMS) and HS-GC-MS were utilized for the study. The limit of detection was determined to be 0.001 µg/sampler.
7. ANALYTICAL METHODS

Older studies have suggested that passive samplers were utilized in the detection of toluene, but performance data on those samplers were unavailable (Ballesta et al. 1992; Periago et al. 1997). Newer studies demonstrate the efficacy of these samplers. SPME, a passive sampling method, was utilized to detect toluene in the indoor air in freshly renovated flats. The detection limit was 0.004 mg/m³ (Gorlo et al. 1999).

Gas purge and trap is the most widely used method for the isolation and concentration of volatile organic compounds in environmental samples (Lesage et al. 1993). The purge and trap technique offers advantages over other techniques in that it allows facile isolation and concentration of target compounds, thereby improving overall limits of detection and recovery of sample. Detection limits of less than 1 µg of toluene per liter of sample have been achieved. Very low detection limits for drinking water are reported for the purge and trap method with GC/PID (0.01–0.02 ppb) (DeMarini et al. 1991, EPA 1991a). Accuracy is very good (94–99% recovery) (DeMarini et al. 1991, EPA 1991a). While the analytical method is selective, confirmation using a second column or GC/MS is recommended (EPA 1992a). Good sensitivity (0.08–0.11 ppb) and accuracy (100–126% recovery) can also be obtained using capillary GC/MS detection (EPA 1992a). Purge-and-trap methodology may be applied to waste water as well (EPA 1982b, 1982c, 1984). Sensitivity is in the low ppb range and recovery is good (77–101%) (EPA 1982b, 1982c, 1984).

Ion mobility spectrometry (IMS) was used in the detection of BTEX compounds in water. Static mode sampling determined the toluene concentration of 0.101 mg/L in purified water, which resulted in a headspace concentration of 2.75 µg/m³ (Wan et al. 1998).

Soil, sediment, and solid waste are more difficult to analyze. Volatilization during sample handling and homogenization can result in analyte loss. Purge-and-trap methods with capillary GC/PID or GC/MS analysis provide detection limits of approximately 0.5 ppm for wastes and 5 µg/g for soil and sediment (EPA 1982b, 1982c, 1984). Static headspace sampling (HS), along with GC-MS, was utilized in a study conducted by Bernardo et al. (2009) to effectively detect toluene in solid residues (waste) produced from the co-pyrolysis of plastics and pine biomass. The detection limit was 0.72 ng/L.

No methods were found for the determination of toluene in fish and biota. Few methods are available for the determination of toluene in food. A purge and trap extraction method is available for determining toluene in a variety of foods. The quantitation limit is 8 ppb; single lab recovery is very good (100–
106%) and precision is good (9.8–25% RSD). Both intra- and inter-laboratory studies were conducted, and precision was found to be ≤25% RSD (Heikes et al. 1995).

7.3 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of toluene is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of toluene.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

7.3.1 Identification of Data Needs

Methods for Determining Biomarkers of Exposure and Effect. Although toluene and its metabolites can be measured in body fluids using a number of techniques (Kawai et al. 1993, 1996; NIOSH 1984a), the metabolites have limited value as biomarkers. A number of common food materials produce the same metabolites, thus measurement of toluene metabolites can be used to confirm a known exposure but cannot be used to determine whether or not exposure occurred in a poorly defined situation. It is also very difficult to quantify the magnitude of exposure from levels of either toluene or its metabolites in biological samples. Despite these limitations, end-of-shift concentrations of 2.5 g hippuric acid/g creatinine and 1.0 mg/L toluene in venous blood have been established as biological exposure indices for toluene (ACGIH 1992a). A technique that could accurately quantify exposure to toluene would be useful.

Exposure. For occupational health monitoring and animal studies, there is also a need for improved and more sensitive methods to determine toluene metabolites. Additional work to develop sensitive methods for analysis of the cresol metabolites and to correlate these metabolites with specific exposure conditions would be valuable.
**Effect.** It is equally difficult to monitor the effects of toluene exposure. MRI and BAER evaluations of the brain have some value in determining the neurological damage resulting from long-term exposures to high levels of toluene, but have no known value for determining the effects of low-level and/or short-term exposures.

**Methods for Determining Parent Compounds and Degradation Products in Environmental Media.** There are methods available for the determination of toluene and its metabolites in environmental samples. Sensitive techniques for air, drinking water, and waste water allow detection of toluene at low levels (Bernado et al. 2009; Campos-Candel et al. 2009; Wan et al. 1998). These techniques are adequate to measure both background toluene levels and the levels of toluene in environmental media that could cause health effects. However, when toluene is present in combination with other volatile materials, interference from the companion volatiles often raises the detection limit and decreases the accuracy and precision of the technique. Improved methods for separation of toluene from other volatiles would be useful.

Research on measuring the levels of metabolites in soil and water would be valuable especially in studying the end products of microbial degradation. Few methods are available for monitoring toluene in foods; reliable methods are needed for evaluating the potential for human exposure that might result from toluene ingestion.

**7.3.2 Ongoing Studies**

The Environmental Health Laboratory Sciences Division of the National Center for Environmental Health, Centers for Disease Control and Prevention, is developing methods for the analysis of toluene and other phenolic compounds in urine. These methods use high-resolution gas chromatography and magnetic sector mass spectrometry, which give detection limits in the low parts per trillion (ppt) range.
8. REGULATIONS, ADVISORIES, AND GUIDELINES

MRLs are substance specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors and other responders to identify contaminants and potential health effects that may be of concern at hazardous waste sites.

ATSDR has derived an acute-duration inhalation MRL of 2 ppm (7.6 mg/m³) for toluene based on a LOAEL for minimally adverse neurological effects in a susceptible human population (Little et al. 1999).

ATSDR has derived a chronic-duration inhalation MRL of 1 ppm (3.8 mg/m³) for toluene based on a NOAEL for neurological effects in humans in series of studies by the same group of investigators (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002).

ATSDR has derived an acute-duration oral MRL of 0.8 mg/kg/day for toluene based on a LOAEL for neurological effects in rats (Dyer et al. 1988).

ATSDR has derived an intermediate-duration oral MRL of 0.2 mg/kg/day for toluene based on a NOAEL for immune depression in mice (Hsieh et al. 1989, 1990a, 1991).

The International Agency for Research on Cancer (IARC) has classified toluene as a Group 3 carcinogen (not classifiable as to its carcinogenicity to humans) based on the evidence of carcinogenicity is inadequate in humans and inadequate or limited in experimental animals (IARC 2013). The World Health Organization (WHO) has not established any air quality guidelines but have concluded that further investigation would be needed before it was clear whether there was sufficient evidence to warrant their inclusion in the guidelines at present (WHO 2010). WHO has established a health-based drinking water guideline for toluene at 0.7 mg/L (WHO 2011).

The EPA and ACGIH also state that there are inadequate data on which to classify toluene in terms of its carcinogenicity in humans or animals (ACGIH 2013; IRIS 2007). Therefore, toluene is assigned the cancer category A4 (not classifiable as a human carcinogen) by ACGIH and Group D (not classifiable as to human carcinogenicity) by EPA (ACGIH 2013; IRIS 2007). The National Toxicology Program (NTP) has not classified toluene as a carcinogen (NTP 2011).
The EPA’s reference concentration (RfC) for toluene is 5 mg/m³ and the EPA’s reference dose (RfD) is 0.08 mg/kg/day (IRIS 2007).

OSHA sets permissible exposure limits (PELs) to protect workers against adverse health effects resulting from exposure to hazardous substances. The PELs determined for hazardous substances are enforceable, regulatory limits on allowable air concentrations in the workplace. OSHA requires employers of workers who are occupationally exposed to these hazardous substances to institute engineering controls and work practices to reduce and maintain employee exposure at or below the PEL. An employer must ensure that an employee’s exposure to toluene in any 8-hour work shift of a 40-hour week does not exceed the 8-hour TWA of 200 ppm (OSHA 2013b). The acceptable ceiling concentration for toluene that shall not be exceeded at any time during an 8-hour shift is 300 ppm (OSHA 2013b). The acceptable maximum peak above the ceiling for an 8-hour shift is 500 ppm for 10 minutes (OSHA 2013b).

The ACGIH (2013) recommends an 8-hour TWA Threshold Limit Value (TLV) of 20 ppm toluene to protect against visual impairment and female reproductive effects including pregnancy loss. NIOSH has established a recommended exposure limit (REL) of 100 ppm that should not be exceeded at any time (NIOSH 2011). NIOSH has also established a short-term exposure limit (STEL) of 150 ppm and an immediately dangerous to life or health (IDLH) value of 500 ppm (NIOSH 2011).

Toluene is regulated as a hazardous air pollutant (EPA 2014a) and is subject to the emission limitations for various processes and operations in the synthetic organic chemicals manufacturing industry.

The American Industrial Hygiene Association (AIHA) and the Department of Energy (DOE) have established values for responding to potential releases of airborne toluene for use in community emergency planning. The values established by AIHA (2013) and the DOE (2012) are the Emergency Response Planning Guidelines (ERPGs-1, -2, -3) and Protective Active Criteria (PAC-1, -2, and -3), respectively. The ERPG-1, -2, and -3 values are 50, 300, and 1,000 ppm, respectively, and the PAC-1, -2, and -3 values are 200, 1,200, and 4,500 ppm, respectively, represent increasing severity of effects (mild, irreversible, and life threatening, respectively) for a 1-hour exposure (AIHA 2013; DOE 2012).

Toluene is listed as a chemical that must meet the requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act (SARA) (EPA 1996a). Title III of SARA, also known as “The Emergency Planning and Community Right-to-Know Act of 1986,” requires owners and operators of certain facilities that manufacture, import, process, or otherwise use the chemicals on this list

***DRAFT FOR PUBLIC COMMENT***
to report annually any release of those chemicals to any environmental media over a specified threshold level (EPA 2013f).

Toluene has been designated as a hazardous substance pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) of 1980 (EPA 1995a). The statutory source for this designation is Section 311(b)(4) of the Clean Water Act (CWA), Section 307 (a) of the CWA, Section 112 of the Clean Air Act (CAA), and Section 300 of the Resource Conservation and Recovery Act (RCRA) (EPA 2013f). The owner and operator of any facility that produces, uses, or stores a CERCLA hazardous substance is required to immediately report releases to any environmental media, if the amount released is equal to or exceeds the specified “reportable quantity” assigned to the substance. The reportable quantity for toluene is 1,000 pounds (454 kg) (EPA 2013g).

Because of its potential to cause adverse health effects in exposed people, toluene is also regulated by the drinking water standards set by the EPA. Toluene generally gets into drinking water by improper waste disposal or leaking underground storage tanks. In order to protect humans from the risk of developing adverse health effects from exposure to toluene through drinking water, the EPA Drinking Water Regulations and Health Advisories (EPA 2012) lists the maximum contaminant level (MCL) and the maximum contaminant level goal (MCLG) for toluene as 1 mg/L.

Under the Toxic Substances Control Act (TSCA), toluene is on the list of chemicals that manufacturers and importers must report for each plant site at which they manufactured or imported toluene during the reporting period specified (EPA 2013l).

The international and national regulations, advisories, and guidelines regarding toluene in air, water, and other media are summarized in Table 8-1.
### Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTERNATIONAL</strong> Guidelines:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IARC</td>
<td>Carcinogenicity classification</td>
<td>Group 3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>IARC 2013</td>
</tr>
<tr>
<td>WHO</td>
<td>Air quality guidelines</td>
<td>Group 2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>WHO 2010</td>
</tr>
<tr>
<td></td>
<td>Drinking water quality guidelines</td>
<td>0.7 mg/L&lt;sup&gt;c&lt;/sup&gt;</td>
<td>WHO 2011</td>
</tr>
<tr>
<td><strong>NATIONAL</strong> Regulations and Guidelines:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Air</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACGIH</td>
<td>TLV-TWA</td>
<td>20 ppm</td>
<td>ACGIH 2013</td>
</tr>
<tr>
<td>AIHA</td>
<td>ERPG-1&lt;sup&gt;d,e&lt;/sup&gt;</td>
<td>50 ppm</td>
<td>AIHA 2013</td>
</tr>
<tr>
<td></td>
<td>ERPG-2</td>
<td>300 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ERPG-3</td>
<td>1,000 ppm</td>
<td></td>
</tr>
<tr>
<td>DOE</td>
<td>PAC-1&lt;sup&gt;f&lt;/sup&gt;</td>
<td>200 ppm</td>
<td>DOE 2012</td>
</tr>
<tr>
<td></td>
<td>PAC-2</td>
<td>1,200 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PAC-3</td>
<td>4,500 ppm</td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td>AEGL-1&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td>EPA 2013c</td>
</tr>
<tr>
<td></td>
<td>10-minutes</td>
<td>200 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30-minutes</td>
<td>200 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>60-minutes</td>
<td>200 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4-hours</td>
<td>200 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8-hours</td>
<td>200 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AEGL-2&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10-minutes</td>
<td>3,100 ppm&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30-minutes</td>
<td>1,600 ppm&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>60-minutes</td>
<td>1,200 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4-hours</td>
<td>790 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8-hours</td>
<td>650 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AEGL-3&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10-minutes</td>
<td>13,000 ppm&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30-minutes</td>
<td>6,100 ppm&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>60-minutes</td>
<td>4,500 ppm&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4-hours</td>
<td>3,000 ppm&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8-hours</td>
<td>2,500 ppm&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hazardous air pollutant</td>
<td>Yes</td>
<td>EPA 2014a 42 USC 7412</td>
</tr>
<tr>
<td>NIOSH</td>
<td>REL</td>
<td>100 ppm</td>
<td>NIOSH 2011</td>
</tr>
<tr>
<td></td>
<td>STEL</td>
<td>150 ppm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IDLH</td>
<td>500 ppm</td>
<td></td>
</tr>
</tbody>
</table>
### Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATIONAL (cont.)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSHA</td>
<td>PEL (8-hour TWA) for general industry</td>
<td>200 ppm</td>
<td>OSHA 2013b</td>
</tr>
<tr>
<td></td>
<td>Acceptable ceiling concentration</td>
<td>300 ppm</td>
<td>29 CFR 1910.1000, Table Z-2</td>
</tr>
<tr>
<td></td>
<td>Acceptable maximum peak above the acceptable ceiling concentration for an 8-hour shift</td>
<td>500 ppm for 10 minutes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Highly hazardous chemicals</td>
<td>No data</td>
<td>OSHA 2013a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>29 CFR 1910.119, Appendix A</td>
</tr>
<tr>
<td><strong>b. Water</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td>Designated as hazardous substances in accordance with Section 311(b)(2)(A) of the Clean Water Act</td>
<td></td>
<td>EPA 2013d</td>
</tr>
<tr>
<td></td>
<td>Drinking water contaminant candidate list</td>
<td>No data</td>
<td>EPA 2009a</td>
</tr>
<tr>
<td></td>
<td>Drinking water standards and health advisories</td>
<td></td>
<td>EPA 2012</td>
</tr>
<tr>
<td></td>
<td>MCL</td>
<td>1 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MCLG</td>
<td>1 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Health advisory for 1 day for 10-kg child</td>
<td>20 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Health advisory for 10 days for 10-kg child</td>
<td>2 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DWEL</td>
<td>3 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National primary drinking water standards</td>
<td></td>
<td>EPA 2009b</td>
</tr>
<tr>
<td></td>
<td>MCL</td>
<td>1 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Potential health effects from long-term exposure above the MCL</td>
<td>Nervous system, kidney, or liver problems</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Common sources of contaminant in drinking water</td>
<td>Discharge from petroleum factories</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Public Health Goal</td>
<td>1 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National recommended water quality criteria: human health for the consumption of (at $10^{-4}$ risk)</td>
<td></td>
<td>EPA 2014e</td>
</tr>
<tr>
<td></td>
<td>Water + organism</td>
<td>1.3 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organism only</td>
<td>15 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reportable quantities of hazardous substances designated pursuant to Section 311 of the Clean Water Act</td>
<td>1,000 pounds</td>
<td>EPA 2013f</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>40 CFR 117.3</td>
</tr>
</tbody>
</table>
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATIONAL (cont.)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Food</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA</td>
<td>Bottled water</td>
<td>1 mg/L</td>
<td>FDA 2013 21 CFR 165.110</td>
</tr>
<tr>
<td>EAFUS</td>
<td></td>
<td>No data</td>
<td>FDA 2014</td>
</tr>
<tr>
<td>d. Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACGIH</td>
<td>Carcinogenicity classification</td>
<td>A4&lt;sup&gt;k&lt;/sup&gt;</td>
<td>ACGIH 2013</td>
</tr>
<tr>
<td>BEI</td>
<td>Toluene in blood; prior to last shift of workweek</td>
<td>0.02 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toluene in urine; end of shift</td>
<td>0.03 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>O-Cresol in urine; end of shift</td>
<td>0.3 mg/g creatinine</td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td>Carcinogenicity classification</td>
<td>Group D&lt;sup&gt;j&lt;/sup&gt;</td>
<td>IRIS 2007</td>
</tr>
<tr>
<td></td>
<td>RfC</td>
<td>5 mg/m&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RfD</td>
<td>0.08 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Identification and listing of hazardous waste</td>
<td>U220</td>
<td>EPA 2013e 40 CFR 261, Appendix VIII</td>
</tr>
<tr>
<td></td>
<td>Inert pesticide ingredients in pesticide products approved for nonfood use only</td>
<td>Yes</td>
<td>EPA 2014b</td>
</tr>
<tr>
<td></td>
<td>Master Testing List</td>
<td>Yes&lt;sup&gt;n&lt;/sup&gt;</td>
<td>EPA 2014c</td>
</tr>
<tr>
<td></td>
<td>RCRA waste minimization PBT priority chemical list</td>
<td>No data</td>
<td>EPA 1998d 63 FR 60332</td>
</tr>
<tr>
<td></td>
<td>Standards for owners and operators of hazardous waste TSD facilities; groundwater monitoring list</td>
<td>Yes</td>
<td>EPA 2013j 40 CFR 264, Appendix IX</td>
</tr>
<tr>
<td></td>
<td>Superfund, emergency planning, and community right-to-know</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Designated CERCLA hazardous substance and reportable quantity pursuant to Section 311(b)(2) of the Clean Water Act, Section 307(a) of the Clean Water Act, Section 112 of the Clean Air Act, and Section 3001 of RCRA</td>
<td>1,000 pounds</td>
<td>EPA 2013g 40 CFR 302.4</td>
</tr>
<tr>
<td></td>
<td>Effective date of toxic chemical release reporting</td>
<td>01/01/1987</td>
<td>EPA 2013h 40 CFR 372.65</td>
</tr>
<tr>
<td></td>
<td>Extremely hazardous substances and its threshold planning quantity</td>
<td>No data</td>
<td>EPA 2013i 40 CFR 355, Appendix A</td>
</tr>
<tr>
<td></td>
<td>TSCA chemical lists and reporting periods</td>
<td>No data</td>
<td>EPA 2013k 40 CFR 712.30</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
### Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATIONAL (cont.)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td>TSCA health and safety data reporting</td>
<td>Effective date: 10/04/1982</td>
<td>EPA 2013i</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reporting date: 10/04/1992</td>
<td>40 CFR 716.120</td>
</tr>
<tr>
<td>NTP</td>
<td>Carcinogenicity classification</td>
<td>No data</td>
<td>NTP 2011</td>
</tr>
</tbody>
</table>

*a* Group 3: not classifiable as to its carcinogenicity to humans.

*b* Group 2 includes pollutants of potential interest, but WHO concluded that further investigation would be needed before it was clear whether there was sufficient evidence to warrant their inclusion in the guidelines at present (WHO 2010).

*c* Concentrations of the substance at or below the health-based guideline value may affect the appearance, taste, or odor of the water, leading to consumer complaints (WHO 2011).

*d* ERPG-1: maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing other than mild transient adverse health effects or perceiving a clearly defined, objectionable odor; ERPG-2: maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing or developing irreversible or other serious health effects or symptoms which could impair an individual's ability to take protective action; ERPG-3: maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing or developing life-threatening health effects (AIHA 2013).

*e* Odor should be detectable near ERPG-1.

*f* PAC-1: mild, transient health effects; PAC-2: irreversible or other serious health effects that could impair the ability to take protective action; PAC-3: life-threatening health effects (DOE 2012).

*g* Lower Explosive Limit (LEL) = 14,000 ppm.

*h* For values denoted as safety considerations against the hazard(s) of explosion(s) must be taken into account; ≥10% LEL.

*i* For values denoted as extreme safety considerations against the hazard(s) of explosion(s) must be taken into account; ≥50% LEL.

*j* The EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food additives or listed or affirmed as GRAS.

*k* Group D: not classifiable as a human carcinogen.

*l* Voluntary chemical testing program underway for SIDS including pharmacokinetic and immunological health effects (EPA 2014c).

ACGIH = American Conference of Governmental Industrial Hygienists; AEGEL = acute exposure guideline levels; AIHA = American Industrial Hygiene Association; BEI = biological exposure indices; CERCLA = Comprehensive Environmental Response, Compensation, and Liability Act; CFR = Code of Federal Regulations; DOE = Department of Energy; DWEL = drinking water equivalent level; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; FR = Federal Register; GRAS = generally recognized as safe; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; LEL = lower explosive limit; MCL = maximum contaminant level; MCLG = maximum contaminant level goal; NAAQS = National Ambient Air Quality Standards; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = protective action criteria; PBT = persistent, bioaccumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; SIDS = Screening Information Data Set; STEL = short-term exposure limit; TLV = threshold limit values; TSCA = Toxic Substances Control Act; TSD = treatment, storage, and disposal; TWA = time-weighted average; USC = United States Code; WHO = World Health Organization

***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


*ACGIH. 1999. TLVs and BEIs: Threshold limit values for chemical substances and physical agents: Biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, 67, 102.


* Cited in text
+ Cited in supplemental document

***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


REFERENCES


9. REFERENCES


*Apawu AK, Matthews TA, Bowen SE. 2014. Striatal dopamine dynamics in mice following acute and repeated toluene exposure. Psychopharmacology [Epub ahead of print]
TOLUENE

9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


9. REFERENCES


++^Banfer VW. 1961. [Studies on the effect of pure toluene on the blood picture of photogravure printers and helper workers.] Zent Arbeitsmed 11:35-40. (German)


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES

*Dobrokhotov VB, Enikeev MI. 1977. The mutagenic action of benzene, toluene and a mixture of these hydrocarbons in a chronic test. Gig Sanit 42:32-34.


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES

*EPA. 2006. Consolidated list of chemicals subject to the Emergency Planning and Right-To-Know Act (EPCRA) and section 112(r) of the Clean Air Act. U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response. EPA550B01003.


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


*Exxon Chemical Co. 1962. Acute eye application - rabbits. Houston, TX: Exxon Chemical Company U.S.A. Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D. OTS0200153.


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


**DRAFT FOR PUBLIC COMMENT**
9. REFERENCES


References


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


**Mullin LS, Krivanek ND. 1982. Comparison of unconditioned reflex and conditioned avoidance tests in rats exposed by inhalation to carbon monoxide, 1,1,1-trichloroethane, toluene or ethanol. Neurotoxicology 3:126-137.


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


---

***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


Pleil JD, Oliver KD, McClenny WA. 1988. Ambient air analyses using nonspecific flame ionization and electron capture detection compared to specific detection by mass spectroscopy. JAPCA 38:1006-1010.


9. REFERENCES


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


+Wang DH, Ishii K, Seno E, et al. 1998. Reduced serum levels of ALT and GGT and high carbohydrate intake among workers exposed to toluene below the threshold limit values. Ind Health 36:14-19.


9. REFERENCES


9. REFERENCES


***DRAFT FOR PUBLIC COMMENT***
9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


Zhao W, Misumi J, Yasui T, et al. 1998a. Effects of methyl ethyl ketone, acetone, or toluene coadministration on 2,5-hexanedione concentration in the sciatic nerve, serum, and urine of rats. Int Arch Occup Environ Health 71:236-244.


This page is intentionally blank.
10. GLOSSARY

Absorption—The taking up of liquids by solids, or of gases by solids or liquids.

**Acute Exposure**—Exposure to a chemical for a duration of 14 days or less, as specified in the Toxicological Profiles.

**Adsorption**—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the surfaces of solid bodies or liquids with which they are in contact.

**Adsorption Coefficient (Koc)**—The ratio of the amount of a chemical adsorbed per unit weight of organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.

**Adsorption Ratio (Kd)**—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or sediment.

**Benchmark Dose (BMD)**—Usually defined as the lower confidence limit on the dose that produces a specified magnitude of changes in a specified adverse response. For example, a BMD<sub>10</sub> would be the dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 10%. The BMD is determined by modeling the dose response curve in the region of the dose response relationship where biologically observable data are feasible.

**Benchmark Dose Model**—A statistical dose-response model applied to either experimental toxicological or epidemiological data to calculate a BMD.

**Bioconcentration Factor (BCF)**—The quotient of the concentration of a chemical in aquatic organisms at a specific time or during a discrete time period of exposure divided by the concentration in the surrounding water at the same time or during the same period.

**Biomarkers**—Broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility.

**Cancer Effect Level (CEL)**—The lowest dose of chemical in a study, or group of studies, that produces significant increases in the incidence of cancer (or tumors) between the exposed population and its appropriate control.

**Carcinogen**—A chemical capable of inducing cancer.

**Case-Control Study**—A type of epidemiological study that examines the relationship between a particular outcome (disease or condition) and a variety of potential causative agents (such as toxic chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is identified and compared to a similar group of people without outcome.

**Case Report**—Describes a single individual with a particular disease or exposure. These may suggest some potential topics for scientific research, but are not actual research studies.

**Case Series**—Describes the experience of a small number of individuals with the same disease or exposure. These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.

Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles.

Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are followed forward from exposure to outcome. At least one exposed group is compared to one unexposed group.

Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines the relationship between exposure and outcome to a chemical or to chemicals at one point in time.

Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human health assessment.

Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism.

Dose-Response Relationship—The quantitative relationship between the amount of exposure to a toxicant and the incidence of the adverse effects.

Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a chemical; the distinguishing feature between the two terms is the stage of development during which the insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero death.

Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.

Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of disease or other health-related conditions within a defined human population during a specified period.

Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific alteration of the molecular structure of the genome.

Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from the body or environmental media.

Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or irreversible health effects.

Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from exposure to environmental agents such as chemicals.
10. GLOSSARY

Immunological Effects—Functional changes in the immune response.

Incidence—The ratio of individuals in a population who develop a specified condition to the total number of individuals in that population who could have developed that condition in a specified time period.

Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the Toxicological Profiles.

In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.

In Vivo—Occurring within the living organism.

Lethal Concentration_{LO} (LC_{LO})—The lowest concentration of a chemical in air that has been reported to have caused death in humans or animals.

Lethal Concentration_{50} (LC_{50})—A calculated concentration of a chemical in air to which exposure for a specific length of time is expected to cause death in 50% of a defined experimental animal population.

Lethal Dose_{LO} (LD_{LO})—The lowest dose of a chemical introduced by a route other than inhalation that has been reported to have caused death in humans or animals.

Lethal Dose_{50} (LD_{50})—The dose of a chemical that has been calculated to cause death in 50% of a defined experimental animal population.

Lethal Time_{50} (LT_{50})—A calculated period of time within which a specific concentration of a chemical is expected to cause death in 50% of a defined experimental animal population.

Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or group of studies, that produces statistically or biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control.

Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the lymph nodes, spleen, and thymus.

Malformations—Permanent structural changes that may adversely affect survival, development, or function.

Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is likely to be without an appreciable risk of adverse noncancer health effects over a specified route and duration of exposure.

Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty factors. The default value for a MF is 1.

Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific population.

Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified interval of time.
Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s DNA. Mutations can lead to birth defects, miscarriages, or cancer.

Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of death or pathological conditions.

Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a chemical.

No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no statistically or biologically significant increases in frequency or severity of adverse effects seen between the exposed population and its appropriate control. Effects may be produced at this dose, but they are not considered to be adverse.

Octanol-Water Partition Coefficient ($K_{ow}$)—The equilibrium ratio of the concentrations of a chemical in $n$-octanol and water, in dilute solution.

Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who were not exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the exposed group compared to the unexposed group.

Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound and especially a pesticide that acts by inhibiting cholinesterase.

Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.

Pesticide—General classification of chemicals specifically developed and produced for use in the control of agricultural and public health pests.

Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate (disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.

Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based and physiologically-based. A data-based model divides the animal system into a series of compartments, which, in general, do not represent real, identifiable anatomic regions of the body, whereas the physiologically-based model compartments represent real anatomic regions of the body.

Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-response model that quantitatively describes the relationship between target tissue dose and toxic endpoints. These models advance the importance of physiologically based models in that they clearly describe the biological effect (response) produced by the system following exposure to an exogenous substance.

Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also called biologically based tissue dosimetry models.

**Prevalence**—The number of cases of a disease or condition in a population at one point in time.

**Prospective Study**—A type of cohort study in which the pertinent observations are made on events occurring after the start of the study. A group is followed over time.

$q_1^*$—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the multistage procedure. The $q_1^*$ can be used to calculate an estimate of carcinogenic potency, the incremental excess cancer risk per unit of exposure (usually $\mu g/L$ for water, $mg/kg/day$ for food, and $\mu g/m^3$ for air).

**Recommended Exposure Limit (REL)**—A National Institute for Occupational Safety and Health (NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour workweek.

**Reference Concentration (RfC)**—An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. The inhalation reference concentration is for continuous inhalation exposures and is appropriately expressed in units of $mg/m^3$ or ppm.

**Reference Dose (RfD)**—An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level (NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect various types of data used to estimate RfD and an additional modifying factor, which is based on a professional judgment of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer.

**Reportable Quantity (RQ)**—The quantity of a hazardous substance that is considered reportable under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 24-hour period.

**Reproductive Toxicity**—The occurrence of adverse effects on the reproductive system that may result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system.

**Retrospective Study**—A type of cohort study based on a group of persons known to have been exposed at some time in the past. Data are collected from routinely recorded events, up to the time the study is undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing records and/or examining survivors of the cohort.

**Risk**—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
**Risk Factor**—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or inherited characteristic that is associated with an increased occurrence of disease or other health-related event or condition.

**Risk Ratio**—The ratio of the risk among persons with specific risk factors compared to the risk among persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed group compared to the unexposed group.

**Short-Term Exposure Limit (STEL)**—The American Conference of Governmental Industrial Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes continually. No more than four excursions are allowed per day, and there must be at least 60 minutes between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may not be exceeded.

**Standardized Mortality Ratio (SMR)**—A ratio of the observed number of deaths and the expected number of deaths in a specific standard population.

**Target Organ Toxicity**—This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.

**Teratogen**—A chemical that causes structural defects that affect the development of an organism.

**Threshold Limit Value (TLV)**—An American Conference of Governmental Industrial Hygienists (ACGIH) concentration of a substance to which most workers can be exposed without adverse effect. The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit (STEL), or as a ceiling limit (CL).

**Time-Weighted Average (TWA)**—An allowable exposure concentration averaged over a normal 8-hour workday or 40-hour workweek.

**Toxic Dose(50) (TD50)**—A calculated dose of a chemical, introduced by a route other than inhalation, which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.

**Toxicokinetic**—The absorption, distribution, and elimination of toxic compounds in the living organism.

**Uncertainty Factor (UF)**—A factor used in operationally deriving the Minimal Risk Level (MRL) or Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to account for (1) the variation in sensitivity among the members of the human population, (2) the uncertainty in extrapolating animal data to the case of humans, (3) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic average of 10 and 1.

**Xenobiotic**—Any chemical that is foreign to the biological system.
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that
have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public. They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and Human
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop
F-57, Atlanta, Georgia 30329-4027.
MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene
CAS Numbers: 108-88-3
Date: September 2015
Profile Status: Final Draft for Public Comment
Route: [X] Inhalation [ ] Oral
Duration: [X] Acute [ ] Intermediate [ ] Chronic
Graph Key: 37
Species: Human

Minimal Risk Level: 2 [ ] mg/kg/day [X] ppm


Experimental design: Twenty subjects with a history of solvent exposure and adverse reactions to toluene (i.e., clinically sensitive to toluene) were assessed in a battery of neuropsychological tests prior to and after a 20-minute exposure to 15 ppm toluene. The battery of tests included immediate and delayed prose memory, reaction time, letter cancellations, digit symbol, focal length, and STROOP color and color-word tasks.

Effect noted in study and corresponding doses: Statistically significant (p<0.05) impairments were measured in immediate and delayed prose memory (number of items recalled decreased 31%), the digit symbol test (number of correct items decreased 11%), and the letter cancellation test (percent correct decreased 5%) following a 20-minute exposure to 15 ppm toluene, compared with pre-exposure scores. A near-significant 15% increase in reaction time was also observed (p=0.06). No significant difference between pre- and post-exposure values was found for focal length or the STROOP tests.

Dose and end point used for MRL derivation: 15 ppm for minimally adverse neurological effects in a susceptible population.

[ ] NOAEL [X] LOAEL

Uncertainty Factors used in MRL derivation:

[ ] 1 [X] 3 [ ] 10 (for use of a LOAEL)
An uncertainty factor of 3 was used to extrapolate from a LOAEL to a NOAEL, because the observed effects at 15 ppm are minimally adverse and expected to be reversible.

[ ] 1 [ ] 3 [ ] 10 (for extrapolation from animals to humans)

[ ] 1 [X] 3 [ ] 10 (for human variability)
The observed effects were noted in a susceptible/sensitive group of individuals; therefore, a full uncertainty factor of 10 for human variability is not necessary.

Total uncertainty factor = 3 x 3 = 9

MRL = 15 ppm ÷ 9 = 2 ppm (7.6 mg/m³)

Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? No. Application of concentration x time (Cxt) adjustments (Haber’s Rule) for acute exposure scenarios to volatile organic solvents like toluene has been questioned (Oshiro et al. 2011; ten Berge et al. 1986). An example of the basis of this questioning is provided by the results from studies of neurobehavior in animals acutely exposed to trichloroethylene (Bushnell 1997; Crofton and Zhao 1997). Cxt adjustments were shown to underestimate toxic effects when adjusting from relatively long acute durations to shorter durations, and to overestimate toxic effects when adjusting from relatively short acute durations to long acute durations.

Haber’s Rule has been modified to reflect observations that concentration often exerts a stronger influence on acute toxicity than does time (ten Berge et al. 1986). The modification raises the concentration term to a power, (n), which is determined empirically with appropriate data (C'xt; ten Berge et al. 1986). However, determination of the exponent (n) requires adequate concentration-duration-response data, and results from animal studies indicate that the exponent (n) can vary across neurobehavioral end points (e.g., Bushnell 1997).

No duration adjustments were made to exposure concentrations in the available neurobehavioral studies of humans exposed to controlled concentrations of toluene for times varying from 15 minutes to 8 hours, because the available data are for a variety of neurological effects (see further discussion in the next section of this worksheet), and duration adjustment by Haber’s rule is likely to overestimate toxic effects when adjusting from short-term (e.g., 15-minute) to longer-term (e.g., 8-hour) exposure durations.

Estimates of brain concentration at the time of testing have been shown in animals to provide a better dose-metric for predicting acute behavioral effects of toluene than cumulative measures of exposure or Cxt adjustments. For rats exposed to varying toluene concentrations in air (1,200–2,400 ppm) and durations (22–70 minutes) and examined for signal detection behavior, effects on accuracy and response-time variables were increased with both increasing concentration and increasing duration (Bushnell et al. 2007). The use of a rat PBPK model to predict internal blood and brain concentrations of toluene as a function of time showed that estimated brain concentration at the time of testing provided a much better explanation of these performance variables than did cumulative measures of dose (AUCs for inhaled dose [ppm-hour] or brain concentration [mg-hour/L]) (Bushnell et al. 2007). Oshiro et al. (2011) tested rats in a signal detection task at various times during exposure to 0, 1,125, 1,450, or 1,660 ppm for up to 24 hours, and reported that brain toluene concentration (estimated using a rat PBPK model) at the time of testing was a better predictor of performance than Cxt adjustment. Analysis of the data also showed that the brain dose-response relationship for the response time variable at 24 hours of exposure was shifted to the right on the dose axis, compared with the relationship determined at 1 hour of exposure. This duration-induced shift of the dose response relationship indicates that extrapolation from 1- to 24-hour exposure would be confounded by an apparent development of tolerance to toluene within this acute time frame.

As discussed in Section 3.4.5, none of the available human PBPK models for toluene contain a brain compartment or have the ability to estimate brain concentrations of toluene. The lack of human data for kinetics of toluene in brain tissue impedes the development of such a model. Such a model could be used to compare results across available acute exposure studies of human neurobehavior, based on estimates of brain concentrations at the time of testing.

Other additional studies or pertinent information that lend support to this MRL: The critical effect of acute inhalation exposure to toluene is on the central nervous system. Multiple studies report subtle neurological effects in healthy individuals following acute exposure to concentrations in the 75–300 ppm
range with durations ranging from 20 minutes to 8 hours (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1999; Gamberale and Hultengren 1972; Rahill et al. 1996; von Oettingen et al. 1942). Effects include increased subjective complaints (e.g., headache, sleepiness, dizziness) following exposure to 100 ppm for 6 or 6.5 hours (Andersen et al. 1983; Baelum et al. 1985) or 200 ppm for 3 or 8 hours (von Oettingen et al. 1942), and impairments in psychomotor tests following exposure to 75 or 150 ppm toluene for 7 hours (Echeverria et al. 1991), 100 ppm for 6–8 hours (Dick et al. 1984; Rahill et al. 1996), and 300 ppm for 20 minutes (Gamberale and Hultengren 1972).

No adverse, dose-related effects have been observed in healthy individuals acutely exposed to 40–50 ppm toluene for 2–6 hours (Andersen et al. 1983; Lammers et al. 2005a; Muttray et al. 2005; Osterberg et al. 2000, 2003). Therefore, a NOAEL of 40 ppm from Anderson et al. (1983) was considered as the basis for the acute MRL, and previously was used as the point of departure (POD) for the acute inhalation MRL (ATSDR, 2000).

However, recent studies indicate that individuals clinically sensitive to toluene experienced subtle neurological effects at lower concentrations in the 15–48 ppm range (Little et al. 1999; Orbaek et al. 1998; Osterberg et al. 2003). In addition to the altered performance in psychomotor tasks observed in individuals clinically sensitive to toluene reported by Little et al. (1999), individuals with multiple chemical sensitivity or toxic encephalopathy had significantly higher self-reported scores of fatigue (headache, drowsiness, decreased concentration) during exposure to increasing toluene concentrations over 2 hours (0 ppm [20 minutes], 3 ppm [10 minutes], 6 ppm [10 minutes], 12 ppm [20 minutes], 24 ppm [10 minutes], 48 ppm [20 minutes], and 0 ppm [10 minutes]), compared with healthy referents (Orbaek et al. 1998; Osterberg et al. 2003). During these studies, psychomotor tests were performed before exposure and during the 12- and 48-ppm exposure periods. Both healthy referents and individuals with multiple chemical sensitivity showed increased response time in the reaction-time test (visual stimuli) following exposure, compared with pre-exposure scores (Osterberg et al. 2003). However, the increase was not dose-related in healthy individuals, and exposure-related impairments were not observed in the reaction time-inhibition test (with auditory alarm) or digit symbol test in either group (Osterberg et al. 2003). In a separate study, there were no observed psychomotor impairments in exposed individuals with toxic encephalopathy or healthy referents using the same protocol (Osterberg et al. 2000). A LOAEL of 48 ppm for the studies conducted by Orbaek et al. (1998) and Osterberg et al. (2003) was determined for susceptible individuals based on increased self-reported fatigue. A NOAEL could not be determined, as fatigue scores were not reported at individual exposure concentrations.

Agency Contacts (Chemical Manager): Robert Williams
MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene  
CAS Numbers: 108-88-3  
Date: September 2015  
Profile Status: Final Draft for Public Comment  
Route: [X] Inhalation   [ ] Oral  
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic  
Graph Key: 229–230, 238  
Species: Human  

Minimal Risk Level: 1 [ ] mg/kg/day   [X] ppm


Experimental design: A series of studies by the same group of investigators assessed subjective neurological symptoms, performance on psychomotor tasks, color vision, and hearing in groups of German photogravure printers employed for an average duration of 13.5 years (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002). These studies compared neurological end points in workers with high exposure to toluene (printers, n=106–181) with workers with low exposure to toluene (end-processors, n=86–152). Current toluene air exposure levels for printers and end-processors were 24.6–26 and 3–3.5 ppm, respectively (measured twice yearly from 1996 to 2001). Historical exposure levels for printers prior to 1995 and prior to 1975 were 40 and 140 ppm, respectively. Historical exposure levels for end-processors prior to 1995 and prior to 1975 were 5 and 40 ppm, respectively. Using job history and current exposure and historical exposure levels, individual TWA exposure levels were calculated. The average TWA levels for printers and end-processors were calculated to be 45 and 10 ppm for subjects included in analyses by Schäper et al. (2003, 2008), 45 and 9 ppm for subjects included in analyses by Seeber et al. (2004, 2005) and Zupanic et al. (2002), and 43 and 9 ppm for subjects included in analyses by Schäper et al. (2004).

Effect noted in study and corresponding doses: Schäper et al. (2003, 2008) did not find any statistically significant differences in audiometric readings from four readings over 5 years in 181 printers, compared with 152 end-processors. Schäper et al. (2004) did not find any differences in color vision assessed.
4 times over 5 years in 154 printers, compared with 124 end-processors. Seeber et al. (2004, 2005) and Zupanic et al. (2002) did not find any increase in subjective neurological complaints or decreased performance in psychomotor tasks in 106–154 printers, compared with 86–124 end-processors.

**Dose and end point used for MRL derivation**: 45 ppm for neurological effects

[X] NOAEL  [ ] LOAEL

**Uncertainty Factors used in MRL derivation**:

- [ ] 1  [ ] 3  [ ] 10 (for use of a LOAEL)
- [ ] 1  [ ] 3  [ ] 10 (for extrapolation from animals to humans)
- [ ] 1  [ ] 3  [X] 10 (for human variability)

MRL = 45 ppm x 5 days/7 days x 8 hours/24 hours ÷ 10 = 1 ppm (3.8 mg/m³)

Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? The exposure concentration was adjusted to continuous exposure basis as shown above.

**Other additional studies or pertinent information that lend support to this MRL**: Twenty-four human occupational studies evaluating neurological end points following exposure predominately or exclusively to toluene were considered for deriving the chronic inhalation MRL (see Table A-1). Numerous studies identified subtle neurological effects following occupational exposure to toluene at concentration estimates ranging from 50 to 140 ppm, including subjective neurological symptoms, altered performance on neurobehavioral and psychomotor tasks, impaired color vision, and hearing loss (Abbate et al. 1993; Boey et al. 1997; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Murata et al. 1993; Neubert et al. 2001; Nordling Nilson et al. 2010; Orbaek and Nise 1989; Ukai et al. 1993; Vrca 1995, 1996, 1997b; Yin et al. 1987; Zavalic et al. 1998a, 1998b, 1998c). Several occupational studies identify NOAELs for these effects in the range of 20–46 ppm toluene (Chouanière et al. 2002; Gericke et al. 2001; Kang et al. 2005; Nakatsuka et al. 1992; Neubert et al. 2001; Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Ukai et al. 1993; Zavalic et al. 1998a, 1998c; Zupanic et al. 2002). One outlier study reported that no increases in subjective symptoms or changed performance on psychomotor tasks were found in printers exposed to 9–83 ppm and laboratory workers exposed to 184–467 ppm when analyzed together, compared with unexposed referents (Deschamps et al. 2001). However, the findings for the two groups were not reported separately. The NOAEL for this study was set at the average of the midpoints of the exposure ranges for the two groups of workers (midpoint factory, 46 ppm; midpoint laboratory, 325.5; average, 185.75 ppm). Studies that evaluated only subjective end points (Ukai et al. 1993; Yin et al. 1987) were not considered for deriving the chronic inhalation MRL.
<table>
<thead>
<tr>
<th>Study author/date</th>
<th>Neurological end point(s) evaluated (altered end points at LOAEL are in bold)</th>
<th>NOAEL</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbate et al. 1993</td>
<td>BAEPs</td>
<td></td>
<td>97</td>
</tr>
<tr>
<td>Boey et al. 1997</td>
<td>Logical memory, digit span, visual reproduction, Benton visual retention test, trail making test, symbol digit modality test, grooved pegboard test, and finger tapping test</td>
<td></td>
<td>90.9</td>
</tr>
<tr>
<td>Chouanière et al. 2002</td>
<td>Subjective symptoms, simple reaction time, symbol digit substitution, digit span forwards and backwards, pattern memory test, associate learning and recall</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td>Deschamps et al. 2001</td>
<td>Subjective symptoms, vocabulary test, simple reaction time, digit symbol, digit span forwards and backwards, continuous tracking, color word vigilance, and switching attention test</td>
<td></td>
<td>186a</td>
</tr>
<tr>
<td>Foo et al. 1990</td>
<td>Benton visual retention, visual reproduction, trail making, grooved peg board, digit span, digit symbol, finger tapping, and simple reaction time</td>
<td></td>
<td>88</td>
</tr>
<tr>
<td>Gericke et al. 2001</td>
<td>Subjective symptoms, assessment of color vision (test used was not specified), and a battery of psychomotor tests (immediate visual memory, digit span forward and backward, and digit symbol)</td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Kang et al. 2005</td>
<td>Finger tapping, selective attention, digit span forward and backward, symbol digit, and simple reaction time tests</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Matsushita et al. 1975</td>
<td>Subjective symptoms, tendon reflexes, grasping power, and tapping tempo</td>
<td></td>
<td>84</td>
</tr>
<tr>
<td>Murata et al. 1993</td>
<td>Nerve conduction (EKG, median nerve)</td>
<td></td>
<td>83</td>
</tr>
<tr>
<td>Nakatsuka et al. 1992</td>
<td>Color vision (Lanthony's new color test and Ishihara's color/vision test)</td>
<td></td>
<td>46</td>
</tr>
<tr>
<td>Neubert et al. 2001</td>
<td>Subjective symptoms, digit span forward/backward, visuomotor performance, visual memory, self-rating of feelings, bisensory vigilance, flicker fusion frequency, and personality dispositions</td>
<td></td>
<td>33</td>
</tr>
<tr>
<td>Orbaek and Nise 1989; Nordling Nilson et al. 2010</td>
<td>Initial: Subjective symptoms and psychometric tests including verbal, logical inductive, spatial memory, perceptual, and psychomotor tests 20-year follow-up: Subjective symptoms and psychometric tests including verbal, logical inductive (reasoning), spatial memory (associative learning), perceptual, psychomotor tests, trail-making test, STROOP test, and memory tests</td>
<td></td>
<td>140</td>
</tr>
<tr>
<td>Schäper et al. 2003, 2008b</td>
<td>Audiometry (two reports of the same study)</td>
<td></td>
<td>45</td>
</tr>
<tr>
<td>Schäper et al. 2004b</td>
<td>Color vision (Lanthony desaturated panel D-15d, Ishihara plates)</td>
<td></td>
<td>43</td>
</tr>
<tr>
<td>Seeber et al. 2004, 2005b</td>
<td>Subjective symptoms, symbol digit substitution, switching attention, and memory span (initial study 2004; follow-up analysis of the same data in 2005)</td>
<td></td>
<td>45</td>
</tr>
<tr>
<td>Vrca 1995, 1997b</td>
<td>VEPs</td>
<td></td>
<td>50</td>
</tr>
<tr>
<td>Vrca et al. 1996</td>
<td>BAEPs</td>
<td></td>
<td>50</td>
</tr>
</tbody>
</table>
### Table A-1. Chronic Occupational Studies Considered for Deriving the Chronic Inhalation MRL

<table>
<thead>
<tr>
<th>Study author/date</th>
<th>Neurological end point(s) evaluated (altered end points at LOAEL are in bold)</th>
<th>NOAEL</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zavalic 1998a, 1998c</td>
<td><strong>Color vision</strong> (Lanthony D-15 desaturated test; Verriest's classification of color vision loss)</td>
<td>35</td>
<td>156</td>
</tr>
<tr>
<td>Zavalic 1998b</td>
<td><strong>Color vision</strong> (Lanthony D-15 desaturated test; Verriest's classification of color vision loss)</td>
<td></td>
<td>120</td>
</tr>
<tr>
<td>Zupanic et al. 2002b</td>
<td>Subjective symptoms, manual dexterity: steadiness, line tracing, aiming, tapping, and peg board</td>
<td>45</td>
<td></td>
</tr>
</tbody>
</table>

aTwo toluene-exposed groups were described by Deschamps et al. (2001): 36 factory workers (9–83 ppm) and 36 laboratory workers (184–467 ppm). No average exposure levels were reported, and the two groups were analyzed together. Therefore, the NOAEL was set at the average of the midpoints of the exposed ranges (midpoint factory, 46 ppm; midpoint laboratory, 325.5; average, 185.75 ppm).

bStudies selected for derivation of the chronic MRL.

BAEP = brainstem auditory evoked potential; LOAEL = lowest-observed-adverse-effect level; MRL = minimal risk level; NOAEL = no-observed-adverse-effect level; VEP = visual-evoked potential

After reviewing all available studies, the series of six recent studies in German rotogravure printers reporting NOAELs of 43–45 ppm for hearing loss (Schäper et al. 2003, 2008), color vision (Schäper et al. 2004), and psychomotor function (Seeber et al. 2004, 2005; Zupanic et al. 2002) were selected to support a POD of 45 ppm. This POD NOAEL value is lower than all LOAEL values in Table A-1 and is consistent with the mean and median NOAEL values from all studies summarized in Table A-1 (50 and 43 ppm, respectively).

The previous draft used a POD based on a LOAEL of 35 ppm for color vision impairment in the studies by Zavalic et al. (1998a, 1998c). The current evaluation of this study arrives at a different LOAEL determination. In Zavalic et al. (1998a), the color confusion index (CCI) was statistically significantly increased by 14% in 32 printers exposed to geometric mean toluene concentrations of 156 ppm, respectively, when compared with 83 unexposed controls on Monday morning prior to their work shift. However, the CCI in 41 shoemakers exposed to geometric mean toluene concentrations of 35 ppm were not significantly elevated when compared with controls. When alcohol consumers were excluded, the CCI in 27 shoemakers and 10 printers was significantly increased by 4 and 11%, respectively, compared with 36 controls. When adjusted for age and alcohol consumption, CCIs were significantly higher in both shoemakers and printers (adjusted mean CCI values were not reported). Individual adjusted CCIs were significantly correlated with individual exposure estimates (air, blood, or urine) in printers, but not shoemakers. In Zavalic et al. (1998c), further analysis of color vision loss in these groups of workers demonstrated that both blue-yellow and red-green color confusion (dyschromatopia type II and II) were significantly increased in printers, compared with unexposed workers, but there was no significant difference in the prevalence of either type of color confusion in shoemakers compared with unexposed workers. Taken together, these studies indicate a clear LOAEL of 156 ppm for color vision loss in printers, based on increased CCIs significantly associated with individual estimates of toluene exposure and increased prevalence of dyschromatopia. A NOAEL of 35 ppm was identified, as it is unclear if the statistically significant findings for increased CCI in the small sample of non-alcohol consuming workers or adjusted CCIs in all workers represents an adverse effect, especially since the magnitude of change was small and individual CCIs in this group were not associated with toluene exposure estimates in the air, blood, or urine. This interpretation of findings is consistent with the interpretation in the most recent Integrated Risk Information System (IRIS) document (EPA 2005a), which considers the lower exposure level to be a NOAEL for color vision impairment.
Agency Contacts (Chemical Manager): Robert Williams
MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene
CAS Numbers: 108-88-3
Date: September 2015
Profile Status: Final Draft for Public Comment
Route: [X] Oral
Duration: [X] Acute [ ] Intermediate [ ] Chronic
Graph Key: 18
Species: Rat

Minimal Risk Level: 0.8 [X] mg/kg [ ] ppm


Experimental design: Male Long-Evans rats (12/group) were administered doses of toluene in corn oil of 0, 250, 500, and 1,000 mg/kg by gavage. FEP tests were administered 45 minutes later as a test of the ability of the nervous system to process visual information. In another study (time-course), toluene was administered to male Long-Evans rats (16/group) at doses of 0 and 500 mg/kg by gavage, and FEP tests were performed 4, 8, 16, and 30 hours later.

Effect noted in study and corresponding doses: The amplitude of the N3 peak of the FEP was significantly decreased (p<0.05) by toluene exposure at all doses. The magnitude of this decrease in peak amplitude was not dose-related. In the time course study, 500 mg/kg also decreased the amplitude of the FEP; at this dose, little change in magnitude of peak N3 depression had occurred 8 hours post-treatment; by 16 hours, recovery was complete.

Dose and end point used for MRL derivation: 250 mg/kg for neurological effects

[ ] NOAEL  [X] LOAEL

Uncertainty Factors used in MRL derivation:

[ ] 1  [X] 3  [ ] 10 (for use of a LOAEL)
[ ] 1  [ ] 3  [X] 10 (for extrapolation from animals to humans)
[ ] 1  [ ] 3  [X] 10 (for human variability)

MRL = 250 mg/kg/day ÷ 300 = 0.8 mg/kg/day

Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? No.

Other additional studies or pertinent information that lend support to this MRL: Human data suitable for deriving an acute oral MRL for toluene are not available.
Only a limited number of acute-exposure rat studies have evaluated neurological end points in addition to the study by Dyer et al. (1988) and all of them evaluated higher doses. These studies report transient increases in motor activity following single oral doses of 650–5,220 mg/kg (Gordon et al. 2007, 2010; MacPhail et al. 2012; Mehta et al. 1998), abnormal gait following single oral doses of 3,915–5,220 mg/kg (Mehta et al. 1998), and ototoxicity following exposure to 780 mg/kg/day, 5 days/week for 2 weeks (Gagnaire and Langlais 2005). Additionally, numerous acute-duration animal inhalation studies have reported neurological effects from toluene (see Table 3-1 for complete list). Human inhalation studies have focused on the central nervous system as the critical toxicity target for acute-duration toluene exposure (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1999; Gamberale and Hultengren 1972; Rahill et al. 1996; von Oettingen et al. 1942).

An additional study that lends support to the MRL is a developmental study that reported altered cortical cell proliferation and migration in offspring following exposure of pregnant rats to gavage doses of 0 or 650 mg/kg/day toluene in corn oil on GDs 6–19 (Gospe and Zhou 2000). Cortical cell density was significantly decreased by 12.5% in all layers of the cerebral cortex in toluene-exposed pups on PND 21, compared with controls. The greatest decrease (26.8%) was observed in layer IV. Decreased density was attributed to altered neurogenesis, as neurons labeled with BrdU from injections on GDs 13–21 were decreased in numbers and exhibited altered migration patterns.

Agency Contacts (Chemical Manager): Robert Williams
MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene
CAS Numbers: 108-88-3
Date: September 2015
Profile Status: Final Draft for Public Comment
Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Graph Key: 45-47
Species: Mouse

Minimal Risk Level: 0.2 [X] mg/kg/day [ ] ppm

References:


Experimental design: A series of studies evaluated immune end points in male CD-1 mice (5/group) administered toluene in their drinking water for 28 days at concentrations of 0, 5, 22, or 105 mg/kg/day (Hsieh et al. 1989, 1991) or 0, 22, or 84 mg/kg/day (Hsieh et al. 1990a). In Hsieh et al. (1989, 1990a), rats were weighed, sacrificed, and examined for gross pathological lesions at 28 days. Spleen and thymus were weighed and hematology was performed. Spleens were assessed for cellularity, and splenocytes were used in \textit{in vitro} immune assays (mitogen-stimulated lymphocyte proliferation, mixed lymphocyte reaction, IL-2 production assay, and antibody PFC response). Hsieh et al. (1990a) also measured the \textit{in vitro} cell-mediated cytolosis response. In Hsieh et al. (1991), immune function was only assessed using the IL-2 assay in cultured splenocytes. A level of p<0.05 was considered statistically significant unless otherwise stated.

Effect noted in study and corresponding doses: In Hsieh et al. (1989), significantly decreased thymus weight and significantly depressed immune responses were observed in all \textit{in vitro} immune assays at 105 mg/kg/day, compared with control. IL-2 production and mitogen-stimulated lymphocyte proliferation were also significantly increased at 22 mg/kg/day compared with control. In Hsieh et al. (1990a), significantly depressed immune responses were observed in the PFC assay and mixed lymphocyte reaction at 84 mg/kg/day. The mixed lymphocyte reaction was also significantly depressed at 22 mg/kg/day. In Hsieh et al. (1991), the IL-2 production assay was significantly depressed at 105 mg/kg/day. Taken together, these studies consistently reported diminished immune responses in multiple \textit{in vitro} immune assays following \textit{in vivo} exposure to 84–105 mg/kg/day in drinking water for 28 days, compared with controls. A couple of immune assays were altered at 22 mg/kg/day, but findings were not consistent between the three Hsieh studies. Additionally, the antibody PFC assay was significantly altered at 84 and 105 mg/kg/day, but not at 22 mg/kg/day (Hsieh et al. 1989, 1990a). The PFC \textit{in vitro} assay is considered the most predictive assay of impaired immune function (Luster et al. 1992). Collectively, results from these studies support a NOAEL of 22 mg/kg/day for immune effects.
Dose and end point used for MRL derivation: 22 mg/kg/day for immune depression

[X] NOAEL  [ ] LOAEL

Uncertainty Factors used in MRL derivation:

[ ] 1  [ ] 3  [ ] 10 (for use of a LOAEL)
[ ] 1  [ ] 3  [ X] 10 (for extrapolation from animals to humans)
[ ] 1  [ ] 3  [ X] 10 (for human variability)

MRL = 22 mg/kg/day ÷ 100 = 0.2 mg/kg/day

Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes. The study authors calculated that exposure to 0, 17, 80, and 405 mg/L in drinking water for 28 days was equivalent to toluene doses of 0, 5, 22, and 105 mg/kg/day, respectively, over this period based on water consumption (Hsieh et al. 1989). These equivalent doses were used for the Hsieh et al. (1991) study. Toluene concentration in Hsieh et al. (1990a) was reported to be 0, 80, or 325 mg/L in drinking water. The equivalent dose for the 80 mg/L group from previous studies was adopted for the 1990a study (22 mg/kg/day). Using the conversion factor from the high-dose group from Hsieh et al. (1989) (1 mg/L = 0.259 mg/kg/day), the equivalent dose for the 325 mg/L group was calculated to be 84 mg/kg/day.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? No.

Other additional studies or pertinent information that lend support to this MRL: Human data suitable for deriving an intermediate oral MRL for toluene are not available.

No other intermediate-duration oral studies evaluating immune function were located. In an acute oral study, Burns et al. (1994) reported that exposure to 600 mg/kg/day via gavage for 14 days did not diminish immune response in in vitro immune assays or decrease host resistance to Listeria monocytogenes, S. pneumoniae, Plasmodium yoelii, B16F10 melanoma, or PYB6 fibrosarcoma in female mice, compared with controls. The EPA (2005) discounted immune effects as a critical effect for the IRIS RfD due to the absence of immune effects in the Burns et al. (1994) study and apparent conflicting evidence for toluene immunotoxicity in animals. However, exposure was under different conditions (gavage versus drinking water) and for a shorter duration (14 days versus 28 days) in the Hseih et al. studies than in the Burns et al. (1994) study. The sex and strain also differed between the studies (B6C3F1 versus CD-1; females versus males). Therefore, the lack of observed effects in the Burns et al. (1994) study may not represent conflicting evidence; rather, it may be due to the shorter duration, different exposure conditions, and/or differences between sexes or strains.

In animal inhalation studies, evidence for toluene effects on the immune system includes the finding of decreased resistance to mortality from respiratory infection by S. zooepidemicus in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm, but not 1 ppm (Aranyi et al. 1985).

Hepatic, renal, and neurological effects were also considered as bases of the intermediate-duration oral MRL. However, the PODs for hepatic, renal, and neurological effects (see Table A-2) are all higher than the selected POD for immune effects. Additionally, findings for increased liver and kidney weight were not consistent between studies, nor were they associated with histopathological changes.
Table A-2. Animals Studies Considered for Deriving the Intermediate-Duration Oral MRL

<table>
<thead>
<tr>
<th>Study</th>
<th>End point(s) evaluated</th>
<th>Significant effects at LOAEL</th>
<th>NOAEL</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immuno/lymphoreticular effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NTP 1990; 13 weeks; F344 rats 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)</td>
<td>Spleen and thymus weight and histology (0, 2,500, and 5,000 mg/kg/day groups only)</td>
<td>All 5,000 mg/kg/day mice died within 1 week, so the NOAEL was set at 2,500 mg/kg/day</td>
<td>2,500</td>
<td>–</td>
</tr>
<tr>
<td>Hsieh et al. 1989a; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water</td>
<td>Immune assays (PFC assay, mixed lymphocyte response, mitogen stimulation, IL-2 immune response); spleen and thymus weight and gross pathology</td>
<td>Decreased thymus weight, depressed immune response in all assays (mitogen-stimulated lymphocyte proliferation and IL-2 immunity were also depressed at 22 mg/kg/day)</td>
<td>22 (males)</td>
<td>105 (males)</td>
</tr>
<tr>
<td>Hsieh et al. 1990a; 28 days; CD-1 male mice 0, 22, and 84 mg/kg/day via drinking water</td>
<td>Immune assays (PFC assay, mixed lymphocyte culture, mitogen stimulation, IL-2 immune response, cell-mediated cytotoxicity); spleen and thymus weight and gross pathology</td>
<td>Depressed immune response in PFC assay and mixed lymphocyte culture (mixed lymphocyte culture was also depressed at 22 mg/kg/day)</td>
<td>22 (males)</td>
<td>84 (males)</td>
</tr>
<tr>
<td>Hsieh et al. 1991a; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water</td>
<td>IL-2 immune response assay</td>
<td>Depressed IL-2 immune response</td>
<td>22 (males)</td>
<td>105 (males)</td>
</tr>
<tr>
<td>NTP 1990; 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)</td>
<td>Spleen and thymus weight and histology (0, 2,500, and 5,000 mg/kg/day groups only)</td>
<td>All 5000 mg/kg/day mice died within 1 week, so the NOAEL was set at 2,500 mg/kg/day</td>
<td>2,500</td>
<td>–</td>
</tr>
<tr>
<td>Hepatic effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NTP 1990; 13 weeks; F344 rats 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)</td>
<td>Liver weight, histology, clinical chemistry</td>
<td>Increased absolute and relative liver weight</td>
<td>312 M 625 M</td>
<td>625 1,250 (females) (females)</td>
</tr>
<tr>
<td>Wolf et al. 1956; 6 months; Wistar rats 0, 118, 354, and 590 mg/kg/day via gavage (5 days/week)</td>
<td>Liver weight, histology</td>
<td>No adverse-effect level determined for liver end points</td>
<td>590</td>
<td>– (females)</td>
</tr>
<tr>
<td>Hsieh et al. 1989; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water</td>
<td>Liver weight, gross pathology</td>
<td>Increased liver weight</td>
<td>22 (males)</td>
<td>105 (males)</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
## Table A-2. Animals Studies Considered for Deriving the Intermediate-Duration Oral MRL

<table>
<thead>
<tr>
<th>Study</th>
<th>End point(s) evaluated</th>
<th>Significant effects at LOAEL</th>
<th>NOAEL</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsieh et al. 1990a; 28 days; CD-1 male mice 0, 22, and 84 mg/kg/day via drinking water</td>
<td>Liver weight, gross pathology</td>
<td>No adverse-effect level determined for liver end points</td>
<td>84 M</td>
<td>–</td>
</tr>
<tr>
<td>NTP 1990(^b); 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)</td>
<td>Liver weight, histology, clinical chemistry</td>
<td>Increased absolute (females) and relative (males and females) liver weight</td>
<td>625 (males)</td>
<td>1,250 (males)</td>
</tr>
<tr>
<td>Wolf et al. 1956; 6 months; Wistar rats 0, 118, 354, and 590 mg/kg/day via gavage (5 days/week)</td>
<td>Kidney weight, gross morphology</td>
<td>No adverse-effect level determined for kidney effects</td>
<td>590 (females)</td>
<td>–</td>
</tr>
<tr>
<td>Hsieh et al. 1989; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water</td>
<td>Kidney weight, gross pathology</td>
<td>No adverse-effect level determined for kidney effects</td>
<td>105 (males)</td>
<td>–</td>
</tr>
<tr>
<td>Hsieh et al. 1990a; 28 days; CD-1 male mice 0, 22, and 84 mg/kg/day via drinking water</td>
<td>Kidney weight, gross pathology</td>
<td>No adverse-effect level determined for kidney effects</td>
<td>84 (males)</td>
<td>–</td>
</tr>
<tr>
<td>NTP 1990; 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)</td>
<td>Kidney weight, histology, clinical chemistry, urinalysis</td>
<td>All 5000 mg/kg/day mice died within 1 week, so the NOAEL was set at 2,500 mg/kg/day</td>
<td>2,500</td>
<td>–</td>
</tr>
<tr>
<td>NTP 1990; 13 weeks; F344 rats 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)</td>
<td>Brain weight, histology, clinical signs</td>
<td>Brain necrosis in hippocampus and cerebellum (increased absolute brain weight and clinical signs of neurotoxicity at 2,500 mg/kg/day)</td>
<td>625 (males)</td>
<td>1,250 (males)</td>
</tr>
<tr>
<td>NTP 1990; 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)</td>
<td>Brain weight, histology, clinical signs</td>
<td>Increased absolute brain weight (males); clinical signs of neurotoxicity at 2,500 mg/kg/day (males and females)</td>
<td>625 (males)</td>
<td>1,250 (males)</td>
</tr>
</tbody>
</table>
Table A-2. Animals Studies Considered for Deriving the Intermediate-Duration Oral MRL

<table>
<thead>
<tr>
<th>Study</th>
<th>End point(s) evaluated</th>
<th>Significant effects at LOAEL</th>
<th>NOAEL</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developmental effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kostas and Hotchin 1981; GDs 0–21 and PNDs 0–55; Nya:NYLAR mice 0, 4, 21, and 106 mg/kg/day via drinking water</td>
<td>Neonatal survival, growth and development; surface righting, startle reflex, rotarod performance, and open-field activity</td>
<td>Increased open-field activity (lack of habituation)</td>
<td>21</td>
<td>106</td>
</tr>
</tbody>
</table>

*Studies and end points selected for deriving the intermediate-duration oral MRL.

GD = gestation day; IL-2 = interleukin-2; LOAEL = lowest-observed-adverse-effect level; MRL = minimal risk level; NOAEL = no-observed-adverse-effect level; NTP = National Toxicology Program; PFC = plaque-forming cell; PND = postnatal day

Impaired neurodevelopment following pre- and postnatal exposure to toluene, as evidenced by altered open-field behavior in offspring, was also considered as basis of the intermediate-duration oral MRL. Pups exposed to 106 mg/kg/day, but not 4 or 21 mg/kg/day, on GDs 0–21 and PNDs 0–55 demonstrated impaired habituation compared with controls (Kostas and Hotchin 1981). The POD of 21 mg/kg/day is comparable to the immune effects POD of 22 mg/kg/day. However, no other neurodevelopmental oral studies were located to support this finding. Therefore, the series of three studies by Hsieh et al. (1989, 1990b, 1991) demonstrating that consistent immune suppression was determined to be a better selection for a critical effect. While not selected as the basis of the MRL, this study does support the use of a NOAEL of 22 mg/kg/day as the POD.

In the previous draft (ATSDR, 2000), the basis of the intermediate-duration oral MRL was a minimally adverse LOAEL of 5 mg/kg/day for increased brain levels of norepinephrine, dopamine, and serotonin (Hsieh et al. 1990b). As mentioned in the 2000 draft, it is unclear how (or if) these effects relate to neurobehavioral changes. Additionally, alterations in neurotransmitters, and their precursors, are inconsistent between brain regions and do not increase with increasing dose. For the majority of findings, increased neurotransmitter levels in mice exposed to 5, 22, or 105 mg/kg/day for 28 days were the highest in the 22 mg/kg/day group. Since neurotransmitter levels were only evaluated at one time point, it is also unknown if these changes are transient. Due to the lack of dose response, lack of information on persistence of changes, and unclear association with neurobehavior, it cannot be determined if these changes are adverse. Therefore, a NOAEL/LOAEL call was not made for the neurological effects in this study. This interpretation is consistent with the interpretation by EPA (2005): “the changes in neurotransmitter levels have not been correlated with behavioral, neuropsychological, or neuroanatomical changes and were not considered further [for deriving RfD].”

Agency Contacts (Chemical Manager): Robert Williams
APPENDIX B. USER’S GUIDE

Chapter 1

Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

Chapter 2

Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

***DRAFT FOR PUBLIC COMMENT***
MRLs should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

Chapter 3

Health Effects

Tables and Figures for Levels of Significant Exposure (LSE)

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CEls).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.
LEGEND

See Sample LSE Table 3-1 (page B-6)

(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.

(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.

(3) Health Effect. The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.

Systemic effects are further defined in the "System" column of the LSE table (see key number 18).

(4) Key to Figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).

(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.

Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.

(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to "Chemical x" via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).

(7) System. This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.

(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").

***DRAFT FOR PUBLIC COMMENT***
(9) **LOAEL.** A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.

(10) **Reference.** The complete reference citation is given in Chapter 9 of the profile.

(11) **CEL.** A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.

(12) **Footnotes.** Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

**LEGEND**

*See Sample Figure 3-1 (page B-7)*

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

(13) **Exposure Period.** The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.

(14) **Health Effect.** These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.

(15) **Levels of Exposure.** Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m³ or ppm and oral exposure is reported in mg/kg/day.

(16) **NOAEL.** In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).

(17) **CEL.** Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.
(18) **Estimated Upper-Bound Human Cancer Risk Levels.** This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA’s Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels ($q_1*$).

(19) **Key to LSE Figure.** The Key explains the abbreviations and symbols used in the figure.
Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation

<table>
<thead>
<tr>
<th>Key to figure&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Exposure frequency/duration</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (effect)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species</td>
<td>System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>INTERMEDIATE EXPOSURE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Systemic</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>4</td>
<td>18</td>
<td>Rat</td>
<td>13 wk</td>
<td>Resp</td>
</tr>
<tr>
<td></td>
<td>5 d/wk</td>
<td></td>
<td>3&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 hr/d</td>
<td></td>
<td>10 (hyperplasia)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nitschke et al. 1981</td>
</tr>
<tr>
<td></td>
<td>CHRONIC EXPOSURE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Rat</td>
<td>18 mo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 d/wk</td>
<td></td>
<td>20 (CEL, multiple organs)</td>
<td>Wong et al. 1982</td>
</tr>
<tr>
<td></td>
<td>7 hr/d</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Rat</td>
<td>89–104 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 d/wk</td>
<td></td>
<td>10 (CEL, lung tumors, nasal tumors)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td>6 hr/d</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Mouse</td>
<td>79–103 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 d/wk</td>
<td></td>
<td>10 (CEL, lung tumors, hemangiosarcomas)</td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td>6 hr/d</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> The number corresponds to entries in Figure 3-1.

<sup>b</sup> Used to derive an intermediate inhalation Minimal Risk Level (MRL) of \(5 \times 10^{-3}\) ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation

*Doses represent the lowest dose tested per study that produced a tumorigenic response and do not imply the existence of a threshold for the cancer end point.
APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
Cl confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor

***DRAFT FOR PUBLIC COMMENT***
DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECD/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F_1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
G gram
GC gas chromatography
GD gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
K_{oc} organic carbon partition coefficient
K_{ow} octanol-water partition coefficient
L liter
LC liquid chromatography
LC_{50} lethal concentration, 50% kill
LC_{Lo} lethal concentration, low
LD_{50} lethal dose, 50% kill
LD_{Lo} lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT_{50} lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie

***DRAFT FOR PUBLIC COMMENT***
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCL</td>
<td>maximum contaminant level</td>
</tr>
<tr>
<td>MCLG</td>
<td>maximum contaminant level goal</td>
</tr>
<tr>
<td>MF</td>
<td>modifying factor</td>
</tr>
<tr>
<td>MFO</td>
<td>mixed function oxidase</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>mL</td>
<td>milliliter</td>
</tr>
<tr>
<td>mm</td>
<td>millimeter</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeters of mercury</td>
</tr>
<tr>
<td>mmol</td>
<td>millimole</td>
</tr>
<tr>
<td>mppcf</td>
<td>millions of particles per cubic foot</td>
</tr>
<tr>
<td>MRL</td>
<td>Minimal Risk Level</td>
</tr>
<tr>
<td>MS</td>
<td>mass spectrometry</td>
</tr>
<tr>
<td>NAAQS</td>
<td>National Ambient Air Quality Standard</td>
</tr>
<tr>
<td>NAS</td>
<td>National Academy of Science</td>
</tr>
<tr>
<td>NATICH</td>
<td>National Air Toxics Information Clearinghouse</td>
</tr>
<tr>
<td>NATO</td>
<td>North Atlantic Treaty Organization</td>
</tr>
<tr>
<td>NCE</td>
<td>normochromatic erythrocytes</td>
</tr>
<tr>
<td>NCEH</td>
<td>National Center for Environmental Health</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>ND</td>
<td>not detected</td>
</tr>
<tr>
<td>NFPA</td>
<td>National Fire Protection Association</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>NIEHS</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>NIOSH</td>
<td>National Institute for Occupational Safety and Health</td>
</tr>
<tr>
<td>NIOSHTIC</td>
<td>NIOSH's Computerized Information Retrieval System</td>
</tr>
<tr>
<td>NLM</td>
<td>National Library of Medicine</td>
</tr>
<tr>
<td>nm</td>
<td>nanometer</td>
</tr>
<tr>
<td>nmol</td>
<td>nanomole</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no-observed-adverse-effect level</td>
</tr>
<tr>
<td>NOES</td>
<td>National Occupational Exposure Survey</td>
</tr>
<tr>
<td>NOHS</td>
<td>National Occupational Hazard Survey</td>
</tr>
<tr>
<td>NPD</td>
<td>nitrogen phosphorus detection</td>
</tr>
<tr>
<td>NPDES</td>
<td>National Pollutant Discharge Elimination System</td>
</tr>
<tr>
<td>NPL</td>
<td>National Priorities List</td>
</tr>
<tr>
<td>NR</td>
<td>not reported</td>
</tr>
<tr>
<td>NRC</td>
<td>National Research Council</td>
</tr>
<tr>
<td>NS</td>
<td>not specified</td>
</tr>
<tr>
<td>NSPS</td>
<td>New Source Performance Standards</td>
</tr>
<tr>
<td>NTIS</td>
<td>National Technical Information Service</td>
</tr>
<tr>
<td>NTP</td>
<td>National Toxicology Program</td>
</tr>
<tr>
<td>ODW</td>
<td>Office of Drinking Water, EPA</td>
</tr>
<tr>
<td>OERR</td>
<td>Office of Emergency and Remedial Response, EPA</td>
</tr>
<tr>
<td>OHM/TADS</td>
<td>Oil and Hazardous Materials/Technical Assistance Data System</td>
</tr>
<tr>
<td>OPP</td>
<td>Office of Pesticide Programs, EPA</td>
</tr>
<tr>
<td>OPPT</td>
<td>Office of Pollution Prevention and Toxics, EPA</td>
</tr>
<tr>
<td>OPPTS</td>
<td>Office of Prevention, Pesticides and Toxic Substances, EPA</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>OSHA</td>
<td>Occupational Safety and Health Administration</td>
</tr>
<tr>
<td>OSW</td>
<td>Office of Solid Waste, EPA</td>
</tr>
<tr>
<td>OTS</td>
<td>Office of Toxic Substances</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>OW</td>
<td>Office of Water</td>
</tr>
<tr>
<td>OWRS</td>
<td>Office of Water Regulations and Standards, EPA</td>
</tr>
<tr>
<td>PAH</td>
<td>polycyclic aromatic hydrocarbon</td>
</tr>
<tr>
<td>PBPD</td>
<td>physiologically based pharmacodynamic</td>
</tr>
<tr>
<td>PBPK</td>
<td>physiologically based pharmacokinetic</td>
</tr>
<tr>
<td>PCE</td>
<td>polychromatic erythrocytes</td>
</tr>
<tr>
<td>PEL</td>
<td>permissible exposure limit</td>
</tr>
<tr>
<td>pg</td>
<td>picogram</td>
</tr>
<tr>
<td>PHS</td>
<td>Public Health Service</td>
</tr>
<tr>
<td>PID</td>
<td>photo ionization detector</td>
</tr>
<tr>
<td>pmol</td>
<td>picomole</td>
</tr>
<tr>
<td>PMR</td>
<td>proportionate mortality ratio</td>
</tr>
<tr>
<td>PND</td>
<td>postnatal day</td>
</tr>
<tr>
<td>ppb</td>
<td>parts per billion</td>
</tr>
<tr>
<td>ppm</td>
<td>parts per million</td>
</tr>
<tr>
<td>ppt</td>
<td>parts per trillion</td>
</tr>
<tr>
<td>PSNS</td>
<td>pretreatment standards for new sources</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell</td>
</tr>
<tr>
<td>REL</td>
<td>recommended exposure level/limit</td>
</tr>
<tr>
<td>RfC</td>
<td>reference concentration</td>
</tr>
<tr>
<td>RfD</td>
<td>reference dose</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>RQ</td>
<td>reportable quantity</td>
</tr>
<tr>
<td>RTECS</td>
<td>Registry of Toxic Effects of Chemical Substances</td>
</tr>
<tr>
<td>SARA</td>
<td>Superfund Amendments and Reauthorization Act</td>
</tr>
<tr>
<td>SCE</td>
<td>sister chromatid exchange</td>
</tr>
<tr>
<td>SGOT</td>
<td>serum glutamic oxaloacetic transaminase</td>
</tr>
<tr>
<td>SGPT</td>
<td>serum glutamic pyruvic transaminase</td>
</tr>
<tr>
<td>SIC</td>
<td>standard industrial classification</td>
</tr>
<tr>
<td>SIM</td>
<td>selected ion monitoring</td>
</tr>
<tr>
<td>SMCL</td>
<td>secondary maximum contaminant level</td>
</tr>
<tr>
<td>SMR</td>
<td>standardized mortality ratio</td>
</tr>
<tr>
<td>SNARL</td>
<td>suggested no adverse response level</td>
</tr>
<tr>
<td>SPEGL</td>
<td>Short-Term Public Emergency Guidance Level</td>
</tr>
<tr>
<td>STEL</td>
<td>short term exposure limit</td>
</tr>
<tr>
<td>STORET</td>
<td>Storage and Retrieval</td>
</tr>
<tr>
<td>TD50</td>
<td>toxic dose, 50% specific toxic effect</td>
</tr>
<tr>
<td>TLV</td>
<td>threshold limit value</td>
</tr>
<tr>
<td>TOC</td>
<td>total organic carbon</td>
</tr>
<tr>
<td>TPQ</td>
<td>threshold planning quantity</td>
</tr>
<tr>
<td>TRI</td>
<td>Toxics Release Inventory</td>
</tr>
<tr>
<td>TSCA</td>
<td>Toxic Substances Control Act</td>
</tr>
<tr>
<td>TWA</td>
<td>time-weighted average</td>
</tr>
<tr>
<td>UF</td>
<td>uncertainty factor</td>
</tr>
<tr>
<td>U.S.</td>
<td>United States</td>
</tr>
<tr>
<td>USDA</td>
<td>United States Department of Agriculture</td>
</tr>
<tr>
<td>USGS</td>
<td>United States Geological Survey</td>
</tr>
<tr>
<td>VOC</td>
<td>volatile organic compound</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
> greater than
\geq greater than or equal to
= equal to
< less than
\leq less than or equal to
% percent
\alpha alpha
\beta beta
\gamma gamma
\delta delta
\mu m micrometer
\mu g microgram
q_{1}^{*} cancer slope factor
− negative
+ positive
(+) weakly positive result
(−) weakly negative result